<SEC-DOCUMENT>0001193125-17-085519.txt : 20170316
<SEC-HEADER>0001193125-17-085519.hdr.sgml : 20170316
<ACCEPTANCE-DATETIME>20170316165928
ACCESSION NUMBER:		0001193125-17-085519
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170316
DATE AS OF CHANGE:		20170316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		17695260

	BUSINESS ADDRESS:	
		STREET 1:		25134 RYE CANYON LOOP
		STREET 2:		SUITE 300
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
		BUSINESS PHONE:		6617755300

	MAIL ADDRESS:	
		STREET 1:		25134 RYE CANYON LOOP
		STREET 2:		SUITE 300
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d305327d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">10-K</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period
from&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: <FONT STYLE="white-space:nowrap">000-50865</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>MannKind Corporation </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">13-3607736</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>25134 Rye Canyon Loop Suite 300</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Valencia, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>91355</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(661) <FONT STYLE="white-space:nowrap">775-5300</FONT> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:44.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:156.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on Which
Registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.01 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Global Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Title of Class)
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is
not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> is
not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form <FONT STYLE="white-space:nowrap">10-K</FONT> or any
amendment to this <FONT STYLE="white-space:nowrap">Form&nbsp;10-K.&nbsp;&nbsp;&#9746;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and
&#147;smaller reporting company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">As of June&nbsp;30, 2016, the aggregate market value of the voting stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the
registrant, computed by reference to the last sale price of such stock as of such date on the NASDAQ Global Market, was approximately $372,097,776. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">As of March&nbsp;10, 2017, there were 95,776,246 shares of the registrant&#146;s Common Stock outstanding. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Portions of the registrant&#146;s definitive Proxy Statement (the &#147;Proxy Statement&#148;) for the 2017 Annual Meeting of Stockholders to be
filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than May&nbsp;1, 2017 are incorporated by reference in Part III of this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>MANNKIND CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Fiscal Year Ended December&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PART I</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_1">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_3">Unresolved Staff Comments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_4">Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_5">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_6">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PART II</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc305327_7">Market for the Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_8">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_9">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_10">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_11">Financial Statements and Supplementary Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_12">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_13">CONSOLIDATED BALANCE SHEETS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_14">CONSOLIDATED STATEMENTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_15">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_16">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_17">CONSOLIDATED STATEMENTS OF CASH FLOWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_18">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_19">Changes in and Disagreements With Accountants on Accounting and Financial
 Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_20">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_21">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PART III</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_22">Directors, Executive Officers and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_23">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc305327_24">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_25">Certain Relationships and Related Transactions, and Director Independence
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item 14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_26">Principal Accounting Fees and Services</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PART IV</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_27">Exhibits. Financial Statement Schedules</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_28">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements in this report that are not strictly historical in nature are &#147;forward-looking statements&#148; within the meaning of the
federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;would,&#148; and similar expressions intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. These statements may include, but are not limited to, statements regarding: our
ability to successfully market, commercialize and achieve market acceptance for Afrezza or any other product candidates or therapies that we may develop; our ability to manufacture sufficient quantities of Afrezza and obtain insulin supply as
needed; our ability to successfully commercialize our Technosphere drug delivery platform; our estimates for future performance; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional
financing; the timing and amount of our future recognition of deferred product sales from collaboration, costs of revenue from collaboration and income from collaboration; the progress or success of our research, development and clinical programs,
including the application for and receipt of regulatory clearances and approvals; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and scientific studies
and the conclusions we draw from them. These statements are only predictions or conclusions based on current information and expectations and involve a number of risks and uncertainties. The underlying information and expectations are likely to
change over time. Actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the caption &#147;Risk Factors&#148; and elsewhere
in this report. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, MedTone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Dreamboat<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Technosphere<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks in the United States. We have also applied for or have registered company trademarks in
other jurisdictions, including Europe and Japan. This document also contains trademarks and service marks of other companies that are the property of their respective owners. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_1"></A>Item&nbsp;1. </B><B><I>Business</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the words &#147;MannKind,&#148; &#147;we,&#148; &#147;Company,&#148; &#147;us&#148; and &#147;our&#148;
refer to MannKind Corporation and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MannKind Corporation is a biopharmaceutical company focused primarily on the
discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the &#147;FDA&#148;) on June&nbsp;27,
2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, approximately
29.1&nbsp;million people in the United States had diabetes in 2012. Globally, the International Diabetes Federation has estimated that approximately 415.0&nbsp;million people had diabetes in 2015 and approximately 642.0&nbsp;million people will have
diabetes by 2040. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes.
The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and delivers insulin quickly to the
bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;11, 2014, we entered into a
license and collaboration agreement (the &#147;Sanofi License Agreement&#148;) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the agreement to Sanofi-Aventis U.S. LLC (&#147;Sanofi&#148;)), pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2016, we received written notification from Sanofi of its election to terminate in its entirety the Sanofi License
Agreement. The effective date of termination was April&nbsp;4, 2016, which was when we assumed responsibility for worldwide development and commercialization of Afrezza. Under the terms of a transition agreement, Sanofi continued to fulfill orders
for Afrezza in the United States until we began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. We began recognizing commercial product sales revenue when MannKind-branded Afrezza was dispensed from pharmacies
to patients in August 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, we entered into a settlement agreement with Sanofi (the &#147;Settlement
Agreement&#148;). Under the terms of the Settlement Agreement, the promissory note (the &#147;Sanofi Loan Facility&#148;) between us and Aventisub LLC (&#147;Aventisub&#148;), a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive
the full outstanding loan balance of $72.0&nbsp;million, which includes $0.5&nbsp;million in the previously uncharged costs. Sanofi also agreed to purchase $10.2&nbsp;million of insulin from us in December 2016 under an existing insulin put option
as well as make a cash payment of $30.6&nbsp;million to us in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option,
without us being required to deliver any insulin for such payment. We were also relieved of our obligation to pay Sanofi $0.5&nbsp;million in previously uncharged costs pursuant to the Sanofi License Agreement. We and Sanofi also agreed to a general
release of potential claims against each other. As of the date of this filing, we have received $30.6&nbsp;million and $10.2&nbsp;million related to this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During our initial transition of the commercial responsibilities from Sanofi, we utilized a contract sales organization to promote Afrezza
while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance programs, a voucher program, data agreements and payor
relationships. In early 2017, we recruited our own sales force, which included some of the sales representatives that previously were employed by the contract sales organization. We intend to continue the commercialization of Afrezza in the United
States through our internal commercial organization. Our current strategy for the future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional
partnerships in foreign jurisdictions where there are appropriate commercial opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the approval of Afrezza, the FDA
required us to conduct certain post-marketing studies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An open-label PK and multiple-dose safety and tolerability dose-titration trial of Afrezza in pediatric patients ages 4 to 17 years with type 1 diabetes followed by a prospective, open-label, randomized, controlled
trial comparing the efficacy and safety of prandial Afrezza to prandial subcutaneous insulin as part used in combination with subcutaneous basal insulin in pediatric patients 4 to 17 years old with type 1 or type 2 diabetes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A five-year, randomized, controlled trial in <FONT STYLE="white-space:nowrap">8,000-10,000</FONT> patients with type 2 diabetes to assess the potential serious risk of pulmonary malignancy with Afrezza use.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation to complete the pediatric study and to conduct the five-year pulmonary safety study reverted to us when the
NDA for Afrezza was transferred back to us in connection with the termination of the Sanofi License Agreement. In addition, we plan to conduct other clinical studies of Afrezza, including dose optimization studies in type 1 and type 2 patients and a
study of the time that Afrezza patients remain within a desirable glycemic range as determined by continuous glucose monitoring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and
Supply </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We manufacture Afrezza in our Danbury, Connecticut facility, where we formulate the Afrezza inhalation powder, fill it into
plastic cartridges and then blister package the cartridges and seal the blister cards inside a foil </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
overwrap. These overwraps are then packaged into cartons along with inhalers and printed material by a third-party packager. The cartridges and inhalers are manufactured for us by a third-party
plastic-molding company; the cartridges are delivered to our Connecticut facility whereas the inhalers are shipped directly to the packaging contractor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The quality management systems of our Connecticut facility were certified to be in conformance with the ISO 13485 and ISO 9001 standards. Our
facility has been inspected twice by the FDA, once for a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection in the fall of 2009 and once for a regular inspection in May 2013. The FDA is expected to conduct additional inspections of our
facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our Connecticut facility has enough capacity to satisfy the current commercial demand for Afrezza. In addition,
the facility includes expansion space to accommodate additional filling lines and other equipment, allowing production capacity to be increased based on the demand for Afrezza over the next several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the only approved source of insulin for Afrezza is manufactured by Amphastar France Pharmaceuticals S.A.S. (&#147;Amphastar&#148;).
In April 2014, Amphastar acquired a manufacturing facility from N.V. Organon, a subsidiary of Merck&nbsp;&amp; Co., Inc., where we had previously obtained the insulin that we use to make Afrezza. On July&nbsp;31, 2014, we entered into a supply
agreement with Amphastar (the &#147;Insulin Supply Agreement&#148;), pursuant to which we agreed to purchase certain annual minimum quantities of insulin for calendar years 2015 through 2019 for an aggregate total purchase price of approximately
&#128;120.1&nbsp;million, of which &#128;93.0&nbsp;million remained unpurchased as of December&nbsp;31, 2016. On November&nbsp;9, 2016, we amended the contract with Amphastar to extend the term over which we are required to purchase insulin, by four
additional years, without reducing the total amount of insulin we will purchase. Unless earlier terminated, the term of the Insulin Supply Agreement now expires on December&nbsp;31, 2023 and can be renewed for additional, successive two year terms
upon 12 months written notice given prior to the end of the initial term or any additional two year term. We and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a
specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, we may terminate the Insulin Supply Agreement upon two years&#146; prior written notice to Amphastar without cause or upon 30 days prior
written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require
us to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we purchase the raw material for our proprietary excipient, FDKP (fumaryl diketopiperazine), which is the primary component of our
Technosphere technology platform, from a major chemical manufacturer with facilities in Europe and North America. However, we also have the capability to manufacture FDKP in our Connecticut facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a supply agreement with the contract manufacturer that produces our inhaler and the corresponding cartridges. We expect to be able to
qualify an additional vendor of plastic-molding contract manufacturing services, if warranted by demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have an agreement with
the contractor that performs the final packaging of Afrezza overwraps, inhalers and printed material into patient kits. We expect to be able to qualify an additional vendor of packaging services, if warranted by demand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party suppliers are subject to extensive governmental regulation. We rely on our suppliers to comply with relevant regulatory
requirements, including compliance with Current Good Manufacturing Practices (&#147;CGMP&#146;s&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Technosphere Formulation Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza utilizes our proprietary Technosphere formulation technology; however, the application of this technology is not limited to insulin
delivery. We believe it represents a versatile drug delivery platform that may allow the oral inhalation of a wide range of therapeutics. We have successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and
hydrophilic drugs, proteins, peptides and small molecules. Technosphere powders are based on our proprietary excipient, FDKP, which is a <FONT STYLE="white-space:nowrap">pH-sensitive</FONT> organic molecule that self-assembles into small particles
under acidic conditions. Certain drugs, such as insulin, can be loaded onto these particles by combining a solution of the drug with a suspension of Technosphere material, which is then dried to powder form. The resulting powder has a consistent and
narrow range of particle sizes with good aerodynamic properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve extremely fast after inhalation when the particles contact the moist lung surface with its neutral pH,
releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also created an innovative line of breath-powered, dry powder inhalers. Our inhalers are easy to use, cost-effective and can be
produced in both a reusable (chronic treatment) and a <FONT STYLE="white-space:nowrap">single-use</FONT> (acute treatment) format. Both the reusable and single use inhaler formats use the same internal
<FONT STYLE="white-space:nowrap">air-flow</FONT> design. Being breath-powered, our inhalers require only the patient&#146;s inhalation effort to deliver the powder. To administer the inhalation powder, a patient loads a cartridge into our inhaler
and inhales through the mouthpiece. Upon inhalation, the dry powder is lifted out of the cartridge and broken (or <FONT STYLE="white-space:nowrap">de-agglomerated)</FONT> into small particles. The inhalers are engineered to produce an aggressive
airstream to <FONT STYLE="white-space:nowrap">de-agglomerate</FONT> the powder while keeping the powder moving slowly. This slow-moving powder effectively navigates the patient&#146;s airways for delivery into the lung with minimal deposition at the
back of the throat. Our inhalers show very little change in performance over a wide range of inhalation efforts and produce high bioavailability. In a handling study, pediatric subjects as young as four years old were readily able to effectively use
the inhaler. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To aid in the development of our oral inhalation products, we have created a number of innovative development tools and
techniques. For example, our BluHale technology is a novel inhalation profiling tool that uses miniature sensors to assess the drug delivery process at the level of an individual inhaler. This tool provides real-time insight into patient usage,
device system performance and pharmacokinetic effects. We can combine this tool with other development tools, such as patient inhalation simulators and anatomically correct airway models, in order to integrate inhaler performance with formulation
development right from the beginning of the development program. The result is a powder/inhaler combination product customized to the target patient population from the first clinical study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As one example of an additional application of our formulation and delivery technologies, we entered into a collaboration and license
agreement with Receptor Life Sciences (&#147;Receptor&#148;) in January 2016, pursuant to which we performed initial formulation studies on compounds identified by Receptor that treat conditions such as chronic pain, neurologic diseases and
inflammatory disorders. Following the successful completion of these formulation studies, Receptor exercised its option to acquire an exclusive license to develop, manufacture and commercialize inhaled formulations of these compounds utilizing our
technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following are the key elements of our strategy: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Commercialization and development of Afrezza. </I>Our primary focus is the commercial
success of Afrezza. Over the course of the last year, we have transformed from a manufacturing-based company into an integrated company with new capabilities in marketing, sales, managed care and market access. During the second half of 2016, we
undertook a number of initiatives, such as launching a new marketing campaign, expanding the patient assistance program, creating a robust speakers program, introducing new product packages that enhance dosing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
flexibility and securing improved insurance coverage, all of which are expected to increase the promotional responsiveness of Afrezza. Our current priority is the commercial opportunity for
Afrezza in the United States; however, in the future we also intend to seek regional partnerships for the development and commercialization of Afrezza in foreign jurisdictions where there are appropriate commercial opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Capitalize on our proprietary Technosphere and inhaler technology for the delivery of active pharmaceutical ingredients. </I>We believe
that Technosphere formulations of active pharmaceutical ingredients have the potential to demonstrate clinical advantages over existing therapeutic options in a variety of therapeutic areas. In addition to our collaboration with Receptor, we are
actively exploring other opportunities to <FONT STYLE="white-space:nowrap">out-license</FONT> our proprietary Technosphere formulation and device technologies. We are also evaluating several product opportunities that we would consider developing as
internally and/or externally funded efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend in large measure on our ability to continue enforcing our intellectual property rights, effectively maintain our trade
secrets and avoid infringing the proprietary rights of third parties. Our policy is to file patent applications on what we deem to be important technological developments that might relate to our product candidates or methods of using our product
candidates and to seek intellectual property protection in the United States, Europe, Japan and selected other jurisdictions for all significant inventions. We have obtained, are seeking, and will continue to seek patent protection on the
compositions of matter, methods and devices flowing from our research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Technosphere drug delivery platform,
including Afrezza, enjoys patent protection relating to the particles, their manufacture, and their use for pulmonary delivery of drugs. We have additional patent coverage relating to dry powder formulations and the treatment of diabetes using
Afrezza. We have been granted patent coverage for the commercial version of our inhaler and cartridges. We have additional pending patent applications, and expect to file further applications, relating to the drug delivery platform, methods of
manufacture, the Afrezza product and its use, and other Technosphere-based products, inhalers and inhaler cartridges. Overall, Afrezza is protected by over 425 issued patents in the United States and selected jurisdictions around the world and we
also have over 250 applications pending that may provide additional protection if and when they are allowed. These include composition and inhaler and cartridge patents providing protection for Afrezza with various expiration dates, the longer-lived
of which will not expire until 2032. In addition, we have certain method of treatment claims that have terms extending into 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
field of pulmonary drug delivery is crowded and a substantial number of patents have been issued in these fields. In addition, because patent positions can be highly uncertain and frequently involve complex legal and factual questions, the breadth
of claims obtained in any application or the enforceability of issued patents cannot be confidently predicted. Further, there can be substantial delays in commercializing pharmaceutical products, which can partially consume the statutory period of
exclusivity through patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the coverage claimed in a patent application can be significantly reduced before a patent is
issued, either in the United States or abroad. Statutory differences in patentable subject matter may limit the protection we can obtain on some of our inventions outside of the United States. For example, methods of treating humans are not
patentable in many countries outside of the United States. These and other issues may limit the patent protection we are able to secure internationally. Consequently, we do not know whether any of our pending or future patent applications will
result in the issuance of patents or, to the extent patents have been issued or will be issued, whether these patents will be subjected to further proceedings limiting their scope, will provide significant proprietary protection or competitive
advantage, or will be circumvented or invalidated. Furthermore, patents already issued to us or our pending applications may become subject to disputes that could be resolved against us. In addition, in certain countries, including the United
States, applications are generally published 18 months after the application&#146;s priority date. In any event, because publication of discoveries in scientific or patent literature often trails behind actual discoveries, we cannot be certain that
we were the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inventor of the subject matter covered by our pending patent applications or that we were the first to file patent applications on such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we own a number of domestic and foreign patents and patent applications relating to Afrezza and our oral inhalation technologies, we
have identified certain third-party patents having claims that may trigger an allegation of infringement by virtue of the commercial manufacture and sale of Afrezza. We do not believe that Afrezza infringes on any patents owned by third parties.
However, if a court were to determine that the manufacture or sale of Afrezza were infringing any of these patent rights, we would have to establish with the court that these patents were invalid in order to avoid legal liability for infringement of
these patents. Proving patent invalidity can be difficult because issued patents are presumed valid. Therefore, in the event that we are unable to prevail in an infringement or invalidity action we will either have to acquire the third-party patents
outright or seek a royalty-bearing license. Royalty-bearing licenses effectively increase costs and therefore may materially affect product profitability. Furthermore, if the patent holder refuses to either assign or license us the infringed
patents, it may be necessary to cease manufacturing the product entirely and/or design around the patents. In either event, our business would be harmed and our profitability could be materially adversely impacted. If third parties file patent
applications, or are issued patents claiming technology also claimed by us in pending applications, we may be required to participate in interference proceedings in the United States Patent and Trademark Office (&#147;USPTO&#148;) to determine
priority of invention. We may also be required to participate in interference proceedings involving our issued patents. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> which are not protected by patents, to
maintain our competitive position. We require our officers, employees, consultants and advisors to execute proprietary information and invention and assignment agreements upon commencement of their relationships with us. These agreements provide
that all confidential information developed or made known to the individual during the course of our relationship must be kept confidential, except in specified circumstances. These agreements also provide that all inventions developed by the
individual on behalf of us must be assigned to us and that the individual will cooperate with us in connection with securing patent protection on the invention if we wish to pursue such protection. There can be no assurance, however, that these
agreements will provide meaningful protection for our inventions, trade secrets or other proprietary information in the event of unauthorized use or disclosure of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also execute confidentiality agreements with outside collaborators. However, disputes may arise as to the ownership of proprietary rights
to the extent that outside collaborators apply technological information to our projects that are developed independently by them or others, or apply our technology to outside projects, and there can be no assurance that any such disputes would be
resolved in our favor. In addition, any of these parties may breach the agreements and disclose our confidential information or our competitors might learn of the information in some other way. If any trade secret,
<FONT STYLE="white-space:nowrap">know-how</FONT> or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business, results of operations and financial condition could be adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
pharmaceutical and biotechnology industries are highly competitive and characterized by rapidly evolving technology and intense research and development efforts. We compete with companies, including major global pharmaceutical companies, and other
institutions that have substantially greater financial, research and development, marketing and sales capabilities and have substantially greater experience in undertaking preclinical and clinical testing of products, obtaining regulatory approvals
and marketing and selling biopharmaceutical products. We face competition based on, among other things, product efficacy and safety, the timing and scope of regulatory approvals, product ease of use and price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Diabetes Treatments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe
that Afrezza has important competitive advantages in the delivery of insulin when compared with currently known alternatives. However, new drugs or further developments in alternative drug delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
methods may provide greater therapeutic benefits, or comparable benefits at lower cost, than Afrezza. There can be no assurance that existing or new competitors will not introduce products or
processes competitive with or superior to our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have set forth below more detailed information about certain of our
competitors. The following is based on information currently available to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapid-acting (Injected) Insulin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there is no approved insulin product that is absorbed into the bloodstream as rapidly as Afrezza, i.e., reaching peak levels within
12 to 15 minutes after administration. There are several formulations of &#147;rapid-acting&#148; insulin analogs that reach peak insulin levels within 45 to 90 minutes after injection. The principal products in this category are insulin lispro,
which is marketed by Eli Lilly&nbsp;&amp; Company, or Lilly; insulin aspart, which is marketed by Novo Nordisk A/S, or Novo Nordisk; and insulin glulisine, which is marketed by Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2017, Novo Nordisk announced that Fiasp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a faster formulation of insulin
aspart, was approved in Europe and Canada. It is currently undergoing regulatory review in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inhaled Insulin Delivery Systems
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2006, Exubera<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, developed by Pfizer in collaboration with
Nektar Therapeutics, Inc., was approved for the treatment of adults with type 1 and type 2 diabetes. Exubera<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> was slow to gain market acceptance and, in October 2007, Pfizer announced that it
was discontinuing the product. Pfizer subsequently withdrew the NDA for Exubera from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2008, Novo Nordisk announced
that it was halting development of its inhaled insulin product, having reached the conclusion that the product did not have adequate commercial potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2008, Lilly announced that it was terminating the development of its AIR<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
inhaled insulin system. Lilly stated that this decision resulted from increasing uncertainties in the regulatory environment and after a thorough evaluation of the evolving commercial and clinical potential of its product compared to existing
medical therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dance Biopharm, Inc. has completed Phase 2 clinical studies of an inhaled insulin product that utilizes a liquid
formulation of human insulin, dispensed through a handheld electronic aerosol device. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-insulin</FONT>
Medications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza also competes with currently available <FONT STYLE="white-space:nowrap">non-insulin</FONT> medication products
for type 2 diabetes. These products include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">GLP-1</FONT> agonists, such as exenatide or liraglutide, which mimic a naturally occurring hormone that stimulates the pancreas to secrete insulin when blood glucose levels are high.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Inhibitors of dipeptidyl peptidase IV, such as sitagliptin or saxagliptin, are a class of drugs that work by blocking the enzyme that normally degrades <FONT STYLE="white-space:nowrap">GLP-1.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sulfonylureas and meglitinides, which are classes of drugs that act on the pancreatic cells to stimulate the secretion of insulin. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Thiazolidinediones, such as pioglitizone and biguanides, such as metformin, which lower blood glucose by improving the sensitivity of cells to insulin, or diminishing insulin resistance. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Alpha-glucosidase inhibitors, which lower the amount of glucose absorbed from the intestines, thereby reducing the rise in blood glucose that occurs after a meal. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">SGLT-2</FONT> inhibitors, such as dapagliflozin and canagliflozin, are a class of medications that lower blood glucose by increasing glucose excretion in urine. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable regulatory agencies in state, local and foreign jurisdictions impose substantial requirements upon the clinical
development, manufacture and marketing of medical devices and new drug and biologic products. These agencies, through regulations that implement the Federal Food, Drug and Cosmetic Act, as amended (&#147;FDCA&#148;), and other regulations, regulate
research and development activities and the development, testing, manufacture, labeling, storage, shipping, approval, recordkeeping, advertising, promotion, sale and distribution of such products. In addition, if any of our products are marketed
abroad, they will also be subject to export requirements and to regulation by foreign governments. The regulatory approval process is generally lengthy, expensive and uncertain. Failure to comply with applicable FDA and other regulatory requirements
can result in sanctions being imposed on us or the manufacturers of our products, including hold letters on clinical research, civil or criminal fines or other penalties, product recalls, or seizures, or total or partial suspension of production or
injunctions, refusals to permit products to be imported into or exported out of the United States, refusals of the FDA to grant approval of drugs or to allow us to enter into government supply contracts, withdrawals of previously approved marketing
applications and criminal prosecutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The steps typically required before an unapproved new drug or biologic product for use in humans
may be marketed in the United States include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Preclinical studies that include laboratory evaluation of product chemistry and formulation, as well as animal studies to assess the potential safety and efficacy of the product. Certain preclinical tests must be
conducted in compliance with good laboratory practice regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, or requiring such studies to be repeated. In some cases, long-term preclinical studies are
conducted while clinical studies are ongoing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of an investigational new drug application (&#147;IND&#148;), which must become effective before human clinical trials may commence. The results of the preclinical studies are submitted to the FDA
as part of the IND. Unless the FDA objects and places a clinical hold, the IND becomes effective 30 days following receipt by the FDA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Approval of clinical protocols by independent institutional review boards (&#147;IRBs&#148;) at each of the participating clinical centers conducting a study. The IRBs consider, among other things, ethical factors, the
potential risks to individuals participating in the trials and the potential liability of the institution. The IRB also approves the consent form signed by the trial participants. The IRB of FDA may place a trial on hold at any time if it believes
the risks to subjects outweigh the potential benefits. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the product. Clinical trials involve the administration of the drug to healthy volunteers or to patients under the supervision
of a qualified medical investigator according to an approved protocol. The clinical trials are conducted in accordance with protocols that detail the objectives of the study, the parameters to be used to monitor participant safety and efficacy or
other criteria to be evaluated. Each protocol is submitted to the FDA as part of the IND. Human clinical trials are typically conducted in the following four sequential phases that may overlap or be combined: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In Phase 1, the drug is initially introduced into a small number of individuals and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion. Phase 1 clinical trials are often conducted in healthy human volunteers and such cases do not provide evidence of efficacy. In the case of severe or life-threatening diseases, the
initial human testing is often conducted in patients rather than healthy volunteers. Because these patients already have the target disease, these studies may provide initial evidence of efficacy that would traditionally be obtained in Phase 2
clinical trials. Consequently, these types of trials are frequently referred to as Phase 1/2 clinical </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
trials. The FDA receives reports on the progress of each phase of clinical testing and it may require the modification, suspension or termination of clinical trials if it concludes that an
unwarranted risk is presented to patients or healthy volunteers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 involves clinical trials in a limited patient population to further identify any possible adverse effects and safety risks, to determine the efficacy of the product for specific targeted diseases and to
determine dosage tolerance and optimal dosage. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3 clinical trials are undertaken to further evaluate dosage, clinical efficacy and to further test for safety in an expanded patient population at geographically dispersed clinical study sites. Phase 3 clinical
trials usually include a broader patient population so that safety and efficacy can be substantially established. Phase 3 clinical trials cannot begin until Phase 2 evaluation demonstrates that a dosage range of the product may be effective and has
an acceptable safety profile. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 4 clinical trials are performed if the FDA requires, or a company pursues, additional clinical trials after a product is approved. These clinical trials may be made a condition to be satisfied after a drug
receives approval. The results of Phase 4 clinical trials can confirm the effectiveness of a product and can provide important safety information to augment the FDA&#146;s voluntary adverse event reporting system. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Concurrent with clinical trials and preclinical studies, companies also must develop information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in
accordance with the FDA&#146;s current good manufacturing practices (&#147;cGMPs&#148;), requirements for drug products. The manufacturing process must be capable of consistently producing quality batches of the product and the manufacturer must
develop methods for testing the quality, purity and potency of the final products. Additionally, appropriate packaging must be selected and tested and chemistry stability studies must be conducted to demonstrate that the product does not undergo
unacceptable deterioration over its shelf-life. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of an NDA based on the clinical trials. The results of product development, preclinical studies and clinical trials are submitted to the FDA in the form of an NDA for approval of the marketing and
commercial shipment of the product. Under the Pediatric Research Equity Act, NDAs are required to include an assessment, generally based on clinical study data, of the safety and efficacy of drugs for all relevant pediatric populations. The statute
provides for waivers or deferrals in certain situations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its review of an NDA, the FDA may also convene an advisory
committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data. The FDA may delay approval of an NDA if applicable regulatory criteria are not satisfied and/or the FDA
requires additional testing or information. Before approving an NDA, the FDA may inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facility complies with cGMPs and will also inspect
clinical trial sites for integrity of data supporting safety and efficacy. The FDA will issue either an approval of the NDA or a Complete Response Letter, detailing the deficiencies and information required in order for reconsideration of the NDA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical products containing a combination of new drugs, biological products, or medical devices are regulated as &#147;combination
products&#148; in the United States. A combination product generally is defined as a product comprised of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). Each component of a combination product
is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic, or device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing
and approval process requires substantial time, effort and financial resources. Data that we submit are subject to varying interpretations, and the FDA and comparable regulatory authorities in foreign
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions may not agree that our product candidates have been shown to be safe and effective. We cannot be certain that any approval of our investigational products will be granted on a
timely basis, if at all. For an approved product such as Afrezza, we are subject to continuing regulation by the FDA, including post marketing study commitments or requirements, risk evaluation and mitigation strategies, record-keeping requirements,
reporting of adverse experiences with the product, submitting other periodic reports, drug sampling and distribution requirements, notifying the FDA and gaining its approval of certain manufacturing or labeling changes, and complying with certain
electronic records and signature requirements. Prior to and following approval, if granted, all manufacturing sites are subject to inspection by the FDA and other national regulatory bodies and must comply with cGMP, QSR and other requirements
enforced by the FDA and other national regulatory bodies through their facilities inspection program. Foreign manufacturing establishments must comply with similar regulations. In addition, our drug-manufacturing facilities located in Danbury and
the facilities of our insulin supplier, the supplier(s) of FDKP and the supplier(s) of our inhaler and cartridges are subject to federal registration and listing requirements and, if applicable, to state licensing requirements. Failure, including
those of our suppliers, to obtain and maintain applicable federal registrations or state licenses, or to meet the inspection criteria of the FDA or the other national regulatory bodies, would disrupt our manufacturing processes and would harm our
business. In complying with standards set forth in these regulations, manufacturers must continue to expend time, money and effort in the area of production and quality control to ensure full compliance. Numerous device regulatory requirements apply
to the device part of a drug-device combination. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general prohibition against promoting products for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corrections and removals (<I>e.g</I>., recalls); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment registration and device listing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general prohibitions against the manufacture and distribution of adulterated and misbranded devices; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Medical Device Reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause
or contribute to a death or serious injury if it were to recur. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the supplier we contract with to manufacture our
inhaler and cartridges is subject to QSRs, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process of medical devices, among other requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to adhere to regulatory requirements at any stage of development, including the preclinical and clinical testing process, the
review process, or at any time afterward, including after approval, may result in various adverse consequences. These consequences include action by the FDA or another national regulatory body that has the effect of delaying approval or refusing to
approve a product; suspending or withdrawing an approved product from the market; seizing or recalling a product; or imposing criminal penalties against the manufacturer. In addition, later discovery of previously unknown problems may result in
restrictions on a product, its manufacturer, or the NDA holder, or market restrictions through labeling changes or product withdrawal. Also, new government requirements may be established or current government requirements may be changed at any
time, which could delay or prevent regulatory approval of our products under development. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either
in the United States or abroad. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA imposes a number of complex regulations on entities that advertise and promote
drugs, which include, among other requirements, standards for and regulations of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT>
promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA has very broad enforcement authority under the FDCA, and failure to comply with these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations can result in penalties, including the issuance of a warning letter requirements for corrective advertising to healthcare providers, a requirement that future advertising and
promotional materials be <FONT STYLE="white-space:nowrap">pre-cleared</FONT> by the FDA, and state and federal civil and criminal investigations and prosecutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as
regulation by the country in which the products are to be sold. We also would be subject to foreign regulatory requirements governing clinical trials and drug product sales if products are studied or marketed abroad. Whether or not FDA approval has
been obtained, approval of a product by the comparable regulatory authorities of foreign countries usually must be obtained prior to the marketing of the product in those countries. The approval process varies from jurisdiction to jurisdiction and
the time required may be longer or shorter than that required for FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the current regulatory
framework will not change or that additional regulation will not arise at any stage of our product development or marketing that may affect approval, delay the submission or review of an application or require additional expenditures by us. There
can be no assurance that we will be able to obtain necessary regulatory clearances or approvals on a timely basis, if at all, for any of our product candidates under development, and delays in receipt or failure to receive such clearances or
approvals, the loss of previously received clearances or approvals, or failure to comply with existing or future regulatory requirements could have a material adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, we are subject to numerous federal, state and local laws relating to such matters as laboratory practices, the
experimental use of animals, the use and disposal of hazardous or potentially hazardous substances, controlled drug substances, privacy of individually identifiable healthcare information, safe working conditions, manufacturing practices,
environmental protection and fire hazard control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare Regulatory and Pharmaceutical Pricing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government coverage and reimbursement policies both directly and indirectly affect our ability to successfully commercialize our approved
products, and such coverage and reimbursement policies will be affected by future healthcare reform measures. Third-party payors, like government health administration authorities, private health insurers and other organizations that provide
healthcare coverage, generally decide which drugs they will pay for and establish reimbursement levels for covered drugs. In particular, in the United States, private third-party payors often provide reimbursement for products and services based on
the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. In the United States, the European Union and other potentially significant markets for our product candidates, government
authorities and other third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices.
Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may
adversely affect our future product sales and results of operations. Recently, in the United States there has been heightened governmental scrutiny of the manner in which drug manufacturers set prices for their marketed products. For example, there
have been several recent U.S. Congressional inquiries regarding certain drug manufacturers&#146; pricing practices and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing
and manufacturer patient programs, reduce the cost of drugs under Medicare and reform government program reimbursement methodologies for drugs. Pricing pressures can arise from rules and practices of managed care organizations, judicial decisions
and governmental laws and regulations related to Medicare, Medicaid, healthcare reform, pharmaceutical reimbursement policies and pricing in general. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions have enacted or are considering a number of additional legislative and regulatory proposals
to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including, most recently, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
(collectively, &#147;PPACA&#148;), enacted in March 2010. The Physician Payments Sunshine Act within PPACA, and its implementing regulations, require certain manufacturers of drugs, devices, biological and medical supplies for which payment is
available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or
to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if a drug product is reimbursed by Medicare, Medicaid or other federal or state healthcare programs, we must comply with, among
others, the federal civil and criminal false claims laws, including the civil False Claims Act, as amended, the federal Anti-Kickback Statute, as amended, and similar state laws. If a drug product is reimbursed by Medicare or Medicaid, pricing and
rebate programs must comply with, as applicable, the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Medicare Prescription Drug Improvement and Modernization Act of 2003. Additionally, PPACA
substantially changed the way healthcare is financed by both governmental and private insurers. Among other cost containment measures, PPACA established: an annual, nondeductible fee on any entity that manufactures or imports certain branded
prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that increased the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. There have been judicial and Congressional
challenges to certain aspects of PPACA. As a result there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the PPACA. In January 2017, President Trump signed an Executive Order directing federal
agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare
providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Further, in January 2017, Congress adopted a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that
would repeal portions of the PPACA. Following the passage of the Budget Resolution, in March 2017, the U.S. House of Representatives introduced legislation known as the American Health Care Act, which, if enacted, would amend or repeal significant
portions of the PPACA. Among other changes, the American Health Care Act would repeal the annual fee on certain brand prescription drugs and biologics imposed on manufacturers and importers, eliminate the 2.3% excise tax on medical devices,
eliminate penalties on individuals and employers that fail to maintain or provide minimum essential coverage, and create refundable tax credits to assist individuals in buying health insurance. The American Health Care Act would also make
significant changes to Medicaid by, among other things, making Medicaid expansion optional for states, repealing the requirement that state Medicaid plans provide the same essential health benefits that are required by plans available on the
exchanges, modifying federal funding, including implementing a per capita cap on federal payments to states, and changing certain eligibility requirements. Other legislative changes have been proposed and adopted in the United States since PPACA.
For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2%&nbsp;per fiscal year, which went into effect in April 2013 and, following passage of the Bipartisan
Budget Act of 2015, will remain in effect through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare
payments to several providers. In the future, there are likely to be additional proposals relating to the reform of the U.S. health care system, some of which could further limit the prices we are able to charge for our products, or the amounts of
reimbursement available for our products. If drug products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also
potentially subject to federal and state consumer protection and unfair competition laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal
government and the states in which we conduct our business. The federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), as amended by the Health Information Technology and Clinical Health Act (&#147;HITECH&#148;),
and their respective implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security
standards directly applicable to &#147;business associates&#148; &#151; independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity.
HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in
federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of
which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many
states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, that apply regardless of the payer. Additional state laws require pharmaceutical
companies to implement a comprehensive compliance program and/or limit expenditure for, or payments to, individual medical or health professionals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may incur significant costs to comply with these laws and regulations now or in the future. If our operations are found to be in violation
of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment,
disgorgement, exclusion of products from reimbursement under government programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
research and development expenses totaled $14.9&nbsp;million, $29.7&nbsp;million and $100.2&nbsp;million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Lived Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-lived assets
are located in the United States and totaled $28.9&nbsp;million, $48.7&nbsp;million and $192.1&nbsp;million as of December&nbsp;31, 2016, 2015 and 2014, respectively. Our long-lived assets as of December&nbsp;31, 2016 do not include an asset held
for sale totaling $16.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had 153 full-time employees, of which 66 were engaged in manufacturing, 34 in research and development, 30 in
general and administrative and 23 in selling and marketing. Fifteen of these employees had a Ph.D. degree and/or M.D. degree and were engaged in activities relating to research and development, manufacturing, quality assurance or business
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our employees is subject to a collective bargaining agreement. We believe relations with our employees are good.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in the State of Delaware on February&nbsp;14, 1991. Our principal executive offices are located at 25134 Rye Canyon Loop Suite 300, Valencia, California 91355, and our telephone number at that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address is <FONT STYLE="white-space:nowrap">(661)&nbsp;775-5300.</FONT> MannKind Corporation and the MannKind Corporation logo are our service marks. Our website address is
http://www.mannkindcorp.com. Our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and
amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available free of charge on our website as soon as reasonably practicable after we electronically file such
material with, or furnish it to, the SEC. The contents of these websites are not incorporated into this Annual Report. Further, our references to the URLs for these websites are intended to be inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2017, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment to our Amended and Restated
Certificate of Incorporation (the &#147;Charter Amendment&#148;) to (i)&nbsp;implement a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-five</FONT></FONT> reverse stock split of our outstanding common stock (the
&#147;Reverse Stock Split&#148;), without any change in par value per share, and (ii)&nbsp;reduce the authorized number of shares of our common stock from 700,000,000 to 140,000,000 shares, as previously authorized and approved at a special meeting
of stockholders on March&nbsp;1, 2017. The Charter Amendment became effective at 5:01 p.m. Eastern Time on March&nbsp;2, 2017 (the &#147;Effective Time&#148;). No fractional shares were issued in connection with the Reverse Stock Split. Instead, we
issued one full share of the post-Reverse Stock Split common stock to any stockholder of record who was entitled to receive a fractional share as a result of the process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and the number of shares issuable
upon the exercise or vesting of all stock options, restricted stock units and warrants issued by us and outstanding immediately prior to the Effective Time, which resulted in a proportionate decrease in the number of shares of our common stock
reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportionate increase in the exercise price of all such stock options and warrants. In
addition, the number of shares authorized for future grant under our equity incentive/compensation plans immediately prior to the Effective Time were reduced proportionately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2017, our common stock began trading on The NASDAQ Global Market on a split-adjusted basis. All references to shares of
common stock, all per share data, and all warrant, stock option and restricted stock unit activity for all periods presented in this Annual Report have been adjusted to reflect the Reverse Stock Split on a retroactive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek advice from
a number of leading scientists and physicians on scientific, technical and medical matters. These advisors are leading scientists in the areas of pharmacology, chemistry, immunology and biology. Our scientific advisors are consulted regularly to
assess, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design and implementation of our clinical programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patent and publication strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market opportunities from a clinical perspective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new technologies relevant to our research and development programs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specific scientific and technical issues relevant to our business. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers of the Registrant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our current executive officers and their ages: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="60%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.90pt; font-size:8pt; font-family:Times New Roman"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew J. Pfeffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, Chief Financial Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael E. Castagna, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Kocinsky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David B. Thomson, Ph.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, General Counsel and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stuart A. Tross, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, Chief People Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond W. Urbanski, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosabel R. Alinaya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Principal Accounting Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Matthew J. Pfeffer </I>has served as our Chief Executive Officer and one of our directors since January
2016 and as our Chief Financial Officer since April 2008. Mr.&nbsp;Pfeffer also served as our Corporate Vice President from April 2008 until January 2016. Previously, Mr.&nbsp;Pfeffer served as Chief Financial Officer and Senior Vice President of
Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr.&nbsp;Pfeffer served as CFO of Cell Genesys,
Inc. During his nine year tenure at Cell Genesys, Mr.&nbsp;Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr.&nbsp;Pfeffer served in a variety of financial management positions at other companies, including
roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr.&nbsp;Pfeffer began his career at Price Waterhouse. Mr.&nbsp;Pfeffer graduated from the University of California, Berkeley and is a Certified Public
Accountant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Michael E. Castagna, Pharm.D. </I>has been our Corporate Vice President, Chief Commercial Officer since March 2016. From
November 2012 until he joined us, Dr.&nbsp;Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen&#146;s Biosimilar Business Unit.
From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Co. Before BMS, Dr.&nbsp;Castagna served as Vice President&nbsp;&amp; Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial
responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy&nbsp;&amp;
Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph Kocinsky </I>has been our Corporate
Vice President, Chief Technology Officer since October 2015<I>. </I>Mr.&nbsp;Kocinsky has over 28 years of experience in the pharmaceutical industry in technical operations and product development. Prior to joining us in 2003, he held a variety of
technical and management positions with increased responsibility at Schering-Plough Corp. Mr.&nbsp;Kocinsky holds a bachelor&#146;s degree in chemical engineering and a master&#146;s degree in Biomedical Engineering from New Jersey Institute of
Technology and a master&#146;s degree in business administration from Seton Hall University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David B. Thomson, Ph.D., J.D. </I>has
been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr.&nbsp;Thomson was a
post-doctoral fellow at the Rockefeller University. Dr.&nbsp;Thomson obtained his bachelor&#146;s degree, master&#146;s degree and Ph.D. from Queens University and obtained his J.D. from the University of Toronto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stuart A. Tross, Ph.D. </I>has been our Corporate Vice President, Chief People Officer since December 2016, with responsibilities for human
resources, information technology and west coast facilities. From 2006 to 2016 he served in various roles of increasing responsibility at Amgen, Inc., most recently as Senior Vice President and Chief Human Resources Officer responsible for human
resources and security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb Co, most recently as Vice President and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organizational Psychology from the Georgia
Institute of Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Raymond W. Urbanski, M.D., Ph.D.</I> has been our Chief Medical Officer since August 2015. Prior to joining
us, he served as Chief Medical Officer at Mylan, Inc. from September 2012 to September 2014 and Chief Medical Officer at Metabolex, Inc. from October 2011 to June 2012. From June 2004 to October 2011, Dr.&nbsp;Urbanski held several positions with
Pfizer Inc. most recently as Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of Research and Development and Chief Medical Officer at Suntory Pharmaceutical, Inc. Dr.&nbsp;Urbanski earned
both his M.D. and Ph.D. in pharmacology and toxicology at the University of Medicine and Dentistry of New Jersey. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ros</I><I>abel R.</I><I> Alinaya </I>has been our Senior Vice President, Principal Accounting Officer since January 2016 with
responsibility for finance, accounting, tax, treasury, investor relations and risk management. Previously, she was our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003. Ms. Alinaya began her career
at Deloitte &amp; Touche LLP, graduating from California State University, Northridge and is a Certified Public Accountant. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of
Certified Public Accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive officers serve at the discretion of our Board of Directors. There are no family relationships
between any of our directors and executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_2"></A>Item&nbsp;1A. </B><B><I>Risk Factors</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the following information about the risks described below, together with the other information contained in
this Annual Report before you decide to buy or maintain an investment in our common stock. We believe the risks described below are the risks that are material to us as of the date of this Annual Report. Additional risks and uncertainties that we
are unaware of may also become important factors that affect us. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In
these circumstances, the market price of our common stock could decline, and you may lose all or part of the money you paid to buy our common stock. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR BUSINESS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to
raise additional capital to fund our operations, and our inability to do so could raise substantial doubt about our ability to continue as a going concern. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report includes disclosures stating that our existing cash resources and our accumulated stockholders&#146; deficit raise substantial
doubt about our ability to continue as a going concern.&nbsp;We will need to raise additional capital, whether through the sale of equity or debt securities, additional strategic business collaborations, the establishment of other funding
facilities, licensing arrangements, asset sales or other means, in order to support our ongoing activities, including the commercialization of Afrezza and the development of our product candidates, and to avoid defaulting under the covenant in our
facility agreement with Deerfield Private Design Fund II, L.P. (&#147;Deerfield Private Design Fund&#148;) and Deerfield Private Design International II, L.P. (collectively, &#147;Deerfield&#148;) dated July&nbsp;1, 2013 (as amended, the
&#147;Facility Agreement&#148;), which requires us to maintain at least $25.0&nbsp;million in cash and cash equivalents or available borrowings under the loan arrangement, dated as of October&nbsp;2, 2007, between us and The Mann Group LLC (as
amended, restated, or otherwise modified as of the date hereof, &#147;The Mann Group Loan Arrangement&#148;), as of the last day of each fiscal quarter. It may be difficult for us to raise additional funds on favorable terms, or at all. As of
December&nbsp;31, 2016, we had cash and cash equivalents of $22.9&nbsp;million and a stockholders&#146; deficit of $183.6&nbsp;million, which raises concerns about our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solvency and ability to continue as a going concern. The extent of our additional funding requirements will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree to which Afrezza is commercially successful; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree to which we are able to generate revenue from our Technosphere drug delivery platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of developing and commercializing Afrezza on our own in the United States, including the costs of building our commercialization capabilities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of finding regional collaboration partners for the development and commercialization of Afrezza in foreign jurisdictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demand by any or all of the holders of the 5.75% Convertible Senior Subordinated Exchange Notes due 2018 (the &#147;2018 notes&#148;), the 9.75% Senior Convertible Notes due 2019 issued to Deerfield (the &#147;2019
notes&#148;), and the 8.75% Senior Convertible Notes due 2019 issued to Deerfield (the &#147;Tranche B notes&#148;) to require us to repay or repurchase such debt securities if and when required; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to repay or refinance existing indebtedness, and the extent to which the 2018 notes or any other convertible debt securities we may issue are converted into or exchanged for shares of our common stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress and costs of our clinical studies and research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of procuring raw materials and operating our manufacturing facilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our obligation to make milestone payments pursuant to the milestone rights issued to Deerfield Private Design Fund and Horizon Sant&eacute; FLML S&Aacute;RL (collectively, the &#147;Milestone Purchasers&#148;) and
pursuant to the Milestone Rights Purchase Agreement dated July&nbsp;1, 2013 (the &#147;Milestone Agreement&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in establishing strategic business collaborations or other sales or licensing of assets, and the timing and amount of any payments we might receive from any such transactions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actions taken by the FDA and other regulatory authorities affecting Afrezza and our product candidates and competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of competing technologies and products and other market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights or defending against claims of infringement by others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of our legal and litigation expenses; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of discontinuing projects and technologies, and/or decommissioning existing facilities, if we undertake any such activities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have raised capital in the past through the sale of equity and debt securities and we may in the future pursue the sale of additional
equity and/or debt securities, or the establishment of other funding facilities including asset-based borrowings. There can be no assurances, however, that we will be able to raise additional capital on acceptable terms, or at all. Issuances of
additional debt or equity securities or the conversion of any of our currently outstanding convertible debt securities into shares of our common stock or the exercise of our currently outstanding warrants for shares of our common stock could impact
the rights of the holders of our common stock and will dilute their ownership percentage. Moreover, the establishment of other funding facilities may impose restrictions on our operations. These restrictions could include limitations on additional
borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments. We also will need to raise additional capital by pursuing opportunities for
the licensing or sale of certain intellectual property and other assets. We cannot offer assurances, however, that any strategic collaborations, sales of securities or sales or licenses of assets will be available to us on a timely basis or on
acceptable terms, if at all. We may be required to enter into relationships </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop independently, and any such relationships may not be on terms as
commercially favorable to us as might otherwise be the case. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that sufficient additional funds are not obtained through
strategic collaboration opportunities, sales of securities, funding facilities, licensing arrangements and/or asset sales on a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment of our projects, or
further reduction of costs for facilities and administration. Moreover, if we do not obtain such additional funds, there will be substantial doubt about our ability to continue as a going concern and increased risk of insolvency and loss of
investment to the holders of our securities. As of the date hereof, we have not obtained a solvency opinion or otherwise conducted a valuation of our properties to determine whether our debts exceed the fair value of our property within the meaning
of applicable solvency laws. If we are or become insolvent, holders of our common stock or other securities may lose the entire value of their investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that changed or unexpected circumstances will not result in the depletion of our capital resources more rapidly
than we currently anticipate, in which case we will be required to raise additional capital. There can be no assurances that we will be able to raise additional capital on favorable terms, or at all. If we are unable to raise adequate additional
capital we will be required to reduce expenses through the delay, reduction or curtailment of our projects, or further reduction of costs for facilities and administration, and there will continue to be substantial doubt about our ability to
continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our prospects are heavily dependent on the successful commercialization of our only approved product, Afrezza. The
continued commercialization and development of Afrezza will require substantial capital that we may not be able to obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
expended significant time, money and effort in the development of our only approved product, Afrezza. We anticipate that in the near term our prospects and ability to generate significant revenues will heavily depend on our ability to successfully
commercialize Afrezza in the United States.&nbsp;We anticipate that our near term revenues will also, to a much lesser extent, depend on our ability to enter into licensing arrangements for our Technosphere platform technology that involve license,
milestone, royalty or other payments to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assumed responsibility for worldwide commercialization of Afrezza in April 2016, prior to
which time Sanofi was responsible for global commercial activities for Afrezza. We began distributing Afrezza in the United States in late July 2016, and intend to continue the commercialization of Afrezza in the United States through our own
commercial organization.&nbsp;Successful commercialization of Afrezza is subject to many risks and there are many factors that could cause the commercialization of Afrezza to be unsuccessful, including a number of factors that are outside our
control. We ultimately may be unable to gain market acceptance of Afrezza for a variety of reasons, including the treatment and dosage regimen, potential adverse effects, relative pricing compared with alternative products, the availability of
alternative treatments and lack of coverage or adequate reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never, as an organization, launched or commercialized a
product other than Afrezza, and there is no guarantee that we will be able to successfully do so with Afrezza. There are numerous examples of unsuccessful product launches, second launches that underperform original expectations and other failures
to fully exploit the market potential of drug products, including by pharmaceutical companies with more experience and resources than us. During our initial transition of the commercial responsibilities from Sanofi, we utilized a contract sales
organization to promote Afrezza while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance programs, a voucher program,
data agreements and payor relationships. In early 2017, we recruited our own sales force, which included some of the sales representatives that previously were employed by the contract sales organization. We intend to continue the commercialization
of Afrezza in the United States through our internal commercial organization. We will need to maintain and continue to build our commercialization capabilities in order to successfully commercialize Afrezza in the United States, and we may not have
sufficient resources to do so. The market for skilled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial personnel is highly competitive, and we may not be able to retain and find and hire all of the personnel we need on a timely basis or retain them for a sufficient period.&nbsp;In
addition, Afrezza is a novel insulin therapy with a distinct profile and <FONT STYLE="white-space:nowrap">non-injectable</FONT> administration, and we are therefore required to expend significant time and resources to train our sales force to be
credible, persuasive and compliant with applicable laws in marketing Afrezza for the treatment diabetes to physicians and to ensure that a consistent and appropriate message about Afrezza is being delivered to our potential customers.&nbsp;If we are
unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits of Afrezza and its proper administration, our efforts
to successfully commercialize Afrezza could be put in jeopardy, which would negatively impact our ability to generate product revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to maintain coverage of, and adequate payment levels for Afrezza, physicians may limit how much or under what circumstances
they will prescribe or administer Afrezza. As a result, patients may decline to purchase Afrezza, which would have an adverse effect on our ability to generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for the NDA for Afrezza and its maintenance.&nbsp;Prior to the termination of the Sanofi License Agreement in April 2016,
we had no experience with the maintenance of an NDA and may fail to comply with maintenance requirements, including timely submitting required reports. Furthermore, we are responsible for the conduct of the remaining required post-approval trials of
Afrezza. Our financial and other resource constraints may result in delays or adversely impact the reliability and completion of these trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maintaining and further building the internal infrastructure to further develop and commercialize Afrezza is costly and time-consuming, and we
may not be successful in our efforts or successful in obtaining financing to support those efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to successfully
commercialize Afrezza in the United States, our business, financial condition and results of operations will be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from
period to period. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating results have fluctuated in the past and are likely to do so in future periods. Some of the factors
that could cause our operating results to fluctuate from period to period include the factors that will affect our funding requirements described above under &#147;Risk Factors &#151; We will need to raise additional capital to fund our operations,
and our inability to do so could raise substantial doubt about our ability to continue as a going concern.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that
comparisons from period to period of our financial results are not necessarily meaningful and should not be relied upon as indications of our future performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain regulatory approval of Afrezza in foreign jurisdictions, we will not be able to market Afrezza in any jurisdiction outside of the
United States, which could limit our commercial revenues. We may not be successful in establishing regional partnerships or other arrangements with third parties for the commercialization of Afrezza outside of the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Afrezza has been approved in the United States by the FDA for glycemic control in adult patients with diabetes, we have not yet sought
approval in any other jurisdiction. In order to market Afrezza outside of the United States, we must obtain regulatory approval in each applicable foreign jurisdiction, and we may never be able to obtain such approvals. The research, testing,
manufacturing, labeling, approval, sale, import, export, marketing, and distribution of pharmaceutical products outside the United States are subject to extensive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulation by foreign regulatory authorities, whose regulations differ from country to country. We will be required to comply with different regulations and policies of the jurisdictions where we
seek approval for Afrezza, and we have not yet identified all of the requirements that we will need to satisfy to submit Afrezza for approval for other jurisdictions. This will require additional time, expertise and expense, including the potential
need to conduct additional studies or development work for other jurisdictions beyond the work that we have conducted to support the NDA for Afrezza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current strategy for the future commercialization of Afrezza outside of the United States, subject to receipt of the necessary regulatory
approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities. It may be difficult to find collaboration partners that are able and willing to devote the time and resources
necessary to successfully commercialize Afrezza. Collaborations with third parties may require us to relinquish material rights, including revenue from commercialization, agree to unfavorable terms or assume material ongoing development obligations
that we would have to fund. These collaboration arrangements are complex and time-consuming to negotiate, and if we are unable to reach agreements with third-party collaborators, we may fail to meet our business objectives and our financial
condition may be adversely affected. We may also face significant competition in seeking collaboration partners, especially in the current market, and may not be able to find a suitable collaboration partner in a timely manner on acceptable terms,
or at all. Any of these factors could cause delay or prevent the successful commercialization of Afrezza in foreign jurisdictions and could have a material and adverse impact on our business, financial condition and results of operations and the
market price of our common stock and other securities could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to develop and commercialize our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sought to develop our product candidates through our internal research programs. All of our product
candidates will require additional research and development and, in some cases, significant preclinical, clinical and other testing prior to seeking regulatory approval to market them. Accordingly, these product candidates will not be commercially
available for a number of years, if at all. Further research and development on these programs will require significant financial resources. Given our limited financial resources and our focus on development and commercialization of Afrezza, we will
not be able to advance these programs unless we are able to enter into collaborations with third parties to fund of these programs or to obtain funding to enable us to continue these programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of the research that we have conducted involves new technologies, including our Technosphere platform technology. Even
if our research programs identify product candidates that initially show promise, these candidates may fail to progress to clinical development for any number of reasons, including discovery upon further research that these candidates have adverse
effects or other characteristics that indicate they are unlikely to be effective. In addition, the clinical results we obtain at one stage are not necessarily indicative of future testing results. If we fail to develop and commercialize our product
candidates, or if we are significantly delayed in doing so, our ability to generate product revenues will be limited to the revenues we can generate from Afrezza. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of operating losses, we expect to incur losses in the future and we may not generate positive cash flow from
operations in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never been profitable or generated positive cash flow from cumulative operations to date.
Historically, we have reported negative cash flow from operations other than for the nine months ended September&nbsp;30, 2014, for the year ended December&nbsp;31, 2014, and for the three months ended March&nbsp;31, 2015 as a result of our receipt
of an upfront payment and milestone payments from Sanofi. As of December&nbsp;31, 2016, we had an accumulated deficit of $2.7&nbsp;billion. The accumulated deficit has resulted principally from costs incurred in our research and development
programs, the <FONT STYLE="white-space:nowrap">write-off</FONT> of goodwill and general operating expenses. We expect to make substantial expenditures and to incur increasing operating losses in the future in order to continue the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of Afrezza. In connection with our quarterly assessment of impairment indicators and inventory valuation for the quarter ended December&nbsp;31, 2015, we identified an
impairment of our long-lived assets and inventory, which resulted in charges of $140.4&nbsp;million and $36.1&nbsp;million, respectively, in such quarter. In addition, under the amended Insulin Supply Agreement with Amphastar, we agreed to purchase
certain annual minimum quantities of insulin for calendar years 2017 through 2023 for an aggregate total remaining purchase price of &#128;93.0&nbsp;million at December&nbsp;31, 2016. We may not have the necessary capital resources on hand in order
to service this contractual commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our losses have had, and are expected to continue to have, an adverse impact on our working
capital, total assets and stockholders&#146; equity. As of December&nbsp;31, 2016, we had stockholders&#146; deficit of $183.6&nbsp;million. Our ability to achieve and sustain positive cash flow from operations and profitability depends heavily upon
successfully commercializing Afrezza, and we cannot be sure when, if ever, we will generate positive cash flow from operations or become profitable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a substantial amount of debt pursuant to the 2018 notes, 2019 notes, Tranche B notes and The Mann Group Loan Arrangement, and we may be unable
to make required payments of interest and principal as they become due. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had $152.1&nbsp;million
principal amount of outstanding debt, consisting of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$27.6&nbsp;million principal amount of 2018 notes bearing interest at 5.75%&nbsp;per annum and maturing on August&nbsp;15, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$55.0&nbsp;million principal amount of 2019 notes bearing interest at 9.75%&nbsp;per annum, $15.0&nbsp;million of which is due and payable in July 2017, $15.0&nbsp;million of which is due and payable in July 2018 and
$25.0&nbsp;million of which is due and payable in July and December 2019; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$20.0&nbsp;million principal amount of Tranche B notes bearing interest at 8.75%&nbsp;per annum, $5.0&nbsp;million of which is due and payable in each of May 2017, 2018 and 2019, and $5.0&nbsp;million of which is due
and payable in December 2019; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$49.5&nbsp;million principal amount of indebtedness under The Mann Group Loan Arrangement bearing interest at 5.84% and maturing and due on January&nbsp;5, 2020. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may borrow an additional $30.1&nbsp;million under The Mann Group Loan Arrangement. The available borrowings may be used to capitalize
accrued interest into principal upon mutual agreement of the parties, as accrued interest becomes due and payable under The Mann Group Loan Arrangement. As of December&nbsp;31, 2016 the accrued and unpaid interest under The Mann Group Loan
Arrangement was $9.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will have sufficient resources to make any required repayments of
principal under the terms of our indebtedness when required. Further, if we undergo a fundamental change, as that term is defined in the indentures governing the terms of the 2018 notes, or certain Major Transactions as defined in the Facility
Agreement in respect of the 2019 notes and the Tranche B notes, the holders of the respective debt securities will have the option to require us to repurchase all or any portion of such debt securities at a repurchase price of 100% of the principal
amount of such debt securities to be repurchased plus accrued and unpaid interest, if any. The 2018 notes bear interest at the rate of 5.75%&nbsp;per year on the outstanding principal amount, payable in cash semiannually in arrears on
February&nbsp;15 and August&nbsp;15 of each year. The 2019 notes bear interest at the rate of 9.75%&nbsp;per year on the outstanding principal amount and the Tranche B notes bear interest at the rate of 8.75% on the outstanding principal amount,
with accrued interest on each payable in cash quarterly in arrears on the last business day of March, June, September and December of each year. Loans under The Mann Group Loan Arrangement accrue interest at a rate of 5.84%&nbsp;per annum, due and
payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as we and The Mann Group mutually agree. While we have been able to timely make our required interest payments to date, we cannot
guarantee that we will be able to do so in the future. If we fail to pay interest on the 2018 notes, 2019 notes, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tranche B notes, or if we fail to repay or repurchase the 2018 notes, 2019 notes, Tranche B notes, or the loans under The Mann Group Loan Arrangement when required, we will be in default under
the instrument for such debt securities or loans, and may also suffer an event of default under the terms of other borrowing arrangements that we may enter into from time to time. Any of these events could have a material adverse effect on our
business, results of operations and financial condition, up to and including the note holders initiating bankruptcy proceedings or causing us to cease operations altogether. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The agreements governing our indebtedness contain covenants that we may not be able to meet and place restrictions on our operating and financial
flexibility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the Facility Agreement, including any indebtedness under the 2019 notes and the Tranche B
notes, and the Milestone Agreement are secured by substantially all of our assets, including our intellectual property, accounts receivables, equipment, general intangibles, inventory (excluding the insulin inventory) and investment property, and
all of the proceeds and products of the foregoing. Our obligations under the Facility Agreement and the Milestone Agreement are also secured by a certain mortgage on our facility in Danbury, Connecticut. The Facility Agreement includes customary
representations, warranties and covenants by us, including restrictions on our ability to incur additional indebtedness, grant certain liens, engage in certain mergers and acquisitions, make certain distributions and make certain voluntary
prepayments. Events of default under the Facility Agreement include: our failure to timely make payments due under the 2019 notes or the Tranche B notes; inaccuracies in our representations and warranties to Deerfield; our failure to comply with any
of our covenants under any of the Facility Agreement, Milestone Agreement or certain other related security agreements and documents entered into in connection with the Facility Agreement, subject to a cure period with respect to most covenants; our
insolvency or the occurrence of certain bankruptcy-related events; certain judgments against us; the suspension, cancellation or revocation of governmental authorizations that are reasonably expected to have a material adverse effect on our
business; the acceleration of a specified amount of our indebtedness; our cash and cash equivalents, including amounts available to us under The Mann Group Loan Arrangement, falling below $25.0&nbsp;million as of the last day of any fiscal quarter.
If we fail to timely pay accrued interest under The Mann Group Loan Arrangement when required, we will be in default under The Mann Group Loan Arrangement. During any such time as an event of default is continuing under The Mann Group Loan
Arrangement, The Mann Group will not be obligated to make additional borrowings available to us. If an event of default is continuing under The Mann Group Loan Arrangement as of the last day of a fiscal quarter, we may be in breach of the financial
covenant under the Facility Agreement that requires us to maintain cash and cash equivalents (including available borrowings under The Mann Group Loan Arrangement) of at least $25.0&nbsp;million if our other cash and cash equivalents on hand do not
equal or exceed $25.0&nbsp;million. If one or more events of default under the Facility Agreement occurs and continues beyond any applicable cure period, the holders of the 2019 notes and Tranche B notes may declare all or any portion of the 2019
notes and Tranche B notes to be immediately due and payable. The Milestone Agreement includes customary representations and warranties and covenants by us, including restrictions on transfers of intellectual property related to Afrezza. The
milestones are subject to acceleration in the event we transfer our intellectual property related to Afrezza in violation of the terms of the Milestone Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to comply with the covenants under any of the foregoing agreements, and we cannot predict
whether the holders of the 2019 notes or Tranche B notes would demand repayment of the outstanding balance of the 2019 notes or the Tranche B notes as applicable or exercise any other remedies available to such holders if we were unable to comply
with these covenants. The covenants and restrictions contained in the foregoing agreements could significantly limit our ability to respond to changes in our business or competitive activities or take advantage of business opportunities that may
create value for our stockholders and the holders of our other securities. In addition, our inability to meet or otherwise comply with the covenants under these agreements could have an adverse impact on our financial position and results of
operations and could result in an event of default under the terms of our other indebtedness, including our indebtedness under the 2018 notes. In the event of certain future defaults under the foregoing agreements for which we are not able to obtain
waivers, the holders of the 2018 notes, 2019 notes and Tranche B notes may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accelerate all of our repayment obligations, and, with respect to the 2019 notes and Tranche B notes, take control of our pledged assets, potentially requiring us to renegotiate the terms of our
indebtedness on terms less favorable to us, or to immediately cease operations. If we enter into additional debt arrangements, the terms of such additional arrangements could further restrict our operating and financial flexibility. In the event we
must cease operations and liquidate our assets, the rights of any holders of our outstanding secured debt would be senior to the rights of the holders of our unsecured debt and our common stock to receive any proceeds from the liquidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be
harmed and the market price of our common stock and other securities could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For planning purposes, we estimate the timing
of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical studies
and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of the achievement of these
milestones can vary dramatically from our estimates, in many cases for reasons beyond our control, depending on numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress, costs and results of our clinical studies and preclinical research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify and enroll patients who meet clinical study eligibility criteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to access sufficient, reliable and affordable supplies of components used in the manufacture of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of expanding and maintaining manufacturing operations, as necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our clinical studies compete for clinical sites and eligible subjects with clinical studies sponsored by other companies; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actions by regulators. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we do not obtain sufficient additional funds through
sales of securities, strategic collaborations or the license or sale of certain of our assets on a timely basis, we may be required to reduce expenses by delaying, reducing or curtailing our development of product candidates. If we fail to commence
or complete, or experience delays in or are forced to curtail, our proposed clinical programs or otherwise fail to adhere to our projected development goals in the timeframes we expect (or within the timeframes expected by analysts or investors),
our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Afrezza or our product candidates may be rendered obsolete by rapid technological change. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of established pharmaceutical companies have or are developing technologies for the treatment of unmet medical needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rapid rate of scientific discoveries and technological changes could result in Afrezza or one or more of our product candidates becoming
obsolete or noncompetitive. Our competitors may develop or introduce new products that render our technology or Afrezza less competitive, uneconomical or obsolete. For example, in January 2017, Novo Nordisk announced that Fiasp<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a faster formulation of insulin aspart, was approved in Europe and Canada. It is currently undergoing regulatory review in the United States. Our future success will depend not only on our
ability to develop our product candidates but to improve them and keep pace with emerging industry developments. We cannot assure you that we will be able to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to face competition from universities and other
<FONT STYLE="white-space:nowrap">non-profit</FONT> research organizations. These institutions carry out a significant amount of research and development in various areas of unmet medical need. These institutions are becoming increasingly aware of
the commercial value of their findings and are more active in seeking patent and other proprietary rights as well as licensing revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Continued
testing of Afrezza or our product candidates may not yield successful results, and even if it does, we may still be unable to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forecasts about the effects of the use of drugs, including Afrezza, over terms longer than the clinical studies or in much larger populations
may not be consistent with the earlier clinical results. For example, with the approval of Afrezza, the FDA has required a five-year, randomized, controlled trial in 8,000 &#151; 10,000 patients with type 2 diabetes, the primary objective of which
is to compare the incidence of pulmonary malignancy observed with Afrezza to that observed in a standard of care control group. If long-term use of a drug results in adverse health effects or reduced efficacy or both, the FDA or other regulatory
agencies may terminate our or any future marketing partner&#146;s ability to market and sell the drug, may narrow the approved indications for use or otherwise require restrictive product labeling or marketing, or may require further clinical
studies, which may be time-consuming and expensive and may not produce favorable results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development programs are
designed to test the safety and efficacy of our product candidates through extensive nonclinical and clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or impact
commercialization of any of our product candidates, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety and efficacy results obtained in our nonclinical and early clinical testing may be inconclusive or may not be predictive of results that we may obtain in our future clinical studies or following long-term use,
and we may as a result be forced to stop developing a product candidate or alter the marketing of an approved product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the analysis of data collected from clinical studies of our product candidates may not reach the statistical significance necessary, or otherwise be sufficient to support FDA or other regulatory approval for the claimed
indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after reviewing clinical data, we or any collaborators may abandon projects that we previously believed were promising; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may not produce the desired effects or may result in adverse health effects or other characteristics that preclude regulatory approval or limit their commercial use once approved.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of any of these events, we, any collaborator, the FDA, or any other regulatory authorities, may suspend or
terminate clinical studies or marketing of the drug at any time. Any suspension or termination of our clinical studies or marketing activities may harm our business, financial condition and results of operations and the market price of our common
stock and other securities may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our suppliers fail to deliver materials and services needed for the production of Afrezza in a timely
and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of our common
stock and other securities could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the commercial manufacture of Afrezza, we need access to sufficient, reliable and
affordable supplies of insulin, our Afrezza inhaler, the related cartridges and other materials. Currently, the only approved source of insulin for Afrezza is manufactured by Amphastar. We must rely on our suppliers, including Amphastar, to comply
with relevant regulatory and other legal requirements, including the production of insulin and FDKP in accordance with the FDA&#146;s cGMP for drug products, and the production of the Afrezza inhaler and related cartridges in accordance with QSRs.
The supply of any of these materials may be limited or any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers may not meet relevant regulatory requirements, and if we are unable to obtain any of these materials in sufficient amounts, in a timely manner and at reasonable prices, or if we
encounter delays or difficulties in our relationships with manufacturers or suppliers, the production of Afrezza may be delayed. Likewise, if Amphastar ceases to manufacture or is otherwise unable to deliver insulin for Afrezza, we will need to
locate an alternative source of supply and the production of Afrezza may be delayed. If any of our suppliers is unwilling or unable to meet its supply obligations and we are unable to secure an alternative supply source in a timely manner and on
favorable terms, our business, financial condition, and results of operations may be harmed and the market price of our common stock and other securities may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail as an effective manufacturing organization or fail to engage third-party manufacturers with this capability, we may be unable to support
commercialization of this product. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our Danbury, Connecticut facility to formulate Afrezza inhalation powder, fill plastic
cartridges with the powder, package the cartridges in blister packs, and place the blister packs into foil pouches. We utilize a contract packager to assemble the final kits of foil-pouched blisters containing cartridges along with inhalers and the
package insert. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often
encounter difficulties in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, quality control and assurance and shortages of qualified personnel, as well as compliance with
strictly enforced federal, state and foreign regulations. If we engage a third-party manufacturer, we would need to transfer our technology to that third-party manufacturer and gain FDA approval, potentially causing delays in product delivery. In
addition, our third-party manufacturer may not perform as agreed or may terminate its agreement with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could cause
us to delay or suspend production, could entail higher costs and may result in our being unable to obtain sufficient quantities for the commercialization of Afrezza at the costs that we currently anticipate. Furthermore, if we or a third-party
manufacturer fail to deliver the required commercial quantities of the product or any raw material on a timely basis, and at commercially reasonable prices, sustainable compliance and acceptable quality, and we were unable to promptly find one or
more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volume and quality on a timely basis, we would likely be unable to meet demand for Afrezza and we would lose potential revenues.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Afrezza or any other product that we develop does not become widely accepted by physicians, patients, third-party payors and the healthcare
community, we may be unable to generate significant revenue, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza and other products that we may develop in the future
may not gain market acceptance among physicians, patients, third-party payors and the healthcare community. Failure to achieve market acceptance would limit our ability to generate revenue and would adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of Afrezza and other products that we may develop in the future depends on many factors, including the: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approved labeling claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectiveness of efforts by us or any future marketing partner to educate physicians about the benefits and advantages of Afrezza or our other products and to provide adequate support for them, and the perceived
advantages and disadvantages of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willingness of the healthcare community and patients to adopt new technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to manufacture the product in sufficient quantities with acceptable quality and cost; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits compared to competing products or therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration relative to existing treatment methods; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">coverage and pricing and reimbursement relative to other treatment therapeutics and methods; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">marketing and distribution support. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of these and other factors, Afrezza and any other
product that we develop may not gain market acceptance, which would materially harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
third-party payors do not cover Afrezza or any of our product candidates for which we receive regulatory approval, Afrezza or such product candidates might not be prescribed, used or purchased, which would adversely affect our revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future revenues and ability to generate positive cash flow from operations may be affected by the continuing efforts of government and
other third-party payors to contain or reduce the costs of healthcare through various means. For example, in certain foreign markets the pricing of prescription pharmaceuticals is subject to governmental control. In the United States, there has
been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental controls. We cannot be certain what legislative proposals will be adopted or what actions federal, state or private payors
for healthcare goods and services may take in response to any drug pricing and reimbursement reform proposals or legislation. Such reforms may limit our ability to generate revenues from sales of Afrezza or other products that we may develop in the
future and achieve profitability. Further, to the extent that such reforms have a material adverse effect on the business, financial condition and profitability of any future marketing partner for Afrezza, and companies that are prospective
collaborators for our product candidates, our ability to commercialize Afrezza and our product candidates under development may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and elsewhere, sales of prescription pharmaceuticals still depend in large part on the availability of coverage and
adequate reimbursement to the consumer from third-party payors, such as governmental and private insurance plans. Third-party payors are increasingly challenging the prices charged for medical products and services. The market for Afrezza and our
product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#146; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry
competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access
to a branded drug when a less costly generic equivalent or other alternative is available. In addition, because each third-party payor individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a
time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval would be obtained. This process could delay the market
acceptance of any product and could have a negative effect on our future revenues and operating results. Even if we succeed in bringing more products to market, we cannot be certain that any such products would be considered cost-effective or that
coverage and adequate reimbursement to the consumer would be available. Patients will be unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to
government control. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to
country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for
human use. A member state may approve a specific price for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for
Afrezza or any of our other product candidates that receives marketing approval from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products
that compete with our own products, which could negatively impact our profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any future marketing partner is unable to
obtain coverage of, and adequate payment levels for, Afrezza or any of our other product candidates that receive marketing approval from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer
them and patients may decline to purchase them. This in turn could affect our and any future marketing partner&#146;s ability to successfully commercialize Afrezza and our ability to successfully commercialize any of our other product candidates
that receives regulatory approval and impact our profitability, results of operations, financial condition, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislation
may make it more difficult to receive revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both the United States and certain foreign jurisdictions, there have been a
number of legislative and regulatory proposals in recent years to change the healthcare system in ways that could impact our ability to sell our products profitably. For example, in March 2010, PPACA became law in the United States. PPACA
substantially changes the way healthcare is financed by both governmental and private insurers and significantly affects the healthcare industry. Among the provisions of PPACA of importance to us are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government
healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 2.3% medical device excise tax on certain transactions, including many U.S. sales of medical devices, which currently includes and we expect will continue to include U.S. sales of certain drug-device combination
products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biological products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the Federal Poverty Level, thereby
potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;)
certain financial arrangements with physicians and teaching hospitals, as defined in PPACA and its implementing regulations, including reporting any &#147;payments or transfers of value&#148; made or distributed to prescribers, teaching hospitals
and other healthcare providers and reporting any ownership and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
investment interests held by physicians and their immediate family members and applicable group purchasing organizations during the preceding calendar year; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new requirement to annually report drug samples that certain manufacturers and authorized distributors provide to physicians; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device excise tax has been suspended by the Consolidated Appropriations Act of 2016 (the &#147;CAA&#148;) through
December&nbsp;31, 2017. Absent further Congressional action, the excise tax will be reinstated for medical device sales beginning January&nbsp;1, 2018. The CAA also temporarily delays implementation of other taxes intended to help fund PPACA
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there have been judicial and Congressional challenges to other aspects of PPACA. As a result there have been delays in
the implementation of, and action taken to repeal or replace, certain aspects of the PPACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the PPACA to waive, defer,
grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices.
Further, in January 2017, Congress adopted a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the PPACA. Following the passage of the Budget Resolution,
in March 2017, the U.S. House of Representatives introduced legislation known as the American Health Care Act, which, if enacted, would amend or repeal significant portions of the PPACA. Among other changes, the American Health Care Act would repeal
the annual fee on certain brand prescription drugs and biologics imposed on manufacturers and importers, eliminate the 2.3% excise tax on medical devices, eliminate penalties on individuals and employers that fail to maintain or provide minimum
essential coverage, and create refundable tax credits to assist individuals in buying health insurance. The American Health Care Act would also make significant changes to Medicaid by, among other things, making Medicaid expansion optional for
states, repealing the requirement that state Medicaid plans provide the same essential health benefits that are required by plans available on the exchanges, modifying federal funding, including implementing a per capita cap on federal payments to
states, and changing certain eligibility requirements. While it is uncertain when or if the provisions in the American Health Care Act will become law, or the extent to which any changes may impact our business, it is clear that concrete steps are
being taken to repeal and replace certain aspects of the PPACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted
since PPACA was enacted. For example, on August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate
reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, starting in 2013, and, following passage of the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. On
January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 (the &#147;ATRA&#148;), which, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer
treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. These new laws and initiatives may result in additional reductions in
Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that PPACA, as well as other healthcare reform measures that may be adopted in the
future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private third-party payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability,
or commercialize our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any future marketing partner fails to comply with federal and state healthcare laws, including fraud and
abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare,
Medicaid or other third-party payors, certain federal and state healthcare laws and regulations, including those pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. For example, we could be subject to
healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute (as amended by PPACA, which modified the intent requirement of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the Statute or
specific intent to violate it to have committed a violation), which constrains our business activities, including our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities by
prohibiting, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item
or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws, including without limitation the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other federal healthcare programs that are false or fraudulent, and knowingly making, or causing to be made, a false record or statement material to a false or
fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government, and under PPACA, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the federal false claims laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or falsifying, concealing, or covering up a
material fact in connection with the delivery of or payment for health care benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by HITECH, and their respective implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on
entities subject to the law, such as healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually
identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal physician sunshine requirements under PPACA, which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the CMS information related to payments and other
transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws
which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state and foreign laws governing the privacy and security of health </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; state laws that require
pharmaceutical companies to comply with the industry&#146;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare
providers and entities; and state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exceptions, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. To the extent that Afrezza or any of our product candidates that receives marketing approval is ultimately sold in a foreign country, we may be subject to similar
foreign laws and regulations. If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines, individual imprisonment, disgorgement, exclusion of products from reimbursement under U.S. federal or state healthcare programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of
our operations could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be
entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business.
Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to
comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, fines, sanctions and exposure under
other laws which could have a material adverse effect on our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
participate in the Medicaid Drug Rebate Program, as administered by CMS, and other federal and state government pricing programs in the United States, and we may participate in additional government pricing programs in the future. These programs
generally require us to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries/recipients of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the
rebates are based on pricing that we report on a monthly and quarterly basis to the government agencies that administer the programs. Pricing requirements and rebate/discount calculations are complex, vary among products and programs, and are often
subject to interpretation by governmental or regulatory agencies and the courts. The requirements of these programs, including, by way of example, their respective terms and scope, change frequently. Responding to current and future changes may
increase our costs, and the complexity of compliance will be time consuming. Invoicing for rebates is provided in arrears, and there is frequently a time lag of up to several months between the sales to which rebate notices relate and our receipt of
those notices, which further complicates our ability to accurately estimate and accrue for rebates related to the Medicaid program as implemented by individual states. Thus, there can be no assurance that we will be able to identify all factors that
may cause our discount and rebate payment obligations to vary from period to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have a material
adverse effect on our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Office of Inspector General of the
Department of Health and Human Services and other Congressional, enforcement and administrative bodies have recently increased their focus on pricing requirements for products, including, but not limited to the methodologies used by manufacturers to
calculate average manufacturer price (&#147;AMP&#148;) and best price (&#147;BP&#148;) for compliance with reporting requirements under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicaid Drug Rebate Program. We are liable for errors associated with our submission of pricing data and for any overcharging of government payors. For example, failure to submit
monthly/quarterly AMP and BP data on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the submission is late beyond the due date. Failure to make necessary disclosures and/or to identify overpayments could
result in allegations against us under the False Claims Act and other laws and regulations. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could
have a material adverse effect on our business, results of operations and financial condition. In addition, in the event that the CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid or Medicare for our
covered outpatient drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability claims are brought against us, we may incur significant liabilities and suffer damage to our
reputation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing, manufacturing, marketing and sale of Afrezza and any clinical testing of our product candidates expose us
to potential product liability claims. A product liability claim may result in substantial judgments as well as consume significant financial and management resources and result in adverse publicity, decreased demand for a product, injury to our
reputation, withdrawal of clinical studies volunteers and loss of revenues. We currently carry worldwide product liability insurance in the amount of $10.0&nbsp;million. Our insurance coverage may not be adequate to satisfy any liability that may
arise, and because insurance coverage in our industry can be very expensive and difficult to obtain, we cannot assure you that we will seek to obtain, or be able to obtain if desired, sufficient additional coverage. If losses from such claims exceed
our liability insurance coverage, we may incur substantial liabilities that we may not have the resources to pay. If we are required to pay a product liability claim our business, financial condition and results of operations would be harmed and the
market price of our common stock and other securities may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we lose any key employees or scientific advisors, our operations and our
ability to execute our business strategy could be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face intense competition for qualified employees among
companies in the biotechnology and biopharmaceutical industries. Our success depends upon our ability to attract, retain and motivate highly skilled employees. We may be unable to attract and retain these individuals on acceptable terms, if at all.
In addition, in order to commercialize Afrezza successfully, we may be required to expand our work force, particularly in the areas of manufacturing and sales and marketing. These activities will require the addition of new personnel, including
management, and the development of additional expertise by existing personnel, and we cannot assure you that we will be able to attract or retain any such new personnel on acceptable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of the services of any principal member of our management and scientific staff could significantly delay or prevent the achievement
of our scientific and business objectives. All of our employees are &#147;at will&#148; and we currently do not have employment agreements with any of the principal members of our management or scientific staff, and we do not have key person life
insurance to cover the loss of any of these individuals. Replacing key employees may be difficult and time-consuming because of the limited number of individuals in our industry with the skills and experience required to develop, gain regulatory
approval of and commercialize products successfully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relationships with scientific advisors at academic and other institutions to
conduct research or assist us in formulating our research, development or clinical strategy. These scientific advisors are not our employees and may have commitments to, and other obligations with, other entities that may limit their availability to
us. We have limited control over the activities of these scientific advisors and can generally expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our
programs could harm our business. In addition, these advisors are not prohibited from, and may have arrangements with, other companies to assist those companies in developing technologies that may compete with Afrezza or our product candidates. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our internal controls over financial reporting are not considered effective, our business, financial
condition and market price of our common stock and other securities could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal controls over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal controls over
financial reporting in our annual report on Form 10-K for that fiscal year. Section&nbsp;404 also requires our independent registered public accounting firm to attest to, and report on, our internal controls over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls over financial
reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Further, the design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure
you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or
procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. A material weakness in our internal controls has been identified in the past, and we cannot assure
you that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future. A material weakness in our internal controls over financial reporting would require management and our
independent registered public accounting firm to evaluate our internal controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an
adverse effect on our business, financial condition and the market price of our common stock and other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may undertake internal
restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating
structure in light of developments in our business strategy and long-term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating plans. These activities may result in write-offs or other restructuring charges. There can be no assurance that any restructuring activities that we undertake will achieve the cost
savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition,
internal restructurings can require a significant amount of time and focus from management and other employees, which may divert attention from commercial operations. If we undertake any internal restructuring activities and fail to achieve some or
all of the expected benefits therefrom, our business, results of operations and financial condition could be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
and certain of our executive officers and directors have been named as defendants in ongoing securities class action lawsuits that could result in substantial costs and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the public announcement of Sanofi&#146;s election to terminate the Sanofi License Agreement and the subsequent decline in our stock
price, several complaints were filed in the U.S. District Court for the Central District of California (the &#147;District Court&#148;) against MannKind and certain of our officers and directors on behalf of certain purchasers of our common stock,
which were consolidated into a single action. The amended complaint alleged that MannKind and certain of our officers and directors violated federal securities laws by making materially false and misleading statements regarding the prospects for
Afrezza, thereby artificially inflating the price of MannKind&#146;s common stock. We and the other defendants brought a motion to dismiss the class action that was pending against MannKind and two of our executives, which the District Court granted
without leave to amend the complaint. The lead plaintiff appealed that decision to the Ninth Circuit Court of Appeals. On March&nbsp;2, 2017, the lead plaintiff filed a voluntary motion to dismiss his appeal, which the Court of Appeals granted on
March&nbsp;9, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and certain of our directors and executive officers have also been named in similar lawsuits filed in Israel. In
November 2016, the court in Israel dismissed one of the actions without prejudice. In the remaining action, a hearing is scheduled for May 2017 to determine whether Israeli or U.S. law is applicable before the case can be certified as a class
action. We intend to vigorously defend against these claims. If we are not successful in our defense, we could be forced to make significant payments to or other settlements with our stockholders and their lawyers, and such payments or settlement
arrangements could have a material adverse effect on our business, operating results or financial condition. Even if such claims are not successful, the litigation could result in substantial costs and significant adverse impact on our reputation
and divert management&#146;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that at least for the foreseeable future, our manufacturing facility in Danbury, Connecticut will be the sole location for the
manufacturing of Afrezza. This facility and the manufacturing equipment we use would be costly to replace and could require substantial lead time to repair or replace. We depend on our facilities and on collaborators, contractors and vendors for the
continued operation of our business, some of whom are located in other countries. Natural disasters or other catastrophic events, including interruptions in the supply of natural resources, political and governmental changes, severe weather
conditions, wildfires and other fires, explosions, actions of animal rights activists, terrorist attacks, volcanic eruptions, earthquakes and wars could disrupt our operations or those of our collaborators, contractors and vendors. We might suffer
losses as a result of business interruptions that exceed the coverage available under our and our contractors&#146; insurance policies or for which we or our contractors do not have coverage. For example, we are not insured against a terrorist
attack. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs or cause interruptions in our
commercialization of Afrezza. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We deal with hazardous materials and must comply with environmental laws and regulations, which can be
expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development and commercialization of Afrezza work involves the
controlled storage and use of hazardous materials, including chemical and biological materials. In addition, our manufacturing operations involve the use of a chemical that may form an explosive mixture under certain conditions. Our operations also
produce hazardous waste products. We are subject to federal, state and local laws and regulations (i)&nbsp;governing how we use, manufacture, store, handle and dispose of these materials (ii)&nbsp;imposing liability for costs of cleaning up, and
damages to natural resources from past spills, waste disposals on and <FONT STYLE="white-space:nowrap">off-site,</FONT> or other releases of hazardous materials or regulated substances, and (iii)&nbsp;regulating workplace safety. Moreover, the risk
of accidental contamination or injury from hazardous materials cannot be completely eliminated, and in the event of an accident, we could be held liable for any damages that may result, and any liability could fall outside the coverage or exceed the
limits of our insurance. Currently, our general liability policy provides coverage up to $1.0&nbsp;million per occurrence and $2.0&nbsp;million in the aggregate and is supplemented by an umbrella policy that provides a further $20.0&nbsp;million of
coverage; however, our insurance policy excludes pollution liability coverage and we do not carry a separate hazardous materials policy. In addition, we could be required to incur significant costs to comply with environmental laws and regulations
in the future. Finally, current or future environmental laws and regulations may impair our research, development or production efforts or have an adverse impact on our business, results of operations and financial condition. When we purchased the
facilities located in Danbury, Connecticut in 2001, a soil and groundwater investigation and remediation was being conducted by a former site operator (the responsible party) under the oversight of the Connecticut Department of Environmental
Protection. During the construction of our expanded manufacturing facility, we excavated contaminated soil under the footprint of our building expansion location. The responsible party reimbursed us for our increased excavation and disposal costs of
contaminated soil in the amount of $1.6&nbsp;million. It has conducted at its expense all work and will make all filings necessary to achieve closure for the environmental remediation conducted at the site, and has agreed to indemnify us for any
future costs and expenses we may incur that are directly related to the final closure. If we are unable to collect these future costs and expenses, if any, from the responsible party, our business, financial condition and results of operations may
be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are increasingly dependent on information technology systems, infrastructure and data security. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are increasingly dependent upon information technology systems, infrastructure and data security. Our business requires manipulating,
analyzing and storing large amounts of data. In addition, we rely on an enterprise software system to operate and manage our business.&nbsp;Our business therefore depends on the continuous, effective, reliable and secure operation of our computer
hardware, software, networks, Internet servers and related infrastructure.&nbsp;The multitude and complexity of our computer systems and the potential value of our data make them inherently vulnerable to service interruption or destruction,
malicious intrusion and random attack. Likewise, data privacy or security breaches by employees or others may pose a risk that sensitive data including intellectual property, trade secrets or personal information belonging to us or our customers or
other business partners may be exposed to unauthorized persons or to the public. Our systems are also potentially subject to cyber-attacks, which can be highly sophisticated and may be difficult to detect. Such attacks are often carried out by
motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups and &#147;hacktivists.&#148; Cyber-attacks could include the deployment of harmful malware and key loggers, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our information technology systems, infrastructure and
data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security status. While we continue to invest in the protection of our critical or sensitive data and information technology, there
can be no assurance that our efforts will prevent or detect service interruptions or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result
in financial, legal, business or reputational harm to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO GOVERNMENT REGULATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates must undergo costly and time-consuming rigorous nonclinical and clinical testing and we must obtain regulatory approval prior to
the sale and marketing of any product in each jurisdiction. The results of this testing or issues that develop in the review and approval by a regulatory agency may subject us to unanticipated delays or prevent us from marketing any products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities, as well as the manufacturing and marketing of Afrezza and our product candidates, are
subject to regulation, including regulation for safety, efficacy and quality, by the FDA in the United States and comparable authorities in other countries. FDA regulations and the regulations of comparable foreign regulatory authorities are
wide-ranging and govern, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product design, development, manufacture and testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product storage and shipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advertising and promotion; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product sales and distribution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements governing the conduct of clinical studies
and manufacturing and marketing of Afrezza and our product candidates outside the United States vary widely from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional
testing and different clinical study designs. Foreign regulatory approval processes include essentially all of the risks associated with the FDA approval processes. Some of those agencies also must approve prices of the products. Approval of a
product by the FDA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory policy in the United States or in foreign countries for product approval during the period of product
development and regulatory agency review of each submitted new application may cause delays or rejections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing can be costly
and take many years, and the outcome is uncertain and susceptible to varying interpretations. We cannot be certain if or when regulatory agencies might request additional studies, under what conditions such studies might be requested, or what the
size or length of any such studies might be. The clinical studies of our product candidates may not be completed on schedule, regulatory agencies may order us to stop or modify our research, or these agencies may not ultimately approve any of our
product candidates for commercial sale. The data collected from our clinical studies may not be sufficient to support regulatory approval of our product candidates. Even if we believe the data collected from our clinical studies are sufficient,
regulatory agencies have substantial discretion in the approval process and may disagree with our interpretation of the data. Our failure to adequately demonstrate the safety and efficacy of any of our product candidates would delay or prevent
regulatory approval of our product candidates, which could prevent us from achieving profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Questions that have been raised about
the safety of marketed drugs generally, including pertaining to the lack of adequate labeling, may result in increased cautiousness by regulatory agencies in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may
result in significant delays in obtaining regulatory approvals. Such regulatory considerations may also result in the imposition of more restrictive drug labeling or marketing requirements as conditions of approval, which may significantly affect
the marketability of our drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities impose significant restrictions on approved products
through regulations on advertising, promotional and distribution activities. This oversight encompasses, but is not limited to, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising,
healthcare provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Internet.&nbsp;Regulatory authorities may also review industry-sponsored scientific and educational activities that make representations regarding product safety or efficacy in a promotional
context. The FDA and other regulatory authorities may take enforcement action against a company for promoting unapproved uses of a product or for other violations of its advertising and labeling laws and regulations. Enforcement action may include
product seizures, injunctions, civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with such regulations also can result in
adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators.&nbsp;Certain states have also adopted regulations and reporting requirements surrounding the promotion of pharmaceuticals. Failure to comply
with state requirements may affect our ability to promote or sell our products in certain states. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not comply with regulatory requirements
at any stage, whether before or after marketing approval is obtained, we may be fined or forced to remove a product from the market, subject to criminal prosecution, or experience other adverse consequences, including restrictions or delays in
obtaining regulatory marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we comply with regulatory requirements, we may not be able to obtain the labeling
claims necessary or desirable for product promotion. We may also be required to undertake post-marketing studies. For example, as part of the approval of Afrezza, the FDA required that we complete a clinical trial to evaluate the potential risk of
pulmonary malignancy with Afrezza. To date, we have not enrolled any subjects in this trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we or other parties identify
adverse effects after any of our products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and a reformulation of our products, additional clinical studies, changes in labeling of, or indications of use
for, our products and/or additional marketing applications may be required. If we encounter any of the foregoing problems, our business, financial condition and results of operations will be harmed and the market price of our common stock and other
securities may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent, ongoing government regulation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture, marketing and sale of Afrezza are subject to stringent and ongoing government regulation. The FDA may also withdraw product
approvals if problems concerning the safety or efficacy of a product appear following approval. We cannot be sure that FDA and United States Congressional initiatives or actions by foreign regulatory bodies pertaining to ensuring the safety of
marketed drugs or other developments pertaining to the pharmaceutical industry will not adversely affect our operations. For example, stability failure of Afrezza could lead to product recall or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also are required to register our establishments and list our products with the FDA and certain state agencies. We and any third-party
manufacturers or suppliers must continually adhere to federal regulations setting forth requirements, known as cGMP (for drugs) and QSR (for medical devices), and their foreign equivalents, which are enforced by the FDA and other national regulatory
bodies through their facilities inspection programs. In complying with cGMP and foreign regulatory requirements, we and any of our potential third-party manufacturers or suppliers will be obligated to expend time, money and effort in production,
record-keeping and quality control to ensure that our products meet applicable specifications and other requirements. QSR requirements also impose extensive testing, control and documentation requirements. State regulatory agencies and the
regulatory agencies of other countries have similar requirements. In addition, we will be required to comply with regulatory requirements of the FDA, state regulatory agencies and the regulatory agencies of other countries concerning the reporting
of adverse events and device malfunctions, corrections and removals (e.g., recalls), promotion and advertising and general prohibitions against the manufacture and distribution of adulterated and misbranded devices. Failure to comply with these
regulatory requirements could result in civil fines, product seizures, injunctions and/or criminal prosecution of responsible individuals and us. Any such actions would have a material adverse effect on our business, financial condition and results
of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA and comparable foreign regulatory authorities subject Afrezza and any approved drug product
to extensive and ongoing regulatory requirements concerning the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown
problems, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other
regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are
not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our suppliers are subject to FDA inspection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on suppliers for insulin and other materials that comprise Afrezza, including our Afrezza inhaler and cartridges. Each supplier must
comply with relevant regulatory requirements and is subject to inspection by the FDA. Although we conduct our own inspections and review and/or approve investigations of each supplier, there can be no assurance that the FDA, upon inspection, would
find that the supplier substantially complies with the QSR or cGMP requirements, where applicable. If we or any potential third-party manufacturer or supplier fails to comply with these requirements or comparable requirements in foreign countries,
regulatory authorities may subject us to regulatory action, including criminal prosecutions, fines and suspension of the manufacture of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to find a new or additional supplier of insulin, we will be required to evaluate the new supplier&#146;s ability to provide
insulin that meets regulatory requirements, including cGMP requirements as well as our specifications and quality requirements, which would require significant time and expense and could delay the manufacturing and commercialization of Afrezza. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reports of side effects or safety concerns in related technology fields or in other companies&#146; clinical studies could delay or prevent us from
obtaining regulatory approval for our product candidates or negatively impact public perception of Afrezza or any other products we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If other pharmaceutical companies announce that they observed frequent adverse events in their studies involving insulin therapies, we may be
subject to class warnings in the label for Afrezza. In addition, the public perception of Afrezza might be adversely affected, which could harm our business, financial condition and results of operations and cause the market price of our common
stock and other securities to decline, even if the concern relates to another company&#146;s products or product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also a number of clinical studies being conducted by other pharmaceutical companies
involving compounds similar to, or potentially competitive with, our product candidates. Adverse results reported by these other companies in their clinical studies could delay or prevent us from obtaining regulatory approval or negatively impact
public perception of our product candidates, which could harm our business, financial condition and results of operations and cause the market price of our common stock and other securities to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO INTELLECTUAL PROPERTY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to protect our proprietary rights, we may not be able to compete effectively, or operate profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends, in large part, on our ability to obtain and maintain intellectual property protection for our technology. Our ability to do so will depend on, among other things, complex legal and factual questions, and it should be noted that the
standards regarding intellectual property rights in our fields are still evolving. We attempt to protect our proprietary technology through a combination of patents, trade secrets and confidentiality agreements. We own a number of domestic and
international patents, have a number of domestic and international patent applications pending and have licenses to additional patents. We cannot assure you that our patents and licenses will successfully preclude others from using our technologies,
and we could incur substantial costs in seeking enforcement of our proprietary rights against infringement. Even if issued, the patents may not give us an advantage over competitors with alternative technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the term of a patent is limited and, as a result, the patents protecting our products expire at various dates. For example, some
patents providing protection for Afrezza inhalation powder have terms extending into 2020, 2026, 2028, 2029, and 2030. In addition, patents providing protection for our inhaler and cartridges have terms extending into 2023, 2031 and 2032, and we
have method of treatment claims that extend into 2026, 2029, 2030 and 2031. As and when these different patents expire, Afrezza could become subject to increased competition. As a consequence, we may not be able to recover our development costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An issued patent is presumed valid unless it is declared otherwise by a court of competent jurisdiction. However, the issuance of a
patent is not conclusive as to its validity or enforceability and it is uncertain how much protection, if any, will be afforded by our patents. A third party may challenge the validity or enforceability of a patent after its issuance by various
proceedings such as oppositions in foreign jurisdictions, or post grant proceedings, including, oppositions, <FONT STYLE="white-space:nowrap">re-examinations</FONT> or other review in the United States. In some instances we may seek <FONT
STYLE="white-space:nowrap">re-examination</FONT> or reissuance of our own patents. If we attempt to enforce our patents, they may be challenged in court where they could be held invalid, unenforceable, or have their breadth narrowed to an extent
that would destroy their value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other
countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or
our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for
patentability are met, in the United States prior to March&nbsp;15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After
March&nbsp;15, 2013, under the Leahy-Smith America Invents Act (&#147;AIA&#148;), or the Leahy-Smith Act, enacted on September&nbsp;16, 2011, the United States moved to a first inventor to file system. The Leahy-Smith Act also includes a number of
significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The full effects of these changes are currently unclear. In general, the Leahy-Smith Act and its implementation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, patent law continues to evolve. Several further changes to patent law are before
Congress. The United States Supreme Court has exhibited an increased interest in patent law and several of its recent decisions have tended to narrow the scope of patentable subject matter related to medical products and methods. These and recent
decisions of lower courts and guidelines issued by the USPTO call into question the patentability of biological inventions that had previously been considered patentable. While none of this has had an immediately apparent impact on our core
technology and patents, the full and ultimate effect of these developments is not yet known. We also rely on unpatented technology, trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and confidentiality agreements. We require our
officers, employees, consultants and advisors to execute proprietary information and invention and assignment agreements upon commencement of their relationships with us. These agreements provide that all inventions developed by the individual on
behalf of us must be assigned to us and that the individual will cooperate with us in connection with securing patent protection on the invention if we wish to pursue such protection. We also execute confidentiality agreements with outside
collaborators. There can be no assurance, however, that our inventions and assignment agreements and our confidentiality agreements will provide meaningful protection for our inventions, trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information in the event of unauthorized use or disclosure of such information. If any trade secret, <FONT STYLE="white-space:nowrap">know-how</FONT> or other technology not
protected by a patent were to be disclosed to or independently developed by a competitor, our business, results of operations and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, we would be required to devote
substantial time and resources to prosecute or defend such proceedings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our
collaborators or licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours
is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. A court may also decide to award us a royalty from an infringing party instead of
issuing an injunction against the infringing activity. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications
at risk of not issuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings brought by the USPTO, may be necessary to determine the priority of inventions with
respect to our <FONT STYLE="white-space:nowrap">pre-AIA</FONT> patent applications or those of our collaborators or licensors. Additionally, the Leahy-Smith Act has greatly expanded the options for post-grant review of patents that can be brought by
third parties. In particular Inter Partes Review (&#147;IPR&#148;), available against any issued United States patent (pre - and <FONT STYLE="white-space:nowrap">post-AIA),</FONT> has resulted in a higher rate of claim invalidation, due in part to
the much reduced opportunity to repair claims by amendment as compared to <FONT STYLE="white-space:nowrap">re-examination,</FONT> as well as the lower standard of proof used at the USPTO as compared to the federal courts. With the passage of time an
increasing number of patents related to successful pharmaceutical products are being subjected to IPR. Moreover, the filing of IPR petitions has been used by short-sellers as a tool to help drive down stock prices. We may not prevail in any
litigation, post-grant review, or interference proceedings in which we are involved and, even if we are successful, these proceedings may result in substantial costs and be a distraction to our management. Further, we may not be able, alone or with
our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price of our common stock and other securities may decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our technologies conflict with the proprietary rights of others, we may incur substantial costs as a
result of litigation or other proceedings and we could face substantial monetary damages and be precluded from commercializing our products, which would materially harm our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biotechnology patents are numerous and may, at times, conflict with one another. As a result, it is not always clear to industry participants,
including us, which patents cover the multitude of biotechnology product types. Ultimately, the courts must determine the scope of coverage afforded by a patent and the courts do not always arrive at uniform conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent owner may claim that we are making, using, selling or offering for sale an invention covered by the owner&#146;s patents and may go
to court to stop us from engaging in such activities. Such litigation is not uncommon in our industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent lawsuits can be expensive
and would consume time and other resources. There is a risk that a court would decide that we are infringing a third party&#146;s patents and would order us to stop the activities covered by the patents, including the commercialization of our
products. In addition, there is a risk that we would have to pay the other party damages for having violated the other party&#146;s patents (which damages may be increased, as well as attorneys&#146; fees ordered paid, if infringement is found to be
willful), or that we will be required to obtain a license from the other party in order to continue to commercialize the affected products, or to design our products in a manner that does not infringe a valid patent. We may not prevail in any legal
action, and a required license under the patent may not be available on acceptable terms or at all, requiring cessation of activities that were found to infringe a valid patent. We also may not be able to develop a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> product design on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, certain
components of Afrezza may be manufactured outside the United States and imported into the United States. As such, third parties could file complaints under 19 U.S.C. Section&nbsp;337(a)(1)(B) (a &#147;337 action&#148;) with the International Trade
Commission (the &#147;ITC&#148;). A 337 action can be expensive and would consume time and other resources. There is a risk that the ITC would decide that we are infringing a third party&#146;s patents and either enjoin us from importing the
infringing products or parts thereof into the United States or set a bond in an amount that the ITC considers would offset our competitive advantage from the continued importation during the statutory review period. The bond could be up to 100% of
the value of the patented products. We may not prevail in any legal action, and a required license under the patent may not be available on acceptable terms, or at all, resulting in a permanent injunction preventing any further importation of the
infringing products or parts thereof into the United States. We also may not be able to develop a <FONT STYLE="white-space:nowrap">non-infringing</FONT> product design on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we own a number of domestic and foreign patents and patent applications relating to Afrezza, we have identified certain third-party
patents having claims that may trigger an allegation of infringement in connection with the commercial manufacture and sale of Afrezza. If a court were to determine that Afrezza was infringing any of these patent rights, we would have to establish
with the court that these patents are invalid or unenforceable in order to avoid legal liability for infringement of these patents. However, proving patent invalidity or unenforceability can be difficult because issued patents are presumed valid.
Therefore, in the event that we are unable to prevail in a <FONT STYLE="white-space:nowrap">non-infringement</FONT> or invalidity action we will have to either acquire the third-party patents outright or seek a royalty-bearing license.
Royalty-bearing licenses effectively increase production costs and therefore may materially affect product profitability. Furthermore, should the patent holder refuse to either assign or license us the infringed patents, it may be necessary to cease
manufacturing the product entirely and/or design around the patents, if possible. In either event, our business, financial condition and results of operations would be harmed and our profitability could be materially and adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price of our
common stock and other securities may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, patent litigation may divert the attention of key personnel and we may not
have sufficient resources to bring these actions to a successful conclusion. At the same time, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater
resources. An adverse determination in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our products or result in substantial monetary damages, which would adversely
affect our business, financial condition and results of operations and cause the market price of our common stock and other securities to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not obtain trademark registrations for our potential trade names. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not selected trade names for some of our product candidates in our pipeline; therefore, we have not filed trademark registrations for
such potential trade names for our product candidates, nor can we assure that we will be granted registration of any potential trade names for which we do file. No assurance can be given that any of our trademarks will be registered in the United
States or elsewhere, or once registered that, prior to our being able to enter a particular market, they will not be cancelled for <FONT STYLE="white-space:nowrap">non-use.</FONT> Nor can we give assurances, that the use of any of our trademarks
will confer a competitive advantage in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, even if we are successful in our trademark registrations, the FDA
has its own process for drug nomenclature and its own views concerning appropriate proprietary names. It also has the power, even after granting market approval, to request a company to reconsider the name for a product because of evidence of
confusion in the marketplace. We cannot assure you that the FDA or any other regulatory authority will approve of any of our trademarks or will not request reconsideration of one of our trademarks at some time in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be
able to generate sufficient cash to service all of our indebtedness. We may be forced to take other actions to satisfy our obligations under our indebtedness or we may experience a financial failure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to make scheduled payments on or to refinance our debt obligations will depend on our financial and operating performance, which is
subject to the commercial success of Afrezza, the extent to which we are able to successfully develop and commercialize our Technosphere drug delivery platform and any other product candidates that we develop, prevailing economic and competitive
conditions, and to certain financial, business and other factors beyond our control. We cannot assure you that we will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and
interest on our indebtedness. If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure
or refinance our indebtedness. We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations or that these actions would be permitted
under the terms of our future debt agreements. In the absence of sufficient operating results and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and
other obligations. We may not be able to consummate those dispositions or obtain sufficient proceeds from those dispositions to meet our debt service and other obligations when due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely
impact the market price of our common stock and other securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders or their distributees sell
substantial amounts of our common stock in the public market, the market price of our common stock could decrease significantly. The perception in the public market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that our existing stockholders might sell shares of common stock could also depress the market price of our common stock and the market price of our other securities. Any such sales of our common
stock in the public market may affect the price of our common stock or the market price of our other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may
sell additional shares of our common stock to raise capital. In addition, a substantial number of shares of our common stock is reserved for: issuance upon the exercise of stock options, warrant exercises, and the vesting of restricted stock unit
awards; the purchase of shares of common stock under our employee stock purchase program; and the issuance of shares upon exchange or conversion of the 2018 notes or any other convertible debt we may issue. We cannot predict the size of future
issuances or the effect, if any, that they may have on the market price for our common stock. The issuance or sale of substantial amounts of common stock, or the perception that such issuances or sales may occur, could adversely affect the market
price of our common stock and other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>As a result of the death of Alfred E. Mann, our founder and former largest
stockholder, the stock that he previously controlled is currently controlled by a trust, and we cannot assure you of the manner in which the trustees will manage the holdings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At February 1, 2017, the estate of Alfred E. Mann beneficially owned approximately 23.7% of our outstanding shares of capital stock, including
shares held in the Alfred E. Mann Living Trust and The Mann Group LLC (collectively, the &#147;Mann Affiliated Entities&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mann passed away on February&nbsp;25, 2016. All of the shares beneficially owned by Mr.&nbsp;Mann in his individual capacity, the
Alfred E. Mann Living Trust and The Mann Group LLC are controlled by the Alfred E. Mann Living Trust. The trustees of the Alfred E. Mann Living Trust are Mr.&nbsp;Mann&#146;s wife and two other trustees. The trustees have the power to sell the
shares or deal with them as an owner. Relatives, other individuals and charities may receive bequests of shares under the trust. The residuary beneficiary of the trust is the Alfred E. Mann Family Foundation, a charitable organization under section
501(c)(3) of the Internal Revenue Code that is a private foundation under section 509 of the Code. The same three trustees control the Alfred E. Mann Family Foundation. The Alfred E. Mann Family Foundation will have the power to sell the shares or
deal with them as an owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been informed by the trustees for the Mann Affiliated Entities that the trustees may seek to dispose
of some or all of the shares beneficially owned by the Mann Affiliated Entities, pursuant to distributions to trust beneficiaries, one or more trading plans under Rule 10b5-1 of the Exchange Act or otherwise. Any sales or other disposition of our
common stock by the Mann Affiliated Entities, or the perception that such sales may occur, including the entry into any such trading plans, could have a material adverse effect on the trading price of our common stock and could make it more
difficult for us to raise capital through the sale of our common stock or securities convertible into or exercisable for our common stock, which could have a material adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price is volatile and may affect the market price of our common stock and other securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2014, our closing stock price as reported on The NASDAQ Global Market has ranged from $1.89 to $54.80 (giving retroactive
effect to our recently completed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> reverse stock split). The trading price of our common stock is likely to continue to be volatile. The stock market, particularly
in recent years, has experienced significant volatility particularly with respect to pharmaceutical and biotechnology stocks, and this trend may continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The volatility of pharmaceutical and biotechnology stocks often does not relate to the operating performance of the companies represented by
the stock. Our business and the market price of our common stock may be influenced by a large variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of our recent commercial launch of Afrezza in the United States and other events or circumstances that we or others estimate will impact the future commercial success of Afrezza; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain marketing approval for Afrezza outside of the United States and to find collaboration partners for the commercialization of Afrezza in foreign jurisdictions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our future estimates of Afrezza sales, prescriptions or other operating metrics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successful commercialize our Technosphere drug delivery platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of preclinical and clinical studies of our product candidates and of post-approval studies of Afrezza required by the FDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of preclinical and clinical studies of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, political or stock market conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">legislative developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us, our collaborators, or our competitors concerning clinical study results, acquisitions, strategic alliances, technological innovations, newly approved commercial products, product discontinuations,
or other developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of critical materials used in developing and manufacturing Afrezza or other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning our relationship with any of our current or future collaborators or third party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning our patents or proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expense and time associated with, and the extent of our ultimate success in, securing regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us concerning our financial condition or operating performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in securities analysts&#146; estimates of our financial condition or operating performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions and fluctuations for emerging growth and pharmaceutical market sectors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability, or the perception of investors of our ability, to continue to meet all applicable requirements for continued listing of our common stock on The NASDAQ Stock Market, and the possible delisting of our common
stock if we are unable to do so; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the status of any legal proceedings or regulatory matters against or involving us or any of our executive officers and directors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussion of Afrezza, our other product candidates, competitors&#146; products, or our stock price by the financial and scientific press, the healthcare community and online investor communities such as chat rooms. In
particular, it may be difficult to verify statements about us and our investigational products that appear on interactive websites that permit users to generate content anonymously or under a pseudonym and statements attributed to company officials
may, in fact, have originated elsewhere. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, as well as other factors, could cause the market value of our
common stock and other securities to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to continue to meet all applicable listing requirements, our common stock may be delisted
from The NASDAQ Global Market, which could have an adverse impact on the liquidity and market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is currently listed on The NASDAQ Global Market, which has qualitative and quantitative listing criteria. If we are unable to meet any of the NASDAQ listing requirements in the future, such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as the corporate governance requirements, the minimum closing bid price requirement, or the minimum market value of listed securities requirement, NASDAQ could determine to delist our common
stock. A delisting of our common stock could adversely affect the market liquidity of our common stock, decrease the market price of our common stock, adversely affect our ability to obtain financing for the continuation of our operations and result
in the loss of confidence in our company. On September&nbsp;14, 2016, we received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the previous 30 consecutive business days, the bid price for our
common stock closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market. The notification letter stated that we would be afforded 180 calendar days, or until March&nbsp;13, 2017, to regain compliance with
the minimum bid price requirement. In order to regain compliance, shares of our common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days. On March&nbsp;1, 2017, our board of
directors and stockholders approved the Charter Amendment to effect the Reverse Stock Split. On March&nbsp;3, 2017, our common stock began trading on The NASDAQ Global Market on a split-adjusted basis at a ratio of 1 share for 5. As of the date of
this filing, the shares of our common stock have maintained a minimum bid closing price of at least $1.00 per share for 10 consecutive business days. Accordingly, we expect to receive a notice from the Listing Qualifications Department of the NASDAQ
Stock Market indicating that we have regained compliance with the minimum closing bid price requirement. Despite effecting the Reverse Stock Split, there can be no assurance that the market price per share of our common stock will remain in excess
of the $1.00 minimum closing bid price requirement in the future. The continuing effect of the Reverse Stock Split on the market price of our common stock cannot be predicted with any certainty, and the history of similar stock split combinations
for companies in like circumstances is varied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If other biotechnology and biopharmaceutical companies or the securities markets in general
encounter problems, the market price of our common stock and other securities could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public companies in
general, including companies listed on The NASDAQ Global Market, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. There has been particular volatility
in the market prices of securities of biotechnology and other life sciences companies, and the market prices of these companies have often fluctuated because of problems or successes in a given market segment or because investor interest has shifted
to other segments. These broad market and industry factors may cause the market price of our common stock and other securities to decline, regardless of our operating performance. We have no control over this volatility and can only focus our
efforts on our own operations, and even these may be affected due to the state of the capital markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, following periods of
large price declines in the public market price of a company&#146;s securities, securities class action litigation has often been initiated against that company. Litigation of this type could result in substantial costs and diversion of
management&#146;s attention and resources, which would hurt our business. Any adverse determination in litigation could also subject us to significant liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The future sale of our common stock, the exchange or conversion of our 2018 notes into common stock or the exercise of our warrants for common stock
could negatively affect the market price of our common stock and other securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;10, 2017, we had 95,776,246
shares of common stock outstanding. Substantially all of these shares are available for public sale, subject in some cases to volume and other limitations or delivery of a prospectus. If our common stockholders sell substantial amounts of common
stock in the public market, or the market perceives that such sales may occur, the market price of our common stock and other securities may decline. Likewise the issuance of additional shares of our common stock upon the exchange or conversion of
some or all of our 2018 notes or upon the exercise of outstanding warrants, could adversely affect the market price of our common stock and other securities. In addition, the existence of these notes and warrants may encourage short selling of our
common stock by market participants, which could adversely affect the market price of our common stock and other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we will need to raise substantial additional capital in the future to fund our
operations. If we raise additional funds by issuing equity securities or additional convertible debt, the market price of our common stock and other securities may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in
Delaware. Certain anti-takeover provisions under Delaware law and in our certificate of incorporation and amended and restated bylaws, as currently in effect, may make a change of control of our company more difficult, even if a change in control
would be beneficial to our stockholders or the holders of our other securities. Our anti-takeover provisions include provisions such as a prohibition on stockholder actions by written consent, the authority of our board of directors to issue
preferred stock without stockholder approval, and supermajority voting requirements for specified actions. In addition, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits
stockholders owning 15% or more of our outstanding voting stock from merging or combining with us in certain circumstances. These provisions may delay or prevent an acquisition of us, even if the acquisition may be considered beneficial by some of
our stockholders. In addition, they may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible
for appointing the members of our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not expect to pay dividends in the foreseeable future, you must rely on stock
appreciation for any return on any investment in our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have paid no cash dividends on any of our capital stock to
date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future, and payment of cash dividends, if any, will
also depend on our financial condition, results of operations, capital requirements and other factors and will be at the discretion of our board of directors. Pursuant to the Facility Agreement, we are subject to contractual restrictions on the
payment of dividends. There is no guarantee that our common stock will appreciate or maintain its current price. You could lose the entire value of any investment in our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited number of unreserved shares available for future issuance, which may impair our ability to conduct future financing and other
transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, as amended on March&nbsp;1, 2017 to effect the Reverse Stock
Split, currently authorizes us to issue up to 140,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of March&nbsp;10, 2017, we had a total of 44,223,754 shares of common stock that were authorized but unissued, and we have
currently reserved a significant number of these shares for future issuance pursuant to outstanding equity awards, outstanding warrants, our equity plans and our 2018 notes. As a result, our ability to issue shares of common stock other than
pursuant to existing arrangements will be limited until such time, if ever, that we are able to amend our amended and restated certificate of incorporation to further increase our authorized shares of common stock or shares currently reserved for
issuance otherwise become available (for example, due to the termination of the underlying agreement to issue the shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are
unable to enter into new arrangements to issue shares of our common stock or securities convertible or exercisable into shares of our common stock, our ability to complete equity-based financings or other transactions that involve the potential
issuance of our common stock or securities convertible or exercisable into our common stock, will be limited. In lieu of issuing common stock or securities convertible into our common stock in any future equity financing transactions, we may need to
issue some or all of our authorized but unissued shares of preferred stock, which would likely have superior rights, preferences and privileges to those of our common stock, or we may need to issue debt that is not convertible into shares of our
common stock, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may require us to grant security interests in our assets and property and/or impose covenants upon us that restrict our business. If we are unable to issue additional shares of common stock or
securities convertible or exercisable into our common stock, our ability to enter into strategic transactions such as acquisitions of companies or technologies, may also be limited. If we propose to amend our amended and restated certificate of
incorporation to increase our authorized shares of common stock, such a proposal would require the approval by the holders of a majority of our outstanding shares of common stock, and we cannot assure you that such a proposal would be adopted. If we
are unable to complete financing, strategic or other transactions due to our inability to issue additional shares of common stock or securities convertible or exercisable into our common stock, our financial condition and business prospects may be
materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_3"></A>Item&nbsp;1B. </B><B><I>Unresolved Staff Comments</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_4"></A>Item&nbsp;2.
</B><B><I>Properties</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2001, we acquired a facility in Danbury, Connecticut that included two buildings comprising
approximately 190,000 square feet encompassing 17.5 acres. In September 2008, we completed the construction of approximately 140,000 square feet of new manufacturing space providing us with two buildings totaling approximately 328,000 square feet,
housing our research and development, administrative and manufacturing functions for Afrezza. We believe the Connecticut facility will have sufficient space to satisfy commercial demand for Afrezza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we owned approximately 142,000 square feet of laboratory, office and warehouse space in Valencia, California. On
February&nbsp;17, 2017, we sold certain parcels of real estate in Valencia, California and certain related improvements, personal property, equipment, supplies and fixtures, including the aforementioned space, to Rexford Industrial Realty, L.P. for
$17.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the Facility Agreement and the Milestone Agreement are secured by certain mortgages on our
facility in Danbury, Connecticut. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also lease approximately 12,500 square feet of office space in Valencia, California pursuant to a
lease that expires in April 2017. The facility contains our principal executive offices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_5"></A>Item&nbsp;3. </B><B><I>Legal
Proceedings</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the public announcement of Sanofi&#146;s election to terminate the Sanofi License Agreement and the
subsequent decline in our stock price, several complaints were filed in the U.S. District Court for the Central District of California (the &#147;District Court&#148;) against MannKind and certain of our officers and directors on behalf of certain
purchasers of our common stock, which were consolidated into a single action. The amended complaint alleged that MannKind and certain of our officers and directors violated federal securities laws by making materially false and misleading statements
regarding the prospects for Afrezza, thereby artificially inflating the price of MannKind&#146;s common stock. We and the named defendants brought a motion to dismiss the class action, which the District Court granted in August 2016 without leave to
amend the complaint. The lead plaintiff appealed that decision to the Ninth Circuit Court of Appeals. On March&nbsp;2, 2017, the lead plaintiff filed a voluntary motion to dismiss his appeal, which the Court of Appeals granted on March&nbsp;9, 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the public announcement of Sanofi&#146;s election to terminate the Sanofi License Agreement and the subsequent decline in our
stock price, two motions were submitted to the district court at Tel Aviv, Economic Department for the certification of a class action against MannKind and certain of our officers and directors. In general, the complaints allege that MannKind and
certain of our officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereby artificially inflating the price of its common stock. The plaintiffs are seeking monetary damages. In November 2016, the district court dismissed one of the actions without prejudice. In
the remaining action, a hearing is scheduled for May 2017 to determine whether Israeli or U.S. law is applicable before the case can be certified as a class action. We will vigorously defend against the claims advanced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to legal proceedings and claims which arise in the ordinary course of our business. As of the date hereof, we believe that
the final disposition of such matters will not have a material adverse effect on our financial position, results of operations or cash flows. We maintain liability insurance coverage to protect our assets from losses arising out of or involving
activities associated with ongoing and normal business operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_6"></A>Item&nbsp;4. </B><B><I>Mine Safety Disclosures</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_7"></A>Item&nbsp;5. </B><B><I>Market for the Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Market Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has been traded on The NASDAQ Global Market under the symbol &#147;MNKD&#148; since July&nbsp;28, 2004. The following table
sets forth for the quarterly periods indicated, the high and low sales prices for our common stock as reported by The NASDAQ Global Market (adjusted for the Reverse Stock Split effective March&nbsp;3, 2017). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Low</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing sales price of our common stock on The NASDAQ Global Market was $1.95 on March&nbsp;10, 2017 and
there were 171 registered holders of record as of that date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Measurement Comparison </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The material in this section is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and shall not be
incorporated by reference by any general statement incorporating by reference this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> into any of our filings under the Securities Act, or the Exchange Act, except to the extent we
specifically incorporate this section by reference. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph illustrates a comparison of the cumulative total stockholder
return (change in stock price plus reinvested dividends) of our common stock with (i)&nbsp;The NASDAQ Composite Index and (ii)&nbsp;The NASDAQ Biotechnology Index. The graph assumes a $100 investment, on December&nbsp;31, 2010, in (i)&nbsp;our
common stock, (ii)&nbsp;the securities comprising The NASDAQ Composite Index and (iii)&nbsp;the securities comprising The NASDAQ Biotechnology Index. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The comparisons in the graph are required by the SEC and are not intended to forecast or be
indicative of possible future performance of our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305327g95u55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future
earnings for use in the operation and expansion of our business. Accordingly, we do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends will be at the discretion of our
board of directors. In addition, under the terms of the Facility Agreement, we are restricted from distributing any of our assets or declaring and distributing a dividend to our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_8"></A>Item&nbsp;6. </B><B><I>Selected Financial Data</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following data has been derived from our audited financial statements, including the consolidated balance sheets at December&nbsp;31, 2016
and 2015 and the related consolidated statements of operations for each of the three years ended December&nbsp;31, 2016 and related notes appearing elsewhere in this report. The consolidated statement of operations data for the years ended
December&nbsp;31, 2013 and 2012 and the consolidated balance sheet data as of December&nbsp;31, 2014, 2013 and 2012 are derived from our audited consolidated financial statements that are not included in this report. The selected financial data set
forth below should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the audited consolidated financial statements, and the notes thereto, and other financial
information included herein this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,965</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue &#151; bulk insulin sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,412</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,265</TD>
<TD NOWRAP VALIGN="bottom">)(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,369</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,024</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,049</TD>
<TD NOWRAP VALIGN="bottom">)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(191,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(191,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(169,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">diluted net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute diluted net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility financing obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest &#151; note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi loan facility and loss share obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,371</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,737,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,863,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,296,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,104,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(350,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amount of revenue recognized in 2016 totaled $172.0&nbsp;million, which consisted of an upfront payment of $150.0&nbsp;million and two milestone payments of $25.0&nbsp;million each, net of $64.9&nbsp;million of net
loss share with Sanofi, as well as $17.5&nbsp;million in sales of Afrezza and $19.4&nbsp;million related to a sale of bulk insulin, both to Sanofi. These payments and sales were made pursuant to the contractual terms of the agreements with Sanofi.
Costs of revenue &#151; collaboration represents the costs of product manufactured and sold to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">In 2016, property and equipment impairment was a result of impairment charges of $695&nbsp;thousand and $564&nbsp;thousand for property, plant and equipment and asset held for sale, respectively. In 2015, in connection
with our quarterly assessment of impairment indicators and inventory valuation, we identified an impairment of our long-lived assets which resulted in charges of $140.4&nbsp;million in the fourth quarter of 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In 2016, the $2.3&nbsp;million gain on purchase commitments was related to a renegotiation of certain of our purchase commitments. In 2015, the $66.2&nbsp;million recognized loss on purchase commitments resulted from
our assessment of excess inventory as a result of lower than expected sales of Afrezza as well as a lower of cost or net realizable value adjustment due to estimated conversion costs in excess of our estimated selling price of Afrezza.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">In 2016, we recognized a change in fair value of warrant liability of $5.4&nbsp;million to reflect the fair value adjustments of the warrant liability from May&nbsp;12, 2016, the date certain warrants were issued in
connection with a registered public offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">The $72.0&nbsp;million gain from extinguishment of debt in 2016 was a result of the termination of the Sanofi License Agreement on November&nbsp;9, 2016 and forgiveness of the full outstanding loan balance on the Sanofi
Loan Facility. The $1.0&nbsp;million loss in 2015 was from extinguishment of debt driven by the settlement of the 5.75% Senior Convertible Notes due 2015 through the payment of cash and issuance of new debt. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_9"></A>Item&nbsp;7. </B><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated
financial statements and notes thereto included in this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only
approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June&nbsp;27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies
in February 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had an accumulated deficit of $2.7&nbsp;billion and a stockholders&#146; deficit of
$183.6&nbsp;million. We had net income (losses) of approximately $125.7&nbsp;million, ($368.4) million and ($198.4) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
million in the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. We have funded our operations primarily through the sale of equity securities and convertible debt securities,
borrowings under the Facility Agreement with Deerfield, borrowings under The Mann Group Loan Arrangement, receipt of upfront and milestone payments under the Sanofi License Agreement and borrowings under the Sanofi Loan Facility to fund our portion
of the loss share. As discussed below in &#147;Liquidity and Capital Resources&#148;, if we are unable to obtain additional funding, there will be substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to significant risks, including but not limited to our need to raise additional capital to fund our operations, our
ability to successfully commercialize Afrezza and manufacture sufficient quantities of Afrezza and the risks inherent in our ongoing clinical trials and the regulatory approval process for our product candidates. Additional significant risks also
include the results of our research and development efforts, competition from other products and technologies and uncertainties associated with obtaining and enforcing patent rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of our consolidated financial statements is in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires management to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, and expenses and related disclosure of contingent assets and liabilities. We consider an accounting estimate to be critical to the consolidated financial statements if (i)&nbsp;the
estimate is complex in nature or requires a high degree of judgment and (ii)&nbsp;different estimates and assumptions were used, the results could have a material impact on the consolidated financial statements. On an ongoing basis, we evaluate our
estimates and the application of our policies. We base our estimates on historical experience, current conditions and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The policies that we believe are critical to
the preparation of the consolidated financial statements are presented below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following critical accounting policies are more fully
described in Note 2 &#151; Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements included in &#147;Part II, Item 8 &#151; Financial Statements and Supplementary Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue</I></B> &#151; Revenue is recognized when the four basic criteria of revenue recognition are met: (1)&nbsp;persuasive evidence
that an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured. When the accounting requirements for revenue recognition are not
met, we defer the recognition of revenue by recording deferred revenue on the balance sheet until such time that all criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into a Commercial Outsourcing Services Agreement with Integrated Commercialization Solutions, Inc. (&#147;ICS&#148;), a third party logistics provider, under which ICS distributes our product to wholesalers on our behalf. To enable us
to distribute product in all necessary jurisdictions, on July&nbsp;1, 2016, we entered into a first amendment to our contract with ICS for an interim period. Under this amendment, ICS, through Integrated Commercialization Solutions Direct (ICS
Direct), purchased product from us and title and risk of loss transferred to ICS Direct. However, we did not recognize revenue upon transfer of product to ICS Direct because (1)&nbsp;we were required to indemnify and hold harmless ICS for all
accounts receivable arising out of product sales under the first amendment that were not collected from the customers according to payment terms, and (2)&nbsp;ICS Direct could return product to us under the right of return. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;26, 2016, we provided notice to ICS of our election to terminate the interim period agreement effective December&nbsp;15,
2016. After that date, ICS no longer took title to inventory. However, the Commercial Outsourcing Services Agreement continues to be in effect and ICS continues to distribute our product to wholesalers on our behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We invoice our customers upon shipment of Afrezza to them and record an accounts receivable, with
a corresponding liability for deferred revenue equal to the gross invoice price net of estimated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments. Given our limited sales history for Afrezza,
we cannot reliably estimate expected returns of the product at the time of shipment. Accordingly, we defer recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time
Afrezza is dispensed through patient prescriptions or expiration of the right of return. We recognize revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. We also analyze additional data
points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand. In addition, the costs of Afrezza associated with the deferred revenue are recorded as
deferred costs until such time as the related deferred revenue is recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, rebates and patient discount and <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance programs, and are
based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with our customers and the levels of inventory within the distribution and retail channels that may result in
future rebates or discounts taken. In certain cases, such as patient support programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these
estimates, which could have an effect on product revenue in the period of adjustment. We record product sales deductions in the statement of operations at the time product revenue is recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Product Returns</I></B> &#151; We do not provide a reserve for product refunds for sales of Afrezza due to our revenue recognition
policy of deferring recognition of revenue on product shipments of Afrezza until the right of return no longer exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred
Costs</I></B> &#151; Deferred costs from collaboration represents the cost of product manufactured and sold to Sanofi as well as certain direct costs associated with a firm purchase commitment entered into in connection with the Sanofi License
Agreement. At December&nbsp;31, 2016, deferred costs from commercial product sales represented the cost of product shipped to ICS and wholesale distributors, but not sold through by pharmacies to patients. Cost of goods sold related to commercial
product sales for the twelve months ended December&nbsp;31, 2016 included $0.3&nbsp;million of cost related to product sold through from pharmacies to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, deferred costs from collaboration of $13.5&nbsp;million represented the costs of product manufactured and sold
to Sanofi. During the third quarter of 2016, the costs related to the Sanofi product sales were recognized as costs of revenue &#151; collaboration in the consolidated statements of operations, as the related revenue was recognized at that time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>License and Collaboration Agreements</I></B> &#151; We analyzed consideration received under the Sanofi License Agreement to
determine whether the consideration, or a portion thereof, could be recognized as revenue. In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit
of accounting. This determination is generally based on whether the deliverable has &#147;stand-alone value&#148; to the customer. The arrangement&#146;s consideration that is fixed and determinable is then allocated to each separate unit of
accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i)&nbsp;vendor-specific objective evidence of fair value,
(ii)&nbsp;third-party evidence of selling price and (iii)&nbsp;best estimate of selling price (BESP). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. In
general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in
time that, or periods over which, revenue should be recognized. Due to the proprietary nature of the manufacturing services to be provided by us, we determined that all of the significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deliverables should be combined into a single unit of accounting. During the term of the Sanofi License Agreement, worldwide profits and losses were determined based on the difference between the
net sales of Afrezza and the costs and expenses incurred by us and Sanofi that were specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of Afrezza. These profits and losses were shared 65%
by Sanofi and 35% by us. Prior to December&nbsp;31, 2015, we did not have the ability to estimate the amount of costs that would potentially be incurred under the loss sharing provision of the Sanofi License Agreement, and accordingly we believed
the fixed and determinable fee requirement for revenue recognition was not met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first and second quarters of 2016, after we
received notice of termination from Sanofi, we evaluated whether the criteria had been met. We determined that the requirement had not been met because Sanofi had not finalized necessary adjustments to the profit and loss share provision statements
and Sanofi had not yet transferred all of the information to enable us to commercialize Afrezza on our own. Therefore, we were still unable to estimate the costs to be incurred under the agreement with Sanofi. During the third quarter of 2016,
Sanofi provided us with enough information to enable us to reasonably estimate the remaining costs under the Sanofi License Agreement and the Sanofi Supply Agreement. Accordingly, the fixed or determinable fee requirement for revenue recognition was
met and there were no future obligations to Sanofi. Therefore, we recognized $172.0&nbsp;million of net revenue &#151; collaboration for the year ended December&nbsp;31, 2016. The revenue recognized includes the upfront payment of
$150.0&nbsp;million and the two milestone payments of $25.0&nbsp;million each, net of $64.9&nbsp;million of net loss share with Sanofi, as well as $17.5&nbsp;million in sales of Afrezza and $19.4&nbsp;million from sales of bulk insulin, both to
Sanofi. These payments and sales were made pursuant to the contractual terms of the agreements with Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, we
entered into the Settlement Agreement with Sanofi. The accounting for this agreement is described in Note 8 &#151; Collaboration Arrangements of the Notes to Consolidated Financial Statements included in &#147;Part II, Item 8 &#151; Financial
Statements and Supplementary Data.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2016, we entered into the CLA with Receptor pursuant to which we performed
initial formulation studies on compounds identified by Receptor. Following successful completion of the studies, Receptor exercised its option to acquire an exclusive license to develop, manufacture and commercialize inhalation formulations of these
compounds utilizing our technology. See Note 8 &#151; Collaboration Arrangements of the Notes to Consolidated Financial Statements included in &#147;Part II, Item 8 &#151; Financial Statements and Supplementary Data&#148; for additional information
related to the accounting for the CLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inventories</I></B> &#151; Inventories are stated at the lower of cost or net realizable
value. We determine the cost of inventory using the <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> (&#147;FIFO&#148;) method. We capitalize inventory costs associated with Afrezza based on
management&#146;s judgment and the future economic benefit expected to be realized; otherwise, such costs are expensed in the period incurred. In addition, Afrezza is subject to strict quality control and monitoring, which we perform throughout the
manufacturing process. If certain batches of Afrezza inhalation powder, the inhaler or cartridges no longer meet quality specifications or become obsolete due to expiration, we will record a charge to write down such unmarketable inventory to its
estimated realizable value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We analyzed our inventory levels to identify inventory that may expire or has a cost basis in excess of its
estimated realizable value. We performed an assessment of projected sales to evaluate the lower of cost or net realizable value and the potential excess inventory on hand at December&nbsp;31, 2016 and 2015. As a result of these assessments, we
recorded a $0.2&nbsp;million charge at December&nbsp;31, 2016 to <FONT STYLE="white-space:nowrap">write-off</FONT> inventory that will expire prior to sale.&nbsp;At December&nbsp;31, 2015, we recorded a charge of $36.1&nbsp;million to record the raw
materials inventory on hand at the lower of cost or net realizable value and inventory expiry, and $3.2&nbsp;million related to the <FONT STYLE="white-space:nowrap">write-off</FONT> of prepaid deposits related to the purchase of inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recognized Loss on Purchase Commitments</I></B> &#151; At December&nbsp;31, 2016 and 2015, in connection with the projected sales
assessment, we also evaluated our inventory purchase commitments totaling $101.0&nbsp;million and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$116.2&nbsp;million, respectively, for potential impairment. As a result of these assessments, we recorded $101.0&nbsp;million and $66.2&nbsp;million, respectively, to the liability for
recognized loss on purchase commitments both from a lower of cost or net realizable value and excess inventory perspective. Prior to December&nbsp;31, 2016, the recognized loss on purchase commitments was reduced to reflect our expectation that a
portion was recoverable from Sanofi. At December&nbsp;31, 2016 the recognized loss on purchase commitments no longer reflects recoverability from Sanofi because it was recognized as a receivable from Sanofi due to the Settlement Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets</I></B> &#151; Assessing long-lived assets for impairment requires us to make assumptions and judgments
regarding the carrying value of these assets. We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The assets are considered to be impaired if
we determine that the carrying value may not be recoverable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we believe an asset to be impaired, the impairment we recognize is the
amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using market, income or cost approaches, as appropriate for the asset. Any write-downs would be treated as permanent reductions in the
carrying amount of the asset and an operating loss would be recognized. In addition, we base the useful lives and related amortization or depreciation expense on our estimate of the useful lives of the assets. If a change were to occur in any of the
above-mentioned factors or estimates, our reported results could materially change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our quarterly assessment of
impairment indicators, we evaluated the continued lower than expected sales of Afrezza as reported by Sanofi throughout the fourth quarter of 2015, revised forecasts for sales of Afrezza provided by Sanofi in the fourth quarter of 2015 and level of
commercial production in the fourth quarter of 2015, as well as the uncertainty associated with Sanofi&#146;s announcement during the fourth quarter of their intent to reorganize their diabetes business. These factors indicated potentially
significant changes in the timing and extent of cash flows, and we therefore determined that an impairment indicator existed in the fourth quarter of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed more fully in Note 4 &#151; Property and Equipment of the Notes to Consolidated Financial Statements included in &#147;Part II,
Item 8 &#151; Financial Statements and Supplementary Data&#148;, based on the above impairment factors in 2015, we identified an impairment charge of $1.8&nbsp;million related to our Valencia property, which was previously our corporate
headquarters, as well as a $138.6&nbsp;million impairment charge to our Danbury manufacturing facility, which currently performs all manufacturing of Afrezza. As disclosed in Note 20 &#151; Subsequent Events of the Notes to Consolidated Financial
Statements included in &#147;Part II, Item 8 &#151; Financial Statements and Supplementary Data&#148;, in 2016 we also recorded an additional $1.2&nbsp;million impairment charge related to facilities of which $0.5&nbsp;million is associated with the
Valencia property, when it became probable that the property would be sold within one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have had cumulative operating
losses, and the recoverability of our long-lived assets is contingent upon executing our business plan. If we are unable to execute our business plan, we may require additional write downs of the value of our long-lived assets in future periods.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Rights Liability</I></B> &#151; In addition to the Facility Financing Obligation, we also issued certain rights to
receive payments of up to $90.0 million upon occurrence of specified strategic and sales milestones (the &#147;Milestone Rights&#148;). These rights are not reflected in the Facility Financing Obligation. The estimated fair value of the Milestone
Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones discounted to present value using a
selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as our forecast, progress made
to date towards meeting the milestones, and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (14.5%) was selected based on an estimation of required rate of returns for similar
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment opportunities using available market data. As of December 31, 2016, the carrying value of the Milestone Rights is $8.9 million, classified as a long-term liability and the fair value
is estimated at $18.4 million. The fair value measurement of the liability is sensitive to the discount rate and the timing and probability of making milestone payments. If the achievement of each of the milestones which require payments were to be
12 months earlier or later than in our current forecast, the fair value of the liability would increase by 15 percent or decrease by 14, respectively. If the probability of achieving each milestones was increased or decreased by 5 percent, the fair
value of the liability would increase or decrease by 17 percent, respectively. If the discount rate were to increase or decrease by 1 percent, the fair value of the liability would increase or decrease by 2 percent, respectively. Over the long term,
these inputs are interrelated because if our performance improves, the timing of meeting the milestones would likely be earlier, the probability of making payments on the milestones would likely be higher, and the discount rate would likely
decrease, all of which would increase the fair value of the liability. The inverse is also true. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trial Expenses</I></B>
&#151; Our clinical trial accrual process seeks to account for expenses resulting from our obligations under contract with vendors, consultants, and clinical site agreements in connection with conducting clinical trials. The financial terms of these
contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the
appropriate trial expenses in our financial statements by matching period expenses with period services and efforts expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of
various aspects of the trial. We determine accrual estimates through discussions with internal clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status
is then compared to the contractual obligated fee to be paid for such services. During the course of a clinical trial, we adjust our rate of clinical expense recognition if actual results differ from our estimates. In the event that we do not
identify certain costs that have begun to be incurred or we underestimate or overestimate the level of services performed or the costs of such services, our reported expenses for a period would be too low or too high. The date on which certain
services commence, the level of services performed on or before a given date and the cost of the services are often judgmental. We make these judgments based upon the facts and circumstances known to us in accordance with generally accepted
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in our reporting amounts that are too high or too low for any particular period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation</I></B> &#151; All share-based payments to employees, including grants of stock options, restricted stock
units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated income statements based upon the fair value of the awards at the grant date. We use the Black-Scholes option valuation
model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Option valuation models require inputs, including the stock price, the exercise price, the expected life of the
stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The expected volatility assumption is based on an assessment of the historical volatility, with consideration of implied
volatility, derived from an analysis of historical trade activity. Restricted stock units are valued based on the market price on the grant date. We evaluate stock awards with performance conditions as to the probability that the performance
conditions will be met and estimate the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B> &#151; We account for our warrants as either equity or liabilities based upon the characteristics and provisions of
each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants classified as derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are
revalued at each subsequent balance sheet date, with fair value changes recognized as increases or decreases in other income (expense) in the consolidated statements of operations. The Company estimates the fair value of its derivative liabilities
using a third party valuation analysis that utilizes a Monte </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Carlo pricing valuation model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, such as probability of a dilutive issuance, as
well as expected volatility, expected life, yield and a risk-free interest rate. The expected volatility assumption is primarily based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis
of historical trade activity. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not remeasured in subsequent periods, unless the underlying assumptions change to trigger liability accounting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for Income Taxes</I></B> &#151; Our management must make judgments when determining our provision for income taxes, our
deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. At December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively, we had established a valuation allowance of $914.5&nbsp;million and
$962.6&nbsp;million against all of our net deferred tax asset balances, due to uncertainties related to the realizability of our deferred tax assets as a result of our history of operating losses. The valuation allowance is based on our estimates of
taxable income by jurisdiction in which we operate and the period over which our deferred tax assets will be recoverable. In the event that actual results differ from these estimates or we adjust these estimates in future periods, we may need to
change the valuation allowance, which could materially impact our financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Years ended December&nbsp;31, 2016 and 2015 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a
comparison of the revenue categories for the years ended December&nbsp;31, 2016 and 2015 (dollars in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Twelve Months Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; commercial product sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross revenue from commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT>
adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wholesale distribution fees and prompt pay discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient discount and <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue &#151; bulk insulin sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, we derived a significant amount of revenue from our collaboration with Sanofi under which we had to
perform certain obligations and we received periodic payments. During the year ended December&nbsp;31, 2016, we recognized net revenue from our collaboration with Sanofi of $172.0&nbsp;million. The recognized collaboration revenue relates to
payments for activities from prior periods which were previously deferred as the transactions did not meet the criteria for revenue recognition until 2016. In the third quarter of 2016, due to the termination of the Sanofi License Agreement, we
determined the costs related to the collaboration with Sanofi were reasonably estimable, resulting in the recognition of revenue as there were no future obligations to Sanofi. The amount of revenue recognized was the upfront payment of
$150.0&nbsp;million and two milestone payments of $25.0&nbsp;million each, offset by $64.9&nbsp;million of net loss share with Sanofi, as well as $17.5&nbsp;million in sales of Afrezza and $19.4&nbsp;million in sales of bulk insulin, both to Sanofi.
During the year ended December&nbsp;31, 2015, we did not recognize any revenues from collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began distributing MannKind-branded Afrezza product to wholesalers through ICS Direct during
the week of July&nbsp;25, 2016. We recognize commercial product revenue based on Afrezza prescriptions dispensed to patients. During the year ended December&nbsp;31, 2016, we recognized net revenue from commercial product sales of $1.9&nbsp;million.
During the year ended December&nbsp;31, 2015, we did not recognize any revenues from commercial product sales. At December&nbsp;31, 2016, year to date total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT>
adjustments were approximately 30% of gross revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2016 we sold $0.9&nbsp;million of bulk
insulin to a third party. During the year ended December&nbsp;31, 2015, we did not sell any bulk insulin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a comparison of the expense categories for the year ended December&nbsp;31, 2016 and 2015 (dollars in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Twelve&nbsp;Months&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">344,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(237,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of revenue from collaboration represents the costs of product manufactured and sold to Sanofi, as well
as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the year ended December&nbsp;31, 2016, we recognized $33.0&nbsp;million of costs of revenue from collaboration,
which consists of $13.5&nbsp;million in Afrezza manufacturing costs for product sold to Sanofi, and $19.5&nbsp;million related to the cost of bulk insulin sold to Sanofi. The Afrezza manufacturing costs were previously deferred on the consolidated
balance sheet at December&nbsp;31, 2015. During the year ended December&nbsp;31, 2015, we did not recognize any costs of revenue from collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well as under-absorbed labor and
overhead and inventory write-offs, which are recorded as expenses in the period in which they are incurred, rather than as a portion of the inventory cost. The decrease in cost of goods sold of $47.6&nbsp;million for the year ended December&nbsp;31,
2016 compared to the same period in the prior year is primarily due to $36.1&nbsp;million of inventory impairment write offs and $3.2&nbsp;million in deposit write offs, which were recorded in other assets, related to impairment in 2015 that did not
recur in 2016 and a $8.6&nbsp;million decrease in under-absorbed labor and overhead due to the reduction in force and decreased depreciation following the fixed asset impairment write-down in 2015. These decreases are offset by $0.3&nbsp;million
cost of goods attributable to commercial product sales, which consists of the manufacturing costs for Afrezza dispensed to patients. This $0.3&nbsp;million attributable to commercial product sales only includes conversion cost as we wrote off the
cost of our raw materials held in inventory at the end of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically our research and development expenses have consisted mainly
of costs associated with research and development of our product candidates, including associated clinical trials and manufacturing process development. This includes the salaries, benefits and stock-based compensation of research and development
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel, raw materials, laboratory supplies and materials, facility costs, costs for consultants and related contract research, licensing fees and depreciation of equipment. The decrease in
research and development expense of $14.8&nbsp;million for the year ended December&nbsp;31, 2016 compared to the same period in the prior year is due to the expense associated with the 2015 reduction in force exceeding the expense associated with
the 2016 reduction in force by $6.2&nbsp;million, as well as decreases in facility spending of $3.3&nbsp;million due to the reduction in force and lower depreciation expense following the <FONT STYLE="white-space:nowrap">write-off</FONT> of
property, plant and equipment in 2015; in research and development project costs of $3.1&nbsp;million due to completion of projects in 2015; in clinical trial expenses of $2.1&nbsp;million due to completion of Afrezza trials in 2015; in stock-based
compensation expense of $1.1&nbsp;million due to fewer employees as a result of the reduction in force and lower stock price; and the receipt of $0.4&nbsp;million research and development reimbursement payment from Receptor in 2016, which was offset
against expense. These decreases were partially offset by an increase in FDA fees for the 2016 filing of a supplemental new drug application for $1.0&nbsp;million and a $0.9&nbsp;million reduction in our research and development tax credit as a
result of lower qualifying expenses coupled with a transition to commercial sales activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our selling and marketing expenses are driven
by salaries, benefits and stock-based compensation for sales and marketing support personnel. The increase in selling and marketing expenses of $18.3&nbsp;million for the year ended December&nbsp;31, 2016 compared to the same period in the prior
year is due to an increase in costs for the support of sales and marketing of Afrezza as a result of our assuming responsibility for these activities which were previously the responsibility of Sanofi. Included in these costs are salaries of
$2.9&nbsp;million, contracted sales force and diabetic educators of $7.6&nbsp;million, travel of $0.4&nbsp;million, and consultants and related expenses for sales and marketing of $7.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses are driven by salaries, benefits and stock-based compensation for administrative, finance, business
development, human resources, legal and information systems support personnel. In addition, general and administrative expenses include professional service fees and business insurance costs. The decrease in general and administrative expenses of
$12.3&nbsp;million for the year ended December&nbsp;31, 2016 compared to the same period in the prior year is primarily due to a decrease in costs associated with the 2015 reduction in force of $6.4&nbsp;million; stock-based compensation expense of
$2.6&nbsp;million due to lower stock price and fewer employees; professional fees of $1.7&nbsp;million due to lower internal communications, information technology, legal and outside service expenses due to concerted efforts to conserve cash; and
facility spending of $1.7&nbsp;million due to a lower operating cost as a result of the reduction in force and move to the leased Valencia offices, which helped save on facility costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment impairment decreased $139.2&nbsp;million for the year ended December&nbsp;31, 2016 compared to year ended
December&nbsp;31, 2015. In the fourth quarter of 2015 and the first quarter of 2016, factors indicated the existence of impairment in connection with the lower than expected sales of Afrezza and the Sanofi termination. The property and equipment
impairment in 2015 and the first quarter of 2016 reduced the carrying amount of our real property and machinery and equipment to fair value based on our impairment assessments. In the fourth quarter of 2016 we recorded a $0.5&nbsp;million impairment
charge associated with the Valencia property when it became probable that the property would be sold within one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Insulin
Supply Agreement with Amphastar, which is denominated in Euros, we were required to record the foreign currency translation impact of the U.S. dollar to euro exchange rate associated with the recognized loss on purchase commitments in 2016. We were
also required to record the foreign currency translation impact of the U.S. dollar to euro exchange rate associated with the deposit we made with Amphastar on this agreement in 2015. The gain on foreign currency translation for the year ended
December&nbsp;31, 2016 was $3.4&nbsp;million as compared to a loss in 2015 of $2.7&nbsp;million, resulting in a $6.1&nbsp;million net variance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on purchase commitments changed by $68.4&nbsp;million as a result of a gain recorded in 2016 compared to a loss in 2015. The
$2.3&nbsp;million gain on purchase commitments in 2016, related to a renegotiation of certain of our purchase commitments (primarily the reduction in cancellation fees under the Amphastar agreement). The $66.2&nbsp;million loss on purchase
commitments in 2015 resulted from our assessment of excess inventory as a result of lower than expected sales of Afrezza as well as a lower of cost or net realizable value adjustment due to estimated conversion costs in excess of our estimated
selling price of Afrezza. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a comparison of the other income (expense) categories for the years ended December&nbsp;31, 2016 and 2015 (dollars
in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Twelve&nbsp;Months&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,966</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(346</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016 we recorded a $5.4&nbsp;million change in the fair value of the
warrant liability from May&nbsp;12, 2016, the date that certain warrants were issued in connection with a registered public offering. There was no warrant liability for the twelve months ended December&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease of $5.7&nbsp;million in the interest expense on notes for the year ended December&nbsp;31, 2016 compared to the same period in
the prior year was primarily due to interest expense paid in 2015 for the achievement and <FONT STYLE="white-space:nowrap">re-measurement</FONT> of the second milestone under the Milestone Agreement. There was no such payment in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $72.0&nbsp;million gain from extinguishment of debt in 2016 was a result of the Settlement Agreement with Sanofi and forgiveness of the
full outstanding loan balance of the Sanofi Loan Facility. The $1.0&nbsp;million loss in 2015 was from extinguishment of debt driven by the settlement of the 5.75% Senior Convertible Notes due 2015 through payment of cash and issuance of new debt.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in other (expense) income of $2.0&nbsp;million for the year ended December&nbsp;31, 2016 compared to the same period in the
prior year was primarily due to a <FONT STYLE="white-space:nowrap">one-time</FONT> adjustment in 2015 for patents we sold to a third party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Years
ended December&nbsp;31, 2015 and 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015 and 2014, we did not recognize any revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a
comparison of the expense categories for the years ended December&nbsp;31, 2015 and 2014 (dollars in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">344,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">179,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of goods sold was $64.7&nbsp;million for the year ended December&nbsp;31, 2015, resulting
from product manufacturing costs associated with Afrezza product sales, which could not be capitalized due to excess capacity as well as inventory write-offs. We had no cost of goods sold for the year ended December&nbsp;31, 2014, as <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> manufacturing costs associated with Afrezza were accounted for as research and development expenses. Cost of goods sold represents under-absorbed labor and overhead of $21.4&nbsp;million which is
expensed in the period in which it is incurred and inventory write-offs of $36.1&nbsp;million and $3.2&nbsp;million in write-offs of deposits placed with inventory suppliers, which were previously included in other assets in the accompanying
consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically our research and development expenses have consisted mainly of costs associated with research
and development of our product candidates, including associated clinical trials and manufacturing process development. This includes the salaries, benefits and stock-based compensation of research and development personnel, raw materials, laboratory
supplies and materials, facility costs, costs for consultants and related contract research, licensing fees and depreciation of equipment. The decrease in research and development expenses of $70.6&nbsp;million for the year ended December&nbsp;31,
2015 compared to the year ended December&nbsp;31, 2014 was primarily due to a decrease of $36.0&nbsp;million in manufacturing process development expenses resulting from the shift to commercial production of Afrezza, a $19.3&nbsp;million decrease in
stock-based compensation expense as a result of a <FONT STYLE="white-space:nowrap">non-recurring</FONT> modification of the settlement terms of certain performance-based restricted stock units recorded in 2014 and the achievement of
performance-based grants in 2014 and the first quarter of 2015, and a decrease in clinical trial related expenses of $16.0&nbsp;million, primarily resulting from the completion of the Phase 3 clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our selling, general and administrative expenses are driven by salaries, benefits and stock-based compensation for sales, administrative,
finance, business development, human resources, legal and information systems support personnel. In addition, selling, general and administrative expenses include professional service fees and business insurance costs. The decrease in selling,
general and administrative expenses of $38.4&nbsp;million for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily due to decreased stock-based compensation expense of $20.6&nbsp;million, resulting
from the modification and achievement of performance-based grants in 2014 and the first quarter of 2015, as described above. Additionally, the decrease is also attributable to professional fees of $13.8&nbsp;million related to the Sanofi License
Agreement incurred in the third quarter of 2014 and decreased expenses of $3.2&nbsp;million following the completion of restructuring activities and decreased personnel costs in early 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment impairment increased $140.4&nbsp;million for the year ended December&nbsp;31, 2015 compared to the year ended
December&nbsp;31, 2014. In connection with the lower than expected sales of Afrezza and the termination of the Sanofi License Agreement, factors indicated the existence of impairment in the fourth quarter of 2015. A property and equipment impairment
was recorded which reduced the carrying amount of our real property and machinery and equipment to fair value based on our impairment assessment in the fourth quarter of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Insulin Supply Agreement with Amphastar, which is denominated in Euros, we were required to record the foreign currency translation
impact of the U.S. dollar to euro exchange rate associated with the deposit on this agreement. The loss on foreign currency translation for the year ended December&nbsp;31, 2015 was $2.7&nbsp;million. There was no gain or loss in the prior year
because we did not have amounts on deposit with Amphastar in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory purchase commitments were analyzed in 2015 for potential
impairment. Loss on purchase commitments increased $66.2&nbsp;million for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014. The loss on purchase commitments was related to the recognized loss on future purchase
commitments resulting from our assessment of excess inventory as a result of lower than expected sales of Afrezza as well as a lower of cost or net realizable value adjustment due to estimated conversion costs in excess of our estimated selling
price of Afrezza. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a comparison of the other income (expense) categories for the years ended December&nbsp;31, 2015 and 2014 (dollars
in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense on notes increased $3.7&nbsp;million from $17.5&nbsp;million for the year ended
December&nbsp;31, 2014 to $21.2&nbsp;million for the year ended December&nbsp;31, 2015. The increase was primarily due to $5.8&nbsp;million interest expense associated with the milestone payment resulting from the achievement and <FONT
STYLE="white-space:nowrap">re-measurement</FONT> of the second milestone under the Milestone Agreement in the first quarter of 2015 compared to the $1.9&nbsp;million interest expense from the payment of the first milestone in 2014. The increase was
also due to an increase of $1.7&nbsp;million related to the Sanofi Loan Facility and $0.8&nbsp;million in interest for 2018 notes, which was offset by a decrease in interest expense of $2.7&nbsp;million resulting from the maturity of the 5.75%
Senior Convertible Notes due 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt was $1.0&nbsp;million for the year ended December&nbsp;31, 2015
compared to no loss on extinguishment of debt for the year ended December&nbsp;31, 2014. The loss on extinguishment is due to the settlement of the 5.75% Senior Convertible Notes due 2015 through payment of cash and issuance of new debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income for the year ended December&nbsp;31, 2015 was $1.4&nbsp;million resulting from the relief of an accrual for potential expenses
associated with the sale of intellectual property related to oncology in 2014, which was subsequently resolved without payment in the first quarter of 2015. For the year ended December&nbsp;31, 2014, other income was $1.7&nbsp;million resulting
primarily from the sale of intellectual property related to oncology in the third quarter of 2014 in the amount of $7.9&nbsp;million, partially offset by a $6.4&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> charge recognized upon the
conversion of 2019 notes into equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have funded our operations through the sale of equity securities and convertible debt securities, borrowings under The Mann Group
Loan Arrangement, borrowings under the Facility Agreement with Deerfield, receipt of upfront and milestone payments under the Sanofi License Agreement, and borrowings under the Sanofi Loan Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had $152.1&nbsp;million principal amount of outstanding debt, consisting of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$27.6&nbsp;million principal amount of 2018 notes bearing interest at 5.75%&nbsp;per annum and maturing on August&nbsp;15, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$55.0&nbsp;million principal amount of 2019 notes bearing interest at 9.75%&nbsp;per annum, $15.0&nbsp;million of which is due and payable in July 2017, $15.0&nbsp;million of which is due and payable in July 2018 and
$25.0&nbsp;million of which is due and payable in July and December 2019; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$20.0&nbsp;million principal amount of Tranche B notes bearing interest at 8.75%&nbsp;per annum, $5.0&nbsp;million of which is due and payable in each of May 2017, 2018 and 2019, and $5.0&nbsp;million of which is due
and payable in December 2019; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$49.5&nbsp;million principal amount of indebtedness under The Mann Group Loan Arrangement bearing interest at 5.84% and maturing and due on January&nbsp;5, 2020. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the amount available for future borrowings under The Mann Group
Loan Arrangement was $30.1&nbsp;million. A portion of these available borrowings may be used to capitalize accrued interests into principal, upon mutual agreement of the parties, as it becomes due and payable. As of December&nbsp;31, 2016, the
accrued and unpaid interest under The Mann Group Loan Arrangement was $9.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding debt is more fully described in Note
6 &#151; Related-Party Arrangements, Note 7 &#151; Borrowings, Note 9 &#151; Fair Value of Financial Instruments and Note 13 &#151; Commitments and Contingencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will have sufficient resources to make any required repayments of principal under the 2018 notes, 2019
notes, Tranche B notes, or The Mann Group Loan Arrangement when required. Further, if we undergo a fundamental change, as that term is defined in the indentures governing the terms of the 2018 notes, or certain Major Transactions as defined in the
Facility Agreement in respect of the 2019 notes and the Tranche B notes, the holders of the respective debt securities will have the option to require us to repurchase all or any portion of such debt securities at a repurchase price of 100% of the
principal amount of such debt securities to be repurchased plus accrued and unpaid interest, if any. The 2018 notes bear interest at the rate of 5.75% per year on the outstanding principal amount, payable in cash semiannually in arrears on
February&nbsp;15 and August&nbsp;15 of each year. The 2019 notes bear interest at the rate of 9.75% per year on the outstanding principal amount and the Tranche B notes bear interest at the rate of 8.75% on the outstanding principal amount, with
accrued interest on each payable in cash quarterly in arrears on the last business day of March, June, September and December of each year. Loans under the Mann Group Loan Arrangement accrue interest at a rate of 5.84% per annum due and payable
quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as we and The Mann Group LLC mutually agree. While we have been able to timely make our required interest payments to date, we cannot
guarantee that we will be able to do so in the future. If we fail to pay interest on the 2018 notes, 2019 notes, or Tranche B notes, or if we fail to repay or repurchase the 2018 notes, 2019 notes, Tranche B notes, or borrowings under the Mann Group
Loan Arrangement when required, we will be in default under the applicable instrument for such indebtedness, and may also suffer an event of default under the terms of other borrowing arrangements that we may enter into from time to time. Any of
these events could have a material adverse effect on our business, results of operations and financial condition, up to and including the note holders initiating bankruptcy proceedings or causing us to cease operations altogether. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Facility Agreement, on July&nbsp;1, 2013, we issued Milestone Rights to the Milestone Purchasers. The
Milestone Rights provide the Milestone Purchasers certain rights to receive payments of up to $90.0&nbsp;million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an Afrezza product and the
achievement of specified net sales figures. In addition, the Facility Agreement includes customary representations, warranties and covenants, including a restriction on the incurrence of additional indebtedness, and a financial covenant which
requires our cash and cash equivalents, which includes available borrowings under The Mann Group Loan Arrangement, on the last day of each fiscal quarter to not be less than $25.0&nbsp;million. See Note 13 &#151; Commitments and Contingencies and
Note 7 &#151; Borrowings for further information related to the Facility Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2014, we entered into the Insulin
Supply Agreement, pursuant to which we agreed to purchase certain annual minimum quantities of insulin. See Note 13 &#151; Commitments and Contingencies for further information related to the Insulin Supply Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Sanofi License Agreement, we received an initial upfront payment of $150.0&nbsp;million and milestone payments totaling
$50.0&nbsp;million in the first quarter of 2015 upon satisfaction of certain manufacturing milestones specified in the Sanofi License Agreement. As a result of the termination of the Sanofi License Agreement, we will not receive any additional
milestone payments from Sanofi under the agreement. In addition, on November&nbsp;9, 2016, in connection with the Settlement Agreement, we and Aventisub LLC, an affiliate of Sanofi, agreed to terminate the Sanofi Loan Facility and the Security
Agreement (the &#147;Security Agreement&#148;). In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with such termination, Aventisub LLC agreed to forgive the full outstanding loan balance on the Sanofi Loan Facility of $72.0&nbsp;million owed by us and agreed to release its security
interests encumbering our assets. Sanofi also agreed to make a cash payment of $30.6 million to the Company, which was received in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been
required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. See Note 8 &#151; Collaboration Arrangements for further information related to the Sanofi agreements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, we sold in a registered public offering (the &#147;May 2016 Offering&#148;) 9,708,737 shares of our common stock, together
with certain warrants exercisable for up to an aggregate of 7,281,553 shares of our common stock and certain warrants exercisable for up to an aggregate of 2,427,184 shares of our common stock. Net proceeds from this offering were approximately
$47.3&nbsp;million after deducting placement agent fees and expenses and paying for offering expenses, and excluding any future proceeds from the exercise of the warrants. See Note 16 &#151; Warrants for further information related to the May 2016
Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities, which consists of net income adjusted for the various
<FONT STYLE="white-space:nowrap">non-cash</FONT> included in income, changes in working capital and changes in certain other balance sheet accounts, totaled $78.1&nbsp;million in 2016. Operating activities used $57.2&nbsp;million and provided
$4.1&nbsp;million of cash in 2015 and 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities in 2016 of $78.1 was primarily driven by an
excess of cash used in operations of approximately $105.1&nbsp;million over cash received from operations of approximately $29.4&nbsp;million. Cash received of approximately $29.4&nbsp;million represented $19.4&nbsp;million from sales of insulin to
Sanofi, $4.8&nbsp;million from Afrezza product sales, $2.7&nbsp;million from sales of insulin to a third party, $1.4&nbsp;million from our collaboration with Receptor and $1.1&nbsp;million from other sources. Cash used in operations of approximately
$105.1&nbsp;million represented by $69.5&nbsp;million in cash used for selling, general and administrative expenses, cost of goods sold, and research and development, a $12.1&nbsp;million decrease in accounts payable between December&nbsp;31, 2015
and December&nbsp;31, 2016, $11.6&nbsp;million in purchases of inventory from Amphastar, $9.0&nbsp;million in interest paid and a $2.5&nbsp;million increase in inventory between December&nbsp;31, 2015 and December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, we used $57.2&nbsp;million of cash for operating activities as a result of our net loss of
$368.4&nbsp;million, adjusted by noncash charges of $273.1&nbsp;million and a net change in operating assets and liabilities of $38.1&nbsp;million. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges included $206.6&nbsp;million of
impairment charges, $22.0&nbsp;million of depreciation and accretion and stock-based compensation, $1.7&nbsp;million interest accrued through borrowings under Sanofi Loan Facility, $1.0&nbsp;million for the loss on extinguishment of debt, with the
remainder due to an adjustment for foreign currency transaction losses. The change in net assets and liabilities was predominately due to the net decreases in receivables from collaboration from the $50.0&nbsp;million received in milestone payments
and $13.5&nbsp;million due to the decrease in prepaids and other current assets at December&nbsp;31, 2015 compared to December&nbsp;31, 2014 primarily due to prepayment on insulin in 2014, which did not occur in 2015. This was offset by net
decreases in inventory as we purchased significant inventory in 2014 related to Amphastar, which did not occur in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year
ended December&nbsp;31, 2014, cash provided by operations was $4.l million as a result of our net loss of $198.4&nbsp;million, adjusted by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $71.6&nbsp;million and a net change in operating
assets and liabilities of $130.9&nbsp;million. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges were predominately related to depreciation and accretion and stock-based compensation. The change in net assets and liabilities was
predominately due to the net increases in receivables and deferred payments from collaboration of $150.0&nbsp;million related to the fee associated with the Sanofi License Agreement, partially offset by the $15.0&nbsp;million deposit to Amphastar as
prepayment for 2015 quantities of insulin as part of the Insulin Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities decreased by
$9.1&nbsp;million for the year ended December&nbsp;31, 2016 versus December&nbsp;31, 2015, which is primarily a result of decreasing expenditures on property and equipment to conserve cash. Cash used in investing activities in 2016 was primarily
comprised of purchases of property and equipment of $1.1&nbsp;million. Investing activities used $10.2&nbsp;million and $24.1&nbsp;million of cash in 2015 and 2014, respectively, which primarily comprised of purchases of property and equipment. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities, which mainly accounts for external activities that allow
us to raise capital, primarily represents proceeds of $47.3&nbsp;million (net of related issuance costs) from the May 2016 Offering, offset by $5.0&nbsp;million from payments of notes payable in 2016. Financing activities provided $5.7&nbsp;million
and $70.1&nbsp;million of cash in 2015 and 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had $22.9&nbsp;million in cash and cash
equivalents. We expect to expend our capital resources primarily for the manufacturing, sales and marketing of Afrezza and to develop our other product candidates. We also intend to use our capital resources for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into strategic business collaborations with respect to our other product candidates, we would expect, as part of the transaction,
to receive additional capital. In addition, we expect to pursue the sale of equity and/or debt securities, or the establishment of other funding facilities. Issuances of debt or additional equity could impact the rights of our existing stockholders,
dilute the ownership percentages of our existing stockholders and may impose restrictions on our operations. These restrictions could include limitations on additional borrowing, specific restrictions on the use of our assets as well as prohibitions
on our ability to create liens, pay dividends, redeem our stock or make investments. We also may seek to raise additional capital by pursuing opportunities for the licensing, sale or divestiture of certain intellectual property and other assets,
including our Technosphere technology platform. There can be no assurance, however, that any strategic collaboration, sale of securities or sale or license of assets will be available to us on a timely basis or on acceptable terms, if at all. If we
are unable to raise additional capital, we may be required to enter into agreements with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop independently, and any such agreements may not
be on terms as commercially favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that our plans will not change or that changed circumstances
will not result in the depletion of our capital resources more rapidly than we currently anticipate. If planned operating results are not achieved or we are not successful in raising additional capital, if needed, through equity or debt financing or
entering business collaborations, we may be required to reduce expenses through the delay, reduction or curtailment of our projects, or further reduction of costs for facilities and administration, and there will continue to be substantial doubt
about our ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent
liabilities for which we cannot reasonably predict future payments. Accordingly, the table below excludes contractual obligations relating to milestone and royalty payments due to third parties, all of which are contingent upon certain future
events. The expected timing of payment of the obligations presented (excluding payments in respect of the Milestone Rights) below are estimated based on current information. Future payments relate to operating lease obligations, the 2018 notes, the
facility financing obligation, open purchase order and supply commitments, and contractual minimum purchase commitments under the Insulin Supply Agreement with Amphastar consisted of the following at December&nbsp;31, 2016 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Payments Due in</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:76.50pt; font-size:8pt; font-family:Times New Roman">Contractual Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Less&nbsp;Than<BR>One Year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">1-3</FONT> Years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">4-5&nbsp;Years</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">More&nbsp;Than<BR>5 Years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Open purchase order and commitments (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior convertible notes &#151; long term (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable to principal stockholder (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility financing obligation (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insulin supply agreement (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contractual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">295,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts included in open purchase order and supply commitments are subject to performance under the purchase order or contract by the supplier of the goods or services and do not become our obligation until such
performance is rendered. The amount shown is principally for the purchase of materials for commercial operations or sales and marketing efforts. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts include future interest payments at fixed rates of 5.75% and payment of the 2018 notes in full upon maturity in 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The obligation for the note payable to the principal stockholder includes future principal and interest payments related to the $49.5&nbsp;million of borrowings as of December&nbsp;31, 2016. Interest is accrued based on
a fixed rate of 5.84% and the outstanding principal amount and all accrued interest thereon will be due on January&nbsp;5, 2020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The facility financing obligation includes future principal and interest payments on $55.0&nbsp;million aggregate principal amount of 2019 notes issued in the first and fourth tranches under the Facility Agreement, and
on $15.0&nbsp;million aggregate principal amount of Tranche B notes, payable in accordance with the provisions of the Facility Agreement, as amended. Interest accrues on the 2019 notes at a fixed rate of 9.75% per annum and on the Tranche B notes at
a fixed rate of 8.75% per annum. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">On July&nbsp;31, 2014, we entered into the Insulin Supply Agreement, pursuant to which we originally agreed to purchase certain annual minimum quantities of insulin for calendar years 2015 through 2019 for an aggregate
total purchase price of approximately &#128;120.1&nbsp;million The Insulin Supply Agreement specifies that Amphastar will be deemed to have satisfied its obligations with respect to quantity, if the actual quantity supplied is within plus or minus
ten percent (+/- 10%) of the quantity set forth in the applicable purchase order. On November&nbsp;9, 2016, we amended the Insulin Supply Agreement to lower the annual minimum quantities purchased of insulin for calendar year 2017 through 2023 to an
aggregate total remaining purchase price of &#128;93.0&nbsp;million at December&nbsp;31, 2016. Future payments due were converted to U.S. dollars using the December&nbsp;31, 2016
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">euro-to-dollar</FONT></FONT> exchange. In addition, the aggregate cancellation fees that we would incur in the event that certain insulin quantities are not purchased was lowered from
$5.3&nbsp;million to $3.4&nbsp;million. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">The amount relates to purchase orders for inhalers in 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions see Note 6 &#151; Related-Party Arrangements of the Notes to Consolidated Financial
Statements included in &#147;Part II, Item 8 &#151; Financial Statements and Supplementary Data&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 &#151; Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements included in &#147;Part II, Item
8 &#151; Financial Statements and Supplementary Data&#148;, for information regarding accounting standards we adopted in 2016 and other new accounting standards that have been issued by the FASB but are not effective until after December&nbsp;31,
2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_10"></A>Item&nbsp;7A. </B><B><I>Quantitative and Qualitative Disclosures about Market Risk</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Rate Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the fixed
interest rates of our debt, we currently do not have an exposure to changes in our interest expense as a result of changes in interest rates. The interest rate on amounts borrowed under The Mann Group Loan Arrangement is fixed at 5.84%. As of
December&nbsp;31, 2016, the total principal amount outstanding under The Mann Group Loan Arrangement was $49.5&nbsp;million. As of December&nbsp;31, 2016, we also had debt related to the 2018 notes at a fixed interest rate of 5.75%, debt related to
the 2019 notes at a fixed interest rate of 9.75% and debt related to the Tranche B notes at a fixed interest rate of 8.75%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current
policy requires us to maintain a highly liquid short-term investment portfolio consisting mainly of U.S. money market funds and investment-grade corporate, government and municipal debt. None of these investments are entered into for trading
purposes. Our cash is deposited in and invested through highly rated financial institutions in North America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a change in interest
rates equal to 10% of the interest rates on December&nbsp;31, 2016 were to have occurred, this change would not have had a material effect on the value of our short-term investment portfolio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Exchange Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur
and will continue to incur significant expenditures for insulin supply obligations under our supply agreement with Amphastar. Such obligations are denominated in euros. At the end of each reporting period, these liabilities, if any, are converted to
U.S. dollars at the then-applicable foreign exchange rate. As a result, our business is affected by fluctuations in exchange rates between the U.S. dollar and foreign currencies. We have not entered into foreign currency hedging transactions to
mitigate our exposure to foreign currency exchange risks, but may enter into foreign currency hedging transactions in the future. Exchange rate fluctuations may adversely affect our expenses, results of operations, financial position and cash flows.
During the year ended December&nbsp;31, 2016, associated with our requirement to purchase insulin contemplated under our supply agreement with Amphastar, if a change in the U.S. dollar to euro exchange rate equal to 10% of the U.S. dollar to euro
exchange rate on December&nbsp;31, 2016 were to occur, this change would have resulted in a foreign currency impact to our <FONT STYLE="white-space:nowrap">pre-tax</FONT> income (losses) of approximately $9.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_11"></A>Item&nbsp;8. </B><B><I>Financial Statements and Supplementary Data</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is included in Items 15(a)(1) and (2)&nbsp;of Part IV of this Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_19"></A>Item&nbsp;9. </B><B><I>Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_20"></A>Item&nbsp;9A.</B><B><I></I></B><B></B><B><I>&nbsp;Controls and
Procedures</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), the Company carried out an
evaluation under the supervision and with the participation of the Company&#146;s management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company&#146;s disclosure controls and procedures. In
designing and evaluating the Company&#146;s disclosure controls and procedures, the Company and its management recognize that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the
possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives.
Additionally, in evaluating and implementing possible controls and procedures, the Company&#146;s management was required to apply its reasonable judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were
effective as of December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as such term
is defined in Rule&nbsp;13a-15(f) under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may not operate effectively because of changes in conditions such as replacing consulting resources with permanent personnel or that the degree of compliance with the policies or procedures may deteriorate. Our
management assessed the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016. In making this assessment, the Company&#146;s management used the criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission (COSO) in the Internal Control-Integrated Framework (2013 Framework).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on this assessment, our management
concluded that, as of December&nbsp;31, 2016, our internal control over financial reporting is effective based on those criteria. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remediation Steps
Taken to Address Prior Material Weaknesses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2015 our management concluded that our internal control over financial
reporting was not effective based on the COSO criteria. In making this assessment, the Company&#146;s management used the criteria set forth by the 2013 COSO Framework. A &#147;material&#148; weakness is defined as a deficiency, or a combination of
deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material weakness previously identified in our internal control over financial reporting: In connection
with the preparation of our annual report on Form 10-K for the year ended December 31, 2015 we did not maintain sufficient internal control over financial reporting due to the lack of operating effectiveness of our controls over the impairment
testing that we performed in accordance with ASC&nbsp;360-10<I>, Impairment and Disposal of Long-Lived Assets</I> and ASC 330-10, <I>Inventories</I>, as of December 31, 2015. Specifically, our review controls did not operate at a sufficient level of
precision to identify certain errors, which management has determined constituted a material weakness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as we learned of the
material weakness as of December 31, 2015, we began taking steps intended to remediate this material weakness and improve our control processes and procedures with respect to operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness regarding our controls over impairment and disposal of long&#150;lived assets and inventories. The following activities have been implemented as part of our efforts to become
compliant with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Improved the design of and increased the level of precision in which documentation of review controls related to the review of the asset impairment assessment and impairment and disposal of long-lived assets and
inventories so these controls would operate effectively to identify errors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Held training sessions with relevant personnel and developed specific review procedures regarding the review of impairment assessments; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Developed checklists to ensure that all appropriate accounting principles were being applied during the accounting for these transactions and to facilitate the review of the accounting of these transactions by
knowledgeable accounting personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the material weakness noted above, as of June 30, 2016 our management
concluded that our internal control over financial reporting was not effective based on the COSO criteria. In making this assessment, the Company&#146;s management used the criteria set forth by the 2013 Framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material weakness previously identified in our internal control over financial reporting: In connection
with the preparation of our quarterly report on Form 10-Q for the quarter ended June 30, 2016 we identified a material weakness in our internal control over significant non-routine transactions. Specifically, this deficiency in operation of internal
controls resulted in an inadequate evaluation of the underlying accounting guidance for transactions entered into during the quarter and insufficient review of underlying analyses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as we learned of the material weakness as of June 30, 2016, we began taking steps intended to remediate this material weakness and
improve our control processes and procedures with respect to operating effectiveness regarding our controls over significant and non-routine transactions. The following activities have been implemented as part of our efforts to become compliant with
the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enhanced the design of the existing controls related to significant non-routine transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Conduct weekly meetings with relevant personnel so that significant non-routine transactions are identified and addressed in a timely manner; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hired consultants with accounting expertise to review the accounting for significant non-routine transactions to ensure that the accounting for these transactions are proper. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, our remediation steps, noted above, were designed and implemented to ensure that the recording of the impairment of long-lived
assets and inventories is appropriate and that adequate evaluations of the underlying accounting guidance for significant non-routine transactions are appropriate, sufficiently reviewed and addressed in a timely manner.&nbsp;The newly implemented
controls have also been tested by management and concluded to be operating effectively. Management believes that as of December 31, 2016, the remediation steps implemented during 2016 successfully remediated the material weaknesses in 2015 and the
quarter ended June&nbsp;30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above related to the remediation of the material weaknesses, there were no changes in internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the fourth quarter of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of MannKind Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valencia, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the
internal control over financial reporting of MannKind Corporation and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2016, based on criteria established in <I>Internal Control &#151; Integrated Framework</I>
<I>(2013)</I><I></I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company&#146;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting, included in the accompanying Management&#146;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#146;s internal control over
financial reporting based on our audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included
obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing
such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, the Company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and effected by the Company&#146;s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#146;s internal control over financial reporting includes those policies and procedures that
(1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2)&nbsp;provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors
of the Company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#146;s assets that could have a material effect on the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper
management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future
periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31,
2016, based on the criteria established in <I>Internal Control &#151; Integrated Framework (2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated
financial statements as of and for the year ended December&nbsp;31, 2016 of the Company and our report dated March&nbsp;16, 2017 expressed an unqualified opinion on those financial statements and includes explanatory paragraphs relating to the
Company&#146;s ability to continue as a going concern and the effects of a reverse stock split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ DELOITTE&nbsp;&amp; TOUCHE LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stamford, Connecticut </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_21"></A>Item&nbsp;9B. </B><B><I>Other Information.</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_22"></A>Item&nbsp;10. </B><B><I>Directors, Executive Officers and Corporate Governance.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Executive Officers &#151; </I>For information regarding the identification and business experience of our executive officers, see
&#147;Executive Officers of the Registrant&#148; in Part I, Item&nbsp;1 of this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Directors &#151; </I>The information required by this Item regarding the identification and business experience of our directors and
corporate governance matters will be contained in the section entitled &#147;Proposal 1 &#151; Election of Directors&#148; and &#147;Corporate Governance Principles and Board and Committee Matters&#148; in our definitive proxy statement for our 2017
Annual Meeting of Stockholders (the &#147;Proxy Statement&#148;), to be filed with the SEC on or before May&nbsp;1, 2017, and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional information required by this Item will be set forth in the Proxy Statement under the section entitled &#147;Section 16(a)
Beneficial Ownership Reporting Compliance,&#148; and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and
Ethics Policy that applies to our directors and employees (including our principal executive officer, principal financial officer, principal accounting officer and controller), and have posted the text of the policy on our website
(<I>www.mannkindcorp.com</I>) in connection with &#147;Investors&#148; materials. In addition, we intend to promptly disclose on our website (i)&nbsp;the nature of any amendment to the policy that applies to our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions and (ii)&nbsp;the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these
specified individuals, the name of such person who is granted the waiver and the date of the waiver, to the extent any such waiver is required to be disclosed pursuant to the rules and regulations of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_23"></A>Item&nbsp;11. </B><B><I>Executive Compensation</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item will be set forth under the caption &#147;Executive Compensation,&#148; &#147;Compensation of
Directors,&#148; &#147;Compensation Committee Interlocks and Insider Participation&#148; and &#147;Compensation Committee Report&#148; in the Proxy Statement, and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_24"></A>Item&nbsp;12. </B><B><I>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item will be set forth under the captions &#147;Security Ownership of Certain
Beneficial Owners and Management&#148; and &#147;Securities Authorized for Issuance under Equity Compensation Plans&#148; in the Proxy Statement, and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_25"></A>Item&nbsp;13. </B><B><I>Certain Relationships, Related Transactions and Director Independence</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information under the caption &#147;Certain Transactions&#148; and &#147;Corporate Governance Principles and Board and Committee
Matters&#148; in the Proxy Statement is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_26"></A>Item&nbsp;14. </B><B><I>Principal Accounting Fees
and Services</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item will be set forth under the caption &#147;Principal Accounting Fees and
Services&#148; and <FONT STYLE="white-space:nowrap">&#147;Pre-Approval</FONT> Policies and Procedures&#148; in the Proxy Statement and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exception of the information specifically incorporated by reference from the Proxy Statement in this Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> the Proxy Statement shall not be deemed to be filed as part of this report. Without limiting the foregoing, the information under the captions &#147;Report of the Audit Committee of the Board of
Directors&#148; in the Proxy Statement is not incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc305327_27"></A>Item&nbsp;15. </B><B><I>Exhibits, Financial Statement Schedules</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K:</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)(2) Financial Statements and Financial Statement Schedules. The following
Financial Statements of MannKind Corporation, Financial Statement Schedules and Report of Independent Registered Public Accounting Firm are included in a separate section of this report beginning on page 81: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_12">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_13">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_14">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_15">Consolidated Statements of Comprehensive Income (Loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_16">Consolidated Statements of Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_17">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_18">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules have been omitted because the required information is not applicable or not
present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements or the notes thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Exhibits. The exhibits listed under Item&nbsp;15(b) hereof are filed or furnished with, or incorporated by reference into,
this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> Each management contract or compensatory plan or arrangement is identified separately in Item&nbsp;15(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Exhibits. The following exhibits are filed or furnished as part of, or incorporated by reference into, this Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K:</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;9, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;2, 2017).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on
November&nbsp;19, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits 3.1, 3.2 and 3.3.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of common stock certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 9.75% Senior Secured Convertible Promissory Note due 2019 (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated 9.75% Senior Secured Convertible Promissory Note due 2019 (incorporated by reference to Exhibit 4.7 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;3, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche B Senior Secured Note due 2019 (incorporated by reference to Exhibit 4.8 to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;12, 2014).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milestone Rights Purchase Agreement, dated as of July&nbsp;1, 2013, by and among MannKind, Deerfield Private Design Fund II, L.P. and Horizon Sant&eacute; FLML S&Aacute;RL (incorporated by reference to MannKind&#146;s Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Guaranty and Security Agreement, dated as of July&nbsp;1, 2013, by and among MannKind, MannKind LLC, Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P. and Horizon Sant&eacute; FLML S&Aacute;RL
(incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facility Agreement, dated as of July&nbsp;1, 2013, by and among MannKind, Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P (incorporated by reference to MannKind&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Facility Agreement and Registration Rights Agreement, dated as of February&nbsp;28, 2014, by and among MannKind, Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P.
(incorporated by reference to Exhibit 10.39 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March 3, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second Amendment to Facility Agreement and Registration Rights Agreement, dated as of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">August&nbsp;11, 2014, by and among MannKind, Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (incorporated by
reference to Exhibit 4.14 to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on November&nbsp;10, 2014).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indenture, by and between MannKind and U.S. Bank (as successor trustee to Wells Fargo Bank, N.A.), dated August&nbsp;10, 2015 (incorporated by reference to Exhibit 4.18 to MannKind&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;10, 2015).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 5.75% Convertible Senior Subordinated Exchange Note due 2018 (included in Exhibit 4.11 as Exhibit A thereto) (incorporated by reference to Exhibit 4.19 to MannKind&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;10, 2015).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant to Purchase Common Stock issued November&nbsp;16, 2015 (incorporated by reference to Exhibit 4.17 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;15, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Series A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to MannKind&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;10, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;10, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 99.1 to MannKind&#146;s Current Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;(File</FONT>
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;10, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Promissory Note made by MannKind in favor of The Mann Group LLC, dated October&nbsp;18, 2012 (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on October&nbsp;19, 2012).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement, dated September&nbsp;13, 2006, between MannKind and Torcon, Inc. (incorporated by reference to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;9, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Securities Purchase Agreement, dated August&nbsp;2, 2005 by and among MannKind and the purchasers listed on Exhibit A thereto (incorporated by reference to MannKind&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;5, 2005).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Supply Agreement, dated December&nbsp;31, 2004, between MannKind and Vaupell, Inc. (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on February&nbsp;23, 2005).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement entered into between MannKind and each of its directors and officers (incorporated by reference to MannKind&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-115020),</FONT> filed with the SEC on April&nbsp;30, 2004, as amended).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Description of Officers&#146; Incentive Program (incorporated by reference to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT>
filed with the SEC on March&nbsp;16, 2006).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Severance Agreement, dated October&nbsp;10, 2007, between MannKind and David Thomson (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> as amended, filed with the SEC on October&nbsp;17, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Separation Agreement, dated March&nbsp;11, 2016, by and between MannKind and Juergen Martens (incorporated by reference to Exhibit 10.8 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March 15, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Severance Agreement, dated April&nbsp;21, 2008, between MannKind and Matthew J. Pfeffer (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> as amended, filed with the SEC on October&nbsp;17, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Change of Control Agreement, dated October&nbsp;10, 2007, between MannKind and David Thomson (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> as amended, filed with the SEC on October&nbsp;17, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Change of Control Agreement, dated April&nbsp;21, 2008, between MannKind and Matthew J. Pfeffer (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> as amended, filed with the SEC on October&nbsp;17, 2007).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2004 Equity Incentive Plan, as amended (incorporated by reference to MannKind&#146;s proxy statement on Schedule 14A (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on April&nbsp;6,
2012).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Stock Option Agreement under the 2004 Equity Incentive Plan (incorporated by reference to MannKind&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-115020),</FONT> originally filed with the SEC on April&nbsp;30, 2004, as amended).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Phantom Stock Award Agreement under the 2004 Equity Incentive Plan (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on December&nbsp;14, 2005).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2004 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Stock Option Plan and form of stock option agreement there under (incorporated by reference to MannKind&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;16, 2006).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2004 Employee Stock Purchase Plan and form of offering document there under (incorporated by reference to MannKind&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-115020),</FONT> originally filed with the SEC on April&nbsp;30, 2004, as amended).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated June&nbsp;4, 2011, between MannKind and N.V. Organon (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Insulin Maintenance and Call-Option Agreement, dated June&nbsp;19, 2009, by and among Pfizer Manufacturing Frankfurt GmbH, Pfizer Inc. and MannKind (incorporated by reference to MannKind&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;4, 2009).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Acknowledgment and Agreement, dated as of October&nbsp;31, 2013, by and between MannKind and The Mann Group LLC (incorporated by reference to MannKind&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on November&nbsp;4, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program (incorporated by reference to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;9, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">MannKind Corporation 2013 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to MannKind&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on August&nbsp;9, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the MannKind 2013 Equity Incentive Plan (incorporated by reference to MannKind&#146;s registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-188790),</FONT> filed with the SEC on May&nbsp;23, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the MannKind 2013 Equity Incentive Plan (incorporated by reference to MannKind&#146;s registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-188790),</FONT> filed with the SEC on May&nbsp;23, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facility Agreement, dated as of July&nbsp;1, 2013, by and among MannKind, Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (incorporated by reference to MannKind&#146;s Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on July&nbsp;1, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Facility Agreement and Registration Rights Agreement, dated as of February&nbsp;28, 2014, by and among MannKind, Deerfield Private Design Fund II, L.P., and Deerfield Private Design International II, L.P.
(incorporated by reference to Exhibit 10.39 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;3, 2014).</TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Supply Agreement, dated as of July&nbsp;31, 2014, by and between MannKind and Amphastar France Pharmaceuticals S.A.S. (incorporated by reference to Exhibit 10.3 to MannKind&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on November&nbsp;10, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sublease Agreement, dated May&nbsp;1, 2015, by and between MannKind and the Alfred Mann Foundation for Scientific Research (incorporated by reference to Exhibit 10.37 to MannKind&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;15, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated March&nbsp;9, 2016, by and between MannKind and Michael Castagna (incorporated by reference to Exhibit 10.38 to MannKind&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on March&nbsp;15, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">At Market Issuance Sales Agreement, by and between MannKind and FBR Capital Markets&nbsp;&amp; Co., dated April&nbsp;26, 2016 (incorporated by reference to MannKind&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;26, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Engagement Letter, dated May&nbsp;8, 2016, by and between MannKind and H.C. Wainwright&nbsp;&amp; Co. LLC (incorporated by reference to Exhibit 99.2 to MannKind&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on May&nbsp;10, 2016).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Settlement Agreement, dated November&nbsp;9, 2016, by and among MannKind, Technosphere International C.V., MannKind Netherlands B.V. and Sanofi-Aventis U.S. LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Supply Agreement, dated October 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals, S.A.S. and Amphastar Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Supply Agreement, dated November&nbsp;9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement of Purchase and Sale and Joint Escrow Instructions, dated January&nbsp;6, 2017, by and between MannKind and Rexford Industrial Realty, L.P. (incorporated by reference to Exhibit 99.1 to MannKind&#146;s Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-50865),</FONT> filed with the SEC on January&nbsp;12, 2017).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First, Second and Third Amendments to Agreement of Purchase and Sale and Joint Escrow Instructions, dated February&nbsp;7, 2017, February&nbsp;10, 2017 and February&nbsp;15, 2017, respectively, by and between MannKind and Rexford
Industrial Realty, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.36*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter dated December 22, 2016, by and between MannKind and Stuart Tross.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (see signature page hereto).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rules <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> and <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> of the Securities Exchange Act of
1934, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Rules <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> and <FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of
1934, as amended and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Interactive Data Files pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_28"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">M<SMALL>ANN</SMALL>K<SMALL>IND</SMALL> C<SMALL>ORPORATION</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/&nbsp;&nbsp;&nbsp;&nbsp;Matthew J. Pfeffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew J. Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, Chief Financial Officer, and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;16, 2017 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW
ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Matthew J. Pfeffer and David Thomson, and each of them, as his or her true and lawful
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to
sign any and all amendments to this Report, and any other documents in connection therewith, and to file the same, with all exhibits thereto, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or any of them or their or his substitute
or substituted, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of
1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew J. Pfeffer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew J. Pfeffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer, Chief Financial</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Officer and Director</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal
Executive Officer and Principal</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Financial Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rosabel R. Alinaya</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Rosabel R. Alinaya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President, Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kent Kresa</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kent Kresa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ronald J. Consiglio</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ronald J. Consiglio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Friedman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Friedman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David H. MacCallum</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David H. MacCallum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry L. Nordhoff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Henry L. Nordhoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James S. Shannon</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James S. Shannon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_12">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_13">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_14">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_15">Consolidated Statements of Comprehensive Income (Loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_16">Consolidated Statements of Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_17">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc305327_18">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_12"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of MannKind Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valencia, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of MannKind Corporation and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2016 and 2015 and the related consolidated statements of operations, comprehensive income (loss), stockholders&#146;
deficit, and cash flows for each of the three years in the period ended December&nbsp;31, 2016. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial
statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of MannKind Corporation and subsidiaries as of December&nbsp;31, 2016 and 2015, and the results of their operations and their cash flows for each of the three years in the period ended December&nbsp;31,
2016, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company&#146;s available cash resources and continuing cash needs raise
substantial doubt about its ability to continue as a going concern. Management&#146;s plans concerning these matters are also described in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any
adjustments that might result from the outcome of these uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1 to the consolidated financial statements,
on March 1, 2017, the Company approved a reverse stock split with a ratio of 1-for-5. As a result, common stock share amounts included in these consolidated financial statements have been retrospectively adjusted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company&#146;s
internal control over financial reporting as of December&nbsp;31, 2016, based on the criteria established in <I>Internal Control &#151; Integrated Framework (2013)</I><I></I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway
Commission and our report dated March&nbsp;16, 2017 expressed an unqualified opinion on the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
DELOITTE&nbsp;&amp; TOUCHE LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stamford, Connecticut </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_13"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Receivable from Sanofi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Asset held for sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred costs from commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred costs from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment &#151; net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Facility financing obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue &#151; net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred payments from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred sales from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Recognized loss on purchase commitments &#151; current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued interest &#151; note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Senior convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sanofi loan facility and loss share obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Recognized loss on purchase commitments &#151; long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Milestone rights liability and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Undesignated preferred stock, $0.01 par value &#151; 10,000,000 shares authorized; no shares issued
or or outstanding at December&nbsp;31, 2016 and 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.05 par value &#151; 140,000,000 and 110,000,000 shares authorized at
December&nbsp;31, 2016 and 2015, respectively; 95,680,831 and 85,734,188 shares issued and outstanding at December&nbsp;31, 2016 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,549,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,737,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,863,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(350,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_14"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue &#151; commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue &#151; bulk insulin sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue &#151; collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share &#151; basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share &#151; diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute diluted net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_15"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:450pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_16"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<br><FONT STYLE="white-space:nowrap">Paid-In</FONT><br>Capital</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>Other<BR>Comprehensive<br>Loss</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<br>Deficit</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BALANCE, JANUARY&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,261,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,296,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares from the release of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares pursuant to warrant exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares under Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares pursuant to debt conversions by Deerfield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Remeasurement of performance based grants pursuant to the modification of terms</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BALANCE, DECEMBER&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares from the release of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares pursuant to warrant exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares under Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted stock units taxes paid in cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital contribution</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares pursuant to conversions of certain 2015 notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock for lender financing fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notes-for-stock</FONT></FONT> exchange</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock pursuant to TASE stock sale</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Return of loaned common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock pursuant to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> issuances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of warrant liability to equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BALANCE, DECEMBER&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,863,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(350,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares from the release of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common shares under Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted stock units taxes paid in cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of direct placement &#151; common stock and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs associated with direct placement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BALANCE, DECEMBER&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,549,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,737,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(183,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:52pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_17"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CASH FLOWS FROM OPERATING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash (used in) provided by operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation, amortization and accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest incurred through borrowings under Sanofi Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest on note payable to principal stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series A Warrant issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on sale, abandonment/disposal or impairment of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Write-off</FONT> of inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Write-off</FONT> of Tranche B commitment asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Write-off</FONT> of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Receivable from Sanofi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Receivables from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred costs from commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred costs from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred payments from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred sales from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Recognized loss on purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Milestone rights liability and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CASH FLOWS FROM INVESTING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CASH FLOWS FROM FINANCING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from direct placement of common stock and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs associated with direct placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of notes payable to Deerfield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of employment taxes related to vested restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of common stock under Tel Aviv Stock Exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs associated with the Tel Aviv Stock Exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of 2015 notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of debt issuance costs on 2018 notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of facility financing obligation&nbsp;and milestone rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of Tranche B of the facility financing obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Milestone payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of common stock pursuant to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> transactions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS, END OF PERIOD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">SUPPLEMENTAL CASH FLOWS DISCLOSURES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest paid in cash, net of amounts capitalized to construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of 2015 notes and interest through issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock pursuant to debt conversion by Deerfield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> construction in progress and property and
equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of property and equipment to asset held for sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc305327_18"></A>MANNKIND CORPORATION AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Business</I> &#151; MannKind Corporation and subsidiaries (the &#147;Company&#148;) is a biopharmaceutical company focused on the discovery
and development of therapeutic products for diseases such as diabetes. The Company&#146;s only approved product, Afrezza, (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug
Administration (the &#147;FDA&#148;) on June&nbsp;27, 2014 to improve glycemic control in adult patients with diabetes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Basis of
Presentation</I> &#151; On August&nbsp;11, 2014, the Company entered into a license and collaboration agreement (the &#147;Sanofi License Agreement&#148;) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations
under the agreement to Sanofi-Aventis U.S. LLC (&#147;Sanofi&#148;)), pursuant to which Sanofi was responsible for Afrezza global commercial, regulatory and development activities for Afrezza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2016, the Company received written notification from Sanofi of its election to terminate in its entirety the Sanofi License
Agreement. The effective date of termination (the &#147;Termination Date&#148;) was April&nbsp;4, 2016, which was when the Company assumed responsibility for worldwide development and commercialization of Afrezza. Under terms of a transition
agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. The Company began recognizing commercial product sales
revenue when MannKind-branded Afrezza was dispensed from pharmacies to patients in August 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, the Company
entered into a settlement agreement with Sanofi (the &#147;Settlement Agreement&#148;). Under the terms of the Settlement Agreement, the promissory note (the &#147;Sanofi Loan Facility&#148;) between the Company and Aventisub LLC
(&#147;Aventisub&#148;), a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0&nbsp;million, which includes $0.5&nbsp;million of previously uncharged costs pursuant to the Sanofi License
Agreement. Sanofi also agreed to purchase $10.2&nbsp;million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6&nbsp;million to the Company in early January 2017 as acceleration
and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company and Sanofi also
agreed to a general release of potential claims against each other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During their initial transition of the commercial responsibilities
from Sanofi, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing <FONT
STYLE="white-space:nowrap">co-pay</FONT> assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited their own sales force, which included some of the sales reps that previously were employed
by the contract sales organization. The Company intend to continue the commercialization of Afrezza in the United States through their own commercial organization. The Company&#146;s current strategy for the future commercialization of Afrezza
outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It has been costly to develop our therapeutic product, conduct clinical studies, and market and sell Afrezza. As of and for the year ended
December&nbsp;31, 2016, the Company has reported an accumulated deficit of $2.7&nbsp;billion and has reported negative cash flow from operations for each year since inception, except for 2014, when the Company received the $150.0&nbsp;million
upfront payment from Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the Company&#146;s capital resources consisted of cash and cash equivalents of
$22.9&nbsp;million. The Company expects to continue to incur significant expenditures to support commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing and sales and marketing of Afrezza and the development of other product candidates. The facility agreement (the &#147;Facility Agreement&#148;) with Deerfield Private Design Fund
II, L.P. (Deerfield Private Design Fund) and Deerfield Private Design International II, L.P. (collectively, &#147;Deerfield&#148;) and the First Amendment to Facility Agreement and Registration Rights Agreement (the &#147;First Amendment&#148;) that
resulted in additional sales of an additional tranche of notes (the &#147;Tranche B notes&#148;) (see Note 7 &#151; Borrowings) requires the Company to maintain at least $25.0&nbsp;million, which can be comprised of cash and cash equivalents and
available borrowings under the loan arrangement, dated as of October&nbsp;2, 2007, between the Company and The Mann Group LLC (as amended, restated, or otherwise modified as of the date hereof, &#147;the Mann Group Loan Arrangement&#148;), as of the
last day of each fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional funding sources that are, or in certain circumstances may be available to the Company,
include approximately $30.1&nbsp;million principal amount of available borrowings under The Mann Group Loan Arrangement. A portion of these available borrowings may be used to capitalize accrued interest into principal, upon mutual agreement of the
parties, as it becomes due and payable under The Mann Group Loan Arrangement (see Note 6 &#151; Related-party Arrangements). The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the
depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company,
the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the commercialization of Afrezza and development of other product candidates and to support its other ongoing activities. The
Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. These factors raise substantial doubt about the Company&#146;s ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2016, the Company received notice
from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the previous 30 consecutive business days, the bid price for the common stock closed below the minimum $1.00 per share required for continued inclusion on The
NASDAQ Global Market. The notification letter stated that the Company would be afforded 180 calendar days, or until March&nbsp;13, 2017, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the
Company&#146;s common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Reverse Stock Split</I> &#151; On March&nbsp;1, 2017, following stockholder approval, the Company&#146;s board of directors approved a
reverse stock split ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5.&nbsp;On</FONT></FONT> March&nbsp;1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of
the Company&#146;s Amended and Restated Certificate of Incorporation to effect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> reverse stock split of the Company&#146;s outstanding common stock and to
reduce the authorized number of shares of the Company&#146;s common stock from 700,000,000 to 140,000,000 shares.&nbsp;The Company&#146;s common stock began trading on The NASDAQ Global Market on a split-adjusted basis when the market opened on
March&nbsp;3, 2017.&nbsp;See Note 20 &#151; Subsequent Events for further information. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all
common stock per share amounts have been increased by a factor of five, with the exception of the Company&#146;s common stock par value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Principles of Consolidation</I> &#151; The consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiaries. Intercompany balances and transactions have been eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Segment Information</I> &#151; Operating segments are
identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the
Company has viewed its operations and manages its business as one segment operating in the United States of America. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Financial Statement Estimates</I> &#151; The preparation of financial statements in conformity with accounting principles generally accepted
in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers
many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more
significant estimates reflected in these accompanying consolidated financial statements include revenue recognition, assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, inventory recoverability, valuation
of the facility financing obligation, loss on purchase commitment, warrant liability, milestone rights, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any
valuation allowance recorded against net deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Reclassifications</I> &#151; Certain amounts from previous periods have
been reclassified to conform to the 2016 presentation. Specifically, accrued interest &#151; note payable to principal stockholder has been reclassified from the previously reported classification of other liabilities in the accompanying
consolidated balance sheets. Additionally, the remaining balance from the previously reported classification of other liabilities is now identified as milestone rights liability, and is disclosed as a separate line item on the consolidated
statements of cash flows. Additionally, on the consolidated statement of operations, product manufacturing has been renamed to cost of goods sold. The Company also reclassified (gain) loss on foreign currency translation from the previously reported
classification of product manufacturing in the accompanying consolidated statements of operations. Additionally, certain balances from prepaid expenses and other current assets were reclassed to (gain) loss on foreign currency translation in the
consolidated statements of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition</I> &#151; Revenue is recognized when the four basic criteria of revenue
recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When the accounting requirements
for revenue recognition are not met, the Company defers the recognition of revenue by recording deferred revenue on the consolidated balance sheets until such time that all criteria are met. To date, the Company has had revenue from collaborations,
commercial sales of Afrezza, and from sales of bulk insulin, which are described more fully below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition
&#151; Net Revenue &#151; Collaborations &#151; </I>The Company enters into collaborations under which we must perform certain obligations and we receive periodic payments. We evaluate the collaborations under the multiple element revenue
recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When
deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and
the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company&#146;s collaborations are described more fully in Note 8 &#151; Collaboration Arrangements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition &#151; Net Revenue &#151; Commercial Product Sales &#151; </I>Between July&nbsp;1, 2016 and
December&nbsp;15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (ICS) and title and risk of loss transferred to ICS upon shipment. After December&nbsp;15, 2016, ICS became a third party logistics provider and
stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as
&#147;customers&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides the right of return to ICS (through December&nbsp;15, 2016)
and its wholesale distributors and, through them, to its retail pharmacy customers for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. Once the product has been prescribed and dispensed
to the patient, any right of return ceases to exist. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the Company&#146;s limited sales history for Afrezza, the
Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists,
which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided
by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable including data related to inventory movements within the channel and ongoing prescription demand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, net revenue from commercial product sales consisted of $1.9&nbsp;million of net
sales of Afrezza dispensed to patients. As of December&nbsp;31, 2016, the Company recorded $3.4&nbsp;million in deferred revenue on its consolidated balance sheet, of which $1.6&nbsp;million (net of estimated <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments) represents product shipped to the Company&#146;s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference represents deferred
revenue from bulk insulin sales, which is described more fully under the heading <I>Revenue Recognition &#151; Revenue &#151; Bulk Insulin Sales</I> below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT> Adjustments &#151;
</I>Estimated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, estimated rebates and patient discount and <FONT
STYLE="white-space:nowrap">co-pay</FONT> assistance programs, and are based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company&#146;s agreements with its customers and
the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of
revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the
consolidated statements of operations at the time product revenue is recognized. At December&nbsp;31, 2016, year to date total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments were
approximately $0.8&nbsp;million, which represents 30% of gross revenue from product sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Wholesaler Distribution Fees
&#151; </I>The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the distribution fees on shipment to the respective wholesale distributors and recognizes the distribution
fees as a reduction of revenue in the same period the related revenue is recognized. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Prompt Pay Discounts &#151;
</I>The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the
discount as a reduction of revenue in the same period the related revenue is recognized. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rebates &#151; </I>The Company
participates in federal and state government-managed Medicare and Medicaid rebate programs and intends to pursue participation in certain other qualifying federal and state government programs whereby discounts and rebates are provided to
participating federal and state government entities. Rebates provided through these other qualifying programs are included in the Medicaid and Medicare rebate accrual. The Company accounts for these rebates by establishing an accrual equal to the
estimate of rebate claims attributable to a sale and determines its estimate of the rebates accrual based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rate for Medicare and
Medicaid. From that data, as well as input received from MannKind&#146;s commercial team, an estimated participation rate for Medicare and Medicaid is determined and applied at the mandated rate for those sales. Any new information regarding changes
in the programs&#146; regulations and guidelines or any changes in the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between
the date the product is sold into the channel and the date such rebates are paid ranges from approximately six to nine months. As such, continuous monitoring of these estimates are performed on a periodic basis and if necessary, adjusted to reflect
new facts and circumstances. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patient Discount and <FONT STYLE="white-space:nowrap">Co-Pay</FONT> Assistance Programs &#151; </I>The Company offers
discount card programs to patients for Afrezza in which patients receive discounts on their prescriptions or a reduction in their <FONT STYLE="white-space:nowrap">co-pay</FONT> amounts that are reimbursed by the Company. The Company estimates the
total amount that will be redeemed based on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Product Returns &#151; </I>The Company does not provide a reserve for product returns of sales of Afrezza due to its revenue
recognition policy of deferring recognition of revenue on product shipments of Afrezza until the right of return no longer exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition &#151; Revenue &#151; Bulk Insulin Sales &#151; </I>In 2016, revenue from bulk insulin sales was recognized after
delivery and customer acceptance of the bulk insulin. When the accounting requirements for revenue recognition of bulk insulin sales are not met, the Company defers recognition of revenue by recording deferred revenue on the balance sheet until such
time that all criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred revenue includes $1.8&nbsp;million received from a sale of surplus bulk insulin to a third party
that was delivered prior to, but accepted after, December&nbsp;31, 2016. No deferred cost was recognized related to this sale because the inventory was written off on December&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deferred Costs from Collaboration &#151; </I>Deferred costs from collaboration represents the costs of product manufactured and sold to
Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the third quarter of 2016, the costs related to the Sanofi product sales were recognized as
costs of revenue &#151; collaboration in the consolidated statements of operations, as related revenue was recognized at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deferred Costs from Commercial Product Sales &#151; </I>Deferred costs from commercial product sales represents the cost of product
(including labor, overhead and costs to ship to third party logistics) shipped to ICS and wholesale distributors, but not yet dispensed by pharmacies to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Goods Sold &#151; </I>Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well
as under-absorbed labor and overhead and inventory write-offs, which are recorded as expenses in the period in which they are incurred, rather than as a portion of the inventory cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents</I> &#151; The Company considers all highly liquid investments with original or remaining maturities of 90 days
or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December&nbsp;31, 2016 and 2015, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of
purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk</I> &#151; Financial instruments which potentially subject the Company to concentration of
credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Accounts Receivable and Allowance for Doubtful Accounts</I> &#151; Accounts receivable are recorded at the invoiced amount and are not
interest bearing. The Company maintains an allowance for doubtful accounts for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its
calculation of the allowance for doubtful accounts. As of December&nbsp;31, 2016 and 2015, there was no allowance for doubtful accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Inventories</I> &#151; Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory
using the <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out,</FONT> or FIFO, method. The Company capitalizes inventory costs associated with the Company&#146;s products based on management&#146;s judgment
that future economic benefits are expected to be realized; otherwise, such costs are expensed as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its
estimated realizable value, and writes down such inventories as appropriate. In addition, the Company&#146;s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain
batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable
value. The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December&nbsp;31, 2016 and 2015. As a result of these assessments, the Company
recorded a $0.2&nbsp;million charge at December&nbsp;31, 2016 to <FONT STYLE="white-space:nowrap">write-off</FONT> inventory that will expire prior to sale. At December&nbsp;31, 2015, the Company recorded a charge of $39.3&nbsp;million to record the
inventory raw materials on hand at the lower of cost or net realizable value, inventory expiry and <FONT STYLE="white-space:nowrap">write-off</FONT> other inventory related assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>State Research and Development Credit Exchange Receivable</I> &#151; The State of Connecticut provides certain companies with the
opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for foregoing the carryforward of the research and development credits. The program provides for an exchange of research and development
income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. These amounts are included in
prepaid expenses and other current assets on the consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Prepaid Expenses and Other Current Assets &#151; </I>As
of December&nbsp;31, 2016 and 2015, prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received and includes a certificate of deposit for $350,000 as collateral as required by an agreement
with the bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale of intellectual property &#151; </I>On July&nbsp;18, 2014, the Company entered into an assignment agreement with a
third party whereby the third party acquired all proprietary rights, technology and <FONT STYLE="white-space:nowrap">know-how</FONT> that related to a small molecule inhibitor compound and all <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
data and results related thereto. Under the terms of the assignment agreement, the Company received total consideration of $9.3&nbsp;million and accrued $1.4&nbsp;million in expense for a net amount of $7.9&nbsp;million recorded as other income. In
2015, the Company recorded other income of $1.4&nbsp;million related to the relief of the $1.4&nbsp;million accrual for expenses associated with the sale of intellectual property related to oncology in 2014, which was subsequently resolved without
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Assets Held for Sale &#151; </I>The Company classifies long-lived assets anticipated to be sold within one year as held for
sale at the lower of their carrying value or fair value less estimated selling costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Property and Equipment</I> &#151; Property and
equipment are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the term of the lease or the service lives of the improvements, whichever is shorter.
Maintenance and repairs are expensed as incurred. Assets under construction are not depreciated until placed into service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Impairment
of Long-Lived Assets</I> &#151; The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.<I> </I>Assets are considered to be impaired if
the carrying value may not be recoverable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company believes an asset to be impaired, the impairment recognized is the amount by which
the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the
asset and an operating loss would be recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded an asset impairment of $1.3 million and $140.4 million for the
years ended December 31, 2016 and 2015, respectively. No asset impairment was recognized during the year ended December 31, 2014 (see Note 4 &#151; Property and Equipment and Note 20<I> &#151; </I>Subsequent Events). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Recognized Loss on Purchase Commitments &#151; </I>The Company assesses whether losses on long term purchase commitments should be accrued.
Losses that are expected to arise from firm, <FONT STYLE="white-space:nowrap">non-cancellable,</FONT> commitments for the future purchases of inventory items are recognized unless recoverable. The recognized loss on purchase commitments is reduced
as inventory items are purchased. Changes in estimates are recorded in the relevant period in (gain) loss on purchase commitments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
the year ended December&nbsp;31, 2015, the Company recorded a loss on purchase commitments amounting to $116.2&nbsp;million offset by $50&nbsp;million expected to be recovered from Sanofi, primarily due to a long term purchase commitment for insulin
raw materials. During the year ended December&nbsp;31, 2016, the balance was adjusted for the recovery received from Sanofi, current purchases on the contracts and a reduction in the recognized loss related to amendments to purchase contracts. No
new contracts were identified in 2016 requiring a new loss on purchase commitment accrual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Rights Liability</I> &#151; On
July&nbsp;1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to Deerfield whereby the Company agreed to provide Deerfield with <FONT STYLE="white-space:nowrap">pre-specified</FONT> Milestone
Payments upon the achievement of 13 specific Milestone Events related to the commercial release and future cumulative net sales of Afrezza. The Company analyzed the Milestone Rights and determined that the agreement does not meet the definition of a
freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Rights Purchase Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone
Rights as a liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash
flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and
probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount
rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as
each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change
in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company&#146;s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement
of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to
the investor for the achievement of the related milestone event (see Note&nbsp;7 &#151; Borrowings). As of December&nbsp;31, 2016, the remaining liability balance is $8.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Financial Instruments</I> &#151; The Company utilizes fair value measurement guidance to value its financial instruments. The
guidance includes a definition of fair value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair value and expands disclosures about the use of fair value measurements. The
valuation techniques utilized are based upon observable and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the
following fair value hierarchy: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&nbsp;&#151;&nbsp;Quoted prices for identical instruments in active markets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&nbsp;&#151;&nbsp;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets
that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level
3&nbsp;&#151;&nbsp;Significant inputs to the valuation model are unobservable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Income Taxes</I> &#151; The provisions for federal,
foreign, state and local income taxes are calculated on <FONT STYLE="white-space:nowrap">pre-tax</FONT> income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred
tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation
allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax
positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.
Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the
period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a
component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant management judgment is involved in determining the provision for income taxes, deferred tax
assets, deferred tax liabilities, and any valuation allowance recorded against deferred tax assets. Due to uncertainties related to the realization of the Company&#146;s deferred tax assets as a result of its history of operating losses, a full
valuation allowance has been established against the total deferred tax asset balance. The valuation allowance is based on management&#146;s estimates of taxable income by jurisdiction in which the Company operates and the period over which deferred
tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Contingencies</I> &#151; The Company records a loss contingency for a liability when it is both probable that a liability has been incurred
and the amount of the loss can be reasonably estimated. These accruals represent management&#146;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably
possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the
determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information
becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation</I> &#151; As of December&nbsp;31, 2016, the Company had three active stock-based compensation plans, which are
described more fully in Note 12 &#151; Stock Award Plans. The Company accounts for all share-based payments to employees, including grants of stock awards and the compensatory elements of the employee stock purchase plan. All share-based payments to
employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of
the awards at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
grant date. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase
plans. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate and the expected dividend yield. The expected volatility
assumption is based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Restricted stock units are valued based on the market price on the grant date. The
Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based
compensation expense over the requisite service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants</I> &#151; The Company has issued warrants to purchase shares of its
common stock. The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants
classified as derivative liabilities are recorded on the Company&#146;s consolidated balance sheets at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized in the
consolidated statements of operations. The Company estimates the fair value of its derivative liabilities using a third party valuation analysis that utilizes a Monte Carlo pricing valuation model and assumptions that are based on the individual
characteristics of the warrants or instruments on the valuation date, as well as expected volatility, expected life, yield and a risk-free interest rate. The expected volatility assumption is primarily based on an assessment of the historical
volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not
<FONT STYLE="white-space:nowrap">re-measured</FONT> in subsequent periods, unless the underlying assumptions change to trigger liability accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Comprehensive Income (Loss)</I> &#151; Other comprehensive income (loss) requires that all components of comprehensive income (loss) to be
reported in the financial statements in the period in which they are recognized. Other comprehensive income (loss) includes certain changes in stockholders&#146; equity that are excluded from net income (loss). Specifically, the Company includes
unrealized gains and losses on foreign exchange translation in accumulated other comprehensive loss on the consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses</I> &#151; Research and development expenses consist of costs associated with the clinical trials of the
Company&#146;s product candidates, manufacturing supplies and other development materials, compensation and other expenses for research and development personnel, costs for consultants and related contract research, facility costs, and depreciation.
Research and development costs, which are net of any tax credit exchange recognized for the Connecticut state research and development credit exchange program, are expensed as incurred. The Company began commercial manufacturing in the latter part
of the fourth quarter of 2014. Commercial manufacturing costs incurred in the fourth quarter of 2014 were included in research and development expense and were immaterial for the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>State Research and Development Credit Exchange Receivable</I> &#151; The State of Connecticut provides certain companies with the
opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for forgoing the carryforward of the research and development income tax credits. The program provides for an exchange of research and
development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. During the years
ended December&nbsp;31, 2016, 2015 and 2014, research and development expenses were offset by research and development tax credits of $246,000, $743,000 and $816,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Expenses</I> &#151; Clinical trial expenses, which are reflected in research and development expenses in the accompanying
consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations
which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such contracts. The appropriate level of trial expenses are reflected in the Company&#146;s consolidated financial statements by matching period expenses with period services and efforts
expended. These expenses are recorded according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Clinical trial accrual estimates are determined through discussions with internal
clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status is then compared to the contractually obligated fee to be paid for such services. During the
course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ from management&#146;s estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense</I> &#151; Interest costs are expensed as incurred, except to the extent such interest is related to construction in
progress, in which case interest is capitalized. Interest cost capitalized for the years ended December&nbsp;31, 2015 and 2014 was $0.1&nbsp;million and $0.8&nbsp;million, respectively. There were no capitalized interest costs for the year ended
December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Net Income (Loss) Per Share of Common Stock</I> &#151; Basic net income (loss) per share excludes dilution for
potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury
method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation
of diluted net loss per share as they would be antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Standards</I> &#151; From time to time, new
accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the
impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s consolidated financial position or results of operations upon adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards Update (ASU) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> <I>Revenue from
Contracts with Customers (Topic 606)</I>, which requires an entity to recognize the amount of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those
goods or services. This new guidance supersedes previous revenue recognition requirements, along with most existing industry-specific guidance. In August 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-14,</FONT> <I>Revenue from
Contracts with Customers (Topic 606): Deferral of the Effective Date</I>, which delayed the effective date of the new standard from January&nbsp;1, 2017 to January&nbsp;1, 2018. The FASB also agreed to allow entities to choose to adopt the standard
as of the original effective date. In 2016 the FASB has issued additional ASUs which clarify certain aspects of the new guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company will adopt the new guidance for the year beginning January&nbsp;1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the
cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company currently anticipates it will apply the new guidance using the modified retrospective approach with the
cumulative effect of initial application recognized as of January&nbsp;1, 2018. The Company plans to continue analyzing the potential impacts of the application throughout 2017 and, depending on factors that may impact the results, could elect to
apply the new guidance on a full retrospective basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, for commercial sales of Afrezza, the Company has limited sales and
returns history, and as such, is unable to reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right
of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed, a
sell-through model, as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and
ongoing prescription demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon adoption of the new guidance, the Company expects that it will move from its current
sell-through model to a <FONT STYLE="white-space:nowrap">sell-to</FONT> model for revenue related to commercial sales of Afrezza and will record revenue at the time title and risk of loss passes to its distributors (generally at shipment or delivery
to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional 12 months of sales history that it will have
obtained by January&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company has historically entered into collaborative agreements with third-parties
under which periodic payments have been received. Revenue recognition for certain payments received has been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited
from recognition until received. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has begun its evaluation of the impact of adoption and plans to continue its evaluation throughout 2017. The financial impact upon
adoption will be dependent upon a number of factors including; the amount of revenue that has been deferred under the sell-through model for Afrezza, the amount of the revenue deferred under collaborative arrangements and the Company&#146;s
estimates of variable consideration at the date of adoption. At this time, the Company has not completed its evaluation of the inputs, assumptions and methodologies that will be used to recognize revenue related to variable consideration under the
new guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2015-11,</FONT> <I>Inventory (Topic 330):
Simplifying the Measurement of Inventory.</I> Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal
profit margin. The amendments indicate that after adoption an entity should measure inventory within the scope of this ASU at the lower of cost or net realizable value. The amendments are effective for fiscal years beginning after December&nbsp;15,
2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2015-11</FONT> will have no impact on the Company&#146;s annual consolidated financial statements because the Company currently measures inventory at the lower of cost or net realizable value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-15,</FONT> <I>Presentation of Financial Statements
&#151; Going Concern</I>, which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#146;s ability to continue as a going concern within one
year after the date that the financial statements are issued or available to be issued. This update was effective for annual periods ending after December&nbsp;15, 2016. The adoption of this standard did not have a material impact on its
consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-01,</FONT>
<I>Financial Instruments &#151; Overall (Subtopic <FONT STYLE="white-space:nowrap">825-10):</FONT> Recognition and Measurement of Financial Assets and Financial Liabilities.</I> The update is intended to improve the recognition and measurement of
financial instruments. The update is effective for fiscal years beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company is evaluating the impact the adoption of ASU
<FONT STYLE="white-space:nowrap">2016-01</FONT> will have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>. The new standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of
financial position a liability to make lease payments (the lease liability) and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset representing its right to use the underlying asset for the lease
term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to
recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The new standard will be effective on January&nbsp;1, 2019. The Company is evaluating the impact the adoption of ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02</FONT> will have on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT>
<I>Compensation &#151; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</I>. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax
consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. For public business entities, the amendments in this standard are effective for annual periods beginning after
December&nbsp;15, 2016, and interim periods within those annual periods. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a
material impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-15,</FONT> <I>Statement of Cash Flows
(Topic 230): Classification of Certain Cash Receipts and Cash Payments</I>. The new standard seeks to reduce diversity in practice related to the classification of certain transactions in the statement of cash flows. For public business entities,
the amendments in this standard are effective for annual periods beginning after December&nbsp;15, 2017, and interim periods within those annual periods. The amendments should be applied using a retrospective transition method to each period
presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the impact the adoption
of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-15</FONT> will have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2016, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> <I>Statement of Cash Flows (Topic 230): Restricted Cash. </I>This ASU requires that the reconciliation of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> amounts shown in the statement of cash flows
include cash and restricted cash equivalents. ASU <FONT STYLE="white-space:nowrap">2016-08</FONT> is effective for fiscal years beginning after December&nbsp;15, 2018, including interim periods within those periods, using a retrospective transition
method to each period presented. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a material impact. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Inventories </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories consist of
the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Work-in-process</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2015, the Company recorded a write-off of all of its inventory. There were no raw materials
as of December 31, 2016 because purchases of raw materials in 2016 were recorded at zero value because they had been accrued at December 31, 2015 through the loss on purchase commitment. Work-in-process and finished goods as of December 31, 2016
include conversion costs but not materials cost because the materials used in its production were previously written off. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Estimated<br>Useful&nbsp;Life<BR>(Years)</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">39-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture, fixtures and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense related to property and equipment for the years ended December&nbsp;31,
2016, 2015 and 2014, was $2.4&nbsp;million, $11.0&nbsp;million and $9.8&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December&nbsp;31, 2016 amounts do
not include the Valencia property because it is classified as held for sale as of that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s
quarterly assessment of impairment indicators, the Company evaluated the continued lower than expected sales of Afrezza as reported by Sanofi throughout the fourth quarter of 2015, revised forecasts for sales of Afrezza provided by Sanofi in the
fourth quarter of 2015 and level of commercial production in the fourth quarter of 2015, as well as the uncertainty associated with Sanofi&#146;s announcement during the fourth quarter of their intent to reorganize their diabetes business. These
factors indicated potentially significant changes in the timing and extent of cash flows, and the Company therefore determined that an impairment indicator existed in the fourth quarter of 2015 and recorded an impairment for the year ended
December&nbsp;31, 2015. No such indications were identified in the current year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified two
primary asset groups to be evaluated for impairment: the Danbury manufacturing facility, which currently performs all the manufacturing of Afrezza, and the Valencia facility, which was previously the Company&#146;s corporate headquarters. The
Danbury manufacturing facility was the primary asset group that was impacted by the impairment indicators noted above but the Company also evaluated the Valencia facility for potential impairment given the circumstances and identified an impairment
charge of $1.8&nbsp;million based on a valuation utilizing a combination of market, income and cost approaches. Within the Danbury manufacturing facility, the Company identified the machinery and equipment as the primary assets within the asset
group as they are associated with the production of Afrezza. As such, the Company performed the fixed asset impairment test and performed the first step to test for recoverability of the Danbury manufacturing facility by utilizing two undiscounted
cash flow projections and applying a probability weighted average to those cash flow projections. The first undiscounted cash flow projection was developed under a scenario assuming Sanofi would continue to sell and market Afrezza as the termination
of the arrangement by Sanofi was not known as of the balance sheet date. The second undiscounted cash flow projection assumed Sanofi would terminate the Sanofi License Agreement and that the Company would manufacture, sell and market Afrezza
independently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the evaluation performed, the probabilities assigned to the two undiscounted cash flows were not significant to
the evaluation due to the projected negative cash flows over the estimation period, and it was determined that the probability weighted undiscounted cash flows were not sufficient to recover the carrying
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value of the Danbury manufacturing facility. As such, the Company was required to determine the fair value of the Danbury manufacturing facility to recognize an impairment loss if the carrying
amount exceeds its fair value. The Company determined the fair value of the Danbury manufacturing facility by applying the highest and best use valuation concept and utilizing the market approach valuation technique to value the machinery and
equipment and a combination of the market approach and cost approach in valuing the land, buildings and building improvements. As a result of this assessment, the Company recorded, as of December&nbsp;31, 2015, an impairment charge of
$138.6&nbsp;million for the Danbury manufacturing facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December&nbsp;31, 2015 balances have been reclassified to the current
year presentation by allocating an impairment of $140.4&nbsp;million, which was previously disclosed in total, to the individual asset groups. An additional impairment of $0.7&nbsp;million was charged to the individual asset groups for the year
ended December&nbsp;31, 2016, which is included in property and equipment impairment in the accompany consolidated statements of operations, additionally with a $0.6&nbsp;million impairment charge related to assets held for sale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities are comprised of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounts and allowances for commercial product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Related-Party Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2007, the Company entered into The Mann Group Loan Arrangement, which has been amended from time to time. On October&nbsp;31, 2013,
the promissory note underlying The Mann Group Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January&nbsp;5, 2020, extend the date through which the Company can borrow under The Mann Group Loan
Arrangement to December&nbsp;31, 2019, increase the aggregate borrowing amount under The Mann Group Loan Arrangement from $350.0&nbsp;million to $370.0&nbsp;million and provide that repayments or cancellations of principal under The Mann Group Loan
Arrangement will not be available for reborrowing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the total principal amount outstanding under The Mann
Group Loan Arrangement was $49.5&nbsp;million, and the amount available for future borrowings is $30.1&nbsp;million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the
preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> and capitalized as additional borrowings at any time upon mutual agreement of the parties, and has been classified as
<FONT STYLE="white-space:nowrap">non-current.</FONT> The Mann Group can require the Company to prepay up to $200.0&nbsp;million in advances that have been outstanding for at least 12 months, less approximately $105.0&nbsp;million aggregate principal
amount that has been cancelled in connection with two common stock purchase agreements. If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice, or the number of days to maturity of the note
if less than 90 days, to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield
pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under The Mann Group Loan Arrangement until the Company&#146;s payment obligations to Deerfield under the Facility Agreement have been satisfied in full.
Subject to the foregoing, in the event of a default under The Mann Group Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group LLC&#146;s option, and the interest rate
will increase to the <FONT STYLE="white-space:nowrap">one-year</FONT> LIBOR rate calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5%&nbsp;per annum. All borrowings under The Mann Group
Loan Arrangement are unsecured. The Mann Group Loan Arrangement contains no financial covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015,
the Company had accrued and unpaid interest related to the above note of $9.3&nbsp;million and $6.4&nbsp;million, respectively, and had $30.1&nbsp;million of available borrowings. Interest expense on the Company&#146;s note payable to the
Company&#146;s principal stockholder for each of the years ended December&nbsp;31, 2016, 2015 and 2014 was $2.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May
2015, the Company entered into a sublease agreement with the Alfred Mann Foundation for Scientific Research (the &#147;Mann Foundation&#148;), a California
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Not-For-Profit</FONT></FONT> Corporation. The lease is for approximately 12,500 square feet of office space in Valencia, California and expires in April 2017. The office space
contains the Company&#146;s principal executive offices. Lease payments to the Mann Foundation for the year ended December&nbsp;31, 2016 and 2015 were $268,000 and $175,000, respectively. There were no lease payments to the Mann Foundation for the
year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with certain meetings of the Company&#146;s board of directors and on other occasions
when the Company&#146;s business necessitated air travel for the Company&#146;s principal stockholder and other Company employees, the Company utilized the principal stockholder&#146;s private aircraft, and the Company paid the charter company that
manages the aircraft on behalf of the Company&#146;s principal stockholder approximately $18,000 and $79,000 for the years ended December&nbsp;31, 2015 and 2014, respectively, on the basis of the corresponding cost of commercial airfare. There were
no payments to the principal stockholder related to the usage of the aircraft during the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in its amended and restated certificate of incorporation and amended and restated bylaws (see Note 13
&#151; Commitments and Contingencies). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Borrowings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrowings consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Facility Financing Obligation (2019 Notes)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net carrying amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior Convertible Notes (2018 Notes)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaccreted debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net carrying amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Note payable to principal stockholder &#151; net carrying amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Facility Financing Obligation (2019 Notes)</I> &#151; As of December&nbsp;31, 2016, there were
$55.0&nbsp;million principal amount of 2019 notes and $20.0&nbsp;million principal amount of Tranche B notes outstanding. As of December&nbsp;31, 2015, there were $60.0&nbsp;million principal amount of 2019 notes and $20.0&nbsp;million principal
amount of Tranche B notes outstanding. The 2019 notes accrue interest at annual rate of 9.75% and the Tranche B notes accrue interest at an annual rate of 8.75%. Interest is paid quarterly in arrears on the last day of each March, June, September
and December. The Facility Financing Obligation principal repayment schedule is comprised of annual payments beginning on July&nbsp;1, 2016 and ending December&nbsp;9, 2019. Future principal payments for the years ended December&nbsp;31, 2017, 2018
and 2019 are $20.0&nbsp;million, $20.0&nbsp;million and $35.0&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the Facility Agreement, the
Company entered into a Milestone Rights Agreement with Deerfield which requires the Company to make contingent payments to Deerfield, totaling up to $90.0&nbsp;million, upon the Company achieving specified commercialization milestones. The Milestone
Rights were initially recorded as a short-term liability equal to $3.2&nbsp;million included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets and a long-term liability equal to $13.1&nbsp;million
included in other liabilities. During the first quarter of 2015, a milestone triggering event was achieved following the Company&#146;s product launch on February&nbsp;3, 2015, which resulted in a $5.8&nbsp;million incremental charge to interest
expense due to the increase in carrying value of the liability to the required $10.0&nbsp;million payment made in February of 2015. During the year ended December&nbsp;31, 2014, the first milestone triggering event was achieved following the
Company&#146;s entry into the Sanofi License Agreement, which resulted in a $1.9&nbsp;million incremental charge to interest expense due to the increase in carrying value of the liability to the required $5.0&nbsp;million payment, which was paid to
Deerfield pursuant to the terms of the Milestone Agreement. As of December&nbsp;31, 2016 and 2015, the remaining liability balance of $8.9&nbsp;million is classified as a long-term liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the unamortized debt discount and debt issuance costs were $3.7&nbsp;million and $0.1&nbsp;million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accretion of debt issuance cost and debt discount in connection with the Deerfield financing during the years ended
December&nbsp;31, 2016, 2015 and 2014 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion expense &#151; debt issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion expense &#151; debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Facility Agreement includes customary representations, warranties and covenants, including, a restriction
on the incurrence of additional indebtedness, and a financial covenant which requires the Company&#146;s cash and cash equivalents, which includes available borrowings on the note payable to principal stockholder, on the last day of each fiscal
quarter to not be less than $25.0&nbsp;million. As discussed in Note 1 &#151; Description of Business, the Company will need to raise additional capital to support its current operating plans. Due to the uncertainties related to maintaining
sufficient resources to comply with the aforementioned covenant, the 2019 notes and the Tranche B notes have been classified as current liabilities in the accompanying consolidated balance sheets as of December&nbsp;31, 2016 and 2015. In the event
of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> Deerfield may declare all or any portion of the 2019 notes and/or Tranche B notes to be immediately due and payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Rights</I> &#151; The Milestone Agreement includes customary representations and warranties and covenants by the Company,
including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of the
Milestone Agreement. The Company has initially recorded the Milestone Rights at their estimated fair value &#151; See Note 2 &#151; Summary of Significant Accounting Policies under Milestone Rights Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the Milestone Rights, the 13 individual milestone payments were adjusted for both (i)&nbsp;the expected
timing and (ii)&nbsp;the probability of achieving the milestones, and then discounted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
present value using a discount rate of 14.5%. Once the initial valuation of each specified milestone payment was determined, the individual milestone payments were then aggregated to arrive at a
total fair value of $18.4&nbsp;million. The discount rate was based on the estimated cost of equity which was derived using the capital asset pricing model. In addition, a 5% risk premium was added to the computation of the cost of equity to adjust
for <FONT STYLE="white-space:nowrap">non-systemic</FONT> risk factors, such as the Company&#146;s lack of product diversification and history of financial losses, which were not captured in other model inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Security Agreement</I> &#151; In connection with the Facility Agreement, the Company and its subsidiary, MannKind LLC, entered into a
Guaranty and Security Agreement (the &#147;Security Agreement&#148;) with Deerfield and Horizon Sante FLML SA&#146;RL (collectively, the &#147;Purchasers&#148;), pursuant to which the Company and MannKind LLC each granted the Purchasers a security
interest in substantially all of their respective assets, including respective intellectual property, accounts, receivables, equipment, general intangibles, inventory and investment property, and all of the proceeds and products of the foregoing.
The Security Agreement includes customary covenants by the Company and MannKind LLC, remedies of the Purchasers and representations and warranties by the Company and MannKind LLC. The security interests granted by the Company and MannKind LLC will
terminate upon repayment of the 2019 notes and Tranche B notes, if applicable, in full. The Company&#146;s obligations under the Facility Agreement and the Milestone Agreement are also secured by the mortgage on the Company&#146;s facilities in
Danbury, Connecticut, which has a carrying value of $28.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Embedded Derivatives</I> &#151; The Company identified and
evaluated a number of embedded features in the notes issued under the Facility Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. In 2014,
the Company analyzed the Tranche&nbsp;B notes and identified embedded derivatives which required separate accounting. However, all of the embedded derivatives were determined to have a <I>de minimis</I> value at December&nbsp;31, 2016 and 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Conversion Option &#151; </I>During 2014, Deerfield elected to convert a total of $93.5&nbsp;million of principal, which consisted of
$20.0&nbsp;million, $33.5&nbsp;million, and $40.0&nbsp;million of Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes, respectively, into an aggregate 3,464,616 shares of common stock. In conjunction with the conversion by Deerfield, we recorded
an aggregate expense of $6.4&nbsp;million for the difference between the principal amount of the notes converted and their carrying amount (which included unamortized discount and debt issuance costs) which consisted of $1.2&nbsp;million,
$3.0&nbsp;million, and $2.2&nbsp;million related to the Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes, respectively. Further, upon Deerfield converting $40.0&nbsp;million of Tranche 3 notes and $20.0&nbsp;million of Tranche 1 notes,
Deerfield has reached the conversion limits (i.e., &#147;Applicable Limits&#148;) with respect to the Facility Agreement and therefore, no additional amount of the 2019 notes is convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of new 5.75% Convertible Senior Subordinated Exchange Notes Due 2018 in Exchange for 2015 Notes</I> &#151; On July&nbsp;28, 2015,
the Company entered into privately-negotiated exchange agreements (the &#147;Note Exchange Agreements&#148;) with a select holder of the Company&#146;s 5.75% Senior Convertible Notes due 2015 (the &#147;2015 notes&#148;), pursuant to which the
Company agreed to issue $27.7&nbsp;million aggregate principal amount of new 5.75% Convertible Senior Subordinated Exchange Notes due 2018 (the &#147;2018 notes&#148;) to such holders in exchange for the delivery to the Company of the same principal
amount of 2015 notes. The 2018 notes were issued at the closing of the exchange on August&nbsp;10, 2015. The Company analyzed this exchange and concluded that the exchange represents an extinguishment of the 2015 notes and a new issuance of 2018
notes and recorded such notes at fair value, which resulted in a premium of $0.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 notes are the Company&#146;s
general, unsecured, senior obligations, except that the 2018 notes were subordinated to the Sanofi Loan facility prior to the extinguishment of the facility on November&nbsp;9, 2016. The 2018 notes rank equally in right of payment with the
Company&#146;s other unsecured senior debt. The 2018 notes bear interest at the rate of 5.75%&nbsp;per year on the principal amount, payable semiannually in arrears in cash on February&nbsp;15 and August&nbsp;15 of each year, beginning
February&nbsp;15, 2016, with interest accruing from August&nbsp;15, 2015. The 2018 notes mature on August&nbsp;15, 2018. Accrued interest related to these notes is recorded in accrued expenses and other current liabilities on the accompanying
consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 notes are convertible, at the option of the holder, at any time on or prior to the close
of business on the business day immediately preceding the stated maturity date, into shares of the Company&#146;s common stock at an initial conversion rate of 29 shares per $1,000 principal amount of the 2018 notes, which is equal to a conversion
price of approximately $34.00 per share, the same conversion price as that of the 2015 notes on the date of exchange. The conversion rate is subject to adjustment under certain circumstances described in an indenture governing the 2018 notes dated
August&nbsp;10, 2015 with Wells Fargo, National Association, including in connection with a make-whole fundamental change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If certain
fundamental changes occur, the Company will be obligated to pay a fundamental change make-whole premium on any 2018 notes converted in connection with such fundamental change by increasing the conversion rate on such 2018 notes. In such instances,
the amount of the fundamental change make-whole premium will be based on the Company&#146;s common stock price and the effective date of the applicable fundamental change. If the Company undergoes certain fundamental changes, except in certain
circumstances, each holder of 2018 notes will have the option to require the Company to repurchase all or any portion of that holder&#146;s 2018 notes. The fundamental change repurchase price will be 100% of the principal amount of the 2018 notes to
be repurchased plus accrued and unpaid interest, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or after the date that is one year following the original issue date of the
2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30
consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid
interest. Under the terms of the 2018 Note Indenture, the conversion option can be <FONT STYLE="white-space:nowrap">net-share</FONT> settled and the maximum number of shares that could be required to be delivered under the indenture, including the
make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments. Applying the Company&#146;s
sequencing policy, the Company performed an analysis at the time of the offering of the 2018 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent
reporting date was sufficient to deliver the number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 notes provide that upon an acceleration of certain indebtedness, including the 9.75% Senior Convertible Notes due in 2019 (the
&#147;2019 notes&#148;) and the 8.75% Senior Convertible Notes due in 2019 (the &#147;Tranche B notes&#148;) issued to Deerfield pursuant to the Facility Agreement, the holders may elect to accelerate the Company&#146;s repayment obligations under
the notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred approximately $0.8&nbsp;million in issuance costs, which are recorded as an offset to the 2018 notes in the accompanying
consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2018 notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accretion of debt issuance expense in connection with the 2018 notes during the years ended December&nbsp;31, 2016 and 2015 was $257,000 and
$93,000, respectively. Amortization of the 2018 notes premium during the years ended December&nbsp;31, 2016 and 2015 was $234,000 and $86,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Common Stock in Exchange for the 2015 Notes</I> &#151; On July&nbsp;28, 2015, the Company entered into separate,
privately-negotiated exchange agreements (the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Stock-for-Note</FONT></FONT> Exchange Agreements&#148;) with certain holders of the 2015 notes pursuant to which the Company agreed
to issue shares of its common stock to such holders in exchange for the delivery to the Company of up to $56.9&nbsp;million aggregate principal amount of the 2015 notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Stock-for-Note</FONT></FONT> Exchange Agreements, the parties agreed to price the exchange transactions over a 10 trading day period spanning from July&nbsp;29, 2015 to and including
August&nbsp;11, 2015. Between July&nbsp;28, 2015 and August&nbsp;10, 2015, the Company issued an aggregate of 380,000 shares of common stock to such holders in exchange for such holders&#146; delivery to the Company of $8.0&nbsp;million aggregate
principal amount of the 2015 notes, resulting in a weighted-average exchange price of $110.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of New 5.75%
Convertible Senior Subordinated Exchange Notes Due 2015 in Exchange for the 2015 Notes</I> &#151; On August&nbsp;14, 2015, the Company exchanged $32.1&nbsp;million aggregate principal amount of newly issued, 5.75% Convertible Senior Subordinated
Exchange Notes due 2015 (the &#147;Exchange Notes&#148;) for the same principal amount of the Company&#146;s previously outstanding 2015 notes. The Exchange Notes, payable at maturity on September&nbsp;30, 2015, were convertible, at the option of
each holder thereof, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date. The holders of the Exchange Notes did not elect to convert any of the outstanding principal amount of the
Exchange Notes into shares of the Company&#146;s common stock. As a result, on September&nbsp;30, 2015, the Company paid $32.1&nbsp;million to settle the Exchange Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Settlement of 2015 Notes and Exchange Notes</I> &#151; On August&nbsp;17, 2015, the Company paid $32.2&nbsp;million to settle the remaining
2015 notes. As of September&nbsp;30, 2015, all 2015 notes, including the Exchange Notes, have been settled resulting in a total loss on extinguishment of debt equal to $1.0&nbsp;million. The loss on extinguishment of debt resulted from the <FONT
STYLE="white-space:nowrap">write-off</FONT> of debt discount and debt issuance costs associated with the 2015 notes and Exchange Notes and the difference between the principal amounts being exchanged for shares of the Company&#146;s common stock,
pursuant to the various <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Stock-for-Note</FONT></FONT> Exchange Agreements, and the fair market value of the Company&#146;s common stock issued in exchange for such reduction in
principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accretion of debt issuance costs in connection with the 2015 notes during the years ended December&nbsp;31, 2015 and 2014 was
$0.6&nbsp;million and $0.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 6 &#151; Related-Party Arrangements for information regarding the
Note payable to principal stockholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Receptor Collaboration and License Agreement</I> &#151; On January&nbsp;20, 2016, the Company entered into a Collaboration and License
Agreement (the &#147;CLA&#148;) with Receptor Life Sciences, Inc. (&#147;Receptor&#148;) pursuant to which the Company performed initial formulation studies on compounds identified by Receptor. Following successful completion of the studies,
Receptor obtained the option to acquire an exclusive license to develop, manufacture and commercialize certain products that use MannKind&#146;s technology to deliver the compounds via oral inhalation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received $0.4&nbsp;million in nonrefundable payments in 2016 prior to Receptor exercising the option. On December&nbsp;30, 2016,
Receptor exercised the option and paid the Company a $1.0&nbsp;million nonrefundable option exercise and license fee. Under the CLA, the Company may receive the following additional payments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nonrefundable milestone payments upon the completion of certain technology transfer activities and the achievement of specified sales targets. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Royalties upon Receptor&#146;s and its sublicensee&#146;s sale of the product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Milestones upon total worldwide sales reaching certain agreed upon levels. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
evaluated the accounting for the payments received in 2016 under the multiple element accounting guidance and determined that the $0.4&nbsp;million in payments received prior to Receptor exercising its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option are separable from the other elements of the agreement and represented payments to offset costs incurred. Therefore, those payments reduced the Company&#146;s research and development
expense in 2016. The $1.0&nbsp;million license fee received in 2016 does not have standalone value from the <FONT STYLE="white-space:nowrap">follow-on</FONT> transfer of technology. Therefore, the license fee was recorded in deferred payments from
collaboration at December&nbsp;31, 2016 and will be recognized in net revenue &#151; collaboration over four years. See Note 2 &#151; Summary of Significant Accounting Policies for additional information on the Company&#146;s accounting for multiple
element arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sanofi License Agreement and Sanofi Supply Agreement and Loan Facility</I> &#151; On August&nbsp;11, 2014, the
Company executed a license and collaboration agreement (the &#147;Sanofi License Agreement&#148;) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (Sanofi)),
pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. The Company manufactured Afrezza at its manufacturing facility in Danbury, Connecticut to supply Sanofi&#146;s demand for the product
pursuant to a supply agreement dated August&nbsp;11, 2014 (the &#147;Sanofi Supply Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of the Sanofi
License Agreement, worldwide profits and losses were determined based on the difference between the net sales of Afrezza and the costs and expenses incurred by the Company and Sanofi that were specifically attributable or related to the development,
regulatory filings, manufacturing, or commercialization of Afrezza. These profits and losses were shared 65% by Sanofi and 35% by the Company. On January&nbsp;4, 2016 the Company received a <FONT STYLE="white-space:nowrap">90-day</FONT> notification
from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination (the &#147;Termination Date&#148;) was April&nbsp;4, 2016. On April&nbsp;5, 2016 the Company assumed responsibility for the
worldwide development and commercialization of Afrezza from Sanofi. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza
product to major wholesalers during the week of July&nbsp;25, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzed the agreements entered into with Sanofi at their
inception to determine whether the consideration, paid or payable to the Company, or a portion thereof, could be recognized as revenue.<I> </I>Under the terms of the Sanofi License Agreement, the Sanofi Supply Agreement and the Sanofi Loan Facility,
the Company determined that the arrangement contained significant deliverables including (i)&nbsp;licenses to develop and commercialize Afrezza and to use the Company&#146;s trademarks, (ii)&nbsp;development activities, and (iii)&nbsp;manufacture
and supply services for Afrezza. Due to the proprietary nature of the manufacturing services to be provided by the Company, the Company determined that all of the significant deliverables should be combined into a single unit of accounting. The
Company believed that the manufacturing services are proprietary due to the fact that since the late 1990&#146;s, the Company has developed proprietary knowledge and patented equipment and tools that are used in the manufacturing process of Afrezza.
Due to the complexities of particle formulation and the specialized knowledge and equipment needed to handle the Afrezza powder, neither Sanofi nor, to the Company&#146;s knowledge, any third-party contract manufacturing organization currently
possesses the capability of manufacturing Afrezza. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for revenue to be recognized, the seller&#146;s price to the buyer must be
fixed or determinable. Prior to December&nbsp;31, 2015, because the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement and the
Sanofi Supply Agreement, the Company believed this requirement for revenue recognition had not been met. Therefore, the Company had recorded the $150.0&nbsp;million <FONT STYLE="white-space:nowrap">up-front</FONT> payment and the two milestone
payments of $25.0&nbsp;million each as deferred payments from collaboration. In addition, as of December&nbsp;31, 2015 the Company had recorded $17.5&nbsp;million in Afrezza product shipments to Sanofi as deferred sales from collaboration and
recorded $13.5&nbsp;million as deferred costs from collaboration. Deferred costs from collaboration represented the costs of product manufactured and shipped to Sanofi, as well as certain direct costs associated with a firm purchase commitment
entered into in connection with the collaboration with Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first and second quarters of 2016, after the Company received
notice of termination from Sanofi, the Company evaluated whether the revenue recognition criteria had been met. The Company determined that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirement had not been met because Sanofi had not finalized necessary adjustments to the profit and loss share provision statements and Sanofi had not yet transferred all of the information to
enable the Company to commercialize Afrezza on its own. Therefore, the Company was still unable to estimate the costs to be incurred under the agreement with Sanofi. During the three months ended September&nbsp;30, 2016, Sanofi provided enough
information to the Company to enable it to reasonably estimate the remaining costs under the Sanofi License Agreement and the Sanofi Supply Agreement. Accordingly, the fixed or determinable fee requirement for revenue recognition was met and there
were no future obligations to Sanofi. Therefore, the Company recognized $172.0&nbsp;million of net revenue &#151; collaboration for the year ended December&nbsp;31, 2016. The revenue recognized includes the upfront payment of $150.0&nbsp;million and
the two milestone payments of $25.0&nbsp;million each, net of $64.9&nbsp;million of net loss share with Sanofi, as well as $17.5&nbsp;million in sales of Afrezza and $19.4&nbsp;million from sales of bulk insulin, both to Sanofi. These payments and
sales were made pursuant to the contractual terms of the agreements with Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sanofi Loan Facility</I> &#151; On September&nbsp;23,
2014, the Company entered into the Sanofi Loan Facility, consisting of a senior secured revolving promissory note and a guaranty and security agreement (the &#147;Security Agreement&#148;) with an affiliate of Sanofi, which provided the Company with
a secured loan facility of up to $175.0&nbsp;million to fund the Company&#146;s share of net losses under the Sanofi License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Company under the Sanofi Loan Facility were guaranteed by the Company&#146;s wholly-owned subsidiary, MannKind LLC, and
were secured by a first priority security interest in certain insulin inventory located in the United States and any contractual rights and obligations pursuant to which the Company purchases or has purchased such insulin, and a second priority
security interest in the Company&#146;s assets that secure the Company&#146;s obligations under the Facility Agreement, as amended. In addition, the Company granted to Sanofi, as additional security for the obligations under the Sanofi Loan
Facility, a first priority mortgage on the Company&#146;s facility in Valencia, California, which had a carrying value of $17.9&nbsp;million as of December&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advances under the Sanofi Loan Facility bore interest at a rate of 8.5%&nbsp;per annum and were payable
<FONT STYLE="white-space:nowrap">in-kind</FONT> and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company was required to make mandatory prepayments on the outstanding loans under the Sanofi
Loan Facility from its share of any profits (as defined in the Sanofi License Agreement) under the Sanofi License Agreement within 30 days of receipt of its share of any such profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s total portion of the loss sharing was $57.7&nbsp;million for the year ended December&nbsp;31, 2015, of which
$44.5&nbsp;million was borrowed under the Sanofi Loan Facility as of December&nbsp;31, 2015. Subsequent to December&nbsp;31, 2015, the Company borrowed $17.9&nbsp;million under the Sanofi Loan Facility to finance the portion of the Company&#146;s
loss for the quarter ended December&nbsp;31, 2015. The total amount owed to Sanofi at December&nbsp;31, 2015 was $62.4&nbsp;million, which includes $1.7&nbsp;million of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, the
Company entered into a settlement agreement with Sanofi (the &#147;Settlement Agreement&#148;). Under the terms of the Settlement Agreement, the promissory note between the Company and Aventisub LLC (&#147;Aventisub&#148;), a Sanofi affiliate, was
terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0&nbsp;million. Sanofi also agreed to purchase $10.2&nbsp;million of insulin from the Company in December 2016 under an existing insulin put option as well as
make a cash payment of $30.6&nbsp;million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without
the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5&nbsp;million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also
agreed to a general release of potential claims against each other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forgiveness of the full outstanding loan balance on the Sanofi
Loan Facility and the previously uncharged costs related to the collaboration were accounted for in (gain) loss on extinguishment of debt in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accompanying consolidated statements of operations. The $10.2&nbsp;million sale of insulin was accounted for as net revenue &#151; collaboration, consistent with the Company&#146; sales of
insulin to Sanofi in the third quarter of 2016 (see Note 2 &#151; Summary of Significant Accounting Policies &#151; <I>Revenue Recognition &#151; Net Revenue &#151; Collaboration</I>). The $30.6&nbsp;million accelerated put option payment was
recognized as a receivable from Sanofi at December&nbsp;31, 2016 and an increase in the recognized loss on purchase commitments as the purchase commitment obligation had previously been reduced to reflect the Company&#146;s expectation that amounts
associated with purchases of insulin were recoverable (see Note 2 &#151; Summary of Significant Accounting Policies &#151; <I>Inventories</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.
Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reported in the accompanying consolidated financial statements for cash,
accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable&nbsp;to principal stockholder,
senior convertible notes, the Facility Financing Obligation (as defined below), the Milestone Rights (as defined below) and warrant liability are discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Equivalents</I> &#151; As of December&nbsp;31, 2016 and 2015, the Company held $20.5&nbsp;million and $55.8&nbsp;million,
respectively, of cash equivalents, consisting of money market funds. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Note Payable to Principal Stockholder</I> &#151; The fair value of the note payable to the Company&#146;s principal stockholder cannot be
reasonably estimated as the Company would not be able to obtain a similar credit arrangement in the current economic environment. Therefore, the fair value is based upon carrying value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Financial Liabilities</I> &#151; The following tables set forth the fair value of the Company&#146;s financial instruments (in millions):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of December&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Carrying&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility Financing Obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability (at recurring fair values)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of December&nbsp;31, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Carrying&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Level&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility Financing Obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a roll forward of the fair values of financial assets and
liabilities that are carried at fair value (in millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Assets&nbsp;Held&nbsp;for<BR>Sale</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value, January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value, December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value, December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Senior Convertible Notes</I> &#151; The estimated fair value of the 2018 notes was calculated based on
model-derived valuations where inputs were observable, such as the Company&#146;s stock price and yields on U.S. Treasury notes and actively traded bonds, and <FONT STYLE="white-space:nowrap">non-observable,</FONT> such as the Company&#146;s
longer-term historical volatility, and estimated yields implied from any available market trades of the Company&#146;s issued debt instruments. As there is no current active and observable market for the 2018 notes, the Company determined the
estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash flows based on terms of the notes with market-based assumptions regarding risk-free rate,
risk-adjusted yields (20%), stock price volatility (111%) and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Facility Financing Obligation</I> &#151; As discussed in Note 7 &#151; Borrowings, in connection with the Facility Agreement, the Company
issued 2019 notes and subsequently issued Tranche B notes (the &#147;Facility Financing Obligation&#148;). As there is no current observable market for the Facility Financing Obligation, the Company determined the estimated fair value using a bond
valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value
using a selected market discount rate. On December&nbsp;31, 2016 the market discount rate was recalculated at 12.0% for the Facility Financing Obligation. Under the terms of the Facility Agreement, the Company is restricted from distributing any of
its assets or declaring and distributing a dividend to its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Rights Liability</I> &#151; In addition to the
Facility Financing Obligation, the Company also issued certain rights to receive payments of up to $90.0&nbsp;million upon occurrence of specified strategic and sales milestones (the &#147;Milestone Rights&#148;). These rights are not reflected in
the Facility Financing Obligation. The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and
the probability of achieving the milestones discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed
with consideration given to both internal data, such as the Company&#146;s forecast, progress made to date towards meeting the milestones, and assessment of criteria required for achievement, and external data, such as market research studies. The
discount rate (14.5%)&nbsp;was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. As of December&nbsp;31, 2016, the carrying value of the Milestone Rights is
$8.9&nbsp;million, classified as a long-term liability and the fair value is estimated at $18.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Liability</I>
&#151; Warrant liabilities are measured at fair value using a Monte Carlo pricing valuation model and various assumptions. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities is the expected
volatility. Significant increases in volatility would result in a higher fair value measurement (Level 3 in the fair value hierarchy). See Note 16 &#151; Warrants for further discussion of the valuation technique and inputs used in the fair value
measurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sanofi Loan Facility</I> &#151; As discussed in Note 8 &#151; Collaboration Arrangements, the
Sanofi Loan Facility consisted of a senior secured revolving promissory note and a guaranty and security agreement with an affiliate of Sanofi which provided the Company with a secured loan facility of up to $175.0&nbsp;million to fund the
Company&#146;s share of net losses under the Sanofi License Agreement. The estimated fair value was determined using a discounted cash flow model where time outstanding and discount rate were primary variables. This method considered the key
elements of the contractual terms of the Sanofi Loan Facility, market-based estimated cost of capital, and time value of money, namely the amount of time to settlement and the estimated discount rate (11%)&nbsp;appropriate for the liability (Level 3
in the fair value hierarchy). The Sanofi Loan Facility was forgiven on November&nbsp;9, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers of assets or
liabilities between the fair value measurement levels during the twelve months ended December&nbsp;31, 2016, 2015 and 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Assets and
Liabilities Measured at Fair Value on a <FONT STYLE="white-space:nowrap">Non-recurring</FONT> Basis</I> &#151; Land, buildings, and machinery and equipment, with a carrying amount of $189.2&nbsp;million, were written down to a fair value of
$48.8&nbsp;million, resulting in an impairment charge of $140.4&nbsp;million, which is included in our consolidated statements of operations for the year ended December&nbsp;31, 2015. See Note <FONT STYLE="white-space:nowrap">4-</FONT> Property and
Equipment for further discussion of the valuation technique and inputs used in the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An additional impairment of
$0.7&nbsp;million was charged for the year ended December&nbsp;31, 2016. At that time, an analysis of the lower of carrying value to fair value, which was deemed to be the sales price of the property, less selling costs determined a loss of $0.6
million, which is included in property and equipment impairment on the consolidated statement of operations for 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our assessment of
the real property includes Level&nbsp;3 inputs, and was based on a combination of the income, market and cost approaches and the market approach was used for machinery and equipment which required Level&nbsp;3 inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Embedded Derivatives</I> &#151; The Company identified and evaluated a number of embedded features in the notes issued under the Facility
Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. The Company analyzed the Tranche B notes and identified embedded derivatives, which
required separate accounting. However, all of the embedded derivatives were determined to have a <I>de minimis</I> value at December&nbsp;31, 2016 and 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common and Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March
1, 2017, the Company effected a 1-for-5 reverse stock split of the Company&#146;s outstanding common stock. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor
of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company&#146;s common stock par value. See Note 1 &#151; Description of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 140,000,000 shares of common stock, par value $0.05 per share, and 10,000,000 shares of undesignated
preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company&#146;s board of directors. No other class of capital stock is authorized. As of December&nbsp;31, 2016 and 2015, 95,680,831 and 85,734,188 shares
of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in
Note 16 &#151; Warrants, in May 2016, the Company sold in a registered offering an aggregate of 9,708,737 shares of common stock together with certain warrants exercisable for up to an aggregate of 7,281,553 shares of common stock (&#147;A
Warrants&#148;) and certain warrants exercisable for up to an aggregate of 2,427,184 shares of common stock (&#147;B Warrants&#148;) in a direct offering for proceeds of $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2015, the Company entered into a series of stock purchase agreements to sell up to an aggregate of 10,000,000 shares of
its common stock in a registered direct offering to selected investment funds in Israel that hold securities included within certain stock indexes of the Tel Aviv Stock Exchange (the &#147;TASE&#148;). Pursuant to the agreements, the shares of
common stock were sold at a price per share equal to 97% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
closing price of the Company&#146;s common stock on the TASE on November&nbsp;12, 2015. During November 2015, the Company sold 2,770,487 shares of common stock for an aggregate price of
approximately $34,710,000, or $13.05 per share, which is net of $1,432,000 of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company engaged Sunrise Securities
Corporation as its exclusive placement agent in connection with the offering of the 10,000,000 shares. In connection with the services provided, the Company issued to Sunrise Securities Corporation, or its designee, restricted warrants to purchase a
number of shares of the Company&#146;s common stock in an aggregate equal to 1.15% of the aggregate shares sold in the offering, which totaled 31,860 shares on November&nbsp;16, 2015. The warrants are exercisable for a five year period at an
exercise price of $13.05, the price paid per share in connection with the offering. The Company had an obligation to register the common stock that may be issued pursuant to the exercise of the warrants, which resulted in their initial
classification as liability and were deemed immaterial. On December&nbsp;15, 2015 the warrants were reclassified to equity as the Company registered the common stock pursuant to a registration statement and continue to be classified in equity as of
December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Included in the common stock outstanding as of December&nbsp;31, 2014 is 1,800,000 shares of common stock loaned
to Bank of America under a share lending agreement in connection with the offering of the $100.0&nbsp;million aggregate principal amount of the 2015 notes. Bank of America was obligated to return the borrowed shares (or, in certain circumstances,
the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early
termination at Bank of America&#146;s option. On October&nbsp;23, 2015, the 1,800,000 shares of common stock loaned to Bank of America were returned, as the Company settled all payments and deliveries in respect of such convertible notes on
August&nbsp;17, 2015. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.05 per share from Bank of America for the use of borrowed shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;8, 2012, the Company sold 7,187,500 units in an underwritten public offering, including 937,500 units sold pursuant to the
full exercise of an over-allotment option granted to the underwriters, with each unit consisting of one share of common stock and a warrant to purchase 0.1 of a share of common stock. All of the securities were offered by the Company at a combined
price to the public of $12.00 per unit and the underwriters purchased the units at a price of $11.28 per unit. Net proceeds from this offering were approximately $80.6&nbsp;million, excluding any warrant exercises. The 4,312,500 shares of common
stock underlying the warrants are exercisable at $12.00 per share and expire four years from the date of the issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years
ended December&nbsp;31, 2015 and 2014, the Company received $10.1&nbsp;million and $27.8&nbsp;million in proceeds, respectively, from the exercise of the February 2012 public offering warrants. There were no warrant exercises during the year ended
December&nbsp;31, 2016 and any unexercised February 2012 public offering warrants expired on February&nbsp;8, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Income (Loss) per Common
Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 1, 2017, the Company effected a 1-for-5 reverse stock split of the Company&#146;s outstanding common stock. As a
result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the
Company&#146;s common stock par value. See Note 1 &#151; Description of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share excludes dilution for
potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury
method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation
of diluted net loss per share as they would be antidilutive. During 2015, 1,800,000 shares of the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock, which were loaned to Bank of America pursuant to the terms of a share lending agreement, were issued and outstanding, with the holder of the borrowed shares having all the rights of
a holder of the Company&#146;s common stock. As the share borrower was required to return all borrowed shares to the Company, the borrowed shares were not considered outstanding for the purpose of computing and reporting basic or diluted loss per
share during the period presented for 2015. These shares were returned to the Company in the third quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables
summarize the components of the basic and diluted net income (loss) per common share computations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(In thousands, except per share data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic EPS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) (numerator)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares (denominator)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted EPS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) (numerator)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities &#151; common shares issuable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted weighted average common shares (denominator)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common shares issuable represents incremental shares of common stock which consist of stock options,
restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potentially dilutive
securities outstanding that are considered antidilutive are summarized as follows (in shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,955,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,308,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of senior convertible notes into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,464,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,740,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,997,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,788,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,946,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,292,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Stock Award Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 1, 2017, the Company effected a 1-for-5 reverse stock split of the Company&#146;s outstanding common stock. As a result, all common
stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company&#146;s
common stock par value. See Note 1 &#151; Description of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;23, 2013, the Company adopted the 2013 Equity Incentive
Plan (the &#147;2013 Plan&#148;) as the successor to and continuation of the 2004 Equity Incentive Plan (the &#147;2004 Plan&#148;). The 2013 Plan consists of 4.3&nbsp;million additional shares and the number of unallocated shares remaining
available for grant for new awards under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2004 Plan. The 2013 Plan provides for the granting of stock awards including stock options and restricted stock units, to employees, directors and consultants. The 2013 Plan also provides for the
automatic, <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant of options to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. No additional awards will be granted under the 2004 Plan or under the 2004 <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Stock Option Plan (the &#147;NED Plan&#148;) as all future awards will be made out of the 2013 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes information about the Company&#146;s stock-based award plans as of December&nbsp;31, 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Outstanding<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Outstanding<BR>Restricted<BR>Stock Units</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares&nbsp;Available<BR>for Future<BR>Issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2004 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,399,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,743,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2004 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Stock Option
Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">737,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2004, as part of the 2004 Plan, the Company&#146;s board of directors approved the Employee Stock
Purchase Plan (&#147;ESPP&#148;), which became effective upon the closing of the Company&#146;s initial public offering. Initially, the aggregate number of shares that could be sold under the 2004 Plan was 400,000 shares of common stock. On
January&nbsp;1 of each year, for a period of ten years beginning January&nbsp;1, 2005, the share reserve automatically increased by the lesser of: 140,000 shares, 1% of the total number of shares of common stock outstanding on that date, or an
amount as may be determined by the board of directors. However, under no event can the annual increase cause the total number of shares reserved under the ESPP to exceed 10% of the total number of shares of capital stock outstanding on
December&nbsp;31 of the prior year. On January&nbsp;1, 2013 and 2014 the ESPP share reserve was increased each year by 140,000 shares. There was no ESPP share reserve increases during 2015 or 2016. As of December&nbsp;31, 2016, 445,782 shares were
available for issuance under the ESPP. For the years ended December&nbsp;31, 2016, 2015 and 2014, the Company sold 104,758, 64,245 and 61,015 shares, respectively, of its common stock to employees participating in the ESPP. The ESPP purchase of
43,672 shares for the period ending December&nbsp;31, 2016 was initiated prior to <FONT STYLE="white-space:nowrap">year-end</FONT> but did not settle until January&nbsp;5, 2017. As a result, the shares sold are reflected in the ESPP share reserves
but are excluded from common stock outstanding as of December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of directors determines
eligibility, vesting schedules and criteria and exercise prices for stock awards granted under the 2013 Plan. Options and restricted stock unit awards under the 2013 Plan expire not more than ten years from the date of the grant and are exercisable
upon vesting. Stock options that vest over time generally vest over four years. Current time-based vesting stock option grants vest and become exercisable at the rate of 25% after one year and ratably on a monthly basis over a period of 36 months
thereafter. Restricted stock units with time-based vesting generally vest at a rate of 25%&nbsp;per year over four years with consideration satisfied by service to the Company. The Company also issues stock awards with performance conditions. The
2013 Plan provides for full acceleration of vesting if an employee is terminated within three months of a change in control, as defined in the 2013 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The
Company accounts for <FONT STYLE="white-space:nowrap">non-employee</FONT> stock-based compensation expense based on the estimated fair value of the options, which is determined using the Black-Scholes option valuation model and amortizes such
expense on a straight-line basis over the service period for time-based awards and over the expected dates of achievement for performance-based awards. These awards are subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> until service
is complete. As of December&nbsp;31, 2016, there were options to purchase 100,697 shares of common stock outstanding to consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2016, 2015 and 2014 the Company recorded stock-based compensation expense of $5.1&nbsp;million,
$8.7&nbsp;million and $48.6&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized in the accompanying consolidated statements of
operations is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consultant-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is
included in the following categories (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee
stock options. The expected term of an option granted is based on combining historical exercise data with expected weighted time outstanding. Expected weighted time outstanding is calculated by assuming the settlement of outstanding awards is at the
midpoint between the remaining weighted average vesting date and the expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected volatility assumption is based on an
assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. The Company has selected risk-free interest rates based on U.S. Treasury securities with an equivalent expected
term in effect on the date the options were granted. Additionally, the Company uses historical data and management judgment to estimate stock option exercise behavior and employee turnover rates to estimate the number of stock option awards that
will eventually vest. The Company calculated the fair value of employee stock options granted during the years ended December&nbsp;31, 2016, 2015 and 2014 using the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.18%&nbsp;&#151;&nbsp;1.80%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.61% &#151;1.86%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.64%&nbsp;&#151;&nbsp;2.11%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected lives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.13&nbsp;&#151;&nbsp;5.82&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.79&nbsp;&#151;&nbsp;5.86&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.77&nbsp;&#151;&nbsp;6.09&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">77.57%&nbsp;&#151;&nbsp;82.75%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">69.76%&nbsp;&#151;&nbsp;71.84%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">73.98%&nbsp;&#151;&nbsp;84.85%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes information about stock options outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average&nbsp;Exercise<BR>Price per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Intrinsic<BR>Value&nbsp;($000)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,955,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,236,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(407,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,399,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,414,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of the stock options granted during the years ended
December&nbsp;31, 2016, 2015 and 2014 was $3.05, $12.80 and $23.80 per option, respectively. The total intrinsic value of options exercised during the years ended December&nbsp;31, 2016, 2015 and 2014 was $0.1&nbsp;million, $6.2&nbsp;million and
$14.9&nbsp;million, respectively. Intrinsic value is measured using the fair market value at the date of exercise for options exercised or at December&nbsp;31 for outstanding options, less the applicable exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash received from the exercise of options during the years ended December&nbsp;31, 2016, 2015 and 2014 was approximately $0.5&nbsp;million,
$3.3&nbsp;million and $11.0&nbsp;million, respectively. The weighted-average remaining contractual terms for options outstanding, vested and expected to vest and exercisable at December&nbsp;31, 2016 was 5.31 years, 5.22 years and 2.93 years,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of restricted stock unit activity for the year ended December&nbsp;31, 2016 is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Grant&nbsp;Date<BR>Fair Value<BR>per Share</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(292,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">737,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total restricted stock units expected to vest as of December&nbsp;31, 2016 was 629,424 with a weighted
average grant date fair value of $8.60 per share. The total intrinsic value of restricted stock units expected to vest as of December&nbsp;31, 2016 was $2.0&nbsp;million. Intrinsic value of restricted stock units expected to vest is measured using
the closing share price at December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total intrinsic value of restricted stock units vested during the years ended
December&nbsp;31, 2016, 2015 and 2014 was $0.6&nbsp;million, $5.2&nbsp;million and $62.7&nbsp;million, respectively. Intrinsic value of restricted stock units vested is measured using the closing share price on the day prior to the vest date. The
total grant date fair value of restricted stock units vested during the years ended December&nbsp;31, 2016, 2015 and 2014 was $2.6&nbsp;million, $5.5&nbsp;million and $36.4&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, there was $4.0&nbsp;million and $4.8&nbsp;million of unrecognized compensation expense related to options and
restricted stock units with performance conditions, respectively, which is expected to be recognized over the weighted average vesting period of 2.9 years. The Company evaluates stock awards with performance conditions as to the probability that the
performance conditions will be met and uses that information to estimate the date at which those performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company reviewed the probability of achieving the performance conditions for each of the four vesting
tranches of the performance-based stock options and determined that it was probable that the Company would achieve the first vesting tranche in December 2017. Therefore, the Company recorded a <FONT STYLE="white-space:nowrap">non-material</FONT>
cumulative catchup of the expense from the grant date through December&nbsp;31, 2016 and will record the unrecognized compensation cost related to the first tranche in the amount of $0.3&nbsp;million through December&nbsp;31, 2017. The Company
further determined that no compensation costs would be recognized for the second, third and fourth vesting tranches as it had not been determined that it was probable that the performance conditions related to these tranches would be achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, there was $1.6&nbsp;million of stock compensation expense related to certain executives who
entered into severance agreements which resulted in a modification to the terms of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards. The severance agreements generally allowed for the separated executives to continue to vest under their original award terms for a stated period of time without providing substantive
services. There were no modifications in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Leases</I> &#151; The Company leases its executive offices in Valencia, California and certain equipment under various operating
leases, which expire at various dates through 2017 and beyond. Future payments are insignificant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rent expense under all operating
leases, including office space and equipment, for the years ended December&nbsp;31, 2016, 2015 and 2014 was approximately $373,000, $426,000 and $737,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Guarantees and Indemnifications</I> &#151; In the ordinary course of its business, the Company makes certain indemnities, commitments and
guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences,
subject to certain limits, while the officer or director is or was serving at the Company&#146;s request in such capacity. The term of the indemnification period is for the officer&#146;s or director&#146;s lifetime. The maximum amount of potential
future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is
minimal. The Company has not recorded any liability for these indemnities in the accompanying consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from
indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Litigation</I> &#151; The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of
December&nbsp;31, 2016, the Company believes that the final disposition of such matters will not have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company and no accrual has been
recorded. The Company maintains liability insurance coverage to protect the Company&#146;s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a
liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company&#146;s policy is to accrue for legal expenses in connection with legal proceeding and claims as they are
incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the public announcement of Sanofi&#146;s election to terminate the Sanofi License Agreement and the subsequent
decline of the price of its common stock, several complaints were filed in the U.S. District Court for the Central District of California against the Company and certain of its officers and directors on behalf of certain purchasers of its common
stock, which were consolidated into a single action. The amended complaint alleged that the Company and certain of its officers and directors violated federal securities laws by making materially false and misleading statements regarding the
prospects for Afrezza, thereby artificially inflating the price of its common stock. The Company and the named defendants brought a motion to dismiss the class action that was pending against them, which the District Court granted in August 2016
without leave to amend the complaint. The lead plaintiff appealed that decision to the Ninth Circuit Court of Appeals. On March&nbsp;2, 2017, the lead plaintiff filed a voluntary motion to dismiss his appeal, which the Court of Appeals granted on
March&nbsp;9, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the public announcement of Sanofi&#146;s election to terminate the Sanofi License Agreement and the
subsequent decline of the price of its common stock, two motions were submitted to the District Court at Tel Aviv, Economic Department for the certification of a class action against the Company and certain of its officers and directors. In general,
the complaints allege that the Company and certain of its officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the
price of its common stock. The plaintiffs are seeking monetary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damages. In November 2016, the district court dismissed one of the actions without prejudice. In the remaining action, a hearing is scheduled for May 2017 to determine whether Israeli or U.S. law
is applicable before the case can be certified as a class action. The Company will vigorously defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to
the filing of the federal securities class action against the Company, two shareholder derivative complaints were filed in the Superior Court for the State of California, County of Los Angeles against certain of the Company&#146;s directors and
officers. The complaints allege breaches of fiduciary duties by the defendants and other violations of law. Among other allegations, the complaints allege that the defendants caused the Company to make false and misleading statements or omissions of
material fact regarding the Company&#146;s business and the prospects for sales of Afrezza, thereby artificially inflating the price of the Company&#146;s common stock. Following the dismissal of the federal securities class action, each derivative
complaint was voluntarily dismissed by its plaintiff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Contingencies &#151;</I> In connection with the Facility Agreement, on
July&nbsp;1, 2013 the Company also entered into a Milestone Rights Purchase Agreement (the &#147;Milestone Agreement&#148;) with Deerfield Private Design Fund and Horizon Sant&eacute; FLML S&Aacute;RL (collectively, the &#147;Milestone
Purchasers&#148;), pursuant to which the Company sold the Milestone Purchasers the Milestone Rights to receive payments up to $90.0&nbsp;million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of
an Afrezza product in the United States and the achievement of specified net sales figures (see Note 7 &#151; Borrowings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Commitment
&#151;</I> On July&nbsp;31, 2014, the Company entered into a supply agreement (the &#147;Insulin Supply Agreement&#148;) with Amphastar France Pharmaceuticals S.A.S., a French corporation (Amphastar), pursuant to which Amphastar will manufacture for
and supply to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar will be responsible for manufacturing the insulin in accordance with the Company&#146;s
specifications and agreed-upon quality standards. The Company had agreed to purchase annual minimum quantities of insulin for calendar years 2015 through 2019 under the Insulin Supply Agreement of an aggregate total of approximately
&#128;120.1&nbsp;million. The Company could have requested to purchase additional quantities of insulin over such annual minimum quantities with a cancellation fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, the supply agreement with Amphastar was amended to extend the term over which the Company is required to purchase
insulin, without reducing the total amount of insulin to be purchased. Under the amendment, annual minimum quantities of insulin to be purchased for calendar years 2017 through 2023 total an aggregate purchase price of &#128;93.0&nbsp;million at
December&nbsp;31, 2016. The Insulin Supply Agreement specifies that Amphastar will be deemed to have satisfied its obligations with respect to quantity, if the actual quantity supplied is within plus or minus ten percent (+/- 10%) of the quantity
set forth in the applicable purchase order. In addition, the aggregate cancellation fees that the Company would incur in the event that the above insulin quantities are not purchased was lowered from $5.3&nbsp;million for the period October&nbsp;1,
2016 through 2018 to $3.4&nbsp;million over the same period. The annual purchase requirements under the contract are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15.5&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15.5&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of the Insulin Supply Agreement expires on December&nbsp;31, 2023 and can
be renewed for additional, successive two year terms upon 12 months&#146; written notice given prior to the end of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a
specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years&#146; prior written notice to Amphastar without cause or upon 30
days&#146; prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply
Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also has another firm commitment with another supplier for an aggregate of $0.9&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Employee Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
administers a 401(k) savings retirement plan (the &#147;MannKind Retirement Plan&#148;) for its employees. For the years ended December&nbsp;31, 2016, 2015 and 2014, the Company contributed $418,000, $593,000 and $623,000, respectively, to the
MannKind Retirement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the Company has concluded that it is more likely than not that the Company may not realize the benefit of its
deferred tax assets due to its history of losses. There is no provision for income taxes in 2015 or 2014 because the Company had incurred operating losses since inception. Accordingly, the net deferred tax assets have been fully reserved. The
provision for income taxes consists of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the tax effects of temporary differences between the carrying
amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established when uncertainty exists as to whether all or a portion of the net deferred tax assets will be realized. Components of the net
deferred tax assets as of December&nbsp;31, 2016 and 2015, are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">712,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">721,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments from collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on purchase commitment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-qualified</FONT> stock option expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized patent costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(914,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(962,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table of deferred tax assets and liabilities does not include certain deferred tax assets as of
December&nbsp;31, 2016, that arose directly from tax deductions related to equity compensation which are greater than the compensation recognized for financial reporting. Equity would be increased by $11.6&nbsp;million if and when such deferred tax
assets are ultimately realized. The Company considers certain realization requirements when excess tax benefits have been realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December&nbsp;31, 2016, 2015 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal tax benefit rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany transfer of intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of
its deferred tax assets. Management has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax
assets have been fully reserved. Management reevaluates the positive and negative evidence on an annual basis. During the years ended December&nbsp;31, 2016, 2015 and 2014, the change in the valuation allowance was $(48.1)&nbsp;million,
$80.1&nbsp;million and $65.5&nbsp;million, respectively, for income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the Company had federal and state
net operating loss carryforwards of approximately $1.9&nbsp;billion and $1.3&nbsp;billion available, respectively, to reduce future taxable income. The federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
net operating loss carryforwards will expire at various dates beginning in 2018 and the state net operating loss carryforwards have started expiring, starting in the current year through various
future dates. As a result of the Company&#146;s initial public offering, an ownership change within the meaning of Internal Revenue Code Section&nbsp;382 occurred in August 2004. As a result, federal net operating loss and credit carry forwards of
approximately $216.0&nbsp;million are subject to an annual use limitation of approximately $13.0&nbsp;million. The annual limitation is cumulative and therefore, if not fully utilized in a year can be utilized in future years in addition to the
Section&nbsp;382 limitation for those years. The federal net operating losses generated subsequent to the Company&#146;s initial public offering in August 2004 are currently not subject to any such limitation as there have been no ownership changes
since August 2004 within the meaning of Internal Revenue Code Section&nbsp;382. At December&nbsp;31, 2016, the Company had research and development credits of $53.0&nbsp;million and $38.5&nbsp;million for federal and state purposes, respectively.
The federal credits begin to expire in 2024, and the state credits may be carried forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the
impact of uncertainty related to income taxes on its consolidated financial statements. The evaluation of an uncertain tax position is a <FONT STYLE="white-space:nowrap">two-step</FONT> process. The first step is recognition: the enterprise
determines whether it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the
position. In evaluating whether a tax position has met the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, the enterprise should presume that the position will be examined by the appropriate taxing authority that
would have full knowledge of all relevant information. The second step is measurement: a tax position that meets the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold is measured to determine the amount of benefit to
recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50&nbsp;percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The Company believes that its income tax filing
positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its consolidated financial position. Therefore, no liabilities for uncertain income tax positions have been
recorded. Tax years since 2012 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Warrants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, the Company sold in a registered offering an aggregate of 9,708,737 shares of common stock together with A Warrants
exercisable for up to an aggregate of 7,281,553 shares of common stock and B Warrants exercisable for up to an aggregate of 2,427,184 shares of common stock with a total fair value of $44.7&nbsp;million. Each of the warrants has an exercise price of
$7.50 per share. The A Warrants became exercisable upon issuance and will expire two years thereafter. The B Warrants will become exercisable beginning in May 2017 and will expire 30 months after the date of issuance. The shares of common stock and
the warrants are immediately separable and issued separately. There have been no warrants exercised as of December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company determined that the A Warrants require liability classification primarily due to a price-protection clause that applies in the event of certain dilutive financings. The fair value of the A Warrants was recorded as warrant liability in the
consolidated balance sheet at issuance and is adjusted to fair value at each reporting period until exercise or expiration. The Company determined that the B Warrants met the criteria for equity classification and has accounted for such warrants in
additional paid in capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and May&nbsp;12, 2016, the fair value of the A Warrants liability was
$7.4&nbsp;million and $12.8&nbsp;million, respectively. As of May&nbsp;12, 2016, the fair value of the B Warrants at issuance was $5.0&nbsp;million. The fair value of the A Warrants liability as of December&nbsp;31, 2016 was estimated using a Monte
Carlo valuation pricing model with the following underlying assumptions: (a)&nbsp;a risk-free interest rate of 1.1%; (b) an assumed dividend yield of zero percent; (c)&nbsp;an expected term of 1.4 years; and (d)&nbsp;an expected volatility of 118%.
The fair </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value of the A Warrants liability as of May&nbsp;12, 2016, was estimated using a Monte Carlo valuation pricing model with the following underlying assumptions: (a)&nbsp;a risk-free interest rate
of 0.76%; (b) an assumed dividend yield of zero percent; (c)&nbsp;an expected term of 2.0 years; and (d)&nbsp;an expected volatility of 95%. The Company assumed a probability of a dilutive financing event or an equity event, as defined in the
agreement, of 10% for the each of the measurement periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, the Company recognized a change in
fair value of warrant liability of $5.4&nbsp;million in the consolidated statements of operations to reflect the fair value adjustments of the A Warrant liability from the date of issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Selling, General and Administrative Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Restructuring Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2016, the Company initiated a restructuring of its organization in order to conserve resources for commercial sales and
marketing of Afrezza and to align cost of goods sold in support of these commercial efforts (2016 Restructuring). In connection with the 2016 Restructuring, the Company reduced its total workforce by approximately 18% to 155 employees. The Company
recorded charges of approximately $1.5&nbsp;million, primarily for employee severance as well as other related termination benefits. The $1.5&nbsp;million of costs associated with the 2016 Restructuring are included in cost of goods sold, research
and development and selling, general and administrative in the consolidated statements of operations as $0.4&nbsp;million, $0.7&nbsp;million and $0.4&nbsp;million, respectively, for the year ended December&nbsp;31, 2016. The Company substantially
paid out the obligation for the 2016 Restructuring in the fourth quarter of 2016, resulting in a remaining accrual balance for the 2016 Restructuring of $0.2 million at December&nbsp;31, 2016. The Company expects to substantially pay out the
remainder of this obligation by the first quarter of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, the Company initiated a restructuring of the organization as a result
of its shift to commercial production of Afrezza (&#147;2015 Restructuring&#148;). In connection with the 2015 Restructuring, the Company reduced its total workforce by approximately 26% to 198 employees. The Company recorded charges of
approximately $6.0&nbsp;million, primarily for employee severance as well as other related termination benefits. The $6.0&nbsp;million of costs associated with the 2015 Restructuring are included in operating expenses for cost of goods sold,
research and development and selling, general and administrative in the consolidated statements of operations as $1.4 million, $1.3&nbsp;million and $3.3&nbsp;million, respectively, for the year ended December&nbsp;31, 2015. As of December&nbsp;31,
2016 and 2015, the Company had a remaining accrual balance for the 2015 Restructuring of $1.2&nbsp;million and $3.0&nbsp;million, respectively. Certain of the severance arrangements for executives in the 2015 Restructuring were long-term, which the
Company expects to substantially pay out the remainder of this obligation by the third quarter of 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of beginning and ending liability balances for the 2016 and 2015 Restructuring
charges, which is included in accrued expenses and other current liabilities, is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016<BR>Restructuring</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015<BR>Restructuring</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual &#151; January 1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs incurred and charged to expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs paid or settled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual &#151; December 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs incurred and charged to expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs paid or settled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual &#151; December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Selected quarterly financial data (unaudited) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Summarized quarterly financial data for the years ended December&nbsp;31, 2016 and 2015, are set forth in the following tables: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">March&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share &#151; basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share &#151; diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute basic net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute diluted net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(277,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairment charges of $242.7&nbsp;million were recorded in the fourth quarter of 2015 related to long-lived
assets, inventory and loss on purchase commitments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2016, the Company recognized net revenue-collaboration of
$161.8&nbsp;million attributable to collaboration with Sanofi (See Note 8 &#151; Collaboration Arrangements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the fourth quarter of
2016, the Company recognized net revenue-collaboration of $10.2&nbsp;million attributable to collaboration with Sanofi and $72.0&nbsp;million gain on extinguishment of debt (See Note 8 &#151; Collaboration Arrangements) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Reverse Stock
Split</I> &#151; On September&nbsp;14, 2016, NASDAQ notified the Company that the bid price of the Company&#146;s common stock had closed below the required $1.00 per share for 30 consecutive trading days, and,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordingly, the Company did not comply with the applicable NASDAQ minimum bid price requirement. The Company was provided 180 calendar days by NASDAQ, or until March&nbsp;13, 2017, to regain
compliance with this requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2017, the Company held a Special Meeting of Stockholders at which the Company&#146;s
stockholders approved a proposal to amend the Company&#146;s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company&#146;s outstanding common stock at a ratio to be determined in the discretion of the
Company&#146;s board of directors and with such reverse stock split to be effected at such time and date as determined by the Company&#146;s board of directors in its sole discretion, and to reduce the number of authorized shares of the
Company&#146;s common stock in a corresponding proportion to the reverse stock split, rounded to the nearest whole share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;1, 2017, following stockholder approval of the reverse split proposal, the Company&#146;s board of directors approved a reverse stock split ratio of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5.&nbsp;On</FONT></FONT> March&nbsp;1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company&#146;s Amended and
Restated Certificate of Incorporation to effect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> reverse stock split of the Company&#146;s outstanding common stock and to reduce the authorized number of
shares of the Company&#146;s common stock from 700,000,000 to 140,000,000 shares.&nbsp;The Company&#146;s common stock began trading on The NASDAQ Global Market on a split-adjusted basis when the market opened on March&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this filing, the shares of the Company&#146;s common stock have maintained a minimum bid closing price of at least $1.00 per
share for 10 consecutive business days. Accordingly, the Company expects to receive a notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company has regained compliance with the minimum closing bid price
requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale of Valencia Facility</I> &#151; On January&nbsp;6, 2017, the Company and Rexford Industrial Realty, L.P.
(&#147;Rexford&#148;) entered into an Agreement of Purchase and Sale and Joint Escrow Instructions (the &#147;Purchase Agreement&#148;), pursuant to which the Company agreed to sell and Rexford agreed to purchase certain parcels of real estate owned
by the Company in Valencia, California and certain related improvements, personal property, equipment, supplies and fixtures (collectively, the &#147;Property&#148;) for $17.3&nbsp;million. The sale and purchase of the aforementioned Property for
$17.3&nbsp;million pursuant to the terms of the Purchase Agreement, as amended, was completed on February&nbsp;17, 2017. Net proceeds were approximately $16.7&nbsp;million after deducting broker&#146;s commission and other fees of approximately
$624,000 paid by the Company.&nbsp;In the fourth quarter of 2016 the property met the requirements for reclassification from property and equipment, net to asset held for sale when it became probable that the property would be sold within one year.
At that time, an analysis of the lower of carrying value which was deemed to be the sales price of the property, to fair value less selling costs determined a loss of $564,000, which was recorded as a property and equipment impairment on the
consolidated statement of operations for 2016.&nbsp;At December, 31 2016, this property had a carrying value of $16.7&nbsp;million and was classified as held for sale. The sale of this property will be reflected in the consolidated financial
statements for the quarter ended March&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>d305327dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305327mn3.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">MANNKIND CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THE CORPORATION WILL FURNISH
TO ANY STOCKHOLDER UPON REQUEST AND WITHOUT CHARGE A FULL STATEMENT OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH AUTHORIZED CLASS OF STOCK OR SERIES THEREOF AND THE QUALIFICATIONS,
LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS, TO THE EXTENT THAT THE SAME HAVE BEEN FIXED, AND OF THE AUTHORITY OF THE BOARD OF DIRECTIONS TO DESIGNATE THE SAME WITH RESPECT TO ANY SHARES. SUCH REQUEST MAY BE MADE TO THE CORPORATION
OR TO ITS TRANSFER AGENT. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written
out in full according to applicable laws or regulations: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">TEN COM - as tenants in common </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">TEN ENT - as tenants by the entireties </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">JT TEN - as joint tenants with right of survivorship
and not as tenants in common </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">UNIF GIFT MIN ACT - (Cust) under Uniform Gifts to Minors Act </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">UNIF TRF MIN ACT - (Cust) (Minor) </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Custodian (Minor) (State) Custodian (until age) under
Uniform Transfers to Minors Act (State) </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Additional abbreviations may also be used though not in the above list. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For value received,
____________________________hereby sell, assign and transfer unto </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Shares </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">of the stock represented by the within Certificate, and do hereby irrevocably
constitute and appoint </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Attorney </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">to transfer the said stock on the books of
the within-named Corporation with full power of substitution in the premises. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Dated: __________________________________________20 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature(s) Guaranteed: Medallion Guarantee Stamp </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN
ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT>
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any
change whatever. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The IRS requires that the named transfer agent (&#147;we&#148;) report the cost basis of certain shares or units acquired after January 1, 2011.
If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested. If you did not specify a cost basis
calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">If you do not keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state
unclaimed property laws and transferred to the appropriate state. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305327mnkd2.jpg" ALT="LOGO">

 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COMMON STOCK </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">PAR VALUE $0.01 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COMMON STOCK </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS CERTIFICATE IS TRANSFERABLE IN CANTON, MA, JERSEY CITY, NJ AND COLLEGE
STATION, TX </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MannKind Corporation </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Certificate </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Number </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ZQ00000000 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MANNKIND CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Shares </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* * 000000 * * * * * * * * * * * * * * * * * * </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* * * 000000 * * * * * * * * * * * * * * * * * </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* * * * 000000 * * * * * * * * * * * * * * * *
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* * * * * 000000 * * * * * * * * * * * * * * * </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* * * * * * 000000 * * * * * *
* * * * * * * * </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS CERTIFIES THAT </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MR. SAMPLE&nbsp;&amp; MRS. SAMPLE &amp;
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">**** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">**** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample **** Mr. Sample </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MR. SAMPLE&nbsp;&amp; MRS. SAMPLE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">is the owner of </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CUSIP 56400P 70 6 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SEE REVERSE FOR CERTAIN DEFINITIONS </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">*** ZERO HUNDRED THOUSAND
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">**000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares***
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">*000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****0
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****00
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****0000
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****00000
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000*
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">*Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**S </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ZERO HUNDRED AND ZERO*** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">FULLY-PAID AND <FONT STYLE="white-space:nowrap">NON-ASSESSABLE</FONT> SHARES OF COMMON STOCK, PAR VALUE $0.01 PER SHARE, OF </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MANNKIND CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Transferable on the books of the Corporation in person or by duly
authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid unless duly countersigned by the Transfer Agent and registered by the Registrar. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">In WITNESS WHEREOF, the said Corporation has caused this </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Certificate to be signed in facsimile
by its duly authorized officers and the facsimile corporate seal to be duly affixed hereto. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CEO, CFO and Director </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MANNKIND CORPORATION CORPORATE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SEAL </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DELAWARE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DATED
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DD-MMM-YYYY</FONT></FONT> </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COUNTERSIGNED AND REGISTERED: COMPUTERSHARE INC. TRANSFER AGENT AND
REGISTRAR, </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Secretary </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SECURITY INSTRUCTIONS ON REVERSE </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">By </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">AUTHORIZED SIGNATURE </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CUSIP </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Holder ID Insurance Value Number of Shares DTC </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Certificate Numbers </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567890/1234567890 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Total Transaction </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">XXXXXX XX X </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">XXXXXXXXXX </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1,000,000.00 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">123456 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">12345678 123456789012345 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Total </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">3
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">4 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">5 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">6 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">7
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Num/No. Denom. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">3 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">4
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">5 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">6 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">3
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">4 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">5 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">6 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MannKind Corporation </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">PO BOX 43004, Providence, RI 02940-3004 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">MR A SAMPLE </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DESIGNATION (IF ANY) ADD 1 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ADD 2 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ADD 3 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ADD 4 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1234567 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Printed by DATA BUSINESS FORMS </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>d305327dex1031.htm
<DESCRIPTION>EX-10.31
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.31</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.31 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ONFIDENTIAL</SMALL> S<SMALL>ETTLEMENT</SMALL> C<SMALL>OMMUNICATION</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>UBJECT</SMALL> T<SMALL>O</SMALL> LCA S<SMALL>ECTION</SMALL> 14.2, FRE 408, CPLR 4547 <SMALL>AND</SMALL> E<SMALL>QUIVALENT</SMALL> L<SMALL>AWS</SMALL>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SETTLEMENT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SETTLEMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is made effective as of November&nbsp;9,&nbsp;2016 (the
&#147;<U>Effective Date</U>&#148;) by and among: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>MannKind Corporation</B>, a Delaware corporation (&#147;<U>MannKind</U>&#148;),
together with <B>Technosphere International C.V.</B>, a Dutch limited partnership (&#147;<U>TICV</U>&#148;), and <B>MannKind Netherlands B.V.</B>, a Dutch limited liability company (&#147;<U>BV</U>,&#148; and together with MannKind, TICV, and their
respective Affiliates, the &#147;<U>MK Entities</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>sanofi-aventis U.S. LLC</B>, a Delaware limited liability company
(&#147;<U>Sanofi</U>&#148; and together with its Affiliates, the &#147;<U>Sanofi Entities</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Agreement, each of the MK
Entities, on the one hand, and the Sanofi Entities, on the other hand, are referred to individually as a &#147;<U>Party</U>&#148; and collectively as the &#147;<U>Parties</U>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B>
Sanofi-Aventis Deutschland GmbH (&#147;<U>Sanofi GmbH</U>&#148;), MannKind, BV and TICV entered into that certain License and Collaboration Agreement, dated August&nbsp;11, 2014 (the &#147;<U>LCA</U>&#148;, and together with the Letter Agreement and
Supply Agreement (each as defined below), the &#147;<U>License and Supply Arrangement</U>&#148;), pursuant to which MannKind, TICV and BV granted Sanofi certain exclusive rights and licenses to Develop and Commercialize Product (each as defined in
the LCA); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to that certain Assignment, dated September&nbsp;19, 2014, by and between Sanofi GmbH and Sanofi,
Sanofi GmbH assigned the License and Supply Arrangement to Sanofi; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> pursuant to that certain letter, dated January&nbsp;1,
2016 (and received by MannKind on January&nbsp;4, 2016), from Sanofi to MannKind (the &#147;<U>Termination Letter</U>&#148;), Sanofi notified MannKind of its decision to terminate the License and Supply Arrangement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to that certain Transition Agreement, dated April&nbsp;4, 2016, by and between Sanofi and MannKind (the
&#147;<U>Transition Agreement</U>&#148;), the Parties transferred certain responsibilities for the Product to MannKind in accordance with Section&nbsp;13.3(c) of the LCA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> MannKind has made certain assertions and allegations about Sanofi relating to the License and Supply Arrangement and
Sanofi&#146;s performance thereunder in letters dated February&nbsp;4, 2016,&nbsp;August&nbsp;5, 2016, and October&nbsp;23, 2016; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Sanofi has responded to and denied such assertions and allegations in letters dated February&nbsp;12, 2016, September 20,
2016, October 13, 2016, and October&nbsp;30, 2016; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> MannKind&#146;s letter dated August&nbsp;5, 2016 provided Sanofi
&#147;Notice of Dispute&#148; and formally invoked the dispute resolution procedure set forth in Section&nbsp;14.1 of the LCA; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> executives from Sanofi and MannKind met on September&nbsp;29, 2016 to
&#147;meet and attempt to resolve the dispute in face-to-face negotiations&#148; as required by Section&nbsp;14.1 of the LCA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the MK Entities and the Sanofi Entities have determined that it is in their mutual benefit to resolve the matters discussed in
the letters referred to above (the <U>Dispute</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the settlement of the Dispute, Sanofi&#146;s
Affiliate, Aventisub LLC (&#147;<U>Aventisub</U>&#148;) has agreed to release MannKind from its obligation to pay Aventisub $71,562,138.31 under the Promissory Note and release certain security interests encumbering MannKind&#146;s assets; and
Sanofi has agreed to accelerate certain payments owed by Sanofi to MannKind under the Supply Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the payments by
Sanofi and release of financial obligations and encumbrances by MannKind are anticipated by MannKind to make available substantial current liquidity and facilitate MannKind&#146;s future financing activities; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the MK Entities agree that the benefits provided by the Sanofi Entities hereunder and in the Pay-Off Letter provide at least
reasonably equivalent value for the release of claims by the MK Entities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in accordance with the
foregoing Recitals, and in consideration of the mutual covenants contained herein, the Parties hereto agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Defined Terms</U></B>. For purposes of this Agreement, the following capitalized terms are defined in this <U>Section&nbsp;1</U> and shall have the meaning specified herein. Capitalized terms which are used in
this Agreement but not defined in this <U>Section&nbsp;1</U> or elsewhere in this Agreement shall have the meanings given to them in the License and Supply Arrangement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Affiliate</U>&#148; of a Party means any Person that, directly or indirectly, through one or more intermediaries, now or hereafter controls, is controlled by, or is under common control with such Person as of
such date. As used herein, the term &#147;<U>control</U>&#148; (including the terms &#147;<U>controlling</U>,&#148; &#147;<U>controlled by</U>&#148; and &#147;<U>under common control with</U>&#148;) means the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or other interests, by contract or otherwise </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Claims</U>&#148; means any and all of the following arising under the laws of the United States or any foreign jurisdiction: claims, counterclaims, cross-claims, demands, causes of action, Liabilities,
lawsuits, arbitrations, proceedings, third-party interventions, or any other form of claim, whether or not fixed, contingent or absolute, matured or unmatured, direct or indirect, liquidated or unliquidated, accrued or unaccrued, known or unknown,
whether or not required to be reflected in financial statements or disclosed in the notes thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Letter Agreement</U>&#148; means that certain Letter Agreement, dated August&nbsp;11, 2014, by and among MannKind, TICV, BV and Sanofi GmbH. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 2</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Liabilities</U>&#148; means debts, liabilities, losses, damages, attorneys&#146; fees, court costs, obligations, expenses, or any other form of cost or compensation, whether or not fixed, contingent or
absolute, matured or unmatured, direct or indirect, liquidated or unliquidated, accrued or unaccrued, known or unknown, whether or not required to be reflected in financial statements or disclosed in the notes thereto. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Pay-Off Letter</U>&#148; means that certain Pay-Off Letter, dated as of even date herewith, by and between Aventisub and MannKind. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Potential Claims</U>&#148; means any and all Claims arising or accruing prior to or as of the Effective Date against any Sanofi Entity or any MK Entity (or any Related Party thereof) of any nature, including
those arising from, relating to, based upon, or in connection with the Dispute, the License and Supply Arrangement, or the Transition Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Promissory Note</U>&#148; means that certain Senior Secured Revolving Promissory Note, dated as of September&nbsp;23, 2014, between MannKind and Aventisub. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Related Parties</U>&#148; means, with respect to each of the MK Entities or the Sanofi Entities, such entity&#146;s predecessors, successors, assigns, agents, representatives, directors, officers and employees,
solely, in each case, with respect to such Person&#146;s representative capacity as such. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Security Agreement</U>&#148; means that certain Guaranty and Security Agreement, dated as of September&nbsp;23, 2014, by and among MannKind, MannKind LLC, and Aventisub. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Supply Agreement</U>&#148; means that certain Supply Agreement, dated August&nbsp;11, 2014, by and between MannKind and Sanofi, as assignee of Sanofi GmbH. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Promissory Note and Security Agreement</U></B>. In consideration of the execution of this Agreement and the mutual release of obligations contained herein, Aventisub and MannKind are terminating the Promissory
Note and the Security Agreement pursuant to the Pay-Off Letter attached hereto as <U>Exhibit A</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U><B>Insulin Payments and Put Options</B></U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><U>Purchase of Insulin</U>. By no later than December&nbsp;3, 2016, Sanofi shall purchase $10,184,504.07 worth of Amphastar Insulin from MannKind, and MannKind shall sell and provide Sanofi with such amount of Insulin,
in accordance with the terms of the Supply Agreement and on terms consistent with Sanofi&#146;s purchases prior to the Effective Date of Amphastar Insulin pursuant to the Insulin Put Option. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><U>Satisfaction and Termination of Insulin Put Option</U>. Sanofi and the MK Entities hereby confirm and agree to terminate the Insulin Put Option as of the Effective Date, and do hereby terminate the Insulin Put Option
subject to Sanofi&#146;s final purchase and MannKind&#146;s final sale referred to in Section&nbsp;3(a) above. Within sixty (60)&nbsp;days after the Effective Date, Sanofi shall pay MannKind $30,553,512.21 as acceleration, and in replacement, of all
other payments Sanofi would otherwise have been required to make in the future pursuant to the Insulin Put Option. Sanofi releases MannKind from its obligation to sell, and MannKind releases Sanofi from any obligation to purchase, any additional
Insulin. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 3</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Forgiveness of RSM Audit Money</U></B>. Sanofi (on behalf of itself and its Affiliates) hereby releases the MK Entities from any obligation to pay Sanofi (or any of its Affiliates) the $461,649.00 in uncharged
costs identified in that certain September&nbsp;28, 2016 audit performed by RSM US LLP. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U><B>Mutual Releases and Covenants Not to Sue or Assist</B></U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><U>MannKind Release and Covenant Not to Sue</U>. The MK Entities, on behalf of themselves, and all of their Related Parties, hereby fully and forever, irrevocably and unconditionally:&nbsp;(i)&nbsp;release, acquit and
forever discharge all their Potential Claims against any Sanofi Entity or any of its Related Parties; and (ii)&nbsp;covenant and agree never to bring, assert, pursue, maintain, or join in any such Potential Claim.</TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><U>MannKind Covenant Not to Assist</U>. The MK Entities, on behalf of themselves and all of their Related Parties, hereby fully and forever, irrevocably and unconditionally covenant and agree never to directly or
indirectly finance, fund, encourage, solicit, assist, or otherwise support any Potential Claim brought against any Sanofi Entity and any of its Related Parties by any other Person (including any Related Party of the MK Entities, or any third
Person). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"><U>Sanofi Release and Covenant Not to Sue</U>. The Sanofi Entities, on behalf of themselves and all of their Related Parties, hereby fully and forever, irrevocably and unconditionally:&nbsp;(i)&nbsp;release, acquit and
forever discharge all of their Potential Claims against each MK Entity and each of its Related Parties; and (ii)&nbsp;covenant and agree never to bring, assert, pursue, maintain, or join in any such Potential Claim.</TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><U>Sanofi Covenant Not to Assist</U>. The Sanofi Entities, on behalf of themselves and all of their Related Parties, hereby fully and forever, irrevocably and unconditionally covenant and agree never to directly or
indirectly finance, fund, encourage, solicit, assist, or otherwise support any Potential Claim brought against any MK Entity and any of its Related Parties by any other Person (including any Related Party of the Sanofi Entities, or any third
Person). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"><U>Waiver of Statutory Provisions</U>. The Parties (on behalf of themselves, their Affiliates, and their Related Parties) expressly waive any right or benefit that may be available under Section&nbsp;1542 of the
California Civil Code or any similar laws of any other jurisdiction. Section&nbsp;1542 of the California Civil Code provides: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his
settlement with the debtor.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"><U>No Release of Certain Transition Agreement Obligations</U>. The releases and covenants granted by the MK Entities in this Section&nbsp;5 will not release Sanofi&#146;s remaining obligations under the Transition
Agreement specifically listed on <U>Exhibit D</U> of this Agreement, to be completed by the dates specified therein. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 4</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>No Admission of Liability</U></B>. It is understood and agreed by the Parties that the execution of this Agreement, the mutual releases contained herein, and the performance by the Parties of their obligations
contained in this Agreement (including the payments made, and releases of indebtedness granted, by the Sanofi Entities) do not constitute an admission of any wrongdoing or liability whatsoever. This Agreement is a compromise in settlement of
disputed claims, and is not to be construed as an admission for any purpose other than as necessary to enforce the terms of this Agreement. Neither this Agreement, nor the statements contained herein, nor any act foregone or performed pursuant to or
in furtherance of this Agreement, is or may be deemed to be or may be used as an admission of, or evidence of, the validity of any right, claim or defense, or in any way referred to for any reason as against any of the Parties hereto in any
proceeding in any court or tribunal; provided, however, that once signed, the Parties may refer to this Agreement as evidence of, and to effectuate, the terms and conditions of this Agreement and the protections granted hereunder, and to enforce or
otherwise effectuate the terms of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Confidentiality</U></B>. The Parties hereby acknowledge and agree that the provisions of the LCA and Transition Agreement with respect to obligations regarding confidentiality and Confidential Information shall
remain in effect. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Press Releases</U></B>. As soon as practicable following the execution of this Agreement, MannKind may issue a press release announcing the existence of this Agreement and the transactions contemplated herein, but
such press release must be in the form attached to this Agreement as <U>Exhibit B</U>. Except as required by Applicable Laws, including disclosure requirements of the SEC, the NASDAQ stock exchange or any other stock exchange on which securities
issued by a Party or its Affiliates are traded, neither Party shall make any published announcement concerning this Agreement or the transactions contemplated herein without the prior written consent of the other, which shall not be unreasonably
withheld or delayed; provided, that it shall not be unreasonable for a Party to withhold consent with respect to any published announcement containing any of such Party&#146;s Confidential Information. In the event of a required published
announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such
other Party a reasonable opportunity to review and comment upon the proposed text. In the event MannKind receives any third party inquiries regarding the License and Supply Arrangement, the Transition Agreement, the Promissory Note, the Security
Agreement, this Agreement, or its relationship with the Sanofi Entities, MannKind shall only reply to such inquiries using a form materially similar as attached to this Agreement as <U>Exhibit C</U> or in a form approved by written consent of Sanofi
(such consent not to be unreasonably withheld or delayed). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Bankruptcy Event</U></B>. The Parties hereby agree that in the event MannKind becomes a debtor under the Bankruptcy Laws, and this Agreement is rejected or avoided in accordance with Bankruptcy Laws with the
result that Sanofi loses the benefits of sections 5(a) and 5(b) hereunder, then the parties shall be returned to their pre-settlement positions and Sanofi shall be entitled to damages resulting from MannKind&#146;s breach of the Agreement.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 5</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Advice of Counsel</U></B>. The Parties acknowledge that they have consulted with sophisticated attorney(s) of their own choosing regarding the rights, obligations, and other terms of this Agreement, that they have
entered into this Agreement knowingly, freely and voluntarily without coercion or undue influence, and that they have negotiated such terms at arm&#146;s length and that they intend to be bound hereby. Each Party has undertaken such independent
investigation and evaluation as it deems appropriate and is entering this Agreement in reliance on the Party&#146;s own investigation and advice, and not in reliance on any advice, disclosure, representation, or information provided by or expected
from any other Party or Party&#146;s lawyers, except as expressly stated in this Agreement. Each Party assumes the risk that the facts or law may be other than it believes, and as such each Party agrees that no misunderstanding or misinformation of
fact or law shall be a ground for rescission hereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"><U><B>Representations, Warranties and Covenants</B>.</U> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><U>MK Entities</U>. As of the Effective Date, the MK Entities signing this Agreement represent, warrant and covenant to the Sanofi Entities that: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">they have all requisite legal right, power and authority to execute, deliver and perform this Agreement and grant the releases, covenants and other rights granted by the applicable parties in this Agreement, without
restriction or requirement of consent of any other Person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">no MK Entity nor any of its respective Related Parties have assigned any Potential Claims to any third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">no MK Entity has granted, and no MK Entity shall grant, any rights to any Person that would conflict with, or prevent, the grant of the releases, covenants, and other rights granted hereunder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">there are no liens, conveyances, mortgages, assignments, encumbrances, or other contracts that would prevent or impair their full and complete performance of the terms and conditions of this Agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">the MK Entities are not aware of any third Person who has asserted or intends to assert a Potential Claim; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">they have the authority to settle and compromise all of the MK Entities&#146;, and their Related Parties&#146;, Potential Claims without the necessity of obtaining the consent of any other Person; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">the transactions contemplated by this Agreement and the Pay-Off Letter constitute the exchange of reasonable equivalent value for the benefits provided by each Party to the other Party; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">the MK Entities are generally able to pay their debts and satisfy their obligations as they come due; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 6</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">the MK Entities have not been, and as of the Effective Date are not presently engaged in, discussions with any creditors relating to any filings by MannKind under any Bankruptcy Laws or similar proceedings.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><U>Sanofi</U>. As of the Effective Date, Sanofi represents, warrants and covenants to the MK Entities that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the Sanofi has all requisite legal right, power and authority to execute, deliver and perform this Agreement and grant the releases, covenants and other rights granted by the applicable parties in this Agreement,
without restriction or requirement of consent of any other Person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">no Sanofi Entity nor any of its respective Related Parties have assigned any Potential Claims to any third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">no Sanofi Entity has granted, and no Sanofi entity shall grant, any rights to any Person that would conflict with, or prevent, the grant of the releases, covenants, and other rights granted hereunder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">there are no liens, conveyances, mortgages, assignments, encumbrances, or other contracts that would prevent or impair its full and complete performance of the terms and conditions of this Agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">the Sanofi Entities are not aware of any third Person who has asserted or intends to assert a Potential Claim; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">it has the authority to settle and compromise all of the Sanofi Entities&#146;, and the Sanofi Entities&#146; Related Parties&#146;, Potential Claims without the necessity of obtaining the consent of any other Person;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">the transactions contemplated by this Agreement and the Pay-Off Letter constitute the exchange of reasonable equivalent value for the benefits provided by each Party to the other Party. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Indemnification</U></B>. Except as provided in this Agreement, the Parties agree that the indemnification obligations under the License and Supply Arrangement and Transition Agreement are terminated as of the
Effective Date. For the avoidance of doubt, Sanofi hereby waives any right it has to indemnification by the MK Entities under any and all product liability lawsuits pending as of the Effective Date, and the MK Entities hereby waive any right they
have to indemnification by the Sanofi Entities under any and all product liability lawsuits pending as of the Effective Date<I>.</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Dispute Resolution</U></B>. In the event of any dispute arising out of or relating to this Agreement or either Party&#146;s rights or obligations hereunder, the provisions of Article 14 of the LCA shall apply and
govern the procedure and resolution of any such dispute. In the event multiple disputes arise out of or relating to any combination of this Agreement, the Parties may join any or all such disputes, and the provisions of Article 14 of the LCA shall
continue to apply and govern the procedure and resolution of any such dispute. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 7</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"><B><U>General Provisions</U>.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><U>Intervening Events</U>. If the performance of any part of this Agreement by either Party (other than making payment when due) is prevented, restricted, interfered with or delayed by any reason or cause beyond the
reasonable control of such Party (including: fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor disturbance (save where such strike, lockout, or other labor disturbance is
initiated by the employees of the Party which seeks to rely on this clause), acts of God or any acts, omissions or delays in acting of the other Party) (an &#147;<U>Intervening Event</U>&#148;), the Party so affected shall, upon giving written
notice to the other Party, be excused from such performance to the extent of such Intervening Event, provided that the affected Party shall use its substantial efforts to avoid or remove such causes of non-performance and shall continue performance
with the utmost dispatch whenever such causes are removed. If either Party becomes aware that such an Intervening Event has occurred, is imminent or likely, it will immediately notify the other Party. The Party which is subject to such Intervening
Event shall exert all reasonable efforts to overcome it. Such Party will keep the other informed as to the progress of overcoming such Intervening Event. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><U>Performance by Affiliates/Related Parties</U>. To the extent that this Agreement imposes obligations on Affiliates or Related Parties of a Party, such Party agrees to cause its Affiliates or Related Parties to
perform such obligation. Either Party may use one or more of its Affiliates or Related Parties to perform its obligation hereunder, provided that the Parties will remain liable hereunder for the prompt payment and performance of all their respective
obligations hereunder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"><U>Modification</U>. No amendment or modification of any provision of this Agreement shall be effective unless in a prior writing signed by all of MannKind and Sanofi. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by the Parties hereto. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><U>No Circumvention of this Agreement</U>. The Parties, on behalf of themselves and all of their Affiliates and Related Parties, agree that none of them shall enter into any arrangements, formal or informal, with the
purpose of circumventing the intent of the terms and conditions of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"><U>Third Party Beneficiaries</U>. The Parties agree that each Sanofi Entity, each MK Entity and each of their respective Related Parties are intended third party beneficiaries of the releases and covenants provided
under this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"><U>Incorporation of Recitals</U>. The Parties hereby incorporate each of the Recitals stated above as material provisions of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"><U>Language</U>. The language of this Agreement and all activities to be pursued under this Agreement is English. Any and all documents proffered by one Party to the other in fulfillment of any provision of this
Agreement shall only be in compliance if in English. Any translation of this Agreement in another language shall be deemed for convenience only and shall never prevail over the original English version. This Agreement is established in the English
language. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 8</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"><U>Interpretation</U>. The captions to this Agreement are not a part of this Agreement but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a)&nbsp;the
word &#147;including&#148; shall be deemed to be followed by the phrase &#147;without limitation&#148; or like expression; (b)&nbsp;the word &#147;or&#148; means &#147;and/or&#148; unless the context dictates otherwise because the subject of the
conjunction are mutually exclusive; (c)&nbsp;the words &#147;herein,&#148; &#147;hereof&#148; and &#147;hereunder&#148; and other words of similar import refer to this Agreement as a whole and not to any particular Article or Section or other
subdivision; (d)&nbsp;references in this Agreement to &#147;days&#148; shall mean calendar days; (e)&nbsp;the singular shall include the plural and vice versa; and (f)&nbsp;masculine, feminine and neuter pronouns and expressions shall be
interchangeable. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under IFRS, or if not defined by IFRS, the meaning applied to it by Sanofi in preparing its publicly reported financial
statements, in each case, consistently applied, but only to the extent consistent with its usage and the other definitions in this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"><U>Counterparts; Electronic or Facsimile Signatures</U>. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This
Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"><U>Taxes</U>. Each Party shall bear its own tax liability in connection with this Agreement and shall make any report, payment or withholding as instructed or required by any regulatory or taxing authority.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"><U>Applicable Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of law. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"><U>Notices</U>. Any notice or communication required or permitted under this Agreement shall be in writing in the English language, delivered personally, sent by facsimile (and promptly confirmed by personal delivery,
registered or certified mail or overnight courier), sent by internationally-recognized courier or sent by registered or certified mail, postage prepaid to the following addresses of the Parties (or such other address for a Party as may be at any
time thereafter specified by like notice): </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>If to MannKind, as follows</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">MannKind Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">25134 Rye
Canyon Loop, Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Valencia, CA 91355 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: 661-775-2081 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 9</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Quinn Emanuel
Urquhart&nbsp;&amp; Sullivan LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">865 S. Figueroa St., 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Los Angeles, CA 90017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: 213-443-3100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Joseph M. Paunovich, Esq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>If to Sanofi, as follows</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">sanofi-aventis U.S. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">55
Corporate Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Mailstop: 55A-515A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Bridgewater, NJ 08807 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: 908-927-8623 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel, NA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Stacy Silkworth, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Christopher Liwski, Esq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with
a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Weil, Gotshal&nbsp;&amp; Manges LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">767 Fifth Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10153 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: (212)&nbsp;310-8000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Yehudah L. Buchweitz, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Jeffrey D. Osterman, Esq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Any
such notice shall be deemed to have been given: (a)&nbsp;when delivered if personally delivered; (b)&nbsp;on the next Business Day after dispatch if sent by confirmed facsimile or by internationally-recognized overnight courier; or (c)&nbsp;on the
third Business Day following the date of mailing if sent by mail or nationally recognized courier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B><I></I></B><I>SETTLEMENT AGREEMENT</I><B><I></I></B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><I>PAGE 10</I>&nbsp;&nbsp;</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be duly executed and delivered by their
respective duly authorized representatives on the day and year first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>sanofi-aventis U.S. LLC</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susan A. Manardo</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Susan A. Manardo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP&nbsp;&amp;&nbsp;Head,&nbsp;N.A.&nbsp;Litigation&nbsp;&amp;&nbsp;Investigations</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Settlement Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be duly executed and delivered by their
respective duly authorized representatives on the day and year first above written. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MannKind Corporation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Pfeffer</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Technosphere International C.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: MannKind Corporation, its General Partner </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Pfeffer</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MannKind Netherlands B.V. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Pfeffer</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Settlement Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pay-Off Letter </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Press Release </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g305327dsp47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Company Contact: </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rose Alinaya </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP, Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">661-775-5300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ralinaya@mannkindcorp.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANNKIND AND SANOFI REACH AGREEMENT ON AFREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VALENCIA, Calif., November&nbsp;9, 2016 (GLOBE NEWSWIRE) &#151; MannKind Corporation (NASDAQ and TASE:MNKD)</B> today announced that MannKind and Sanofi
have entered into an agreement with the following terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The promissory note and security agreement between MannKind and Aventisub LLC, a Sanofi affiliate, are terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $71.56 million.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MannKind is also relieved from its obligation to pay $0.5 million in previously uncharged costs related to the collaboration. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sanofi will purchase $10.2 million worth of insulin from MannKind in early December as part of its preexisting commitment to purchase insulin following termination of the collaboration and MannKind&#146;s exercise of a
&#147;put&#148; option. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The balance of the insulin &#147;put&#148; option ($30.6 million) is accelerated with Sanofi completing the cash payment of $30.6 million to MannKind by January&nbsp;9, 2017. This payment will be made without MannKind
being required to deliver any insulin to Sanofi. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MannKind Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MannKind Corporation (NASDAQ
and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at <U>http://www.mannkindcorp.com</U> to which MannKind regularly posts
copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the
Securities and Exchange Commission or posts certain other information to the website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Agreed Form of Statement </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
November&nbsp;9, 2016, MannKind and Sanofi reached an agreement to resolve all the outstanding contractual issues related to Afrezza. We refer you to the press release dated November&nbsp;9, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>If MannKind is asked about claims, disputes or liabilities: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties have mutually released one another from any and all potential claims arising out of the license and collaboration agreement, the supply agreement,
the promissory note, the security agreement and the transition agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Outstanding Transition Agreement Deliverables/Transition Activities </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Transition Agreement</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:75.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deliverable/Transition Activity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><U>Delivery/Completion</U></B><br><B>Deadline</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C, Deliverable Number 30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regulatory Reporting of Sample Distribution (XML files) reporting period up to and including April 4th, 2016 filed to the NDA.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">April 30, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E, Transition Service Number 11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sanofi to honor 2016 Sanofi Savings Cards for patients who have registered with Sanofi on or before April 4, 2016 until December</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">31, 2016.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December 31, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E, Transition Service Number 28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sanofi to work with Veteran Affairs (VA) to remove the Sanofi Afrezza NDCs from the Federal Supply Schedule (FSS).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">January 1, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>4
<FILENAME>d305327dex1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.32 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This first amendment (&#147;First Amendment&#148;) to the Supply Agreement by and between MannKind Corporation (&#147;MannKind&#148;) and
Amphastar France Pharmaceuticals S.A.S. (&#147;AFP&#148;), dated July&nbsp;31, 2014 (the &#147;Agreement&#148;), is hereby made as of the&nbsp;31st&nbsp;day of October, 2014, by and between MannKind on the one hand, and on the other hand, AFP and
Amphastar Pharmaceuticals, Inc., a Delaware Corporation, having its principal office and place of business at 11570 6th Street, Rancho Cucamonga, CA 91730 (&#147;Amphastar&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
MannKind and AFP entered into the Agreement pursuant to which AFP is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS MannKind and AFP, together with Amphastar, the parent company of AFP, have determined it to be mutually beneficial to amend the
Agreement as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, MannKind and AFP, together with Amphastar, hereby
agree to amend the Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;<U>Definitions</U>.&nbsp;Unless otherwise defined herein, each of the capitalized terms
used in this First Amendment shall have the definition and meaning ascribed to it in the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;<U>Amendments to the
Agreement</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;All references to &#147;AFP&#148; in the Agreement are replaced with &#147;Amphastar.&#148;&nbsp;For avoidance of
doubt, Amphastar shall replace AFP as a party to the Agreement, and AFP shall no longer be a party to the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;For
avoidance of doubt, Amphastar shall assume all of AFP&#146;s rights and obligations under the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;With respect to
Amphastar&#146;s obligations under the Agreement, Amphastar either shall perform, or shall cause AFP to perform, all such obligations under the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;Section 4.4 of the Agreement is amended and replaced in its entirety with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4&nbsp;Audits.</B>&nbsp;Upon MannKind&#146;s written request to Amphastar, which shall be not less than thirty
(30)&nbsp;days in advance, MannKind, or a mutually agreed upon independent third party representative on behalf of MannKind&#146;s licensee(s) identified in such a written request (&#147;Licensee&#146;s Representative&#148;), shall have the right to
visit Amphastar&#146;s facility located at Usine Saint Charles, 60590 Eragny-sur-Epte, France, during normal business hours to review and inspect Amphastar&#146;s manufacturing operations and quality systems related to the Product and to discuss any
related issues with Amphastar&#146;s manufacturing and management personnel.&nbsp;Such audits of Amphastar shall not exceed one (1)&nbsp;time per calendar year for MannKind and shall not exceed one (1)&nbsp;time per calendar year for MannKind&#146;s
Licensee&#146;s Representative.&nbsp;For the avoidance of doubt, only two (2)&nbsp;audits in total are allowed per calendar year.&nbsp;MannKind, or the Licensee&#146;s Representative will be entitled to perform additional audits, upon shorter
notice, if Non-conforming Products are produced by Amphastar or complaints or other inquiries by regulatory authorities relating to the Products produced hereunder are received by either Party, or for any additional reasons where good cause is
articulated in writing by MannKind. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;The following sentence in section 6.1 of the Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;All amounts due under this &#167; 6.1 shall be due and payable by MannKind to AFP in EUR in accordance with &#167; 6.2.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">is amended and replaced in its entirety with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;All amounts due under this &#167; 6.1 shall be due and payable by MannKind to Amphastar in U.S. dollars, and the conversion of the
Purchase Price from euros (EUR) to U.S. dollars shall be made using the exchange rate at the close (Eastern time) of the last business day immediately prior to the shipment date, as reported by the Bloomberg Currency Spot Exchange Rate
(<U>http://www.bloomberg.com/quote/EURUSD:CUR</U>), and otherwise in accordance with &#167; 6.2.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;Section 11.1 of the
Agreement is amended by adding the following sentence at the end of section 11.1:&nbsp;&#147;MannKind&#146;s obligations under this section 11.1 shall apply to Confidential Information MannKind receives from Amphastar or Amphastar&#146;s
Affiliates.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;<U>Final Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the execution of this First Amendment, all references in the Agreement (or in the First Amendment) to &#147;this
Agreement,&#148; &#147;hereof,&#148; &#147;herein,&#148; &#147;hereto,&#148; and similar words or phrases shall mean and refer to the Agreement as amended by this First Amendment.&nbsp;The Agreement as amended by this First Amendment constitutes the
entire agreement by and between the Parties as to the subject matter hereof.&nbsp;Except as expressly modified by this First Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of MannKind, AFP, and Amphastar has caused this First Amendment to be
executed by their duly authorized officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MannKind Corporation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kathleen M. Farley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kathleen M. Farley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">V.P. Strategic Operations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Amphastar France Pharmaceuticals S.A.S.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Franck Vitali</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Franck Vitali</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Plant Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Amphastar Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Shandell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jason Shandell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>d305327dex1033.htm
<DESCRIPTION>EX-10.33
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.33</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.33 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Text Omitted and Filed Separately </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>with the Securities and Exchange Commission. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Confidential Treatment Requested </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Under 17 C.F.R. Sections 200.80(b)(4) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>and 240.24b-2. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND
AMENDMENT TO SUPPLY AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This second amendment (&#147;Second Amendment&#148;) to the Supply Agreement by and between MannKind
Corporation (&#147;MannKind&#148;) and Amphastar Pharmaceuticals, Inc. (&#147;Amphastar&#148;), originally dated July&nbsp;31, 2014 and as previously amended on October&nbsp;31, 2014 (collectively, the &#147;Agreement&#148;), is hereby made as of
the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of November, 2016, by and between MannKind on the one hand, and on the other hand, Amphastar. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, MannKind and Amphastar are concurrently entering into a first amendment to the Insulin Purchase Option Agreement originally dated
January&nbsp;1, 2015 (the &#147;Option Amendment&#148;) and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS MannKind and Amphastar have determined it to be mutually beneficial
to amend the Agreement as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, MannKind and Amphastar, hereby agree to
amend the Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. Unless otherwise defined herein, each of the capitalized terms used in this Second
Amendment shall have the definition and meaning ascribed to it in the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Amendments to the Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 The following sentence in <B>Section&nbsp;5.1</B> of the Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Upon delivery to MannKind, AFP shall ensure Product will have a remaining expiry date of not less than four (4)&nbsp;years.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Is amended and replaced in its entirety with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;In calendar year 2017 and 2018, upon delivery to MannKind, Amphastar shall ensure that Product will have a remaining expiry date of not
less than two (2)&nbsp;years. In calendar year 2019 and the remainder of the term of the Agreement, Amphastar shall ensure Product will have a remaining expiry date of not less than three (3)&nbsp;years.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 The following sentence in <B>Section&nbsp;6.1</B> of the Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>&#147;Purchase Commitment and Purchase Price</B>. MannKind shall purchase from AFP the minimum quantities of Product (the
&#147;<B><I>Purchase Commitment Quantities</I></B>&#148;) at the purchase price per gram (the &#147;<B><I>Purchase Price</I></B>&#148;) in each calendar year as provided in the table set forth below. In the event that MannKind fails to meet the
Purchase Commitment Quantities in any given calendar year, MannKind shall pay AFP for the difference in the amount of the Purchase Commitment Quantities and the actual amount purchased for the corresponding calendar year (such difference, the
&#147;<B><I>Purchase Commitment Difference</I></B>&#148;). AFP shall issue an invoice and MannKind shall pay the Purchase Commitment Difference no later than thirty (30)&nbsp;days after the close of the corresponding calendar year.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">is amended and replaced in its entirety with the following: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Purchase Commitment and Purchase Price</B>. MannKind shall purchase from Amphastar the minimum
quantities of Product (the &#147;<B><I>Purchase Commitment Quantities</I></B>&#148;) at the purchase price per gram (the &#147;<B><I>Purchase Price</I></B>&#148;) in each calendar year as provided in the table set forth below. This annual Purchase
Commitment Quantities will be divided into four (4)&nbsp;equal quarterly commitments (the &#147;<B><I>Quarterly Commitment</I></B>&#148;). In the event that MannKind fails to meet the Quarterly Commitment in any given calendar quarter, MannKind
shall pay Amphastar for the difference in the amount of the Quarterly Commitment and the actual amount purchased for the corresponding calendar quarter (such difference, the &#147;<B><I>Payment Commitment Difference</I></B>&#148;). Amphastar shall
issue an invoice and MannKind shall pay the Payment Commitment Difference no later than thirty (30)&nbsp;days after the close of the corresponding calendar quarter. Notwithstanding the foregoing, the parties hereby agree that the Purchase Commitment
Quantities for 2017 shall not be divided into four (4)&nbsp;equal quarterly payments but rather MannKind shall take receipt of the entire [<B><I><SUP STYLE="font-size:85%; vertical-align:top">*</SUP></I></B>&#133;***&#133;] Kgs of Product in the
fourth (4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;quarter of 2017 but no later than November&nbsp;15, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 The table in Section&nbsp;6.1 of the Agreement is amended and replaced in its entirety with the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman">Calendar<BR>Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Purchase&nbsp;Commitment<BR>Quantities (kg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Purchase&nbsp;Price<BR>(per gram)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Delivery and Payment</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100% of the Purchase Commitment Quantities Payment shall be paid no later than November&nbsp;5, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EUR [***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>***</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Confidential Treatment Requested </I></B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 Section&nbsp;6.2 of the Agreement shall be amended and replaced in its
entirety with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>6.2 Payment. </B>In calendar year 2017 and 2018, MannKind shall pre-pay Amphastar for the Product at least
ten (10)&nbsp;days prior to the estimated delivery date. For the avoidance of doubt, Amphastar shall not ship the Product to MannKind until such payment is received. Beginning in 2019 and for the remainder of the term of the Agreement, MannKind
shall pay Amphastar for the Product within forty-five (45)&nbsp;days from shipment date of the Product. Amphastar shall submit an invoice electronically to MannKind, Attention: Account Payable, <U>valenciaap@mannkindcorp.com</U>. If any portion of
an invoice is disputed then MannKind shall pay the undisputed amount and the Parties shall use good faith efforts to reconcile the disputed amount as soon as practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 A new <B>Section&nbsp;6.5</B> shall be added to the Agreement as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>6.5 Right of First Refusal in China.</B> In consideration of the amendments contained in this Second Amendment and in the Option Amendment,
MannKind hereby grants Amphastar the right of first refusal to participate in the development and commercialization of Afrezza in China through a collaborative arrangement. Specifically, Amphastar and MannKind agree that MannKind will not commence
the process of obtaining approval of Afrezza in China without first providing Amphastar with (i)&nbsp;at least ninety (90)&nbsp;days prior written notice of MannKind&#146;s intention to commence the process of obtaining approval of Afrezza in China,
and (ii)&nbsp;if Amphastar confirms its interest in collaborating in the development or commercialization of Afrezza in China in writing within thirty (30)&nbsp;days of receipt of MannKind&#146;s notice, then the Parties shall reserve sixty
(60)&nbsp;days to negotiate in good faith the terms of such a collaborative arrangement for Afrezza in China. In the event that the Parties are unable to agree on commercial terms for a collaborative agreement after the sixty (60)&nbsp;day
negotiation period, then MannKind shall have the right to negotiate a collaborative agreement with another party (&#147;Competing Terms&#148;). MannKind shall present the Competing Terms to Amphastar in writing, and within sixty (60)&nbsp;days of
receipt of the Competing Terms, Amphastar shall have the option to either (i)&nbsp;decline to match the Competing Terms, or (ii)&nbsp;agree to match the same Competing Terms and enter into a collaborative agreement with MannKind in China. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <B>Section&nbsp;10.1</B> of the Agreement shall be extended until December&nbsp;31, 2023. All other terms and conditions in
paragraph 10.1 shall remain in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Final Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the execution of this Second Amendment, all references in the Agreement (or in the Second Amendment) to &#147;this
Agreement,&#148; &#147;hereof,&#148; &#147;herein,&#148; &#147;hereto,&#148; and similar words or phrases shall mean and refer to the Agreement as amended by this Second Amendment. The Agreement as amended by this Second Amendment constitutes the
entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Second Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Second Amendment to be
executed by their duly authorized officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MannKind Corporation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Pfeffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Amphastar Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Shandell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jason Shandell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>6
<FILENAME>d305327dex1035.htm
<DESCRIPTION>EX-10.35
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.35</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.35 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO AGREEMENT OF PURCHASE AND SALE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND JOINT ESCROW INSTRUCTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT TO AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS (this &#147;<B>First Amendment</B>&#148;) is made and
entered into as of February&nbsp;7, 2017, by and between MANNKIND CORPORATION, a Delaware corporation (&#147;<B>Seller</B>&#148;), and REXFORD INDUSTRIAL REALTY, L.P., a Maryland limited partnership (&#147;<B>Buyer</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Seller and Buyer entered into that certain Agreement of Purchase and Sale and Joint Escrow Instructions dated for reference purposes as of
January&nbsp;6, 2017 (the &#147;<B>Original Agreement</B>&#148;), relating to certain real property located in the City of Valencia, County of Los Angeles, State of California, more particularly described in the Original Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Seller and Buyer now desire to amend the terms of the Original Agreement as provided in this First Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer hereby
amend the Original Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Recitals; Definitions</U>. The recitals set forth above are not merely recitals, but form
an integral part of this First Amendment. All capitalized terms used and not otherwise defined in this First Amendment shall have the meanings respectively assigned to them in the Original Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Contingency Date</U>. The parties agree that the Contingency Date shall be extended to, and all references to &#147;Contingency
Date&#148; in the Agreement shall mean and refer to, 5:00 p.m. Pacific Time on February&nbsp;10, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Equipment</U>.
Notwithstanding anything in the Original Agreement to the contrary, <U>Exhibit B</U> and <U>Exhibit 2</U> to <U>Exhibit E</U> attached to the Original Agreement are hereby deleted in their entirety and replaced with <U>Exhibit B </U>attached hereto.
Additionally, without limitation of Section&nbsp;7.9 of the Original Agreement, Buyer and its agents and designees shall have the right, prior to Closing, to enter onto the Property from time to time, subject to the terms and conditions of
Section&nbsp;14 of the Original Agreement, to confirm there has been no Material Change to the Property, including, without limitation, the removal of, or damage to, any of the Equipment. Without limitation of Buyer&#146;s other rights and remedies
in the Original Agreement, in the event of any Material Change under this provision, Buyer shall have the right to defer the Closing until such Material Change is remedied or addressed to Buyer&#146;s reasonable satisfaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Allocation of Purchase Price</U>. The parties agree that the allocation of the Purchase Price is $215,000.00 for the Equipment and
$17,060,000.00 for the Real Property. The parties further agree that the sale is indivisible notwithstanding the fact that the amounts have been allocated separately. No party to this Agreement shall file any tax return, filing or report or take a
position with any tax authority (whether federal, state or local) that is inconsistent with such allocation. Each of the parties to this Agreement shall cooperate with the other in the filing of any forms with any taxing authority with respect to
the reporting of the allocation of the Purchase Price. Seller represents and warrants to, and covenants with, Buyer that as of the Closing, including the sale to Buyer, Seller shall not have made more than two (2)&nbsp;sales of tangible personal
property during the twelve (12)&nbsp;month period immediately prior to Closing. Seller shall be responsible for any and all sales tax in connection with the transfer of the Equipment to Buyer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Removal of Certain Hazardous Substances</U>. Seller has engaged Clean Harbors, Inc. (Nasdaq
symbol &#147;CLH&#148;) (&#147;<B>Clean Harbors</B>&#148;) to remove certain Hazardous Substances stored at, on or upon the Property, as well as any and all containers storing same. Seller shall (a)&nbsp;prior to the Contingency Date provide Buyer,
a reasonably detailed summary or list of the Hazardous Substances, containers and locations thereof that are to be removed prior to Closing and scope of any other work to be performed by Clean Harbors, as well as a list of any chemicals or Hazardous
Materials identified by Clean Harbors or Seller that are not being cleaned, removed or treated by Clean Harbors, and (b)&nbsp;prior to Closing, shall (i)&nbsp;cause such removal to be completed in accordance with all applicable laws and in a good
and workmanlike manner, and (ii)&nbsp;provide Buyer a manifest executed by Clean Harbors describing the Hazardous Materials and containers that Clean Harbors has removed. Additionally, without limitation of Section&nbsp;7.9 of the Original
Agreement, Buyer and its agents and designees shall have the right, prior to Closing, to enter onto the Property from time to time, subject to the terms and conditions of Section&nbsp;14 of the Original Agreement, to confirm the removal of such
Hazardous Substances has been completed in accordance with the terms of this Section. Seller&#146;s obligations in this provision shall be a condition precedent to Buyer&#146;s obligation to consummate the transaction contemplated by the Agreement,
and without limitation of Buyer&#146;s other rights and remedies in the Original Agreement, Buyer shall have the right to defer the Closing until the foregoing condition(s) are satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Assumed Contracts</U>. The Service Contracts listed on <U>Schedule 1</U> attached hereto shall be deemed to be the &#147;Assumed
Contracts&#148; as described in the Original Agreement. Pursuant to the Original Agreement, at Closing, Seller shall, at its sole cost, terminate all other Service Contracts other than the Assumed Contracts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. Except as otherwise expressly provided in this First Amendment, the provisions of the Original Agreement shall be and
remain unmodified and in full force and effect (such Original Agreement being hereby ratified, reaffirmed and confirmed by Buyer and Seller), and if any provision of this First Amendment conflicts with the Original Agreement, then the provisions of
this First Amendment shall prevail. Except as otherwise expressly provided in this First Amendment, nothing contained in this First Amendment shall operate to waive the rights of Buyer or Seller under the Original Agreement. This First Amendment may
be executed in one or more counterparts (by original, facsimile or electronic PDF signatures), each of which shall be deemed to constitute an original, but all of which, when taken together, shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[END OF TEXT; SIGNATURES ON FOLLOWING PAGE] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Seller and Buyer have executed this First Amendment as of the date first set
forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;BUYER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REXFORD INDUSTRIAL REALTY, L.P.,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Maryland limited
partnership</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Rexford Industrial Realty, Inc.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a Maryland corporation,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its General Partner</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: <U>/s/ Howard
Schwimmer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:
Howard Schwimmer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its:
Co-CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SELLER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MANNKIND CORPORATION,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <U>/s/ David
Thomson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: David
Thomson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its: Vice
President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;B&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF EQUIPMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCLUDED ITEMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUTSIDE </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spectrum Int. Combustion
Mod. R163-7K36, 1115 KW Diesel Generator, Detroit Diesel 16-Cycle Engine, Turbo Charged, After Cooled w/ Arco 7000 Series Transfer Switch in Elec. Room w/ Wire. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Cleaver Brooks Mod. FLX700-450 Flex Water Tube Boilers w/ Arleta Mod. CSB50 Controllers, Still &amp; Pumps </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Filter D.I. Unit Mod. 90/01096-607 w/ (2)&nbsp;R.O. Systems. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2006) Kaesar Mod. AS20, Rotary Screw Air Compressor w/ Receiver. S/N 1156 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) (2001&nbsp;&amp; 2008) McQuay Mod. E2612BE2-A, 300 Ton Chillers w/ Electrical&nbsp;&amp; Microtech Controllers. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Evapco Cooling Towers. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Armstong Water Re-Circulation System
w/ Pumps&nbsp;&amp; Electrical </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quincy Twin Stage 5 H.P. Air Compressors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCH Twin Stage Vacuum Pump System. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Quincy QRD 30 H.P. High Pressure Air Compressors </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magliner Aluminum Dock Ramp. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INSIDE </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Metallurgical
Microscope Per Images below </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LOBBY </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reception Desk w/ Chairs, Sofa. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WAIKIKI
ROOM </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairs&nbsp;&amp; Furniture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lunch Room w/
Microwaves, Ref, Tables&nbsp;&amp; Chair. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROOMS #136, #131, #132, #134, #122, #123, #130, <U>#129, #128, #1102, #1104, #1105, #1107</U>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fisher Scientific Isotemp Oven. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heraeus Megafuge 2.0,
Centrifuge. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Packard Cobra II, Auto. Gama. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Baker Sterligard VBM500, S.S. Fume Hoods. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak X-Omat 2000A, Developer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Fisher Hamilton Safeaire Fume Hoods. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Castle 8666, Washer Disinfector. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2001) Gettinge Mod. GE2609AR1,
Steam Washer-Dryer. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) New Brunswick Hot Plate Stirrers. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Room #125&#151;R.W. Smith 12&#146; x 15&#146; Modular Controlled Environmental Rooms. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gas Tech 128, Monitor. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) NuAire Class II Type A/B3, S.S. Bio.
Safety Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Napco CO2 Environmental Ovens. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Western
Innovator Industrial Manifolds. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Thermo Forma Class II, A2 Bio. Safety Cabinets. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) New Brunswick Classic C25&nbsp;&amp; C24, Incubator Shakers. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justrite Flammable Storage Cabinet. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beckman Coulter Microplate
Carousel. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Isotemp 20T, Bath. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab Line III, Incubator. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(20) Lab Benches: 6&#146; x 24&#146; w/ Sink, Gas Lines, Electrical Outlets, Chairs. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supply Cabinets w/ Glass Doors. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Olympus BX41 Met. Microscope.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Eppendorf 5415, Centrifuges. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leica 090-135-001, Stereo
Zoom Microscope. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) VWR Wash. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bio Tek ELX50. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MJ PTC100, Prog. Thermal Controller. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Varian Pro Star
Chromatography System w/ (2)&nbsp;Solvent Delivery Modules, UV-VIS Detector w/ PC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gemini Twin Shaking Water Bath. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Savant Speed Vac Centrifuges. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab Line Orbit Environ-Shaker.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) Steel Supply Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Hanson Fume Hood. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Titer Plate Shakers. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Branson 8510, Ultrasonic Cleaner. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Port. S.S. Cart. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) New Brunswick Biofold 3000, Batch Cont.
Bio. Reactors. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Thermo Scientific Class II A/B3, Biological Safety Cabinets. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Forma Scientific CO2 Water Jacketed Incubators. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Newport
Lab. Tables. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beckman Coulter System Gold 128, Solvent Module. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurora Discovery. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Molecular Device Mod. 0310-3895,
Chemilluminescence Imaging Plate Reader w/ 600 Camera Controller. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S/N CL-115 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Digital Analysis Lab. Treat LT-50, Ph Adjustment System w/ Effluent Monitor. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steam Generator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ROOM #142 </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Scientek S.S. Downdraft Necropsy Tables, 2&#146; x 8&#146; w/ Hoods. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TSI Fluidized Bed Aerosol Generator w/
Bias Flow Generator. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scientek Mod. SBS-48, Lab. Table w/ Fume Hood. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Port. S.S. Carts. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Scientek S.S. Backdraft Work Benches&nbsp;&amp; Sins. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gettinge MTP 1800 S.S. Cage&nbsp;&amp; Bottle Washer.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Gettinge Vivarium Autoclave II, Vacuum Steam Sterilizers w/ 4&#146; x 4&#146; x 4&#146; Wheel-In Cart Chamber w/ PACS 2000 Controller, Dbl. End. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WAREHOUSE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Revo Ultima II, Freezers. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ELECTRICAL </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Square &#145;D&#146; 2000 Amp., 480/277 Volts Breakers&nbsp;&amp; Wire. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">GE Zenith Transfer Switches&nbsp;&amp; Wire. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Square &#145;D&#146; Mod. 6, M.C.C. Panels&nbsp;&amp; Wire. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Crown 3000 Lb. Elec. Forklift w/ Legacy Charger.
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Hyd. Pallet Jacks. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genie AWP-30S, Elec. Manlift. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harris Refrigerator. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Thermo Orion CO2 Incubators, Water Jacketed, </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presto Die Lift. Cart. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Freezers. (Hallway) </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fisher Scientific Lab. Ref. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Arc Welder. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Port. A-Frame Hoist. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Beckman Coulter 25R, Centrifuge. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Fire King Fire Proof Cabinets. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Powerwave 9390, U.P.S. w/ New Batteries&nbsp;&amp; Capacitors. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misc. Office Furniture&nbsp;&amp; Cubicles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUDED ITEMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12&#146; Single Axle Equipment Trailer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Praxair Liquid Nitrogen
Tank, Approx. 300 Gal. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment In Rooms #1109, #1110&nbsp;&amp; #1112 (including Hanson fume hood). </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab. Benches from Rooms #1109, #1110 and #1112. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab. Sink in
general lab area. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fume Hood in general lab area. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keurig
Coffee Maker </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSUMED CONTRACTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Fire Protection Systems Annual Testing Proposal/Agreement with Red Hawk Fire&nbsp;&amp; Security dated September&nbsp;28, 2015. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Standard Landscape Maintenance Agreement with American Landscape Maintenance dated June&nbsp;6, 2001. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO AGREEMENT OF PURCHASE AND SALE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND JOINT ESCROW INSTRUCTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECOND AMENDMENT TO AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS (this &#147;<B>Second Amendment</B>&#148;) is made and
entered into as of February&nbsp;10, 2017, by and between MANNKIND CORPORATION, a Delaware corporation (&#147;<B>Seller</B>&#148;), and REXFORD INDUSTRIAL REALTY, L.P., a Maryland limited partnership (&#147;<B>Buyer</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Seller and Buyer entered into that certain Agreement of Purchase and Sale and Joint Escrow Instructions dated for reference purposes as of
January&nbsp;6, 2017 (the &#147;<B>Original Agreement</B>&#148;), as modified by that certain First Amendment to Agreement of Purchase and Sale and Joint Escrow Instructions dated February&nbsp;7, 2017 (the &#147;<B>First Amendment</B>&#148;;
together with the Original Agreement, the &#147;<B>Amended Agreement</B>&#148;), relating to certain real property located in the City of Valencia, County of Los Angeles, State of California, more particularly described in the Original Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Seller and Buyer now desire to amend the terms of the Amended Agreement as provided in this Second Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer hereby amend
the Amended Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Recitals; Definitions</U>. The recitals set forth above are not merely recitals, but form an
integral part of this Second Amendment. All capitalized terms used and not otherwise defined in this Second Amendment shall have the meanings respectively assigned to them in the Amended Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Approval of Certain Matters</U>. Buyer hereby waives any and all contingencies that are scheduled to expire as of the Contingency Date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Closing Date</U>. Notwithstanding anything in the Amended Agreement to the contrary, the Closing Date shall be February&nbsp;17,
2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Letter from MannKind LLC</U>. At least one (1)&nbsp;business day prior to the Close of Escrow, Seller shall cause Mannkind
LLC, a Delaware limited liability company, to deliver to Escrow Holder a duly executed original letter in the form of <U>Exhibit &#147;A&#148;</U> attached hereto. Upon the Close of Escrow, Escrow Holder shall deliver the original of such letter to
Buyer in accordance with Section&nbsp;12.4 of the Original Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>UCC-3</U>. At least one (1)&nbsp;business day prior to the
Close of Escrow, Seller shall cause to be completed a UCC-3 statement in the form of <U>Exhibit &#147;B&#148;</U> attached hereto and deliver same to Escrow Holder for filing by Escrow Holder, or Buyer (at Buyer&#146;s request), with the appropriate
secretary of state, such that Buyer shall receive the Equipment and Personal Property free and clear of liens at Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.
<U>Miscellaneous</U>. Except as otherwise expressly provided in this Second Amendment, the provisions of the Amended Agreement shall be and remain unmodified and in full force and effect (such Amended Agreement being hereby ratified, reaffirmed and
confirmed by Buyer and Seller), and if any provision of this Second Amendment conflicts with the Amended Agreement, then the provisions of this Second Amendment shall prevail. Except as otherwise expressly provided in this Second Amendment, nothing
contained in this Second Amendment shall operate to waive the rights of Buyer or Seller under the Amended Agreement. This Second Amendment may be executed in one or more counterparts (by original, facsimile or electronic PDF signatures), each of
which shall be deemed to constitute an original, but all of which, when taken together, shall constitute one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Seller and Buyer have executed this Second Amendment as of the date first set
forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;BUYER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REXFORD INDUSTRIAL REALTY, L.P.,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Maryland limited
partnership</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;Rexford
Industrial Realty, Inc.,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">a Maryland corporation,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Its General Partner</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Howard Schwimmer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Name: Howard Schwimmer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Its: Co-CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SELLER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MANNKIND CORPORATION,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <U>/s/ David
Thomson</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: David
Thomson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its: Vice
President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;A&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF LETTER FROM MANNKIND LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rexford Industrial
Realty, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11620 Wilshire Blvd., Suite 1000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Angeles,
California 90025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Acquisition of Property in Valencia, CA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom It May Concern: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is hereby made to that certain
Agreement of Purchase and Sale and Joint Escrow Instructions dated as of January&nbsp;6, 2017, by and between MannKind Corporation, a Delaware corporation (&#147;<B>MannKind Corp</B>&#148;) and Rexford Industrial Realty, L.P., a Maryland limited
partnership (&#147;<B>Rexford</B>&#148;), as amended by that certain First Amendment to Agreement of Purchase and Sale and Joint Escrow Instructions dated as of February&nbsp;7, 2017 (collectively, together with any additional amendments thereto,
the &#147;<B>Agreement</B>&#148;), respecting the sale of certain parcels of land located at 28901-03 N. Avenue Paine, in the City of Valencia, County of Los Angeles, State of California, as more particularly described in the Agreement (the
&#147;<B>Property</B>&#148;). The undersigned hereby certifies that it owns no tangible property, furniture, fixtures or equipment physically located at or used in connection with MannKind Corp&#146;s business operations at the Property and further
certifies that it has no business operations at the Property. The undersigned recognizes that Rexford and its successors and assigns are relying on this letter and the accuracy of the information contained herein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MANNKIND LLC,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited
liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT &#147;A&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;B&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UCC-3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See attached </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g305327dsp29.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;B&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF EQUIPMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCLUDED ITEMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUTSIDE </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spectrum Int. Combustion
Mod. R163-7K36, 1115 KW Diesel Generator, Detroit Diesel 16-Cycle Engine, Turbo Charged, After Cooled w/ Arco 7000 Series Transfer Switch in Elec. Room w/ Wire. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Cleaver Brooks Mod. FLX700-450 Flex Water Tube Boilers w/ Arleta Mod. CSB50 Controllers, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Still&nbsp;&amp; Pumps </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Filter D.I. Unit Mod. 90/01096-607
w/ (2)&nbsp;R.O. Systems. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2006) Kaesar Mod. AS20, Rotary Screw Air Compressor w/ Receiver. S/N 1156 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) (2001&nbsp;&amp; 2008) McQuay Mod. E2612BE2-A, 300 Ton Chillers w/ Electrical&nbsp;<I>&amp;</I> Microtech Controllers. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Evapco Cooling Towers. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Armstong Water Re-Circulation System
w/ Pumps&nbsp;&amp; Electrical </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quincy Twin Stage 5 H.P. Air Compressors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCH Twin Stage Vacuum Pump System. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Quincy QRD 30 H.P. High
Pressure Air Compressors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magliner Aluminum Dock Ramp. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INSIDE</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Metallurgical
Microscope Per Images below </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305327dsp30a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LOBBY</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reception Desk w/ Chairs, Sofa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WAIKIKI ROOM</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairs&nbsp;&amp; Furniture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lunch Room w/ Microwaves, Ref,
Tables&nbsp;&amp; Chair. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROOMS #136, #131, #132, #134, #122, #123, #130, <U>#129, #128, #1102, #1104, #1105, #1107</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fisher Scientific Isotemp Oven. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heraeus Megafuge 2.0,
Centrifuge. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Packard Cobra II, Auto. Gama. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Baker
Sterligard VBM500, S.S. Fume Hoods. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kodiak X-Omat 2000A, Developer. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Fisher Hamilton Safeaire Fume Hoods. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Castle 8666, Washer
Disinfector. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2001) Gettinge Mod. GE2609AR1, Steam Washer-Dryer. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) New Brunswick Hot Plate Stirrers. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Room #125 - R.W. Smith
12&#146; x 15&#146; Modular Controlled Environmental Rooms. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gas Tech 128, Monitor. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) NuAire Class II Type A/B3, S.S. Bio. Safety Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Napco
C02 Environmental Ovens. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Western Innovator Industrial Manifolds. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Thermo Forma Class II, A2 Bio. Safety Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) New
Brunswick Classic C25&nbsp;&amp; C24, Incubator Shakers. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justrite Flammable Storage Cabinet. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beckman Coulter Microplate Carousel. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Isotemp 20T, Bath. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab Line III, Incubator. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(20) Lab Benches: 6&#146; x 24&#146; w/
Sink, Gas Lines, Electrical Outlets, Chairs. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supply Cabinets w/ Glass Doors. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Olympus BX41 Met. Microscope. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Eppendorf 5415, Centrifuges.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leica 090-135-001, Stereo Zoom Microscope. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) VWR Wash.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bio Tek ELX50. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MJPTC100, Prog. Thermal Controller. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Varian Pro Star Chromatography System w/ (2)&nbsp;Solvent Delivery Modules, UV-VIS Detector w/ PC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gemini Twin Shaking Water Bath. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Savant Speed Vac
Centrifuges. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lab Line Orbit Environ-Shaker. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) Steel
Supply Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Hanson Fume Hood. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Titer Plate
Shakers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Branson 8510, Ultrasonic Cleaner. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Port. S.S. Cart. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) New Brunswick Biofold 3000, Batch Cont.
Bio. Reactors. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Thermo Scientific Class II A/B3, Biological Safety Cabinets. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Forma Scientific CO2 Water Jacketed Incubators. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Newport
Lab. Tables. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beckman Coulter System Gold 128, Solvent Module. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurora Discovery. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Molecular Device Mod. 0310-3895,
Chemilluminescence Imaging Plate Reader w/ 600 Camera Controller. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;S/N CL-115 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Digital Analysis Lab. Treat LT-50, Ph Adjustment System w/ Effluent Monitor. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steam Generator. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ROOM #142</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Scientek S.S. Downdraft Necropsy Tables, 2&#146; x 8&#146; w/ Hoods. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TSI Fluidized Bed Aerosol Generator w/ Bias Flow Generator. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scientek Mod. SBS-48, Lab. Table w/ Fume Hood. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Port. S.S.
Carts. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) Scientek S.S. Backdraft Work Benches&nbsp;&amp; Sins. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gettinge MTP 1800 S.S. Cage&nbsp;&amp; Bottle Washer. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2)
Gettinge Vivarium Autoclave II, Vacuum Steam Sterilizers w/ 4&#146; x 4&#146; x 4&#146; Wheel-In Cart Chamber w/ PACS 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Controller, Dbl. End. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WAREHOUSE</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(7) Revo Ultima II,
Freezers. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ELECTRICAL</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3)
Square &#145;D&#146; 2000 Amp., 480/277 Volts Breakers&nbsp;&amp; Wire. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) GE Zenith Transfer Switches&nbsp;&amp; Wire. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Square &#145;D&#146; Mod. 6, M.C.C. Panels&nbsp;&amp; Wire. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Crown 3000 Lb. Elec. Forklift w/ Legacy Charger. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Hyd. Pallet
Jacks. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genie AWP-30S, Elec. Manlift. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harris Refrigerator.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Thermo Orion CO2 Incubators, Water Jacketed, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presto Die
Lift. Cart. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(10) Freezers. (Hallway) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fisher Scientific Lab.
Ref. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Arc Welder. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Port. A-Frame Hoist. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Beckman Coulter 25R, Centrifuge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(13) Fire King Fire Proof
Cabinets. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Powerwave 9390, U.P.S. w/ New Batteries&nbsp;&amp; Capacitors. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misc. Office Furniture&nbsp;&amp; Cubicles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit &#147;B&#148;
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO AGREEMENT OF PURCHASE AND SALE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND JOINT ESCROW INSTRUCTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDMENT TO AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS (this &#147;<B>Third Amendment</B>&#148;) is made and
entered into as of February&nbsp;15, 2017, by and between MANNKIND CORPORATION, a Delaware corporation (&#147;<B>Seller</B>&#148;), and REXFORD INDUSTRIAL REALTY, L.P., a Maryland limited partnership (&#147;<B>Buyer</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Seller and Buyer entered into that certain Agreement of Purchase and Sale and Joint Escrow Instructions dated for reference purposes as of
January&nbsp;6, 2017 (the &#147;<B>Original Agreement</B>&#148;), as modified by that certain First Amendment to Agreement of Purchase and Sale and Joint Escrow Instructions dated February&nbsp;7, 2017 (the &#147;<B>First Amendment</B>&#148;) and
the Second Amendment to Agreement of Purchase and Sale and Joint Escrow Instructions dated February&nbsp;10, 2017 (the &#147;<B>Second Amendment</B>&#148;; together with the Original Agreement and the First Amendment, the &#147;<B>Amended
Agreement</B>&#148;), relating to certain real property located in the City of Valencia, County of Los Angeles, State of California, more particularly described in the Original Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Seller and Buyer now desire to amend the terms of the Amended Agreement as provided in this Third Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer hereby
amend the Amended Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Recitals; Definitions</U>. The recitals set forth above are not merely recitals, but form an
integral part of this Third Amendment. All capitalized terms used and not otherwise defined in this Third Amendment shall have the meanings respectively assigned to them in the Amended Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase Price</U>. Section VIII of the Basic Provisions of the Original Agreement is hereby deleted in its entirety and replaced with
the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The sum of Seventeen Million Two Hundred Seventy-Three Thousand and 00/100 Dollars ($17,273,000) (the
&#147;<B>Purchase Price</B>&#148;).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references in the Amended Agreement to the &#147;Purchase Price&#148; shall mean such term as amended
hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Allocation of Purchase Price</U>. The first sentence of Section&nbsp;4 of the First Amendment is hereby deleted in its
entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The parties agree that the allocation of the Purchase Price is $213,000.00 for the
Equipment and $17,060,000.00 for the Real Property.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Equipment</U>. The list of Equipment set forth in <U>Exhibit B</U> to the
First Amendment is hereby amended by deleting the following equipment: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;TSI Fluidized Bed Aerosol Generator w/ Bias Flow
Generator.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Assumed Contracts</U>. The list of Assumed Contracts set forth in <U>Schedule 1</U> to the First Amendment is
hereby amended by deleting the following contract: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;Fire Protection Systems Annual Testing Proposal/Agreement with Red Hawk
Fire&nbsp;&amp; Security dated September&nbsp;28, 2015.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references in the Amended Agreement to the &#147;Assumed Contracts&#148; shall mean such term as amended
hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>UCC-3</U>. The form UCC-3 statement attached as <U>Exhibit &#147;B&#148;</U> to the Second Amendment is hereby amended by
deleting the following equipment therefrom: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;TSI Fluidized Bed Aerosol Generator w/ Bias Flow Generator.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. Except as otherwise expressly provided in this Third Amendment, the provisions of the Amended Agreement shall be and
remain unmodified and in full force and effect (such Amended Agreement being hereby ratified, reaffirmed and confirmed by Buyer and Seller), and if any provision of this Third Amendment conflicts with the Amended Agreement, then the provisions of
this Third Amendment shall prevail. Except as otherwise expressly provided in this Third Amendment, nothing contained in this Third Amendment shall operate to waive the rights of Buyer or Seller under the Amended Agreement. This Third Amendment may
be executed in one or more counterparts (by original, facsimile or electronic PDF signatures), each of which shall be deemed to constitute an original, but all of which, when taken together, shall constitute one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Seller and Buyer have executed this Third Amendment as of the date first set
forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;BUYER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REXFORD INDUSTRIAL REALTY, L.P.,<BR>a Maryland limited partnership</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;Rexford Industrial Realty, Inc.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">a Maryland corporation,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Its General Partner</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Howard Schwimmer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Name: Howard Schwimmer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Its: Co-CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SELLER&#148;</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MANNKIND CORPORATION,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <U>/s/ David
Thomson</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: David
Thomson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its: Vice
President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>7
<FILENAME>d305327dex1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.36</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.36 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g305327dsp47.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Casper Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Danbury, CT 06810</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Main:
203-798-8000</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Fax: 203-798-7740</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">www.mannkindcorp.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Stuart&nbsp;A. Tross, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1024 Cheshire Hills Court
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westlake Village, CA 91361 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stuart, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment
with MannKind Corporation, in the exempt position Chief People Officer Officer located in Valencia CA. In this position you will initially report directly to Matthew J. Pfeffer, Chief Executive Officer and CFO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will target your employment to commence on December&nbsp;23, 2016. Please be advised that continued employment is contingent upon satisfactory reference
and background checks and receipt of results of a satisfactory drug screening test. You will receive an email with information regarding the test, contact and location information for the laboratory as well as the hours of operation. This screening
test must be completed within two weeks from the date of this letter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be paid on a bi-weekly basis, on regular payroll schedule, in the amount
of $14,038.47, equating to an annualized amount of $365,000.22. You will be eligible to participate in the MannKind Discretionary Bonus Plan, with a target bonus opportunity of 50% of annual earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, you will receive a one-time sign-on bonus in the gross amount of $35,000.00, less appropriate withholdings and other payroll deductions, payable
as a lump sum on the first pay period at the end of the first ninety (90)&nbsp;days of your employment. By accepting this offer, you agree that, in the event that you voluntarily leave the Company, or if you are terminated by the Company for
&#147;cause&#148;, within the twelve (12)&nbsp;months following receipt of payment, you will repay the full amount of the payment, net any with-holdings within thirty (30)&nbsp;days after the last day of your employment. By accepting this offer, you
further agree that the Company may deduct this amount from any other amounts The Company owes you should you be obligated to repay this amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will
be eligible to participate in MannKind&#146;s Equity Incentive Plan, under which stock options and restricted stock will be awarded to you at a future date, as approved by the Board of Directors. At the next quarterly Board meeting after your hire
date, we will recommend that you be granted an equity award of 400,000 stock options and 100,000 restricted stock units which is comparable to grants made for other individuals in similar level positions throughout the company. You will also be
eligible for 400,000 stock options for Performance Grants. This is not a guarantee for a specific number of restricted stock units, but is only intended to provide you with an understanding of grant guidelines for your position. If your start date
is less than two weeks prior to the next quarterly Board meeting, the recommendation will be submitted in the following quarter. Grants will begin vesting based on your hire date. You will also be eligible for an annual equity grant. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart A. Tross, page two </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a substantial list of fringe benefits, including the following: 20 days PTO annually, which accrues
on a bi-weekly basis; short term and long term disability insurance; company&#150;paid life insurance; a 401(k) tax deferred savings program; flexible spending accounts; health, vision and dental insurance, Executive Medical Reimbursement plan and
paid holidays which includes a full week in July and December for the holiday break. The holidays and other time off benefits will be prorated based on your date of hire. All benefits, policies and rules are subject to change from time to time at
the Company&#146;s discretion. All benefits outlined in this offer letter are contingent on your continuing employment with MannKind Corporation in a benefit eligible status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shortly after we are in receipt of your acceptance, you will receive a welcome email from our onboarding manager, with a link to your personalized onboarding
portal. Through this portal you will have access to most of the required MannKind policies and agreements that will require your signature such as, the Employee Proprietary Information and Inventions Agreement, an Arbitration Agreement, a Policy
Against Insider Trading, Code of Business Conduct and Ethics, and an Employee Acknowledgement Form, required after reading the MannKind Employee Sourcebook. Of course, the company may require additional policies or agreements to be signed and
acknowledged in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employment at MannKind is at will, which means that either you or MannKind can end the employment relationship at any time,
and for any reason or for no reason, with or without cause or notice. The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether oral or written, and cannot be modified or amended except in writing
by an officer of the company. As required by law, this offer is subject to satisfactory proof of your right to work in the United States. This at will employment relationship cannot be changed except in writing as approved by the Board of Directors
of MannKind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We appreciate the energy and enthusiasm you demonstrated during our interview and selection process and we look forward to a favorable
response to our offer. We have many exciting challenges ahead and believe you can make a significant contribution to MannKind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At your earliest
convenience, please sign and date this letter and return it to Diana Champagne, Director, Compensation and Benefits and HRIS (<U>dchampagne@mannkindcorp.com</U>) to indicate your acceptance of this written offer of employment. Please also include
proof of your annual compensation in the form of a recent pay stub or W2/1099. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you should have any questions, please don&#146;t hesitate to contact
me. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Matthew J. Pfeffer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew J. Pfeffer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and CFO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart A. Tross, page three </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I have carefully read and understand all of the terms of the above letter and freely and voluntarily accept
and agree to all of its terms. I represent that, in agreeing to this offer letter, I am not relying on any representations or promises of any kind other than set forth in this letter. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stuart A. Tross</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stuart A. Tross, Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">December&nbsp;22, 2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date Signed</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">December&nbsp;23, 2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmed Start Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>d305327dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in Registration Statement Nos. <FONT STYLE="white-space:nowrap">333-117811,</FONT>
<FONT STYLE="white-space:nowrap">333-127876,</FONT> <FONT STYLE="white-space:nowrap">333-137332,</FONT> <FONT STYLE="white-space:nowrap">333-149049,</FONT> <FONT STYLE="white-space:nowrap">333-160225,</FONT>
<FONT STYLE="white-space:nowrap">333-176409,</FONT> <FONT STYLE="white-space:nowrap">333-182457,</FONT> <FONT STYLE="white-space:nowrap">333-188790</FONT> and <FONT STYLE="white-space:nowrap">333-213366</FONT> on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> of our reports dated March&nbsp;16, 2017, relating to the consolidated financial statements of MannKind Corporation and subsidiaries (&#147;MannKind Corporation&#148;) (which report expresses an
unqualified opinion and includes explanatory paragraphs relating to the Company&#146;s ability to continue as a going concern and the effects of a reverse stock split), and the effectiveness of MannKind Corporation&#146;s internal control over
financial reporting, appearing in this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of MannKind Corporation for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ DELOITTE&nbsp;&amp; TOUCHE LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stamford, Connecticut </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>9
<FILENAME>d305327dex31.htm
<DESCRIPTION>EX-31
<TEXT>
<HTML><HEAD>
<TITLE>EX-31</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RULE <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">13a-14(a)/15d-14(a)</FONT></FONT> CERTIFICATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Matthew J. Pfeffer, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have
reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of MannKind Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those
entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the
registrant&#146;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew J. Pfeffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew J. Pfeffer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer
and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;16, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>d305327dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule
<FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Matthew J.
Pfeffer, Chief Executive Officer and Chief Financial Officer of MannKind Corporation (the &#147;Company&#148;), hereby certifies that, to the best of his knowledge: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31,
2016, to which this Certification is attached as Exhibit 32 (the &#147;Annual Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the undersigned has set his hand hereto as of the 16th day of March, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew J. Pfeffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew J. Pfeffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This certification accompanies the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
reference into any filing of MannKind Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> to which this certification relates), irrespective of any general incorporation language contained in such filing. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>mnkd-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:mnkd="http://imetrix.edgar-online.com/20161231" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mnkd-20161231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <mnkd:UnitsSoldUnderPublicOfferUnderwritten contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0" unitRef="shares" decimals="0" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_3001_0">7187500</mnkd:UnitsSoldUnderPublicOfferUnderwritten>
  <mnkd:UnitsSoldWarrantPortionConvertibleIntoCommonStock contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0" unitRef="iso4217_USD_per_Right" decimals="1" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_3001_3">0.1</mnkd:UnitsSoldWarrantPortionConvertibleIntoCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0_1331314x1359335" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_4001_8">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0_1331314x1359335" unitRef="shares" decimals="INF" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_4001_7">4312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <mnkd:UnitsSoldByUnderwritingPrice contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0_1509889x1405414" unitRef="iso4217_USD_per_Right" decimals="INF" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_5001_4">12.00</mnkd:UnitsSoldByUnderwritingPrice>
  <mnkd:UnitsSoldByUnderwritingPrice contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0_1509889x1436435" unitRef="iso4217_USD_per_Right" decimals="INF" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_6001_5">11.28</mnkd:UnitsSoldByUnderwritingPrice>
  <mnkd:UnitsSoldUnderPublicOfferUnderwritten contextRef="eol_PE126000--1610-K0019_STD_0_20120208_0_1509889x1436435" unitRef="shares" decimals="0" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_6001_1">937500</mnkd:UnitsSoldUnderPublicOfferUnderwritten>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_38">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_679A1CE4-4429-404F-AE5C-9AC830D3D369_2001_1">24.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_41">110000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_43">85734188</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:OwnshareLendingArrangementSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_73C6B739-7C92-4C96-8A79-53D79EA72849_1001_0">1800000</us-gaap:OwnshareLendingArrangementSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_40">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_42">85734188</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_37">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_2001_1">3955845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_2001_1">22.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_36">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_35">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_2C0665E9-F65D-4AFA-A67F-17BEA8D926AD_2001_1">360924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_46">-2863229000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_34" />
  <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_27">62371000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_31">476741000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_48">126412000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_0">2634000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_45">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_16">15599000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_47">-350329000</us-gaap:StockholdersEquity>
  <us-gaap:RestructuringReserve contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_3003_4">3028000</us-gaap:RestructuringReserve>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_24">49521000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_5">615000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_39">4287000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_44">2508633000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_1002_8">119513000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_3">931000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_1">3028000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:ConstructionPayableCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_7">238000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_32" />
  <us-gaap:OtherLongTermDebtCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_18">74582000</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_2_6">483000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_23">268319000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_14">962623000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_26">27613000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_17">7929000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_10">76654000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_5">52484000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_12">48755000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_11">48749000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_2">59074000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_1">721588000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_4">23000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_8">13539000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_2">73646000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_9">16941000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_7FA31BFC-739F-4AD8-BAAB-69BFD325C1C8_2_0">55800000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_1002_7">168262000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:Assets contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_13">126412000</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_13">962623000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_15">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_11">7186000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_C85270AE-9901-45E3-B5C0-97188A0F33B6_2_0">0</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_12">1009000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_9">4018000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <mnkd:DeferredTaxAssetsCapitalizedResearchExpenses contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_3">5872000</mnkd:DeferredTaxAssetsCapitalizedResearchExpenses>
  <mnkd:DeferredTaxAssetsLossOnPurchaseCommitment contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_8">24084000</mnkd:DeferredTaxAssetsLossOnPurchaseCommitment>
  <mnkd:PurchaseObligationNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_28">53692000</mnkd:PurchaseObligationNoncurrent>
  <mnkd:AccruedInterestOfRelatedPartyDebt contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_35F87CA4-D41F-4D53-9D1C-053A165D22C9_1002_0">6400000</mnkd:AccruedInterestOfRelatedPartyDebt>
  <mnkd:DeferredCollaborativeRevenueCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_21">17503000</mnkd:DeferredCollaborativeRevenueCurrent>
  <mnkd:DeferredTaxAssetsMilestoneRights contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_6">3242000</mnkd:DeferredTaxAssetsMilestoneRights>
  <mnkd:EstimatedAmountsCreditExchangeReceivable contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_6FFF3FEA-F9E1-4C42-8A47-7A3761B7735A_1002_1">743000</mnkd:EstimatedAmountsCreditExchangeReceivable>
  <mnkd:PurchaseObligationCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_22">12475000</mnkd:PurchaseObligationCurrent>
  <mnkd:DeferredTaxAssetsCapitalizedCosts contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_10">8574000</mnkd:DeferredTaxAssetsCapitalizedCosts>
  <mnkd:SharesReservedForEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="shares" decimals="0" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_3003_2">140000</mnkd:SharesReservedForEmployeeStockPurchasePlan>
  <mnkd:DeferredCollaborativeCreditCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_20">140231000</mnkd:DeferredCollaborativeCreditCurrent>
  <mnkd:AccruedInterestNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_25">6380000</mnkd:AccruedInterestNoncurrent>
  <mnkd:MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_2_30">8845000</mnkd:MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent>
  <mnkd:DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1002_7">251000</mnkd:DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324319x1333758" unitRef="iso4217_USD" decimals="0" id="id_9004857_23E7D4E0-F255-4BC3-80A1-556922E61939_1002_0">350000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1387193_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_3002_2">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1324896x1324925_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_1004_3">14400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_3002_2">8900000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_1005_3">14400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_1001_3">8900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324529x1510602_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_570CF4C7-2713-4903-B68A-394530C756FC_1001_0">17900000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C06DD231-49E5-4F7D-B6CC-CF004DF954CD_2001_1">48800000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328480x1469303_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_2004_4">36500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328615x1380739_1331210x1324874_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_3004_1">21300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328615x1483091_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_4004_2">78400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_4_5">150600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1325880x1332226_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BBAEFD73-9927-4FDC-9173-F4E8088FC49E_1002_2">17500000</us-gaap:DeferredRevenue>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1325994x1500563" unitRef="iso4217_USD" decimals="-5" id="id_9004857_35F87CA4-D41F-4D53-9D1C-053A165D22C9_2002_1">30100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1E64F945-D248-4E97-86B1-80ADD2BB61F5_3001_2">62400000</us-gaap:LongTermLoansPayable>
  <us-gaap:DeferredCosts contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BBAEFD73-9927-4FDC-9173-F4E8088FC49E_2002_3">13500000</us-gaap:DeferredCosts>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_4002_0">60000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1469303_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_2005_4">36500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1469303_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_2001_4">44500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentUnamortizedPremium contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2002_5">660000</us-gaap:DebtInstrumentUnamortizedPremium>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2002_4">27690000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2002_7">27613000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2002_6">737000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1380739_1331210x1324874_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_3005_1">21300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1380739_1331210x1333737_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_3001_1">27600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3002_1">80000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3002_3">74582000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3002_2">5418000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1483091_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_4005_2">78400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1483091_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_4001_2">74600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_5003_600037">2508633000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_5004_700037">-20000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_5001_400037">85735000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_5001_500037">4287000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_5005_800037">-2863229000</us-gaap:StockholdersEquity>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_5_5">150600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_FD47304D-10CF-4062-9F3C-F9176EA85507_1_5">155600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C06DD231-49E5-4F7D-B6CC-CF004DF954CD_3001_0">189200000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1324247" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_2002_1">21590000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1324436" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_3002_6">586000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1325519" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_4002_3">68434000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1330541" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_5002_2">60584000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1334838" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_6002_0">3435000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1348884" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_7002_5">9519000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1349273" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_8002_4">4114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:RestructuringReserve contextRef="eol_PE126000--1610-K0019_STD_0_20151231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_3002_4">3028000</us-gaap:RestructuringReserve>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE126000--1610-K0019_STD_0_20160531_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_4001_4">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20160531_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_4001_3">44700000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-K0019_STD_0_20160531_0_1333769x1344495_1335482x1328677" unitRef="shares" decimals="0" id="id_9004857_39D8AFD6-447C-496B-BA49-431B2F36CAEB_3001_2">2427184</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-K0019_STD_0_20160531_0_1333769x1514964_1335482x1328677" unitRef="shares" decimals="0" id="id_9004857_39D8AFD6-447C-496B-BA49-431B2F36CAEB_4001_1">7281553</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_040746A4-F1C9-4477-82F2-04E8D16994B1_1002_2">13.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_38">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_679A1CE4-4429-404F-AE5C-9AC830D3D369_1001_5">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1001_7">16.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_41">140000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_43">95680831</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1004_3">3840587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1001_7">5399777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_40">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_42">95680831</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_37">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1001_8">3414586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1001_8">22.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1004_1">5530256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1001_6">16.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_36">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_35">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1004_2">737966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_46">-2737565000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PurchaseObligation contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C5999C71-BA10-44E7-AAB4-97778F71E511_2001_0">116200000</us-gaap:PurchaseObligation>
  <us-gaap:PreferredStockValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_34" />
  <us-gaap:Liabilities contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_31">290656000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_48">107063000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_0">3814000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_29">7381000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_19">3419000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_45">-24000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_16">3263000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_47">-183593000</us-gaap:StockholdersEquity>
  <us-gaap:RestructuringReserve contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_5003_7">1376000</us-gaap:RestructuringReserve>
  <us-gaap:PurchaseObligationDueInSecondYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_2">8900000</us-gaap:PurchaseObligationDueInSecondYear>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_24">49521000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_5">619000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_39">4784000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_44">2549212000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_1001_8">99575000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_3">875000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_1">1376000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:PurchaseObligationDueInThirdYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_3">11600000</us-gaap:PurchaseObligationDueInThirdYear>
  <us-gaap:PurchaseObligationDueInFifthYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_5">15500000</us-gaap:PurchaseObligationDueInFifthYear>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_2001_6">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_32" />
  <us-gaap:PurchaseObligationDueInFourthYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_4">15500000</us-gaap:PurchaseObligationDueInFourthYear>
  <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_1">2700000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
  <us-gaap:OtherLongTermDebtCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_18">71339000</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_6">355000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_2001_8">35000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_2001_7">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_23">92051000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_14">914498000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_26">27635000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_17">7937000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_10">77488000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-8" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_2001_1">1300000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_12">45310000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_C85270AE-9901-45E3-B5C0-97188A0F33B6_1_1">2120000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_11">28927000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_E5A7659C-8FB4-482D-8BB2-C1182A4B225A_1001_8">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_6">16730000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_2">22895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_1">712124000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:InventoryNet contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_5">2331000</us-gaap:InventoryNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_E5A7659C-8FB4-482D-8BB2-C1182A4B225A_1001_7">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_3">302000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_4">30557000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-8" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_2001_0">1900000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_2">77998000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_9">17331000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_7FA31BFC-739F-4AD8-BAAB-69BFD325C1C8_1_0">20500000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_1001_7">128502000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:Assets contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_13">107063000</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_13">914498000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_15">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_11">7380000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_C85270AE-9901-45E3-B5C0-97188A0F33B6_1_0">0</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_C85270AE-9901-45E3-B5C0-97188A0F33B6_1_2">211000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_12">648000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherDeferredCostsNet contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_7">309000</us-gaap:OtherDeferredCostsNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_9">4364000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_E5A7659C-8FB4-482D-8BB2-C1182A4B225A_1001_6">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <mnkd:WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_DE8FACDC-A091-4F4F-949E-D3D9CA30FA45_1001_1">8.60</mnkd:WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest>
  <mnkd:SalesAndMarketingRelatedExpensesAccrued contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_2">144000</mnkd:SalesAndMarketingRelatedExpensesAccrued>
  <mnkd:DeferredTaxAssetsCapitalizedResearchExpenses contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_3">5117000</mnkd:DeferredTaxAssetsCapitalizedResearchExpenses>
  <mnkd:ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_DE8FACDC-A091-4F4F-949E-D3D9CA30FA45_1001_0">629424</mnkd:ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest>
  <mnkd:DeferredTaxAssetsLossOnPurchaseCommitment contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_8">36775000</mnkd:DeferredTaxAssetsLossOnPurchaseCommitment>
  <mnkd:PurchaseObligationNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_28">95942000</mnkd:PurchaseObligationNoncurrent>
  <mnkd:AccruedInterestOfRelatedPartyDebt contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_35F87CA4-D41F-4D53-9D1C-053A165D22C9_1001_0">9300000</mnkd:AccruedInterestOfRelatedPartyDebt>
  <mnkd:DeferredTaxAssetsMilestoneRights contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_6">3242000</mnkd:DeferredTaxAssetsMilestoneRights>
  <mnkd:EstimatedAmountsCreditExchangeReceivable contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_6FFF3FEA-F9E1-4C42-8A47-7A3761B7735A_1001_1">246000</mnkd:EstimatedAmountsCreditExchangeReceivable>
  <mnkd:PurchaseObligationCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_22">5093000</mnkd:PurchaseObligationCurrent>
  <mnkd:DeferredTaxAssetsCapitalizedCosts contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_10">8781000</mnkd:DeferredTaxAssetsCapitalizedCosts>
  <mnkd:CashDiscountPercent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="pure" decimals="2" id="id_9004857_57612721-04C9-4A27-BA23-A4D683F78971_1001_0">0.02</mnkd:CashDiscountPercent>
  <mnkd:CustomerDiscountsAndAllowances contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AB33D30C-6A32-45B8-9279-F34392E15A4C_1_4">754000</mnkd:CustomerDiscountsAndAllowances>
  <mnkd:DeferredCollaborativeCreditCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_20">1000000</mnkd:DeferredCollaborativeCreditCurrent>
  <mnkd:PurchaseObligationDueInSixthYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_6">19400000</mnkd:PurchaseObligationDueInSixthYear>
  <mnkd:AccruedInterestNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_25">9281000</mnkd:AccruedInterestNoncurrent>
  <mnkd:MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_536F12E9-AD7A-4192-9FA8-2335E53E1959_1_30">8845000</mnkd:MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent>
  <mnkd:DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_8AFD3CBC-7B5E-4912-94BD-E8CC6A692B71_1001_7">440000</mnkd:DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment>
  <mnkd:PurchaseObligationDueInSeventhYear contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_25647126-6546-4E82-98DB-EDE0AF0BC2DF_1_7">19400000</mnkd:PurchaseObligationDueInSeventhYear>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324199x1331109" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BFDB18A7-17B7-4053-93DB-2EE8592F6E89_1001_0">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324199x1335583" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BFDB18A7-17B7-4053-93DB-2EE8592F6E89_2001_1">4800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324319x1333758" unitRef="iso4217_USD" decimals="0" id="id_9004857_23E7D4E0-F255-4BC3-80A1-556922E61939_1001_0">350000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792" unitRef="pure" decimals="INF" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_3001_3">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_3001_2">20000000</us-gaap:DebtInstrumentFaceAmount>
  <mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874" unitRef="iso4217_USD" decimals="INF" id="id_9004857_93C26A66-C001-4746-96CA-16040469C3C7_2001_1">25000000</mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity>
  <mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874_1447597x1353440" unitRef="iso4217_USD" decimals="INF" id="id_9004857_750782B8-0DE1-4E3D-BA73-C3C2D38A209F_1001_0">25000000</mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_9004857_6DA04552-CB28-4FFB-A49B-EAB033818B5C_2001_1">18400000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1324896x1324925_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_1004_3">18400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_6DA04552-CB28-4FFB-A49B-EAB033818B5C_3001_2">8900000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_67543772-0CBA-4621-919C-1ACB12368B68_1001_0">8900000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352_1328615x1466792_1335427x1366952" unitRef="iso4217_USD" decimals="-5" id="id_9004857_B1E469F1-417D-4DED-89F3-5AA756D864F9_1001_0">28700000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_1005_3">18400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_1001_3">8900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324738x1334129" unitRef="iso4217_USD" decimals="-5" id="id_9004857_15E10D02-79DB-4518-A56F-73625EE88E68_5001_9">16700000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1328615x1380739_1331210x1324874_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_2004_1">22900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1328615x1483091_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_3004_2">74500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_4_5">123200000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1331210x1324874_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_4004_4">7400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325224x1325288" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_3001_5">53000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325224x1335913" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_4001_6">38500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1365910" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_4004_0">445782</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1445632" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1001_3">97574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1445632" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1001_1">2052345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1445632" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1001_2">14203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1468282" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1002_3">3743013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1468282" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1002_1">3399245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1468282" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1002_2">723763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1503078" unitRef="shares" decimals="INF" id="id_9004857_A260E9E1-AD31-4998-AA89-0B4B1C5F056B_1003_1">78666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563" unitRef="iso4217_USD" decimals="-5" id="id_9004857_35F87CA4-D41F-4D53-9D1C-053A165D22C9_2001_1">30100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563_1326002x1335383" unitRef="pure" decimals="INF" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_6001_2">0.0584</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_9004857_ABF5ABE3-7D16-4010-9C0D-A38C0E5FF6B6_1001_0">30100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LineOfCredit contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_6001_0">49500000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="INF" id="id_9004857_8110098F-6A8C-433C-8558-BF4EFE72EB65_3001_0">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BBAEFD73-9927-4FDC-9173-F4E8088FC49E_2001_0">150000000</us-gaap:DeferredRevenue>
  <mnkd:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_BBAEFD73-9927-4FDC-9173-F4E8088FC49E_2001_1">25000000</mnkd:PotentialMilestonePaymentsToBeReceived>
  <us-gaap:DeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1543513" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C0FB47FF-118A-4B1F-A0A7-92A1E21F773A_2001_1">1000000</us-gaap:DeferredRevenue>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792" unitRef="pure" decimals="INF" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_4001_1">0.0975</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_4001_0">55000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792_1447597x1353440" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4055EE1C-F715-4A75-A1D0-5D4ABC60FC8C_1001_1">100000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792_1447597x1353440" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4055EE1C-F715-4A75-A1D0-5D4ABC60FC8C_1001_0">3700000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentUnamortizedPremium contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2001_5">426000</us-gaap:DebtInstrumentUnamortizedPremium>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2001_4">27690000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2001_7">27635000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1373094" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_2001_6">481000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1380739_1331210x1324874_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_2005_1">22900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1380739_1331210x1333737_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_2001_1">27600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3001_1">75000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3001_3">71339000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1466792" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6DDC0935-02FC-42D7-AFC2-1C647E0AE9F2_3001_2">3661000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1483091_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_3005_2">74500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1483091_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_3001_2">71300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_8003_600049">2549212000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_8004_700049">-24000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_8001_400049">95681000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_8001_500049">4784000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_8005_800049">-2737565000</us-gaap:StockholdersEquity>
  <us-gaap:PurchaseObligation contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1330148x1326956" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0D896511-D5E1-4A17-B44F-71296BE076A9_1001_0">900000</us-gaap:PurchaseObligation>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1324874" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_5_5">123200000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1324874_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_4005_4">7400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1333737" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_1_5">115200000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1333737_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0786F290-CE48-45EB-8D33-A678ECE1FD00_4001_4">7400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D1A68127-5601-42B5-839E-D7ABC2924DD7_5001_9">7400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1333769x1514964" unitRef="iso4217_USD" decimals="-5" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1002_0">7400000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1334994x1472762" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9DF13AAF-CB94-42ED-9DF7-2F6B94759BE1_2001_1">1600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1324247" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_2001_1">17389000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1324436" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_3001_6">202000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1325519" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_4001_3">62992000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1330541" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_5001_2">34957000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1334838" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_6001_0">875000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1348884" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_7001_5">8531000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1349273" unitRef="iso4217_USD" decimals="-3" id="id_9004857_AE360E5B-3350-4974-9710-C0C46D305096_8001_4">3556000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:RestructuringReserve contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_5002_7">1167000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335586x1530804" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_5001_7">209000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1335586x1530804" unitRef="iso4217_USD" decimals="-5" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_5002_3">1500000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1330024" unitRef="iso4217_USD" decimals="INF" id="id_9004857_552B0454-4F20-4EAB-9501-7573C1D8668A_2001_3">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1333173" unitRef="iso4217_USD" decimals="-5" id="id_9004857_552B0454-4F20-4EAB-9501-7573C1D8668A_3001_0">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1335846" unitRef="iso4217_USD" decimals="INF" id="id_9004857_552B0454-4F20-4EAB-9501-7573C1D8668A_4001_2">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1448981" unitRef="iso4217_USD" decimals="INF" id="id_9004857_552B0454-4F20-4EAB-9501-7573C1D8668A_5001_4">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE126000--1610-K0019_STD_0_20161231_0_1428469x1409449" unitRef="shares" decimals="INF" id="id_9004857_A3D2A42E-A974-4DB6-BCEA-57FA7B30CC3A_1001_0">100697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20170310_0" unitRef="shares" decimals="INF" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_2_500008">95776246</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE126000--1610-K0019_STD_0_20040331_0_1325804x1365910" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_4001_0">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20130523_0_1325804x1468282" unitRef="shares" decimals="INF" id="id_9004857_9C0102AB-FE70-4941-985B-BC6FE221A245_2001_1">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <mnkd:AreaOfOfficeSpaceLeased contextRef="eol_PE126000--1610-K0019_STD_0_20150531_0_1325994x1454078_1467970x1441734" unitRef="sqft" decimals="0" id="id_9004857_B337D5A7-9CCA-49D2-82EE-25A704045570_2001_0">12500</mnkd:AreaOfOfficeSpaceLeased>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20160512_0_1333769x1344495" unitRef="iso4217_USD" decimals="-5" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_2001_1">5000000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-K0019_STD_0_20160512_0_1333769x1514964" unitRef="iso4217_USD" decimals="-5" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1001_0">12800000</us-gaap:LiabilitiesFairValueDisclosure>
  <mnkd:OperatingLossCarryforwardsSubjectToLimitation contextRef="eol_PE126000--1610-K0019_STD_0_20040831_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_2002_3">216000000</mnkd:OperatingLossCarryforwardsSubjectToLimitation>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE126000--1610-K0019_STD_0_20100818_0_1328615x1373094" unitRef="iso4217_USD" decimals="-5" id="id_9004857_14849047-24F4-4491-8A62-32C134AF05EA_1001_0">800000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:OtherShortTermBorrowings contextRef="eol_PE126000--1610-K0019_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_1005_1">3200000</us-gaap:OtherShortTermBorrowings>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-K0019_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_1005_2">13100000</us-gaap:OtherLongTermDebtNoncurrent>
  <mnkd:ContingentLiability contextRef="eol_PE126000--1610-K0019_STD_0_20130701_0_1324497x1494756_1328480x1426352_1335482x1328677" unitRef="iso4217_USD" decimals="INF" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_4005_0">90000000</mnkd:ContingentLiability>
  <mnkd:AccruedExpensesIntellectualProperty contextRef="eol_PE126000--1610-K0019_STD_0_20140718_0_1331352x1331573" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D329FB91-E19E-4F0B-891A-86D733A9F607_2001_2">1400000</mnkd:AccruedExpensesIntellectualProperty>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1373094" unitRef="pure" decimals="INF" id="id_9004857_98ECAF41-07DC-4286-971D-2AA39554D79F_1001_1">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1373094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_B4C317D0-7943-4F19-8800-2F642C9D55CE_2001_2">34.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentUnamortizedPremium contextRef="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1373094" unitRef="iso4217_USD" decimals="-5" id="id_9004857_98ECAF41-07DC-4286-971D-2AA39554D79F_1001_2">700000</us-gaap:DebtInstrumentUnamortizedPremium>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1373094" unitRef="iso4217_USD" decimals="-5" id="id_9004857_98ECAF41-07DC-4286-971D-2AA39554D79F_1001_0">27700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1451439" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_0B6BE506-14F3-42ED-A713-C98A3DA372EC_2001_2">110.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-K0019_STD_0_20150814_0_1328615x1451439" unitRef="pure" decimals="INF" id="id_9004857_5B0CAAA1-2EB8-4093-88E0-EFE90FE8FDA1_2001_1">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20150814_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_5B0CAAA1-2EB8-4093-88E0-EFE90FE8FDA1_2001_0">32100000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-K0019_STD_0_20140923_0_1327036x1425803" unitRef="pure" decimals="INF" id="id_9004857_1A09BCA6-CE02-4FE2-A453-016E03D5CB95_1001_0">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE126000--1610-K0019_STD_0_20140923_0_1327036x1425803" unitRef="iso4217_USD" decimals="INF" id="id_9004857_29B7F52E-ED76-4238-B6C4-773515FE9658_1001_0">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <mnkd:SharesReturnedUnderShareLendingAgreement contextRef="eol_PE126000--1610-K0019_STD_0_20151023_0" unitRef="shares" decimals="0" id="id_9004857_C9AE09B8-0049-40FA-97F1-2814C099288C_1002_3">1800000</mnkd:SharesReturnedUnderShareLendingAgreement>
  <us-gaap:SharePrice contextRef="eol_PE126000--1610-K0019_STD_0_20151101_0_1334238x1326373" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_2002_4">13.05</us-gaap:SharePrice>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20151116_0" unitRef="shares" decimals="INF" id="id_9004857_040746A4-F1C9-4477-82F2-04E8D16994B1_1001_1">31860</us-gaap:ClassOfWarrantOrRightOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE126000--1610-K0019_STD_0_20160630_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_3_600009">372097776</dei:EntityPublicFloat>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_9004857_09DA92DB-F5B2-452D-8E0E-AC55DA943F26_1_2">700000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20161109_0_1334238x1326373" unitRef="shares" decimals="INF" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_2001_0">10000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1006_900001">-30713000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3001_57">70790000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherLongTermDebt contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E56DEC80-D81E-472A-AD56-5A1CF13E3508_2001_2">18400000</us-gaap:OtherLongTermDebt>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1003_600001">2261996000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1004_700001">-4000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1001_400001">73878000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1001_500001">3697000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_1005_800001">-2296402000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3006_900013">-73770000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2003_57">120841000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <mnkd:EstimatedAmountsCreditExchangeReceivable contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_6FFF3FEA-F9E1-4C42-8A47-7A3761B7735A_1003_1">816000</mnkd:EstimatedAmountsCreditExchangeReceivable>
  <mnkd:SharesReservedForEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0" unitRef="shares" decimals="0" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_3002_2">140000</mnkd:SharesReservedForEmployeeStockPurchasePlan>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C9AE09B8-0049-40FA-97F1-2814C099288C_2001_1">100000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3003_600013">2416967000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3004_700013">-14000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3001_400013">81212000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3001_500013">4061000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_3005_800013">-2494784000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-K0019_STD_0_20170301_0_1335955x1330134" unitRef="shares" decimals="INF" id="id_9004857_09DA92DB-F5B2-452D-8E0E-AC55DA943F26_3002_1">140000000</us-gaap:CommonStockSharesAuthorized>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="eol_PE126000--1610-K0019_STD_1_20120208_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_1_6">80600000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrants>
  <mnkd:UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription contextRef="eol_PE126000--1610-K0019_STD_1_20120208_0_1326002x1513368" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_1001_2">Each unit consisting of  one share of common stock and a warrant to purchase 0.1 of a share of common  stock</mnkd:UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription>
  <mnkd:WarrantsExercisableExpirationPeriod contextRef="eol_PE126000--1610-K0019_STD_1_20120208_0_1331314x1359335" id="id_9004857_C0D99995-98F5-4B87-8B7F-02E7B085359B_2001_9">P4Y</mnkd:WarrantsExercisableExpirationPeriod>
  <mnkd:TerminationDateOfLicenseAgreement contextRef="eol_PE126000--1610-K0019_STD_1_20160104_0_1327036x1425803" id="id_9004857_D33F73B5-0156-401D-A444-F04660622BC0_1002_2">2016-04-04</mnkd:TerminationDateOfLicenseAgreement>
  <mnkd:ClosingBidPriceOfCommonStockRequiredPricePerShare contextRef="eol_PE126000--1610-K0019_STD_1_20160914_0_1325983x1532499" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_B0A1193C-C97D-44EE-909D-B6DECE962E49_1001_0">1.00</mnkd:ClosingBidPriceOfCommonStockRequiredPricePerShare>
  <mnkd:ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare contextRef="eol_PE126000--1610-K0019_STD_1_20160914_0_1325983x1532499" id="id_9004857_B0A1193C-C97D-44EE-909D-B6DECE962E49_1001_1">P30Y</mnkd:ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare>
  <mnkd:ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare contextRef="eol_PE126000--1610-K0019_STD_1_20160914_0_1325983x1532499" id="id_9004857_B0A1193C-C97D-44EE-909D-B6DECE962E49_1001_2">P180Y</mnkd:ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare>
  <mnkd:ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare contextRef="eol_PE126000--1610-K0019_STD_1_20160914_0_1325983x1532499" id="id_9004857_B0A1193C-C97D-44EE-909D-B6DECE962E49_1001_3">2017-03-13</mnkd:ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare>
  <mnkd:ProceedsFromOptionExerciseAndLicenseFeesReceived contextRef="eol_PE126000--1610-K0019_STD_1_20161230_0_1327036x1543513" unitRef="iso4217_USD" decimals="-5" id="id_9004857_84016527-03E6-48CF-B13D-2F16BA87D7B6_1002_1">1000000</mnkd:ProceedsFromOptionExerciseAndLicenseFeesReceived>
  <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="eol_PE126000--1610-K0019_STD_1_20170106_0_1330098x1330589_1335427x1325371_1335955x1330134" unitRef="iso4217_USD" decimals="-5" id="id_9004857_05E8D621-907C-486C-8B73-C2B8C9F05BBD_1001_0">17300000</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE126000--1610-K0019_STD_1_20170106_0_1330098x1330589_1335427x1325371_1335955x1330134" unitRef="iso4217_USD" decimals="0" id="id_9004857_05E8D621-907C-486C-8B73-C2B8C9F05BBD_1001_4">-564000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <mnkd:NetProceedsFromSaleOfProperty contextRef="eol_PE126000--1610-K0019_STD_1_20170106_0_1330098x1330589_1335427x1325371_1335955x1330134" unitRef="iso4217_USD" decimals="-5" id="id_9004857_05E8D621-907C-486C-8B73-C2B8C9F05BBD_1001_2">16700000</mnkd:NetProceedsFromSaleOfProperty>
  <mnkd:PaymentsForCommissionsAndOtherFees contextRef="eol_PE126000--1610-K0019_STD_1_20170106_0_1330098x1330589_1335427x1325371_1335955x1330134" unitRef="iso4217_USD" decimals="0" id="id_9004857_05E8D621-907C-486C-8B73-C2B8C9F05BBD_1001_3">624000</mnkd:PaymentsForCommissionsAndOtherFees>
  <mnkd:MinimumClosingBidPriceOfCommonStock contextRef="eol_PE126000--1610-K0019_STD_1_20170316_0_1335955x1330134" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_414EAE58-6A7D-4E3C-8F34-C6CA5F16D856_1001_0">1.00</mnkd:MinimumClosingBidPriceOfCommonStock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1004_4">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueInputsProbabilityOfDefault contextRef="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1004_7">0.10</us-gaap:FairValueInputsProbabilityOfDefault>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1004_6">0.95</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964" unitRef="pure" decimals="4" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1004_3">0.0076</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1004_5">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="eol_PE126000--1610-K0019_STD_1_20140718_0_1331352x1331573" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D329FB91-E19E-4F0B-891A-86D733A9F607_1001_1">7900000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
  <mnkd:ConsiderationReceived contextRef="eol_PE126000--1610-K0019_STD_1_20140718_0_1331352x1331573" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D329FB91-E19E-4F0B-891A-86D733A9F607_1001_0">9300000</mnkd:ConsiderationReceived>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE126000--1610-K0019_STD_1_20140731_0_1447597x1406233" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_2221525A-A271-4F1E-BB5F-C244627E25EA_1001_0">120100000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_1_20150728_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2D599C2A-5575-4BBC-8E04-71B07D6A3110_1001_0">56900000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" id="id_9004857_CC1B9646-9FCC-464A-9109-895937A4A49D_1001_3">P30D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="INF" id="id_9004857_C42012A7-BBA7-4734-B0A9-3DC57349EE09_1001_0">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="0" id="id_9004857_B4C317D0-7943-4F19-8800-2F642C9D55CE_1001_0">29</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" unitRef="D" decimals="INF" id="id_9004857_CC1B9646-9FCC-464A-9109-895937A4A49D_1001_2">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="2" id="id_9004857_CC1B9646-9FCC-464A-9109-895937A4A49D_1001_1">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <mnkd:PrincipalAmountPerShare contextRef="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9004857_B4C317D0-7943-4F19-8800-2F642C9D55CE_1001_1">1000</mnkd:PrincipalAmountPerShare>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE126000--1610-K0019_STD_1_20150817_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C80C7CD9-68A7-4D50-A13A-C637B4527150_1001_1">1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:RepaymentsOfSeniorDebt contextRef="eol_PE126000--1610-K0019_STD_1_20150817_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C80C7CD9-68A7-4D50-A13A-C637B4527150_1001_0">32200000</us-gaap:RepaymentsOfSeniorDebt>
  <us-gaap:RepaymentsOfSeniorDebt contextRef="eol_PE126000--1610-K0019_STD_1_20150930_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_5B0CAAA1-2EB8-4093-88E0-EFE90FE8FDA1_1002_2">32100000</us-gaap:RepaymentsOfSeniorDebt>
  <mnkd:ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice contextRef="eol_PE126000--1610-K0019_STD_1_20151116_0" unitRef="pure" decimals="4" id="id_9004857_040746A4-F1C9-4477-82F2-04E8D16994B1_1_0">0.0115</mnkd:ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE126000--1610-K0019_STD_1_20161109_0_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4C57A0C1-208E-454A-A06B-7244936009D7_2001_3">500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="eol_PE126000--1610-K0019_STD_1_20161109_0_1328480x1543736" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4C57A0C1-208E-454A-A06B-7244936009D7_4001_0">72000000</us-gaap:DebtInstrumentDecreaseForgiveness>
  <mnkd:StockIssuedDuringPeriodSharesNewIssuesPercentage contextRef="eol_PE126000--1610-K0019_STD_1_20161109_0_1334238x1326373" unitRef="pure" decimals="2" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_1001_1">0.97</mnkd:StockIssuedDuringPeriodSharesNewIssuesPercentage>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-K0019_STD_1_20131231_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="pure" decimals="3" id="id_9004857_E56DEC80-D81E-472A-AD56-5A1CF13E3508_1001_0">0.145</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsEntityCreditRisk contextRef="eol_PE126000--1610-K0019_STD_1_20131231_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="pure" decimals="2" id="id_9004857_E56DEC80-D81E-472A-AD56-5A1CF13E3508_1001_1">0.05</us-gaap:FairValueInputsEntityCreditRisk>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="eol_PE126000--1610-K0019_STD_1_20160210_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1E64F945-D248-4E97-86B1-80ADD2BB61F5_2002_1">17900000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_1_20170217_0_1330098x1330589_1335427x1325371_1335955x1330134" unitRef="iso4217_USD" decimals="-5" id="id_9004857_05E8D621-907C-486C-8B73-C2B8C9F05BBD_1002_1">17300000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE126000--1610-K0019_STD_1_20170301_0_1335955x1330134" unitRef="pure" decimals="INF" id="id_9004857_974DBADB-B155-4932-839F-74FA2D71016A_1001_0">0.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE126000--1610-K0019_STD_13_20150810_0_1328615x1451439" unitRef="shares" decimals="INF" id="id_9004857_0B6BE506-14F3-42ED-A713-C98A3DA372EC_1001_0">380000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE126000--1610-K0019_STD_13_20150810_0_1328615x1451439" unitRef="iso4217_USD" decimals="-5" id="id_9004857_0B6BE506-14F3-42ED-A713-C98A3DA372EC_1001_1">8000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <mnkd:SaleOfCommonStockInUnderwrittenPublicOffering contextRef="eol_PE126000--1610-K0019_STD_29_20160531_0_1327036x1532316" unitRef="shares" decimals="0" id="id_9004857_39D8AFD6-447C-496B-BA49-431B2F36CAEB_1001_0">9708737</mnkd:SaleOfCommonStockInUnderwrittenPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="eol_PE126000--1610-K0019_STD_29_20160531_0_1327036x1543951" unitRef="iso4217_USD" decimals="-5" id="id_9004857_39D8AFD6-447C-496B-BA49-431B2F36CAEB_2001_4">50000000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <mnkd:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE126000--1610-K0019_STD_29_20160531_0_1333769x1344495" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_2001_7">P30M</mnkd:ClassOfWarrantOrRightExpirationPeriod>
  <mnkd:ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable contextRef="eol_PE126000--1610-K0019_STD_29_20160531_0_1333769x1344495" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_2001_6">2017-05</mnkd:ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable>
  <mnkd:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE126000--1610-K0019_STD_29_20160531_0_1333769x1514964" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_3001_5">P2Y</mnkd:ClassOfWarrantOrRightExpirationPeriod>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="eol_PE126000--1610-K0019_STD_30_20160930_0_1335586x1530804" unitRef="Employee" decimals="INF" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_4001_1">155</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="eol_PE126000--1610-K0019_STD_30_20160930_0_1335586x1530804" unitRef="pure" decimals="2" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_4001_0">0.18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_30_20160930_0_1335586x1530804" unitRef="iso4217_USD" decimals="-5" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_4001_2">1500000</us-gaap:RestructuringCharges>
  <mnkd:PercentageOfCommonStockSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_31_20040331_0" unitRef="pure" decimals="2" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_1_3">0.01</mnkd:PercentageOfCommonStockSharesOutstanding>
  <mnkd:EmployeeStockPurchasePlanAnnualIncreaseInReservedShares contextRef="eol_PE126000--1610-K0019_STD_31_20040331_0_1325804x1365910" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_1001_1">140000</mnkd:EmployeeStockPurchasePlanAnnualIncreaseInReservedShares>
  <mnkd:PercentageOfShareReservedForShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_31_20040331_0_1335482x1328677" unitRef="pure" decimals="2" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_2001_4">0.10</mnkd:PercentageOfShareReservedForShareBasedCompensation>
  <mnkd:NetOperatingLossCarryforwardAnnualLimitation contextRef="eol_PE126000--1610-K0019_STD_31_20040831_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_2_4">13000000</mnkd:NetOperatingLossCarryforwardAnnualLimitation>
  <mnkd:LoanAgreementWithRelatedParty contextRef="eol_PE126000--1610-K0019_STD_31_20071031_0_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_9004857_47E16A8B-21BA-4B71-A787-D8B1D3E3F07D_2001_0">350000000</mnkd:LoanAgreementWithRelatedParty>
  <mnkd:LoanAgreementWithRelatedParty contextRef="eol_PE126000--1610-K0019_STD_31_20131031_0_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_9004857_47E16A8B-21BA-4B71-A787-D8B1D3E3F07D_2002_0">370000000</mnkd:LoanAgreementWithRelatedParty>
  <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="eol_PE126000--1610-K0019_STD_31_20170131_0_1328480x1469303_1328867x1325939_1335955x1330134" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4C57A0C1-208E-454A-A06B-7244936009D7_3003_2">30600000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE126000--1610-K0019_STD_32_20151101_0_1334238x1326373" unitRef="shares" decimals="INF" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_1002_2">2770487</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_32_20151101_0_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_1002_5">1432000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_32_20151101_0_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_ACC0F422-C5D6-448C-B03D-9A9F0A1BD377_1002_3">34710000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_2_4">5946249</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_27">-4.54</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="INF" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_2_0">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_2_3">-0.340</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_33">-57232000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2_5">0.7184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_29">81233000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_28">81233000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="2" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2_4">0.6976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2_0">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_2_1">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_2_0">12.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_26">-4.54</us-gaap:EarningsPerShareBasic>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_2_2">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2_1">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_3_5">64245</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="pure" decimals="2" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_2_4">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_445A3C2E-3387-4752-9F66-847E61BAD243_2_0">80100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_35">10285000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900035">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_21">-50413000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_20">-1049000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_6">-2697000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900020">-1856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900023">7926000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900018">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:RepaymentsOfSeniorDebt contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_47">64287000</us-gaap:RepaymentsOfSeniorDebt>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_53">548000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_14">-344655000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_25">-368445000</us-gaap:NetIncomeLoss>
  <us-gaap:LoansAssumed1 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_65">59337000</us-gaap:LoansAssumed1>
  <us-gaap:InterestPaid contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_60">13355000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_25">-150000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_20">26434000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_23">13539000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_252ABACA-BD0D-4911-9C45-1497B935CC9D_2_3">-368451000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900019">8725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_42">1858000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_48">831000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PartnersCapitalAccountContributions contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900021">40000</us-gaap:PartnersCapitalAccountContributions>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_17">18000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900014">3258000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900031">27843000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssued1 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_62">8253000</us-gaap:StockIssued1>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_21">1366000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_22">-23790000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_24">-13481000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_23">-368445000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_12">-140582000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_11">-2697000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900033">202000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4C2D9F09-5685-431C-82D7-C15262A2BCB0_2_0">8725000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_6">109512000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_10">-80118000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_7">-29394000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_13DD444A-0683-42A6-874A-83CEB2AFB72C_2_0">11000000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_10">140412000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_24">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_29">950000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_27">-12467000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_26">8413000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_37">-10203000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_52">28392000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProductionRelatedImpairmentsOrCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_14">36104000</us-gaap:ProductionRelatedImpairmentsOrCharges>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_36">82000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_19">2894000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_4">8725000</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_1">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_3">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_4">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_9">80118000</us-gaap:DeferredOtherTaxExpenseBenefit>
  <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_833AB922-3738-40F5-9B3E-C304FA4BB61D_2_0">593000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_3">13276000</us-gaap:DepreciationAndAmortization>
  <us-gaap:InventoryWriteDown contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_A521568E-A71D-44D1-8478-2DADD4DCF878_2_0">39300000</us-gaap:InventoryWriteDown>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_8">1652000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_54">40000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_8">29674000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_2_0">1587000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_9">40960000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_13">344655000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_2_1">39373000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_32">33000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_18">21231000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_55">5668000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_C42065A0-2FE9-49DC-9456-D27313BB54E6_2_0">426000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_46">10123000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_2_1">6200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_2_0">5200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_56">-61767000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_7">64745000</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_8">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_2_0">3300000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:ImpairmentChargeOnReclassifiedAssets contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1FC0617E-85C3-40DF-9A0C-6E3E2E57B23E_1_0">140400000</us-gaap:ImpairmentChargeOnReclassifiedAssets>
  <us-gaap:InterestCostsCapitalized contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_10AABD50-DA36-40EB-BADA-557DC7F26D42_2_0">100000</us-gaap:InterestCostsCapitalized>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_4003_2">6040000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_4003_3">3012000</us-gaap:RestructuringReserveSettledWithoutCash2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_2_1">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <mnkd:IncomeTaxExpenseBenefitNet contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_2_11">0</mnkd:IncomeTaxExpenseBenefitNet>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900034">109000</mnkd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity>
  <mnkd:IncreaseDecreaseInDeferredCollaborativeRevenue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_30">17067000</mnkd:IncreaseDecreaseInDeferredCollaborativeRevenue>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900026">169000</mnkd:AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion>
  <mnkd:GainLossOnPurchaseCommitments contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_2_12">-66167000</mnkd:GainLossOnPurchaseCommitments>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900017">10123000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <mnkd:StockIssuedDuringPeriodValueShareLendingAgreement contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6006_900025">160000</mnkd:StockIssuedDuringPeriodValueShareLendingAgreement>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_43">4146000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:PaymentsForUseOfAircrafts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_EB01B6C6-F4BF-470D-8D9E-630B6B86889A_2_0">18000</mnkd:PaymentsForUseOfAircrafts>
  <mnkd:MilestonePayments contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_51">4219000</mnkd:MilestonePayments>
  <mnkd:InterestOnNotePayableToPrincipalStockholder contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_2_9">2894000</mnkd:InterestOnNotePayableToPrincipalStockholder>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1324529x1470870" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D6521FC0-07C0-4E6C-A07B-438B134F928E_1001_0">600000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1324529x1487319" unitRef="iso4217_USD" decimals="0" id="id_9004857_0FDE88D0-66A9-4CA1-BC56-C8FE84A0C2EE_1002_0">93000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <mnkd:PaymentsForFinancialAssets contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1324738x1334129" unitRef="iso4217_USD" decimals="-6" id="id_9004857_15E10D02-79DB-4518-A56F-73625EE88E68_4001_4">0</mnkd:PaymentsForFinancialAssets>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1324896x1324925" unitRef="iso4217_USD" decimals="-3" id="id_9004857_C06DD231-49E5-4F7D-B6CC-CF004DF954CD_1001_2">-140412000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <mnkd:LossSharingAgreementAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1327036x1425803_1327271x1443229_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1E64F945-D248-4E97-86B1-80ADD2BB61F5_1001_0">57700000</mnkd:LossSharingAgreementAmount>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1E64F945-D248-4E97-86B1-80ADD2BB61F5_2001_1">44500000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1E64F945-D248-4E97-86B1-80ADD2BB61F5_2001_3">1700000</us-gaap:PaidInKindInterest>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1002_1">1553000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1002_0">35000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1328615x1373094" unitRef="iso4217_USD" decimals="0" id="id_9004857_0FDE88D0-66A9-4CA1-BC56-C8FE84A0C2EE_2002_1">86000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600015">-7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600020">-1856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600023">7907000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600018">884000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600019">8725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PartnersCapitalAccountContributions contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600021">40000</us-gaap:PartnersCapitalAccountContributions>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600014">3241000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600031">27754000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600033">202000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600034">109000</mnkd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity>
  <mnkd:CommonStockLoanedUnderShareLendingAgreementValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600030">90000</mnkd:CommonStockLoanedUnderShareLendingAgreementValue>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600026">169000</mnkd:AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600017">10081000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <mnkd:StockIssuedDuringPeriodValueShareLendingAgreement contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6003_600025">160000</mnkd:StockIssuedDuringPeriodValueShareLendingAgreement>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_7003_600028">34571000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6004_700035">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400022">375000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400015">144000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400018">54000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400014">340000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400032">1788000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500015">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500023">19000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500018">3000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500014">17000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500031">89000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <mnkd:CommonStockLoanedUnderShareLendingAgreementShares contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400029">1800000</mnkd:CommonStockLoanedUnderShareLendingAgreementShares>
  <mnkd:StockIssuedDuringPeriodSharesWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400016">843000</mnkd:StockIssuedDuringPeriodSharesWarrantExercises>
  <mnkd:CommonStockLoanedUnderShareLendingAgreementValue contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500030">-90000</mnkd:CommonStockLoanedUnderShareLendingAgreementValue>
  <mnkd:StockIssuedDuringPeriodSharesShareLendingAgreement contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_400024">8000</mnkd:StockIssuedDuringPeriodSharesShareLendingAgreement>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6001_500017">42000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806_1334238x1326373" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_7001_400027">2771000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_7001_500028">139000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_6005_800036">-368445000</us-gaap:NetIncomeLoss>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1327949_1335586x1331107" unitRef="iso4217_USD" decimals="-5" id="id_9004857_646FA0F0-D952-42EB-AAEA-24F0466094BA_1001_0">1600000</us-gaap:ShareBasedCompensation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1352081" unitRef="iso4217_USD" decimals="-3" id="id_9004857_592A9BA7-142C-42E0-AAB4-F39415BDBF22_1002_0">8407000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1409449" unitRef="iso4217_USD" decimals="-3" id="id_9004857_592A9BA7-142C-42E0-AAB4-F39415BDBF22_2002_1">318000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1331314x1359335" unitRef="iso4217_USD" decimals="-6" id="id_9004857_D1A68127-5601-42B5-839E-D7ABC2924DD7_4001_4">0</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1324465" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_1002_1">814561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1331109" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_2002_0">3955845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1332392" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_3002_3">360924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1336129" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_4002_2">814919</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1002_45">1432000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_7006_900028">34710000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334238x1326373" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1002_44">36142000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1326228" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_1002_2">5696000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1326228_1335586x1350207" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1BB09B6E-4A49-444E-807B-133A66915A79_1002_5">3300000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1327554_1335586x1350207" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1BB09B6E-4A49-444E-807B-133A66915A79_2002_3">1400000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_3002_1">3029000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1332399_1335586x1350207" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1BB09B6E-4A49-444E-807B-133A66915A79_3002_4">1300000</us-gaap:RestructuringCharges>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335427x1366952" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DA9ED2F9-80C2-4993-98B4-5FF26E0C3BEC_1001_0">138600000</us-gaap:AssetImpairmentCharges>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335482x1328677" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1002_3">P5Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335482x1331874" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2002_2">P5Y9M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335586x1350207" unitRef="Employee" decimals="INF" id="id_9004857_1BB09B6E-4A49-444E-807B-133A66915A79_4002_1">198</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335586x1350207" unitRef="pure" decimals="2" id="id_9004857_1BB09B6E-4A49-444E-807B-133A66915A79_4002_0">0.26</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_4002_2">6040000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="eol_PE126000--1610-K0019_STD_365_20151231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_4002_3">3012000</us-gaap:RestructuringReserveSettledWithoutCash2>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_3_4">10292667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_27">-2.57</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_3_0">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_3_3">-0.318</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_33">4086000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_3_5">0.8485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_29">77045000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_28">77045000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_3_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_3_4">0.7398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_3_0">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_3_1">P2Y11M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_3_0">23.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_26">-2.57</us-gaap:EarningsPerShareBasic>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_3_2">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_3_1">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_2_5">61015</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_3_4">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_445A3C2E-3387-4752-9F66-847E61BAD243_3_0">65500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900003">-26908000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_35">24097000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900011">-10000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_21">50436000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_6">10000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_63">93500000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_64">1768000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900006">1363000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_14">-179627000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_25">-198382000</us-gaap:NetIncomeLoss>
  <us-gaap:LoansAssumed1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_65">3034000</us-gaap:LoansAssumed1>
  <us-gaap:InterestPaid contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_60">11218000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_25">615000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_20">9670000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_252ABACA-BD0D-4911-9C45-1497B935CC9D_3_3">-198392000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900010">22962000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900007">25660000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_42">26908000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_17">9000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900002">10978000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_21">1679000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_22">-18755000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_24">14734000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_23">-198382000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_12">-97000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4C2D9F09-5685-431C-82D7-C15262A2BCB0_3_0">48622000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_6">57873000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_10">-65504000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_7">7631000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_13DD444A-0683-42A6-874A-83CEB2AFB72C_3_0">9800000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_ACDB65E1-1950-4750-98FD-92142114D87D_3_0">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_24">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_29">200436000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_27">2276000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_26">3622000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_37">-24097000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_19">2894000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_4">48622000</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_1">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_3">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_4">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_9">65504000</us-gaap:DeferredOtherTaxExpenseBenefit>
  <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_833AB922-3738-40F5-9B3E-C304FA4BB61D_3_0">623000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_3">18575000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_8">100244000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_3_0">3556000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_9">79383000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_13">179627000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_3_1">75827000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_32">21000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_3_18">17549000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_55">70062000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_C42065A0-2FE9-49DC-9456-D27313BB54E6_3_0">737000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_46">27779000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_3_1">14900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_3_0">62700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_56">50051000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_8">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_3_0">11000000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:InterestCostsCapitalized contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_10AABD50-DA36-40EB-BADA-557DC7F26D42_3_0">800000</us-gaap:InterestCostsCapitalized>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_49">40000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_50">20000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_3_1">36400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <mnkd:IncomeTaxExpenseBenefitNet contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_3_11">0</mnkd:IncomeTaxExpenseBenefitNet>
  <mnkd:WriteOffOfCommitmentAsset contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_15">1753000</mnkd:WriteOffOfCommitmentAsset>
  <mnkd:WriteOffOfDerivativeLiability contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_16">363000</mnkd:WriteOffOfDerivativeLiability>
  <mnkd:CommonStockLoanedUnderShareLendingAgreementShares contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_9004857_C9AE09B8-0049-40FA-97F1-2814C099288C_1_0">1800000</mnkd:CommonStockLoanedUnderShareLendingAgreementShares>
  <mnkd:StockIssuedDuringPeriodValueForDebtExchange contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900009">93501000</mnkd:StockIssuedDuringPeriodValueForDebtExchange>
  <mnkd:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_3_1">0.009</mnkd:EffectiveIncomeTaxRateReconciliationPermanentItems>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4006_900005">27779000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_43">12341000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:PaymentsForUseOfAircrafts contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_EB01B6C6-F4BF-470D-8D9E-630B6B86889A_3_0">79000</mnkd:PaymentsForUseOfAircrafts>
  <mnkd:MilestonePayments contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_51">3150000</mnkd:MilestonePayments>
  <mnkd:InterestOnNotePayableToPrincipalStockholder contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_3_9">2894000</mnkd:InterestOnNotePayableToPrincipalStockholder>
  <mnkd:NominalLendingFee contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_C9AE09B8-0049-40FA-97F1-2814C099288C_1_2">0.05</mnkd:NominalLendingFee>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1455824_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_1001_3">40000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1455824_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_1001_8">2200000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1477399_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_2001_1">20000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1477399_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_2001_6">1200000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1488748_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_3001_2">33500000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1488748_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_3001_7">3000000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1494756_1328480x1469303_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_2003_5">1900000</us-gaap:InterestExpenseDebt>
  <mnkd:PaymentForContingentLiabilities contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1494756_1328480x1469303_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_2003_6">5000000</mnkd:PaymentForContingentLiabilities>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1324529x1470870" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D6521FC0-07C0-4E6C-A07B-438B134F928E_1002_0">900000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <mnkd:OfficeLeaseExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1325994x1454078_1467970x1441734" unitRef="iso4217_USD" decimals="INF" id="id_9004857_B337D5A7-9CCA-49D2-82EE-25A704045570_1004_2">0</mnkd:OfficeLeaseExpense>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352" unitRef="shares" decimals="INF" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_4001_4">3464616</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_4001_0">93500000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E981E696-FBB7-4625-BF69-DACE3E361D7E_4001_5">6400000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1003_1">7550000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1003_0">326000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600003">-26946000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600006">1361000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600010">22962000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600007">25660000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600002">10943000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <mnkd:StockIssuedDuringPeriodValueForDebtExchange contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600009">93327000</mnkd:StockIssuedDuringPeriodValueForDebtExchange>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4003_600005">27664000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4004_700011">-10000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_400003">799000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_400006">65000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_400002">650000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_500003">38000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_500006">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_500002">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <mnkd:StockIssuedDuringPeriodSharesWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_400004">2315000</mnkd:StockIssuedDuringPeriodSharesWarrantExercises>
  <mnkd:StockIssuedDuringPeriodSharesForDebtExchange contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_400008">3505000</mnkd:StockIssuedDuringPeriodSharesForDebtExchange>
  <mnkd:StockIssuedDuringPeriodValueForDebtExchange contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_500009">174000</mnkd:StockIssuedDuringPeriodValueForDebtExchange>
  <mnkd:StockIssuedDuringPeriodValueWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4001_500005">115000</mnkd:StockIssuedDuringPeriodValueWarrantExercises>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_4005_800012">-198382000</us-gaap:NetIncomeLoss>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1330194x1352081" unitRef="iso4217_USD" decimals="-3" id="id_9004857_592A9BA7-142C-42E0-AAB4-F39415BDBF22_1003_0">48622000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1331352x1331573" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D329FB91-E19E-4F0B-891A-86D733A9F607_1002_3">1400000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1324465" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_1003_1">3464616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1331109" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_2003_0">4308332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1332392" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_3003_3">522144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1336129" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_4003_2">1997575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1334666x1326228" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_1003_2">26265000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_3003_1">22357000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1335482x1328677" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1003_3">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_365_20141231_0_1335482x1331874" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2003_2">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <mnkd:OfficeLeaseExpense contextRef="eol_PE126000--1610-K0019_STD_365_20150131_0_1325994x1454078_1467970x1441734" unitRef="iso4217_USD" decimals="0" id="id_9004857_B337D5A7-9CCA-49D2-82EE-25A704045570_1003_2">175000</mnkd:OfficeLeaseExpense>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_C64E4477-6E45-4920-98D8-A2BA749C35CD_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities are comprised of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Salary and related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,634&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restructuring&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sales and marketing services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;875&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;931&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Discounts and allowances for commercial product sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;483&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,937&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,929&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_1_4">16788281</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_1B2BDA2D-B212-4936-99B3-FFE86CC90E7A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt; &amp;#x2014; The Company considers all
 highly liquid investments with original or remaining maturities of
 90 days or less at the time of purchase, that are readily
 convertible into cash to be cash equivalents. As of
 December&amp;#xA0;31, 2016 and 2015, cash equivalents were comprised of
 money market accounts with maturities less than 90 days from the
 date of purchase.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_10CFCA96-9BBD-4B43-B65B-924986A808B7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;8. Collaboration Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Receptor Collaboration and License Agreement&lt;/i&gt;&amp;#xA0;&amp;#x2014; On January&amp;#xA0;20,
 2016, the Company entered into a Collaboration and License
 Agreement (the &amp;#x201C;CLA&amp;#x201D;) with Receptor Life Sciences, Inc.
 (&amp;#x201C;Receptor&amp;#x201D;) pursuant to which the Company performed
 initial formulation studies on compounds identified by Receptor.
 Following successful completion of the studies, Receptor obtained
 the option to acquire an exclusive license to develop, manufacture
 and commercialize certain products that use MannKind&amp;#x2019;s
 technology to deliver the compounds via oral inhalation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company received $0.4&amp;#xA0;million in nonrefundable payments in
 2016 prior to Receptor exercising the option. On December&amp;#xA0;30,
 2016, Receptor exercised the option and paid the Company a
 $1.0&amp;#xA0;million nonrefundable option exercise and license fee.
 Under the CLA, the Company may receive the following additional
 payments:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Nonrefundable milestone payments upon
 the completion of certain technology transfer activities and the
 achievement of specified sales targets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Royalties upon Receptor&amp;#x2019;s and
 its sublicensee&amp;#x2019;s sale of the product.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Milestones upon total worldwide sales
 reaching certain agreed upon levels.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company evaluated the accounting for the payments received in
 2016 under the multiple element accounting guidance and determined
 that the $0.4&amp;#xA0;million in payments received prior to Receptor
 exercising its option are separable from the other elements of the
 agreement and represented payments to offset costs incurred.
 Therefore, those payments reduced the Company&amp;#x2019;s research and
 development expense in 2016. The $1.0&amp;#xA0;million license fee
 received in 2016 does not have standalone value from
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;follow-on&lt;/font&gt;&amp;#xA0;transfer of technology.
 Therefore, the license fee was recorded in deferred payments from
 collaboration at December&amp;#xA0;31, 2016 and will be recognized in
 net revenue &amp;#x2014; collaboration over four years. See Note 2
 &amp;#x2014; Summary of Significant Accounting Policies for additional
 information on the Company&amp;#x2019;s accounting for multiple element
 arrangements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sanofi License Agreement and Sanofi Supply Agreement and Loan
 Facility&lt;/i&gt;&amp;#xA0;&amp;#x2014; On August&amp;#xA0;11,
 2014, the Company executed a license and collaboration agreement
 (the &amp;#x201C;Sanofi License Agreement&amp;#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (Sanofi)), pursuant to which Sanofi was responsible for global
 commercial, regulatory and development activities for Afrezza. The
 Company manufactured Afrezza at its manufacturing facility in
 Danbury, Connecticut to supply Sanofi&amp;#x2019;s demand for the
 product pursuant to a supply agreement dated August&amp;#xA0;11, 2014
 (the &amp;#x201C;Sanofi Supply Agreement&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 During the term of the Sanofi License Agreement, worldwide profits
 and losses were determined based on the difference between the net
 sales of Afrezza and the costs and expenses incurred by the Company
 and Sanofi that were specifically attributable or related to the
 development, regulatory filings, manufacturing, or
 commercialization of Afrezza. These profits and losses were shared
 65% by Sanofi and 35% by the Company. On January&amp;#xA0;4, 2016 the
 Company received a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;90-day&lt;/font&gt;&amp;#xA0;notification from Sanofi of
 its election to terminate in its entirety the Sanofi License
 Agreement. The effective date of termination (the
 &amp;#x201C;Termination Date&amp;#x201D;) was April&amp;#xA0;4, 2016. On
 April&amp;#xA0;5, 2016 the Company assumed responsibility for the
 worldwide development and commercialization of Afrezza from Sanofi.
 Under the terms of the transition agreement, Sanofi continued to
 fulfill orders for Afrezza in the United States until the Company
 began distributing MannKind-branded Afrezza product to major
 wholesalers during the week of July&amp;#xA0;25, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company analyzed the agreements entered into with Sanofi at
 their inception to determine whether the consideration, paid or
 payable to the Company, or a portion thereof, could be recognized
 as revenue.&lt;i&gt;&amp;#xA0;&lt;/i&gt;Under the terms of the
 Sanofi License Agreement, the Sanofi Supply Agreement and the
 Sanofi Loan Facility, the Company determined that the arrangement
 contained significant deliverables including (i)&amp;#xA0;licenses to
 develop and commercialize Afrezza and to use the Company&amp;#x2019;s
 trademarks, (ii)&amp;#xA0;development activities, and
 (iii)&amp;#xA0;manufacture and supply services for Afrezza. Due to the
 proprietary nature of the manufacturing services to be provided by
 the Company, the Company determined that all of the significant
 deliverables should be combined into a single unit of accounting.
 The Company believed that the manufacturing services are
 proprietary due to the fact that since the late 1990&amp;#x2019;s, the
 Company has developed proprietary knowledge and patented equipment
 and tools that are used in the manufacturing process of Afrezza.
 Due to the complexities of particle formulation and the specialized
 knowledge and equipment needed to handle the Afrezza powder,
 neither Sanofi nor, to the Company&amp;#x2019;s knowledge, any
 third-party contract manufacturing organization currently possesses
 the capability of manufacturing Afrezza.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In order for revenue to be recognized, the seller&amp;#x2019;s price to
 the buyer must be fixed or determinable. Prior to December&amp;#xA0;31,
 2015, because the Company did not have the ability to estimate the
 amount of costs that would potentially be incurred under the loss
 share provision related to the Sanofi License Agreement and the
 Sanofi Supply Agreement, the Company believed this requirement for
 revenue recognition had not been met. Therefore, the Company had
 recorded the $150.0&amp;#xA0;million&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt;&amp;#xA0;payment and the two milestone
 payments of $25.0&amp;#xA0;million each as deferred payments from
 collaboration. In addition, as of December&amp;#xA0;31, 2015 the
 Company had recorded $17.5&amp;#xA0;million in Afrezza product
 shipments to Sanofi as deferred sales from collaboration and
 recorded $13.5&amp;#xA0;million as deferred costs from collaboration.
 Deferred costs from collaboration represented the costs of product
 manufactured and shipped to Sanofi, as well as certain direct costs
 associated with a firm purchase commitment entered into in
 connection with the collaboration with Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In the first and second quarters of 2016, after the Company
 received notice of termination from Sanofi, the Company evaluated
 whether the revenue recognition criteria had been met. The Company
 determined that the requirement had not been met because Sanofi had
 not finalized necessary adjustments to the profit and loss share
 provision statements and Sanofi had not yet transferred all of the
 information to enable the Company to commercialize Afrezza on its
 own. Therefore, the Company was still unable to estimate the costs
 to be incurred under the agreement with Sanofi. During the three
 months ended September&amp;#xA0;30, 2016, Sanofi provided enough
 information to the Company to enable it to reasonably estimate the
 remaining costs under the Sanofi License Agreement and the Sanofi
 Supply Agreement. Accordingly, the fixed or determinable fee
 requirement for revenue recognition was met and there were no
 future obligations to Sanofi. Therefore, the Company recognized
 $172.0&amp;#xA0;million of net revenue &amp;#x2014; collaboration for the
 year ended December&amp;#xA0;31, 2016. The revenue recognized includes
 the upfront payment of $150.0&amp;#xA0;million and the two milestone
 payments of $25.0&amp;#xA0;million each, net of $64.9&amp;#xA0;million of
 net loss share with Sanofi, as well as $17.5&amp;#xA0;million in sales
 of Afrezza and $19.4&amp;#xA0;million from sales of bulk insulin, both
 to Sanofi. These payments and sales were made pursuant to the
 contractual terms of the agreements with Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sanofi Loan Facility&lt;/i&gt;&amp;#xA0;&amp;#x2014; On September&amp;#xA0;23,
 2014, the Company entered into the Sanofi Loan Facility, consisting
 of a senior secured revolving promissory note and a guaranty and
 security agreement (the &amp;#x201C;Security Agreement&amp;#x201D;) with an
 affiliate of Sanofi, which provided the Company with a secured loan
 facility of up to $175.0&amp;#xA0;million to fund the Company&amp;#x2019;s
 share of net losses under the Sanofi License Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The obligations of the Company under the Sanofi Loan Facility were
 guaranteed by the Company&amp;#x2019;s wholly-owned subsidiary, MannKind
 LLC, and were secured by a first priority security interest in
 certain insulin inventory located in the United States and any
 contractual rights and obligations pursuant to which the Company
 purchases or has purchased such insulin, and a second priority
 security interest in the Company&amp;#x2019;s assets that secure the
 Company&amp;#x2019;s obligations under the Facility Agreement, as
 amended. In addition, the Company granted to Sanofi, as additional
 security for the obligations under the Sanofi Loan Facility, a
 first priority mortgage on the Company&amp;#x2019;s facility in
 Valencia, California, which had a carrying value of
 $17.9&amp;#xA0;million as of December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Advances under the Sanofi Loan Facility bore interest at a rate of
 8.5%&amp;#xA0;per annum and were payable&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;in-kind&lt;/font&gt;&amp;#xA0;and compounded quarterly and
 added to the outstanding principal balance under the Sanofi Loan
 Facility. The Company was required to make mandatory prepayments on
 the outstanding loans under the Sanofi Loan Facility from its share
 of any profits (as defined in the Sanofi License Agreement) under
 the Sanofi License Agreement within 30 days of receipt of its share
 of any such profits.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s total portion of the loss sharing was
 $57.7&amp;#xA0;million for the year ended December&amp;#xA0;31, 2015, of
 which $44.5&amp;#xA0;million was borrowed under the Sanofi Loan
 Facility as of December&amp;#xA0;31, 2015. Subsequent to
 December&amp;#xA0;31, 2015, the Company borrowed $17.9&amp;#xA0;million
 under the Sanofi Loan Facility to finance the portion of the
 Company&amp;#x2019;s loss for the quarter ended December&amp;#xA0;31, 2015.
 The total amount owed to Sanofi at December&amp;#xA0;31, 2015 was
 $62.4&amp;#xA0;million, which includes $1.7&amp;#xA0;million of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in-kind&lt;/font&gt;&lt;/font&gt;&amp;#xA0;interest.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On November&amp;#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &amp;#x201C;Settlement Agreement&amp;#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 between the Company and Aventisub LLC (&amp;#x201C;Aventisub&amp;#x201D;), a
 Sanofi affiliate, was terminated, with Aventisub agreeing to
 forgive the full outstanding loan balance of $72.0&amp;#xA0;million.
 Sanofi also agreed to purchase $10.2&amp;#xA0;million of insulin from
 the Company in December 2016 under an existing insulin put option
 as well as make a cash payment of $30.6&amp;#xA0;million to the Company
 in early January 2017 as acceleration and in replacement of all
 other payments that Sanofi would otherwise have been required to
 make in the future pursuant to the insulin put option, without the
 Company being required to deliver any insulin for such payment. The
 Company was also relieved of its obligation to pay Sanofi
 $0.5&amp;#xA0;million in previously uncharged costs pursuant to the
 Sanofi License Agreement. The Company and Sanofi also agreed to a
 general release of potential claims against each other.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The forgiveness of the full outstanding loan balance on the Sanofi
 Loan Facility and the previously uncharged costs related to the
 collaboration were accounted for in (gain) loss on extinguishment
 of debt in the accompanying consolidated statements of operations.
 The $10.2&amp;#xA0;million sale of insulin was accounted for as net
 revenue &amp;#x2014; collaboration, consistent with the Company&amp;#x2019;
 sales of insulin to Sanofi in the third quarter of 2016 (see Note 2
 &amp;#x2014; Summary of Significant Accounting Policies
 &amp;#x2014;&amp;#xA0;&lt;i&gt;Revenue
 Recognition &amp;#x2014; Net Revenue &amp;#x2014; Collaboration&lt;/i&gt;). The
 $30.6&amp;#xA0;million accelerated put option payment was recognized as
 a receivable from Sanofi at December&amp;#xA0;31, 2016 and an increase
 in the recognized loss on purchase commitments as the purchase
 commitment obligation had previously been reduced to reflect the
 Company&amp;#x2019;s expectation that amounts associated with purchases
 of insulin were recoverable (see Note 2 &amp;#x2014; Summary of
 Significant Accounting Policies &amp;#x2014;&amp;#xA0;&lt;i&gt;Inventories&lt;/i&gt;).&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_BC097CCE-9DCA-4957-9979-410DB0EF343A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;13. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Operating Leases&lt;/i&gt;&amp;#xA0;&amp;#x2014; The Company leases its
 executive offices in Valencia, California and certain equipment
 under various operating leases, which expire at various dates
 through 2017 and beyond. Future payments are insignificant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Rent expense under all operating leases, including office space and
 equipment, for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014 was approximately $373,000, $426,000 and $737,000,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Guarantees and Indemnifications&lt;/i&gt;&amp;#xA0;&amp;#x2014; In the ordinary course
 of its business, the Company makes certain indemnities, commitments
 and guarantees under which it may be required to make payments in
 relation to certain transactions. The Company, as permitted under
 Delaware law and in accordance with its Bylaws, indemnifies its
 officers and directors for certain events or occurrences, subject
 to certain limits, while the officer or director is or was serving
 at the Company&amp;#x2019;s request in such capacity. The term of the
 indemnification period is for the officer&amp;#x2019;s or
 director&amp;#x2019;s lifetime. The maximum amount of potential future
 indemnification is unlimited; however, the Company has a director
 and officer insurance policy that may enable it to recover a
 portion of any future amounts paid. The Company believes the fair
 value of these indemnification agreements is minimal. The Company
 has not recorded any liability for these indemnities in the
 accompanying consolidated balance sheets. However, the Company
 accrues for losses for any known contingent liability, including
 those that may arise from indemnification provisions, when future
 payment is probable and the amount can be reasonably estimated. No
 such losses have been recorded to date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Litigation&lt;/i&gt;&amp;#xA0;&amp;#x2014; The Company is subject
 to legal proceedings and claims which arise in the ordinary course
 of its business. As of December&amp;#xA0;31, 2016, the Company believes
 that the final disposition of such matters will not have a material
 adverse effect on the consolidated financial position, results of
 operations or cash flows of the Company and no accrual has been
 recorded. The Company maintains liability insurance coverage to
 protect the Company&amp;#x2019;s assets from losses arising out of or
 involving activities associated with ongoing and normal business
 operations. The Company records a provision for a liability when it
 is both probable that a liability has been incurred and the amount
 of the loss can be reasonably estimated. The Company&amp;#x2019;s policy
 is to accrue for legal expenses in connection with legal proceeding
 and claims as they are incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Following the public announcement of Sanofi&amp;#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 of the price of its common stock, several complaints were filed in
 the U.S. District Court for the Central District of California
 against the Company and certain of its officers and directors on
 behalf of certain purchasers of its common stock, which were
 consolidated into a single action. The amended complaint alleged
 that the Company and certain of its officers and directors violated
 federal securities laws by making materially false and misleading
 statements regarding the prospects for Afrezza, thereby
 artificially inflating the price of its common stock. The Company
 and the named defendants brought a motion to dismiss the class
 action that was pending against them, which the District Court
 granted in August 2016 without leave to amend the complaint. The
 lead plaintiff appealed that decision to the Ninth Circuit Court of
 Appeals. On March&amp;#xA0;2, 2017, the lead plaintiff filed a
 voluntary motion to dismiss his appeal, which the Court of Appeals
 granted on March&amp;#xA0;9, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Following the public announcement of Sanofi&amp;#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 of the price of its common stock, two motions were submitted to the
 District Court at Tel Aviv, Economic Department for the
 certification of a class action against the Company and certain of
 its officers and directors. In general, the complaints allege that
 the Company and certain of its officers and directors violated
 Israeli and U.S. securities laws by making materially false and
 misleading statements regarding the prospects for Afrezza, thereby
 artificially inflating the price of its common stock. The
 plaintiffs are seeking monetary damages. In November 2016, the
 district court dismissed one of the actions without prejudice. In
 the remaining action, a hearing is scheduled for May 2017 to
 determine whether Israeli or U.S. law is applicable before the case
 can be certified as a class action. The Company will vigorously
 defend against these claims.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Subsequent to the filing of the federal securities class action
 against the Company, two shareholder derivative complaints were
 filed in the Superior Court for the State of California, County of
 Los Angeles against certain of the Company&amp;#x2019;s directors and
 officers. The complaints allege breaches of fiduciary duties by the
 defendants and other violations of law. Among other allegations,
 the complaints allege that the defendants caused the Company to
 make false and misleading statements or omissions of material fact
 regarding the Company&amp;#x2019;s business and the prospects for sales
 of Afrezza, thereby artificially inflating the price of the
 Company&amp;#x2019;s common stock. Following the dismissal of the
 federal securities class action, each derivative complaint was
 voluntarily dismissed by its plaintiff.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Contingencies &amp;#x2014;&lt;/i&gt;&amp;#xA0;In connection with the
 Facility Agreement, on July&amp;#xA0;1, 2013 the Company also entered
 into a Milestone Rights Purchase Agreement (the &amp;#x201C;Milestone
 Agreement&amp;#x201D;) with Deerfield Private Design Fund and Horizon
 Sant&amp;#xE9; FLML S&amp;#xC1;RL (collectively, the &amp;#x201C;Milestone
 Purchasers&amp;#x201D;), pursuant to which the Company sold the
 Milestone Purchasers the Milestone Rights to receive payments up to
 $90.0&amp;#xA0;million upon the occurrence of specified strategic and
 sales milestones, including the first commercial sale of an Afrezza
 product in the United States and the achievement of specified net
 sales figures (see Note 7 &amp;#x2014; Borrowings).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Commitment &amp;#x2014;&lt;/i&gt;&amp;#xA0;On July&amp;#xA0;31, 2014, the
 Company entered into a supply agreement (the &amp;#x201C;Insulin Supply
 Agreement&amp;#x201D;) with Amphastar France Pharmaceuticals S.A.S., a
 French corporation (Amphastar), pursuant to which Amphastar will
 manufacture for and supply to the Company certain quantities of
 recombinant human insulin for use in Afrezza. Under the terms of
 the Insulin Supply Agreement, Amphastar will be responsible for
 manufacturing the insulin in accordance with the Company&amp;#x2019;s
 specifications and agreed-upon quality standards. The Company had
 agreed to purchase annual minimum quantities of insulin for
 calendar years 2015 through 2019 under the Insulin Supply Agreement
 of an aggregate total of approximately &amp;#x20AC;120.1&amp;#xA0;million.
 The Company could have requested to purchase additional quantities
 of insulin over such annual minimum quantities with a cancellation
 fee.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On November&amp;#xA0;9, 2016, the supply agreement with Amphastar was
 amended to extend the term over which the Company is required to
 purchase insulin, without reducing the total amount of insulin to
 be purchased. Under the amendment, annual minimum quantities of
 insulin to be purchased for calendar years 2017 through 2023 total
 an aggregate purchase price of &amp;#x20AC;93.0&amp;#xA0;million at
 December&amp;#xA0;31, 2016. The Insulin Supply Agreement specifies that
 Amphastar will be deemed to have satisfied its obligations with
 respect to quantity, if the actual quantity supplied is within plus
 or minus ten percent (+/- 10%) of the quantity set forth in the
 applicable purchase order. In addition, the aggregate cancellation
 fees that the Company would incur in the event that the above
 insulin quantities are not purchased was lowered from
 $5.3&amp;#xA0;million for the period October&amp;#xA0;1, 2016 through 2018
 to $3.4&amp;#xA0;million over the same period. The annual purchase
 requirements under the contract are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.7&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.6&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.5&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2021&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.5&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2022&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.4&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2023&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.4&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Unless earlier terminated, the term of the Insulin Supply Agreement
 expires on December&amp;#xA0;31, 2023 and can be renewed for
 additional, successive two year terms upon 12 months&amp;#x2019; written
 notice given prior to the end of the initial term or any additional
 two year term. The Company and Amphastar each have normal and
 customary termination rights, including termination for material
 breach that is not cured within a specific time frame or in the
 event of liquidation, bankruptcy or insolvency of the other party.
 In addition, the Company may terminate the Insulin Supply Agreement
 upon two years&amp;#x2019; prior written notice to Amphastar without
 cause or upon 30 days&amp;#x2019; prior written notice to Amphastar if a
 controlling regulatory authority withdraws approval for Afrezza,
 provided, however, in the event of a termination pursuant to either
 of the latter two scenarios, the provisions of the Insulin Supply
 Agreement require the Company to pay the full amount of all unpaid
 purchase commitments due over the initial term within 60 calendar
 days of the effective date of such termination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company also has another firm commitment with another supplier
 for an aggregate of $0.9&amp;#xA0;million.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_C5B9D3EC-8496-4303-9569-120F4DEC0511_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;12. Stock Award Plans&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&amp;#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&amp;#x2019;s common
 stock par value. See Note 1 &amp;#x2014; Description of Business.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On May&amp;#xA0;23, 2013, the Company adopted the 2013 Equity Incentive
 Plan (the &amp;#x201C;2013 Plan&amp;#x201D;) as the successor to and
 continuation of the 2004 Equity Incentive Plan (the &amp;#x201C;2004
 Plan&amp;#x201D;). The 2013 Plan consists of 4.3&amp;#xA0;million additional
 shares and the number of unallocated shares remaining available for
 grant for new awards under the 2004 Plan. The 2013 Plan provides
 for the granting of stock awards including stock options and
 restricted stock units, to employees, directors and consultants.
 The 2013 Plan also provides for the automatic,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-discretionary&lt;/font&gt;&amp;#xA0;grant of options to the
 Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;directors. No additional
 awards will be granted under the 2004 Plan or under the
 2004&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Employee&lt;/font&gt;&amp;#xA0;Directors&amp;#x2019; Stock Option
 Plan (the &amp;#x201C;NED Plan&amp;#x201D;) as all future awards will be made
 out of the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes information about the
 Company&amp;#x2019;s stock-based award plans as of December&amp;#xA0;31,
 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Outstanding&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Outstanding&lt;br /&gt;
 Restricted&lt;br /&gt;
 Stock Units&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&amp;#xA0;Available&lt;br /&gt;
 for Future&lt;br /&gt;
 Issuance&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2004 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,052,345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,203&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2013 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,399,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;723,763&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,743,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2004&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Employee&lt;/font&gt;&amp;#xA0;Directors&amp;#x2019; Stock Option
 Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;737,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,840,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2004, as part of the 2004 Plan, the Company&amp;#x2019;s board
 of directors approved the Employee Stock Purchase Plan
 (&amp;#x201C;ESPP&amp;#x201D;), which became effective upon the closing of
 the Company&amp;#x2019;s initial public offering. Initially, the
 aggregate number of shares that could be sold under the 2004 Plan
 was 400,000 shares of common stock. On January&amp;#xA0;1 of each year,
 for a period of ten years beginning January&amp;#xA0;1, 2005, the share
 reserve automatically increased by the lesser of: 140,000 shares,
 1% of the total number of shares of common stock outstanding on
 that date, or an amount as may be determined by the board of
 directors. However, under no event can the annual increase cause
 the total number of shares reserved under the ESPP to exceed 10% of
 the total number of shares of capital stock outstanding on
 December&amp;#xA0;31 of the prior year. On January&amp;#xA0;1, 2013 and
 2014 the ESPP share reserve was increased each year by 140,000
 shares. There was no ESPP share reserve increases during 2015 or
 2016. As of December&amp;#xA0;31, 2016, 445,782 shares were available
 for issuance under the ESPP. For the years ended December&amp;#xA0;31,
 2016, 2015 and 2014, the Company sold 104,758, 64,245 and 61,015
 shares, respectively, of its common stock to employees
 participating in the ESPP. The ESPP purchase of 43,672 shares for
 the period ending December&amp;#xA0;31, 2016 was initiated prior
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;year-end&lt;/font&gt;&amp;#xA0;but did not settle until
 January&amp;#xA0;5, 2017. As a result, the shares sold are reflected in
 the ESPP share reserves but are excluded from common stock
 outstanding as of December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s board of directors determines eligibility,
 vesting schedules and criteria and exercise prices for stock awards
 granted under the 2013 Plan. Options and restricted stock unit
 awards under the 2013 Plan expire not more than ten years from the
 date of the grant and are exercisable upon vesting. Stock options
 that vest over time generally vest over four years. Current
 time-based vesting stock option grants vest and become exercisable
 at the rate of 25% after one year and ratably on a monthly basis
 over a period of 36 months thereafter. Restricted stock units with
 time-based vesting generally vest at a rate of 25%&amp;#xA0;per year
 over four years with consideration satisfied by service to the
 Company. The Company also issues stock awards with performance
 conditions. The 2013 Plan provides for full acceleration of vesting
 if an employee is terminated within three months of a change in
 control, as defined in the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Share-based payment transactions are recognized as compensation
 cost based on the fair value of the instrument on the date of
 grant. The Company accounts for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;stock-based compensation
 expense based on the estimated fair value of the options, which is
 determined using the Black-Scholes option valuation model and
 amortizes such expense on a straight-line basis over the service
 period for time-based awards and over the expected dates of
 achievement for performance-based awards. These awards are subject
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;re-measurement&lt;/font&gt;&amp;#xA0;until service is complete. As
 of December&amp;#xA0;31, 2016, there were options to purchase 100,697
 shares of common stock outstanding to consultants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 During the years ended December&amp;#xA0;31, 2016, 2015 and 2014 the
 Company recorded stock-based compensation expense of
 $5.1&amp;#xA0;million, $8.7&amp;#xA0;million and $48.6&amp;#xA0;million,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is as follows
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Consultant-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,725&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is included in
 the following categories (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;695&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,725&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company uses the Black-Scholes option valuation model to
 estimate the grant date fair value of employee stock options. The
 expected term of an option granted is based on combining historical
 exercise data with expected weighted time outstanding. Expected
 weighted time outstanding is calculated by assuming the settlement
 of outstanding awards is at the midpoint between the remaining
 weighted average vesting date and the expiration date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. The Company
 has selected risk-free interest rates based on U.S. Treasury
 securities with an equivalent expected term in effect on the date
 the options were granted. Additionally, the Company uses historical
 data and management judgment to estimate stock option exercise
 behavior and employee turnover rates to estimate the number of
 stock option awards that will eventually vest. The Company
 calculated the fair value of employee stock options granted during
 the years ended December&amp;#xA0;31, 2016, 2015 and 2014 using the
 following assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="31%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 1.18%&amp;#xA0;&amp;#x2014;&amp;#xA0;1.80%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;1.61%
 &amp;#x2014;1.86%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 1.64%&amp;#xA0;&amp;#x2014;&amp;#xA0;2.11%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.13&amp;#xA0;&amp;#x2014;&amp;#xA0;5.82&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.79&amp;#xA0;&amp;#x2014;&amp;#xA0;5.86&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.77&amp;#xA0;&amp;#x2014;&amp;#xA0;6.09&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 77.57%&amp;#xA0;&amp;#x2014;&amp;#xA0;82.75%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 69.76%&amp;#xA0;&amp;#x2014;&amp;#xA0;71.84%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 73.98%&amp;#xA0;&amp;#x2014;&amp;#xA0;84.85%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes information about stock options
 outstanding:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number of&lt;br /&gt;
 Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price per&amp;#xA0;Share&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&amp;#xA0;($000)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,955,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,236,693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55,231&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(407,161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(199,890&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,399,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,414,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The weighted average grant date fair value of the stock options
 granted during the years ended December&amp;#xA0;31, 2016, 2015 and
 2014 was $3.05, $12.80 and $23.80 per option, respectively. The
 total intrinsic value of options exercised during the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014 was $0.1&amp;#xA0;million,
 $6.2&amp;#xA0;million and $14.9&amp;#xA0;million, respectively. Intrinsic
 value is measured using the fair market value at the date of
 exercise for options exercised or at December&amp;#xA0;31 for
 outstanding options, less the applicable exercise price.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Cash received from the exercise of options during the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014 was approximately
 $0.5&amp;#xA0;million, $3.3&amp;#xA0;million and $11.0&amp;#xA0;million,
 respectively. The weighted-average remaining contractual terms for
 options outstanding, vested and expected to vest and exercisable at
 December&amp;#xA0;31, 2016 was 5.31 years, 5.22 years and 2.93 years,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 A summary of restricted stock unit activity for the year ended
 December&amp;#xA0;31, 2016 is presented below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Grant&amp;#xA0;Date&lt;br /&gt;
 Fair Value&lt;br /&gt;
 per Share&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;800,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(131,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(292,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;737,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The total restricted stock units expected to vest as of
 December&amp;#xA0;31, 2016 was 629,424 with a weighted average grant
 date fair value of $8.60 per share. The total intrinsic value of
 restricted stock units expected to vest as of December&amp;#xA0;31,
 2016 was $2.0&amp;#xA0;million. Intrinsic value of restricted stock
 units expected to vest is measured using the closing share price at
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Total intrinsic value of restricted stock units vested during the
 years ended December&amp;#xA0;31, 2016, 2015 and 2014 was
 $0.6&amp;#xA0;million, $5.2&amp;#xA0;million and $62.7&amp;#xA0;million,
 respectively. Intrinsic value of restricted stock units vested is
 measured using the closing share price on the day prior to the vest
 date. The total grant date fair value of restricted stock units
 vested during the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 was $2.6&amp;#xA0;million, $5.5&amp;#xA0;million and $36.4&amp;#xA0;million,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 As of December&amp;#xA0;31, 2016, there was $4.0&amp;#xA0;million and
 $4.8&amp;#xA0;million of unrecognized compensation expense related to
 options and restricted stock units with performance conditions,
 respectively, which is expected to be recognized over the weighted
 average vesting period of 2.9 years. The Company evaluates stock
 awards with performance conditions as to the probability that the
 performance conditions will be met and uses that information to
 estimate the date at which those performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 As of December&amp;#xA0;31, 2016, the Company reviewed the probability
 of achieving the performance conditions for each of the four
 vesting tranches of the performance-based stock options and
 determined that it was probable that the Company would achieve the
 first vesting tranche in December 2017. Therefore, the Company
 recorded a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-material&lt;/font&gt;&amp;#xA0;cumulative catchup of the
 expense from the grant date through December&amp;#xA0;31, 2016 and will
 record the unrecognized compensation cost related to the first
 tranche in the amount of $0.3&amp;#xA0;million through
 December&amp;#xA0;31, 2017. The Company further determined that no
 compensation costs would be recognized for the second, third and
 fourth vesting tranches as it had not been determined that it was
 probable that the performance conditions related to these tranches
 would be achieved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 During the year ended December&amp;#xA0;31, 2015, there was
 $1.6&amp;#xA0;million of stock compensation expense related to certain
 executives who entered into severance agreements which resulted in
 a modification to the terms of their awards. The severance
 agreements generally allowed for the separated executives to
 continue to vest under their original award terms for a stated
 period of time without providing substantive services. There were
 no modifications in 2016.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2589D172-55D5-4077-AAE8-6478DC893E93_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2589D172-55D5-4077-AAE8-6478DC893E93_1_3">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2589D172-55D5-4077-AAE8-6478DC893E93_1_0">10-K</dei:DocumentType>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_27">1.36</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_0665318C-4E31-420E-B623-C2130389B255_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Net Income (Loss) Per Share of Common Stock&lt;/i&gt; &amp;#x2014; Basic
 net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="INF" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_1_0">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_1_3">-0.340</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <dei:EntityCentralIndexKey contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400002">0000899460</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400004">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_F12AA567-3E38-40D9-B5B4-A7BBDCE4CCC7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt; &amp;#x2014; The Company
 utilizes fair value measurement guidance to value its financial
 instruments. The guidance includes a definition of fair value,
 prescribes methods for measuring fair value, establishes a fair
 value hierarchy based on the inputs used to measure fair value and
 expands disclosures about the use of fair value measurements. The
 valuation techniques utilized are based upon observable and
 unobservable inputs. Observable inputs reflect market data obtained
 from independent sources, while unobservable inputs reflect
 internal market assumptions. These two types of inputs create the
 following fair value hierarchy:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 1&amp;#xA0;&amp;#x2014;&amp;#xA0;Quoted prices for identical instruments
 in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 2&amp;#xA0;&amp;#x2014;&amp;#xA0;Quoted prices for similar instruments in
 active markets; quoted prices for identical or similar instruments
 in markets that are not active; and model-derived valuations whose
 inputs are observable or whose significant value drivers are
 observable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 3&amp;#xA0;&amp;#x2014;&amp;#xA0;Significant inputs to the valuation model
 are unobservable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="-3" id="id_9004857_E2BF2F63-8A32-4A74-80D2-C86C969D2CDB_1_7">32000</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_FEDFD11E-2CFF-4464-B637-F9DCD2095E06_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;3. Inventories&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Inventories consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Work-in-process&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,120&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,331&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December 31, 2015, the Company recorded a write-off of all of
 its inventory. There were no raw materials as of December 31, 2016
 because purchases of raw materials in 2016 were recorded at zero
 value because they had been accrued at December 31, 2015 through
 the loss on purchase commitment. Work-in-process and finished goods
 as of December 31, 2016 include conversion costs but not materials
 cost because the materials used in its production were previously
 written off.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_D5F7C5E2-034E-47F0-9ECE-60EA03E0BB2E_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Inventories&lt;/i&gt; &amp;#x2014; Inventories are stated at the lower of
 cost or net realizable value. The Company determines the cost of
 inventory using the &lt;font style="white-space:nowrap"&gt;first-in,&lt;/font&gt; &lt;font style="white-space:nowrap"&gt;first-out,&lt;/font&gt; or FIFO, method. The Company
 capitalizes inventory costs associated with the Company&amp;#x2019;s
 products based on management&amp;#x2019;s judgment that future economic
 benefits are expected to be realized; otherwise, such costs are
 expensed as cost of goods sold. The Company periodically analyzes
 its inventory levels to identify inventory that may expire or has a
 cost basis in excess of its estimated realizable value, and writes
 down such inventories as appropriate. In addition, the
 Company&amp;#x2019;s products are subject to strict quality control and
 monitoring which the Company performs throughout the manufacturing
 process. If certain batches or units of product no longer meet
 quality specifications or become obsolete due to expiration, the
 Company will record a charge to write down such unmarketable
 inventory to its estimated net realizable value.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company analyzed its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value. The Company performed an assessment of projected
 sales and evaluated the lower of cost or net realizable value and
 the potential excess inventory on hand at December&amp;#xA0;31, 2016
 and 2015. As a result of these assessments, the Company recorded a
 $0.2&amp;#xA0;million charge at December&amp;#xA0;31, 2016 to &lt;font style="white-space:nowrap"&gt;write-off&lt;/font&gt; inventory that will expire
 prior to sale. At December&amp;#xA0;31, 2015, the Company recorded a
 charge of $39.3&amp;#xA0;million to record the inventory raw materials
 on hand at the lower of cost or net realizable value, inventory
 expiry and &lt;font style="white-space:nowrap"&gt;write-off&lt;/font&gt; other
 inventory related assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_33">-78090000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_9062D844-F289-4470-8883-1968BAB13824_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Reclassifications&lt;/i&gt; &amp;#x2014; Certain amounts from previous
 periods have been reclassified to conform to the 2016 presentation.
 Specifically, accrued interest &amp;#x2014; note payable to principal
 stockholder has been reclassified from the previously reported
 classification of other liabilities in the accompanying
 consolidated balance sheets. Additionally, the remaining balance
 from the previously reported classification of other liabilities is
 now identified as milestone rights liability, and is disclosed as a
 separate line item on the consolidated statements of cash flows.
 Additionally, on the consolidated statement of operations, product
 manufacturing has been renamed to cost of goods sold. The Company
 also reclassified (gain) loss on foreign currency translation from
 the previously reported classification of product manufacturing in
 the accompanying consolidated statements of operations.
 Additionally, certain balances from prepaid expenses and other
 current assets were reclassed to (gain) loss on foreign currency
 translation in the consolidated statements of cash flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B96E3785-7817-4042-AB52-7446843EC808_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Potentially dilutive securities outstanding that are considered
 antidilutive are summarized as follows (in shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,955,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,308,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion of senior convertible notes into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,464,616&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,740,597&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,919&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,997,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;702,867&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;522,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,788,281&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,946,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,292,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_A05D4662-92B4-44F7-9F75-F3FD69402E38_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The provision for income taxes consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. state&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-U.S.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,814&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,873&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. state&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,631&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-U.S.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(48,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(80,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(65,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_D795FDDE-D47E-416E-82A9-349F42716EFA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables set forth the fair value of the
 Company&amp;#x2019;s financial instruments (in millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"&gt;As of December&amp;#xA0;31, 2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Carrying&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility Financing Obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability (at recurring fair values)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"&gt;As of December&amp;#xA0;31, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Carrying&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility Financing Obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_3A5682C9-208F-4E63-B147-0918D9DA7398_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of restricted stock unit activity for the year ended
 December&amp;#xA0;31, 2016 is presented below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Grant&amp;#xA0;Date&lt;br /&gt;
 Fair Value&lt;br /&gt;
 per Share&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;800,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(131,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(292,488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;737,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1_5">0.8275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1_5">199890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1_3">8.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1_5">23.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B1B3A976-202B-4FED-B5E0-480DAB4C7D5D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Financial Statement Estimates&lt;/i&gt; &amp;#x2014; The preparation of
 financial statements in conformity with accounting principles
 generally accepted in the United States of America (GAAP) requires
 management to make estimates and assumptions that affect the
 amounts reported in the financial statements and accompanying
 notes. Actual results could differ from those estimates. Management
 considers many factors in selecting appropriate financial
 accounting policies, and in developing the estimates and
 assumptions that are used in the preparation of the financial
 statements. Management must apply significant judgment in this
 process. The more significant estimates reflected in these
 accompanying consolidated financial statements include revenue
 recognition, assessing long-lived assets for impairment, accrued
 expenses, including clinical study expenses, inventory
 recoverability, valuation of the facility financing obligation,
 loss on purchase commitment, warrant liability, milestone rights,
 stock-based compensation and the determination of the provision for
 income taxes and corresponding deferred tax assets and liabilities
 and any valuation allowance recorded against net deferred tax
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Reclassifications&lt;/i&gt; &amp;#x2014; Certain amounts from previous
 periods have been reclassified to conform to the 2016 presentation.
 Specifically, accrued interest &amp;#x2014; note payable to principal
 stockholder has been reclassified from the previously reported
 classification of other liabilities in the accompanying
 consolidated balance sheets. Additionally, the remaining balance
 from the previously reported classification of other liabilities is
 now identified as milestone rights liability, and is disclosed as a
 separate line item on the consolidated statements of cash flows.
 Additionally, on the consolidated statement of operations, product
 manufacturing has been renamed to cost of goods sold. The Company
 also reclassified (gain) loss on foreign currency translation from
 the previously reported classification of product manufacturing in
 the accompanying consolidated statements of operations.
 Additionally, certain balances from prepaid expenses and other
 current assets were reclassed to (gain) loss on foreign currency
 translation in the consolidated statements of cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt; &amp;#x2014; Revenue is recognized when the
 four basic criteria of revenue recognition are met: (1) persuasive
 evidence that an arrangement exists; (2) delivery has occurred or
 services have been rendered; (3) the fee is fixed or determinable;
 and (4) collectability is reasonably assured. When the accounting
 requirements for revenue recognition are not met, the Company
 defers the recognition of revenue by recording deferred revenue on
 the consolidated balance sheets until such time that all criteria
 are met. To date, the Company has had revenue from collaborations,
 commercial sales of Afrezza, and from sales of bulk insulin, which
 are described more fully below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Net Revenue &amp;#x2014; Collaborations
 &amp;#x2014;&lt;/i&gt; The Company enters into collaborations under which we
 must perform certain obligations and we receive periodic payments.
 We evaluate the collaborations under the multiple element revenue
 recognition accounting guidance. Revenue arrangements with multiple
 elements are divided into separate units of accounting if certain
 criteria are met, including whether the delivered elements have
 stand-alone value to the customer. When deliverables are separable,
 consideration received is allocated to the separate units of
 accounting based on the relative selling price of each deliverable
 and the appropriate revenue recognition principles are applied to
 each unit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The assessment of multiple element arrangements requires judgment
 in order to determine the appropriate units of accounting and the
 points in time that, or periods over which, revenue should be
 recognized. The terms of and the accounting for the Company&amp;#x2019;s
 collaborations are described more fully in Note 8 &amp;#x2014;
 Collaboration Arrangements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Net Revenue &amp;#x2014; Commercial
 Product Sales &amp;#x2014;&lt;/i&gt; Between July&amp;#xA0;1, 2016 and
 December&amp;#xA0;15, 2016, the Company sold Afrezza to Integrated
 Commercialization Solutions Direct (ICS) and title and risk of loss
 transferred to ICS upon shipment. After December&amp;#xA0;15, 2016, ICS
 became a third party logistics provider and stopped taking title
 and risk of loss upon shipment of Afrezza to ICS. The Company sells
 Afrezza in the United States to wholesale pharmaceutical
 distributors through ICS, and ultimately to retail pharmacies,
 which are collectively referred to as &amp;#x201C;customers&amp;#x201D;.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company provides the right of return to ICS (through
 December&amp;#xA0;15, 2016) and its wholesale distributors and, through
 them, to its retail pharmacy customers for unopened product for a
 period beginning six months prior to and ending twelve months after
 its expiration date. Once the product has been prescribed and
 dispensed to the patient, any right of return ceases to exist.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Given the Company&amp;#x2019;s limited sales history for Afrezza, the
 Company cannot reliably estimate expected returns of the product at
 the time of shipment into the distribution channel. Accordingly,
 the Company defers recognition of revenue on Afrezza product
 shipments until the right of return no longer exists, which occurs
 at the earlier of the time Afrezza is dispensed from pharmacies to
 patients or expiration of the right of return. The Company
 recognizes revenue based on Afrezza patient prescriptions dispensed
 as estimated by syndicated data provided by a third party. The
 Company also analyzes additional data points to ensure that such
 third-party data is reasonable including data related to inventory
 movements within the channel and ongoing prescription demand.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the year ended December&amp;#xA0;31, 2016, net revenue from
 commercial product sales consisted of $1.9&amp;#xA0;million of net
 sales of Afrezza dispensed to patients. As of December&amp;#xA0;31,
 2016, the Company recorded $3.4&amp;#xA0;million in deferred revenue on
 its consolidated balance sheet, of which $1.6&amp;#xA0;million (net of
 estimated &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt; adjustments)
 represents product shipped to the Company&amp;#x2019;s third-party
 logistics provider and wholesale distributors, but not yet
 dispensed to patients. The difference represents deferred revenue
 from bulk insulin sales, which is described more fully under the
 heading &lt;i&gt;Revenue Recognition &amp;#x2014; Revenue &amp;#x2014; Bulk Insulin
 Sales&lt;/i&gt; below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Gross-to-net&lt;/font&gt;&lt;/font&gt; Adjustments
 &amp;#x2014;&lt;/i&gt; Estimated &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt;
 adjustments for Afrezza include wholesaler distribution fees,
 prompt pay discounts, estimated rebates and patient discount and
 &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; assistance
 programs, and are based on estimated amounts owed or to be claimed
 on the related sales. These estimates take into consideration the
 terms of the Company&amp;#x2019;s agreements with its customers and the
 levels of inventory within the distribution and retail channels
 that may result in future rebates or discounts taken. In certain
 cases, such as patient support programs, the Company recognizes the
 cost of patient discounts as a reduction of revenue based on
 estimated utilization. If actual future results vary, the Company
 may need to adjust these estimates, which could have an effect on
 product revenue in the period of adjustment. The Company records
 product sales deductions in the consolidated statements of
 operations at the time product revenue is recognized. At
 December&amp;#xA0;31, 2016, year to date total &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt; adjustments were
 approximately $0.8&amp;#xA0;million, which represents 30% of gross
 revenue from product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Wholesaler Distribution Fees &amp;#x2014;&lt;/i&gt; The Company pays
 distribution fees to certain wholesale distributors based on
 contractually determined rates. The Company accrues the
 distribution fees on shipment to the respective wholesale
 distributors and recognizes the distribution fees as a reduction of
 revenue in the same period the related revenue is recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Prompt Pay Discounts &amp;#x2014;&lt;/i&gt; The Company offers cash
 discounts to its customers, generally 2% of the sales price, as an
 incentive for prompt payment. The Company accounts for cash
 discounts by reducing accounts receivable by the prompt pay
 discount amount and recognizes the discount as a reduction of
 revenue in the same period the related revenue is recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Rebates &amp;#x2014;&lt;/i&gt; The Company participates in federal and
 state government-managed Medicare and Medicaid rebate programs and
 intends to pursue participation in certain other qualifying federal
 and state government programs whereby discounts and rebates are
 provided to participating federal and state government entities.
 Rebates provided through these other qualifying programs are
 included in the Medicaid and Medicare rebate accrual. The Company
 accounts for these rebates by establishing an accrual equal to the
 estimate of rebate claims attributable to a sale and determines its
 estimate of the rebates accrual based on historical payor data
 provided by a third-party vendor along with additional data
 including a forecasted participation rate for Medicare and
 Medicaid. From that data, as well as input received from
 MannKind&amp;#x2019;s commercial team, an estimated participation rate
 for Medicare and Medicaid is determined and applied at the mandated
 rate for those sales. Any new information regarding changes in the
 programs&amp;#x2019; regulations and guidelines or any changes in the
 Company&amp;#x2019;s government price reporting calculations that would
 impact the amount of the rebates will also be taken into account in
 determining or modifying the appropriate reserve. The time period
 between the date the product is sold into the channel and the date
 such rebates are paid ranges from approximately six to nine months.
 As such, continuous monitoring of these estimates are performed on
 a periodic basis and if necessary, adjusted to reflect new facts
 and circumstances. Rebates are recognized as a reduction of revenue
 in the period the related revenue is recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Patient Discount and &lt;font style="WHITE-SPACE: nowrap"&gt;Co-Pay&lt;/font&gt; Assistance Programs &amp;#x2014;&lt;/i&gt;
 The Company offers discount card programs to patients for Afrezza
 in which patients receive discounts on their prescriptions or a
 reduction in their &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt;
 amounts that are reimbursed by the Company. The Company estimates
 the total amount that will be redeemed based on levels of inventory
 in the distribution and retail channels and recognizes the discount
 as a reduction of revenue in the same period the related revenue is
 recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Product Returns &amp;#x2014;&lt;/i&gt; The Company does not provide a
 reserve for product returns of sales of Afrezza due to its revenue
 recognition policy of deferring recognition of revenue on product
 shipments of Afrezza until the right of return no longer
 exists.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Revenue &amp;#x2014; Bulk Insulin Sales
 &amp;#x2014;&lt;/i&gt; In 2016, revenue from bulk insulin sales was recognized
 after delivery and customer acceptance of the bulk insulin. When
 the accounting requirements for revenue recognition of bulk insulin
 sales are not met, the Company defers recognition of revenue by
 recording deferred revenue on the balance sheet until such time
 that all criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Deferred revenue includes $1.8&amp;#xA0;million received from a sale of
 surplus bulk insulin to a third party that was delivered prior to,
 but accepted after, December&amp;#xA0;31, 2016. No deferred cost was
 recognized related to this sale because the inventory was written
 off on December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Deferred Costs from Collaboration &amp;#x2014;&lt;/i&gt; Deferred costs
 from collaboration represents the costs of product manufactured and
 sold to Sanofi, as well as certain direct costs associated with a
 firm purchase commitment entered into in connection with the
 collaboration with Sanofi. During the third quarter of 2016, the
 costs related to the Sanofi product sales were recognized as costs
 of revenue &amp;#x2014; collaboration in the consolidated statements of
 operations, as related revenue was recognized at that time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Deferred Costs from Commercial Product Sales &amp;#x2014;&lt;/i&gt;
 Deferred costs from commercial product sales represents the cost of
 product (including labor, overhead and costs to ship to third party
 logistics) shipped to ICS and wholesale distributors, but not yet
 dispensed by pharmacies to patients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Cost of Goods Sold &amp;#x2014;&lt;/i&gt; Cost of goods sold includes the
 costs related to Afrezza product dispensed by pharmacies to
 patients as well as under-absorbed labor and overhead and inventory
 write-offs, which are recorded as expenses in the period in which
 they are incurred, rather than as a portion of the inventory
 cost.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt; &amp;#x2014; The Company considers all
 highly liquid investments with original or remaining maturities of
 90 days or less at the time of purchase, that are readily
 convertible into cash to be cash equivalents. As of
 December&amp;#xA0;31, 2016 and 2015, cash equivalents were comprised of
 money market accounts with maturities less than 90 days from the
 date of purchase.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Concentration of Credit Risk&lt;/i&gt; &amp;#x2014; Financial instruments
 which potentially subject the Company to concentration of credit
 risk consist of cash and cash equivalents. Cash and cash
 equivalents are held in high credit quality institutions. Cash
 equivalents consist of interest-bearing money market accounts,
 which are regularly monitored by management.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;
 &amp;#x2014; Accounts receivable are recorded at the invoiced amount and
 are not interest bearing. The Company maintains an allowance for
 doubtful accounts for estimated losses resulting from the inability
 of its customers to make required payments. The Company makes
 ongoing assumptions relating to the collectability of its accounts
 receivable in its calculation of the allowance for doubtful
 accounts. As of December&amp;#xA0;31, 2016 and 2015, there was no
 allowance for doubtful accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Inventories&lt;/i&gt; &amp;#x2014; Inventories are stated at the lower of
 cost or net realizable value. The Company determines the cost of
 inventory using the &lt;font style="WHITE-SPACE: nowrap"&gt;first-in,&lt;/font&gt; &lt;font style="WHITE-SPACE: nowrap"&gt;first-out,&lt;/font&gt; or FIFO, method. The
 Company capitalizes inventory costs associated with the
 Company&amp;#x2019;s products based on management&amp;#x2019;s judgment that
 future economic benefits are expected to be realized; otherwise,
 such costs are expensed as cost of goods sold. The Company
 periodically analyzes its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value, and writes down such inventories as appropriate.
 In addition, the Company&amp;#x2019;s products are subject to strict
 quality control and monitoring which the Company performs
 throughout the manufacturing process. If certain batches or units
 of product no longer meet quality specifications or become obsolete
 due to expiration, the Company will record a charge to write down
 such unmarketable inventory to its estimated net realizable
 value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company analyzed its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value. The Company performed an assessment of projected
 sales and evaluated the lower of cost or net realizable value and
 the potential excess inventory on hand at December&amp;#xA0;31, 2016
 and 2015. As a result of these assessments, the Company recorded a
 $0.2&amp;#xA0;million charge at December&amp;#xA0;31, 2016 to &lt;font style="WHITE-SPACE: nowrap"&gt;write-off&lt;/font&gt; inventory that will expire
 prior to sale. At December&amp;#xA0;31, 2015, the Company recorded a
 charge of $39.3&amp;#xA0;million to record the inventory raw materials
 on hand at the lower of cost or net realizable value, inventory
 expiry and &lt;font style="WHITE-SPACE: nowrap"&gt;write-off&lt;/font&gt; other
 inventory related assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;State Research and Development Credit Exchange Receivable&lt;/i&gt;
 &amp;#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for foregoing the
 carryforward of the research and development credits. The program
 provides for an exchange of research and development income tax
 credits for cash equal to 65% of the value of corporation tax
 credit available for exchange. Estimated amounts receivable under
 the program are recorded as a reduction of research and development
 expenses. These amounts are included in prepaid expenses and other
 current assets on the consolidated balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Prepaid Expenses and Other Current Assets &amp;#x2014;&lt;/i&gt; As of
 December&amp;#xA0;31, 2016 and 2015, prepaid expenses and other current
 assets primarily consist of prepaid expenses for goods and services
 to be received and includes a certificate of deposit for $350,000
 as collateral as required by an agreement with the bank.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Sale of intellectual property &amp;#x2014;&lt;/i&gt; On July&amp;#xA0;18, 2014,
 the Company entered into an assignment agreement with a third party
 whereby the third party acquired all proprietary rights, technology
 and &lt;font style="WHITE-SPACE: nowrap"&gt;know-how&lt;/font&gt; that related
 to a small molecule inhibitor compound and all &lt;font style="WHITE-SPACE: nowrap"&gt;pre-clinical&lt;/font&gt; data and results related
 thereto. Under the terms of the assignment agreement, the Company
 received total consideration of $9.3&amp;#xA0;million and accrued
 $1.4&amp;#xA0;million in expense for a net amount of $7.9&amp;#xA0;million
 recorded as other income. In 2015, the Company recorded other
 income of $1.4&amp;#xA0;million related to the relief of the
 $1.4&amp;#xA0;million accrual for expenses associated with the sale of
 intellectual property related to oncology in 2014, which was
 subsequently resolved without payment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Assets Held for Sale &amp;#x2014;&lt;/i&gt; The Company classifies
 long-lived assets anticipated to be sold within one year as held
 for sale at the lower of their carrying value or fair value less
 estimated selling costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Property and Equipment&lt;/i&gt; &amp;#x2014; Property and equipment are
 depreciated using the straight-line method over the estimated
 useful lives of the related assets. Leasehold improvements are
 amortized over the term of the lease or the service lives of the
 improvements, whichever is shorter. Maintenance and repairs are
 expensed as incurred. Assets under construction are not depreciated
 until placed into service.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt; &amp;#x2014; The Company
 evaluates long-lived assets for impairment whenever events or
 changes in circumstances indicate that the carrying value of an
 asset may not be recoverable. Assets are considered to be impaired
 if the carrying value may not be recoverable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 If the Company believes an asset to be impaired, the impairment
 recognized is the amount by which the carrying value of the asset
 exceeds the fair value of the asset. Fair value is determined using
 the market, income or cost approaches as appropriate for the asset.
 Any write-downs are treated as permanent reductions in the carrying
 amount of the asset and an operating loss would be recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recorded an asset impairment of $1.3 million and $140.4
 million for the years ended December 31, 2016 and 2015,
 respectively. No asset impairment was recognized during the year
 ended December 31, 2014 (see Note 4 &amp;#x2014; Property and Equipment
 and Note 20 &lt;i&gt;&amp;#x2014;&lt;/i&gt; Subsequent Events).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Recognized Loss on Purchase Commitments &amp;#x2014;&lt;/i&gt; The Company
 assesses whether losses on long term purchase commitments should be
 accrued. Losses that are expected to arise from firm, &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancellable,&lt;/font&gt; commitments for the
 future purchases of inventory items are recognized unless
 recoverable. The recognized loss on purchase commitments is reduced
 as inventory items are purchased. Changes in estimates are recorded
 in the relevant period in (gain) loss on purchase commitments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the year ended December&amp;#xA0;31, 2015, the Company recorded
 a loss on purchase commitments amounting to $116.2&amp;#xA0;million
 offset by $50&amp;#xA0;million expected to be recovered from Sanofi,
 primarily due to a long term purchase commitment for insulin raw
 materials. During the year ended December&amp;#xA0;31, 2016, the
 balance was adjusted for the recovery received from Sanofi, current
 purchases on the contracts and a reduction in the recognized loss
 related to amendments to purchase contracts. No new contracts were
 identified in 2016 requiring a new loss on purchase commitment
 accrual.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Milestone Rights Liability&lt;/i&gt; &amp;#x2014; On July&amp;#xA0;1, 2013, in
 conjunction with the execution of the Facility Agreement, the
 Company issued Milestone Rights to Deerfield whereby the Company
 agreed to provide Deerfield with &lt;font style="WHITE-SPACE: nowrap"&gt;pre-specified&lt;/font&gt; Milestone Payments upon
 the achievement of 13 specific Milestone Events related to the
 commercial release and future cumulative net sales of Afrezza. The
 Company analyzed the Milestone Rights and determined that the
 agreement does not meet the definition of a freestanding
 derivative. Since the Company has not elected to apply the fair
 value option to the Milestone Rights Purchase Agreement, the
 Company recorded the Milestone Rights at their estimated initial
 fair value and accounted for the Milestone Rights as a
 liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The initial fair value estimate of the Milestone Rights was
 calculated using the income approach in which the cash flows
 associated with the specified contractual payments were adjusted
 for both the expected timing and the probability of achieving the
 milestones and discounted to present value using a selected market
 discount rate. The expected timing and probability of achieving the
 milestones was developed with consideration given to both internal
 data, such as progress made to date and assessment of criteria
 required for achievement, and external data, such as market
 research studies. The discount rate was selected based on an
 estimation of required rate of returns for similar investment
 opportunities using available market data. The Milestone Rights
 liability will be remeasured as the specified milestone events are
 achieved. Specifically, as each milestone event is achieved, the
 portion of the initially recorded Milestone Rights liability that
 pertains to the milestone event being achieved, will be remeasured
 to the amount of the specified related milestone payment. The
 resulting change in the balance of the Milestone Rights liability
 due to remeasurement will be recorded in the Company&amp;#x2019;s
 consolidated statements of operations as interest expense.
 Furthermore, the Milestone Rights liability will be reduced upon
 the settlement of each milestone payment. As a result, each
 milestone payment would be effectively allocated between a
 reduction of the recorded Milestone Rights liability and an expense
 representing a return on a portion of the Milestone Rights
 liability paid to the investor for the achievement of the related
 milestone event (see Note&amp;#xA0;7 &amp;#x2014; Borrowings). As of
 December&amp;#xA0;31, 2016, the remaining liability balance is
 $8.9&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt; &amp;#x2014; The Company
 utilizes fair value measurement guidance to value its financial
 instruments. The guidance includes a definition of fair value,
 prescribes methods for measuring fair value, establishes a fair
 value hierarchy based on the inputs used to measure fair value and
 expands disclosures about the use of fair value measurements. The
 valuation techniques utilized are based upon observable and
 unobservable inputs. Observable inputs reflect market data obtained
 from independent sources, while unobservable inputs reflect
 internal market assumptions. These two types of inputs create the
 following fair value hierarchy:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 1&amp;#xA0;&amp;#x2014;&amp;#xA0;Quoted prices for identical instruments
 in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 2&amp;#xA0;&amp;#x2014;&amp;#xA0;Quoted prices for similar instruments in
 active markets; quoted prices for identical or similar instruments
 in markets that are not active; and model-derived valuations whose
 inputs are observable or whose significant value drivers are
 observable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 3&amp;#xA0;&amp;#x2014;&amp;#xA0;Significant inputs to the valuation model
 are unobservable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Income Taxes&lt;/i&gt; &amp;#x2014; The provisions for federal, foreign,
 state and local income taxes are calculated on &lt;font style="WHITE-SPACE: nowrap"&gt;pre-tax&lt;/font&gt; income based on current tax
 law and include the cumulative effect of any changes in tax rates
 from those used previously in determining deferred tax assets and
 liabilities. Deferred income tax assets and liabilities are
 measured using enacted tax rates expected to apply to taxable
 income in the year in which the temporary differences are expected
 to be recovered or settled. A valuation allowance is recorded to
 reduce net deferred income tax assets to amounts that are more
 likely than not to be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Income tax positions are considered for uncertainty. The Company
 believes that its income tax filing positions and deductions will
 be sustained on audit and does not anticipate any adjustments that
 will result in a material change to its financial position.
 Therefore, no liabilities for uncertain income tax positions have
 been recorded. If a tax position does not meet the minimum
 statutory threshold to avoid payment of penalties, the Company
 recognizes an expense for the amount of the penalty in the period
 the tax position is claimed in the tax return of the Company. The
 Company recognizes interest accrued related to unrecognized tax
 benefits in income tax expense, if any. Penalties, if probable and
 reasonably estimable, are recognized as a component of income tax
 expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Significant management judgment is involved in determining the
 provision for income taxes, deferred tax assets, deferred tax
 liabilities, and any valuation allowance recorded against deferred
 tax assets. Due to uncertainties related to the realization of the
 Company&amp;#x2019;s deferred tax assets as a result of its history of
 operating losses, a full valuation allowance has been established
 against the total deferred tax asset balance. The valuation
 allowance is based on management&amp;#x2019;s estimates of taxable
 income by jurisdiction in which the Company operates and the period
 over which deferred tax assets will be recoverable. In the event
 that actual results differ from these estimates or the Company
 adjusts these estimates in future periods, a change in the
 valuation allowance may be needed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Contingencies&lt;/i&gt; &amp;#x2014; The Company records a loss contingency
 for a liability when it is both probable that a liability has been
 incurred and the amount of the loss can be reasonably estimated.
 These accruals represent management&amp;#x2019;s best estimate of
 probable loss. Disclosure also is provided when it is reasonably
 possible that a loss will be incurred or when it is reasonably
 possible that the amount of a loss will exceed the recorded
 provision. On a quarterly basis, the Company reviews the status of
 each significant matter and assesses its potential financial
 exposure. Significant judgment is required in both the
 determination of probability and the determination as to whether an
 exposure is reasonably estimable. Because of uncertainties related
 to these matters, accruals are based only on the best information
 available at the time. As additional information becomes available,
 the Company reassesses the potential liability related to pending
 claims and litigation and may revise its estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#x2014; As of December&amp;#xA0;31,
 2016, the Company had three active stock-based compensation plans,
 which are described more fully in Note 12 &amp;#x2014; Stock Award
 Plans. The Company accounts for all share-based payments to
 employees, including grants of stock awards and the compensatory
 elements of the employee stock purchase plan. All share-based
 payments to employees, including grants of stock options,
 restricted stock units, performance-based awards and the
 compensatory elements of employee stock purchase plans, are
 recognized in the consolidated statements of operations based upon
 the fair value of the awards at the grant date. The Company uses
 the Black-Scholes option valuation model to estimate the grant date
 fair value of employee stock options and the compensatory elements
 of employee stock purchase plans. Option valuation models require
 the input of assumptions, including the expected life of the
 stock-based awards, the estimated stock price volatility, the
 risk-free interest rate and the expected dividend yield. The
 expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Restricted
 stock units are valued based on the market price on the grant date.
 The Company evaluates stock awards with performance conditions as
 to the probability that the performance conditions will be met and
 estimates the date at which the performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Warrants&lt;/i&gt; &amp;#x2014; The Company has issued warrants to purchase
 shares of its common stock. The Company accounts for its warrants
 as either equity or liabilities based upon the characteristics and
 provisions of each instrument and evaluation of sufficient
 authorized shares available to satisfy the obligations. Warrants
 classified as derivative liabilities are recorded on the
 Company&amp;#x2019;s consolidated balance sheets at their fair value on
 the date of issuance and are revalued at each subsequent balance
 sheet date, with fair value changes recognized in the consolidated
 statements of operations. The Company estimates the fair value of
 its derivative liabilities using a third party valuation analysis
 that utilizes a Monte Carlo pricing valuation model and assumptions
 that are based on the individual characteristics of the warrants or
 instruments on the valuation date, as well as expected volatility,
 expected life, yield and a risk-free interest rate. The expected
 volatility assumption is primarily based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not &lt;font style="WHITE-SPACE: nowrap"&gt;re-measured&lt;/font&gt; in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt; &amp;#x2014; Other comprehensive
 income (loss) requires that all components of comprehensive income
 (loss) to be reported in the financial statements in the period in
 which they are recognized. Other comprehensive income (loss)
 includes certain changes in stockholders&amp;#x2019; equity that are
 excluded from net income (loss). Specifically, the Company includes
 unrealized gains and losses on foreign exchange translation in
 accumulated other comprehensive loss on the consolidated balance
 sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Research and Development Expenses&lt;/i&gt; &amp;#x2014; Research and
 development expenses consist of costs associated with the clinical
 trials of the Company&amp;#x2019;s product candidates, manufacturing
 supplies and other development materials, compensation and other
 expenses for research and development personnel, costs for
 consultants and related contract research, facility costs, and
 depreciation. Research and development costs, which are net of any
 tax credit exchange recognized for the Connecticut state research
 and development credit exchange program, are expensed as incurred.
 The Company began commercial manufacturing in the latter part of
 the fourth quarter of 2014. Commercial manufacturing costs incurred
 in the fourth quarter of 2014 were included in research and
 development expense and were immaterial for the year ended
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;State Research and Development Credit Exchange Receivable&lt;/i&gt;
 &amp;#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for forgoing the
 carryforward of the research and development income tax credits.
 The program provides for an exchange of research and development
 income tax credits for cash equal to 65% of the value of
 corporation tax credit available for exchange. Estimated amounts
 receivable under the program are recorded as a reduction of
 research and development expenses. During the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014, research and development
 expenses were offset by research and development tax credits of
 $246,000, $743,000 and $816,000, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Clinical Trial Expenses&lt;/i&gt; &amp;#x2014; Clinical trial expenses,
 which are reflected in research and development expenses in the
 accompanying consolidated statements of operations, result from
 obligations under contracts with vendors, consultants and clinical
 site agreements in connection with conducting clinical trials. The
 financial terms of these contracts are subject to negotiations
 which vary from contract to contract and may result in payment
 flows that do not match the periods over which materials or
 services are provided to the Company under such contracts. The
 appropriate level of trial expenses are reflected in the
 Company&amp;#x2019;s consolidated financial statements by matching
 period expenses with period services and efforts expended. These
 expenses are recorded according to the progress of the trial as
 measured by patient progression and the timing of various aspects
 of the trial. Clinical trial accrual estimates are determined
 through discussions with internal clinical personnel and outside
 service providers as to the progress or state of completion of
 trials, or the services completed. Service provider status is then
 compared to the contractually obligated fee to be paid for such
 services. During the course of a clinical trial, the Company may
 adjust the rate of clinical expense recognized if actual results
 differ from management&amp;#x2019;s estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Interest Expense&lt;/i&gt; &amp;#x2014; Interest costs are expensed as
 incurred, except to the extent such interest is related to
 construction in progress, in which case interest is capitalized.
 Interest cost capitalized for the years ended December&amp;#xA0;31,
 2015 and 2014 was $0.1&amp;#xA0;million and $0.8&amp;#xA0;million,
 respectively. There were no capitalized interest costs for the year
 ended December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Net Income (Loss) Per Share of Common Stock&lt;/i&gt; &amp;#x2014; Basic
 net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt; &amp;#x2014; From time to
 time, new accounting pronouncements are issued by the Financial
 Accounting Standards Board (FASB) or other standard setting bodies
 that are adopted by the Company as of the specified effective date.
 Unless otherwise discussed, the Company believes that the impact of
 recently issued standards that are not yet effective will not have
 a material impact on the Company&amp;#x2019;s consolidated financial
 position or results of operations upon adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB issued Accounting Standards Update (ASU)
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09,&lt;/font&gt;
 &lt;i&gt;Revenue from Contracts with Customers (Topic 606)&lt;/i&gt;, which
 requires an entity to recognize the amount of revenue when promised
 goods or services are transferred to customers in an amount that
 reflects the consideration that is expected to be received for
 those goods or services. This new guidance supersedes previous
 revenue recognition requirements, along with most existing
 industry-specific guidance. In August 2015, the FASB issued ASU
 &lt;font style="WHITE-SPACE: nowrap"&gt;2015-14,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date&lt;/i&gt;, which delayed the effective date of the new standard from
 January&amp;#xA0;1, 2017 to January&amp;#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In 2016 the FASB has issued additional
 ASUs which clarify certain aspects of the new guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company will adopt the new guidance for the year beginning
 January&amp;#xA0;1, 2018. The Company has the option to either apply
 the new guidance retrospectively for all prior reporting periods
 presented (full retrospective) or retrospectively with the
 cumulative effect of initially applying the guidance recognized at
 the date of initial application (modified retrospective). The
 Company currently anticipates it will apply the new guidance using
 the modified retrospective approach with the cumulative effect of
 initial application recognized as of January&amp;#xA0;1, 2018. The
 Company plans to continue analyzing the potential impacts of the
 application throughout 2017 and, depending on factors that may
 impact the results, could elect to apply the new guidance on a full
 retrospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Currently, for commercial sales of Afrezza, the Company has limited
 sales and returns history, and as such, is unable to reliably
 estimate expected returns of the product at the time of shipment
 into the distribution channel. Accordingly, the Company defers
 recognition of revenue on Afrezza product shipments until the right
 of return no longer exists, which occurs at the earlier of the time
 Afrezza is dispensed from pharmacies to patients or expiration of
 the right of return. The Company recognizes revenue based on
 Afrezza patient prescriptions dispensed, a sell-through model, as
 estimated by syndicated data provided by a third party. The Company
 also analyzes additional data points to ensure that such
 third-party data is reasonable, including data related to inventory
 movements within the channel and ongoing prescription demand.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Upon adoption of the new guidance, the Company expects that it will
 move from its current sell-through model to a &lt;font style="WHITE-SPACE: nowrap"&gt;sell-to&lt;/font&gt; model for revenue related to
 commercial sales of Afrezza and will record revenue at the time
 title and risk of loss passes to its distributors (generally at
 shipment or delivery to the distributors) along with an estimate of
 potential returns as variable consideration. The Company also
 anticipates that its ability to estimate potential returns will
 improve with an additional 12 months of sales history that it will
 have obtained by January&amp;#xA0;1, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, the Company has historically entered into
 collaborative agreements with third-parties under which periodic
 payments have been received. Revenue recognition for certain
 payments received has been deferred until the price is fixed and
 determinable. Further, revenue for certain payments to be received
 in the future has been prohibited from recognition until received.
 The Company expects that some of these amounts will be considered
 variable consideration and may be able to be recognized earlier
 under the new guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has begun its evaluation of the impact of adoption and
 plans to continue its evaluation throughout 2017. The financial
 impact upon adoption will be dependent upon a number of factors
 including; the amount of revenue that has been deferred under the
 sell-through model for Afrezza, the amount of the revenue deferred
 under collaborative arrangements and the Company&amp;#x2019;s estimates
 of variable consideration at the date of adoption. At this time,
 the Company has not completed its evaluation of the inputs,
 assumptions and methodologies that will be used to recognize
 revenue related to variable consideration under the new
 guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July 2015, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; &lt;i&gt;Inventory (Topic
 330): Simplifying the Measurement of Inventory.&lt;/i&gt; Topic 330
 currently requires an entity to measure inventory at the lower of
 cost or market. Market could be replacement cost, net realizable
 value, or net realizable value less an approximately normal profit
 margin. The amendments indicate that after adoption an entity
 should measure inventory within the scope of this ASU at the lower
 of cost or net realizable value. The amendments are effective for
 fiscal years beginning after December&amp;#xA0;15, 2016, including
 interim periods within those fiscal years. The amendments should be
 applied prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The adoption of
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11&lt;/font&gt; will
 have no impact on the Company&amp;#x2019;s annual consolidated financial
 statements because the Company currently measures inventory at the
 lower of cost or net realizable value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August&amp;#xA0;2014, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15,&lt;/font&gt; &lt;i&gt;Presentation of
 Financial Statements &amp;#x2014; Going Concern&lt;/i&gt;, which requires
 management of an entity to evaluate whether there are conditions or
 events, considered in the aggregate, that raise substantial doubt
 about the entity&amp;#x2019;s ability to continue as a going concern
 within one year after the date that the financial statements are
 issued or available to be issued. This update was effective for
 annual periods ending after December&amp;#xA0;15, 2016. The adoption of
 this standard did not have a material impact on its consolidated
 financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In January 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-01,&lt;/font&gt; &lt;i&gt;Financial
 Instruments &amp;#x2014; Overall (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;825-10):&lt;/font&gt; Recognition and Measurement
 of Financial Assets and Financial Liabilities.&lt;/i&gt; The update is
 intended to improve the recognition and measurement of financial
 instruments. The update is effective for fiscal years beginning
 after December&amp;#xA0;15, 2017, including interim periods within
 those fiscal years. The Company is evaluating the impact the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-01&lt;/font&gt;
 will have on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02,&lt;/font&gt; &lt;i&gt;Leases (Topic
 842)&lt;/i&gt;. The new standard requires that a lessee recognize the
 assets and liabilities that arise from operating leases. A lessee
 should recognize in the statement of financial position a liability
 to make lease payments (the lease liability) and a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset representing
 its right to use the underlying asset for the lease term. For
 leases with a term of 12 months or less, a lessee is permitted to
 make an accounting policy election by class of underlying asset not
 to recognize lease assets and lease liabilities. In transition,
 lessees and lessors are required to recognize and measure leases at
 the beginning of the earliest period presented using a modified
 retrospective approach. The new standard will be effective on
 January&amp;#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02&lt;/font&gt; will have on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 In March 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt; &lt;i&gt;Compensation
 &amp;#x2014; Stock Compensation (Topic 718): Improvements to Employee
 Share-Based Payment Accounting&lt;/i&gt;. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 those annual periods. The Company has evaluated the effect that
 this guidance will have on its consolidated financial statements
 and related disclosures and has determined it will not result in a
 material impact.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments&lt;/i&gt;. The new standard seeks to reduce diversity in
 practice related to the classification of certain transactions in
 the statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2017, and interim periods within
 those annual periods. The amendments should be applied using a
 retrospective transition method to each period presented. If it is
 impracticable to apply the amendments retrospectively for some of
 the issues, the amendments for those issues would be applied
 prospectively as of the earliest date practicable. The Company is
 evaluating the impact the adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15&lt;/font&gt; will have on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In November 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-18,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Restricted Cash.&lt;/i&gt; This ASU requires that the
 reconciliation of the &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;beginning-of-period&lt;/font&gt;&lt;/font&gt;
 and &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;end-of-period&lt;/font&gt;&lt;/font&gt; amounts shown in
 the statement of cash flows include cash and restricted cash
 equivalents. ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-08&lt;/font&gt;
 is effective for fiscal years beginning after December&amp;#xA0;15,
 2018, including interim periods within those periods, using a
 retrospective transition method to each period presented. The
 Company has evaluated the effect that this guidance will have on
 its consolidated financial statements and related disclosures and
 has determined it will not result in a material impact.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400000">MNKD</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_29">92085000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_28">92053000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <dei:AmendmentFlag contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2589D172-55D5-4077-AAE8-6478DC893E93_1_1">false</dei:AmendmentFlag>
  <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B3E02AA1-6E17-48D2-9D61-508AA3E5DDFE_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Contingencies&lt;/i&gt; &amp;#x2014; The Company records a loss contingency
 for a liability when it is both probable that a liability has been
 incurred and the amount of the loss can be reasonably estimated.
 These accruals represent management&amp;#x2019;s best estimate of
 probable loss. Disclosure also is provided when it is reasonably
 possible that a loss will be incurred or when it is reasonably
 possible that the amount of a loss will exceed the recorded
 provision. On a quarterly basis, the Company reviews the status of
 each significant matter and assesses its potential financial
 exposure. Significant judgment is required in both the
 determination of probability and the determination as to whether an
 exposure is reasonably estimable. Because of uncertainties related
 to these matters, accruals are based only on the best information
 available at the time. As additional information becomes available,
 the Company reassesses the potential liability related to pending
 claims and litigation and may revise its estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_37CB29DD-6A22-4C1D-9C5C-CF5429350422_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Concentration of Credit Risk&lt;/i&gt; &amp;#x2014; Financial instruments
 which potentially subject the Company to concentration of credit
 risk consist of cash and cash equivalents. Cash and cash
 equivalents are held in high credit quality institutions. Cash
 equivalents consist of interest-bearing money market accounts,
 which are regularly monitored by management.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_37BC14DC-62FE-4CC7-ADAE-F85486AB4C88_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Principles of Consolidation&lt;/i&gt; &amp;#x2014; The consolidated
 financial statements include the accounts of the Company and its
 wholly-owned subsidiaries. Intercompany balances and transactions
 have been eliminated.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_066F9751-AFB1-458A-93CC-56E680433A3B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table provides a roll forward of the fair values of
 financial assets and liabilities that are carried at fair value (in
 millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Warrants&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Assets&amp;#xA0;Held&amp;#xA0;for&lt;br /&gt;
 Sale&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, January&amp;#xA0;1, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_23DEC46F-9E33-4D34-8177-D9D5F5E428C9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;15. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 At December&amp;#xA0;31, 2016, the Company has concluded that it is
 more likely than not that the Company may not realize the benefit
 of its deferred tax assets due to its history of losses. There is
 no provision for income taxes in 2015 or 2014 because the Company
 had incurred operating losses since inception. Accordingly, the net
 deferred tax assets have been fully reserved. The provision for
 income taxes consists of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. state&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-U.S.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,814&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,873&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. state&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,631&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-U.S.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(48,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(80,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(65,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Deferred income taxes reflect the tax effects of temporary
 differences between the carrying amounts of assets and liabilities
 for financial reporting and income tax purposes. A valuation
 allowance is established when uncertainty exists as to whether all
 or a portion of the net deferred tax assets will be realized.
 Components of the net deferred tax assets as of December&amp;#xA0;31,
 2016 and 2015, are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;712,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;721,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,646&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized research&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments from collaboration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss on purchase commitment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,084&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-qualified&lt;/font&gt;&amp;#xA0;stock option expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,941&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized patent costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,310&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;914,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;962,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(914,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(962,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The table of deferred tax assets and liabilities does not include
 certain deferred tax assets as of December&amp;#xA0;31, 2016, that
 arose directly from tax deductions related to equity compensation
 which are greater than the compensation recognized for financial
 reporting. Equity would be increased by $11.6&amp;#xA0;million if and
 when such deferred tax assets are ultimately realized. The Company
 considers certain realization requirements when excess tax benefits
 have been realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s effective income tax rate differs from the
 statutory federal income tax rate as follows for the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal tax benefit rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intercompany transfer of intellectual property&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effective income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Management of the Company has evaluated the positive and negative
 evidence bearing upon the realizability of its deferred tax assets.
 Management has concluded, in accordance with the applicable
 accounting standards, that it is more likely than not that the
 Company may not realize the benefit of its deferred tax assets.
 Accordingly, the net deferred tax assets have been fully reserved.
 Management reevaluates the positive and negative evidence on an
 annual basis. During the years ended December&amp;#xA0;31, 2016, 2015
 and 2014, the change in the valuation allowance was
 $(48.1)&amp;#xA0;million, $80.1&amp;#xA0;million and $65.5&amp;#xA0;million,
 respectively, for income taxes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 At December&amp;#xA0;31, 2016, the Company had federal and state net
 operating loss carryforwards of approximately $1.9&amp;#xA0;billion and
 $1.3&amp;#xA0;billion available, respectively, to reduce future taxable
 income. The federal net operating loss carryforwards will expire at
 various dates beginning in 2018 and the state net operating loss
 carryforwards have started expiring, starting in the current year
 through various future dates. As a result of the Company&amp;#x2019;s
 initial public offering, an ownership change within the meaning of
 Internal Revenue Code Section&amp;#xA0;382 occurred in August 2004. As
 a result, federal net operating loss and credit carry forwards of
 approximately $216.0&amp;#xA0;million are subject to an annual use
 limitation of approximately $13.0&amp;#xA0;million. The annual
 limitation is cumulative and therefore, if not fully utilized in a
 year can be utilized in future years in addition to the
 Section&amp;#xA0;382 limitation for those years. The federal net
 operating losses generated subsequent to the Company&amp;#x2019;s
 initial public offering in August 2004 are currently not subject to
 any such limitation as there have been no ownership changes since
 August 2004 within the meaning of Internal Revenue Code
 Section&amp;#xA0;382. At December&amp;#xA0;31, 2016, the Company had
 research and development credits of $53.0&amp;#xA0;million and
 $38.5&amp;#xA0;million for federal and state purposes, respectively.
 The federal credits begin to expire in 2024, and the state credits
 may be carried forward indefinitely.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company has evaluated the impact of uncertainty related to
 income taxes on its consolidated financial statements. The
 evaluation of an uncertain tax position is a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;two-step&lt;/font&gt;&amp;#xA0;process. The first step is
 recognition: the enterprise determines whether it is&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;that a tax position will be
 sustained upon examination, including resolution of any related
 appeals or litigation processes, based on the technical merits of
 the position. In evaluating whether a tax position has met
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;recognition threshold, the
 enterprise should presume that the position will be examined by the
 appropriate taxing authority that would have full knowledge of all
 relevant information. The second step is measurement: a tax
 position that meets the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;recognition threshold is
 measured to determine the amount of benefit to recognize in the
 financial statements. The tax position is measured at the largest
 amount of benefit that is greater than 50&amp;#xA0;percent likely of
 being realized upon ultimate settlement. Tax positions that
 previously failed to meet the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;recognition threshold should
 be recognized in the first subsequent financial reporting period in
 which that threshold is met. Previously recognized tax positions
 that no longer meet the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;recognition threshold should
 be derecognized in the first subsequent financial reporting period
 in which that threshold is no longer met. The Company believes that
 its income tax filing positions and deductions will be sustained on
 audit and does not anticipate any adjustments that will result in a
 material change to its consolidated financial position. Therefore,
 no liabilities for uncertain income tax positions have been
 recorded. Tax years since 2012 remain subject to examination by the
 major tax jurisdictions in which the Company is subject to tax.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:LongTermPurchaseCommitmentTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_57A8BFD2-C6AE-449E-905E-C8D7D745C002_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The annual purchase requirements under the contract are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.7&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.6&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.5&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2021&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.5&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2022&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.4&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2023&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.4&amp;#xA0;million&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:LongTermPurchaseCommitmentTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_EC7DABA3-C3CE-4429-B5E2-ED9557BF6F97_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;1. Description of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Business&lt;/i&gt; &amp;#x2014; MannKind Corporation and subsidiaries (the
 &amp;#x201C;Company&amp;#x201D;) is a biopharmaceutical company focused on
 the discovery and development of therapeutic products for diseases
 such as diabetes. The Company&amp;#x2019;s only approved product,
 Afrezza, (insulin human [rDNA origin]) inhalation powder, is a
 rapid-acting inhaled insulin that was approved by the U.S. Food and
 Drug Administration (the &amp;#x201C;FDA&amp;#x201D;) on June&amp;#xA0;27, 2014
 to improve glycemic control in adult patients with diabetes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt; &amp;#x2014; On August&amp;#xA0;11, 2014, the
 Company entered into a license and collaboration agreement (the
 &amp;#x201C;Sanofi License Agreement&amp;#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (&amp;#x201C;Sanofi&amp;#x201D;)), pursuant to which Sanofi was responsible
 for Afrezza global commercial, regulatory and development
 activities for Afrezza.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On January&amp;#xA0;4, 2016, the Company received written notification
 from Sanofi of its election to terminate in its entirety the Sanofi
 License Agreement. The effective date of termination (the
 &amp;#x201C;Termination Date&amp;#x201D;) was April&amp;#xA0;4, 2016, which was
 when the Company assumed responsibility for worldwide development
 and commercialization of Afrezza. Under terms of a transition
 agreement, Sanofi continued to fulfill orders for Afrezza in the
 United States until the Company began distributing MannKind-branded
 Afrezza product to major wholesalers in late July 2016. The Company
 began recognizing commercial product sales revenue when
 MannKind-branded Afrezza was dispensed from pharmacies to patients
 in August 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On November&amp;#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &amp;#x201C;Settlement Agreement&amp;#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 (the &amp;#x201C;Sanofi Loan Facility&amp;#x201D;) between the Company and
 Aventisub LLC (&amp;#x201C;Aventisub&amp;#x201D;), a Sanofi affiliate, was
 terminated, with Aventisub agreeing to forgive the full outstanding
 loan balance of $72.0&amp;#xA0;million, which includes
 $0.5&amp;#xA0;million of previously uncharged costs pursuant to the
 Sanofi License Agreement. Sanofi also agreed to purchase
 $10.2&amp;#xA0;million of insulin from the Company in December 2016
 under an existing insulin put option as well as make a cash payment
 of $30.6&amp;#xA0;million to the Company in early January 2017 as
 acceleration and in replacement of all other payments that Sanofi
 would otherwise have been required to make in the future pursuant
 to the insulin put option, without the Company being required to
 deliver any insulin for such payment. The Company and Sanofi also
 agreed to a general release of potential claims against each
 other.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During their initial transition of the commercial responsibilities
 from Sanofi, the Company utilized a contract sales organization to
 promote Afrezza while the Company focused its internal resources on
 establishing a channel strategy, entering into distribution
 agreements and developing &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; assistance programs, a voucher
 program, data agreements and payor relationships. In early 2017,
 the Company recruited their own sales force, which included some of
 the sales reps that previously were employed by the contract sales
 organization. The Company intend to continue the commercialization
 of Afrezza in the United States through their own commercial
 organization. The Company&amp;#x2019;s current strategy for the future
 commercialization of Afrezza outside of the United States, subject
 to receipt of the necessary foreign regulatory approvals, is to
 seek and establish regional partnerships in foreign jurisdictions
 where there are appropriate commercial opportunities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 It has been costly to develop our therapeutic product, conduct
 clinical studies, and market and sell Afrezza. As of and for the
 year ended December&amp;#xA0;31, 2016, the Company has reported an
 accumulated deficit of $2.7&amp;#xA0;billion and has reported negative
 cash flow from operations for each year since inception, except for
 2014, when the Company received the $150.0&amp;#xA0;million upfront
 payment from Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2016, the Company&amp;#x2019;s capital resources
 consisted of cash and cash equivalents of $22.9&amp;#xA0;million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &amp;#x201C;Facility Agreement&amp;#x201D;) with Deerfield
 Private Design Fund II, L.P. (Deerfield Private Design Fund) and
 Deerfield Private Design International II, L.P. (collectively,
 &amp;#x201C;Deerfield&amp;#x201D;) and the First Amendment to Facility
 Agreement and Registration Rights Agreement (the &amp;#x201C;First
 Amendment&amp;#x201D;) that resulted in additional sales of an
 additional tranche of notes (the &amp;#x201C;Tranche B notes&amp;#x201D;)
 (see Note 7 &amp;#x2014; Borrowings) requires the Company to maintain at
 least $25.0&amp;#xA0;million, which can be comprised of cash and cash
 equivalents and available borrowings under the loan arrangement,
 dated as of October&amp;#xA0;2, 2007, between the Company and The Mann
 Group LLC (as amended, restated, or otherwise modified as of the
 date hereof, &amp;#x201C;the Mann Group Loan Arrangement&amp;#x201D;), as of
 the last day of each fiscal quarter.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Additional funding sources that are, or in certain circumstances
 may be available to the Company, include approximately
 $30.1&amp;#xA0;million principal amount of available borrowings under
 The Mann Group Loan Arrangement. A portion of these available
 borrowings may be used to capitalize accrued interest into
 principal, upon mutual agreement of the parties, as it becomes due
 and payable under The Mann Group Loan Arrangement (see Note 6
 &amp;#x2014; Related-party Arrangements). The Company cannot provide
 assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 will need to raise additional capital, whether through a sale of
 equity or debt securities, a strategic business collaboration with
 a pharmaceutical company, the establishment of other funding
 facilities, licensing arrangements, asset sales or other means, in
 order to continue the commercialization of Afrezza and development
 of other product candidates and to support its other ongoing
 activities. The Company cannot provide assurances that such
 additional capital will be available on acceptable terms or at all.
 These factors raise substantial doubt about the Company&amp;#x2019;s
 ability to continue as a going concern. The financial statements do
 not include any adjustments that might result from the outcome of
 this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;14, 2016, the Company received notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that, for the previous 30 consecutive business days, the
 bid price for the common stock closed below the minimum $1.00 per
 share required for continued inclusion on The NASDAQ Global Market.
 The notification letter stated that the Company would be afforded
 180 calendar days, or until March&amp;#xA0;13, 2017, to regain
 compliance with the minimum bid price requirement. In order to
 regain compliance, shares of the Company&amp;#x2019;s common stock must
 maintain a minimum bid closing price of at least $1.00 per share
 for a minimum of 10 consecutive business days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Reverse Stock Split&lt;/i&gt; &amp;#x2014; On March&amp;#xA0;1, 2017, following
 stockholder approval, the Company&amp;#x2019;s board of directors
 approved a reverse stock split ratio of &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5.&amp;#xA0;On&lt;/font&gt;&lt;/font&gt; March&amp;#xA0;1,
 2017, the Company filed with the Secretary of State of the State of
 Delaware a Certificate of Amendment of the Company&amp;#x2019;s Amended
 and Restated Certificate of Incorporation to effect the
 &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5&lt;/font&gt;&lt;/font&gt; reverse stock split of
 the Company&amp;#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&amp;#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&amp;#xA0;The Company&amp;#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&amp;#xA0;3,
 2017.&amp;#xA0;See Note 20 &amp;#x2014; Subsequent Events for further
 information. As a result, all common stock share amounts included
 in these consolidated financial statements have been retroactively
 reduced by a factor of five, and all common stock per share amounts
 have been increased by a factor of five, with the exception of the
 Company&amp;#x2019;s common stock par value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Principles of Consolidation&lt;/i&gt; &amp;#x2014; The consolidated
 financial statements include the accounts of the Company and its
 wholly-owned subsidiaries. Intercompany balances and transactions
 have been eliminated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Segment Information&lt;/i&gt; &amp;#x2014; Operating segments are
 identified as components of an enterprise about which separate
 discrete financial information is available for evaluation by the
 chief operating decision-maker in making decisions regarding
 resource allocation and assessing performance. To date, the Company
 has viewed its operations and manages its business as one segment
 operating in the United States of America.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_D1D88465-EC90-4497-800B-DF8FFA0CB68D_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Estimated&lt;br /&gt;
 Useful&amp;#xA0;Life&lt;br /&gt;
 (Years)&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Land&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;875&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Buildings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;39-40&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,389&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Building improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;5-40&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,957&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Machinery and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;3-15&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,992&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,434&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture, fixtures and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;5-10&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,531&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,502&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(99,575&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,513&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,927&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,749&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RepurchaseAndResaleAgreementsPolicy contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_A6F98F82-CE6E-4205-B16A-4D9D0816ED3F_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;State Research and Development Credit Exchange Receivable&lt;/i&gt;
 &amp;#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for forgoing the
 carryforward of the research and development income tax credits.
 The program provides for an exchange of research and development
 income tax credits for cash equal to 65% of the value of
 corporation tax credit available for exchange. Estimated amounts
 receivable under the program are recorded as a reduction of
 research and development expenses. During the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014, research and development
 expenses were offset by research and development tax credits of
 $246,000, $743,000 and $816,000, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RepurchaseAndResaleAgreementsPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_57EBBE9E-5E4C-4A12-9757-BD96F4F4D0C7_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt; &amp;#x2014; Revenue is recognized when the
 four basic criteria of revenue recognition are met: (1) persuasive
 evidence that an arrangement exists; (2) delivery has occurred or
 services have been rendered; (3) the fee is fixed or determinable;
 and (4) collectability is reasonably assured. When the accounting
 requirements for revenue recognition are not met, the Company
 defers the recognition of revenue by recording deferred revenue on
 the consolidated balance sheets until such time that all criteria
 are met. To date, the Company has had revenue from collaborations,
 commercial sales of Afrezza, and from sales of bulk insulin, which
 are described more fully below.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_4EC5A153-C480-4A6D-A0EC-65EB461EE069_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Borrowings consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Facility Financing Obligation (2019 Notes)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unamortized debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,661&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,418&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,339&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,582&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Senior Convertible Notes (2018 Notes)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unamortized premium&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;660&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unaccreted debt issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(481&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(737&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,635&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,613&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note payable to principal stockholder &amp;#x2014; net carrying
 amount&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,521&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,521&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_F3DB2030-4F39-4BAA-8BAE-4211F79104F6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Components of the net deferred tax assets as of December&amp;#xA0;31,
 2016 and 2015, are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;712,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;721,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,646&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized research&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments from collaboration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss on purchase commitment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,084&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-qualified&lt;/font&gt;&amp;#xA0;stock option expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,941&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized patent costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,310&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;914,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;962,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(914,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(962,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2448C9F0-D035-4442-9364-A045B1CC3C5D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables summarize the components of the basic and
 diluted net income (loss) per common share computations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(In thousands,
 except per share data)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic EPS:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) (numerator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(198,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average common shares (denominator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted EPS:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) (numerator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(198,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities &amp;#x2014; common shares issuable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted weighted average common shares (denominator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,085&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_3743FEDA-3BC3-40B2-BB7B-1C9F88291A02_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Inventories consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Work-in-process&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,120&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,331&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_A8AC687C-EE7E-4427-B01E-C8556D2689CC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company calculated the fair value of employee stock options
 granted during the years ended December&amp;#xA0;31, 2016, 2015 and
 2014 using the following assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="31%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 1.18%&amp;#xA0;&amp;#x2014;&amp;#xA0;1.80%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;1.61%
 &amp;#x2014;1.86%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 1.64%&amp;#xA0;&amp;#x2014;&amp;#xA0;2.11%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.13&amp;#xA0;&amp;#x2014;&amp;#xA0;5.82&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.79&amp;#xA0;&amp;#x2014;&amp;#xA0;5.86&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.77&amp;#xA0;&amp;#x2014;&amp;#xA0;6.09&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 77.57%&amp;#xA0;&amp;#x2014;&amp;#xA0;82.75%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 69.76%&amp;#xA0;&amp;#x2014;&amp;#xA0;71.84%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 73.98%&amp;#xA0;&amp;#x2014;&amp;#xA0;84.85%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_2C0665E9-F65D-4AFA-A67F-17BEA8D926AD_1_4">292488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="2" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1_4">0.7757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1_0">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_1_1">P5Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1_4">407161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_1_0">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1_4">13.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_FB74FC0F-0C1A-4DD4-BEA9-A4B198381723_1_2">4.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_3BD8434B-557F-464A-8F40-F2F08D19B4F9_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt; &amp;#x2014; Other comprehensive
 income (loss) requires that all components of comprehensive income
 (loss) to be reported in the financial statements in the period in
 which they are recognized. Other comprehensive income (loss)
 includes certain changes in stockholders&amp;#x2019; equity that are
 excluded from net income (loss). Specifically, the Company includes
 unrealized gains and losses on foreign exchange translation in
 accumulated other comprehensive loss on the consolidated balance
 sheets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_86583F7C-0C03-488D-9299-930075DED7C6_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Cost of Goods Sold &amp;#x2014;&lt;/i&gt; Cost of goods sold includes the
 costs related to Afrezza product dispensed by pharmacies to
 patients as well as under-absorbed labor and overhead and inventory
 write-offs, which are recorded as expenses in the period in which
 they are incurred, rather than as a portion of the inventory
 cost.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_C6234674-4D8D-4D6B-9240-9452C62539BE_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;7. Borrowings&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Borrowings consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Facility Financing Obligation (2019 Notes)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unamortized debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,661&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,418&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,339&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,582&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Senior Convertible Notes (2018 Notes)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unamortized premium&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;660&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unaccreted debt issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(481&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(737&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,635&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,613&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note payable to principal stockholder &amp;#x2014; net carrying
 amount&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,521&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,521&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Facility Financing Obligation (2019 Notes)&lt;/i&gt; &amp;#x2014; As of
 December&amp;#xA0;31, 2016, there were $55.0&amp;#xA0;million principal
 amount of 2019 notes and $20.0&amp;#xA0;million principal amount of
 Tranche B notes outstanding. As of December&amp;#xA0;31, 2015, there
 were $60.0&amp;#xA0;million principal amount of 2019 notes and
 $20.0&amp;#xA0;million principal amount of Tranche B notes outstanding.
 The 2019 notes accrue interest at annual rate of 9.75% and the
 Tranche B notes accrue interest at an annual rate of 8.75%.
 Interest is paid quarterly in arrears on the last day of each
 March, June, September and December. The Facility Financing
 Obligation principal repayment schedule is comprised of annual
 payments beginning on July&amp;#xA0;1, 2016 and ending December&amp;#xA0;9,
 2019. Future principal payments for the years ended
 December&amp;#xA0;31, 2017, 2018 and 2019 are $20.0&amp;#xA0;million,
 $20.0&amp;#xA0;million and $35.0&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In conjunction with the Facility Agreement, the Company entered
 into a Milestone Rights Agreement with Deerfield which requires the
 Company to make contingent payments to Deerfield, totaling up to
 $90.0&amp;#xA0;million, upon the Company achieving specified
 commercialization milestones. The Milestone Rights were initially
 recorded as a short-term liability equal to $3.2&amp;#xA0;million
 included in accrued expenses and other current liabilities in the
 accompanying consolidated balance sheets and a long-term liability
 equal to $13.1&amp;#xA0;million included in other liabilities. During
 the first quarter of 2015, a milestone triggering event was
 achieved following the Company&amp;#x2019;s product launch on
 February&amp;#xA0;3, 2015, which resulted in a $5.8&amp;#xA0;million
 incremental charge to interest expense due to the increase in
 carrying value of the liability to the required $10.0&amp;#xA0;million
 payment made in February of 2015. During the year ended
 December&amp;#xA0;31, 2014, the first milestone triggering event was
 achieved following the Company&amp;#x2019;s entry into the Sanofi
 License Agreement, which resulted in a $1.9&amp;#xA0;million
 incremental charge to interest expense due to the increase in
 carrying value of the liability to the required $5.0&amp;#xA0;million
 payment, which was paid to Deerfield pursuant to the terms of the
 Milestone Agreement. As of December&amp;#xA0;31, 2016 and 2015, the
 remaining liability balance of $8.9&amp;#xA0;million is classified as a
 long-term liability.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2016, the unamortized debt discount and
 debt issuance costs were $3.7&amp;#xA0;million and $0.1&amp;#xA0;million,
 respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion of debt issuance cost and debt discount in connection
 with the Deerfield financing during the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014 are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion expense &amp;#x2014; debt issuance cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;326&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion expense &amp;#x2014; debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,722&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,553&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,550&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Facility Agreement includes customary representations,
 warranties and covenants, including, a restriction on the
 incurrence of additional indebtedness, and a financial covenant
 which requires the Company&amp;#x2019;s cash and cash equivalents, which
 includes available borrowings on the note payable to principal
 stockholder, on the last day of each fiscal quarter to not be less
 than $25.0&amp;#xA0;million. As discussed in Note 1 &amp;#x2014; Description
 of Business, the Company will need to raise additional capital to
 support its current operating plans. Due to the uncertainties
 related to maintaining sufficient resources to comply with the
 aforementioned covenant, the 2019 notes and the Tranche B notes
 have been classified as current liabilities in the accompanying
 consolidated balance sheets as of December&amp;#xA0;31, 2016 and 2015.
 In the event of &lt;font style="white-space:nowrap"&gt;non-compliance,&lt;/font&gt; Deerfield may declare
 all or any portion of the 2019 notes and/or Tranche B notes to be
 immediately due and payable.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Milestone Rights&lt;/i&gt; &amp;#x2014; The Milestone Agreement includes
 customary representations and warranties and covenants by the
 Company, including restrictions on transfers of intellectual
 property related to Afrezza. The Milestone Rights are subject to
 acceleration in the event the Company transfers its intellectual
 property related to Afrezza in violation of the terms of the
 Milestone Agreement. The Company has initially recorded the
 Milestone Rights at their estimated fair value &amp;#x2014; See Note 2
 &amp;#x2014; Summary of Significant Accounting Policies under Milestone
 Rights Liability.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In determining the fair value of the Milestone Rights, the 13
 individual milestone payments were adjusted for both (i)&amp;#xA0;the
 expected timing and (ii)&amp;#xA0;the probability of achieving the
 milestones, and then discounted to present value using a discount
 rate of 14.5%. Once the initial valuation of each specified
 milestone payment was determined, the individual milestone payments
 were then aggregated to arrive at a total fair value of
 $18.4&amp;#xA0;million. The discount rate was based on the estimated
 cost of equity which was derived using the capital asset pricing
 model. In addition, a 5% risk premium was added to the computation
 of the cost of equity to adjust for &lt;font style="white-space:nowrap"&gt;non-systemic&lt;/font&gt; risk factors, such as the
 Company&amp;#x2019;s lack of product diversification and history of
 financial losses, which were not captured in other model
 inputs.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Security Agreement&lt;/i&gt; &amp;#x2014; In connection with the Facility
 Agreement, the Company and its subsidiary, MannKind LLC, entered
 into a Guaranty and Security Agreement (the &amp;#x201C;Security
 Agreement&amp;#x201D;) with Deerfield and Horizon Sante FLML SA&amp;#x2019;RL
 (collectively, the &amp;#x201C;Purchasers&amp;#x201D;), pursuant to which the
 Company and MannKind LLC each granted the Purchasers a security
 interest in substantially all of their respective assets, including
 respective intellectual property, accounts, receivables, equipment,
 general intangibles, inventory and investment property, and all of
 the proceeds and products of the foregoing. The Security Agreement
 includes customary covenants by the Company and MannKind LLC,
 remedies of the Purchasers and representations and warranties by
 the Company and MannKind LLC. The security interests granted by the
 Company and MannKind LLC will terminate upon repayment of the 2019
 notes and Tranche B notes, if applicable, in full. The
 Company&amp;#x2019;s obligations under the Facility Agreement and the
 Milestone Agreement are also secured by the mortgage on the
 Company&amp;#x2019;s facilities in Danbury, Connecticut, which has a
 carrying value of $28.7&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Embedded Derivatives&lt;/i&gt; &amp;#x2014; The Company identified and
 evaluated a number of embedded features in the notes issued under
 the Facility Agreement to determine if they represented embedded
 derivatives that are required to be separated from the notes and
 accounted for as freestanding instruments. In 2014, the Company
 analyzed the Tranche&amp;#xA0;B notes and identified embedded
 derivatives which required separate accounting. However, all of the
 embedded derivatives were determined to have a &lt;i&gt;de minimis&lt;/i&gt;
 value at December&amp;#xA0;31, 2016 and 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Conversion Option &amp;#x2014;&lt;/i&gt; During 2014, Deerfield elected to
 convert a total of $93.5&amp;#xA0;million of principal, which consisted
 of $20.0&amp;#xA0;million, $33.5&amp;#xA0;million, and $40.0&amp;#xA0;million
 of Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes,
 respectively, into an aggregate 3,464,616 shares of common stock.
 In conjunction with the conversion by Deerfield, we recorded an
 aggregate expense of $6.4&amp;#xA0;million for the difference between
 the principal amount of the notes converted and their carrying
 amount (which included unamortized discount and debt issuance
 costs) which consisted of $1.2&amp;#xA0;million, $3.0&amp;#xA0;million, and
 $2.2&amp;#xA0;million related to the Tranche 1 notes, Tranche 2 notes,
 and Tranche 3 notes, respectively. Further, upon Deerfield
 converting $40.0&amp;#xA0;million of Tranche 3 notes and
 $20.0&amp;#xA0;million of Tranche 1 notes, Deerfield has reached the
 conversion limits (i.e., &amp;#x201C;Applicable Limits&amp;#x201D;) with
 respect to the Facility Agreement and therefore, no additional
 amount of the 2019 notes is convertible.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Issuance of new 5.75% Convertible Senior Subordinated Exchange
 Notes Due 2018 in Exchange for 2015 Notes&lt;/i&gt; &amp;#x2014; On
 July&amp;#xA0;28, 2015, the Company entered into privately-negotiated
 exchange agreements (the &amp;#x201C;Note Exchange Agreements&amp;#x201D;)
 with a select holder of the Company&amp;#x2019;s 5.75% Senior
 Convertible Notes due 2015 (the &amp;#x201C;2015 notes&amp;#x201D;), pursuant
 to which the Company agreed to issue $27.7&amp;#xA0;million aggregate
 principal amount of new 5.75% Convertible Senior Subordinated
 Exchange Notes due 2018 (the &amp;#x201C;2018 notes&amp;#x201D;) to such
 holders in exchange for the delivery to the Company of the same
 principal amount of 2015 notes. The 2018 notes were issued at the
 closing of the exchange on August&amp;#xA0;10, 2015. The Company
 analyzed this exchange and concluded that the exchange represents
 an extinguishment of the 2015 notes and a new issuance of 2018
 notes and recorded such notes at fair value, which resulted in a
 premium of $0.7&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The 2018 notes are the Company&amp;#x2019;s general, unsecured, senior
 obligations, except that the 2018 notes were subordinated to the
 Sanofi Loan facility prior to the extinguishment of the facility on
 November&amp;#xA0;9, 2016. The 2018 notes rank equally in right of
 payment with the Company&amp;#x2019;s other unsecured senior debt. The
 2018 notes bear interest at the rate of 5.75%&amp;#xA0;per year on the
 principal amount, payable semiannually in arrears in cash on
 February&amp;#xA0;15 and August&amp;#xA0;15 of each year, beginning
 February&amp;#xA0;15, 2016, with interest accruing from August&amp;#xA0;15,
 2015. The 2018 notes mature on August&amp;#xA0;15, 2018. Accrued
 interest related to these notes is recorded in accrued expenses and
 other current liabilities on the accompanying consolidated balance
 sheets.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The 2018 notes are convertible, at the option of the holder, at any
 time on or prior to the close of business on the business day
 immediately preceding the stated maturity date, into shares of the
 Company&amp;#x2019;s common stock at an initial conversion rate of 29
 shares per $1,000 principal amount of the 2018 notes, which is
 equal to a conversion price of approximately $34.00 per share, the
 same conversion price as that of the 2015 notes on the date of
 exchange. The conversion rate is subject to adjustment under
 certain circumstances described in an indenture governing the 2018
 notes dated August&amp;#xA0;10, 2015 with Wells Fargo, National
 Association, including in connection with a make-whole fundamental
 change.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 If certain fundamental changes occur, the Company will be obligated
 to pay a fundamental change make-whole premium on any 2018 notes
 converted in connection with such fundamental change by increasing
 the conversion rate on such 2018 notes. In such instances, the
 amount of the fundamental change make-whole premium will be based
 on the Company&amp;#x2019;s common stock price and the effective date of
 the applicable fundamental change. If the Company undergoes certain
 fundamental changes, except in certain circumstances, each holder
 of 2018 notes will have the option to require the Company to
 repurchase all or any portion of that holder&amp;#x2019;s 2018 notes.
 The fundamental change repurchase price will be 100% of the
 principal amount of the 2018 notes to be repurchased plus accrued
 and unpaid interest, if any.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On or after the date that is one year following the original issue
 date of the 2018 notes, the Company will have the right to redeem
 for cash all or part of the 2018 notes if the last reported sale
 price of its common stock exceeds 130% of the conversion price then
 in effect for 20 or more trading days during the 30 consecutive
 trading day period ending on the trading day immediately prior to
 the date of the redemption notice. The redemption price will equal
 the sum of 100% of the principal amount of the 2018 notes to be
 redeemed, plus accrued and unpaid interest. Under the terms of the
 2018 Note Indenture, the conversion option can be &lt;font style="white-space:nowrap"&gt;net-share&lt;/font&gt; settled and the maximum
 number of shares that could be required to be delivered under the
 indenture, including the make-whole shares, is fixed and less than
 the number of authorized and unissued shares less the maximum
 number of shares that could be required to be delivered during the
 term of the 2018 notes under existing commitments. Applying the
 Company&amp;#x2019;s sequencing policy, the Company performed an
 analysis at the time of the offering of the 2018 notes and each
 reporting date since and has concluded that the number of available
 authorized shares at the time of the offering and each subsequent
 reporting date was sufficient to deliver the number of shares that
 could be required to be delivered during the term of the 2018 notes
 under existing commitments.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The 2018 notes provide that upon an acceleration of certain
 indebtedness, including the 9.75% Senior Convertible Notes due in
 2019 (the &amp;#x201C;2019 notes&amp;#x201D;) and the 8.75% Senior
 Convertible Notes due in 2019 (the &amp;#x201C;Tranche B notes&amp;#x201D;)
 issued to Deerfield pursuant to the Facility Agreement, the holders
 may elect to accelerate the Company&amp;#x2019;s repayment obligations
 under the notes if such acceleration is not cured, waived,
 rescinded or annulled. There can be no assurance that the holders
 would not choose to exercise these rights in the event such events
 were to occur.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company incurred approximately $0.8&amp;#xA0;million in issuance
 costs, which are recorded as an offset to the 2018 notes in the
 accompanying consolidated balance sheets. These costs are being
 accreted to interest expense using the effective interest method
 over the term of the 2018 notes.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion of debt issuance expense in connection with the 2018
 notes during the years ended December&amp;#xA0;31, 2016 and 2015 was
 $257,000 and $93,000, respectively. Amortization of the 2018 notes
 premium during the years ended December&amp;#xA0;31, 2016 and 2015 was
 $234,000 and $86,000, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Issuance of Common Stock in Exchange for the 2015 Notes&lt;/i&gt;
 &amp;#x2014; On July&amp;#xA0;28, 2015, the Company entered into separate,
 privately-negotiated exchange agreements (the &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;&amp;#x201C;Stock-for-Note&lt;/font&gt;&lt;/font&gt; Exchange
 Agreements&amp;#x201D;) with certain holders of the 2015 notes pursuant
 to which the Company agreed to issue shares of its common stock to
 such holders in exchange for the delivery to the Company of up to
 $56.9&amp;#xA0;million aggregate principal amount of the 2015
 notes.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Pursuant to the &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Stock-for-Note&lt;/font&gt;&lt;/font&gt; Exchange
 Agreements, the parties agreed to price the exchange transactions
 over a 10 trading day period spanning from July&amp;#xA0;29, 2015 to
 and including August&amp;#xA0;11, 2015. Between July&amp;#xA0;28, 2015 and
 August&amp;#xA0;10, 2015, the Company issued an aggregate of 380,000
 shares of common stock to such holders in exchange for such
 holders&amp;#x2019; delivery to the Company of $8.0&amp;#xA0;million
 aggregate principal amount of the 2015 notes, resulting in a
 weighted-average exchange price of $110.00 per share.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Issuance of New 5.75% Convertible Senior Subordinated Exchange
 Notes Due 2015 in Exchange for the 2015 Notes&lt;/i&gt; &amp;#x2014; On
 August&amp;#xA0;14, 2015, the Company exchanged $32.1&amp;#xA0;million
 aggregate principal amount of newly issued, 5.75% Convertible
 Senior Subordinated Exchange Notes due 2015 (the &amp;#x201C;Exchange
 Notes&amp;#x201D;) for the same principal amount of the Company&amp;#x2019;s
 previously outstanding 2015 notes. The Exchange Notes, payable at
 maturity on September&amp;#xA0;30, 2015, were convertible, at the
 option of each holder thereof, at any time on or prior to the close
 of business on the business day immediately preceding the stated
 maturity date. The holders of the Exchange Notes did not elect to
 convert any of the outstanding principal amount of the Exchange
 Notes into shares of the Company&amp;#x2019;s common stock. As a result,
 on September&amp;#xA0;30, 2015, the Company paid $32.1&amp;#xA0;million to
 settle the Exchange Notes.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Settlement of 2015 Notes and Exchange Notes&lt;/i&gt; &amp;#x2014; On
 August&amp;#xA0;17, 2015, the Company paid $32.2&amp;#xA0;million to settle
 the remaining 2015 notes. As of September&amp;#xA0;30, 2015, all 2015
 notes, including the Exchange Notes, have been settled resulting in
 a total loss on extinguishment of debt equal to $1.0&amp;#xA0;million.
 The loss on extinguishment of debt resulted from the &lt;font style="white-space:nowrap"&gt;write-off&lt;/font&gt; of debt discount and debt
 issuance costs associated with the 2015 notes and Exchange Notes
 and the difference between the principal amounts being exchanged
 for shares of the Company&amp;#x2019;s common stock, pursuant to the
 various &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Stock-for-Note&lt;/font&gt;&lt;/font&gt; Exchange
 Agreements, and the fair market value of the Company&amp;#x2019;s common
 stock issued in exchange for such reduction in principal.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion of debt issuance costs in connection with the 2015 notes
 during the years ended December&amp;#xA0;31, 2015 and 2014 was
 $0.6&amp;#xA0;million and $0.9&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Refer to Note 6 &amp;#x2014; Related-Party Arrangements for information
 regarding the Note payable to principal stockholder.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_1A56E135-AF1B-47F4-BF37-A6D599589F23_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Milestone Rights Liability&lt;/i&gt; &amp;#x2014; On July&amp;#xA0;1, 2013, in
 conjunction with the execution of the Facility Agreement, the
 Company issued Milestone Rights to Deerfield whereby the Company
 agreed to provide Deerfield with &lt;font style="white-space:nowrap"&gt;pre-specified&lt;/font&gt; Milestone Payments upon
 the achievement of 13 specific Milestone Events related to the
 commercial release and future cumulative net sales of Afrezza. The
 Company analyzed the Milestone Rights and determined that the
 agreement does not meet the definition of a freestanding
 derivative. Since the Company has not elected to apply the fair
 value option to the Milestone Rights Purchase Agreement, the
 Company recorded the Milestone Rights at their estimated initial
 fair value and accounted for the Milestone Rights as a
 liability.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The initial fair value estimate of the Milestone Rights was
 calculated using the income approach in which the cash flows
 associated with the specified contractual payments were adjusted
 for both the expected timing and the probability of achieving the
 milestones and discounted to present value using a selected market
 discount rate. The expected timing and probability of achieving the
 milestones was developed with consideration given to both internal
 data, such as progress made to date and assessment of criteria
 required for achievement, and external data, such as market
 research studies. The discount rate was selected based on an
 estimation of required rate of returns for similar investment
 opportunities using available market data. The Milestone Rights
 liability will be remeasured as the specified milestone events are
 achieved. Specifically, as each milestone event is achieved, the
 portion of the initially recorded Milestone Rights liability that
 pertains to the milestone event being achieved, will be remeasured
 to the amount of the specified related milestone payment. The
 resulting change in the balance of the Milestone Rights liability
 due to remeasurement will be recorded in the Company&amp;#x2019;s
 consolidated statements of operations as interest expense.
 Furthermore, the Milestone Rights liability will be reduced upon
 the settlement of each milestone payment. As a result, each
 milestone payment would be effectively allocated between a
 reduction of the recorded Milestone Rights liability and an expense
 representing a return on a portion of the Milestone Rights
 liability paid to the investor for the achievement of the related
 milestone event (see Note&amp;#xA0;7 &amp;#x2014; Borrowings). As of
 December&amp;#xA0;31, 2016, the remaining liability balance is
 $8.9&amp;#xA0;million.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_91A66517-7A08-4CDA-B158-2DF3FAB2AA83_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes information about the
 Company&amp;#x2019;s stock-based award plans as of December&amp;#xA0;31,
 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Outstanding&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Outstanding&lt;br /&gt;
 Restricted&lt;br /&gt;
 Stock Units&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&amp;#xA0;Available&lt;br /&gt;
 for Future&lt;br /&gt;
 Issuance&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2004 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,052,345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,203&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2013 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,399,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;723,763&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,743,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2004 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Employee&lt;/font&gt;
 Directors&amp;#x2019; Stock Option Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;737,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,840,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2589D172-55D5-4077-AAE8-6478DC893E93_1_2">2016-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_26">1.37</us-gaap:EarningsPerShareBasic>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_1_2">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400005">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400007">Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:InterestExpensePolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_D241BB5F-8BFA-4725-A048-6660BA0D74FB_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Interest Expense&lt;/i&gt; &amp;#x2014; Interest costs are expensed as
 incurred, except to the extent such interest is related to
 construction in progress, in which case interest is capitalized.
 Interest cost capitalized for the years ended December&amp;#xA0;31,
 2015 and 2014 was $0.1&amp;#xA0;million and $0.8&amp;#xA0;million,
 respectively. There were no capitalized interest costs for the year
 ended December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InterestExpensePolicyTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_78674D30-0CAA-49AB-A2A5-E610498C15AC_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;14. Employee Benefit Plans&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company administers a 401(k) savings retirement plan (the
 &amp;#x201C;MannKind Retirement Plan&amp;#x201D;) for its employees. For the
 years ended December&amp;#xA0;31, 2016, 2015 and 2014, the Company
 contributed $418,000, $593,000 and $623,000, respectively, to the
 MannKind Retirement Plan.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_CF39DFFF-2E37-4F47-ADB6-CE3CD3A1617F_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;4. Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Estimated&lt;br /&gt;
 Useful&amp;#xA0;Life&lt;br /&gt;
 (Years)&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Land&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;875&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Buildings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;39-40&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,389&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Building improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;5-40&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,957&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Machinery and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;3-15&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,992&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,434&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture, fixtures and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="white-space:nowrap"&gt;5-10&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,531&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,502&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(99,575&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,513&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,927&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,749&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Depreciation and amortization expense related to property and
 equipment for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014, was $2.4&amp;#xA0;million, $11.0&amp;#xA0;million and
 $9.8&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The December&amp;#xA0;31, 2016 amounts do not include the Valencia
 property because it is classified as held for sale as of that
 date.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with the Company&amp;#x2019;s quarterly assessment of
 impairment indicators, the Company evaluated the continued lower
 than expected sales of Afrezza as reported by Sanofi throughout the
 fourth quarter of 2015, revised forecasts for sales of Afrezza
 provided by Sanofi in the fourth quarter of 2015 and level of
 commercial production in the fourth quarter of 2015, as well as the
 uncertainty associated with Sanofi&amp;#x2019;s announcement during the
 fourth quarter of their intent to reorganize their diabetes
 business. These factors indicated potentially significant changes
 in the timing and extent of cash flows, and the Company therefore
 determined that an impairment indicator existed in the fourth
 quarter of 2015 and recorded an impairment for the year ended
 December&amp;#xA0;31, 2015. No such indications were identified in the
 current year ended December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company identified two primary asset groups to be evaluated for
 impairment: the Danbury manufacturing facility, which currently
 performs all the manufacturing of Afrezza, and the Valencia
 facility, which was previously the Company&amp;#x2019;s corporate
 headquarters. The Danbury manufacturing facility was the primary
 asset group that was impacted by the impairment indicators noted
 above but the Company also evaluated the Valencia facility for
 potential impairment given the circumstances and identified an
 impairment charge of $1.8&amp;#xA0;million based on a valuation
 utilizing a combination of market, income and cost approaches.
 Within the Danbury manufacturing facility, the Company identified
 the machinery and equipment as the primary assets within the asset
 group as they are associated with the production of Afrezza. As
 such, the Company performed the fixed asset impairment test and
 performed the first step to test for recoverability of the Danbury
 manufacturing facility by utilizing two undiscounted cash flow
 projections and applying a probability weighted average to those
 cash flow projections. The first undiscounted cash flow projection
 was developed under a scenario assuming Sanofi would continue to
 sell and market Afrezza as the termination of the arrangement by
 Sanofi was not known as of the balance sheet date. The second
 undiscounted cash flow projection assumed Sanofi would terminate
 the Sanofi License Agreement and that the Company would
 manufacture, sell and market Afrezza independently.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Based on the evaluation performed, the probabilities assigned to
 the two undiscounted cash flows were not significant to the
 evaluation due to the projected negative cash flows over the
 estimation period, and it was determined that the probability
 weighted undiscounted cash flows were not sufficient to recover the
 carrying value of the Danbury manufacturing facility. As such, the
 Company was required to determine the fair value of the Danbury
 manufacturing facility to recognize an impairment loss if the
 carrying amount exceeds its fair value. The Company determined the
 fair value of the Danbury manufacturing facility by applying the
 highest and best use valuation concept and utilizing the market
 approach valuation technique to value the machinery and equipment
 and a combination of the market approach and cost approach in
 valuing the land, buildings and building improvements. As a result
 of this assessment, the Company recorded, as of December&amp;#xA0;31,
 2015, an impairment charge of $138.6&amp;#xA0;million for the Danbury
 manufacturing facility.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The December&amp;#xA0;31, 2015 balances have been reclassified to the
 current year presentation by allocating an impairment of
 $140.4&amp;#xA0;million, which was previously disclosed in total, to
 the individual asset groups. An additional impairment of
 $0.7&amp;#xA0;million was charged to the individual asset groups for
 the year ended December&amp;#xA0;31, 2016, which is included in
 property and equipment impairment in the accompany consolidated
 statements of operations, additionally with a $0.6&amp;#xA0;million
 impairment charge related to assets held for sale.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_8E6F15AB-A9E9-4D8C-9B51-184D89E74F08_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;State Research and Development Credit Exchange Receivable&lt;/i&gt;
 &amp;#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for foregoing the
 carryforward of the research and development credits. The program
 provides for an exchange of research and development income tax
 credits for cash equal to 65% of the value of corporation tax
 credit available for exchange. Estimated amounts receivable under
 the program are recorded as a reduction of research and development
 expenses. These amounts are included in prepaid expenses and other
 current assets on the consolidated balance sheets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_4126A686-7E64-41AE-A51E-05107D647216_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;18. Restructuring Charges&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In September&amp;#xA0;2016, the Company initiated a restructuring of
 its organization in order to conserve resources for commercial
 sales and marketing of Afrezza and to align cost of goods sold in
 support of these commercial efforts (2016 Restructuring). In
 connection with the 2016 Restructuring, the Company reduced its
 total workforce by approximately 18% to 155 employees. The Company
 recorded charges of approximately $1.5&amp;#xA0;million, primarily for
 employee severance as well as other related termination benefits.
 The $1.5&amp;#xA0;million of costs associated with the 2016
 Restructuring are included in cost of goods sold, research and
 development and selling, general and administrative in the
 consolidated statements of operations as $0.4&amp;#xA0;million,
 $0.7&amp;#xA0;million and $0.4&amp;#xA0;million, respectively, for the year
 ended December&amp;#xA0;31, 2016. The Company substantially paid out
 the obligation for the 2016 Restructuring in the fourth quarter of
 2016, resulting in a remaining accrual balance for the 2016
 Restructuring of $0.2 million at December&amp;#xA0;31, 2016. The
 Company expects to substantially pay out the remainder of this
 obligation by the first quarter of 2017.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In 2015, the Company initiated a restructuring of the organization
 as a result of its shift to commercial production of Afrezza
 (&amp;#x201C;2015 Restructuring&amp;#x201D;). In connection with the 2015
 Restructuring, the Company reduced its total workforce by
 approximately 26% to 198 employees. The Company recorded charges of
 approximately $6.0&amp;#xA0;million, primarily for employee severance
 as well as other related termination benefits. The
 $6.0&amp;#xA0;million of costs associated with the 2015 Restructuring
 are included in operating expenses for cost of goods sold, research
 and development and selling, general and administrative in the
 consolidated statements of operations as $1.4 million,
 $1.3&amp;#xA0;million and $3.3&amp;#xA0;million, respectively, for the year
 ended December&amp;#xA0;31, 2015. As of December&amp;#xA0;31, 2016 and
 2015, the Company had a remaining accrual balance for the 2015
 Restructuring of $1.2&amp;#xA0;million and $3.0&amp;#xA0;million,
 respectively. Certain of the severance arrangements for executives
 in the 2015 Restructuring were long-term, which the Company expects
 to substantially pay out the remainder of this obligation by the
 third quarter of 2017.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 A reconciliation of beginning and ending liability balances for the
 2016 and 2015 Restructuring charges, which is included in accrued
 expenses and other current liabilities, is as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;br /&gt;
 Restructuring&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;br /&gt;
 Restructuring&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; January 1, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs incurred and charged to expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,040&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,040&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs paid or settled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,012&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,012&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; December 31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs incurred and charged to expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,475&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs paid or settled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,266&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,421&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,687&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,167&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_184708F5-846C-4EEF-B518-51B55AC1936F_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Research and Development Expenses&lt;/i&gt; &amp;#x2014; Research and
 development expenses consist of costs associated with the clinical
 trials of the Company&amp;#x2019;s product candidates, manufacturing
 supplies and other development materials, compensation and other
 expenses for research and development personnel, costs for
 consultants and related contract research, facility costs, and
 depreciation. Research and development costs, which are net of any
 tax credit exchange recognized for the Connecticut state research
 and development credit exchange program, are expensed as incurred.
 The Company began commercial manufacturing in the latter part of
 the fourth quarter of 2014. Commercial manufacturing costs incurred
 in the fourth quarter of 2014 were included in research and
 development expense and were immaterial for the year ended
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RevenueRecognitionDeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_EE9CBED8-0649-46A7-85AB-9A64DC4BEA20_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Deferred Costs from Collaboration &amp;#x2014;&lt;/i&gt; Deferred costs
 from collaboration represents the costs of product manufactured and
 sold to Sanofi, as well as certain direct costs associated with a
 firm purchase commitment entered into in connection with the
 collaboration with Sanofi. During the third quarter of 2016, the
 costs related to the Sanofi product sales were recognized as costs
 of revenue &amp;#x2014; collaboration in the consolidated statements of
 operations, as related revenue was recognized at that time.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Deferred Costs from Commercial Product Sales &amp;#x2014;&lt;/i&gt;
 Deferred costs from commercial product sales represents the cost of
 product (including labor, overhead and costs to ship to third party
 logistics) shipped to ICS and wholesale distributors, but not yet
 dispensed by pharmacies to patients.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:RevenueRecognitionDiscounts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_208A013A-0110-482B-9383-FF275627CACC_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Prompt Pay Discounts &amp;#x2014;&lt;/i&gt; The Company offers cash
 discounts to its customers, generally 2% of the sales price, as an
 incentive for prompt payment. The Company accounts for cash
 discounts by reducing accounts receivable by the prompt pay
 discount amount and recognizes the discount as a reduction of
 revenue in the same period the related revenue is recognized.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Rebates &amp;#x2014;&lt;/i&gt; The Company participates in federal and
 state government-managed Medicare and Medicaid rebate programs and
 intends to pursue participation in certain other qualifying federal
 and state government programs whereby discounts and rebates are
 provided to participating federal and state government entities.
 Rebates provided through these other qualifying programs are
 included in the Medicaid and Medicare rebate accrual. The Company
 accounts for these rebates by establishing an accrual equal to the
 estimate of rebate claims attributable to a sale and determines its
 estimate of the rebates accrual based on historical payor data
 provided by a third-party vendor along with additional data
 including a forecasted participation rate for Medicare and
 Medicaid. From that data, as well as input received from
 MannKind&amp;#x2019;s commercial team, an estimated participation rate
 for Medicare and Medicaid is determined and applied at the mandated
 rate for those sales. Any new information regarding changes in the
 programs&amp;#x2019; regulations and guidelines or any changes in the
 Company&amp;#x2019;s government price reporting calculations that would
 impact the amount of the rebates will also be taken into account in
 determining or modifying the appropriate reserve. The time period
 between the date the product is sold into the channel and the date
 such rebates are paid ranges from approximately six to nine months.
 As such, continuous monitoring of these estimates are performed on
 a periodic basis and if necessary, adjusted to reflect new facts
 and circumstances. Rebates are recognized as a reduction of revenue
 in the period the related revenue is recognized.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionDiscounts>
  <us-gaap:RevenueRecognitionMultipleElementArrangements contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_70B2F1AB-9251-4E25-B74A-CDFC11302A21_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Net Revenue &amp;#x2014; Collaborations
 &amp;#x2014;&lt;/i&gt; The Company enters into collaborations under which we
 must perform certain obligations and we receive periodic payments.
 We evaluate the collaborations under the multiple element revenue
 recognition accounting guidance. Revenue arrangements with multiple
 elements are divided into separate units of accounting if certain
 criteria are met, including whether the delivered elements have
 stand-alone value to the customer. When deliverables are separable,
 consideration received is allocated to the separate units of
 accounting based on the relative selling price of each deliverable
 and the appropriate revenue recognition principles are applied to
 each unit.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The assessment of multiple element arrangements requires judgment
 in order to determine the appropriate units of accounting and the
 points in time that, or periods over which, revenue should be
 recognized. The terms of and the accounting for the Company&amp;#x2019;s
 collaborations are described more fully in Note 8 &amp;#x2014;
 Collaboration Arrangements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionMultipleElementArrangements>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_1A323914-71E2-4CEF-82EE-78E6CBCF9C3D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s effective income tax rate differs from the
 statutory federal income tax rate as follows for the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal tax benefit rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intercompany transfer of intellectual property&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effective income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B5931914-D976-4C2A-9ECD-9E34B3AC933C_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion of debt issuance cost and debt discount in connection
 with the Deerfield financing during the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014 are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion expense &amp;#x2014; debt issuance cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;326&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accretion expense &amp;#x2014; debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,722&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,553&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,550&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_CF9614E0-C0CB-42BF-A1B3-BBA7EFF86752_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 A reconciliation of beginning and ending liability balances for the
 2016 and 2015 Restructuring charges, which is included in accrued
 expenses and other current liabilities, is as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;br /&gt;
 Restructuring&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;br /&gt;
 Restructuring&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; January 1, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs incurred and charged to expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,040&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,040&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs paid or settled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,012&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,012&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; December 31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs incurred and charged to expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,475&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Costs paid or settled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,266&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,421&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,687&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrual &amp;#x2014; December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,167&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_11C974C4-606E-47E2-9488-0E25DD2F4881_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is as follows
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Consultant-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,725&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_DA742A45-9EAA-48D3-A85F-D31DC3929E8E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes information about stock options
 outstanding:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number of&lt;br /&gt;
 Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price per&amp;#xA0;Share&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&amp;#xA0;($000)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,955,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,236,693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55,231&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(407,161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(199,890&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,399,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,414,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_9C235D6F-630D-4B4A-9A7D-90EE775ABF16_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Segment Information&lt;/i&gt; &amp;#x2014; Operating segments are
 identified as components of an enterprise about which separate
 discrete financial information is available for evaluation by the
 chief operating decision-maker in making decisions regarding
 resource allocation and assessing performance. To date, the Company
 has viewed its operations and manages its business as one segment
 operating in the United States of America.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1_2">2236693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_679A1CE4-4429-404F-AE5C-9AC830D3D369_1_4">11.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_679A1CE4-4429-404F-AE5C-9AC830D3D369_1_2">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1_1">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B8EEC408-B96D-48D4-87C0-94724866597E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;16. Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2016, the Company sold in a registered offering an aggregate
 of 9,708,737 shares of common stock together with A Warrants
 exercisable for up to an aggregate of 7,281,553 shares of common
 stock and B Warrants exercisable for up to an aggregate of
 2,427,184 shares of common stock with a total fair value of
 $44.7&amp;#xA0;million. Each of the warrants has an exercise price of
 $7.50 per share. The A Warrants became exercisable upon issuance
 and will expire two years thereafter. The B Warrants will become
 exercisable beginning in May 2017 and will expire 30 months after
 the date of issuance. The shares of common stock and the warrants
 are immediately separable and issued separately. There have been no
 warrants exercised as of December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company determined that the A Warrants require liability
 classification primarily due to a price-protection clause that
 applies in the event of certain dilutive financings. The fair value
 of the A Warrants was recorded as warrant liability in the
 consolidated balance sheet at issuance and is adjusted to fair
 value at each reporting period until exercise or expiration. The
 Company determined that the B Warrants met the criteria for equity
 classification and has accounted for such warrants in additional
 paid in capital.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2016 and May&amp;#xA0;12, 2016, the fair value
 of the A Warrants liability was $7.4&amp;#xA0;million and
 $12.8&amp;#xA0;million, respectively. As of May&amp;#xA0;12, 2016, the fair
 value of the B Warrants at issuance was $5.0&amp;#xA0;million. The fair
 value of the A Warrants liability as of December&amp;#xA0;31, 2016 was
 estimated using a Monte Carlo valuation pricing model with the
 following underlying assumptions: (a)&amp;#xA0;a risk-free interest
 rate of 1.1%; (b) an assumed dividend yield of zero percent;
 (c)&amp;#xA0;an expected term of 1.4 years; and (d)&amp;#xA0;an expected
 volatility of 118%. The fair value of the A Warrants liability as
 of May&amp;#xA0;12, 2016, was estimated using a Monte Carlo valuation
 pricing model with the following underlying assumptions: (a)&amp;#xA0;a
 risk-free interest rate of 0.76%; (b) an assumed dividend yield of
 zero percent; (c)&amp;#xA0;an expected term of 2.0 years; and
 (d)&amp;#xA0;an expected volatility of 95%. The Company assumed a
 probability of a dilutive financing event or an equity event, as
 defined in the agreement, of 10% for the each of the measurement
 periods.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 For the year ended December&amp;#xA0;31, 2016, the Company recognized a
 change in fair value of warrant liability of $5.4&amp;#xA0;million in
 the consolidated statements of operations to reflect the fair value
 adjustments of the A Warrant liability from the date of
 issuance.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_4_5">104758</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_69F7D083-1F93-4060-A9D4-39C8CF942182_1_3">55231</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_91035B87-87E3-4A63-A89A-CA0E8F79BD04_4_6">43672</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:UseOfEstimates contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_5218A098-C2AD-45E2-88EA-1F99D8EF86A6_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Financial Statement Estimates&lt;/i&gt; &amp;#x2014; The preparation of
 financial statements in conformity with accounting principles
 generally accepted in the United States of America (GAAP) requires
 management to make estimates and assumptions that affect the
 amounts reported in the financial statements and accompanying
 notes. Actual results could differ from those estimates. Management
 considers many factors in selecting appropriate financial
 accounting policies, and in developing the estimates and
 assumptions that are used in the preparation of the financial
 statements. Management must apply significant judgment in this
 process. The more significant estimates reflected in these
 accompanying consolidated financial statements include revenue
 recognition, assessing long-lived assets for impairment, accrued
 expenses, including clinical study expenses, inventory
 recoverability, valuation of the facility financing obligation,
 loss on purchase commitment, warrant liability, milestone rights,
 stock-based compensation and the determination of the provision for
 income taxes and corresponding deferred tax assets and liabilities
 and any valuation allowance recorded against net deferred tax
 assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B5DB5464-34C3-40E7-B53F-70E0A4B47308_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#x2014; As of December&amp;#xA0;31,
 2016, the Company had three active stock-based compensation plans,
 which are described more fully in Note 12 &amp;#x2014; Stock Award
 Plans. The Company accounts for all share-based payments to
 employees, including grants of stock awards and the compensatory
 elements of the employee stock purchase plan. All share-based
 payments to employees, including grants of stock options,
 restricted stock units, performance-based awards and the
 compensatory elements of employee stock purchase plans, are
 recognized in the consolidated statements of operations based upon
 the fair value of the awards at the grant date. The Company uses
 the Black-Scholes option valuation model to estimate the grant date
 fair value of employee stock options and the compensatory elements
 of employee stock purchase plans. Option valuation models require
 the input of assumptions, including the expected life of the
 stock-based awards, the estimated stock price volatility, the
 risk-free interest rate and the expected dividend yield. The
 expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Restricted
 stock units are valued based on the market price on the grant date.
 The Company evaluates stock awards with performance conditions as
 to the probability that the performance conditions will be met and
 estimates the date at which the performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_43B31B75-43DF-493F-AAF0-E40EB763AFE6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;11. Net Income (Loss) per Common Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&amp;#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&amp;#x2019;s common
 stock par value. See Note 1 &amp;#x2014; Description of Business.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive. During 2015, 1,800,000 shares of the Company&amp;#x2019;s
 common stock, which were loaned to Bank of America pursuant to the
 terms of a share lending agreement, were issued and outstanding,
 with the holder of the borrowed shares having all the rights of a
 holder of the Company&amp;#x2019;s common stock. As the share borrower
 was required to return all borrowed shares to the Company, the
 borrowed shares were not considered outstanding for the purpose of
 computing and reporting basic or diluted loss per share during the
 period presented for 2015. These shares were returned to the
 Company in the third quarter of 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables summarize the components of the basic and
 diluted net income (loss) per common share computations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(In thousands,
 except per share data)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic EPS:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) (numerator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(198,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average common shares (denominator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted EPS:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) (numerator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(198,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities &amp;#x2014; common shares issuable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted weighted average common shares (denominator)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,085&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Common shares issuable represents incremental shares of common
 stock which consist of stock options, restricted stock units,
 warrants, and shares that could be issued upon conversion of the
 senior convertible notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Potentially dilutive securities outstanding that are considered
 antidilutive are summarized as follows (in shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,530,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,955,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,308,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion of senior convertible notes into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,464,616&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,740,597&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;814,919&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,997,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;702,867&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;522,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,788,281&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,946,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,292,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="2" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_1_4">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <dei:EntityRegistrantName contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400001">MANNKIND CORP</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6F7D00DA-A69D-4DCF-BFB4-B34D907D0768_1_400006">No</dei:EntityVoluntaryFilers>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_BFDB18A7-17B7-4053-93DB-2EE8592F6E89_1_2">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_829D106E-61D3-44E7-AA8F-7FEFB2E03FC0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;9. Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The carrying amounts reported in the accompanying consolidated
 financial statements for cash, accounts receivable, accounts
 payable and accrued expenses and other current liabilities
 approximate their fair value due to their relatively short
 maturities. The fair value of the cash equivalents, note
 payable&amp;#xA0;to principal stockholder, senior convertible notes,
 the Facility Financing Obligation (as defined below), the Milestone
 Rights (as defined below) and warrant liability are discussed
 below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Cash Equivalents&lt;/i&gt; &amp;#x2014; As of December&amp;#xA0;31, 2016 and
 2015, the Company held $20.5&amp;#xA0;million and $55.8&amp;#xA0;million,
 respectively, of cash equivalents, consisting of money market
 funds. The fair value of these money market funds was determined by
 using quoted prices for identical investments in an active market
 (Level 1 in the fair value hierarchy).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Note Payable to Principal Stockholder&lt;/i&gt; &amp;#x2014; The fair value
 of the note payable to the Company&amp;#x2019;s principal stockholder
 cannot be reasonably estimated as the Company would not be able to
 obtain a similar credit arrangement in the current economic
 environment. Therefore, the fair value is based upon carrying
 value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Financial Liabilities&lt;/i&gt; &amp;#x2014; The following tables set forth
 the fair value of the Company&amp;#x2019;s financial instruments (in
 millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;As of December&amp;#xA0;31, 2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Carrying&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility Financing Obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability (at recurring fair values)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;As of December&amp;#xA0;31, 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Carrying&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility Financing Obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone Rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table provides a roll forward of the fair values of
 financial assets and liabilities that are carried at fair value (in
 millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Warrants&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Assets&amp;#xA0;Held&amp;#xA0;for&lt;br /&gt;
 Sale&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, January&amp;#xA0;1, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value, December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Senior Convertible Notes&lt;/i&gt; &amp;#x2014; The estimated fair value of
 the 2018 notes was calculated based on model-derived valuations
 where inputs were observable, such as the Company&amp;#x2019;s stock
 price and yields on U.S. Treasury notes and actively traded bonds,
 and &lt;font style="WHITE-SPACE: nowrap"&gt;non-observable,&lt;/font&gt; such
 as the Company&amp;#x2019;s longer-term historical volatility, and
 estimated yields implied from any available market trades of the
 Company&amp;#x2019;s issued debt instruments. As there is no current
 active and observable market for the 2018 notes, the Company
 determined the estimated fair value using a convertible bond
 valuation model within a lattice framework. The convertible bond
 valuation model combined expected cash flows based on terms of the
 notes with market-based assumptions regarding risk-free rate,
 risk-adjusted yields (20%), stock price volatility (111%) and
 recent price quotes and trading information regarding Company
 issued debt instruments and shares of common stock into which the
 notes are convertible.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Facility Financing Obligation&lt;/i&gt; &amp;#x2014; As discussed in Note 7
 &amp;#x2014; Borrowings, in connection with the Facility Agreement, the
 Company issued 2019 notes and subsequently issued Tranche B notes
 (the &amp;#x201C;Facility Financing Obligation&amp;#x201D;). As there is no
 current observable market for the Facility Financing Obligation,
 the Company determined the estimated fair value using a bond
 valuation model based on a discounted cash flow methodology. The
 bond valuation model combined expected cash flows associated with
 principal repayment and interest based on the contractual terms of
 the debt agreement discounted to present value using a selected
 market discount rate. On December&amp;#xA0;31, 2016 the market discount
 rate was recalculated at 12.0% for the Facility Financing
 Obligation. Under the terms of the Facility Agreement, the Company
 is restricted from distributing any of its assets or declaring and
 distributing a dividend to its stockholders.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Milestone Rights Liability&lt;/i&gt; &amp;#x2014; In addition to the
 Facility Financing Obligation, the Company also issued certain
 rights to receive payments of up to $90.0&amp;#xA0;million upon
 occurrence of specified strategic and sales milestones (the
 &amp;#x201C;Milestone Rights&amp;#x201D;). These rights are not reflected in
 the Facility Financing Obligation. The estimated fair value of the
 Milestone Rights was calculated using the income approach in which
 the cash flows associated with the specified contractual payments
 were adjusted for both the expected timing and the probability of
 achieving the milestones discounted to present value using a
 selected market discount rate (Level 3 in the fair value
 hierarchy). The expected timing and probability of achieving the
 milestones, starting in 2014, was developed with consideration
 given to both internal data, such as the Company&amp;#x2019;s forecast,
 progress made to date towards meeting the milestones, and
 assessment of criteria required for achievement, and external data,
 such as market research studies. The discount rate (14.5%)&amp;#xA0;was
 selected based on an estimation of required rate of returns for
 similar investment opportunities using available market data. As of
 December&amp;#xA0;31, 2016, the carrying value of the Milestone Rights
 is $8.9&amp;#xA0;million, classified as a long-term liability and the
 fair value is estimated at $18.4&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Warrant Liability&lt;/i&gt; &amp;#x2014; Warrant liabilities are measured
 at fair value using a Monte Carlo pricing valuation model and
 various assumptions. The significant unobservable input used in
 measuring the fair value of the common stock warrant liabilities is
 the expected volatility. Significant increases in volatility would
 result in a higher fair value measurement (Level 3 in the fair
 value hierarchy). See Note 16 &amp;#x2014; Warrants for further
 discussion of the valuation technique and inputs used in the fair
 value measurement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Sanofi Loan Facility&lt;/i&gt; &amp;#x2014; As discussed in Note 8 &amp;#x2014;
 Collaboration Arrangements, the Sanofi Loan Facility consisted of a
 senior secured revolving promissory note and a guaranty and
 security agreement with an affiliate of Sanofi which provided the
 Company with a secured loan facility of up to $175.0&amp;#xA0;million
 to fund the Company&amp;#x2019;s share of net losses under the Sanofi
 License Agreement. The estimated fair value was determined using a
 discounted cash flow model where time outstanding and discount rate
 were primary variables. This method considered the key elements of
 the contractual terms of the Sanofi Loan Facility, market-based
 estimated cost of capital, and time value of money, namely the
 amount of time to settlement and the estimated discount rate
 (11%)&amp;#xA0;appropriate for the liability (Level 3 in the fair value
 hierarchy). The Sanofi Loan Facility was forgiven on
 November&amp;#xA0;9, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There were no transfers of assets or liabilities between the fair
 value measurement levels during the twelve months ended
 December&amp;#xA0;31, 2016, 2015 and 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Assets and Liabilities Measured at Fair Value on a &lt;font style="WHITE-SPACE: nowrap"&gt;Non-recurring&lt;/font&gt; Basis&lt;/i&gt; &amp;#x2014; Land,
 buildings, and machinery and equipment, with a carrying amount of
 $189.2&amp;#xA0;million, were written down to a fair value of
 $48.8&amp;#xA0;million, resulting in an impairment charge of
 $140.4&amp;#xA0;million, which is included in our consolidated
 statements of operations for the year ended December&amp;#xA0;31, 2015.
 See Note &lt;font style="WHITE-SPACE: nowrap"&gt;4-&lt;/font&gt; Property and
 Equipment for further discussion of the valuation technique and
 inputs used in the fair value measurement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 An additional impairment of $0.7&amp;#xA0;million was charged for the
 year ended December&amp;#xA0;31, 2016. At that time, an analysis of the
 lower of carrying value to fair value, which was deemed to be the
 sales price of the property, less selling costs determined a loss
 of $0.6 million, which is included in property and equipment
 impairment on the consolidated statement of operations for
 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our assessment of the real property includes Level&amp;#xA0;3 inputs,
 and was based on a combination of the income, market and cost
 approaches and the market approach was used for machinery and
 equipment which required Level&amp;#xA0;3 inputs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Embedded Derivatives&lt;/i&gt; &amp;#x2014; The Company identified and
 evaluated a number of embedded features in the notes issued under
 the Facility Agreement to determine if they represented embedded
 derivatives that are required to be separated from the notes and
 accounted for as freestanding instruments. The Company analyzed the
 Tranche B notes and identified embedded derivatives, which required
 separate accounting. However, all of the embedded derivatives were
 determined to have a &lt;i&gt;de minimis&lt;/i&gt; value at December&amp;#xA0;31,
 2016 and 2015.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_198A9FBD-18BC-4F3B-AEE1-44A253662E4A_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Income Taxes&lt;/i&gt; &amp;#x2014; The provisions for federal, foreign,
 state and local income taxes are calculated on &lt;font style="white-space:nowrap"&gt;pre-tax&lt;/font&gt; income based on current tax law
 and include the cumulative effect of any changes in tax rates from
 those used previously in determining deferred tax assets and
 liabilities. Deferred income tax assets and liabilities are
 measured using enacted tax rates expected to apply to taxable
 income in the year in which the temporary differences are expected
 to be recovered or settled. A valuation allowance is recorded to
 reduce net deferred income tax assets to amounts that are more
 likely than not to be realized.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Income tax positions are considered for uncertainty. The Company
 believes that its income tax filing positions and deductions will
 be sustained on audit and does not anticipate any adjustments that
 will result in a material change to its financial position.
 Therefore, no liabilities for uncertain income tax positions have
 been recorded. If a tax position does not meet the minimum
 statutory threshold to avoid payment of penalties, the Company
 recognizes an expense for the amount of the penalty in the period
 the tax position is claimed in the tax return of the Company. The
 Company recognizes interest accrued related to unrecognized tax
 benefits in income tax expense, if any. Penalties, if probable and
 reasonably estimable, are recognized as a component of income tax
 expense.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Significant management judgment is involved in determining the
 provision for income taxes, deferred tax assets, deferred tax
 liabilities, and any valuation allowance recorded against deferred
 tax assets. Due to uncertainties related to the realization of the
 Company&amp;#x2019;s deferred tax assets as a result of its history of
 operating losses, a full valuation allowance has been established
 against the total deferred tax asset balance. The valuation
 allowance is based on management&amp;#x2019;s estimates of taxable
 income by jurisdiction in which the Company operates and the period
 over which deferred tax assets will be recoverable. In the event
 that actual results differ from these estimates or the Company
 adjusts these estimates in future periods, a change in the
 valuation allowance may be needed.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_312B7B0D-D5A1-4364-9CEF-C00A842F3C6D_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Property and Equipment&lt;/i&gt; &amp;#x2014; Property and equipment are
 depreciated using the straight-line method over the estimated
 useful lives of the related assets. Leasehold improvements are
 amortized over the term of the lease or the service lives of the
 improvements, whichever is shorter. Maintenance and repairs are
 expensed as incurred. Assets under construction are not depreciated
 until placed into service.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt; &amp;#x2014; The Company
 evaluates long-lived assets for impairment whenever events or
 changes in circumstances indicate that the carrying value of an
 asset may not be recoverable. Assets are considered to be impaired
 if the carrying value may not be recoverable.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 If the Company believes an asset to be impaired, the impairment
 recognized is the amount by which the carrying value of the asset
 exceeds the fair value of the asset. Fair value is determined using
 the market, income or cost approaches as appropriate for the asset.
 Any write-downs are treated as permanent reductions in the carrying
 amount of the asset and an operating loss would be recognized.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recorded an asset impairment of $1.3 million and $140.4
 million for the years ended December 31, 2016 and 2015,
 respectively. No asset impairment was recognized during the year
 ended December 31, 2014 (see Note 4 &amp;#x2014; Property and Equipment
 and Note 20 &lt;i&gt;&amp;#x2014;&lt;/i&gt; Subsequent Events).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_88BB513C-5289-4E2F-80EC-37B45FF418D8_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;19. Selected quarterly financial data (unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Summarized quarterly financial data for the years ended
 December&amp;#xA0;31, 2016 and 2015, are set forth in the following
 tables:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;March&amp;#xA0;31&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;September&amp;#xA0;30&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;162,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,873&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,959&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;126,520&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,976&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss) per share &amp;#x2014; basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.33&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.32&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss) per share &amp;#x2014; diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.33&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute basic net income
 (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,771&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,061&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,627&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,676&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute diluted net income
 (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,771&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,061&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,510&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,658&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,910&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,857&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(277,020&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss per share &amp;#x2014; basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.38&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.36&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.39&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.30&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute basic and diluted
 net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,783&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,203&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,862&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Impairment charges of $242.7&amp;#xA0;million were recorded in the
 fourth quarter of 2015 related to long-lived assets, inventory and
 loss on purchase commitments.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In the third quarter of 2016, the Company recognized net
 revenue-collaboration of $161.8&amp;#xA0;million attributable to
 collaboration with Sanofi (See Note 8 &amp;#x2014; Collaboration
 Arrangements).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In the fourth quarter of 2016, the Company recognized net
 revenue-collaboration of $10.2&amp;#xA0;million attributable to
 collaboration with Sanofi and $72.0&amp;#xA0;million gain on
 extinguishment of debt (See Note 8 &amp;#x2014; Collaboration
 Arrangements)&lt;/p&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_C82C93FF-EF51-475F-9B11-0459A3C47D81_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Related-Party Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October 2007, the Company entered into The Mann Group Loan
 Arrangement, which has been amended from time to time. On
 October&amp;#xA0;31, 2013, the promissory note underlying The Mann
 Group Loan Arrangement was amended to, among other things, extend
 the maturity date of the loan to January&amp;#xA0;5, 2020, extend the
 date through which the Company can borrow under The Mann Group Loan
 Arrangement to December&amp;#xA0;31, 2019, increase the aggregate
 borrowing amount under The Mann Group Loan Arrangement from
 $350.0&amp;#xA0;million to $370.0&amp;#xA0;million and provide that
 repayments or cancellations of principal under The Mann Group Loan
 Arrangement will not be available for reborrowing.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2016, the total principal amount
 outstanding under The Mann Group Loan Arrangement was
 $49.5&amp;#xA0;million, and the amount available for future borrowings
 is $30.1&amp;#xA0;million. Interest, at a fixed rate of 5.84%, is due
 and payable quarterly in arrears on the first day of each calendar
 quarter for the preceding quarter, or at such other time as the
 Company and The Mann Group mutually agree. All or any portion of
 accrued and unpaid interest that becomes due and payable may be
 &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;paid-in-kind&lt;/font&gt;&lt;/font&gt; and capitalized as
 additional borrowings at any time upon mutual agreement of the
 parties, and has been classified as &lt;font style="white-space:nowrap"&gt;non-current.&lt;/font&gt; The Mann Group can require
 the Company to prepay up to $200.0&amp;#xA0;million in advances that
 have been outstanding for at least 12 months, less approximately
 $105.0&amp;#xA0;million aggregate principal amount that has been
 cancelled in connection with two common stock purchase agreements.
 If The Mann Group exercises this right, the Company will have 90
 days after The Mann Group provides written notice, or the number of
 days to maturity of the note if less than 90 days, to prepay such
 advances. However, pursuant to a letter agreement entered into in
 August 2010, The Mann Group has agreed to not require the Company
 to prepay amounts outstanding under the amended and restated
 promissory note if the prepayment would require the Company to use
 its working capital resources. In addition, The Mann Group entered
 into a subordination agreement with Deerfield pursuant to which The
 Mann Group agreed with Deerfield not to demand or accept any
 payment under The Mann Group Loan Arrangement until the
 Company&amp;#x2019;s payment obligations to Deerfield under the Facility
 Agreement have been satisfied in full. Subject to the foregoing, in
 the event of a default under The Mann Group Loan Arrangement, all
 unpaid principal and interest either becomes immediately due and
 payable or may be accelerated at The Mann Group LLC&amp;#x2019;s option,
 and the interest rate will increase to the &lt;font style="white-space:nowrap"&gt;one-year&lt;/font&gt; LIBOR rate calculated on the
 date of the initial advance or in effect on the date of default,
 whichever is greater, plus 5%&amp;#xA0;per annum. All borrowings under
 The Mann Group Loan Arrangement are unsecured. The Mann Group Loan
 Arrangement contains no financial covenants.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the Company had accrued and
 unpaid interest related to the above note of $9.3&amp;#xA0;million and
 $6.4&amp;#xA0;million, respectively, and had $30.1&amp;#xA0;million of
 available borrowings. Interest expense on the Company&amp;#x2019;s note
 payable to the Company&amp;#x2019;s principal stockholder for each of
 the years ended December&amp;#xA0;31, 2016, 2015 and 2014 was
 $2.9&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2015, the Company entered into a sublease agreement with the
 Alfred Mann Foundation for Scientific Research (the &amp;#x201C;Mann
 Foundation&amp;#x201D;), a California &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Not-For-Profit&lt;/font&gt;&lt;/font&gt; Corporation. The
 lease is for approximately 12,500 square feet of office space in
 Valencia, California and expires in April 2017. The office space
 contains the Company&amp;#x2019;s principal executive offices. Lease
 payments to the Mann Foundation for the year ended
 December&amp;#xA0;31, 2016 and 2015 were $268,000 and $175,000,
 respectively. There were no lease payments to the Mann Foundation
 for the year ended December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with certain meetings of the Company&amp;#x2019;s board of
 directors and on other occasions when the Company&amp;#x2019;s business
 necessitated air travel for the Company&amp;#x2019;s principal
 stockholder and other Company employees, the Company utilized the
 principal stockholder&amp;#x2019;s private aircraft, and the Company
 paid the charter company that manages the aircraft on behalf of the
 Company&amp;#x2019;s principal stockholder approximately $18,000 and
 $79,000 for the years ended December&amp;#xA0;31, 2015 and 2014,
 respectively, on the basis of the corresponding cost of commercial
 airfare. There were no payments to the principal stockholder
 related to the usage of the aircraft during the year ended
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has entered into indemnification agreements with each
 of its directors and executive officers, in addition to the
 indemnification provided for in its amended and restated
 certificate of incorporation and amended and restated bylaws (see
 Note 13 &amp;#x2014; Commitments and Contingencies).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_C1F13D49-6A0D-4172-A55B-09AFD43CA9D7_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities are comprised of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Salary and related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,634&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restructuring&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sales and marketing services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;875&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;931&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Discounts and allowances for commercial product sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;483&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,937&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,929&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:RevenueRecognitionSalesOfGoods contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_27F52082-336D-471F-AFEC-7840AA9ADAF6_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Net Revenue &amp;#x2014; Commercial
 Product Sales &amp;#x2014;&lt;/i&gt; Between July&amp;#xA0;1, 2016 and
 December&amp;#xA0;15, 2016, the Company sold Afrezza to Integrated
 Commercialization Solutions Direct (ICS) and title and risk of loss
 transferred to ICS upon shipment. After December&amp;#xA0;15, 2016, ICS
 became a third party logistics provider and stopped taking title
 and risk of loss upon shipment of Afrezza to ICS. The Company sells
 Afrezza in the United States to wholesale pharmaceutical
 distributors through ICS, and ultimately to retail pharmacies,
 which are collectively referred to as &amp;#x201C;customers&amp;#x201D;.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company provides the right of return to ICS (through
 December&amp;#xA0;15, 2016) and its wholesale distributors and, through
 them, to its retail pharmacy customers for unopened product for a
 period beginning six months prior to and ending twelve months after
 its expiration date. Once the product has been prescribed and
 dispensed to the patient, any right of return ceases to exist.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Given the Company&amp;#x2019;s limited sales history for Afrezza, the
 Company cannot reliably estimate expected returns of the product at
 the time of shipment into the distribution channel. Accordingly,
 the Company defers recognition of revenue on Afrezza product
 shipments until the right of return no longer exists, which occurs
 at the earlier of the time Afrezza is dispensed from pharmacies to
 patients or expiration of the right of return. The Company
 recognizes revenue based on Afrezza patient prescriptions dispensed
 as estimated by syndicated data provided by a third party. The
 Company also analyzes additional data points to ensure that such
 third-party data is reasonable including data related to inventory
 movements within the channel and ongoing prescription demand.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 For the year ended December&amp;#xA0;31, 2016, net revenue from
 commercial product sales consisted of $1.9&amp;#xA0;million of net
 sales of Afrezza dispensed to patients. As of December&amp;#xA0;31,
 2016, the Company recorded $3.4&amp;#xA0;million in deferred revenue on
 its consolidated balance sheet, of which $1.6&amp;#xA0;million (net of
 estimated &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt; adjustments)
 represents product shipped to the Company&amp;#x2019;s third-party
 logistics provider and wholesale distributors, but not yet
 dispensed to patients. The difference represents deferred revenue
 from bulk insulin sales, which is described more fully under the
 heading &lt;i&gt;Revenue Recognition &amp;#x2014; Revenue &amp;#x2014; Bulk Insulin
 Sales&lt;/i&gt; below.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionSalesOfGoods>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_E4086BE3-46E8-4D38-A2A4-E93C4724C2AC_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Summarized quarterly financial data for the years ended
 December&amp;#xA0;31, 2016 and 2015, are set forth in the following
 tables:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;March&amp;#xA0;31&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;September&amp;#xA0;30&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;162,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,873&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,959&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;126,520&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,976&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss) per share &amp;#x2014; basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.33&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.32&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net income (loss) per share &amp;#x2014; diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.33&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute basic net income
 (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,771&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,061&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,627&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,676&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute diluted net income
 (loss) per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,771&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,061&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,510&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,658&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,910&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,857&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(277,020&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss per share &amp;#x2014; basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.38&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.36&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.39&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.30&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average common shares used to compute basic and diluted
 net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,783&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,203&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,862&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_1_4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_679A1CE4-4429-404F-AE5C-9AC830D3D369_1_3">21.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_2C0665E9-F65D-4AFA-A67F-17BEA8D926AD_1_2">800530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_2C0665E9-F65D-4AFA-A67F-17BEA8D926AD_1_3">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StandardProductWarrantyPolicy contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_2C17B711-E646-41F6-8546-F05341943052_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Product Returns &amp;#x2014;&lt;/i&gt; The Company does not provide a
 reserve for product returns of sales of Afrezza due to its revenue
 recognition policy of deferring recognition of revenue on product
 shipments of Afrezza until the right of return no longer
 exists.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_DB15C725-C681-4745-A4A7-15884D54EE1B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;20. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Reverse Stock Split&lt;/i&gt;&amp;#xA0;&amp;#x2014; On September&amp;#xA0;14,
 2016, NASDAQ notified the Company that the bid price of the
 Company&amp;#x2019;s common stock had closed below the required $1.00
 per share for 30 consecutive trading days, and, accordingly, the
 Company did not comply with the applicable NASDAQ minimum bid price
 requirement. The Company was provided 180 calendar days by NASDAQ,
 or until March&amp;#xA0;13, 2017, to regain compliance with this
 requirement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;1, 2017, the Company held a Special Meeting of
 Stockholders at which the Company&amp;#x2019;s stockholders approved a
 proposal to amend the Company&amp;#x2019;s Amended and Restated
 Certificate of Incorporation to effect a reverse stock split of the
 Company&amp;#x2019;s outstanding common stock at a ratio to be
 determined in the discretion of the Company&amp;#x2019;s board of
 directors and with such reverse stock split to be effected at such
 time and date as determined by the Company&amp;#x2019;s board of
 directors in its sole discretion, and to reduce the number of
 authorized shares of the Company&amp;#x2019;s common stock in a
 corresponding proportion to the reverse stock split, rounded to the
 nearest whole share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;1, 2017, following stockholder approval of the
 reverse split proposal, the Company&amp;#x2019;s board of directors
 approved a reverse stock split ratio of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5.&amp;#xA0;On&lt;/font&gt;&lt;/font&gt;&amp;#xA0;March&amp;#xA0;1, 2017, the
 Company filed with the Secretary of State of the State of Delaware
 a Certificate of Amendment of the Company&amp;#x2019;s Amended and
 Restated Certificate of Incorporation to effect the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5&lt;/font&gt;&lt;/font&gt;&amp;#xA0;reverse stock split of the
 Company&amp;#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&amp;#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&amp;#xA0;The Company&amp;#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&amp;#xA0;3,
 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 As of the date of this filing, the shares of the Company&amp;#x2019;s
 common stock have maintained a minimum bid closing price of at
 least $1.00 per share for 10 consecutive business days.
 Accordingly, the Company expects to receive a notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that the Company has regained compliance with the
 minimum closing bid price requirement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sale of Valencia Facility&lt;/i&gt;&amp;#xA0;&amp;#x2014; On January&amp;#xA0;6,
 2017, the Company and Rexford Industrial Realty, L.P.
 (&amp;#x201C;Rexford&amp;#x201D;) entered into an Agreement of Purchase and
 Sale and Joint Escrow Instructions (the &amp;#x201C;Purchase
 Agreement&amp;#x201D;), pursuant to which the Company agreed to sell and
 Rexford agreed to purchase certain parcels of real estate owned by
 the Company in Valencia, California and certain related
 improvements, personal property, equipment, supplies and fixtures
 (collectively, the &amp;#x201C;Property&amp;#x201D;) for $17.3&amp;#xA0;million.
 The sale and purchase of the aforementioned Property for
 $17.3&amp;#xA0;million pursuant to the terms of the Purchase Agreement,
 as amended, was completed on February&amp;#xA0;17, 2017. Net proceeds
 were approximately $16.7&amp;#xA0;million after deducting
 broker&amp;#x2019;s commission and other fees of approximately $624,000
 paid by the Company.&amp;#xA0;In the fourth quarter of 2016 the
 property met the requirements for reclassification from property
 and equipment, net to asset held for sale when it became probable
 that the property would be sold within one year. At that time, an
 analysis of the lower of carrying value which was deemed to be the
 sales price of the property, to fair value less selling costs
 determined a loss of $564,000, which was recorded as a property and
 equipment impairment on the consolidated statement of operations
 for 2016.&amp;#xA0;At December, 31 2016, this property had a carrying
 value of $16.7&amp;#xA0;million and was classified as held for sale.
 The sale of this property will be reflected in the consolidated
 financial statements for the quarter ended March&amp;#xA0;31, 2017.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_445A3C2E-3387-4752-9F66-847E61BAD243_1_0">-48100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_4">174758000</us-gaap:SalesRevenueNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_35">1144000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_40">2690000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900047">-4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_20">72024000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_24EFE8CB-05D6-4E5B-A453-9476583112AF_1_1">-600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_6">3433000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_64">588000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900042">-165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900040">426000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_2">1895000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_14">67260000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_25">125664000</us-gaap:NetIncomeLoss>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_9004857_D0393631-1395-486B-85F9-73AB815133F1_1_0">93000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:LoansAssumed1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_65">5174000</us-gaap:LoansAssumed1>
  <us-gaap:InterestPaid contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_60">8991000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_25">-361000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_20">2331000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_23">-13539000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_18">302000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_252ABACA-BD0D-4911-9C45-1497B935CC9D_1_3">125660000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900041">5135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_42">165000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_17">85000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_19">30534000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900038">467000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_21">-597000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_11">-19000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_22">58404000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_24">346000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_23">125664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_12">-1259000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_11">3433000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900046">12750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4C2D9F09-5685-431C-82D7-C15262A2BCB0_1_0">5135000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_6">-43814000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_10">48125000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_7">-4311000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_13DD444A-0683-42A6-874A-83CEB2AFB72C_1_0">2400000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_10">1259000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_24">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_29">-134056000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_27">348000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_26">-12118000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_37">-1127000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_36">17000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_19">2901000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_4">5135000</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_1">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_3">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_4">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_9">-48125000</us-gaap:DeferredOtherTaxExpenseBenefit>
  <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_833AB922-3738-40F5-9B3E-C304FA4BB61D_1_0">418000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_3">4158000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_28">3419000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InventoryWriteDown contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_A521568E-A71D-44D1-8478-2DADD4DCF878_1_0">200000</us-gaap:InventoryWriteDown>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_8">4478000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_39">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_8">14917000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_1_0">19854000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_9">46928000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_13">107498000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_6D6D0E3F-1B0B-4BDF-8959-84FF730C77C3_1_1">27074000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_18">15576000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_55">43038000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_C42065A0-2FE9-49DC-9456-D27313BB54E6_1_0">373000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_9004857_8F25067A-5CB2-4ACC-B85C-B086E1F6AECF_3_0">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_41">-5000000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E18B1A30-57E3-4A6E-995E-53476F236A80_1_1">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_1_0">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_56">-36179000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_7">17121000</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_8">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_9AA54920-9F44-4A5A-8894-0286F592350B_1_0">500000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:InterestCostsCapitalized contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_10AABD50-DA36-40EB-BADA-557DC7F26D42_1_0">0</us-gaap:InterestCostsCapitalized>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7003_5">2035000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7003_6">3687000</us-gaap:RestructuringReserveSettledWithoutCash2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2FAC6068-42DA-4407-9A00-93654D4B964E_1_1">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <mnkd:IncomeTaxExpenseBenefitNet contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_DA0A2DD3-6304-4425-97AA-1DDC2A9DE42D_1_11">0</mnkd:IncomeTaxExpenseBenefitNet>
  <mnkd:LongtermPurchaseCommitmentRenewalTimePeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B332C754-F7AC-4B13-8D98-75CB67DAC2D1_1_1">P2Y</mnkd:LongtermPurchaseCommitmentRenewalTimePeriod>
  <mnkd:ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_9BEBD207-9159-4000-B400-DB3115BB4024_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is included in
 the following categories (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;Year Ended December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;695&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,725&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mnkd:ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock>
  <mnkd:DeferredTaxAssetIncreaseDecreaseInEquity contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_86B58C8D-6672-4BA2-9E50-5949A5ADF799_1_0">11600000</mnkd:DeferredTaxAssetIncreaseDecreaseInEquity>
  <mnkd:IncreaseDecreaseInDeferredCollaborativeRevenue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_30">-17503000</mnkd:IncreaseDecreaseInDeferredCollaborativeRevenue>
  <mnkd:BasisOfPresentationPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_EA89ED36-262B-436E-B26F-492804DCAE39_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt; &amp;#x2014; On August&amp;#xA0;11, 2014, the
 Company entered into a license and collaboration agreement (the
 &amp;#x201C;Sanofi License Agreement&amp;#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (&amp;#x201C;Sanofi&amp;#x201D;)), pursuant to which Sanofi was responsible
 for Afrezza global commercial, regulatory and development
 activities for Afrezza.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On January&amp;#xA0;4, 2016, the Company received written notification
 from Sanofi of its election to terminate in its entirety the Sanofi
 License Agreement. The effective date of termination (the
 &amp;#x201C;Termination Date&amp;#x201D;) was April&amp;#xA0;4, 2016, which was
 when the Company assumed responsibility for worldwide development
 and commercialization of Afrezza. Under terms of a transition
 agreement, Sanofi continued to fulfill orders for Afrezza in the
 United States until the Company began distributing MannKind-branded
 Afrezza product to major wholesalers in late July 2016. The Company
 began recognizing commercial product sales revenue when
 MannKind-branded Afrezza was dispensed from pharmacies to patients
 in August 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On November&amp;#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &amp;#x201C;Settlement Agreement&amp;#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 (the &amp;#x201C;Sanofi Loan Facility&amp;#x201D;) between the Company and
 Aventisub LLC (&amp;#x201C;Aventisub&amp;#x201D;), a Sanofi affiliate, was
 terminated, with Aventisub agreeing to forgive the full outstanding
 loan balance of $72.0&amp;#xA0;million, which includes
 $0.5&amp;#xA0;million of previously uncharged costs pursuant to the
 Sanofi License Agreement. Sanofi also agreed to purchase
 $10.2&amp;#xA0;million of insulin from the Company in December 2016
 under an existing insulin put option as well as make a cash payment
 of $30.6&amp;#xA0;million to the Company in early January 2017 as
 acceleration and in replacement of all other payments that Sanofi
 would otherwise have been required to make in the future pursuant
 to the insulin put option, without the Company being required to
 deliver any insulin for such payment. The Company and Sanofi also
 agreed to a general release of potential claims against each
 other.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During their initial transition of the commercial responsibilities
 from Sanofi, the Company utilized a contract sales organization to
 promote Afrezza while the Company focused its internal resources on
 establishing a channel strategy, entering into distribution
 agreements and developing &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; assistance programs, a voucher
 program, data agreements and payor relationships. In early 2017,
 the Company recruited their own sales force, which included some of
 the sales reps that previously were employed by the contract sales
 organization. The Company intend to continue the commercialization
 of Afrezza in the United States through their own commercial
 organization. The Company&amp;#x2019;s current strategy for the future
 commercialization of Afrezza outside of the United States, subject
 to receipt of the necessary foreign regulatory approvals, is to
 seek and establish regional partnerships in foreign jurisdictions
 where there are appropriate commercial opportunities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 It has been costly to develop our therapeutic product, conduct
 clinical studies, and market and sell Afrezza. As of and for the
 year ended December&amp;#xA0;31, 2016, the Company has reported an
 accumulated deficit of $2.7&amp;#xA0;billion and has reported negative
 cash flow from operations for each year since inception, except for
 2014, when the Company received the $150.0&amp;#xA0;million upfront
 payment from Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2016, the Company&amp;#x2019;s capital resources
 consisted of cash and cash equivalents of $22.9&amp;#xA0;million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &amp;#x201C;Facility Agreement&amp;#x201D;) with Deerfield
 Private Design Fund II, L.P. (Deerfield Private Design Fund) and
 Deerfield Private Design International II, L.P. (collectively,
 &amp;#x201C;Deerfield&amp;#x201D;) and the First Amendment to Facility
 Agreement and Registration Rights Agreement (the &amp;#x201C;First
 Amendment&amp;#x201D;) that resulted in additional sales of an
 additional tranche of notes (the &amp;#x201C;Tranche B notes&amp;#x201D;)
 (see Note 7 &amp;#x2014; Borrowings) requires the Company to maintain at
 least $25.0&amp;#xA0;million, which can be comprised of cash and cash
 equivalents and available borrowings under the loan arrangement,
 dated as of October&amp;#xA0;2, 2007, between the Company and The Mann
 Group LLC (as amended, restated, or otherwise modified as of the
 date hereof, &amp;#x201C;the Mann Group Loan Arrangement&amp;#x201D;), as of
 the last day of each fiscal quarter.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Additional funding sources that are, or in certain circumstances
 may be available to the Company, include approximately
 $30.1&amp;#xA0;million principal amount of available borrowings under
 The Mann Group Loan Arrangement. A portion of these available
 borrowings may be used to capitalize accrued interest into
 principal, upon mutual agreement of the parties, as it becomes due
 and payable under The Mann Group Loan Arrangement (see Note 6
 &amp;#x2014; Related-party Arrangements). The Company cannot provide
 assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 will need to raise additional capital, whether through a sale of
 equity or debt securities, a strategic business collaboration with
 a pharmaceutical company, the establishment of other funding
 facilities, licensing arrangements, asset sales or other means, in
 order to continue the commercialization of Afrezza and development
 of other product candidates and to support its other ongoing
 activities. The Company cannot provide assurances that such
 additional capital will be available on acceptable terms or at all.
 These factors raise substantial doubt about the Company&amp;#x2019;s
 ability to continue as a going concern. The financial statements do
 not include any adjustments that might result from the outcome of
 this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;14, 2016, the Company received notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that, for the previous 30 consecutive business days, the
 bid price for the common stock closed below the minimum $1.00 per
 share required for continued inclusion on The NASDAQ Global Market.
 The notification letter stated that the Company would be afforded
 180 calendar days, or until March&amp;#xA0;13, 2017, to regain
 compliance with the minimum bid price requirement. In order to
 regain compliance, shares of the Company&amp;#x2019;s common stock must
 maintain a minimum bid closing price of at least $1.00 per share
 for a minimum of 10 consecutive business days.&lt;/p&gt;
 &lt;/div&gt;</mnkd:BasisOfPresentationPolicyTextBlock>
  <mnkd:ClassOfWarrantsOrRightsExpirationDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_8F25067A-5CB2-4ACC-B85C-B086E1F6AECF_3_1">2016-02-08</mnkd:ClassOfWarrantsOrRightsExpirationDate>
  <mnkd:SellingGeneralAndAdministrativeExpensesTableTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_30E7FBC9-5EDD-475A-9089-D9CCA753C01A_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Selling, general and administrative expenses consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;Year Ended
 December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Selling and marketing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,854&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,587&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,074&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,373&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75,827&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,928&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,960&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,383&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mnkd:SellingGeneralAndAdministrativeExpensesTableTextBlock>
  <mnkd:ClassOfWarrantOrRightExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_9004857_3AA7B283-ADAE-47C0-88FE-334DAFC3B0B5_2_8">0</mnkd:ClassOfWarrantOrRightExercised>
  <mnkd:MaturityPeriodOfCashEquivalents contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_A1F63A01-771D-4A14-BFBD-27D75B092E6B_1_0">90 days or less at the time of  purchase</mnkd:MaturityPeriodOfCashEquivalents>
  <mnkd:ValueOfRestrictedStockUnitsVested contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_DE8FACDC-A091-4F4F-949E-D3D9CA30FA45_1_2">2000000</mnkd:ValueOfRestrictedStockUnitsVested>
  <mnkd:SaleOfIntellectualPropertyPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_9735F1F0-B32D-4AA5-8821-04E87DBC76DE_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Sale of intellectual property &amp;#x2014;&lt;/i&gt; On July&amp;#xA0;18, 2014,
 the Company entered into an assignment agreement with a third party
 whereby the third party acquired all proprietary rights, technology
 and &lt;font style="white-space:nowrap"&gt;know-how&lt;/font&gt; that related
 to a small molecule inhibitor compound and all &lt;font style="white-space:nowrap"&gt;pre-clinical&lt;/font&gt; data and results related
 thereto. Under the terms of the assignment agreement, the Company
 received total consideration of $9.3&amp;#xA0;million and accrued
 $1.4&amp;#xA0;million in expense for a net amount of $7.9&amp;#xA0;million
 recorded as other income. In 2015, the Company recorded other
 income of $1.4&amp;#xA0;million related to the relief of the
 $1.4&amp;#xA0;million accrual for expenses associated with the sale of
 intellectual property related to oncology in 2014, which was
 subsequently resolved without payment.&lt;/p&gt;
 &lt;/div&gt;</mnkd:SaleOfIntellectualPropertyPolicyTextBlock>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900045">-2037000</mnkd:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement>
  <mnkd:PercentageOfCreditExchangeReceivable contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="2" id="id_9004857_EEFC3F7A-BA8C-43A3-AD86-D5CE090B2610_1_0">0.65</mnkd:PercentageOfCreditExchangeReceivable>
  <mnkd:BusinessPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_F1486C35-15BC-41FF-97FB-AD0192D8E19B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Business&lt;/i&gt; &amp;#x2014; MannKind Corporation and subsidiaries (the
 &amp;#x201C;Company&amp;#x201D;) is a biopharmaceutical company focused on
 the discovery and development of therapeutic products for diseases
 such as diabetes. The Company&amp;#x2019;s only approved product,
 Afrezza, (insulin human [rDNA origin]) inhalation powder, is a
 rapid-acting inhaled insulin that was approved by the U.S. Food and
 Drug Administration (the &amp;#x201C;FDA&amp;#x201D;) on June&amp;#xA0;27, 2014
 to improve glycemic control in adult patients with diabetes.&lt;/p&gt;
 &lt;/div&gt;</mnkd:BusinessPolicyTextBlock>
  <mnkd:WarrantsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B0093B9A-305D-49B0-9B04-31F8697CD04A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Warrants&lt;/i&gt; &amp;#x2014; The Company has issued warrants to purchase
 shares of its common stock. The Company accounts for its warrants
 as either equity or liabilities based upon the characteristics and
 provisions of each instrument and evaluation of sufficient
 authorized shares available to satisfy the obligations. Warrants
 classified as derivative liabilities are recorded on the
 Company&amp;#x2019;s consolidated balance sheets at their fair value on
 the date of issuance and are revalued at each subsequent balance
 sheet date, with fair value changes recognized in the consolidated
 statements of operations. The Company estimates the fair value of
 its derivative liabilities using a third party valuation analysis
 that utilizes a Monte Carlo pricing valuation model and assumptions
 that are based on the individual characteristics of the warrants or
 instruments on the valuation date, as well as expected volatility,
 expected life, yield and a risk-free interest rate. The expected
 volatility assumption is primarily based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not &lt;font style="WHITE-SPACE: nowrap"&gt;re-measured&lt;/font&gt; in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.&lt;/p&gt;
 &lt;/div&gt;</mnkd:WarrantsPolicyTextBlock>
  <mnkd:LongTermPurchaseCommitmentExpirationDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_B332C754-F7AC-4B13-8D98-75CB67DAC2D1_1_0">2023-12-31</mnkd:LongTermPurchaseCommitmentExpirationDate>
  <mnkd:CommonAndPreferredStockTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_D287F666-F39D-4156-A6CD-3755FEB546A8_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;10. Common and Preferred Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&amp;#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&amp;#x2019;s common
 stock par value. See Note 1 &amp;#x2014; Description of Business.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is authorized to issue 140,000,000 shares of common
 stock, par value $0.05 per share, and 10,000,000 shares of
 undesignated preferred stock, par value $0.01 per share, issuable
 in one or more series as designated by the Company&amp;#x2019;s board of
 directors. No other class of capital stock is authorized. As of
 December&amp;#xA0;31, 2016 and 2015, 95,680,831 and 85,734,188 shares
 of common stock, respectively, were issued and outstanding and no
 shares of preferred stock were outstanding.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As more fully described in Note 16 &amp;#x2014; Warrants, in May 2016,
 the Company sold in a registered offering an aggregate of 9,708,737
 shares of common stock together with certain warrants exercisable
 for up to an aggregate of 7,281,553 shares of common stock
 (&amp;#x201C;A Warrants&amp;#x201D;) and certain warrants exercisable for up
 to an aggregate of 2,427,184 shares of common stock (&amp;#x201C;B
 Warrants&amp;#x201D;) in a direct offering for proceeds of
 $50.0&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On November&amp;#xA0;9, 2015, the Company entered into a series of
 stock purchase agreements to sell up to an aggregate of 10,000,000
 shares of its common stock in a registered direct offering to
 selected investment funds in Israel that hold securities included
 within certain stock indexes of the Tel Aviv Stock Exchange (the
 &amp;#x201C;TASE&amp;#x201D;). Pursuant to the agreements, the shares of
 common stock were sold at a price per share equal to 97% of the
 closing price of the Company&amp;#x2019;s common stock on the TASE on
 November&amp;#xA0;12, 2015. During November 2015, the Company sold
 2,770,487 shares of common stock for an aggregate price of
 approximately $34,710,000, or $13.05 per share, which is net of
 $1,432,000 of issuance costs.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company engaged Sunrise Securities Corporation as its exclusive
 placement agent in connection with the offering of the 10,000,000
 shares. In connection with the services provided, the Company
 issued to Sunrise Securities Corporation, or its designee,
 restricted warrants to purchase a number of shares of the
 Company&amp;#x2019;s common stock in an aggregate equal to 1.15% of the
 aggregate shares sold in the offering, which totaled 31,860 shares
 on November&amp;#xA0;16, 2015. The warrants are exercisable for a five
 year period at an exercise price of $13.05, the price paid per
 share in connection with the offering. The Company had an
 obligation to register the common stock that may be issued pursuant
 to the exercise of the warrants, which resulted in their initial
 classification as liability and were deemed immaterial. On
 December&amp;#xA0;15, 2015 the warrants were reclassified to equity as
 the Company registered the common stock pursuant to a registration
 statement and continue to be classified in equity as of
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Included in the common stock outstanding as of December&amp;#xA0;31,
 2014 is 1,800,000 shares of common stock loaned to Bank of America
 under a share lending agreement in connection with the offering of
 the $100.0&amp;#xA0;million aggregate principal amount of the 2015
 notes. Bank of America was obligated to return the borrowed shares
 (or, in certain circumstances, the cash value thereof) to the
 Company on or about the 45th business day following the date as of
 which the entire principal amount of the 2015 notes ceases to be
 outstanding, subject to extension or acceleration in certain
 circumstances or early termination at Bank of America&amp;#x2019;s
 option. On October&amp;#xA0;23, 2015, the 1,800,000 shares of common
 stock loaned to Bank of America were returned, as the Company
 settled all payments and deliveries in respect of such convertible
 notes on August&amp;#xA0;17, 2015. The Company did not receive any
 proceeds from the sale of the borrowed shares by Bank of America,
 but the Company did receive a nominal lending fee of $0.05 per
 share from Bank of America for the use of borrowed shares.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On February&amp;#xA0;8, 2012, the Company sold 7,187,500 units in an
 underwritten public offering, including 937,500 units sold pursuant
 to the full exercise of an over-allotment option granted to the
 underwriters, with each unit consisting of one share of common
 stock and a warrant to purchase 0.1 of a share of common stock. All
 of the securities were offered by the Company at a combined price
 to the public of $12.00 per unit and the underwriters purchased the
 units at a price of $11.28 per unit. Net proceeds from this
 offering were approximately $80.6&amp;#xA0;million, excluding any
 warrant exercises. The 4,312,500 shares of common stock underlying
 the warrants are exercisable at $12.00 per share and expire four
 years from the date of the issuance.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 For the years ended December&amp;#xA0;31, 2015 and 2014, the Company
 received $10.1&amp;#xA0;million and $27.8&amp;#xA0;million in proceeds,
 respectively, from the exercise of the February 2012 public
 offering warrants. There were no warrant exercises during the year
 ended December&amp;#xA0;31, 2016 and any unexercised February 2012
 public offering warrants expired on February&amp;#xA0;8, 2016.&lt;/p&gt;
 &lt;/div&gt;</mnkd:CommonAndPreferredStockTextBlock>
  <mnkd:ChangeInFairValueOfWarrantLiability contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_16">5369000</mnkd:ChangeInFairValueOfWarrantLiability>
  <mnkd:AssetsHeldForSalePolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6705D8F5-95F2-4962-8AD9-AB0660DFAA4C_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Assets Held for Sale &amp;#x2014;&lt;/i&gt; The Company classifies
 long-lived assets anticipated to be sold within one year as held
 for sale at the lower of their carrying value or fair value less
 estimated selling costs.&lt;/p&gt;
 &lt;/div&gt;</mnkd:AssetsHeldForSalePolicyTextBlock>
  <mnkd:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_9004857_230F8C49-2E8B-4132-A073-45984A9B53D6_1_1">-0.019</mnkd:EffectiveIncomeTaxRateReconciliationPermanentItems>
  <mnkd:ClinicalTrialExpensePolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_3A4425BD-F4D1-4E5E-BF68-04DEFE585C27_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Clinical Trial Expenses&lt;/i&gt; &amp;#x2014; Clinical trial expenses,
 which are reflected in research and development expenses in the
 accompanying consolidated statements of operations, result from
 obligations under contracts with vendors, consultants and clinical
 site agreements in connection with conducting clinical trials. The
 financial terms of these contracts are subject to negotiations
 which vary from contract to contract and may result in payment
 flows that do not match the periods over which materials or
 services are provided to the Company under such contracts. The
 appropriate level of trial expenses are reflected in the
 Company&amp;#x2019;s consolidated financial statements by matching
 period expenses with period services and efforts expended. These
 expenses are recorded according to the progress of the trial as
 measured by patient progression and the timing of various aspects
 of the trial. Clinical trial accrual estimates are determined
 through discussions with internal clinical personnel and outside
 service providers as to the progress or state of completion of
 trials, or the services completed. Service provider status is then
 compared to the contractually obligated fee to be paid for such
 services. During the course of a clinical trial, the Company may
 adjust the rate of clinical expense recognized if actual results
 differ from management&amp;#x2019;s estimates.&lt;/p&gt;
 &lt;/div&gt;</mnkd:ClinicalTrialExpensePolicyTextBlock>
  <mnkd:SellingGeneralAndAdministrativeExpensesDisclosureTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_DE6554F9-0E47-4271-9257-DDF8E329455C_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;17. Selling, General and Administrative Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Selling, general and administrative expenses consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;Year Ended
 December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Selling and marketing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,854&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,587&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,074&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,373&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75,827&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,928&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,960&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,383&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mnkd:SellingGeneralAndAdministrativeExpensesDisclosureTextBlock>
  <mnkd:ReverseStockSplitPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_DCDD9C7A-2961-418E-8936-7C263AD8BA7B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Reverse Stock Split&lt;/i&gt; &amp;#x2014; On March&amp;#xA0;1, 2017, following
 stockholder approval, the Company&amp;#x2019;s board of directors
 approved a reverse stock split ratio of &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5.&amp;#xA0;On&lt;/font&gt;&lt;/font&gt; March&amp;#xA0;1,
 2017, the Company filed with the Secretary of State of the State of
 Delaware a Certificate of Amendment of the Company&amp;#x2019;s Amended
 and Restated Certificate of Incorporation to effect the
 &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-5&lt;/font&gt;&lt;/font&gt; reverse stock split of
 the Company&amp;#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&amp;#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&amp;#xA0;The Company&amp;#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&amp;#xA0;3,
 2017.&amp;#xA0;See Note 20 &amp;#x2014; Subsequent Events for further
 information. As a result, all common stock share amounts included
 in these consolidated financial statements have been retroactively
 reduced by a factor of five, and all common stock per share amounts
 have been increased by a factor of five, with the exception of the
 Company&amp;#x2019;s common stock par value.&lt;/p&gt;
 &lt;/div&gt;</mnkd:ReverseStockSplitPolicyTextBlock>
  <mnkd:GainLossOnPurchaseCommitments contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_12">2265000</mnkd:GainLossOnPurchaseCommitments>
  <mnkd:ClassOfWarrantExercisablePeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_040746A4-F1C9-4477-82F2-04E8D16994B1_2_3">P5Y</mnkd:ClassOfWarrantExercisablePeriod>
  <mnkd:RecentlyIssuedAccountingStandardsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_ADF037AF-7596-433E-9F44-12B10E6E7CB9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt; &amp;#x2014; From time to
 time, new accounting pronouncements are issued by the Financial
 Accounting Standards Board (FASB) or other standard setting bodies
 that are adopted by the Company as of the specified effective date.
 Unless otherwise discussed, the Company believes that the impact of
 recently issued standards that are not yet effective will not have
 a material impact on the Company&amp;#x2019;s consolidated financial
 position or results of operations upon adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB issued Accounting Standards Update (ASU)
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09,&lt;/font&gt;
 &lt;i&gt;Revenue from Contracts with Customers (Topic 606)&lt;/i&gt;, which
 requires an entity to recognize the amount of revenue when promised
 goods or services are transferred to customers in an amount that
 reflects the consideration that is expected to be received for
 those goods or services. This new guidance supersedes previous
 revenue recognition requirements, along with most existing
 industry-specific guidance. In August 2015, the FASB issued ASU
 &lt;font style="WHITE-SPACE: nowrap"&gt;2015-14,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date&lt;/i&gt;, which delayed the effective date of the new standard from
 January&amp;#xA0;1, 2017 to January&amp;#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In 2016 the FASB has issued additional
 ASUs which clarify certain aspects of the new guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company will adopt the new guidance for the year beginning
 January&amp;#xA0;1, 2018. The Company has the option to either apply
 the new guidance retrospectively for all prior reporting periods
 presented (full retrospective) or retrospectively with the
 cumulative effect of initially applying the guidance recognized at
 the date of initial application (modified retrospective). The
 Company currently anticipates it will apply the new guidance using
 the modified retrospective approach with the cumulative effect of
 initial application recognized as of January&amp;#xA0;1, 2018. The
 Company plans to continue analyzing the potential impacts of the
 application throughout 2017 and, depending on factors that may
 impact the results, could elect to apply the new guidance on a full
 retrospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Currently, for commercial sales of Afrezza, the Company has limited
 sales and returns history, and as such, is unable to reliably
 estimate expected returns of the product at the time of shipment
 into the distribution channel. Accordingly, the Company defers
 recognition of revenue on Afrezza product shipments until the right
 of return no longer exists, which occurs at the earlier of the time
 Afrezza is dispensed from pharmacies to patients or expiration of
 the right of return. The Company recognizes revenue based on
 Afrezza patient prescriptions dispensed, a sell-through model, as
 estimated by syndicated data provided by a third party. The Company
 also analyzes additional data points to ensure that such
 third-party data is reasonable, including data related to inventory
 movements within the channel and ongoing prescription demand.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Upon adoption of the new guidance, the Company expects that it will
 move from its current sell-through model to a &lt;font style="WHITE-SPACE: nowrap"&gt;sell-to&lt;/font&gt; model for revenue related to
 commercial sales of Afrezza and will record revenue at the time
 title and risk of loss passes to its distributors (generally at
 shipment or delivery to the distributors) along with an estimate of
 potential returns as variable consideration. The Company also
 anticipates that its ability to estimate potential returns will
 improve with an additional 12 months of sales history that it will
 have obtained by January&amp;#xA0;1, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, the Company has historically entered into
 collaborative agreements with third-parties under which periodic
 payments have been received. Revenue recognition for certain
 payments received has been deferred until the price is fixed and
 determinable. Further, revenue for certain payments to be received
 in the future has been prohibited from recognition until received.
 The Company expects that some of these amounts will be considered
 variable consideration and may be able to be recognized earlier
 under the new guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has begun its evaluation of the impact of adoption and
 plans to continue its evaluation throughout 2017. The financial
 impact upon adoption will be dependent upon a number of factors
 including; the amount of revenue that has been deferred under the
 sell-through model for Afrezza, the amount of the revenue deferred
 under collaborative arrangements and the Company&amp;#x2019;s estimates
 of variable consideration at the date of adoption. At this time,
 the Company has not completed its evaluation of the inputs,
 assumptions and methodologies that will be used to recognize
 revenue related to variable consideration under the new
 guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July 2015, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; &lt;i&gt;Inventory (Topic
 330): Simplifying the Measurement of Inventory.&lt;/i&gt; Topic 330
 currently requires an entity to measure inventory at the lower of
 cost or market. Market could be replacement cost, net realizable
 value, or net realizable value less an approximately normal profit
 margin. The amendments indicate that after adoption an entity
 should measure inventory within the scope of this ASU at the lower
 of cost or net realizable value. The amendments are effective for
 fiscal years beginning after December&amp;#xA0;15, 2016, including
 interim periods within those fiscal years. The amendments should be
 applied prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The adoption of
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11&lt;/font&gt; will
 have no impact on the Company&amp;#x2019;s annual consolidated financial
 statements because the Company currently measures inventory at the
 lower of cost or net realizable value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August&amp;#xA0;2014, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15,&lt;/font&gt; &lt;i&gt;Presentation of
 Financial Statements &amp;#x2014; Going Concern&lt;/i&gt;, which requires
 management of an entity to evaluate whether there are conditions or
 events, considered in the aggregate, that raise substantial doubt
 about the entity&amp;#x2019;s ability to continue as a going concern
 within one year after the date that the financial statements are
 issued or available to be issued. This update was effective for
 annual periods ending after December&amp;#xA0;15, 2016. The adoption of
 this standard did not have a material impact on its consolidated
 financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In January 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-01,&lt;/font&gt; &lt;i&gt;Financial
 Instruments &amp;#x2014; Overall (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;825-10):&lt;/font&gt; Recognition and Measurement
 of Financial Assets and Financial Liabilities.&lt;/i&gt; The update is
 intended to improve the recognition and measurement of financial
 instruments. The update is effective for fiscal years beginning
 after December&amp;#xA0;15, 2017, including interim periods within
 those fiscal years. The Company is evaluating the impact the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-01&lt;/font&gt;
 will have on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02,&lt;/font&gt; &lt;i&gt;Leases (Topic
 842)&lt;/i&gt;. The new standard requires that a lessee recognize the
 assets and liabilities that arise from operating leases. A lessee
 should recognize in the statement of financial position a liability
 to make lease payments (the lease liability) and a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset representing
 its right to use the underlying asset for the lease term. For
 leases with a term of 12 months or less, a lessee is permitted to
 make an accounting policy election by class of underlying asset not
 to recognize lease assets and lease liabilities. In transition,
 lessees and lessors are required to recognize and measure leases at
 the beginning of the earliest period presented using a modified
 retrospective approach. The new standard will be effective on
 January&amp;#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02&lt;/font&gt; will have on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 In March 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt; &lt;i&gt;Compensation
 &amp;#x2014; Stock Compensation (Topic 718): Improvements to Employee
 Share-Based Payment Accounting&lt;/i&gt;. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 those annual periods. The Company has evaluated the effect that
 this guidance will have on its consolidated financial statements
 and related disclosures and has determined it will not result in a
 material impact.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments&lt;/i&gt;. The new standard seeks to reduce diversity in
 practice related to the classification of certain transactions in
 the statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2017, and interim periods within
 those annual periods. The amendments should be applied using a
 retrospective transition method to each period presented. If it is
 impracticable to apply the amendments retrospectively for some of
 the issues, the amendments for those issues would be applied
 prospectively as of the earliest date practicable. The Company is
 evaluating the impact the adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15&lt;/font&gt; will have on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In November 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-18,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Restricted Cash.&lt;/i&gt; This ASU requires that the
 reconciliation of the &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;beginning-of-period&lt;/font&gt;&lt;/font&gt;
 and &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;end-of-period&lt;/font&gt;&lt;/font&gt; amounts shown in
 the statement of cash flows include cash and restricted cash
 equivalents. ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-08&lt;/font&gt;
 is effective for fiscal years beginning after December&amp;#xA0;15,
 2018, including interim periods within those periods, using a
 retrospective transition method to each period presented. The
 Company has evaluated the effect that this guidance will have on
 its consolidated financial statements and related disclosures and
 has determined it will not result in a material impact.&lt;/p&gt;
 &lt;/div&gt;</mnkd:RecentlyIssuedAccountingStandardsPolicyTextBlock>
  <mnkd:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_FB305C47-658C-4374-8BDD-499CD73B1E2A_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Prepaid Expenses and Other Current Assets &amp;#x2014;&lt;/i&gt; As of
 December&amp;#xA0;31, 2016 and 2015, prepaid expenses and other current
 assets primarily consist of prepaid expenses for goods and services
 to be received and includes a certificate of deposit for $350,000
 as collateral as required by an agreement with the bank.&lt;/p&gt;
 &lt;/div&gt;</mnkd:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
  <mnkd:StockOptionsGrantedVestingRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="pure" decimals="2" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_1_0">0.25</mnkd:StockOptionsGrantedVestingRate>
  <mnkd:NumberOfAssetGroups contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="asset_group" decimals="INF" id="id_9004857_09CA97DD-FEF7-4212-864F-8806252B65EF_1_0">2</mnkd:NumberOfAssetGroups>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_43">893000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:PaymentsForUseOfAircrafts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_9004857_EB01B6C6-F4BF-470D-8D9E-630B6B86889A_1_0">0</mnkd:PaymentsForUseOfAircrafts>
  <mnkd:LossOnPurchaseCommitmentsPolicyPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_83D85DC1-992F-44F2-9000-1187C09786D3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Recognized Loss on Purchase Commitments &amp;#x2014;&lt;/i&gt; The Company
 assesses whether losses on long term purchase commitments should be
 accrued. Losses that are expected to arise from firm, &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancellable,&lt;/font&gt; commitments for the
 future purchases of inventory items are recognized unless
 recoverable. The recognized loss on purchase commitments is reduced
 as inventory items are purchased. Changes in estimates are recorded
 in the relevant period in (gain) loss on purchase commitments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the year ended December&amp;#xA0;31, 2015, the Company recorded
 a loss on purchase commitments amounting to $116.2&amp;#xA0;million
 offset by $50&amp;#xA0;million expected to be recovered from Sanofi,
 primarily due to a long term purchase commitment for insulin raw
 materials. During the year ended December&amp;#xA0;31, 2016, the
 balance was adjusted for the recovery received from Sanofi, current
 purchases on the contracts and a reduction in the recognized loss
 related to amendments to purchase contracts. No new contracts were
 identified in 2016 requiring a new loss on purchase commitment
 accrual.&lt;/p&gt;
 &lt;/div&gt;</mnkd:LossOnPurchaseCommitmentsPolicyPolicyTextBlock>
  <mnkd:WarrantIssuanceCosts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_10">653000</mnkd:WarrantIssuanceCosts>
  <mnkd:InterestOnNotePayableToPrincipalStockholder contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_9">2901000</mnkd:InterestOnNotePayableToPrincipalStockholder>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_1">171965000</mnkd:NetRevenueFromCollaboration>
  <mnkd:IncreaseDecreaseInOtherDeferredCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_22">309000</mnkd:IncreaseDecreaseInOtherDeferredCharges>
  <mnkd:WholesalerDistributionFeesPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_0D3EFDB8-18F6-4944-9AEC-1F07ED1C97B2_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Wholesaler Distribution Fees &amp;#x2014;&lt;/i&gt; The Company pays
 distribution fees to certain wholesale distributors based on
 contractually determined rates. The Company accrues the
 distribution fees on shipment to the respective wholesale
 distributors and recognizes the distribution fees as a reduction of
 revenue in the same period the related revenue is recognized.&lt;/p&gt;
 &lt;/div&gt;</mnkd:WholesalerDistributionFeesPolicyTextBlock>
  <mnkd:GrossToNetAdjustmentsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_BE3D1E8E-B20B-4334-991C-B1774A72E835_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;Gross-to-net&lt;/font&gt;&lt;/font&gt; Adjustments
 &amp;#x2014;&lt;/i&gt; Estimated &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt; adjustments for
 Afrezza include wholesaler distribution fees, prompt pay discounts,
 estimated rebates and patient discount and &lt;font style="white-space:nowrap"&gt;co-pay&lt;/font&gt; assistance programs, and are
 based on estimated amounts owed or to be claimed on the related
 sales. These estimates take into consideration the terms of the
 Company&amp;#x2019;s agreements with its customers and the levels of
 inventory within the distribution and retail channels that may
 result in future rebates or discounts taken. In certain cases, such
 as patient support programs, the Company recognizes the cost of
 patient discounts as a reduction of revenue based on estimated
 utilization. If actual future results vary, the Company may need to
 adjust these estimates, which could have an effect on product
 revenue in the period of adjustment. The Company records product
 sales deductions in the consolidated statements of operations at
 the time product revenue is recognized. At December&amp;#xA0;31, 2016,
 year to date total &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;gross-to-net&lt;/font&gt;&lt;/font&gt; adjustments were
 approximately $0.8&amp;#xA0;million, which represents 30% of gross
 revenue from product sales.&lt;/p&gt;
 &lt;/div&gt;</mnkd:GrossToNetAdjustmentsPolicyTextBlock>
  <mnkd:PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_1A8021A6-ECD2-4CDE-BF9A-2B593ABEFFF9_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Patient Discount and &lt;font style="white-space:nowrap"&gt;Co-Pay&lt;/font&gt; Assistance Programs &amp;#x2014;&lt;/i&gt;
 The Company offers discount card programs to patients for Afrezza
 in which patients receive discounts on their prescriptions or a
 reduction in their &lt;font style="white-space:nowrap"&gt;co-pay&lt;/font&gt;
 amounts that are reimbursed by the Company. The Company estimates
 the total amount that will be redeemed based on levels of inventory
 in the distribution and retail channels and recognizes the discount
 as a reduction of revenue in the same period the related revenue is
 recognized.&lt;/p&gt;
 &lt;/div&gt;</mnkd:PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock>
  <mnkd:IncreaseDecreaseInPurchaseCommitmentLoss contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_31">40566000</mnkd:IncreaseDecreaseInPurchaseCommitmentLoss>
  <mnkd:ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_4926128B-DD3A-4F4B-91C6-18DB75FB3601_1_66">17294000</mnkd:ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash>
  <mnkd:DeferredCostRelatedToSaleOfRawInsulin contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_9004857_092B9465-DFD6-4BC8-8507-F49C540C16A1_1_1">0</mnkd:DeferredCostRelatedToSaleOfRawInsulin>
  <mnkd:DeferredRevenueFromSaleOfRawInsulin contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_092B9465-DFD6-4BC8-8507-F49C540C16A1_1_0">1800000</mnkd:DeferredRevenueFromSaleOfRawInsulin>
  <mnkd:AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_6863A84B-E144-41A0-9C1D-58E758661F88_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;
 &amp;#x2014; Accounts receivable are recorded at the invoiced amount and
 are not interest bearing. The Company maintains an allowance for
 doubtful accounts for estimated losses resulting from the inability
 of its customers to make required payments. The Company makes
 ongoing assumptions relating to the collectability of its accounts
 receivable in its calculation of the allowance for doubtful
 accounts. As of December&amp;#xA0;31, 2016 and 2015, there was no
 allowance for doubtful accounts.&lt;/p&gt;
 &lt;/div&gt;</mnkd:AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock>
  <mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10006_900043">50000000</mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue>
  <mnkd:NetRevenueFromBulkInsulin contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_3">898000</mnkd:NetRevenueFromBulkInsulin>
  <mnkd:CostsOfRevenueCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_F859118A-34A4-4DAE-B458-8CA8144062D8_1_6">32971000</mnkd:CostsOfRevenueCollaboration>
  <mnkd:RevenueRecognitionBulkSalesPolicyTextBlock contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0" id="id_9004857_7247D467-0B23-46E6-8E0F-B7A19BC36F70_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Revenue Recognition &amp;#x2014; Revenue &amp;#x2014; Bulk Insulin Sales
 &amp;#x2014;&lt;/i&gt; In 2016, revenue from bulk insulin sales was recognized
 after delivery and customer acceptance of the bulk insulin. When
 the accounting requirements for revenue recognition of bulk insulin
 sales are not met, the Company defers recognition of revenue by
 recording deferred revenue on the balance sheet until such time
 that all criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Deferred revenue includes $1.8&amp;#xA0;million received from a sale of
 surplus bulk insulin to a third party that was delivered prior to,
 but accepted after, December&amp;#xA0;31, 2016. No deferred cost was
 recognized related to this sale because the inventory was written
 off on December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</mnkd:RevenueRecognitionBulkSalesPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324199x1331109" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_1001_2">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324199x1332392" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_2001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324497x1494756_1324896x1324925_1327094x1325206" unitRef="pure" decimals="3" id="id_9004857_6DA04552-CB28-4FFB-A49B-EAB033818B5C_1001_0">0.145</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324529x1487319" unitRef="iso4217_USD" decimals="0" id="id_9004857_0FDE88D0-66A9-4CA1-BC56-C8FE84A0C2EE_1001_0">257000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324738x1334129" unitRef="iso4217_USD" decimals="-5" id="id_9004857_15E10D02-79DB-4518-A56F-73625EE88E68_7001_7">600000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:AssetsFairValueAdjustment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324738x1334129" unitRef="iso4217_USD" decimals="-5" id="id_9004857_15E10D02-79DB-4518-A56F-73625EE88E68_7001_6">17300000</us-gaap:AssetsFairValueAdjustment>
  <mnkd:PaymentsForFinancialAssets contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324738x1334129" unitRef="iso4217_USD" decimals="-6" id="id_9004857_15E10D02-79DB-4518-A56F-73625EE88E68_7001_8">0</mnkd:PaymentsForFinancialAssets>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_9004857_24EFE8CB-05D6-4E5B-A453-9476583112AF_1001_0">700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1325206_1328480x1469303" unitRef="pure" decimals="2" id="id_9004857_8110098F-6A8C-433C-8558-BF4EFE72EB65_1001_1">0.11</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1325206_1328615x1466792" unitRef="pure" decimals="3" id="id_9004857_36635C8B-7049-4E39-8CE5-06CE73F7711D_1001_0">0.120</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465" unitRef="pure" decimals="2" id="id_9004857_50DE6BDF-590C-4966-BB6C-5CE587881DB7_1001_1">1.11</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465" unitRef="pure" decimals="2" id="id_9004857_50DE6BDF-590C-4966-BB6C-5CE587881DB7_1001_0">0.20</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <mnkd:ResearchAndDevelopmentCreditsBeginToExpire contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325224x1325288" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_1001_7">2024</mnkd:ResearchAndDevelopmentCreditsBeginToExpire>
  <mnkd:NetOperatingLossCarryforwardsBeginsToExpire contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325224x1325288" id="id_9004857_DD6735CB-CD30-46EF-B49F-9C4844D4BF8D_1001_2">2018</mnkd:NetOperatingLossCarryforwardsBeginsToExpire>
  <mnkd:ProductSalesRevenueGrossToNetAdjustments contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226" unitRef="iso4217_USD" decimals="-5" id="id_9004857_70D7DD32-6BF2-482A-9B48-9F44B0943E2E_1001_0">800000</mnkd:ProductSalesRevenueGrossToNetAdjustments>
  <mnkd:ProductSalesRevenueGrossToNetAdjustmentsPercentage contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226" unitRef="pure" decimals="2" id="id_9004857_70D7DD32-6BF2-482A-9B48-9F44B0943E2E_1001_1">0.30</mnkd:ProductSalesRevenueGrossToNetAdjustmentsPercentage>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_1001_5">17500000</mnkd:NetRevenueFromCollaboration>
  <mnkd:SalesReturnPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1335482x1328677" id="id_9004857_D5B4BCC5-3B94-46DC-B862-1E208A8FC19D_1001_1">P12M</mnkd:SalesReturnPeriod>
  <mnkd:SalesReturnPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1335482x1331874" id="id_9004857_D5B4BCC5-3B94-46DC-B862-1E208A8FC19D_2001_0">P6M</mnkd:SalesReturnPeriod>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1382533" unitRef="iso4217_USD" decimals="-5" id="id_9004857_4C57A0C1-208E-454A-A06B-7244936009D7_1002_1">10200000</mnkd:NetRevenueFromCollaboration>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1382533_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_2001_6">19400000</mnkd:NetRevenueFromCollaboration>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1435325_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_3001_3">25000000</mnkd:NetRevenueFromCollaboration>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1443830_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_4001_2">25000000</mnkd:NetRevenueFromCollaboration>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1507406_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_5001_1">150000000</mnkd:NetRevenueFromCollaboration>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1367294_1326002x1335383" id="id_9004857_47E16A8B-21BA-4B71-A787-D8B1D3E3F07D_1003_1">2020-01-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1444803_1326002x1365453" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_1001_8">The interest rate will increase to the one-year LIBOR rate  calculated on the date of the initial advance or in effect on the date of  default, whichever is greater, plus 5% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1444803_1326002x1365453_1333456x1331776" unitRef="pure" decimals="2" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_2001_7">0.05</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <mnkd:OfficeLeaseExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1454078_1467970x1441734" unitRef="iso4217_USD" decimals="0" id="id_9004857_B337D5A7-9CCA-49D2-82EE-25A704045570_1002_2">268000</mnkd:OfficeLeaseExpense>
  <mnkd:LeaseExpirationMonthYear contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1454078_1467970x1441734" id="id_9004857_B337D5A7-9CCA-49D2-82EE-25A704045570_1002_1">2017-04</mnkd:LeaseExpirationMonthYear>
  <mnkd:RelatedPartyTransactionPrepaymentPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_3001_5">P90D</mnkd:RelatedPartyTransactionPrepaymentPeriod>
  <mnkd:AvailableLoanBalanceCancelled contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_3001_6">105000000</mnkd:AvailableLoanBalanceCancelled>
  <mnkd:RelatedPartyTransactionDebtInstrumentPrepayment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383_1335482x1328677" unitRef="iso4217_USD" decimals="INF" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_4001_3">200000000</mnkd:RelatedPartyTransactionDebtInstrumentPrepayment>
  <mnkd:NumberOfMonthsAdvancesOutstanding contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383_1335482x1331874" id="id_9004857_46AB39EA-2361-4BAF-A059-8C957A8B6CB3_5001_4">P12M</mnkd:NumberOfMonthsAdvancesOutstanding>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803" unitRef="pure" decimals="2" id="id_9004857_D33F73B5-0156-401D-A444-F04660622BC0_1001_1">0.35</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1327271x1443229_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_6001_4">-64900000</mnkd:NetRevenueFromCollaboration>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1328480x1469303" unitRef="pure" decimals="2" id="id_9004857_D33F73B5-0156-401D-A444-F04660622BC0_2001_0">0.65</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <mnkd:UpfrontFee contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_76BEEC90-81C5-488E-8A46-4C9785DBB69E_1001_1">150000000</mnkd:UpfrontFee>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_59AD7699-E668-4A65-9DDC-5A5F316104DB_7001_0">172000000</mnkd:NetRevenueFromCollaboration>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1543513" unitRef="iso4217_USD" decimals="-5" id="id_9004857_84016527-03E6-48CF-B13D-2F16BA87D7B6_1001_0">400000</us-gaap:ProceedsFromCollaborators>
  <mnkd:ResearchAndDevelopmentExpensesOffsetAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1543513" unitRef="iso4217_USD" decimals="-5" id="id_9004857_C0FB47FF-118A-4B1F-A0A7-92A1E21F773A_1001_0">400000</mnkd:ResearchAndDevelopmentExpensesOffsetAmount>
  <mnkd:RecognitionPeriodForDeferredRevenue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1543513" id="id_9004857_C0FB47FF-118A-4B1F-A0A7-92A1E21F773A_1001_2">P4Y</mnkd:RecognitionPeriodForDeferredRevenue>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1426352" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_1001_4">2016-07-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1001_1">1722000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_9004857_EAA101F0-DAEA-4E59-9CDA-081EEBA75FCF_1001_0">35000</us-gaap:AmortizationOfFinancingCosts>
  <mnkd:DebtInstrumentDateOfLastRequiredPayment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1426352" id="id_9004857_9C97AE34-223C-4A3D-A870-FAEEA1427DA6_1001_5">2019-12-09</mnkd:DebtInstrumentDateOfLastRequiredPayment>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1469303" unitRef="iso4217_USD" decimals="-6" id="id_9004857_C5999C71-BA10-44E7-AAB4-97778F71E511_1001_1">50000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <mnkd:LoanFacilityForgivenDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1469303" id="id_9004857_8110098F-6A8C-433C-8558-BF4EFE72EB65_2001_2">2016-11-09</mnkd:LoanFacilityForgivenDate>
  <us-gaap:DebtInstrumentRedemptionDescription contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328615x1373094" id="id_9004857_CC1B9646-9FCC-464A-9109-895937A4A49D_1002_0">On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest.</us-gaap:DebtInstrumentRedemptionDescription>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328615x1373094" id="id_9004857_30057D2E-596A-46B0-A2C5-1E297B63DE13_1001_0">2018-08-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328615x1373094" unitRef="iso4217_USD" decimals="0" id="id_9004857_0FDE88D0-66A9-4CA1-BC56-C8FE84A0C2EE_2001_1">234000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1328644x1353762" unitRef="iso4217_USD" decimals="-5" id="id_9004857_09CA97DD-FEF7-4212-864F-8806252B65EF_1001_1">1800000</us-gaap:AssetImpairmentCharges>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600039">-7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600042">-165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600040">424000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600041">5135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600038">464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600046">12750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <mnkd:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600045">-2037000</mnkd:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement>
  <mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10003_600043">49515000</mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333538" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10004_700047">-4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_400039">131000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_400040">51000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_400038">55000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_500039">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_500040">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_500038">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_500043">485000</mnkd:CommonStockAndWarrantsIssuedInDirectPlacementValue>
  <mnkd:CommonStockAndWarrantsIssuedInDirectPlacementShares contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806" unitRef="shares" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10001_400044">9709000</mnkd:CommonStockAndWarrantsIssuedInDirectPlacementShares>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1442049" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5152B83E-4998-443E-9E70-EB02DA053FCA_10005_800048">125664000</us-gaap:NetIncomeLoss>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1330194x1352081" unitRef="iso4217_USD" decimals="-3" id="id_9004857_592A9BA7-142C-42E0-AAB4-F39415BDBF22_1001_0">5135000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LiabilitiesFairValueAdjustment contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D1A68127-5601-42B5-839E-D7ABC2924DD7_7001_6">12800000</us-gaap:LiabilitiesFairValueAdjustment>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1331314x1359335" unitRef="iso4217_USD" decimals="-6" id="id_9004857_D1A68127-5601-42B5-839E-D7ABC2924DD7_7001_8">0</us-gaap:FairValueAdjustmentOfWarrants>
  <mnkd:GainLossFromChangeInFairValueOfWarrantLiabilities contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1331314x1359335" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D1A68127-5601-42B5-839E-D7ABC2924DD7_7001_7">-5400000</mnkd:GainLossFromChangeInFairValueOfWarrantLiabilities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1324465" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_1001_1">814561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1331109" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_2001_0">5530256</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1332392" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_3001_3">702867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1336129" unitRef="shares" decimals="0" id="id_9004857_A83A1F9B-B672-48FE-A0E5-44945590E026_4001_2">9740597</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_4">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueInputsProbabilityOfDefault contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_7">0.10</us-gaap:FairValueInputsProbabilityOfDefault>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" unitRef="pure" decimals="2" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_6">1.18</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" unitRef="pure" decimals="4" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_3">0.0110</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueMeasurementsValuationTechniques contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_2">Monte  Carlo valuation pricing model</us-gaap:FairValueMeasurementsValuationTechniques>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" id="id_9004857_A166A7FD-EC20-4A88-995C-76A814B2ED62_1003_5">P1Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964" unitRef="iso4217_USD" decimals="-5" id="id_9004857_AE3BB05F-E01E-4982-9236-246E07977AF7_1001_0">5400000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1326228" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_1001_2">3131000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1326228_1335586x1530804" unitRef="iso4217_USD" decimals="-5" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_1002_6">400000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1327554" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_2001_0">695000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1327554_1335586x1530804" unitRef="iso4217_USD" decimals="-5" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_2002_4">400000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_9004857_28DE7903-8F72-4119-86A0-B51535CE88C4_3001_1">1309000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1332399_1335586x1530804" unitRef="iso4217_USD" decimals="-5" id="id_9004857_90DF8696-E33A-41A5-8DE7-307A835DC8FF_3002_5">700000</us-gaap:RestructuringCharges>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1416340" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1FC0617E-85C3-40DF-9A0C-6E3E2E57B23E_1002_1">700000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1470922" unitRef="iso4217_USD" decimals="-5" id="id_9004857_1FC0617E-85C3-40DF-9A0C-6E3E2E57B23E_2002_2">600000</us-gaap:AssetImpairmentCharges>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1324247_1335482x1328677" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_1001_1">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1324247_1335482x1331874" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_2001_0">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1325519_1335482x1328677" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_3001_5">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1325519_1335482x1331874" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_4001_4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1330541_1335482x1328677" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_5001_3">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1330541_1335482x1331874" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_6001_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1348884" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_7001_8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1349273_1335482x1328677" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_8001_7">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1349273_1335482x1331874" id="id_9004857_2E40F582-4FB6-4A87-BEA8-9ADB73E84A2C_9001_6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335482x1328677" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_3001_5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335482x1328677" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_1001_3">P5Y9M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335482x1331874" id="id_9004857_D8CB97AC-65B7-4F8F-8F15-C43AE93F899F_2001_2">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7002_5">560000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1350207" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7002_6">2421000</us-gaap:RestructuringReserveSettledWithoutCash2>
  <us-gaap:RestructuringCharges contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1530804" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7001_5">1475000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1530804" unitRef="iso4217_USD" decimals="-3" id="id_9004857_2CABC45C-5F88-415B-A825-B1D01F716BF5_7001_6">1266000</us-gaap:RestructuringReserveSettledWithoutCash2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1336123x1333173" unitRef="pure" decimals="2" id="id_9004857_18D4C5CD-1BCA-4BF4-9749-A9C5A568CC26_4001_1">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <mnkd:TrancheAchievementDate contextRef="eol_PE126000--1610-K0019_STD_366_20161231_0_1336123x1333173" id="id_9004857_552B0454-4F20-4EAB-9501-7573C1D8668A_1001_1">2017-12</mnkd:TrancheAchievementDate>
  <mnkd:LongTermPurchaseCommitmentCancellationFees contextRef="eol_PE126000--1610-K0019_STD_731_20181001_0_1333245x1326102" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D0393631-1395-486B-85F9-73AB815133F1_1002_2">3400000</mnkd:LongTermPurchaseCommitmentCancellationFees>
  <mnkd:LongTermPurchaseCommitmentCancellationFees contextRef="eol_PE126000--1610-K0019_STD_731_20181001_0_1333245x1326102_1447597x1406233" unitRef="iso4217_USD" decimals="-5" id="id_9004857_D0393631-1395-486B-85F9-73AB815133F1_2002_1">5300000</mnkd:LongTermPurchaseCommitmentCancellationFees>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_90_20150331_0" unitRef="shares" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_1_2">79783000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_1_1">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_1_0">-30658000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-K0019_STD_90_20150331_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_1004_3">5800000</us-gaap:InterestExpenseDebt>
  <mnkd:PaymentForContingentLiabilities contextRef="eol_PE126000--1610-K0019_STD_90_20150331_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_9004857_E85E2A89-6403-4E16-84B0-BCA42A41273C_1004_4">10000000</mnkd:PaymentForContingentLiabilities>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_91_20150630_0" unitRef="shares" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_2_2">80203000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_2_1">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_2_0">-28910000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_1_3">-0.29</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_1_5">85771000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_1_4">85771000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_1_2">-0.29</us-gaap:EarningsPerShareBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_1_1">-24873000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_2_3">-0.33</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_91_20160630_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_2_5">91061000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_91_20160630_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_2_4">91061000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_2_2">-0.33</us-gaap:EarningsPerShareBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_2_1">-29959000</us-gaap:NetIncomeLoss>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20151231_0" unitRef="shares" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_4_2">83862000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_4_1">-3.30</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_4_0">-277020000</us-gaap:NetIncomeLoss>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE126000--1610-K0019_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9004857_21D6E74B-E0BC-40E6-86CB-35A394F77077_1_0">242700000</us-gaap:AssetImpairmentCharges>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_3">0.56</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_5">96510000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_4">95676000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_2">0.56</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_0">12404000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_4_1">53976000</us-gaap:NetIncomeLoss>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_AFAFDB68-6B17-4C54-B2DE-6DC59284C63C_1001_1">72000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_92_20161231_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_AFAFDB68-6B17-4C54-B2DE-6DC59284C63C_1001_0">10200000</mnkd:NetRevenueFromCollaboration>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20150930_0" unitRef="shares" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_3_2">81039000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_3_1">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_92_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_12A8BD84-37C9-46D5-9BB1-EC7DB0E412C8_3_0">-31857000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_3">1.31</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_5">96548000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="shares" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_4">95627000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_2">1.32</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_0">162354000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_9004857_5F798FE1-82CA-4D3A-AD6E-9E66337A0675_3_1">126520000</us-gaap:NetIncomeLoss>
  <mnkd:NetRevenueFromCollaboration contextRef="eol_PE126000--1610-K0019_STD_92_20160930_0_1327036x1425803_1328480x1469303" unitRef="iso4217_USD" decimals="-5" id="id_9004857_2E06C6D8-B732-4094-98E3-26077F29985D_1001_0">161800000</mnkd:NetRevenueFromCollaboration>
  <context id="eol_PE126000--1610-K0019_STD_92_20160930_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_92_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_92_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_92_20161231_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_92_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_92_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_91_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_90_20150331_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_731_20181001_0_1333245x1326102_1447597x1406233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:AgreementsAxis">mnkd:BeforeAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2018-10-01</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_731_20181001_0_1333245x1326102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2018-10-01</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1336123x1333173">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1349273_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1349273_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1330541_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1330541_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1325519_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1325519_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1324247_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1335427x1324247_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1470922">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mnkd:AssetHeldForSaleMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1416340">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mnkd:PropertyAndEquipmentImpairmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1332399_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1327554_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1327554">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1326228_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1333589x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1330194x1352081">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnkd:EmployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1328644x1353762">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">mnkd:ValenciaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1543513">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:ReceptorLifeScienceIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803_1327271x1443229_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">mnkd:OperatingLossSharingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1500563_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1454078_1467970x1441734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:LeaseAgreementTypeOfAgreementAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1444803_1326002x1365453_1333456x1331776">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LetterOfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:RelatedPartyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1444803_1326002x1365453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LetterOfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:RelatedPartyDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325994x1367294_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1507406_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mnkd:UpFrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1443830_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mnkd:MilestonePaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1435325_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mnkd:MilestonePaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1382533_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mnkd:InsulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1382533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mnkd:InsulinMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325880x1332226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1325224x1325288">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1325206_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925_1327094x1325206_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324738x1334129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324529x1487319">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:TwoThousandEighteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324497x1494756_1324896x1324925_1327094x1325206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324199x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_366_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20150131_0_1325994x1454078_1467970x1441734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:LeaseAgreementTypeOfAgreementAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1333589x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1331352x1331573">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1330194x1352081">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnkd:EmployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1325994x1454078_1467970x1441734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:LeaseAgreementTypeOfAgreementAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1324529x1470870">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:TwoThousandFifteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1494756_1328480x1469303_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1488748_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1477399_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0_1324497x1455824_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1335427x1366952">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:DanburyFacilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1332399_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1327554_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1326228_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1333589x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1409449">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnkd:ConsultantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1352081">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnkd:EmployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330194x1327949_1335586x1331107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1327036x1425803_1327271x1443229_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">mnkd:OperatingLossSharingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1324738x1334129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1324529x1487319">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:TwoThousandEighteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0_1324529x1470870">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:TwoThousandFifteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_32_20151101_0_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20170131_0_1328480x1469303_1328867x1325939_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20131031_0_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20071031_0_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-10-01</startDate>
      <endDate>2007-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20040831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2004-08-01</startDate>
      <endDate>2004-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20040331_0_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-03-01</startDate>
      <endDate>2004-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20040331_0_1325804x1365910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:EmployeeStockPurchasePlansMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-03-01</startDate>
      <endDate>2004-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_31_20040331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2004-03-01</startDate>
      <endDate>2004-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_30_20160930_0_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_29_20160531_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_29_20160531_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_29_20160531_0_1327036x1543951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:DirectOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_29_20160531_0_1327036x1532316">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:RegisteredOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_13_20150810_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-29</startDate>
      <endDate>2015-08-10</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20170301_0_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-03-01</startDate>
      <endDate>2017-03-01</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20170217_0_1330098x1330589_1335427x1325371_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-17</startDate>
      <endDate>2017-02-17</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20160210_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-02-10</startDate>
      <endDate>2016-02-10</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20131231_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-12-31</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20161109_0_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-11-09</startDate>
      <endDate>2016-11-09</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20161109_0_1328480x1543736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:AventisubLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-11-09</startDate>
      <endDate>2016-11-09</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20161109_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-11-09</startDate>
      <endDate>2016-11-09</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20151116_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-11-16</startDate>
      <endDate>2015-11-16</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20150930_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20150817_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-08-17</startDate>
      <endDate>2015-08-17</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20150810_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-08-10</startDate>
      <endDate>2015-08-10</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20150728_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-28</startDate>
      <endDate>2015-07-28</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20140731_0_1447597x1406233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:AgreementsAxis">mnkd:BeforeAmendmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-31</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20140718_0_1331352x1331573">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-18</startDate>
      <endDate>2014-07-18</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20160512_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-12</startDate>
      <endDate>2016-05-12</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20170316_0_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-03-16</startDate>
      <endDate>2017-03-16</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20170106_0_1330098x1330589_1335427x1325371_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-06</startDate>
      <endDate>2017-01-06</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20161230_0_1327036x1543513">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:ReceptorLifeScienceIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-12-30</startDate>
      <endDate>2016-12-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20160914_0_1325983x1532499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">mnkd:NasdaqStockMarketMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-14</startDate>
      <endDate>2016-09-14</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20160104_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-04</startDate>
      <endDate>2016-01-04</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20120208_0_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-08</startDate>
      <endDate>2012-02-08</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20120208_0_1326002x1513368">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:RelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-08</startDate>
      <endDate>2012-02-08</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_1_20120208_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2012-02-08</startDate>
      <endDate>2012-02-08</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20170301_0_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161109_0_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-11-09</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151116_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-11-16</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151101_0_1334238x1326373">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XTAE</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-11-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151023_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-10-23</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20140923_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-23</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20150814_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-14</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1451439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-10</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20150810_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-10</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20140718_0_1331352x1331573">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-07-18</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20130701_0_1324497x1494756_1328480x1426352_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20100818_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-08-18</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20040831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2004-08-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160512_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-12</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160512_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-12</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20150531_0_1325994x1454078_1467970x1441734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:LeaseAgreementTypeOfAgreementAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20130523_0_1325804x1468282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:EquityIncentivePlanTwentyThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-23</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20040331_0_1325804x1365910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:EmployeeStockPurchasePlansMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2004-03-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20170310_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2017-03-10</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1428469x1409449">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:StockAwardPlanTypeAxis">mnkd:ConsultantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1448981">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnkd:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1335846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1333173">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1336123x1330024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335586x1530804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentySixteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1349273">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1334838">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1330541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1325519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1324436">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1335427x1324247">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1334994x1472762">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mnkd:ThirdPartyLogisticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1333737_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1324874_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1330148x1326956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1483091_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1483091_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1380739_1331210x1333737_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1380739_1331210x1324874_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792_1447597x1353440">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnkd:AgreementsAxis">mnkd:FacilityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1543513">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:ReceptorLifeScienceIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325994x1500563">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1503078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1468282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:EquityIncentivePlanTwentyThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1445632">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:TwoThousandFourEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325804x1365910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnkd:EmployeeStockPurchasePlansMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325224x1335913">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1325224x1325288">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1331210x1324874_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1328615x1483091_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324896x1324925_1328615x1380739_1331210x1324874_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324738x1334129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352_1328615x1466792_1335427x1366952">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:DanburyFacilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1324896x1324925_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1494756_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874_1447597x1353440">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnkd:AgreementsAxis">mnkd:FacilityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324497x1387193_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324319x1333758">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160531_0_1333769x1514964_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160531_0_1333769x1344495_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20160531_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335586x1350207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mnkd:TwentyFifteenRestructuringPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1349273">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1334838">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1330541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1325519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1324436">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1335427x1324247">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1442049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnkd:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1333538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1483091_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1483091_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1380739_1331210x1333737_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1380739_1331210x1324874_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1469303_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1469303_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1325994x1500563">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1325880x1332226_1327036x1425803_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328615x1483091_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328615x1380739_1331210x1324874_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925_1328480x1469303_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324529x1510602_1328480x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:MortgageLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1331210x1333737">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1494756_1324896x1324925_1331210x1324874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324497x1387193_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0_1324319x1333758">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20120208_0_1509889x1436435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:CommonStockIssuedToByPartyAxis">mnkd:UnderwritersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-02-08</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20120208_0_1509889x1405414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="mnkd:CommonStockIssuedToByPartyAxis">mnkd:PublicMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-02-08</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20120208_0_1331314x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-02-08</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-K0019_STD_0_20120208_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2012-02-08</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>mnkd:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="D">
    <measure>utr:D</measure>
  </unit>
  <unit id="Employee">
    <measure>mnkd:Employee</measure>
  </unit>
  <unit id="asset_group">
    <measure>mnkd:asset_group</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>mnkd-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
  xmlns:us-types="http://fasb.org/us-types/2016-01-31"
  xmlns:mnkd="http://imetrix.edgar-online.com/20161231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://imetrix.edgar-online.com/20161231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome" id="Role_StatementOfOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>107 - Statement - Statements of Stockholders' (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>109 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>111 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>112 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>113 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>114 - Disclosure - Related-Party Arrangements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>115 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>116 - Disclosure - Collaboration Arrangements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>117 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock" id="Role_NotesToFinancialStatementsCommonAndPreferredStockTextBlock">
        <link:definition>118 - Disclosure - Common and Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>119 - Disclosure - Net Income (Loss) per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>120 - Disclosure - Stock Award Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>121 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>122 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>123 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>124 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock" id="Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock">
        <link:definition>125 - Disclosure - Selling, General and Administrative Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
        <link:definition>126 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>127 - Disclosure - Selected quarterly financial data (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>128 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>129 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
        <link:definition>130 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables">
        <link:definition>133 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>134 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>135 - Disclosure - Net Income (Loss) per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>136 - Disclosure - Stock Award Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>137 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>138 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables">
        <link:definition>139 - Disclosure - Selling, General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
        <link:definition>140 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>141 - Disclosure - Selected quarterly financial data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation" id="DisclosureDescriptionOfBusinessAdditionalInformation">
        <link:definition>142 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>143 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories" id="DisclosureComponentsOfInventories">
        <link:definition>144 - Disclosure - Components of Inventories (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation" id="DisclosureInventoryAdditionalInformation">
        <link:definition>145 - Disclosure - Inventory - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>146 - Disclosure - Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>147 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>148 - Disclosure - Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation" id="DisclosureRelatedPartyArrangementsAdditionalInformation">
        <link:definition>149 - Disclosure - Related-Party Arrangements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings" id="DisclosureSummaryOfBorrowings">
        <link:definition>150 - Disclosure - Summary of Borrowings (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation" id="DisclosureBorrowingsAdditionalInformation">
        <link:definition>151 - Disclosure - Borrowings - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement" id="DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement">
        <link:definition>152 - Disclosure - Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation" id="DisclosureCollaborativeArrangementAdditionalInformation">
        <link:definition>153 - Disclosure - Collaborative Arrangement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation" id="DisclosureFairValueOfFinancialInstrumentsAdditionalInformation">
        <link:definition>154 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>155 - Disclosure - Fair Value of Financial Instruments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue" id="DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue">
        <link:definition>156 - Disclosure - Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation" id="DisclosureCommonAndPreferredStockAdditionalInformation">
        <link:definition>157 - Disclosure - Common and Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation" id="DisclosureNetIncomeLossPerCommonShareAdditionalInformation">
        <link:definition>158 - Disclosure - Net Income (Loss) per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations" id="DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations">
        <link:definition>159 - Disclosure - Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive" id="DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive">
        <link:definition>160 - Disclosure - Potentially Dilutive Securities Outstanding that are Antidilutive (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation" id="DisclosureStockAwardPlansAdditionalInformation">
        <link:definition>161 - Disclosure - Stock Award Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans" id="DisclosureStockBasedAwardPlans">
        <link:definition>162 - Disclosure - Stock Based Award Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation" id="DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation">
        <link:definition>163 - Disclosure - Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory" id="DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory">
        <link:definition>164 - Disclosure - Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions" id="DisclosureFairValueOfEmployeeStockOptionsAssumptions">
        <link:definition>165 - Disclosure - Fair Value of Employee Stock Options Assumptions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding" id="DisclosureSummaryOfStockOptionsOutstanding">
        <link:definition>166 - Disclosure - Summary of Stock Options Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity" id="DisclosureSummaryOfRestrictedStockUnitActivity">
        <link:definition>167 - Disclosure - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>168 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract" id="DisclosureAnnualPurchaseRequirementsUnderContract">
        <link:definition>169 - Disclosure - Annual Purchase Requirements under Contract (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation" id="DisclosureEmployeeBenefitPlansAdditionalInformation">
        <link:definition>170 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes" id="DisclosureProvisionForIncomeTaxes">
        <link:definition>171 - Disclosure - Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets" id="DisclosureComponentsOfNetDeferredTaxAssets">
        <link:definition>172 - Disclosure - Components of Net Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>173 - Disclosure - Income Taxes -Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate" id="DisclosureEffectiveIncomeTaxRate">
        <link:definition>174 - Disclosure - Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation" id="DisclosureWarrantsAdditionalInformation">
        <link:definition>175 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses" id="DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses">
        <link:definition>176 - Disclosure - Schedule of Selling, General and Administrative Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation" id="DisclosureRestructuringChargesAdditionalInformation">
        <link:definition>177 - Disclosure - Restructuring Charges - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges" id="DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges">
        <link:definition>178 - Disclosure - Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData" id="DisclosureSelectedQuarterlyFinancialData">
        <link:definition>179 - Disclosure - Selected Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation" id="DisclosureSelectedQuarterlyFinancialDataAdditionalInformation">
        <link:definition>180 - Disclosure - Selected Quarterly Financial Data - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>181 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mnkd-20161231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mnkd-20161231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mnkd-20161231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mnkd-20161231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" id="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedExpensesAndOtherCurrentLiabilitiesLineItems" id="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedExpensesAndOtherCurrentLiabilitiesTable" id="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="AccruedExpensesIntellectualProperty" id="mnkd_AccruedExpensesIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedInterestNoncurrent" id="mnkd_AccruedInterestNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedInterestOfRelatedPartyDebt" id="mnkd_AccruedInterestOfRelatedPartyDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" id="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" id="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" id="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementsAxis" id="mnkd_AgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="AgreementsDomain" id="mnkd_AgreementsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AlfredMannFoundationMember" id="mnkd_AlfredMannFoundationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmendedAgreementMember" id="mnkd_AmendedAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AreaOfOfficeSpaceLeased" id="mnkd_AreaOfOfficeSpaceLeased" type="num:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AssetHeldForSaleMember" id="mnkd_AssetHeldForSaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AssetsHeldForSalePolicyTextBlock" id="mnkd_AssetsHeldForSalePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableLoanBalanceCancelled" id="mnkd_AvailableLoanBalanceCancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AventisubLlcMember" id="mnkd_AventisubLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BasisOfPresentationPolicyTextBlock" id="mnkd_BasisOfPresentationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BeforeAmendmentMember" id="mnkd_BeforeAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessPolicyTextBlock" id="mnkd_BusinessPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashDiscountPercent" id="mnkd_CashDiscountPercent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInFairValueOfWarrantLiability" id="mnkd_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassAWarrantsMember" id="mnkd_ClassAWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassBWarrantsMember" id="mnkd_ClassBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantExercisablePeriod" id="mnkd_ClassOfWarrantExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" id="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercised" id="mnkd_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpirationPeriod" id="mnkd_ClassOfWarrantOrRightExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" id="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantsOrRightsExpirationDate" id="mnkd_ClassOfWarrantsOrRightsExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalTrialExpensePolicyTextBlock" id="mnkd_ClinicalTrialExpensePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" id="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" id="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" id="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClosingBidPriceOfCommonStockRequiredPricePerShare" id="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementMember" id="mnkd_CollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesLineItems" id="mnkd_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesTable" id="mnkd_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CommonAndPreferredStockTextBlock" id="mnkd_CommonAndPreferredStockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockAndWarrantsIssuedInDirectPlacementShares" id="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockAndWarrantsIssuedInDirectPlacementValue" id="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockIssuedToByPartyAxis" id="mnkd_CommonStockIssuedToByPartyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="CommonStockIssuedToByPartyDomain" id="mnkd_CommonStockIssuedToByPartyDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockLoanedUnderShareLendingAgreementShares" id="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockLoanedUnderShareLendingAgreementValue" id="mnkd_CommonStockLoanedUnderShareLendingAgreementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComputationOfEarningsPerShareLineItems" id="mnkd_ComputationOfEarningsPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComputerEquipmentAndSoftwareMember" id="mnkd_ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsiderationReceived" id="mnkd_ConsiderationReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultantMember" id="mnkd_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentLiability" id="mnkd_ContingentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CostsOfRevenueCollaboration" id="mnkd_CostsOfRevenueCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CustomerDiscountsAndAllowances" id="mnkd_CustomerDiscountsAndAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DanburyFacilityMember" id="mnkd_DanburyFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentDateOfLastRequiredPayment" id="mnkd_DebtInstrumentDateOfLastRequiredPayment" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeerfieldManagementCompanyLpMember" id="mnkd_DeerfieldManagementCompanyLpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredCollaborativeCreditCurrent" id="mnkd_DeferredCollaborativeCreditCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredCollaborativeRevenueCurrent" id="mnkd_DeferredCollaborativeRevenueCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredCostRelatedToSaleOfRawInsulin" id="mnkd_DeferredCostRelatedToSaleOfRawInsulin" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueFromSaleOfRawInsulin" id="mnkd_DeferredRevenueFromSaleOfRawInsulin" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetIncreaseDecreaseInEquity" id="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedCosts" id="mnkd_DeferredTaxAssetsCapitalizedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedResearchExpenses" id="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsLineItems" id="mnkd_DeferredTaxAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsLossOnPurchaseCommitment" id="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsMilestoneRights" id="mnkd_DeferredTaxAssetsMilestoneRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsTable" id="mnkd_DeferredTaxAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" id="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeficitAccumulatedDuringDevelopmentStageMember" id="mnkd_DeficitAccumulatedDuringDevelopmentStageMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciationAndOtherAmortizationExpensesLineItems" id="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciationAndOtherAmortizationExpensesTable" id="mnkd_DepreciationAndOtherAmortizationExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DirectOfferingMember" id="mnkd_DirectOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mnkd_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EarningsPerShareTable" id="mnkd_EarningsPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="EffectiveIncomeTaxRateReconciliationPermanentItems" id="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeMember" id="mnkd_EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" id="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlansMember" id="mnkd_EmployeeStockPurchasePlansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanTwentyThirteenMember" id="mnkd_EquityIncentivePlanTwentyThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedAmountsCreditExchangeReceivable" id="mnkd_EstimatedAmountsCreditExchangeReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FacilityAgreementMember" id="mnkd_FacilityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FacilityFinancingObligationMember" id="mnkd_FacilityFinancingObligationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfFinancialInstrumentsLineItems" id="mnkd_FairValueOfFinancialInstrumentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfFinancialInstrumentsTable" id="mnkd_FairValueOfFinancialInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="FurnitureFixturesAndOfficeEquipmentMember" id="mnkd_FurnitureFixturesAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GainLossFromChangeInFairValueOfWarrantLiabilities" id="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GainLossOnPurchaseCommitments" id="mnkd_GainLossOnPurchaseCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrossToNetAdjustmentsPolicyTextBlock" id="mnkd_GrossToNetAdjustmentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesLineItems" id="mnkd_IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" id="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" id="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxesTable" id="mnkd_IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxExpenseBenefitNet" id="mnkd_IncomeTaxExpenseBenefitNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredCollaborativeRevenue" id="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInOtherDeferredCharges" id="mnkd_IncreaseDecreaseInOtherDeferredCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInPurchaseCommitmentLoss" id="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InsulinMember" id="mnkd_InsulinMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestOnNotePayableToPrincipalStockholder" id="mnkd_InterestOnNotePayableToPrincipalStockholder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterimReportingLineItems" id="mnkd_InterimReportingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterimReportingTable" id="mnkd_InterimReportingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LeaseAgreementTypeOfAgreementAxis" id="mnkd_LeaseAgreementTypeOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="LeaseAgreementTypeOfAgreementDomain" id="mnkd_LeaseAgreementTypeOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseExpirationMonthYear" id="mnkd_LeaseExpirationMonthYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LetterOfAgreementMember" id="mnkd_LetterOfAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LineOfCreditFacilityRestrictedBorrowingCapacity" id="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LoanAgreementWithRelatedParty" id="mnkd_LoanAgreementWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LoanArrangementMember" id="mnkd_LoanArrangementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LoanFacilityForgivenDate" id="mnkd_LoanFacilityForgivenDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LongTermPurchaseCommitmentCancellationFees" id="mnkd_LongTermPurchaseCommitmentCancellationFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LongTermPurchaseCommitmentExpirationDate" id="mnkd_LongTermPurchaseCommitmentExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LongtermPurchaseCommitmentRenewalTimePeriod" id="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LossOnPurchaseCommitmentsPolicyPolicyTextBlock" id="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LossSharingAgreementAmount" id="mnkd_LossSharingAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaturityPeriodOfCashEquivalents" id="mnkd_MaturityPeriodOfCashEquivalents" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentOneMember" id="mnkd_MilestonePaymentOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePayments" id="mnkd_MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentTwoMember" id="mnkd_MilestonePaymentTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" id="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRightsLiabilityMember" id="mnkd_MilestoneRightsLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumClosingBidPriceOfCommonStock" id="mnkd_MinimumClosingBidPriceOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MortgageLoanMember" id="mnkd_MortgageLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NasdaqStockMarketMember" id="mnkd_NasdaqStockMarketMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetIncomeLossPerCommonShareLineItems" id="mnkd_NetIncomeLossPerCommonShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetIncomeLossPerCommonShareTable" id="mnkd_NetIncomeLossPerCommonShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="NetOperatingLossCarryforwardAnnualLimitation" id="mnkd_NetOperatingLossCarryforwardAnnualLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetOperatingLossCarryforwardsBeginsToExpire" id="mnkd_NetOperatingLossCarryforwardsBeginsToExpire" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromSaleOfProperty" id="mnkd_NetProceedsFromSaleOfProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetRevenueFromBulkInsulin" id="mnkd_NetRevenueFromBulkInsulin" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetRevenueFromCollaboration" id="mnkd_NetRevenueFromCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NominalLendingFee" id="mnkd_NominalLendingFee" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAssetGroups" id="mnkd_NumberOfAssetGroups" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfMonthsAdvancesOutstanding" id="mnkd_NumberOfMonthsAdvancesOutstanding" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeLeaseExpense" id="mnkd_OfficeLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsSubjectToLimitation" id="mnkd_OperatingLossCarryforwardsSubjectToLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossSharingMember" id="mnkd_OperatingLossSharingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" id="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" id="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" id="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentForContingentLiabilities" id="mnkd_PaymentForContingentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsForCommissionsAndOtherFees" id="mnkd_PaymentsForCommissionsAndOtherFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsForFinancialAssets" id="mnkd_PaymentsForFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsForUseOfAircrafts" id="mnkd_PaymentsForUseOfAircrafts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfCommonStockSharesOutstanding" id="mnkd_PercentageOfCommonStockSharesOutstanding" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfCreditExchangeReceivable" id="mnkd_PercentageOfCreditExchangeReceivable" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfShareReservedForShareBasedCompensation" id="mnkd_PercentageOfShareReservedForShareBasedCompensation" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMilestonePaymentsToBeReceived" id="mnkd_PotentialMilestonePaymentsToBeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrincipalAmountPerShare" id="mnkd_PrincipalAmountPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfCommonStockAndWarrants" id="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" id="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromOptionExerciseAndLicenseFeesReceived" id="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductSalesRevenueGrossToNetAdjustments" id="mnkd_ProductSalesRevenueGrossToNetAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductSalesRevenueGrossToNetAdjustmentsPercentage" id="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProfitLossSharingAgreementAllocationPercentage" id="mnkd_ProfitLossSharingAgreementAllocationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyAndEquipmentImpairmentMember" id="mnkd_PropertyAndEquipmentImpairmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PublicMember" id="mnkd_PublicMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseObligationCurrent" id="mnkd_PurchaseObligationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseObligationDueInSeventhYear" id="mnkd_PurchaseObligationDueInSeventhYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseObligationDueInSixthYear" id="mnkd_PurchaseObligationDueInSixthYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseObligationNoncurrent" id="mnkd_PurchaseObligationNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RecentlyIssuedAccountingStandardsPolicyTextBlock" id="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReceptorLifeScienceIncMember" id="mnkd_ReceptorLifeScienceIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" id="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RecognitionPeriodForDeferredRevenue" id="mnkd_RecognitionPeriodForDeferredRevenue" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegisteredOfferingMember" id="mnkd_RegisteredOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyDebtMember" id="mnkd_RelatedPartyDebtMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyMember" id="mnkd_RelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyTransactionDebtInstrumentPrepayment" id="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyTransactionPrepaymentPeriod" id="mnkd_RelatedPartyTransactionPrepaymentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentCreditsBeginToExpire" id="mnkd_ResearchAndDevelopmentCreditsBeginToExpire" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentExpensesOffsetAmount" id="mnkd_ResearchAndDevelopmentExpensesOffsetAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionBulkSalesPolicyTextBlock" id="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseStockSplitPolicyTextBlock" id="mnkd_ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SaleOfCommonStockInUnderwrittenPublicOffering" id="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SaleOfIntellectualPropertyPolicyTextBlock" id="mnkd_SaleOfIntellectualPropertyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesAndMarketingRelatedExpensesAccrued" id="mnkd_SalesAndMarketingRelatedExpensesAccrued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesReturnPeriod" id="mnkd_SalesReturnPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SanofiAventisMember" id="mnkd_SanofiAventisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfIncomeTaxesLineItems" id="mnkd_ScheduleOfIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfIncomeTaxesTable" id="mnkd_ScheduleOfIncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" id="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" id="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SellingGeneralAndAdministrativeExpensesLineItems" id="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SellingGeneralAndAdministrativeExpensesTable" id="mnkd_SellingGeneralAndAdministrativeExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SellingGeneralAndAdministrativeExpensesTableTextBlock" id="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorConvertibleNotesDueTwoThousandEighteenMember" id="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorConvertibleNotesDueTwoThousandFifteenMember" id="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorConvertibleNotesMember" id="mnkd_SeniorConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" id="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" id="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationAwardTrancheFourMember" id="mnkd_ShareBasedCompensationAwardTrancheFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesReservedForEmployeeStockPurchasePlan" id="mnkd_SharesReservedForEmployeeStockPurchasePlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesReturnedUnderShareLendingAgreement" id="mnkd_SharesReturnedUnderShareLendingAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockAwardPlanTypeAxis" id="mnkd_StockAwardPlanTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="StockAwardPlanTypeDomain" id="mnkd_StockAwardPlanTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesForDebtExchange" id="mnkd_StockIssuedDuringPeriodSharesForDebtExchange" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesNewIssuesPercentage" id="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesShareLendingAgreement" id="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesWarrantExercises" id="mnkd_StockIssuedDuringPeriodSharesWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueForDebtExchange" id="mnkd_StockIssuedDuringPeriodValueForDebtExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueShareLendingAgreement" id="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueWarrantExercises" id="mnkd_StockIssuedDuringPeriodValueWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionActivityAndChangesLineItems" id="mnkd_StockOptionActivityAndChangesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionActivityAndChangesTable" id="mnkd_StockOptionActivityAndChangesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockOptionsGrantedVestingRate" id="mnkd_StockOptionsGrantedVestingRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseAgreementMember" id="mnkd_SubleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesTable" id="mnkd_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TerminationDateOfLicenseAgreement" id="mnkd_TerminationDateOfLicenseAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdPartyLogisticsMember" id="mnkd_ThirdPartyLogisticsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrancheAchievementDate" id="mnkd_TrancheAchievementDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrancheBMember" id="mnkd_TrancheBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrancheOneMember" id="mnkd_TrancheOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrancheThreeMember" id="mnkd_TrancheThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrancheTwoMember" id="mnkd_TrancheTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TransfersFromToParentAbstract" id="mnkd_TransfersFromToParentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwentyFifteenRestructuringPlanMember" id="mnkd_TwentyFifteenRestructuringPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwentySixteenRestructuringPlanMember" id="mnkd_TwentySixteenRestructuringPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandEighteenNotesMember" id="mnkd_TwoThousandEighteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFifteenNotesMember" id="mnkd_TwoThousandFifteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFourEquityIncentivePlanMember" id="mnkd_TwoThousandFourEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" id="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandNineteenNotesMember" id="mnkd_TwoThousandNineteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UncategorizedAbstract" id="mnkd_UncategorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnderwritersMember" id="mnkd_UnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnitsSoldByUnderwritingPrice" id="mnkd_UnitsSoldByUnderwritingPrice" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnitsSoldUnderPublicOfferUnderwritten" id="mnkd_UnitsSoldUnderPublicOfferUnderwritten" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" id="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnitsSoldWarrantPortionConvertibleIntoCommonStock" id="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFee" id="mnkd_UpfrontFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpFrontPaymentMember" id="mnkd_UpFrontPaymentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ValenciaMember" id="mnkd_ValenciaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ValueOfRestrictedStockUnitsVested" id="mnkd_ValueOfRestrictedStockUnitsVested" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantIssuanceCosts" id="mnkd_WarrantIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantLiabilityMember" id="mnkd_WarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsExercisableExpirationPeriod" id="mnkd_WarrantsExercisableExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsPolicyTextBlock" id="mnkd_WarrantsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" id="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WholesalerDistributionFeesPolicyTextBlock" id="mnkd_WholesalerDistributionFeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WriteOffOfCommitmentAsset" id="mnkd_WriteOffOfCommitmentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WriteOffOfDerivativeLiability" id="mnkd_WriteOffOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>mnkd-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfInventories" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRelatedPartyArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfBorrowings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureBorrowingsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCollaborativeArrangementAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstrumentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommonAndPreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureNetIncomeLossPerCommonShareAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockAwardPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedAwardPlans" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfEmployeeStockOptionsAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfStockOptionsOutstanding" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAnnualPurchaseRequirementsUnderContract" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureProvisionForIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEffectiveIncomeTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRestructuringChargesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommonAndPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestNoncurrent" xlink:label="mnkd_AccruedInterestNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeCreditCurrent" xlink:label="mnkd_DeferredCollaborativeCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeRevenueCurrent" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationCurrent" xlink:label="mnkd_PurchaseObligationCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationNoncurrent" xlink:label="mnkd_PurchaseObligationNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherDeferredCostsNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="mnkd_AccruedInterestNoncurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LossContingencyAccrualCarryingValueNoncurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="mnkd_PurchaseObligationNoncurrent" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.3300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mnkd_DeferredCollaborativeCreditCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mnkd_DeferredCollaborativeRevenueCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mnkd_PurchaseObligationCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CostsOfRevenueCollaboration" xlink:label="mnkd_CostsOfRevenueCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromBulkInsulin" xlink:label="mnkd_NetRevenueFromBulkInsulin"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="mnkd_CostsOfRevenueCollaboration" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseDebt" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="mnkd_NetRevenueFromBulkInsulin" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInOtherDeferredCharges" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterestOnNotePayableToPrincipalStockholder" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePayments" xlink:label="mnkd_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantIssuanceCosts" xlink:label="mnkd_WarrantIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfCommitmentAsset" xlink:label="mnkd_WriteOffOfCommitmentAsset"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfDerivativeLiability" xlink:label="mnkd_WriteOffOfDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.3400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.4900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.3500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.3600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.3700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.3800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="1.3900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.4000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="1.4100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1.4200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.4300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.4400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="mnkd_MilestonePayments" order="1.4500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.4600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.4700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.4800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.3200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.3300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_InterestOnNotePayableToPrincipalStockholder" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_WarrantIssuanceCosts" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_WriteOffOfCommitmentAsset" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_WriteOffOfDerivativeLiability" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_IncreaseDecreaseInOtherDeferredCharges" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.3000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CustomerDiscountsAndAllowances" xlink:label="mnkd_CustomerDiscountsAndAllowances"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesAndMarketingRelatedExpensesAccrued" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mnkd_SalesAndMarketingRelatedExpensesAccrued" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mnkd_CustomerDiscountsAndAllowances" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxExpenseBenefitNet" xlink:label="mnkd_IncomeTaxExpenseBenefitNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mnkd_IncomeTaxExpenseBenefitNet" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mnkd_IncomeTaxExpenseBenefitNet" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mnkd_IncomeTaxExpenseBenefitNet" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedCosts" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsMilestoneRights" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mnkd_DeferredTaxAssetsMilestoneRights" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mnkd_DeferredTaxAssetsCapitalizedCosts" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>mnkd-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfInventories" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRelatedPartyArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfBorrowings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureBorrowingsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCollaborativeArrangementAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstrumentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommonAndPreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureNetIncomeLossPerCommonShareAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockAwardPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedAwardPlans" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfEmployeeStockOptionsAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfStockOptionsOutstanding" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAnnualPurchaseRequirementsUnderContract" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureProvisionForIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEffectiveIncomeTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRestructuringChargesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommonAndPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestNoncurrent" xlink:label="mnkd_AccruedInterestNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeCreditCurrent" xlink:label="mnkd_DeferredCollaborativeCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeRevenueCurrent" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationCurrent" xlink:label="mnkd_PurchaseObligationCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationNoncurrent" xlink:label="mnkd_PurchaseObligationNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherDeferredCostsNet" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_AccruedInterestNoncurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LossContingencyAccrualCarryingValueNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_PurchaseObligationNoncurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLongTermDebtCurrent" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_DeferredCollaborativeCreditCurrent" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_DeferredCollaborativeRevenueCurrent" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_PurchaseObligationCurrent" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CostsOfRevenueCollaboration" xlink:label="mnkd_CostsOfRevenueCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromBulkInsulin" xlink:label="mnkd_NetRevenueFromBulkInsulin"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="mnkd_CostsOfRevenueCollaboration" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mnkd_NetRevenueFromBulkInsulin" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementValue" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnkd_DeficitAccumulatedDuringDevelopmentStageMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesWarrantExercises" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueWarrantExercises" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesForDebtExchange" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueForDebtExchange" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountContributions" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementValue" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_EntityListingsExchangeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInOtherDeferredCharges" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterestOnNotePayableToPrincipalStockholder" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansAssumed1" xlink:label="us-gaap_LoansAssumed1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePayments" xlink:label="mnkd_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantIssuanceCosts" xlink:label="mnkd_WarrantIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfCommitmentAsset" xlink:label="mnkd_WriteOffOfCommitmentAsset"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfDerivativeLiability" xlink:label="mnkd_WriteOffOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_InterestOnNotePayableToPrincipalStockholder" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WarrantIssuanceCosts" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WriteOffOfCommitmentAsset" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WriteOffOfDerivativeLiability" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInOtherDeferredCharges" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="mnkd_MilestonePayments" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.6100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.6200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.6300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.6400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.6500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.6600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.6700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_LoansAssumed1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_EntityListingsExchangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AventisubLlcMember" xlink:label="mnkd_AventisubLlcMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InsulinMember" xlink:label="mnkd_InsulinMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanArrangementMember" xlink:label="mnkd_LoanArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheBMember" xlink:label="mnkd_TrancheBMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpfrontFee" xlink:label="mnkd_UpfrontFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheBMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_AventisubLlcMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="us-gaap_PutOptionMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_UpfrontFee" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_OpenOptionContractsWrittenTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ProductOrServiceAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_CreditFacilityAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_InsulinMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LoanArrangementMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesIntellectualProperty" xlink:label="mnkd_AccruedExpensesIntellectualProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CashDiscountPercent" xlink:label="mnkd_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsiderationReceived" xlink:label="mnkd_ConsiderationReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCostRelatedToSaleOfRawInsulin" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredRevenueFromSaleOfRawInsulin" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EstimatedAmountsCreditExchangeReceivable" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MaturityPeriodOfCashEquivalents" xlink:label="mnkd_MaturityPeriodOfCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCreditExchangeReceivable" xlink:label="mnkd_PercentageOfCreditExchangeReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustments" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesReturnPeriod" xlink:label="mnkd_SalesReturnPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ThirdPartyLogisticsMember" xlink:label="mnkd_ThirdPartyLogisticsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mnkd_ThirdPartyLogisticsMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_SalesReturnPeriod" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_CashDiscountPercent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_DeferredRevenueFromSaleOfRawInsulin" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_DeferredCostRelatedToSaleOfRawInsulin" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_MaturityPeriodOfCashEquivalents" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_PercentageOfCreditExchangeReceivable" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ConsiderationReceived" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_AccruedExpensesIntellectualProperty" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_EstimatedAmountsCreditExchangeReceivable" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InterestCostsCapitalized" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ProductOrServiceAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="8.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputerEquipmentAndSoftwareMember" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_FurnitureFixturesAndOfficeEquipmentMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_ComputerEquipmentAndSoftwareMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetHeldForSaleMember" xlink:label="mnkd_AssetHeldForSaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DanburyFacilityMember" xlink:label="mnkd_DanburyFacilityMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfAssetGroups" xlink:label="mnkd_NumberOfAssetGroups"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PropertyAndEquipmentImpairmentMember" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValenciaMember" xlink:label="mnkd_ValenciaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="mnkd_DepreciationAndOtherAmortizationExpensesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="mnkd_NumberOfAssetGroups" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="mnkd_PropertyAndEquipmentImpairmentMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="mnkd_AssetHeldForSaleMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="mnkd_ValenciaMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_DanburyFacilityMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CustomerDiscountsAndAllowances" xlink:label="mnkd_CustomerDiscountsAndAllowances"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesAndMarketingRelatedExpensesAccrued" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_SalesAndMarketingRelatedExpensesAccrued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_CustomerDiscountsAndAllowances" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_ConstructionPayableCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestOfRelatedPartyDebt" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AlfredMannFoundationMember" xlink:label="mnkd_AlfredMannFoundationMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AmendedAgreementMember" xlink:label="mnkd_AmendedAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AreaOfOfficeSpaceLeased" xlink:label="mnkd_AreaOfOfficeSpaceLeased"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AvailableLoanBalanceCancelled" xlink:label="mnkd_AvailableLoanBalanceCancelled"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseExpirationMonthYear" xlink:label="mnkd_LeaseExpirationMonthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LetterOfAgreementMember" xlink:label="mnkd_LetterOfAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanAgreementWithRelatedParty" xlink:label="mnkd_LoanAgreementWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanArrangementMember" xlink:label="mnkd_LoanArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfMonthsAdvancesOutstanding" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OfficeLeaseExpense" xlink:label="mnkd_OfficeLeaseExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForUseOfAircrafts" xlink:label="mnkd_PaymentsForUseOfAircrafts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyDebtMember" xlink:label="mnkd_RelatedPartyDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionPrepaymentPeriod" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SubleaseAgreementMember" xlink:label="mnkd_SubleaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:to="mnkd_LeaseAgreementTypeOfAgreementDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:to="mnkd_LeaseAgreementTypeOfAgreementDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:to="mnkd_SubleaseAgreementMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mnkd_RelatedPartyDebtMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LoanArrangementMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_AlfredMannFoundationMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_AmendedAgreementMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LetterOfAgreementMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_LoanAgreementWithRelatedParty" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_NumberOfMonthsAdvancesOutstanding" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_RelatedPartyTransactionPrepaymentPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AvailableLoanBalanceCancelled" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AccruedInterestOfRelatedPartyDebt" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AreaOfOfficeSpaceLeased" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_LeaseExpirationMonthYear" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_OfficeLeaseExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_PaymentsForUseOfAircrafts" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VariableRateAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="mnkd_LeaseAgreementTypeOfAgreementAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="1.2200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsAxis" xlink:label="mnkd_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DanburyFacilityMember" xlink:label="mnkd_DanburyFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DebtInstrumentDateOfLastRequiredPayment" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityAgreementMember" xlink:label="mnkd_FacilityAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="us-gaap_OtherShortTermBorrowings"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentForContingentLiabilities" xlink:label="mnkd_PaymentForContingentLiabilities"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrincipalAmountPerShare" xlink:label="mnkd_PrincipalAmountPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheBMember" xlink:label="mnkd_TrancheBMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheOneMember" xlink:label="mnkd_TrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheThreeMember" xlink:label="mnkd_TrancheThreeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheTwoMember" xlink:label="mnkd_TrancheTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandEighteenNotesMember" xlink:label="mnkd_TwoThousandEighteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFifteenNotesMember" xlink:label="mnkd_TwoThousandFifteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AgreementsDomain" xlink:to="mnkd_FacilityAgreementMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheBMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheOneMember" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheTwoMember" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheThreeMember" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_DebtInstrumentDateOfLastRequiredPayment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_ContingentLiability" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherShortTermBorrowings" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_PaymentForContingentLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueInputsEntityCreditRisk" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherLongTermDebt" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_PrincipalAmountPerShare" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionDescription" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_TwoThousandEighteenNotesMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_TwoThousandFifteenNotesMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="mnkd_AgreementsAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_DanburyFacilityMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AventisubLlcMember" xlink:label="mnkd_AventisubLlcMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InsulinMember" xlink:label="mnkd_InsulinMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossSharingAgreementAmount" xlink:label="mnkd_LossSharingAgreementAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentOneMember" xlink:label="mnkd_MilestonePaymentOneMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentTwoMember" xlink:label="mnkd_MilestonePaymentTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MortgageLoanMember" xlink:label="mnkd_MortgageLoanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossSharingMember" xlink:label="mnkd_OperatingLossSharingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PotentialMilestonePaymentsToBeReceived" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProfitLossSharingAgreementAllocationPercentage" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReceptorLifeScienceIncMember" xlink:label="mnkd_ReceptorLifeScienceIncMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecognitionPeriodForDeferredRevenue" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentExpensesOffsetAmount" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TerminationDateOfLicenseAgreement" xlink:label="mnkd_TerminationDateOfLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpFrontPaymentMember" xlink:label="mnkd_UpFrontPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_ReceptorLifeScienceIncMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="mnkd_OperatingLossSharingMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ResearchAndDevelopmentExpensesOffsetAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_RecognitionPeriodForDeferredRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ProfitLossSharingAgreementAllocationPercentage" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_TerminationDateOfLicenseAgreement" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_PotentialMilestonePaymentsToBeReceived" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCosts" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_LossSharingAgreementAmount" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_MortgageLoanMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_AventisubLlcMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="us-gaap_PutOptionMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_UpFrontPaymentMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_MilestonePaymentOneMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_MilestonePaymentTwoMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_InsulinMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_OpenOptionContractsWrittenTypeAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsTable" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanFacilityForgivenDate" xlink:label="mnkd_LoanFacilityForgivenDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember" xlink:label="us-gaap_MarketApproachValuationTechniqueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_FairValueOfFinancialInstrumentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_ContingentLiability" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_LoanFacilityForgivenDate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_CreditFacilityAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="dei_LegalEntityAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_RangeAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_MarketApproachValuationTechniqueMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember" order="1.2400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityFinancingObligationMember" xlink:label="mnkd_FacilityFinancingObligationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesMember" xlink:label="mnkd_SeniorConvertibleNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CreditFacilityAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_FacilityFinancingObligationMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForFinancialAssets" xlink:label="mnkd_PaymentsForFinancialAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mnkd_PaymentsForFinancialAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassAWarrantsMember" xlink:label="mnkd_ClassAWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassBWarrantsMember" xlink:label="mnkd_ClassBWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisablePeriod" xlink:label="mnkd_ClassOfWarrantExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantsOrRightsExpirationDate" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyAxis" xlink:label="mnkd_CommonStockIssuedToByPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyDomain" xlink:label="mnkd_CommonStockIssuedToByPartyDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyDomain" xlink:label="mnkd_CommonStockIssuedToByPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DirectOfferingMember" xlink:label="mnkd_DirectOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NominalLendingFee" xlink:label="mnkd_NominalLendingFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PublicMember" xlink:label="mnkd_PublicMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RegisteredOfferingMember" xlink:label="mnkd_RegisteredOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyMember" xlink:label="mnkd_RelatedPartyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReturnedUnderShareLendingAgreement" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnderwritersMember" xlink:label="mnkd_UnderwritersMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldByUnderwritingPrice" xlink:label="mnkd_UnitsSoldByUnderwritingPrice"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwritten" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsExercisableExpirationPeriod" xlink:label="mnkd_WarrantsExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_RegisteredOfferingMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_DirectOfferingMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantExercisablePeriod" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_NominalLendingFee" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_SharesReturnedUnderShareLendingAgreement" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwritten" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldByUnderwritingPrice" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_WarrantsExercisableExpirationPeriod" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantsOrRightsExpirationDate" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassAWarrantsMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassBWarrantsMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mnkd_CommonStockIssuedToByPartyAxis" xlink:to="mnkd_CommonStockIssuedToByPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mnkd_CommonStockIssuedToByPartyAxis" xlink:to="mnkd_CommonStockIssuedToByPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommonStockIssuedToByPartyDomain" xlink:to="mnkd_UnderwritersMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommonStockIssuedToByPartyDomain" xlink:to="mnkd_PublicMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mnkd_RelatedPartyMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_EntityListingsExchangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="mnkd_CommonStockIssuedToByPartyAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareLineItems" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareTable" xlink:label="mnkd_NetIncomeLossPerCommonShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesOutstanding" xlink:label="us-gaap_OwnshareLendingArrangementSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="mnkd_NetIncomeLossPerCommonShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_OwnshareLendingArrangementSharesOutstanding" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputationOfEarningsPerShareLineItems" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EarningsPerShareTable" xlink:label="mnkd_EarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="mnkd_EarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_EarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsultantMember" xlink:label="mnkd_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlansMember" xlink:label="mnkd_EmployeeStockPurchasePlansMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCommonStockSharesOutstanding" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfShareReservedForShareBasedCompensation" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationAwardTrancheFourMember" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReservedForEmployeeStockPurchasePlan" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeAxis" xlink:label="mnkd_StockAwardPlanTypeAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeDomain" xlink:label="mnkd_StockAwardPlanTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeDomain" xlink:label="mnkd_StockAwardPlanTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionsGrantedVestingRate" xlink:label="mnkd_StockOptionsGrantedVestingRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheAchievementDate" xlink:label="mnkd_TrancheAchievementDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValueOfRestrictedStockUnitsVested" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EquityIncentivePlanTwentyThirteenMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EmployeeStockPurchasePlansMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="mnkd_StockAwardPlanTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_SharesReservedForEmployeeStockPurchasePlan" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_PercentageOfCommonStockSharesOutstanding" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_PercentageOfShareReservedForShareBasedCompensation" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_StockOptionsGrantedVestingRate" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_ValueOfRestrictedStockUnitsVested" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_TrancheAchievementDate" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mnkd_StockAwardPlanTypeAxis" xlink:to="mnkd_StockAwardPlanTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mnkd_StockAwardPlanTypeAxis" xlink:to="mnkd_StockAwardPlanTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockAwardPlanTypeDomain" xlink:to="mnkd_ConsultantMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="mnkd_ShareBasedCompensationAwardTrancheFourMember" order="1.4400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourEquityIncentivePlanMember" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_TwoThousandFourEquityIncentivePlanMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EquityIncentivePlanTwentyThirteenMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsultantMember" xlink:label="mnkd_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeMember" xlink:label="mnkd_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mnkd_EmployeeMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mnkd_ConsultantMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesLineItems" xlink:label="mnkd_StockOptionActivityAndChangesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesTable" xlink:label="mnkd_StockOptionActivityAndChangesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="mnkd_StockOptionActivityAndChangesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_StockOptionActivityAndChangesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsAxis" xlink:label="mnkd_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BeforeAmendmentMember" xlink:label="mnkd_BeforeAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesLineItems" xlink:label="mnkd_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesTable" xlink:label="mnkd_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentCancellationFees" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentExpirationDate" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:label="us-gaap_SupplyCommitmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_AgreementsDomain" xlink:to="mnkd_BeforeAmendmentMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_ContingentLiability" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongTermPurchaseCommitmentCancellationFees" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongTermPurchaseCommitmentExpirationDate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="mnkd_AgreementsAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSeventhYear" xlink:label="mnkd_PurchaseObligationDueInSeventhYear"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSixthYear" xlink:label="mnkd_PurchaseObligationDueInSixthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInFourthYear" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInFifthYear" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="mnkd_PurchaseObligationDueInSixthYear" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="mnkd_PurchaseObligationDueInSeventhYear" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxExpenseBenefitNet" xlink:label="mnkd_IncomeTaxExpenseBenefitNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxExpenseBenefitNet" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedCosts" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLineItems" xlink:label="mnkd_DeferredTaxAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsMilestoneRights" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTable" xlink:label="mnkd_DeferredTaxAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsMilestoneRights" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsCapitalizedCosts" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_DeferredTaxAssetsLineItems" xlink:to="mnkd_DeferredTaxAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_DeferredTaxAssetsLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_DeferredTaxAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesTable" xlink:label="mnkd_IncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardAnnualLimitation" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardsBeginsToExpire" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossCarryforwardsSubjectToLimitation" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentCreditsBeginToExpire" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_NetOperatingLossCarryforwardsBeginsToExpire" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_OperatingLossCarryforwardsSubjectToLimitation" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_NetOperatingLossCarryforwardAnnualLimitation" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_ResearchAndDevelopmentCreditsBeginToExpire" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_IncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesLineItems" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesTable" xlink:label="mnkd_ScheduleOfIncomeTaxesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="mnkd_ScheduleOfIncomeTaxesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_ScheduleOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassAWarrantsMember" xlink:label="mnkd_ClassAWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassBWarrantsMember" xlink:label="mnkd_ClassBWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExercised" xlink:label="mnkd_ClassOfWarrantOrRightExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsValuationTechniques" xlink:label="us-gaap_FairValueMeasurementsValuationTechniques"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RegisteredOfferingMember" xlink:label="mnkd_RegisteredOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_RegisteredOfferingMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassAWarrantsMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassBWarrantsMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightExpirationPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightExercised" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueMeasurementsValuationTechniques" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentyFifteenRestructuringPlanMember" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentySixteenRestructuringPlanMember" xlink:label="mnkd_TwentySixteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentySixteenRestructuringPlanMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentyFifteenRestructuringPlanMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2" xlink:label="us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentyFifteenRestructuringPlanMember" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentySixteenRestructuringPlanMember" xlink:label="mnkd_TwentySixteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveSettledWithoutCash2" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentySixteenRestructuringPlanMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentyFifteenRestructuringPlanMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingLineItems" xlink:label="mnkd_InterimReportingLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingTable" xlink:label="mnkd_InterimReportingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_InterimReportingLineItems" xlink:to="mnkd_InterimReportingTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_InterimReportingTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingLineItems" xlink:label="mnkd_InterimReportingLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingTable" xlink:label="mnkd_InterimReportingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mnkd_InterimReportingLineItems" xlink:to="mnkd_InterimReportingTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_InterimReportingTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mnkd_InterimReportingTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandBuildingsAndImprovementsMember" xlink:label="us-gaap_LandBuildingsAndImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MinimumClosingBidPriceOfCommonStock" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NasdaqStockMarketMember" xlink:label="mnkd_NasdaqStockMarketMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetProceedsFromSaleOfProperty" xlink:label="mnkd_NetProceedsFromSaleOfProperty"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForCommissionsAndOtherFees" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandBuildingsAndImprovementsMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="mnkd_NasdaqStockMarketMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="stpr_CA" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_MinimumClosingBidPriceOfCommonStock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_NetProceedsFromSaleOfProperty" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_PaymentsForCommissionsAndOtherFees" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementGeographicalAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetsHeldForSalePolicyTextBlock" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BasisOfPresentationPolicyTextBlock" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BusinessPolicyTextBlock" xlink:label="mnkd_BusinessPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClinicalTrialExpensePolicyTextBlock" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GrossToNetAdjustmentsPolicyTextBlock" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAndResaleAgreementsPolicy" xlink:label="us-gaap_RepurchaseAndResaleAgreementsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDiscounts" xlink:label="us-gaap_RevenueRecognitionDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:label="us-gaap_RevenueRecognitionMultipleElementArrangements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="us-gaap_RevenueRecognitionSalesOfGoods"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReverseStockSplitPolicyTextBlock" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfIntellectualPropertyPolicyTextBlock" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsPolicyTextBlock" xlink:label="mnkd_WarrantsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WholesalerDistributionFeesPolicyTextBlock" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_BusinessPolicyTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_BasisOfPresentationPolicyTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ReverseStockSplitPolicyTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleElementArrangements" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionSalesOfGoods" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_GrossToNetAdjustmentsPolicyTextBlock" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_WholesalerDistributionFeesPolicyTextBlock" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionDiscounts" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StandardProductWarrantyPolicy" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SaleOfIntellectualPropertyPolicyTextBlock" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AssetsHeldForSalePolicyTextBlock" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_WarrantsPolicyTextBlock" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepurchaseAndResaleAgreementsPolicy" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ClinicalTrialExpensePolicyTextBlock" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonAndPreferredStockTextBlock" xlink:label="mnkd_CommonAndPreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonAndPreferredStockTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>mnkd-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_9004857_1324050_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_9004857_1324050_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_9004857_1341984_1_1">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_9004857_1341984_2_1">Balance payment of settlement agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_9004857_1341984_12_1">Receivable from Sanofi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324076_1_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324076_2_1">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1337522_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1337522_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1543519_3_1">Accounts Receivable Allowance For Doubtful Accounts [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1543519_1_1">Accounts Receivable Allowance For Doubtful Accounts [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1543519_2_1">Accounts Receivable and Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" xlink:to="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_9004857_1341977_1_1">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_9004857_1341977_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_9004857_1349285_3_1">Accrued Expenses and Other Current Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_9004857_1349285_1_1">Accrued Expenses and Other Current Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_9004857_1349285_2_1">Accrued Expenses and Other Current Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xml:lang="en-US" id="id_9004857_1508047_3_1">Accrued Expenses and Other Current Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xml:lang="en-US" id="id_9004857_1508047_1_1">Accrued Expenses and Other Current Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xml:lang="en-US" id="id_9004857_1508047_2_1">Accrued Expenses and Other Current Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesIntellectualProperty" xlink:label="mnkd_AccruedExpensesIntellectualProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccruedExpensesIntellectualProperty_lbl" xml:lang="en-US" id="id_9004857_1543954_3_1">Accrued Expenses Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccruedExpensesIntellectualProperty_lbl" xml:lang="en-US" id="id_9004857_1543954_1_1">Accrued Expenses Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccruedExpensesIntellectualProperty_lbl" xml:lang="en-US" id="id_9004857_1543954_2_1">Accrued expense associated with intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccruedExpensesIntellectualProperty" xlink:to="mnkd_AccruedExpensesIntellectualProperty_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestNoncurrent" xlink:label="mnkd_AccruedInterestNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccruedInterestNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543505_3_1">Accrued Interest Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccruedInterestNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543505_1_1">Accrued Interest Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccruedInterestNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543505_2_1">Accrued interest - note payable to principal stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccruedInterestNoncurrent" xlink:to="mnkd_AccruedInterestNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestOfRelatedPartyDebt" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt_lbl" xml:lang="en-US" id="id_9004857_1425377_3_1">Accrued interest of related party debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt_lbl" xml:lang="en-US" id="id_9004857_1425377_1_1">Accrued Interest Of Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt_lbl" xml:lang="en-US" id="id_9004857_1425377_2_1">Accrued interest of related party debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AccruedInterestOfRelatedPartyDebt" xlink:to="mnkd_AccruedInterestOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1340102_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1340102_2_1">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1340102_6_1">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_9004857_1338341_1_1">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_9004857_1338341_2_1">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1338338_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1338338_14_1">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1337496_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1337496_2_1">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_9004857_1333538_1_1">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_9004857_1333538_2_1">Accumulated Other Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_9004857_1338333_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_9004857_1338333_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_9004857_1327190_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_9004857_1327190_2_1">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US" id="id_9004857_1338328_1_1">Adjustments to Additional Paid in Capital, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US" id="id_9004857_1338328_2_1">Remeasurement of performance based grants pursuant to the modification of terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" id="id_9004857_1348048_3_1">Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" id="id_9004857_1348048_1_1">Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" id="id_9004857_1348048_2_1">Reclassification of warrant liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_9004857_1338330_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_9004857_1338330_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="id_9004857_1337493_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="id_9004857_1337493_2_1">Restricted stock units taxes paid in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement_lbl" xml:lang="en-US" id="id_9004857_1413192_3_1">Adjustments To Additional Paid In Capital Shares Issued In Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement_lbl" xml:lang="en-US" id="id_9004857_1413192_1_1">Adjustments To Additional Paid In Capital Shares Issued In Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement_lbl" xml:lang="en-US" id="id_9004857_1413192_2_1">Issuance costs associated with direct placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion_lbl" xml:lang="en-US" id="id_9004857_1456333_3_1">Adjustments To Additional Paid In Capital Stock Option Issued Upon Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion_lbl" xml:lang="en-US" id="id_9004857_1456333_1_1">Adjustments To Additional Paid In Capital Stock Option Issued Upon Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion_lbl" xml:lang="en-US" id="id_9004857_1456333_2_1">Discount on notes-for-stock exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_9004857_1340072_1_1">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_9004857_1340072_14_1">Issuance of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_9004857_1333553_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_9004857_1333553_2_1">Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsAxis" xlink:label="mnkd_AgreementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AgreementsAxis_lbl" xml:lang="en-US" id="id_9004857_1447597_3_1">Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AgreementsAxis_lbl" xml:lang="en-US" id="id_9004857_1447597_1_1">Agreements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AgreementsAxis_lbl" xml:lang="en-US" id="id_9004857_1447597_2_1">Agreements [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AgreementsDomain_lbl" xml:lang="en-US" id="id_9004857_1503243_3_1">Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AgreementsDomain_lbl" xml:lang="en-US" id="id_9004857_1503243_1_1">Agreements [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AgreementsDomain_lbl" xml:lang="en-US" id="id_9004857_1503243_2_1">Agreements [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AgreementsDomain" xlink:to="mnkd_AgreementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AlfredMannFoundationMember" xlink:label="mnkd_AlfredMannFoundationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AlfredMannFoundationMember_lbl" xml:lang="en-US" id="id_9004857_1454078_3_1">Alfred Mann Foundation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AlfredMannFoundationMember_lbl" xml:lang="en-US" id="id_9004857_1454078_1_1">Alfred Mann Foundation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AlfredMannFoundationMember_lbl" xml:lang="en-US" id="id_9004857_1454078_2_1">Mann Foundation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AlfredMannFoundationMember" xlink:to="mnkd_AlfredMannFoundationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9004857_1340135_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9004857_1340135_2_1">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9004857_1340135_12_1">Stock based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AmendedAgreementMember" xlink:label="mnkd_AmendedAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1367294_3_1">Amended Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1367294_1_1">Amended Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1367294_2_1">Amended Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AmendedAgreementMember" xlink:to="mnkd_AmendedAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_9004857_1327225_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_9004857_1327225_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_9004857_1341057_1_1">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_9004857_1341057_2_1">Accretion expense - debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_9004857_1341057_12_1">Premium of issuance of 2018 debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="id_9004857_1342986_1_1">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="id_9004857_1342986_2_1">Accretion expense - debt issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="id_9004857_1342009_1_1">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="id_9004857_1342009_2_1">Accretion of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_9004857_1324144_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_9004857_1324144_2_1">Potentially dilutive securities outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_9004857_1333589_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_9004857_1333589_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1327231_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1327231_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_9004857_1333590_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_9004857_1333590_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AreaOfOfficeSpaceLeased" xlink:label="mnkd_AreaOfOfficeSpaceLeased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AreaOfOfficeSpaceLeased_lbl" xml:lang="en-US" id="id_9004857_1465895_3_1">Area Of Office Space Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AreaOfOfficeSpaceLeased_lbl" xml:lang="en-US" id="id_9004857_1465895_1_1">Area Of Office Space Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AreaOfOfficeSpaceLeased_lbl" xml:lang="en-US" id="id_9004857_1465895_2_1">Area of office space leased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AreaOfOfficeSpaceLeased" xlink:to="mnkd_AreaOfOfficeSpaceLeased_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_9004857_1330434_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_9004857_1330434_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetHeldForSaleMember" xlink:label="mnkd_AssetHeldForSaleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AssetHeldForSaleMember_lbl" xml:lang="en-US" id="id_9004857_1470922_3_1">Asset Held For Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AssetHeldForSaleMember_lbl" xml:lang="en-US" id="id_9004857_1470922_1_1">Asset Held For Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AssetHeldForSaleMember_lbl" xml:lang="en-US" id="id_9004857_1470922_2_1">Asset held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AssetHeldForSaleMember" xlink:to="mnkd_AssetHeldForSaleMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_9004857_1341070_1_1">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_9004857_1341070_2_1">Asset impairment charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_9004857_1341070_12_1">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_9004857_1342997_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_9004857_1342997_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_9004857_1324158_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_9004857_1324158_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_9004857_1340155_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_9004857_1340155_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_9004857_1333606_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_9004857_1333606_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xml:lang="en-US" id="id_9004857_1342020_1_1">Assets, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xml:lang="en-US" id="id_9004857_1342020_2_1">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US" id="id_9004857_1341083_1_1">Assets Held-for-sale, Not Part of Disposal Group, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US" id="id_9004857_1341083_2_1">Asset held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetsHeldForSalePolicyTextBlock" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1450437_3_1">Assets Held for Sale, Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1450437_1_1">Assets Held for Sale [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1450437_2_1">Assets Held for Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AssetsHeldForSalePolicyTextBlock" xlink:to="mnkd_AssetsHeldForSalePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl" xml:lang="en-US" id="id_9004857_1327271_1_1">Securities or Other Assets Sold under Agreements to Repurchase [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl" xml:lang="en-US" id="id_9004857_1327271_2_1">Securities or Other Assets Sold under Agreements to Repurchase [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1330452_1_1">Assets Sold under Agreements to Repurchase, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1330452_2_1">Assets Sold under Agreements to Repurchase, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AvailableLoanBalanceCancelled" xlink:label="mnkd_AvailableLoanBalanceCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AvailableLoanBalanceCancelled_lbl" xml:lang="en-US" id="id_9004857_1383071_3_1">Available Loan Balance Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AvailableLoanBalanceCancelled_lbl" xml:lang="en-US" id="id_9004857_1383071_1_1">Available Loan Balance Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AvailableLoanBalanceCancelled_lbl" xml:lang="en-US" id="id_9004857_1383071_2_1">Aggregate principal amount cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AvailableLoanBalanceCancelled" xlink:to="mnkd_AvailableLoanBalanceCancelled_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AventisubLlcMember" xlink:label="mnkd_AventisubLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_AventisubLlcMember_lbl" xml:lang="en-US" id="id_9004857_1543736_3_1">Aventisub LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_AventisubLlcMember_lbl" xml:lang="en-US" id="id_9004857_1543736_1_1">Aventisub LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_AventisubLlcMember_lbl" xml:lang="en-US" id="id_9004857_1543736_2_1">Aventisub LLC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_AventisubLlcMember" xlink:to="mnkd_AventisubLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1324199_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1324199_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BasisOfPresentationPolicyTextBlock" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1364981_3_1">Basis of Presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1364981_1_1">Basis Of Presentation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1364981_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_BasisOfPresentationPolicyTextBlock" xlink:to="mnkd_BasisOfPresentationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BeforeAmendmentMember" xlink:label="mnkd_BeforeAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_BeforeAmendmentMember_lbl" xml:lang="en-US" id="id_9004857_1406233_3_1">Before Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_BeforeAmendmentMember_lbl" xml:lang="en-US" id="id_9004857_1406233_1_1">Before Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_BeforeAmendmentMember_lbl" xml:lang="en-US" id="id_9004857_1406233_2_1">Before Amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_BeforeAmendmentMember" xlink:to="mnkd_BeforeAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US" id="id_9004857_1330541_1_1">Building Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US" id="id_9004857_1330541_2_1">Building Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" id="id_9004857_1324247_1_1">Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" id="id_9004857_1324247_2_1">Buildings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BusinessPolicyTextBlock" xlink:label="mnkd_BusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_BusinessPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1418308_3_1">Business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_BusinessPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1418308_1_1">Business [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_BusinessPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1418308_2_1">Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_BusinessPolicyTextBlock" xlink:to="mnkd_BusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" id="id_9004857_1330589_1_1">CALIFORNIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US" id="id_9004857_1330589_2_1">California</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1333737_1_1">Reported Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1333737_2_1">Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1341134_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1341134_4_1">CASH AND CASH EQUIVALENTS, END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1341134_5_1">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1341134_2_1">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1341134_12_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_9004857_1324319_1_1">Cash and Cash Equivalents [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_9004857_1324319_2_1">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_9004857_1343060_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_9004857_1343060_6_1">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324323_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324323_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CashDiscountPercent" xlink:label="mnkd_CashDiscountPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CashDiscountPercent_lbl" xml:lang="en-US" id="id_9004857_1503862_3_1">Cash Discount Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CashDiscountPercent_lbl" xml:lang="en-US" id="id_9004857_1503862_1_1">Cash Discount Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CashDiscountPercent_lbl" xml:lang="en-US" id="id_9004857_1503862_2_1">Cash discount as incentive for prompt payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CashDiscountPercent" xlink:to="mnkd_CashDiscountPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_9004857_1333758_1_1">Certificates of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_9004857_1333758_2_1">Certificates of Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US" id="id_9004857_1447713_3_1">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US" id="id_9004857_1447713_1_1">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US" id="id_9004857_1447713_2_1">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US" id="id_9004857_1447713_14_1">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ChangeInFairValueOfWarrantLiability" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassAWarrantsMember" xlink:label="mnkd_ClassAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassAWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1514964_3_1">Class A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassAWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1514964_1_1">Class A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassAWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1514964_2_1">A Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassAWarrantsMember" xlink:to="mnkd_ClassAWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassBWarrantsMember" xlink:label="mnkd_ClassBWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassBWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1344495_3_1">Class B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassBWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1344495_1_1">Class B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassBWarrantsMember_lbl" xml:lang="en-US" id="id_9004857_1344495_2_1">B Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassBWarrantsMember" xlink:to="mnkd_ClassBWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_9004857_1330668_1_1">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_9004857_1330668_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisablePeriod" xlink:label="mnkd_ClassOfWarrantExercisablePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_9004857_1488139_3_1">Class of warrant exercisable period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_9004857_1488139_1_1">Class Of Warrant Exercisable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantExercisablePeriod_lbl" xml:lang="en-US" id="id_9004857_1488139_2_1">Warrants exercisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantExercisablePeriod" xlink:to="mnkd_ClassOfWarrantExercisablePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice_lbl" xml:lang="en-US" id="id_9004857_1381772_3_1">Class Of Warrant Exercise Price Of Warrants Stated As Percentage Of Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice_lbl" xml:lang="en-US" id="id_9004857_1381772_1_1">Class Of Warrant Exercise Price Of Warrants Stated As Percentage Of Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice_lbl" xml:lang="en-US" id="id_9004857_1381772_2_1">Percentage of shares of common stock issued for offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" xlink:to="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_9004857_1333769_1_1">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_9004857_1333769_2_1">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_9004857_1327448_1_1">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_9004857_1327448_2_1">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExercised" xlink:label="mnkd_ClassOfWarrantOrRightExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" id="id_9004857_1391312_3_1">Class Of Warrant Or Right Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" id="id_9004857_1391312_1_1">Class Of Warrant Or Right Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" id="id_9004857_1391312_2_1">Class of warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantOrRightExercised" xlink:to="mnkd_ClassOfWarrantOrRightExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_9004857_1324362_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_9004857_1324362_2_1">Exercise price of restricted warrants per share in connection with the offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_9004857_1324362_12_1">Exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1392081_3_1">Class of Warrant or Right, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1392081_1_1">Class of Warrant or Right, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1392081_2_1">Class of warrants expiration period upon issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantOrRightExpirationPeriod" xlink:to="mnkd_ClassOfWarrantOrRightExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_9004857_1333771_1_1">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_9004857_1333771_2_1">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="id_9004857_1327450_1_1">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="id_9004857_1327450_2_1">Warrants to purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_9004857_1330670_1_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_9004857_1330670_2_1">Number of warrants are exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_9004857_1333772_1_1">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_9004857_1333772_2_1">Restricted warrants issued to purchase number of common stock for offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" id="id_9004857_1409797_3_1">Class Of Warrant Or Rights Month Year From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" id="id_9004857_1409797_1_1">Class Of Warrant Or Rights Month Year From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" id="id_9004857_1409797_2_1">Warrants exercisable date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" xlink:to="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_9004857_1333774_1_1">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_9004857_1333774_2_1">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantsOrRightsExpirationDate" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1384428_3_1">Class Of Warrants Or Rights Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1384428_1_1">Class Of Warrants Or Rights Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1384428_2_1">Warrants expiration, date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClassOfWarrantsOrRightsExpirationDate" xlink:to="mnkd_ClassOfWarrantsOrRightsExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClinicalTrialExpensePolicyTextBlock" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1461314_3_1">Clinical Trial Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1461314_1_1">Clinical Trial Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1461314_2_1">Clinical Trial Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClinicalTrialExpensePolicyTextBlock" xlink:to="mnkd_ClinicalTrialExpensePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543746_3_1">Closing Bid Price of Common Stock, Closing Date Provided to Regain Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543746_1_1">Closing Bid Price of Common Stock, Closing Date Provided to Regain Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543746_2_1">Bid price of common stock, date provided to regain compliance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" xlink:to="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543744_3_1">Closing Bid Price of Common Stock, Period Below Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543744_1_1">Closing Bid Price of Common Stock, Period Below Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543744_2_1">Bid price of common stock, period less than required closing bid price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543745_3_1">Closing Bid Price of Common Stock, Period Provided to Regain Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543745_1_1">Closing Bid Price of Common Stock, Period Provided to Regain Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543745_2_1">Bid price of common stock, period provided to regain compliance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543743_3_1">Closing Bid Price of Common Stock, Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543743_1_1">Closing Bid Price of Common Stock, Required Price per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare_lbl" xml:lang="en-US" id="id_9004857_1543743_2_1">Bid price of common stock, closing price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" xlink:to="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1425803_3_1">Collaboration and License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1425803_1_1">Collaboration and License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1425803_2_1">License and Collaboration Agreement with Sanofi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CollaborationAndLicenseAgreementMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324386_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324386_2_1">Collaboration Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_9004857_1327462_1_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_9004857_1327462_2_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_9004857_1339112_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_9004857_1339112_2_1">Commitments and contingencies (Note 13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1333796_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1333796_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324400_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324400_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesLineItems" xlink:label="mnkd_CommitmentsAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1415709_3_1">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1415709_1_1">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1415709_2_1">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_CommitmentsAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327477_1_1">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327477_2_1">Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesTable" xlink:label="mnkd_CommitmentsAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9004857_1375174_3_1">Commitments and Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9004857_1375174_1_1">Commitments and Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9004857_1375174_2_1">Commitments and Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="mnkd_CommitmentsAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonAndPreferredStockTextBlock" xlink:label="mnkd_CommonAndPreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" id="id_9004857_1431973_3_1">Common and preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" id="id_9004857_1431973_1_1">Common And Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" id="id_9004857_1431973_2_1">Common and Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonAndPreferredStockTextBlock" xlink:to="mnkd_CommonAndPreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares_lbl" xml:lang="en-US" id="id_9004857_1543527_3_1">Common Stock and Warrants Issued in Direct Placement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares_lbl" xml:lang="en-US" id="id_9004857_1543527_1_1">Common Stock and Warrants Issued in Direct Placement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares_lbl" xml:lang="en-US" id="id_9004857_1543527_2_1">Issuance of direct placement - common stock and warrants (shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue_lbl" xml:lang="en-US" id="id_9004857_1543526_3_1">Common Stock and Warrants Issued in Direct Placement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue_lbl" xml:lang="en-US" id="id_9004857_1543526_1_1">Common Stock and Warrants Issued in Direct Placement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue_lbl" xml:lang="en-US" id="id_9004857_1543526_2_1">Issuance of direct placement - common stock and warrants (value)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_9004857_1333804_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_9004857_1333804_2_1">Shares reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyAxis" xlink:label="mnkd_CommonStockIssuedToByPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockIssuedToByPartyAxis_lbl" xml:lang="en-US" id="id_9004857_1509889_3_1">Common stock issued to by party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockIssuedToByPartyAxis_lbl" xml:lang="en-US" id="id_9004857_1509889_1_1">Common Stock Issued To By Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockIssuedToByPartyAxis_lbl" xml:lang="en-US" id="id_9004857_1509889_2_1">Common Stock Issued To By Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockIssuedToByPartyAxis" xlink:to="mnkd_CommonStockIssuedToByPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyDomain" xlink:label="mnkd_CommonStockIssuedToByPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockIssuedToByPartyDomain_lbl" xml:lang="en-US" id="id_9004857_1494566_3_1">Common stock issued to by party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockIssuedToByPartyDomain_lbl" xml:lang="en-US" id="id_9004857_1494566_1_1">Common Stock Issued To By Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockIssuedToByPartyDomain_lbl" xml:lang="en-US" id="id_9004857_1494566_2_1">Common Stock Issued To By Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockIssuedToByPartyDomain" xlink:to="mnkd_CommonStockIssuedToByPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares_lbl" xml:lang="en-US" id="id_9004857_1367640_3_1">Common stock loaned under share lending agreement, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares_lbl" xml:lang="en-US" id="id_9004857_1367640_1_1">Common Stock Loaned Under Share Lending Agreement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares_lbl" xml:lang="en-US" id="id_9004857_1367640_2_1">Common stock loaned under share lending agreement, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares_lbl" xml:lang="en-US" id="id_9004857_1367640_14_1">Return of loaned common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementValue" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue_lbl" xml:lang="en-US" id="id_9004857_1454134_3_1">Common Stock Loaned Under Share Lending Agreement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue_lbl" xml:lang="en-US" id="id_9004857_1454134_1_1">Common Stock Loaned Under Share Lending Agreement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue_lbl" xml:lang="en-US" id="id_9004857_1454134_2_1">Return of loaned common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CommonStockLoanedUnderShareLendingAgreementValue" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_9004857_1333806_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_9004857_1333806_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9004857_1330695_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9004857_1330695_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1327483_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1327483_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_9004857_1330697_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_9004857_1330697_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327484_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327484_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_9004857_1338248_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_9004857_1338248_2_1">Common stock, $0.05 par value - 140,000,000 and 110,000,000 shares authorized at December 31, 2016 and 2015, respectively; 95,680,831 and 85,734,188 shares issued and outstanding at December 31, 2016 and 2015, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1324417_1_1">Compensation and Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1324417_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333815_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333815_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_9004857_1324420_1_1">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_9004857_1324420_2_1">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1338246_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1338246_6_1">Comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330710_1_1">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330710_2_1">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputationOfEarningsPerShareLineItems" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1467675_3_1">Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1467675_1_1">Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1467675_2_1">Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="mnkd_ComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputerEquipmentAndSoftwareMember" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_9004857_1348884_3_1">Computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_9004857_1348884_1_1">Computer Equipment And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_9004857_1348884_2_1">Computer Equipment and Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ComputerEquipmentAndSoftwareMember" xlink:to="mnkd_ComputerEquipmentAndSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_9004857_1327498_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_9004857_1327498_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsiderationReceived" xlink:label="mnkd_ConsiderationReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ConsiderationReceived_lbl" xml:lang="en-US" id="id_9004857_1409479_3_1">Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ConsiderationReceived_lbl" xml:lang="en-US" id="id_9004857_1409479_1_1">Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ConsiderationReceived_lbl" xml:lang="en-US" id="id_9004857_1409479_2_1">Total consideration received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ConsiderationReceived" xlink:to="mnkd_ConsiderationReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327525_1_1">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327525_2_1">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_9004857_1337411_1_1">Construction in Progress Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_9004857_1337411_2_1">Non-cash construction in progress and property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_9004857_1324436_1_1">Construction in Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_9004857_1324436_2_1">Construction in Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1339100_1_1">Construction Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1339100_2_1">Construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsultantMember" xlink:label="mnkd_ConsultantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ConsultantMember_lbl" xml:lang="en-US" id="id_9004857_1409449_3_1">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ConsultantMember_lbl" xml:lang="en-US" id="id_9004857_1409449_1_1">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ConsultantMember_lbl" xml:lang="en-US" id="id_9004857_1409449_2_1">Consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ConsultantMember" xlink:to="mnkd_ConsultantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ContingentLiability_lbl" xml:lang="en-US" id="id_9004857_1415212_3_1">Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ContingentLiability_lbl" xml:lang="en-US" id="id_9004857_1415212_1_1">Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ContingentLiability_lbl" xml:lang="en-US" id="id_9004857_1415212_2_1">Contingent liability for milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ContingentLiability" xlink:to="mnkd_ContingentLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_9004857_1340254_1_1">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_9004857_1340254_2_1">Conversion Option, aggregate expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_9004857_1324465_1_1">Convertible Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_9004857_1324465_2_1">Convertible Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_9004857_1339991_1_1">Convertible Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_9004857_1339991_2_1">Senior convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_9004857_1343106_1_1">Cost of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_9004857_1343106_2_1">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="id_9004857_1327554_1_1">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="id_9004857_1327554_2_1">Cost of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330756_1_1">Cost of Sales, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330756_2_1">Cost of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_9004857_1342157_1_1">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_9004857_1342157_6_1">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_9004857_1324486_1_1">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_9004857_1324486_2_1">Expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CostsOfRevenueCollaboration" xlink:label="mnkd_CostsOfRevenueCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CostsOfRevenueCollaboration_lbl" xml:lang="en-US" id="id_9004857_1543959_3_1">Costs of Revenue Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CostsOfRevenueCollaboration_lbl" xml:lang="en-US" id="id_9004857_1543959_1_1">Costs of Revenue Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CostsOfRevenueCollaboration_lbl" xml:lang="en-US" id="id_9004857_1543959_2_1">Costs of revenue - collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CostsOfRevenueCollaboration" xlink:to="mnkd_CostsOfRevenueCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_9004857_1324497_1_1">Credit Facility [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_9004857_1324497_2_1">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_9004857_1324498_1_1">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_9004857_1324498_2_1">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341213_1_1">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341213_2_1">U.S. federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_9004857_1330780_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_9004857_1330780_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341214_1_1">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341214_2_1">Non-U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341215_1_1">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341215_6_1">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330781_1_1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330781_2_1">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1343125_1_1">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1343125_2_1">U.S. state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CustomerDiscountsAndAllowances" xlink:label="mnkd_CustomerDiscountsAndAllowances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_CustomerDiscountsAndAllowances_lbl" xml:lang="en-US" id="id_9004857_1506339_3_1">Customer Discounts And Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_CustomerDiscountsAndAllowances_lbl" xml:lang="en-US" id="id_9004857_1506339_1_1">Customer Discounts And Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_CustomerDiscountsAndAllowances_lbl" xml:lang="en-US" id="id_9004857_1506339_2_1">Discounts and allowances for commercial product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_CustomerDiscountsAndAllowances" xlink:to="mnkd_CustomerDiscountsAndAllowances_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DanburyFacilityMember" xlink:label="mnkd_DanburyFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DanburyFacilityMember_lbl" xml:lang="en-US" id="id_9004857_1366952_3_1">Danbury Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DanburyFacilityMember_lbl" xml:lang="en-US" id="id_9004857_1366952_1_1">Danbury Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DanburyFacilityMember_lbl" xml:lang="en-US" id="id_9004857_1366952_2_1">Danbury Facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DanburyFacilityMember" xlink:to="mnkd_DanburyFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_9004857_1338232_1_1">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_9004857_1338232_2_1">Principal amount of debt converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_9004857_1333905_1_1">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_9004857_1333905_2_1">Conversion Option, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" id="id_9004857_1337391_1_1">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" id="id_9004857_1337391_2_1">Aggregate principal amount for conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" id="id_9004857_1337391_12_1">Issuance of common stock pursuant to debt conversion by Deerfield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1330799_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1330799_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330800_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330800_2_1">Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_9004857_1324529_1_1">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_9004857_1324529_2_1">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_9004857_1324530_1_1">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_9004857_1324530_2_1">Interest rate (LIBOR)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_9004857_1338231_1_1">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_9004857_1338231_2_1">Carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_9004857_1338231_6_1">Net carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_9004857_1333928_1_1">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_9004857_1333928_2_1">Conversion price of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" id="id_9004857_1330801_1_1">Debt Instrument, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" id="id_9004857_1330801_2_1">No of convertible shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" id="id_9004857_1327604_1_1">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" id="id_9004857_1327604_2_1">Consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" id="id_9004857_1333932_1_1">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" id="id_9004857_1333932_2_1">Percentage of conversion price equaling stock price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US" id="id_9004857_1330803_1_1">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US" id="id_9004857_1330803_2_1">Number of trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xml:lang="en-US" id="id_9004857_1324543_1_1">Debt Instrument, Date of First Required Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xml:lang="en-US" id="id_9004857_1324543_2_1">Principal repayment schedule, start date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DebtInstrumentDateOfLastRequiredPayment" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment_lbl" xml:lang="en-US" id="id_9004857_1473027_3_1">Debt Instrument Date Of Last Required Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment_lbl" xml:lang="en-US" id="id_9004857_1473027_1_1">Debt Instrument Date Of Last Required Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment_lbl" xml:lang="en-US" id="id_9004857_1473027_2_1">Principal repayment schedule, end date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DebtInstrumentDateOfLastRequiredPayment" xlink:to="mnkd_DebtInstrumentDateOfLastRequiredPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" id="id_9004857_1340277_1_1">Debt Instrument, Decrease, Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" id="id_9004857_1340277_2_1">Outstanding loan balance forgive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" id="id_9004857_1340277_12_1">Outstanding loan balance forgiven</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US" id="id_9004857_1330805_1_1">Debt Instrument, Description of Variable Rate Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US" id="id_9004857_1330805_2_1">Description of variable rate interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_9004857_1338229_1_1">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_9004857_1338229_2_1">Debt facility principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_9004857_1338229_12_1">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_9004857_1327611_1_1">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_9004857_1327611_2_1">Senior notes, effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_9004857_1333918_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_9004857_1333918_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_9004857_1333919_1_1">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_9004857_1333919_2_1">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_9004857_1330814_1_1">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_9004857_1330814_2_1">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US" id="id_9004857_1327614_1_1">Debt Instrument, Redemption, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US" id="id_9004857_1327614_2_1">Debt Instrument, redemption description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" id="id_9004857_1327618_1_1">Debt Instrument, Redemption Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" id="id_9004857_1327618_2_1">Percentage of repurchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_9004857_1333926_1_1">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_9004857_1333926_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_9004857_1342170_1_1">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_9004857_1342170_2_1">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_9004857_1342170_14_1">Unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" id="id_9004857_1338227_1_1">Debt Instrument, Unamortized Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" id="id_9004857_1338227_2_1">Unamortized premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330819_1_1">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1330819_2_1">Milestone Rights Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeerfieldManagementCompanyLpMember_lbl" xml:lang="en-US" id="id_9004857_1426352_3_1">Deerfield Management Company L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeerfieldManagementCompanyLpMember_lbl" xml:lang="en-US" id="id_9004857_1426352_1_1">Deerfield Management Company LP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeerfieldManagementCompanyLpMember_lbl" xml:lang="en-US" id="id_9004857_1426352_2_1">Deerfield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeerfieldManagementCompanyLpMember" xlink:to="mnkd_DeerfieldManagementCompanyLpMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeCreditCurrent" xlink:label="mnkd_DeferredCollaborativeCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredCollaborativeCreditCurrent_lbl" xml:lang="en-US" id="id_9004857_1535088_3_1">Deferred Collaborative Credit Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredCollaborativeCreditCurrent_lbl" xml:lang="en-US" id="id_9004857_1535088_1_1">Deferred Collaborative Credit Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredCollaborativeCreditCurrent_lbl" xml:lang="en-US" id="id_9004857_1535088_2_1">Deferred payments from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredCollaborativeCreditCurrent" xlink:to="mnkd_DeferredCollaborativeCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeRevenueCurrent" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1435331_3_1">Deferred Collaborative Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1435331_1_1">Deferred Collaborative Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1435331_2_1">Deferred sales from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredCollaborativeRevenueCurrent" xlink:to="mnkd_DeferredCollaborativeRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCostRelatedToSaleOfRawInsulin" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543517_3_1">Deferred Cost Related To Sale Of Raw Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543517_1_1">Deferred Cost Related To Sale Of Raw Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543517_2_1">Deferred cost related to sale of raw insulin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredCostRelatedToSaleOfRawInsulin" xlink:to="mnkd_DeferredCostRelatedToSaleOfRawInsulin_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" id="id_9004857_1342174_1_1">Deferred Costs, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" id="id_9004857_1342174_2_1">Deferred cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US" id="id_9004857_1342177_1_1">Deferred Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US" id="id_9004857_1342177_2_1">Deferred costs from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340293_1_1">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340293_2_1">U.S. federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" id="id_9004857_1341235_1_1">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" id="id_9004857_1341235_2_1">Debt Issuance Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1343141_1_1">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1343141_2_1">Non-U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340298_1_1">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340298_2_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330840_1_1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330840_2_1">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341241_1_1">Deferred Other Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1341241_6_1">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1338207_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1338207_2_1">Deferred revenue - nonrefundable license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1337375_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1337375_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_9004857_1337375_12_1">Deferred revenue - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredRevenueFromSaleOfRawInsulin" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543518_3_1">Deferred Revenue From Sale Of Raw Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543518_1_1">Deferred Revenue From Sale Of Raw Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin_lbl" xml:lang="en-US" id="id_9004857_1543518_2_1">Deferred revenue from sale of raw insulin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredRevenueFromSaleOfRawInsulin" xlink:to="mnkd_DeferredRevenueFromSaleOfRawInsulin_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340304_1_1">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340304_2_1">U.S. state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity_lbl" xml:lang="en-US" id="id_9004857_1351188_3_1">Deferred Tax Asset Increase Decrease in Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity_lbl" xml:lang="en-US" id="id_9004857_1351188_1_1">Deferred Tax Asset Increase Decrease in Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity_lbl" xml:lang="en-US" id="id_9004857_1351188_2_1">Amount Equity would be increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" xlink:to="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedCosts" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts_lbl" xml:lang="en-US" id="id_9004857_1480096_3_1">Deferred Tax Assets Capitalized Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts_lbl" xml:lang="en-US" id="id_9004857_1480096_1_1">Deferred Tax Assets Capitalized Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts_lbl" xml:lang="en-US" id="id_9004857_1480096_2_1">Capitalized patent costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsCapitalizedCosts" xlink:to="mnkd_DeferredTaxAssetsCapitalizedCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xml:lang="en-US" id="id_9004857_1372391_3_1">Deferred Tax Assets Capitalized Research Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xml:lang="en-US" id="id_9004857_1372391_1_1">Deferred Tax Assets Capitalized Research Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses_lbl" xml:lang="en-US" id="id_9004857_1372391_2_1">Capitalized research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:to="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_9004857_1340306_1_1">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_9004857_1340306_2_1">Payments from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_9004857_1343152_1_1">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_9004857_1343152_6_1">Total net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLineItems" xlink:label="mnkd_DeferredTaxAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsLineItems_lbl" xml:lang="en-US" id="id_9004857_1445531_3_1">Deferred Tax Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsLineItems_lbl" xml:lang="en-US" id="id_9004857_1445531_1_1">Deferred Tax Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsLineItems_lbl" xml:lang="en-US" id="id_9004857_1445531_2_1">Deferred Tax Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsLineItems" xlink:to="mnkd_DeferredTaxAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment_lbl" xml:lang="en-US" id="id_9004857_1380799_3_1">Deferred Tax Assets Loss on Purchase Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment_lbl" xml:lang="en-US" id="id_9004857_1380799_1_1">Deferred Tax Assets Loss on Purchase Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment_lbl" xml:lang="en-US" id="id_9004857_1380799_2_1">Loss on purchase commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" xlink:to="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsMilestoneRights" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights_lbl" xml:lang="en-US" id="id_9004857_1450427_3_1">Deferred Tax Assets Milestone Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights_lbl" xml:lang="en-US" id="id_9004857_1450427_1_1">Deferred Tax Assets Milestone Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights_lbl" xml:lang="en-US" id="id_9004857_1450427_2_1">Milestone Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsMilestoneRights" xlink:to="mnkd_DeferredTaxAssetsMilestoneRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_9004857_1343154_1_1">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_9004857_1343154_6_1">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_9004857_1341254_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_9004857_1341254_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_9004857_1342200_1_1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_9004857_1342200_2_1">Federal operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_9004857_1340309_1_1">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_9004857_1340309_2_1">State operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_9004857_1340310_1_1">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_9004857_1340310_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTable" xlink:label="mnkd_DeferredTaxAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsTable_lbl" xml:lang="en-US" id="id_9004857_1370760_3_1">Deferred Tax Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsTable_lbl" xml:lang="en-US" id="id_9004857_1370760_1_1">Deferred Tax Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsTable_lbl" xml:lang="en-US" id="id_9004857_1370760_2_1">Deferred Tax Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsTable" xlink:to="mnkd_DeferredTaxAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_9004857_1342205_1_1">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_9004857_1342205_2_1">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment_lbl" xml:lang="en-US" id="id_9004857_1544056_3_1">Deferred Tax Assets, Tax Deferred Expense (Accrual Adjustment)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment_lbl" xml:lang="en-US" id="id_9004857_1544056_1_1">Deferred Tax Assets, Tax Deferred Expense (Accrual Adjustment)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment_lbl" xml:lang="en-US" id="id_9004857_1544056_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" xlink:to="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_9004857_1342209_1_1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_9004857_1342209_2_1">Non-qualified stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US" id="id_9004857_1343160_1_1">Deferred Tax Assets, Tax Deferred Expense, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US" id="id_9004857_1343160_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9004857_1339944_1_1">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9004857_1339944_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US" id="id_9004857_1442049_3_1">Deficit accumulated during the development stage member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US" id="id_9004857_1442049_1_1">Deficit Accumulated During Development Stage [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US" id="id_9004857_1442049_2_1">Deficit Accumulated During the Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DeficitAccumulatedDuringDevelopmentStageMember" xlink:to="mnkd_DeficitAccumulatedDuringDevelopmentStageMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US" id="id_9004857_1341281_1_1">Defined Benefit Plan, Contributions by Employer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US" id="id_9004857_1341281_2_1">Employer contribution savings retirement plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" id="id_9004857_1333999_1_1">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" id="id_9004857_1333999_2_1">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_lbl" xml:lang="en-US" id="id_9004857_1334000_1_1">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_lbl" xml:lang="en-US" id="id_9004857_1334000_2_1">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_9004857_1341291_1_1">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_9004857_1341291_2_1">Depreciation, amortization and accretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1523656_3_1">Depreciation and Other Amortization Expenses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1523656_1_1">Depreciation and Other Amortization Expenses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1523656_2_1">Depreciation and Other Amortization Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="mnkd_DepreciationAndOtherAmortizationExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1369832_3_1">Depreciation and Other Amortization Expenses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1369832_1_1">Depreciation and Other Amortization Expenses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1369832_2_1">Depreciation and Other Amortization Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="mnkd_DepreciationAndOtherAmortizationExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_9004857_1340337_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_9004857_1340337_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337338_1_1">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337338_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DirectOfferingMember" xlink:label="mnkd_DirectOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DirectOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1543951_3_1">Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DirectOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1543951_1_1">Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DirectOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1543951_2_1">Direct Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DirectOfferingMember" xlink:to="mnkd_DirectOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_9004857_1331000_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_9004857_1331000_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324717_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324717_2_1">Stock Award Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" id="id_9004857_1331003_1_1">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" id="id_9004857_1331003_2_1">Stock Based Award Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US" id="id_9004857_1324738_1_1">Disposal Group Classification [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US" id="id_9004857_1324738_2_1">Disposal Group Classification [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US" id="id_9004857_1331019_1_1">Disposal Group Classification [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US" id="id_9004857_1331019_2_1">Disposal Group Classification [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl" xml:lang="en-US" id="id_9004857_1334129_1_1">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl" xml:lang="en-US" id="id_9004857_1334129_2_1">Assets Held for Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DocumentAndEntityInformationAbstract" xlink:label="mnkd_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9004857_1386744_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9004857_1386744_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9004857_1386744_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_DocumentAndEntityInformationAbstract" xlink:to="mnkd_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_9004857_1324767_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_9004857_1324767_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_9004857_1324768_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_9004857_1324768_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_9004857_1324770_1_1">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_9004857_1324770_2_1">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" id="id_9004857_1327843_1_1">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" id="id_9004857_1327843_2_1">Document Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_9004857_1331044_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_9004857_1331044_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_9004857_1324772_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_9004857_1324772_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_9004857_1331060_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_9004857_1331060_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_9004857_1331061_1_1">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_9004857_1331061_2_1">Net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_9004857_1331061_12_1">Net income (loss) per share - basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" id="id_9004857_1334164_1_1">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" id="id_9004857_1334164_2_1">Basic EPS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_9004857_1334165_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_9004857_1334165_2_1">Net loss per share - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_9004857_1324782_1_1">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_9004857_1324782_2_1">Net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_9004857_1324782_12_1">Net income (loss) per share - diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" id="id_9004857_1331063_1_1">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" id="id_9004857_1331063_2_1">Diluted EPS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324786_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1324786_2_1">Net Income (Loss) Per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EarningsPerShareTable" xlink:label="mnkd_EarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EarningsPerShareTable_lbl" xml:lang="en-US" id="id_9004857_1370831_3_1">Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EarningsPerShareTable_lbl" xml:lang="en-US" id="id_9004857_1370831_1_1">Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EarningsPerShareTable_lbl" xml:lang="en-US" id="id_9004857_1370831_2_1">Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EarningsPerShareTable" xlink:to="mnkd_EarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334173_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334173_2_1">Net Income (Loss) per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1334178_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1334178_6_1">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_9004857_1324790_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_9004857_1324790_2_1">Federal tax benefit rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9004857_1324791_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9004857_1324791_2_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_9004857_1331081_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_9004857_1331081_2_1">Intercompany transfer of intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9004857_1453478_3_1">Effective Income Tax Rate Reconciliation Permanent Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9004857_1453478_1_1">Effective Income Tax Rate Reconciliation Permanent Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9004857_1453478_2_1">Permanent items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeMember" xlink:label="mnkd_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EmployeeMember_lbl" xml:lang="en-US" id="id_9004857_1352081_3_1">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EmployeeMember_lbl" xml:lang="en-US" id="id_9004857_1352081_1_1">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EmployeeMember_lbl" xml:lang="en-US" id="id_9004857_1352081_2_1">Employee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EmployeeMember" xlink:to="mnkd_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1337308_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1337308_2_1">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_9004857_1343246_1_1">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_9004857_1343246_2_1">Cash received from the exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_9004857_1341344_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_9004857_1341344_2_1">Unrecognized compensation cost related to non vested stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_9004857_1334251_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_9004857_1334251_2_1">Weighted average vesting period for unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_9004857_1342294_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_9004857_1342294_2_1">Unrecognized compensation cost related to options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" id="id_9004857_1331107_1_1">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" id="id_9004857_1331107_2_1">Employee Severance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_9004857_1331109_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_9004857_1331109_2_1">Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares_lbl" xml:lang="en-US" id="id_9004857_1408896_3_1">Employee Stock Purchase Plan Annual Increase In Reserved Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares_lbl" xml:lang="en-US" id="id_9004857_1408896_1_1">Employee Stock Purchase Plan Annual Increase In Reserved Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares_lbl" xml:lang="en-US" id="id_9004857_1408896_2_1">Share reserve automatic increase each year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" xlink:to="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlansMember" xlink:label="mnkd_EmployeeStockPurchasePlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EmployeeStockPurchasePlansMember_lbl" xml:lang="en-US" id="id_9004857_1365910_3_1">Employee Stock Purchase Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EmployeeStockPurchasePlansMember_lbl" xml:lang="en-US" id="id_9004857_1365910_1_1">Employee Stock Purchase Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EmployeeStockPurchasePlansMember_lbl" xml:lang="en-US" id="id_9004857_1365910_2_1">Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EmployeeStockPurchasePlansMember" xlink:to="mnkd_EmployeeStockPurchasePlansMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_9004857_1324832_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_9004857_1324832_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1331127_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1331127_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_9004857_1331130_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_9004857_1331130_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_9004857_1331131_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_9004857_1331131_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_9004857_1331132_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_9004857_1331132_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsExchangeAxis_lbl" xml:lang="en-US" id="id_9004857_1334238_1_1">Entity Listings, Exchange [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityListingsExchangeAxis_lbl" xml:lang="en-US" id="id_9004857_1334238_2_1">Entity Listings, Exchange [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_EntityListingsExchangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_9004857_1337305_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_9004857_1337305_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_9004857_1334246_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_9004857_1334246_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_9004857_1334249_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_9004857_1334249_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_9004857_1324845_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_9004857_1324845_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1327926_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1327926_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_9004857_1334257_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_9004857_1334257_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember_lbl" xml:lang="en-US" id="id_9004857_1468282_3_1">Equity Incentive Plan Twenty Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember_lbl" xml:lang="en-US" id="id_9004857_1468282_1_1">Equity Incentive Plan Twenty Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember_lbl" xml:lang="en-US" id="id_9004857_1468282_2_1">2013 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:to="mnkd_EquityIncentivePlanTwentyThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EstimatedAmountsCreditExchangeReceivable" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1450936_3_1">Estimated amounts credit exchange receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1450936_1_1">Estimated Amounts Credit Exchange Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1450936_2_1">Estimated amounts receivable under program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_EstimatedAmountsCreditExchangeReceivable" xlink:to="mnkd_EstimatedAmountsCreditExchangeReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1324874_1_1">Estimate of Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1324874_2_1">Estimate of Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ExchangeDomain_lbl" xml:lang="en-US" id="id_9004857_1331173_1_1">Exchange [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ExchangeDomain_lbl" xml:lang="en-US" id="id_9004857_1331173_2_1">Exchange [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ExchangeDomain" xlink:to="dei_ExchangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_9004857_1327949_1_1">Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_9004857_1327949_2_1">Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="us-gaap_ExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityAgreementMember" xlink:label="mnkd_FacilityAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_FacilityAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1353440_3_1">Facility Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_FacilityAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1353440_1_1">Facility Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_FacilityAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1353440_2_1">Facility Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_FacilityAgreementMember" xlink:to="mnkd_FacilityAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityFinancingObligationMember" xlink:label="mnkd_FacilityFinancingObligationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_FacilityFinancingObligationMember_lbl" xml:lang="en-US" id="id_9004857_1483091_3_1">Facility Financing Obligation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_FacilityFinancingObligationMember_lbl" xml:lang="en-US" id="id_9004857_1483091_1_1">Facility Financing Obligation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_FacilityFinancingObligationMember_lbl" xml:lang="en-US" id="id_9004857_1483091_2_1">Facility Financing Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_FacilityFinancingObligationMember" xlink:to="mnkd_FacilityFinancingObligationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_9004857_1341372_1_1">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_9004857_1341372_2_1">Warrant fair value adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_9004857_1341372_14_1">Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_9004857_1334310_1_1">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_9004857_1334310_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9004857_1327975_1_1">Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9004857_1327975_2_1">Warrant liability fair value assumptions, dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_9004857_1334314_1_1">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_9004857_1334314_2_1">Warrant liability fair value assumptions, remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_9004857_1331206_1_1">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_9004857_1331206_2_1">Fair value assumption, stock price volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_9004857_1331206_12_1">Warrant liability fair value assumptions, volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_9004857_1331207_1_1">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_9004857_1331207_2_1">Fair value assumption, risk-free rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_9004857_1331207_12_1">Warrant liability fair value assumptions, risk-free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" id="id_9004857_1334316_1_1">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" id="id_9004857_1334316_2_1">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_9004857_1334317_1_1">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_9004857_1334317_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" id="id_9004857_1331209_1_1">Fair Value, by Balance Sheet Grouping [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" id="id_9004857_1331209_2_1">Fair Value, by Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_9004857_1324896_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_9004857_1324896_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" id="id_9004857_1331210_1_1">Measurement Basis [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" id="id_9004857_1331210_2_1">Measurement Basis [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" id="id_9004857_1324907_1_1">Fair Value Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" id="id_9004857_1324907_2_1">Fair Value Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_9004857_1324909_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_9004857_1324909_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334324_1_1">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334324_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" id="id_9004857_1324922_1_1">Fair Value Inputs, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" id="id_9004857_1324922_2_1">Discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" id="id_9004857_1324922_12_1">Market discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsEntityCreditRisk_lbl" xml:lang="en-US" id="id_9004857_1324923_1_1">Fair Value Inputs, Entity Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsEntityCreditRisk_lbl" xml:lang="en-US" id="id_9004857_1324923_2_1">Risk premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsEntityCreditRisk" xlink:to="us-gaap_FairValueInputsEntityCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_9004857_1324925_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_9004857_1324925_2_1">Fair Value, Inputs, Level 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_lbl" xml:lang="en-US" id="id_9004857_1331241_1_1">Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_lbl" xml:lang="en-US" id="id_9004857_1331241_2_1">Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_lbl" xml:lang="en-US" id="id_9004857_1324926_1_1">Fair Value Inputs, Liabilities, Quantitative Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_lbl" xml:lang="en-US" id="id_9004857_1324926_2_1">Fair Value Inputs, Liabilities, Quantitative Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327984_1_1">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1327984_2_1">Fair Values of Financial Liabilities which Include Level 3 Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault_lbl" xml:lang="en-US" id="id_9004857_1327986_1_1">Fair Value Inputs, Probability of Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault_lbl" xml:lang="en-US" id="id_9004857_1327986_2_1">Warrant liability fair value assumptions, assumed probability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_9004857_1324950_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_9004857_1324950_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsValuationTechniques" xlink:label="us-gaap_FairValueMeasurementsValuationTechniques"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsValuationTechniques_lbl" xml:lang="en-US" id="id_9004857_1331262_1_1">Fair Value Measurements, Valuation Techniques</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsValuationTechniques_lbl" xml:lang="en-US" id="id_9004857_1331262_2_1">Valuation technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsValuationTechniques" xlink:to="us-gaap_FairValueMeasurementsValuationTechniques_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_9004857_1427097_3_1">Fair Value of Financial Instruments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_9004857_1427097_1_1">Fair Value of Financial Instruments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_9004857_1427097_2_1">Fair Value of Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_FairValueOfFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_9004857_1324959_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_9004857_1324959_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsTable" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_9004857_1470356_3_1">Fair Value of Financial Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_9004857_1470356_1_1">Fair Value of Financial Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_9004857_1470356_2_1">Fair Value of Financial Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="mnkd_FairValueOfFinancialInstrumentsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US" id="id_9004857_1337273_1_1">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US" id="id_9004857_1337273_14_1">Changes in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_9004857_1331314_1_1">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_9004857_1331314_2_1">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US" id="id_9004857_1340440_1_1">Financial Instruments, Owned, at Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US" id="id_9004857_1340440_4_1">Fair values of financial assets, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US" id="id_9004857_1340440_5_1">Fair values of financial assets, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1337233_1_1">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1337233_4_1">Fair values of financial liabilities, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1337233_5_1">Fair values of financial liabilities, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1337233_2_1">Financial liabilities fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1334454_1_1">Financial Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1334454_2_1">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_9004857_1331352_1_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_9004857_1331352_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_9004857_1328108_1_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_9004857_1328108_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="id_9004857_1337225_1_1">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="id_9004857_1337225_14_1">(Gain) loss on foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US" id="id_9004857_1339813_1_1">Foreign Currency Transaction Gain (Loss), Realized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US" id="id_9004857_1339813_14_1">(Gain) loss on foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_9004857_1349273_3_1">Furniture, fixtures and office equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_9004857_1349273_1_1">Furniture Fixtures And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_9004857_1349273_2_1">Furniture, fixtures and office equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_FurnitureFixturesAndOfficeEquipmentMember" xlink:to="mnkd_FurnitureFixturesAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_9004857_1350616_3_1">Gain Loss From Change In Fair Value Of Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_9004857_1350616_1_1">Gain Loss From Change In Fair Value Of Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_9004857_1350616_2_1">Changes in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" xlink:to="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_9004857_1339795_1_1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_9004857_1339795_14_1">Loss on sale, abandonment/disposal or impairment of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xml:lang="en-US" id="id_9004857_1338046_1_1">Gain (Loss) on Disposition of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xml:lang="en-US" id="id_9004857_1338046_2_1">Intellectual property sold, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_GainLossOnPurchaseCommitments_lbl" xml:lang="en-US" id="id_9004857_1480908_3_1">(Gain) Loss on Purchase Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_GainLossOnPurchaseCommitments_lbl" xml:lang="en-US" id="id_9004857_1480908_1_1">Gain (Loss) on Purchase Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_GainLossOnPurchaseCommitments_lbl" xml:lang="en-US" id="id_9004857_1480908_14_1">(Gain) loss on purchase commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_GainLossOnPurchaseCommitments" xlink:to="mnkd_GainLossOnPurchaseCommitments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_9004857_1337199_1_1">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_9004857_1337199_2_1">Gain (loss) on property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_9004857_1337190_1_1">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_9004857_1337190_32_1">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_9004857_1337190_2_1">Gain (loss) on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_9004857_1337190_12_1">Gain on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_9004857_1337190_14_1">(Gain) loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9004857_1342392_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9004857_1342392_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GrossToNetAdjustmentsPolicyTextBlock" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535383_3_1">Gross To Net Adjustments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535383_1_1">Gross To Net Adjustments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535383_2_1">Gross-to-net Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_GrossToNetAdjustmentsPolicyTextBlock" xlink:to="mnkd_GrossToNetAdjustmentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl" xml:lang="en-US" id="id_9004857_1343379_1_1">Impairment Charge on Reclassified Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl" xml:lang="en-US" id="id_9004857_1343379_2_1">Impairment charges allocated to assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="id_9004857_1340498_1_1">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="id_9004857_1340498_2_1">Property and equipment impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember_lbl" xml:lang="en-US" id="id_9004857_1325206_1_1">Income Approach Valuation Technique [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember_lbl" xml:lang="en-US" id="id_9004857_1325206_2_1">Income Approach Valuation Technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_9004857_1339760_1_1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_9004857_1339760_6_1">Income (loss) before benefit for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_9004857_1325223_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_9004857_1325223_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_9004857_1334666_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_9004857_1334666_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_9004857_1334667_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_9004857_1334667_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_9004857_1325224_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_9004857_1325224_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_9004857_1334668_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_9004857_1334668_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1325228_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1325228_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328298_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328298_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1515266_3_1">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1515266_1_1">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1515266_2_1">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1365251_3_1">Income Taxes Provision Benefit Summary Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1365251_1_1">Income Taxes Provision Benefit Summary Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1365251_2_1">Income Taxes Provision Benefit Summary Of Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1401489_3_1">Income Taxes Provision Benefit Summary Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1401489_1_1">Income Taxes Provision Benefit Summary Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1401489_2_1">Income Taxes Provision Benefit Summary Of Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:to="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesTable" xlink:label="mnkd_IncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1395155_3_1">Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1395155_1_1">Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1395155_2_1">Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncomeTaxesTable" xlink:to="mnkd_IncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340505_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9004857_1340505_14_1">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxExpenseBenefitNet" xlink:label="mnkd_IncomeTaxExpenseBenefitNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncomeTaxExpenseBenefitNet_lbl" xml:lang="en-US" id="id_9004857_1346102_3_1">Income Tax Expense Benefit Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncomeTaxExpenseBenefitNet_lbl" xml:lang="en-US" id="id_9004857_1346102_1_1">Income Tax Expense Benefit Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mnkd_IncomeTaxExpenseBenefitNet_lbl" xml:lang="en-US" id="id_9004857_1346102_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncomeTaxExpenseBenefitNet" xlink:to="mnkd_IncomeTaxExpenseBenefitNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334674_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1334674_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_lbl" xml:lang="en-US" id="id_9004857_1338840_1_1">Increase (Decrease) in Accounts and Notes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_lbl" xml:lang="en-US" id="id_9004857_1338840_14_1">Receivable from Sanofi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" id="id_9004857_1337163_1_1">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" id="id_9004857_1337163_14_1">Receivables from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_9004857_1340519_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_9004857_1340519_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_9004857_1337998_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_9004857_1337998_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9004857_1340516_1_1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9004857_1340516_2_1">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_lbl" xml:lang="en-US" id="id_9004857_1340514_1_1">Increase (Decrease) in Customer Advances and Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_lbl" xml:lang="en-US" id="id_9004857_1340514_2_1">Deferred payments from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:to="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US" id="id_9004857_1337984_1_1">Increase (Decrease) in Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US" id="id_9004857_1337984_14_1">Deferred costs from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue_lbl" xml:lang="en-US" id="id_9004857_1363413_3_1">Increase Decrease In Deferred Collaborative Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue_lbl" xml:lang="en-US" id="id_9004857_1363413_1_1">Increase Decrease In Deferred Collaborative Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue_lbl" xml:lang="en-US" id="id_9004857_1363413_2_1">Deferred sales from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" xlink:to="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1341503_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1341503_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_9004857_1337978_1_1">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_9004857_1337978_14_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_9004857_1328317_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_9004857_1328317_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInOtherDeferredCharges" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges_lbl" xml:lang="en-US" id="id_9004857_1535242_3_1">Increase (Decrease) in Other Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges_lbl" xml:lang="en-US" id="id_9004857_1535242_1_1">Increase (Decrease) in Other Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges_lbl" xml:lang="en-US" id="id_9004857_1535242_14_1">Deferred costs from commercial product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncreaseDecreaseInOtherDeferredCharges" xlink:to="mnkd_IncreaseDecreaseInOtherDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_9004857_1337969_1_1">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_9004857_1337969_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9004857_1342456_1_1">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9004857_1342456_2_1">Milestone rights liability and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_9004857_1339720_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_9004857_1339720_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss_lbl" xml:lang="en-US" id="id_9004857_1535402_3_1">Increase Decrease in Purchase Commitment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss_lbl" xml:lang="en-US" id="id_9004857_1535402_1_1">Increase Decrease in Purchase Commitment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss_lbl" xml:lang="en-US" id="id_9004857_1535402_2_1">Recognized loss on purchase commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" xlink:to="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xml:lang="en-US" id="id_9004857_1325242_1_1">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xml:lang="en-US" id="id_9004857_1325242_2_1">Effect of dilutive securities - common shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InsulinMember" xlink:label="mnkd_InsulinMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_InsulinMember_lbl" xml:lang="en-US" id="id_9004857_1382533_3_1">Insulin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_InsulinMember_lbl" xml:lang="en-US" id="id_9004857_1382533_1_1">Insulin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_InsulinMember_lbl" xml:lang="en-US" id="id_9004857_1382533_2_1">Insulin Put</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_InsulinMember" xlink:to="mnkd_InsulinMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" id="id_9004857_1331573_1_1">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" id="id_9004857_1331573_2_1">Intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xml:lang="en-US" id="id_9004857_1343460_1_1">Interest Costs Capitalized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xml:lang="en-US" id="id_9004857_1343460_2_1">Interest cost capitalized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsCapitalized" xlink:to="us-gaap_InterestCostsCapitalized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="id_9004857_1342485_1_1">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="id_9004857_1342485_2_1">Interest expense on notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="id_9004857_1342485_14_1">Interest expense on notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1331591_1_1">Interest Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1331591_2_1">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterestOnNotePayableToPrincipalStockholder" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder_lbl" xml:lang="en-US" id="id_9004857_1532400_3_1">Interest on Note Payable to Principal Stockholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder_lbl" xml:lang="en-US" id="id_9004857_1532400_1_1">Interest on Note Payable to Principal Stockholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder_lbl" xml:lang="en-US" id="id_9004857_1532400_2_1">Interest on note payable to principal stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_InterestOnNotePayableToPrincipalStockholder" xlink:to="mnkd_InterestOnNotePayableToPrincipalStockholder_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_9004857_1337940_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_9004857_1337940_2_1">Interest paid in cash, net of amounts capitalized to construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1337942_1_1">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_9004857_1337942_2_1">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingLineItems" xlink:label="mnkd_InterimReportingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_InterimReportingLineItems_lbl" xml:lang="en-US" id="id_9004857_1505853_3_1">Interim Reporting [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_InterimReportingLineItems_lbl" xml:lang="en-US" id="id_9004857_1505853_1_1">Interim Reporting [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_InterimReportingLineItems_lbl" xml:lang="en-US" id="id_9004857_1505853_2_1">Interim Reporting [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_InterimReportingLineItems" xlink:to="mnkd_InterimReportingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingTable" xlink:label="mnkd_InterimReportingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_InterimReportingTable_lbl" xml:lang="en-US" id="id_9004857_1385219_3_1">Interim Reporting [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_InterimReportingTable_lbl" xml:lang="en-US" id="id_9004857_1385219_1_1">Interim Reporting [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_InterimReportingTable_lbl" xml:lang="en-US" id="id_9004857_1385219_2_1">Interim Reporting [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_InterimReportingTable" xlink:to="mnkd_InterimReportingTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" id="id_9004857_1325288_1_1">Internal Revenue Service (IRS) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" id="id_9004857_1325288_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" id="id_9004857_1331609_1_1">Inventory, Current [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" id="id_9004857_1331609_2_1">Inventory, Current [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1331610_1_1">Inventory Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1331610_2_1">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1325291_1_1">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1325291_2_1">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1343488_1_1">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1343488_2_1">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" id="id_9004857_1325295_1_1">Inventory [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" id="id_9004857_1325295_2_1">Inventory [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_9004857_1341567_1_1">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_9004857_1341567_2_1">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_9004857_1341567_6_1">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1325296_1_1">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1325296_2_1">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1343483_1_1">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1343483_2_1">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1340597_1_1">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" id="id_9004857_1340597_2_1">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" id="id_9004857_1341572_1_1">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" id="id_9004857_1341572_2_1">Inventory charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_9004857_1338776_1_1">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_9004857_1338776_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandBuildingsAndImprovementsMember" xlink:label="us-gaap_LandBuildingsAndImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandBuildingsAndImprovementsMember_lbl" xml:lang="en-US" id="id_9004857_1325371_1_1">Land, Buildings and Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandBuildingsAndImprovementsMember_lbl" xml:lang="en-US" id="id_9004857_1325371_2_1">Land, Buildings and Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandBuildingsAndImprovementsMember" xlink:to="us-gaap_LandBuildingsAndImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" id="id_9004857_1334838_1_1">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" id="id_9004857_1334838_2_1">Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis_lbl" xml:lang="en-US" id="id_9004857_1467970_3_1">Lease Agreement Type Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis_lbl" xml:lang="en-US" id="id_9004857_1467970_1_1">Lease Agreement Type Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis_lbl" xml:lang="en-US" id="id_9004857_1467970_2_1">Lease Agreement Type Of Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:to="mnkd_LeaseAgreementTypeOfAgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain_lbl" xml:lang="en-US" id="id_9004857_1363089_3_1">Lease Agreement Type Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain_lbl" xml:lang="en-US" id="id_9004857_1363089_1_1">Lease Agreement Type Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain_lbl" xml:lang="en-US" id="id_9004857_1363089_2_1">Lease Agreement Type Of Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:to="mnkd_LeaseAgreementTypeOfAgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseExpirationMonthYear" xlink:label="mnkd_LeaseExpirationMonthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LeaseExpirationMonthYear_lbl" xml:lang="en-US" id="id_9004857_1383056_3_1">Lease Expiration Month Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LeaseExpirationMonthYear_lbl" xml:lang="en-US" id="id_9004857_1383056_1_1">Lease Expiration Month Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LeaseExpirationMonthYear_lbl" xml:lang="en-US" id="id_9004857_1383056_2_1">Lease expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LeaseExpirationMonthYear" xlink:to="mnkd_LeaseExpirationMonthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_9004857_1328480_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_9004857_1328480_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LetterOfAgreementMember" xlink:label="mnkd_LetterOfAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LetterOfAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1444803_3_1">Letter agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LetterOfAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1444803_1_1">Letter Of Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LetterOfAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1444803_2_1">Letter Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LetterOfAgreementMember" xlink:to="mnkd_LetterOfAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_9004857_1337090_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_9004857_1337090_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337091_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337091_6_1">Total liabilities and stockholders' deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1328488_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1328488_2_1">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1339671_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1339671_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_9004857_1334857_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_9004857_1334857_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" id="id_9004857_1338759_1_1">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" id="id_9004857_1338759_2_1">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1339672_1_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1339672_2_1">Fair value of warrants liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1339672_12_1">Fair value of Milestone Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_9004857_1339659_1_1">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_9004857_1339659_2_1">Principal amount outstanding under credit facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1337893_1_1">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1337893_2_1">Maximum secured loan facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1339655_1_1">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1339655_2_1">Amount available for future borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1399794_3_1">Line Of Credit Facility Restricted Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1399794_1_1">Line Of Credit Facility Restricted Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity_lbl" xml:lang="en-US" id="id_9004857_1399794_2_1">Available amount of credit facility under covenant restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:to="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanAgreementWithRelatedParty" xlink:label="mnkd_LoanAgreementWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LoanAgreementWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1461082_3_1">Loan agreement with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LoanAgreementWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1461082_1_1">Loan Agreement With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LoanAgreementWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1461082_2_1">Loan agreement with related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LoanAgreementWithRelatedParty" xlink:to="mnkd_LoanAgreementWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanArrangementMember" xlink:label="mnkd_LoanArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LoanArrangementMember_lbl" xml:lang="en-US" id="id_9004857_1500563_3_1">Loan arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LoanArrangementMember_lbl" xml:lang="en-US" id="id_9004857_1500563_1_1">Loan Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LoanArrangementMember_lbl" xml:lang="en-US" id="id_9004857_1500563_2_1">Loan Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LoanArrangementMember" xlink:to="mnkd_LoanArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanFacilityForgivenDate" xlink:label="mnkd_LoanFacilityForgivenDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LoanFacilityForgivenDate_lbl" xml:lang="en-US" id="id_9004857_1543514_3_1">Loan Facility Forgiven Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LoanFacilityForgivenDate_lbl" xml:lang="en-US" id="id_9004857_1543514_1_1">Loan Facility Forgiven Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LoanFacilityForgivenDate_lbl" xml:lang="en-US" id="id_9004857_1543514_2_1">Loan facility forgiven date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LoanFacilityForgivenDate" xlink:to="mnkd_LoanFacilityForgivenDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansAssumed1" xlink:label="us-gaap_LoansAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAssumed1_lbl" xml:lang="en-US" id="id_9004857_1337883_1_1">Loans Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansAssumed1_lbl" xml:lang="en-US" id="id_9004857_1337883_2_1">Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAssumed1" xlink:to="us-gaap_LoansAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" id="id_9004857_1331776_1_1">London Interbank Offered Rate (LIBOR) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" id="id_9004857_1331776_2_1">LIBOR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" id="id_9004857_1339638_1_1">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" id="id_9004857_1339638_2_1">Facility Agreement, total principle payment in 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" id="id_9004857_1339639_1_1">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" id="id_9004857_1339639_2_1">Facility Agreement, total principle payment in 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" id="id_9004857_1338701_1_1">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" id="id_9004857_1338701_2_1">Facility Agreement, total principle payment in 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="id_9004857_1328606_1_1">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="id_9004857_1328606_2_1">Fixed borrowing rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1328615_1_1">Long-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1328615_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1331802_1_1">Long-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1331802_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_9004857_1339628_1_1">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_9004857_1339628_2_1">Secured loan facility, amount owed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_9004857_1337871_1_1">Long-term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_9004857_1337871_2_1">long term purchase commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_9004857_1337871_12_1">Purchase commitment amount under Insulin Supply Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentCancellationFees" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees_lbl" xml:lang="en-US" id="id_9004857_1467758_3_1">Long Term Purchase Commitment Cancellation Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees_lbl" xml:lang="en-US" id="id_9004857_1467758_1_1">Long Term Purchase Commitment Cancellation Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees_lbl" xml:lang="en-US" id="id_9004857_1467758_2_1">Purchase commitment cancellation fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LongTermPurchaseCommitmentCancellationFees" xlink:to="mnkd_LongTermPurchaseCommitmentCancellationFees_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentExpirationDate" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1427700_3_1">Long Term Purchase Commitment, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1427700_1_1">Long Term Purchase Commitment, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate_lbl" xml:lang="en-US" id="id_9004857_1427700_2_1">Supply Agreement expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LongTermPurchaseCommitmentExpirationDate" xlink:to="mnkd_LongTermPurchaseCommitmentExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US" id="id_9004857_1325495_1_1">Long-term Purchase Commitment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US" id="id_9004857_1325495_2_1">Long-term Purchase Commitment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod_lbl" xml:lang="en-US" id="id_9004857_1346485_3_1">Long-term purchase commitment, renewal time period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod_lbl" xml:lang="en-US" id="id_9004857_1346485_1_1">Long-term Purchase Commitment, Renewal Time Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod_lbl" xml:lang="en-US" id="id_9004857_1346485_2_1">Supply Agreement renewal period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" xlink:to="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xml:lang="en-US" id="id_9004857_1334974_1_1">Long-term Purchase Commitment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xml:lang="en-US" id="id_9004857_1334974_2_1">Long-term Purchase Commitment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328613_1_1">Long-term Purchase Commitment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328613_2_1">Annual Purchase Requirements under Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337033_1_1">Loss Contingency, Accrual, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337033_2_1">Sanofi loan facility and loss share obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:to="us-gaap_LossContingencyAccrualCarryingValueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1532335_3_1">Loss on Purchase Commitments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1532335_1_1">Loss on Purchase Commitments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1532335_2_1">Recognized Loss on Purchase Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" xlink:to="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossSharingAgreementAmount" xlink:label="mnkd_LossSharingAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_LossSharingAgreementAmount_lbl" xml:lang="en-US" id="id_9004857_1505912_3_1">Loss Sharing Agreement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_LossSharingAgreementAmount_lbl" xml:lang="en-US" id="id_9004857_1505912_1_1">Loss Sharing Agreement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_LossSharingAgreementAmount_lbl" xml:lang="en-US" id="id_9004857_1505912_2_1">Company's total portion of loss sharing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_LossSharingAgreementAmount" xlink:to="mnkd_LossSharingAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" id="id_9004857_1325519_1_1">Machinery and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" id="id_9004857_1325519_2_1">Machinery and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_9004857_1334994_1_1">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_9004857_1334994_2_1">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xml:lang="en-US" id="id_9004857_1328644_1_1">Major Property Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xml:lang="en-US" id="id_9004857_1328644_2_1">Major Property Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xml:lang="en-US" id="id_9004857_1328645_1_1">Major Property Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xml:lang="en-US" id="id_9004857_1328645_2_1">Major Property Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_MajorPropertyClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember" xlink:label="us-gaap_MarketApproachValuationTechniqueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketApproachValuationTechniqueMember_lbl" xml:lang="en-US" id="id_9004857_1328686_1_1">Market Approach Valuation Technique [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketApproachValuationTechniqueMember_lbl" xml:lang="en-US" id="id_9004857_1328686_2_1">Market Approach Valuation Technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketApproachValuationTechniqueMember" xlink:to="us-gaap_MarketApproachValuationTechniqueMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MaturityPeriodOfCashEquivalents" xlink:label="mnkd_MaturityPeriodOfCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MaturityPeriodOfCashEquivalents_lbl" xml:lang="en-US" id="id_9004857_1392380_3_1">Maturity period of cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MaturityPeriodOfCashEquivalents_lbl" xml:lang="en-US" id="id_9004857_1392380_1_1">Maturity Period Of Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MaturityPeriodOfCashEquivalents_lbl" xml:lang="en-US" id="id_9004857_1392380_2_1">Maturity period of cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MaturityPeriodOfCashEquivalents" xlink:to="mnkd_MaturityPeriodOfCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_9004857_1328677_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_9004857_1328677_2_1">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentOneMember" xlink:label="mnkd_MilestonePaymentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MilestonePaymentOneMember_lbl" xml:lang="en-US" id="id_9004857_1443830_3_1">Milestone Payment One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MilestonePaymentOneMember_lbl" xml:lang="en-US" id="id_9004857_1443830_1_1">Milestone Payment One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MilestonePaymentOneMember_lbl" xml:lang="en-US" id="id_9004857_1443830_2_1">Milestone Payment One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MilestonePaymentOneMember" xlink:to="mnkd_MilestonePaymentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePayments" xlink:label="mnkd_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MilestonePayments_lbl" xml:lang="en-US" id="id_9004857_1523676_3_1">Milestone payments include payments to our partners related to alliance and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MilestonePayments_lbl" xml:lang="en-US" id="id_9004857_1523676_1_1">Milestone payments for intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_MilestonePayments_lbl" xml:lang="en-US" id="id_9004857_1523676_14_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MilestonePayments" xlink:to="mnkd_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentTwoMember" xlink:label="mnkd_MilestonePaymentTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MilestonePaymentTwoMember_lbl" xml:lang="en-US" id="id_9004857_1435325_3_1">Milestone Payment Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MilestonePaymentTwoMember_lbl" xml:lang="en-US" id="id_9004857_1435325_1_1">Milestone Payment Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MilestonePaymentTwoMember_lbl" xml:lang="en-US" id="id_9004857_1435325_2_1">Milestone Payment Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MilestonePaymentTwoMember" xlink:to="mnkd_MilestonePaymentTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543748_3_1">Milestone Rights Liability and Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543748_1_1">Milestone Rights Liability and Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1543748_2_1">Milestone rights liability and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" xlink:to="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MilestoneRightsLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1494756_3_1">Milestone Rights Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MilestoneRightsLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1494756_1_1">Milestone Rights Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MilestoneRightsLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1494756_2_1">Milestone Rights Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MilestoneRightsLiabilityMember" xlink:to="mnkd_MilestoneRightsLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MinimumClosingBidPriceOfCommonStock" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock_lbl" xml:lang="en-US" id="id_9004857_1372753_3_1">Minimum Closing Bid Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock_lbl" xml:lang="en-US" id="id_9004857_1372753_1_1">Minimum Closing Bid Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock_lbl" xml:lang="en-US" id="id_9004857_1372753_2_1">Minimum closing bid price of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MinimumClosingBidPriceOfCommonStock" xlink:to="mnkd_MinimumClosingBidPriceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_9004857_1331874_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_9004857_1331874_2_1">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1342605_1_1">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" id="id_9004857_1342605_2_1">Cash equivalents, money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MortgageLoanMember" xlink:label="mnkd_MortgageLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_MortgageLoanMember_lbl" xml:lang="en-US" id="id_9004857_1510602_3_1">Mortgage Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_MortgageLoanMember_lbl" xml:lang="en-US" id="id_9004857_1510602_1_1">Mortgage Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_MortgageLoanMember_lbl" xml:lang="en-US" id="id_9004857_1510602_2_1">Mortgage Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_MortgageLoanMember" xlink:to="mnkd_MortgageLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_9004857_1328762_1_1">Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_9004857_1328762_2_1">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NasdaqStockMarketMember" xlink:label="mnkd_NasdaqStockMarketMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NasdaqStockMarketMember_lbl" xml:lang="en-US" id="id_9004857_1532499_3_1">Nasdaq Stock Market [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NasdaqStockMarketMember_lbl" xml:lang="en-US" id="id_9004857_1532499_1_1">Nasdaq Stock Market [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NasdaqStockMarketMember_lbl" xml:lang="en-US" id="id_9004857_1532499_2_1">NASDAQ</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NasdaqStockMarketMember" xlink:to="mnkd_NasdaqStockMarketMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1342613_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1342613_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328785_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328785_2_1">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1340686_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1340686_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328782_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328782_2_1">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1325627_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9004857_1325627_6_1">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1325628_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9004857_1325628_2_1">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337830_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337830_2_1">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337830_6_1">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337830_12_1">Net income (loss) (numerator)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareLineItems" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1476170_3_1">Net Income Loss Per Common Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1476170_1_1">Net Income Loss Per Common Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems_lbl" xml:lang="en-US" id="id_9004857_1476170_2_1">Net Income Loss Per Common Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="mnkd_NetIncomeLossPerCommonShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareTable" xlink:label="mnkd_NetIncomeLossPerCommonShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetIncomeLossPerCommonShareTable_lbl" xml:lang="en-US" id="id_9004857_1427374_3_1">Net Income Loss Per Common Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetIncomeLossPerCommonShareTable_lbl" xml:lang="en-US" id="id_9004857_1427374_1_1">Net Income Loss Per Common Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetIncomeLossPerCommonShareTable_lbl" xml:lang="en-US" id="id_9004857_1427374_2_1">Net Income Loss Per Common Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="mnkd_NetIncomeLossPerCommonShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardAnnualLimitation" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation_lbl" xml:lang="en-US" id="id_9004857_1454268_3_1">Net Operating Loss Carryforward Annual Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation_lbl" xml:lang="en-US" id="id_9004857_1454268_1_1">Net Operating Loss Carryforward Annual Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation_lbl" xml:lang="en-US" id="id_9004857_1454268_2_1">Net operating loss and credit carryforwards, annual use limitation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetOperatingLossCarryforwardAnnualLimitation" xlink:to="mnkd_NetOperatingLossCarryforwardAnnualLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardsBeginsToExpire" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire_lbl" xml:lang="en-US" id="id_9004857_1498694_3_1">Net Operating Loss Carryforwards Begins To Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire_lbl" xml:lang="en-US" id="id_9004857_1498694_1_1">Net Operating Loss Carryforwards Begins To Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire_lbl" xml:lang="en-US" id="id_9004857_1498694_2_1">Net operating loss carryforwards, expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetOperatingLossCarryforwardsBeginsToExpire" xlink:to="mnkd_NetOperatingLossCarryforwardsBeginsToExpire_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetProceedsFromSaleOfProperty" xlink:label="mnkd_NetProceedsFromSaleOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetProceedsFromSaleOfProperty_lbl" xml:lang="en-US" id="id_9004857_1379618_3_1">Net Proceeds From Sale Of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetProceedsFromSaleOfProperty_lbl" xml:lang="en-US" id="id_9004857_1379618_1_1">Net Proceeds From Sale Of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetProceedsFromSaleOfProperty_lbl" xml:lang="en-US" id="id_9004857_1379618_2_1">Net cash received from property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetProceedsFromSaleOfProperty" xlink:to="mnkd_NetProceedsFromSaleOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromBulkInsulin" xlink:label="mnkd_NetRevenueFromBulkInsulin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetRevenueFromBulkInsulin_lbl" xml:lang="en-US" id="id_9004857_1543956_3_1">Net Revenue From Bulk Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetRevenueFromBulkInsulin_lbl" xml:lang="en-US" id="id_9004857_1543956_1_1">Net Revenue From Bulk Insulin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetRevenueFromBulkInsulin_lbl" xml:lang="en-US" id="id_9004857_1543956_2_1">Revenue - bulk insulin sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetRevenueFromBulkInsulin" xlink:to="mnkd_NetRevenueFromBulkInsulin_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NetRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_9004857_1534952_3_1">Net Revenue From Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NetRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_9004857_1534952_1_1">Net Revenue From Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NetRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_9004857_1534952_2_1">Net revenue - collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mnkd_NetRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_9004857_1534952_12_1">Net revenue from collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NetRevenueFromCollaboration" xlink:to="mnkd_NetRevenueFromCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NominalLendingFee" xlink:label="mnkd_NominalLendingFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NominalLendingFee_lbl" xml:lang="en-US" id="id_9004857_1543521_3_1">Nominal lending fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NominalLendingFee_lbl" xml:lang="en-US" id="id_9004857_1543521_1_1">Nominal Lending Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NominalLendingFee_lbl" xml:lang="en-US" id="id_9004857_1543521_2_1">Nominal lending fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NominalLendingFee" xlink:to="mnkd_NominalLendingFee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_9004857_1331972_1_1">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_9004857_1331972_2_1">NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339577_1_1">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339577_6_1">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_9004857_1325659_1_1">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_9004857_1325659_2_1">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337817_1_1">Notes Payable, Related Parties, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337817_2_1">Note payable to principal stockholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1337817_12_1">Note payable to principal stockholder - net carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfAssetGroups" xlink:label="mnkd_NumberOfAssetGroups"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NumberOfAssetGroups_lbl" xml:lang="en-US" id="id_9004857_1514276_3_1">Number of Asset Groups</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NumberOfAssetGroups_lbl" xml:lang="en-US" id="id_9004857_1514276_1_1">Number of Asset Groups</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NumberOfAssetGroups_lbl" xml:lang="en-US" id="id_9004857_1514276_2_1">Number of primary asset groups</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NumberOfAssetGroups" xlink:to="mnkd_NumberOfAssetGroups_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfMonthsAdvancesOutstanding" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1362569_3_1">Number of months advances outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1362569_1_1">Number Of Months Advances Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1362569_2_1">Number of months advances outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_NumberOfMonthsAdvancesOutstanding" xlink:to="mnkd_NumberOfMonthsAdvancesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OfficeLeaseExpense" xlink:label="mnkd_OfficeLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_OfficeLeaseExpense_lbl" xml:lang="en-US" id="id_9004857_1345229_3_1">Office Lease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_OfficeLeaseExpense_lbl" xml:lang="en-US" id="id_9004857_1345229_1_1">Office Lease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_OfficeLeaseExpense_lbl" xml:lang="en-US" id="id_9004857_1345229_2_1">Lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_OfficeLeaseExpense" xlink:to="mnkd_OfficeLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1328867_1_1">Open Option Contracts Written Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1328867_2_1">Open Option Contracts Written Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1332024_1_1">Open Option Contracts Written Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1332024_2_1">Open Option Contracts Written Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337808_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_9004857_1337808_6_1">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_9004857_1342639_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_9004857_1342639_2_1">Operating lease rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossCarryforwardsSubjectToLimitation" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation_lbl" xml:lang="en-US" id="id_9004857_1451908_3_1">Operating Loss Carryforwards Subject To Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation_lbl" xml:lang="en-US" id="id_9004857_1451908_1_1">Operating Loss Carryforwards Subject To Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation_lbl" xml:lang="en-US" id="id_9004857_1451908_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_OperatingLossCarryforwardsSubjectToLimitation" xlink:to="mnkd_OperatingLossCarryforwardsSubjectToLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossSharingMember" xlink:label="mnkd_OperatingLossSharingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_OperatingLossSharingMember_lbl" xml:lang="en-US" id="id_9004857_1443229_3_1">Operating loss Sharing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_OperatingLossSharingMember_lbl" xml:lang="en-US" id="id_9004857_1443229_1_1">Operating loss Sharing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_OperatingLossSharingMember_lbl" xml:lang="en-US" id="id_9004857_1443229_2_1">Operating loss Sharing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_OperatingLossSharingMember" xlink:to="mnkd_OperatingLossSharingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328883_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328883_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xml:lang="en-US" id="id_9004857_1478147_3_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xml:lang="en-US" id="id_9004857_1478147_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xml:lang="en-US" id="id_9004857_1478147_2_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xml:lang="en-US" id="id_9004857_1354085_3_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xml:lang="en-US" id="id_9004857_1354085_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xml:lang="en-US" id="id_9004857_1354085_2_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328884_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1328884_2_1">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1339563_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9004857_1339563_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1343602_1_1">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1343602_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1336956_1_1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1336956_2_1">Cumulative translation loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_9004857_1336956_12_1">Unrealized gain/(loss) on foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_9004857_1335231_1_1">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_9004857_1335231_2_1">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xml:lang="en-US" id="id_9004857_1343623_1_1">Other Deferred Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xml:lang="en-US" id="id_9004857_1343623_2_1">Deferred costs from commercial product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCostsNet" xlink:to="us-gaap_OtherDeferredCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_9004857_1328911_1_1">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_9004857_1328911_2_1">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl" xml:lang="en-US" id="id_9004857_1339532_1_1">Other Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebt_lbl" xml:lang="en-US" id="id_9004857_1339532_2_1">Fair value of milestone rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtCurrent_lbl" xml:lang="en-US" id="id_9004857_1339533_1_1">Other Long-term Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebtCurrent_lbl" xml:lang="en-US" id="id_9004857_1339533_2_1">Facility financing obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1338624_1_1">Other Long-term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1338624_2_1">Long term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339529_1_1">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339529_14_1">Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339526_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339526_2_1">Other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9004857_1339526_12_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="us-gaap_OtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US" id="id_9004857_1337782_1_1">Other Short-term Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US" id="id_9004857_1337782_2_1">Short term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesOutstanding" xlink:label="us-gaap_OwnshareLendingArrangementSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OwnshareLendingArrangementSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1328963_1_1">Own-share Lending Arrangement, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OwnshareLendingArrangementSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1328963_2_1">Common shares loaned under the share lending arrangement, issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OwnshareLendingArrangementSharesOutstanding" xlink:to="us-gaap_OwnshareLendingArrangementSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_9004857_1341718_1_1">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_9004857_1341718_2_1">Interest incurred through borrowings under Sanofi Loan Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_9004857_1341718_12_1">Paid-in-kind interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountContributions_lbl" xml:lang="en-US" id="id_9004857_1338601_1_1">Partners' Capital Account, Contributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartnersCapitalAccountContributions_lbl" xml:lang="en-US" id="id_9004857_1338601_2_1">Capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountContributions" xlink:to="us-gaap_PartnersCapitalAccountContributions_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535384_3_1">Patient Discount and Co Pay Assistance Programs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535384_1_1">Patient Discount and Co Pay Assistance Programs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535384_2_1">Patient Discount and Co-Pay Assistance Programs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" xlink:to="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328978_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_9004857_1328978_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentForContingentLiabilities" xlink:label="mnkd_PaymentForContingentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PaymentForContingentLiabilities_lbl" xml:lang="en-US" id="id_9004857_1506920_3_1">Payment For Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PaymentForContingentLiabilities_lbl" xml:lang="en-US" id="id_9004857_1506920_1_1">Payment For Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PaymentForContingentLiabilities_lbl" xml:lang="en-US" id="id_9004857_1506920_2_1">Required payment pursuant to the terms of the Milestone Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PaymentForContingentLiabilities" xlink:to="mnkd_PaymentForContingentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1336907_1_1">Payment of Financing and Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1336907_14_1">Issuance costs associated with direct placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForCommissionsAndOtherFees" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees_lbl" xml:lang="en-US" id="id_9004857_1543515_3_1">Payments For Commissions And Other Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees_lbl" xml:lang="en-US" id="id_9004857_1543515_1_1">Payments For Commissions And Other Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees_lbl" xml:lang="en-US" id="id_9004857_1543515_2_1">Payments for commissions and other fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PaymentsForCommissionsAndOtherFees" xlink:to="mnkd_PaymentsForCommissionsAndOtherFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl" xml:lang="en-US" id="id_9004857_1337757_1_1">Payments for Derivative Instrument, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl" xml:lang="en-US" id="id_9004857_1337757_2_1">Payment for insulin put option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForFinancialAssets" xlink:label="mnkd_PaymentsForFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PaymentsForFinancialAssets_lbl" xml:lang="en-US" id="id_9004857_1543740_3_1">Payments for Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PaymentsForFinancialAssets_lbl" xml:lang="en-US" id="id_9004857_1543740_1_1">Payments for Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_PaymentsForFinancialAssets_lbl" xml:lang="en-US" id="id_9004857_1543740_14_1">Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PaymentsForFinancialAssets" xlink:to="mnkd_PaymentsForFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForUseOfAircrafts" xlink:label="mnkd_PaymentsForUseOfAircrafts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PaymentsForUseOfAircrafts_lbl" xml:lang="en-US" id="id_9004857_1522431_3_1">Payments for Use of Aircrafts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PaymentsForUseOfAircrafts_lbl" xml:lang="en-US" id="id_9004857_1522431_1_1">Payments for Use of Aircrafts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PaymentsForUseOfAircrafts_lbl" xml:lang="en-US" id="id_9004857_1522431_2_1">Expenses related to charter service on behalf of principal shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PaymentsForUseOfAircrafts" xlink:to="mnkd_PaymentsForUseOfAircrafts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1338575_1_1">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1338575_14_1">Payment of debt issuance costs on 2018 notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1337719_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1337719_2_1">Issuance costs associated with the Tel Aviv Stock Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1337719_14_1">Issuance costs associated with the Tel Aviv Stock Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1338563_1_1">Payments Related to Tax Withholding for Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1338563_14_1">Payment of employment taxes related to vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1336880_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1336880_14_1">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332141_1_1">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332141_2_1">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCommonStockSharesOutstanding" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1481319_3_1">Percentage Of Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1481319_1_1">Percentage Of Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1481319_2_1">Share of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PercentageOfCommonStockSharesOutstanding" xlink:to="mnkd_PercentageOfCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCreditExchangeReceivable" xlink:label="mnkd_PercentageOfCreditExchangeReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PercentageOfCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1415583_3_1">Percentage of credit exchange receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PercentageOfCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1415583_1_1">Percentage Of Credit Exchange Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PercentageOfCreditExchangeReceivable_lbl" xml:lang="en-US" id="id_9004857_1415583_2_1">Percentage of credit exchange receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PercentageOfCreditExchangeReceivable" xlink:to="mnkd_PercentageOfCreditExchangeReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfShareReservedForShareBasedCompensation" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1397799_3_1">Percentage Of Share Reserved For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1397799_1_1">Percentage Of Share Reserved For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1397799_2_1">Shares reserved under ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PercentageOfShareReservedForShareBasedCompensation" xlink:to="mnkd_PercentageOfShareReservedForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_9004857_1325804_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_9004857_1325804_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_9004857_1335326_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_9004857_1335326_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1332169_1_1">Portion at Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" id="id_9004857_1332169_2_1">Portion at Fair Value Measurement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PotentialMilestonePaymentsToBeReceived" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_9004857_1399252_3_1">Potential Milestone Payments To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_9004857_1399252_1_1">Potential Milestone Payments To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_9004857_1399252_2_1">Milestone receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PotentialMilestonePaymentsToBeReceived" xlink:to="mnkd_PotentialMilestonePaymentsToBeReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9004857_1335367_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9004857_1335367_2_1">Undesignated preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1335362_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1335362_2_1">Undesignated preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_9004857_1332188_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_9004857_1332188_2_1">Undesignated preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1325830_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1325830_2_1">Undesignated preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_9004857_1336848_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_9004857_1336848_2_1">Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2016 and 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_9004857_1343684_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_9004857_1343684_2_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1502380_3_1">Prepaid Expenses And Other Current Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1502380_1_1">Prepaid Expenses And Other Current Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1502380_2_1">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrincipalAmountPerShare" xlink:label="mnkd_PrincipalAmountPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PrincipalAmountPerShare_lbl" xml:lang="en-US" id="id_9004857_1497043_3_1">Principal amount per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PrincipalAmountPerShare_lbl" xml:lang="en-US" id="id_9004857_1497043_1_1">Principal Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PrincipalAmountPerShare_lbl" xml:lang="en-US" id="id_9004857_1497043_2_1">Principal amount per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PrincipalAmountPerShare" xlink:to="mnkd_PrincipalAmountPerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US" id="id_9004857_1335383_1_1">Principal Owner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US" id="id_9004857_1335383_2_1">Principal stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_9004857_1325848_1_1">Reclassification, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_9004857_1325848_2_1">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" id="id_9004857_1340792_1_1">Proceeds from Collaborators</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" id="id_9004857_1340792_2_1">Nonrefundable payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9004857_1340826_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9004857_1340826_2_1">Proceeds from issuance of common stock pursuant to at-the-market issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" id="id_9004857_1523234_3_1">Issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" id="id_9004857_1523234_1_1">Proceeds From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" id="id_9004857_1523234_2_1">Net proceeds from offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US" id="id_9004857_1522266_3_1">The cash inflow from the additional capital contribution to the entity including any warrants issued. Proceeds are net of cash outflows for issuance costs related to the transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US" id="id_9004857_1522266_1_1">Proceeds From Issuance Of Common Stock And Warrants Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US" id="id_9004857_1522266_2_1">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" id="id_9004857_1343718_1_1">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" id="id_9004857_1343718_2_1">Proceeds from issuance of facility financing obligation and milestone rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" id="id_9004857_1343719_1_1">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" id="id_9004857_1343719_2_1">Proceeds from issuance of Tranche B of the facility financing obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_9004857_1341831_1_1">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_9004857_1341831_2_1">Proceeds from direct placement of common stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_9004857_1343769_1_1">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_9004857_1343769_2_1">Proceeds from issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived_lbl" xml:lang="en-US" id="id_9004857_1543735_3_1">Proceeds from Option Exercise and License Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived_lbl" xml:lang="en-US" id="id_9004857_1543735_1_1">Proceeds from Option Exercise and License Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived_lbl" xml:lang="en-US" id="id_9004857_1543735_2_1">Nonrefundable option exercise and license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" xlink:to="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" id="id_9004857_1341817_1_1">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" id="id_9004857_1341817_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" id="id_9004857_1340846_1_1">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" id="id_9004857_1340846_2_1">Secured loan facility, amount borrowed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_9004857_1342802_1_1">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_9004857_1342802_2_1">Payment of notes payable to Deerfield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1340856_1_1">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1340856_2_1">Cash received from property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9004857_1340856_12_1">Proceeds from sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1342792_1_1">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1342792_2_1">Exercise of warrants for common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1342792_12_1">Proceeds from exercise warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" id="id_9004857_1340850_1_1">Production Related Impairments or Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" id="id_9004857_1340850_2_1">Write-off of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" id="id_9004857_1332226_1_1">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" id="id_9004857_1332226_2_1">AFREZZA product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_9004857_1325880_1_1">Products and Services [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_9004857_1325880_2_1">Products and Services [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustments" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments_lbl" xml:lang="en-US" id="id_9004857_1543725_3_1">Product sales revenue gross to net adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments_lbl" xml:lang="en-US" id="id_9004857_1543725_1_1">Product sales revenue gross to net adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments_lbl" xml:lang="en-US" id="id_9004857_1543725_2_1">Product sales revenue gross to net adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProductSalesRevenueGrossToNetAdjustments" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage_lbl" xml:lang="en-US" id="id_9004857_1543726_3_1">Product sales revenue gross to net adjustments percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage_lbl" xml:lang="en-US" id="id_9004857_1543726_1_1">Product sales revenue gross to net adjustments percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage_lbl" xml:lang="en-US" id="id_9004857_1543726_2_1">Product sales revenue gross to net adjustments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_9004857_1325881_1_1">Products and Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_9004857_1325881_2_1">Products and Services [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProfitLossSharingAgreementAllocationPercentage" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage_lbl" xml:lang="en-US" id="id_9004857_1366910_3_1">Profit Loss Sharing Agreement Allocation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage_lbl" xml:lang="en-US" id="id_9004857_1366910_1_1">Profit Loss Sharing Agreement Allocation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage_lbl" xml:lang="en-US" id="id_9004857_1366910_2_1">Profits and losses sharing percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ProfitLossSharingAgreementAllocationPercentage" xlink:to="mnkd_ProfitLossSharingAgreementAllocationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PropertyAndEquipmentImpairmentMember" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember_lbl" xml:lang="en-US" id="id_9004857_1416340_3_1">Property And Equipment Impairment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember_lbl" xml:lang="en-US" id="id_9004857_1416340_1_1">Property And Equipment Impairment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember_lbl" xml:lang="en-US" id="id_9004857_1416340_2_1">Property And Equipment Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PropertyAndEquipmentImpairmentMember" xlink:to="mnkd_PropertyAndEquipmentImpairmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_9004857_1329107_1_1">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_9004857_1329107_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1335427_1_1">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1335427_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332237_1_1">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332237_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" id="id_9004857_1336836_1_1">Property, Plant and Equipment, Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" id="id_9004857_1336836_2_1">Amount of divestiture of long-lived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1342808_1_1">Property, Plant, and Equipment, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US" id="id_9004857_1342808_2_1">Property, plant, and equipment, fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_9004857_1342809_1_1">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_9004857_1342809_2_1">Property and equipment - gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_9004857_1332242_1_1">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_9004857_1332242_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9004857_1340873_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9004857_1340873_2_1">Property and equipment - net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9004857_1340873_6_1">Total property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9004857_1340873_12_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335441_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335441_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329120_1_1">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329120_2_1">Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1332245_1_1">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1332245_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_9004857_1332246_1_1">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_9004857_1332246_2_1">Estimated Useful Life (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PublicMember" xlink:label="mnkd_PublicMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PublicMember_lbl" xml:lang="en-US" id="id_9004857_1405414_3_1">Public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PublicMember_lbl" xml:lang="en-US" id="id_9004857_1405414_1_1">Public [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PublicMember_lbl" xml:lang="en-US" id="id_9004857_1405414_2_1">Public</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PublicMember" xlink:to="mnkd_PublicMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" id="id_9004857_1336830_1_1">Purchase Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" id="id_9004857_1336830_2_1">Purchase commitment obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationCurrent" xlink:label="mnkd_PurchaseObligationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PurchaseObligationCurrent_lbl" xml:lang="en-US" id="id_9004857_1452104_3_1">Purchase Obligation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PurchaseObligationCurrent_lbl" xml:lang="en-US" id="id_9004857_1452104_1_1">Purchase Obligation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PurchaseObligationCurrent_lbl" xml:lang="en-US" id="id_9004857_1452104_2_1">Recognized loss on purchase commitments - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PurchaseObligationCurrent" xlink:to="mnkd_PurchaseObligationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInFifthYear_lbl" xml:lang="en-US" id="id_9004857_1338502_1_1">Purchase Obligation, Due in Fifth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInFifthYear_lbl" xml:lang="en-US" id="id_9004857_1338502_2_1">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFifthYear" xlink:to="us-gaap_PurchaseObligationDueInFifthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xml:lang="en-US" id="id_9004857_1339415_1_1">Purchase Obligation, Due in Fourth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xml:lang="en-US" id="id_9004857_1339415_2_1">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFourthYear" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" id="id_9004857_1339416_1_1">Purchase Obligation, Due in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" id="id_9004857_1339416_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" id="id_9004857_1337670_1_1">Purchase Obligation, Due in Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" id="id_9004857_1337670_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSeventhYear" xlink:label="mnkd_PurchaseObligationDueInSeventhYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PurchaseObligationDueInSeventhYear_lbl" xml:lang="en-US" id="id_9004857_1544059_3_1">Purchase Obligation Due In Seventh Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PurchaseObligationDueInSeventhYear_lbl" xml:lang="en-US" id="id_9004857_1544059_1_1">Purchase Obligation Due In Seventh Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PurchaseObligationDueInSeventhYear_lbl" xml:lang="en-US" id="id_9004857_1544059_2_1">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PurchaseObligationDueInSeventhYear" xlink:to="mnkd_PurchaseObligationDueInSeventhYear_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSixthYear" xlink:label="mnkd_PurchaseObligationDueInSixthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" id="id_9004857_1535365_3_1">Purchase Obligation Due In Sixth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" id="id_9004857_1535365_1_1">Purchase Obligation Due In Sixth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" id="id_9004857_1535365_2_1">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PurchaseObligationDueInSixthYear" xlink:to="mnkd_PurchaseObligationDueInSixthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" id="id_9004857_1338499_1_1">Purchase Obligation, Due in Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" id="id_9004857_1338499_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" id="id_9004857_1329148_1_1">Purchase Obligation, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" id="id_9004857_1329148_2_1">Annual Purchase Requirements under Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationNoncurrent" xlink:label="mnkd_PurchaseObligationNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_PurchaseObligationNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1396555_3_1">Purchase Obligation Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_PurchaseObligationNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1396555_1_1">Purchase Obligation Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_PurchaseObligationNoncurrent_lbl" xml:lang="en-US" id="id_9004857_1396555_2_1">Recognized loss on purchase commitments - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_PurchaseObligationNoncurrent" xlink:to="mnkd_PurchaseObligationNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PutOptionMember_lbl" xml:lang="en-US" id="id_9004857_1325939_1_1">Put Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PutOptionMember_lbl" xml:lang="en-US" id="id_9004857_1325939_2_1">Put Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PutOptionMember" xlink:to="us-gaap_PutOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1335480_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_9004857_1335480_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335481_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335481_2_1">Selected quarterly financial data (unaudited)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_9004857_1335482_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_9004857_1335482_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_9004857_1325933_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_9004857_1325933_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332308_1_1">Receivables, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332308_2_1">State Research and Development Credit Exchange Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1501049_3_1">Recently issued accounting standards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1501049_1_1">Recently Issued Accounting Standards [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1501049_2_1">Recently Issued Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" xlink:to="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReceptorLifeScienceIncMember" xlink:label="mnkd_ReceptorLifeScienceIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ReceptorLifeScienceIncMember_lbl" xml:lang="en-US" id="id_9004857_1543513_3_1">Receptor Life Science Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ReceptorLifeScienceIncMember_lbl" xml:lang="en-US" id="id_9004857_1543513_1_1">Receptor Life Science Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ReceptorLifeScienceIncMember_lbl" xml:lang="en-US" id="id_9004857_1543513_2_1">Receptor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ReceptorLifeScienceIncMember" xlink:to="mnkd_ReceptorLifeScienceIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash_lbl" xml:lang="en-US" id="id_9004857_1543501_3_1">Reclassification Of Property Plant And Equipment To Assets Held For Sale Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash_lbl" xml:lang="en-US" id="id_9004857_1543501_1_1">Reclassification Of Property Plant And Equipment To Assets Held For Sale Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash_lbl" xml:lang="en-US" id="id_9004857_1543501_2_1">Reclassification of property and equipment to asset held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" xlink:to="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecognitionPeriodForDeferredRevenue" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1393819_3_1">Recognition Period for Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1393819_1_1">Recognition Period for Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1393819_2_1">Deferred revenue recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RecognitionPeriodForDeferredRevenue" xlink:to="mnkd_RecognitionPeriodForDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RegisteredOfferingMember" xlink:label="mnkd_RegisteredOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RegisteredOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1532316_3_1">Registered Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RegisteredOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1532316_1_1">Registered Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RegisteredOfferingMember_lbl" xml:lang="en-US" id="id_9004857_1532316_2_1">Registered Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RegisteredOfferingMember" xlink:to="mnkd_RegisteredOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xml:lang="en-US" id="id_9004857_1325983_1_1">Regulatory Agency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xml:lang="en-US" id="id_9004857_1325983_2_1">Regulatory Agency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xml:lang="en-US" id="id_9004857_1329212_1_1">Regulatory Agency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xml:lang="en-US" id="id_9004857_1329212_2_1">Regulatory Agency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="us-gaap_RegulatoryAgencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyDebtMember" xlink:label="mnkd_RelatedPartyDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RelatedPartyDebtMember_lbl" xml:lang="en-US" id="id_9004857_1365453_3_1">Related party debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RelatedPartyDebtMember_lbl" xml:lang="en-US" id="id_9004857_1365453_1_1">Related Party Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RelatedPartyDebtMember_lbl" xml:lang="en-US" id="id_9004857_1365453_2_1">Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RelatedPartyDebtMember" xlink:to="mnkd_RelatedPartyDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_9004857_1326001_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_9004857_1326001_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyMember" xlink:label="mnkd_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RelatedPartyMember_lbl" xml:lang="en-US" id="id_9004857_1513368_3_1">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RelatedPartyMember_lbl" xml:lang="en-US" id="id_9004857_1513368_1_1">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RelatedPartyMember_lbl" xml:lang="en-US" id="id_9004857_1513368_2_1">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RelatedPartyMember" xlink:to="mnkd_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_9004857_1325994_1_1">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_9004857_1325994_2_1">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment_lbl" xml:lang="en-US" id="id_9004857_1397917_3_1">Related Party Transaction Debt Instrument Prepayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment_lbl" xml:lang="en-US" id="id_9004857_1397917_1_1">Related Party Transaction Debt Instrument Prepayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment_lbl" xml:lang="en-US" id="id_9004857_1397917_2_1">Amount prepaid for cancellation of indebtedness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" xlink:to="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_9004857_1325997_1_1">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_9004857_1325997_2_1">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1340909_1_1">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1340909_2_1">Interest expense on note payable principal stockholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_9004857_1340909_14_1">Interest expense on note payable to principal stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_9004857_1329230_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_9004857_1329230_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionPrepaymentPeriod" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod_lbl" xml:lang="en-US" id="id_9004857_1370724_3_1">Related party transaction prepayment period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod_lbl" xml:lang="en-US" id="id_9004857_1370724_1_1">Related Party Transaction Prepayment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod_lbl" xml:lang="en-US" id="id_9004857_1370724_2_1">Related party transaction prepayment period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RelatedPartyTransactionPrepaymentPeriod" xlink:to="mnkd_RelatedPartyTransactionPrepaymentPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_9004857_1332351_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_9004857_1332351_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_9004857_1326002_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_9004857_1326002_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335553_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335553_2_1">Related-Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xml:lang="en-US" id="id_9004857_1337643_1_1">Repayments of Senior Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xml:lang="en-US" id="id_9004857_1337643_2_1">Payments on senior notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xml:lang="en-US" id="id_9004857_1337643_14_1">Payment of 2015 notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSeniorDebt" xlink:to="us-gaap_RepaymentsOfSeniorDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAndResaleAgreementsPolicy" xlink:label="us-gaap_RepurchaseAndResaleAgreementsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAndResaleAgreementsPolicy_lbl" xml:lang="en-US" id="id_9004857_1329247_1_1">Repurchase and Resale Agreements Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAndResaleAgreementsPolicy_lbl" xml:lang="en-US" id="id_9004857_1329247_2_1">State Research and Development Credit Exchange Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAndResaleAgreementsPolicy" xlink:to="us-gaap_RepurchaseAndResaleAgreementsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentCreditsBeginToExpire" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire_lbl" xml:lang="en-US" id="id_9004857_1459417_3_1">Research and Development Credits, Begin to Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire_lbl" xml:lang="en-US" id="id_9004857_1459417_1_1">Research and Development Credits, Begin to Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire_lbl" xml:lang="en-US" id="id_9004857_1459417_2_1">Federal research and development credits begin to expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ResearchAndDevelopmentCreditsBeginToExpire" xlink:to="mnkd_ResearchAndDevelopmentCreditsBeginToExpire_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" id="id_9004857_1341884_1_1">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" id="id_9004857_1341884_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_9004857_1332399_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_9004857_1332399_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_9004857_1332400_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_9004857_1332400_2_1">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentExpensesOffsetAmount" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount_lbl" xml:lang="en-US" id="id_9004857_1383553_3_1">Research And Development Expenses Offset Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount_lbl" xml:lang="en-US" id="id_9004857_1383553_1_1">Research And Development Expenses Offset Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount_lbl" xml:lang="en-US" id="id_9004857_1383553_2_1">Reduction in research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ResearchAndDevelopmentExpensesOffsetAmount" xlink:to="mnkd_ResearchAndDevelopmentExpensesOffsetAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_9004857_1326020_1_1">Cash and Cash Equivalents [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_9004857_1326020_2_1">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_9004857_1332392_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_9004857_1332392_2_1">Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_9004857_1335583_1_1">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_9004857_1335583_2_1">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_9004857_1326026_1_1">Restructuring and Related Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_9004857_1326026_2_1">Restructuring and Related Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332398_1_1">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332398_2_1">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" id="id_9004857_1329273_1_1">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" id="id_9004857_1329273_2_1">Number of employees eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" id="id_9004857_1329274_1_1">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" id="id_9004857_1329274_2_1">Percentage of workforce reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="id_9004857_1343826_1_1">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="id_9004857_1343826_2_1">Costs incurred and charged to expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="id_9004857_1343826_12_1">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_9004857_1335586_1_1">Restructuring Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_9004857_1335586_2_1">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_9004857_1335587_1_1">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_9004857_1335587_2_1">Restructuring Cost and Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_9004857_1337637_1_1">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_9004857_1337637_4_1">Accrual - Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_9004857_1337637_5_1">Accrual - Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_9004857_1337637_2_1">Remaining accrual balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_9004857_1338463_1_1">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_9004857_1338463_2_1">Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_9004857_1338463_12_1">Restructuring liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2" xlink:label="us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveSettledWithoutCash2_lbl" xml:lang="en-US" id="id_9004857_1343836_1_1">Restructuring Reserve, Settled without Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RestructuringReserveSettledWithoutCash2_lbl" xml:lang="en-US" id="id_9004857_1343836_14_1">Costs paid or settled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="us-gaap_RestructuringReserveSettledWithoutCash2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_9004857_1336790_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_9004857_1336790_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1544091_3_1">Revenue Recognition, Bulk Sales [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1544091_1_1">Revenue Recognition, Bulk Sales [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1544091_2_1">Revenue Recognition - Revenue - Bulk Insulin Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" xlink:to="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1332423_1_1">Revenue Recognition, Deferred Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US" id="id_9004857_1332423_2_1">Deferred costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDiscounts" xlink:label="us-gaap_RevenueRecognitionDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDiscounts_lbl" xml:lang="en-US" id="id_9004857_1332424_1_1">Revenue Recognition, Discounts [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionDiscounts_lbl" xml:lang="en-US" id="id_9004857_1332424_2_1">Prompt Pay Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDiscounts" xlink:to="us-gaap_RevenueRecognitionDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:label="us-gaap_RevenueRecognitionMultipleElementArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMultipleElementArrangements_lbl" xml:lang="en-US" id="id_9004857_1332434_1_1">Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMultipleElementArrangements_lbl" xml:lang="en-US" id="id_9004857_1332434_2_1">Revenue Recognition - Net Revenue - Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:to="us-gaap_RevenueRecognitionMultipleElementArrangements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329294_1_1">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329294_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="us-gaap_RevenueRecognitionSalesOfGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionSalesOfGoods_lbl" xml:lang="en-US" id="id_9004857_1335681_1_1">Revenue Recognition, Sales of Goods [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionSalesOfGoods_lbl" xml:lang="en-US" id="id_9004857_1335681_2_1">Revenue Recognition - Net Revenue - Commercial Product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionSalesOfGoods" xlink:to="us-gaap_RevenueRecognitionSalesOfGoods_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_9004857_1329300_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_9004857_1329300_2_1">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReverseStockSplitPolicyTextBlock" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1477665_3_1">Reverse Stock Split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1477665_1_1">Reverse Stock Split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1477665_2_1">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ReverseStockSplitPolicyTextBlock" xlink:to="mnkd_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_9004857_1488534_3_1">Sale Of Common Stock In Underwritten Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_9004857_1488534_1_1">Sale Of Common Stock In Underwritten Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_9004857_1488534_2_1">Number of shares sold in underwritten public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:to="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfIntellectualPropertyPolicyTextBlock" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1410884_3_1">Sale of intellectual property [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1410884_1_1">Sale of Intellectual Property [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1410884_2_1">Sale of intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SaleOfIntellectualPropertyPolicyTextBlock" xlink:to="mnkd_SaleOfIntellectualPropertyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesAndMarketingRelatedExpensesAccrued" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued_lbl" xml:lang="en-US" id="id_9004857_1356487_3_1">Sales And Marketing Related Expenses Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued_lbl" xml:lang="en-US" id="id_9004857_1356487_1_1">Sales And Marketing Related Expenses Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued_lbl" xml:lang="en-US" id="id_9004857_1356487_2_1">Sales and marketing services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SalesAndMarketingRelatedExpensesAccrued" xlink:to="mnkd_SalesAndMarketingRelatedExpensesAccrued_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesReturnPeriod" xlink:label="mnkd_SalesReturnPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SalesReturnPeriod_lbl" xml:lang="en-US" id="id_9004857_1431915_3_1">Sales Return Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SalesReturnPeriod_lbl" xml:lang="en-US" id="id_9004857_1431915_1_1">Sales Return Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SalesReturnPeriod_lbl" xml:lang="en-US" id="id_9004857_1431915_2_1">Sales return right following product expiration in months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SalesReturnPeriod" xlink:to="mnkd_SalesReturnPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_9004857_1337615_1_1">Sales Revenue, Goods, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_9004857_1337615_2_1">Net revenue - commercial product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_9004857_1336770_1_1">Revenue, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_9004857_1336770_2_1">Net revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_9004857_1336770_6_1">Total net revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SanofiAventisMember_lbl" xml:lang="en-US" id="id_9004857_1469303_3_1">Sanofi Aventis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SanofiAventisMember_lbl" xml:lang="en-US" id="id_9004857_1469303_1_1">Sanofi Aventis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SanofiAventisMember_lbl" xml:lang="en-US" id="id_9004857_1469303_2_1">Sanofi-Aventis Deutschland GmbH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SanofiAventisMember" xlink:to="mnkd_SanofiAventisMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_9004857_1326102_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_9004857_1326102_2_1">Scenario Forecast</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_9004857_1329317_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_9004857_1329317_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335618_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335618_2_1">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_9004857_1332472_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_9004857_1332472_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326109_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326109_2_1">Potential Dilutive Securities Outstanding that are Considered Antidilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_9004857_1326121_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_9004857_1326121_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326123_1_1">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326123_2_1">Provision for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329340_1_1">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329340_2_1">Summary of Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329341_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329341_2_1">Components of Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329350_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329350_2_1">Components of Basic and Diluted Net Income (Loss) Per Common Share Computations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332502_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1332502_2_1">Effective Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326137_1_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326137_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesLineItems" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1416542_3_1">Schedule Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1416542_1_1">Schedule Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_9004857_1416542_2_1">Schedule Of Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="mnkd_ScheduleOfIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesTable" xlink:label="mnkd_ScheduleOfIncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1494313_3_1">Schedule Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1494313_1_1">Schedule Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_9004857_1494313_2_1">Schedule Of Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ScheduleOfIncomeTaxesTable" xlink:to="mnkd_ScheduleOfIncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329882_1_1">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329882_2_1">Components of Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333066_1_1">Schedule of Other Assets and Other Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333066_2_1">Accretion of Debt Issuance Cost and Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_9004857_1326167_1_1">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_9004857_1326167_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335722_1_1">Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335722_2_1">Selected Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_9004857_1333077_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_9004857_1333077_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_9004857_1335729_1_1">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_9004857_1335729_2_1">Schedule of Restructuring and Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333080_1_1">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333080_2_1">Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1351181_3_1">Schedule of Share Based Compensation Activity by Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1351181_1_1">Schedule of Share Based Compensation Activity by Category [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1351181_2_1">Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" xlink:to="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333086_1_1">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333086_2_1">Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_9004857_1326186_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_9004857_1326186_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326187_1_1">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326187_2_1">Summary of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333092_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333092_2_1">Summary of Stock Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329921_1_1">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1329921_2_1">Assumptions Used to Calculate Fair Value of Employee Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_9004857_1326191_1_1">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_9004857_1326191_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_9004857_1335783_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_9004857_1335783_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333124_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333124_2_1">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" id="id_9004857_1341922_1_1">Selling and Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" id="id_9004857_1341922_2_1">Selling and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9004857_1341923_1_1">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9004857_1341923_2_1">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9004857_1341923_6_1">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1465733_3_1">Selling General And Administrative Expenses Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1465733_1_1">Selling General And Administrative Expenses Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1465733_2_1">Selling, General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1408670_3_1">Selling General And Administrative Expenses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1408670_1_1">Selling General And Administrative Expenses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US" id="id_9004857_1408670_2_1">Selling General And Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_9004857_1326228_1_1">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_9004857_1326228_2_1">Selling, General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1442740_3_1">Selling General And Administrative Expenses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1442740_1_1">Selling General And Administrative Expenses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable_lbl" xml:lang="en-US" id="id_9004857_1442740_2_1">Selling General And Administrative Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1384796_3_1">Selling General and Administrative Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1384796_1_1">Selling General and Administrative Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US" id="id_9004857_1384796_2_1">Schedule of Selling, General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember_lbl" xml:lang="en-US" id="id_9004857_1373094_3_1">Senior Convertible Notes Due Two Thousand Eighteen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember_lbl" xml:lang="en-US" id="id_9004857_1373094_1_1">Senior Convertible Notes Due Two Thousand Eighteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember_lbl" xml:lang="en-US" id="id_9004857_1373094_2_1">5.75% Senior convertible notes due August 15, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember_lbl" xml:lang="en-US" id="id_9004857_1451439_3_1">Senior convertible notes due two thousand fifteen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember_lbl" xml:lang="en-US" id="id_9004857_1451439_1_1">Senior Convertible Notes Due Two Thousand Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember_lbl" xml:lang="en-US" id="id_9004857_1451439_2_1">Senior convertible notes due August 15, 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesMember" xlink:label="mnkd_SeniorConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SeniorConvertibleNotesMember_lbl" xml:lang="en-US" id="id_9004857_1380739_3_1">Senior Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SeniorConvertibleNotesMember_lbl" xml:lang="en-US" id="id_9004857_1380739_1_1">Senior Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SeniorConvertibleNotesMember_lbl" xml:lang="en-US" id="id_9004857_1380739_2_1">Senior Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SeniorConvertibleNotesMember" xlink:to="mnkd_SeniorConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1340955_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1340955_2_1">Stock compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_9004857_1340955_12_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_9004857_1335813_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_9004857_1335813_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_9004857_1333154_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_9004857_1333154_2_1">Restricted stock vesting rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US" id="id_9004857_1342891_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US" id="id_9004857_1342891_2_1">Total intrinsic value of restricted stock units vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_9004857_1329998_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_9004857_1329998_14_1">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1333179_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1333179_2_1">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_9004857_1335841_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_9004857_1335841_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1333181_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1333181_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9004857_1335842_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9004857_1335842_4_1">Outstanding at December 31, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9004857_1335842_5_1">Outstanding at January 1, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9004857_1335842_2_1">Outstanding Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="id_9004857_1330000_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="id_9004857_1330000_2_1">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1326259_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1326259_4_1">Outstanding at December 31, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1326259_5_1">Outstanding at January 1, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="id_9004857_1333183_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="id_9004857_1333183_2_1">Weighted average grant date fair value Per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_9004857_1335861_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_9004857_1335861_14_1">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_9004857_1343883_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_9004857_1343883_2_1">Fair value of restricted stock units vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1335816_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1335816_2_1">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1326260_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1326260_2_1">Options granted expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9004857_1330003_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9004857_1330003_2_1">Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_9004857_1326262_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_9004857_1326262_2_1">Expected lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" id="id_9004857_1326264_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" id="id_9004857_1326264_2_1">Volatility, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" id="id_9004857_1330004_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" id="id_9004857_1330004_2_1">Volatility, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_9004857_1333184_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_9004857_1333184_2_1">Risk free interest rate, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_9004857_1330007_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_9004857_1330007_2_1">Risk free interest rate, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_9004857_1333156_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_9004857_1333156_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1326266_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_9004857_1326266_2_1">Equity incentive plan, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_9004857_1330011_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_9004857_1330011_2_1">Shares Available for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_9004857_1480978_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_9004857_1480978_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_9004857_1480978_2_1">Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_9004857_1340956_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_9004857_1340956_2_1">Exercisable at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_9004857_1333161_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_9004857_1333161_2_1">Exercisable at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1333162_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1333162_2_1">Exercisable at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9004857_1330012_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9004857_1330012_2_1">Weighted-average remaining contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1342890_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1342890_2_1">Total intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="id_9004857_1326814_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="id_9004857_1326814_14_1">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_9004857_1330013_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_9004857_1330013_14_1">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_9004857_1333165_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_9004857_1333165_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1330014_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9004857_1330014_2_1">Weighted average grant date fair value of the stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1343876_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1343876_4_1">Outstanding at December 31, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1343876_5_1">Outstanding at January 1, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1333167_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1333167_4_1">Outstanding at December 31, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1333167_5_1">Outstanding at January 1, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1333167_2_1">Options to purchase common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1333167_12_1">Outstanding Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_9004857_1326821_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_9004857_1326821_2_1">Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1333169_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1333169_4_1">Outstanding at December 31, 2016</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1333169_5_1">Outstanding at January 1, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_9004857_1326822_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_9004857_1326822_2_1">Weighted Average Exercise Price per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1341928_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_9004857_1341928_2_1">Vested and expected to vest at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1330017_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_9004857_1330017_2_1">Vested and expected to vest at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326828_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326828_2_1">Vested and expected to vest at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1378255_3_1">Share Based Compensation Arrangement Restricted Stock Units Number Of Units Expected To Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1378255_1_1">Share Based Compensation Arrangement Restricted Stock Units Number Of Units Expected To Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1378255_2_1">Restricted stock units expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" xlink:to="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_9004857_1326835_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_9004857_1326835_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326836_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326836_2_1">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326837_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1326837_2_1">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1330022_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1330022_2_1">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1330023_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9004857_1330023_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationAwardTrancheFourMember" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" id="id_9004857_1448981_3_1">Share Based Compensation Award Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" id="id_9004857_1448981_1_1">Share Based Compensation Award Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" id="id_9004857_1448981_2_1">Tranche Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ShareBasedCompensationAwardTrancheFourMember" xlink:to="mnkd_ShareBasedCompensationAwardTrancheFourMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_9004857_1333173_1_1">Share-based Compensation Award, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_9004857_1333173_2_1">Tranche One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" id="id_9004857_1330024_1_1">Share-based Compensation Award, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" id="id_9004857_1330024_2_1">Tranche Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" id="id_9004857_1335846_1_1">Share-based Compensation Award, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" id="id_9004857_1335846_2_1">Tranche Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_9004857_1335856_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_9004857_1335856_2_1">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1335859_1_1">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1335859_4_1">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1335859_5_1">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReservedForEmployeeStockPurchasePlan" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9004857_1499741_3_1">Shares Reserved For Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9004857_1499741_1_1">Shares Reserved For Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9004857_1499741_2_1">Share reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SharesReservedForEmployeeStockPurchasePlan" xlink:to="mnkd_SharesReservedForEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReturnedUnderShareLendingAgreement" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1394614_3_1">Shares Returned Under Share Lending Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1394614_1_1">Shares Returned Under Share Lending Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1394614_2_1">Returned shares of common stock under share lending agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SharesReturnedUnderShareLendingAgreement" xlink:to="mnkd_SharesReturnedUnderShareLendingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326904_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_9004857_1326904_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US" id="id_9004857_1335908_1_1">Standard Product Warranty, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US" id="id_9004857_1335908_2_1">Product Returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_9004857_1335913_1_1">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_9004857_1335913_2_1">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_9004857_1330097_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_9004857_1330097_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_9004857_1330098_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_9004857_1330098_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_9004857_1330099_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_9004857_1330099_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_9004857_1326913_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_9004857_1326913_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_9004857_1333243_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_9004857_1333243_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_9004857_1326914_1_1">Statement of Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_9004857_1326914_2_1">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1330100_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1330100_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_9004857_1333245_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_9004857_1333245_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_9004857_1335914_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_9004857_1335914_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeAxis" xlink:label="mnkd_StockAwardPlanTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockAwardPlanTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1428469_3_1">Stock Award Plan Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockAwardPlanTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1428469_1_1">Stock Award Plan Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockAwardPlanTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1428469_2_1">Stock Award Plan Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockAwardPlanTypeAxis" xlink:to="mnkd_StockAwardPlanTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeDomain" xlink:label="mnkd_StockAwardPlanTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockAwardPlanTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1447476_3_1">Stock Award Plan Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockAwardPlanTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1447476_1_1">Stock Award Plan Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockAwardPlanTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1447476_2_1">Stock Award Plan Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockAwardPlanTypeDomain" xlink:to="mnkd_StockAwardPlanTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337582_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337582_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337582_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9004857_1337582_6_1">Total stockholders' deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1333273_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9004857_1333273_2_1">Stockholders' deficit:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333259_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9004857_1333259_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_9004857_1333262_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_9004857_1333262_2_1">Stock split of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_9004857_1339290_1_1">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_9004857_1339290_2_1">Payment of 2015 notes and interest through issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_9004857_1330107_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_9004857_1330107_2_1">Issuance of common shares pursuant to conversions of certain 2015 note holders (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9004857_1333265_1_1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9004857_1333265_2_1">Issuance of common shares under Employee Stock Purchase Plan (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9004857_1333265_12_1">Shares sold to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1379387_3_1">Stock Issued During Period, Shares, For Debt Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1379387_1_1">Stock Issued During Period, Shares, For Debt Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1379387_2_1">Issuance of common shares pursuant to debt conversions by Deerfield (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodSharesForDebtExchange" xlink:to="mnkd_StockIssuedDuringPeriodSharesForDebtExchange_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9004857_1335930_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9004857_1335930_2_1">Common stock shares sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9004857_1335930_12_1">Issuance of common stock (Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage_lbl" xml:lang="en-US" id="id_9004857_1436810_3_1">Stock Issued During Period Shares New Issues Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage_lbl" xml:lang="en-US" id="id_9004857_1436810_1_1">Stock Issued During Period Shares New Issues Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage_lbl" xml:lang="en-US" id="id_9004857_1436810_2_1">Percentage of shares price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" xlink:to="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_9004857_1330109_1_1">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_9004857_1330109_2_1">Issuance of common shares from the release of restricted stock units (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1484733_3_1">Stock issued during period shares share lending agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1484733_1_1">Stock Issued During Period Shares Share Lending Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1484733_2_1">Issuance of common stock for lender financing fees (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" xlink:to="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9004857_1333270_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9004857_1333270_2_1">Exercise of stock options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9004857_1333270_14_1">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1373304_3_1">Stock Issued During Period Shares Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1373304_1_1">Stock Issued During Period Shares Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1373304_2_1">Issuance of common shares pursuant to warrant exercises (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="mnkd_StockIssuedDuringPeriodSharesWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_9004857_1337578_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_9004857_1337578_2_1">Issuance of common shares pursuant to conversions of certain 2015 notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9004857_1337580_1_1">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9004857_1337580_2_1">Issuance of common shares under Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1451472_3_1">Issuance of common shares pursuant to debt conversions by Deerfield.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1451472_1_1">Stock Issued During Period, Value, For Debt Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange_lbl" xml:lang="en-US" id="id_9004857_1451472_2_1">Issuance of common shares pursuant to debt conversions by Deerfield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodValueForDebtExchange" xlink:to="mnkd_StockIssuedDuringPeriodValueForDebtExchange_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_9004857_1339288_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_9004857_1339288_2_1">Common stock shares sold aggregate price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_9004857_1339288_12_1">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_9004857_1336728_1_1">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_9004857_1336728_2_1">Issuance of common shares from the release of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1516265_3_1">Stock issued during period value share lending agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1516265_1_1">Stock Issued During Period Value Share Lending Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement_lbl" xml:lang="en-US" id="id_9004857_1516265_2_1">Issuance of common stock for lender financing fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" xlink:to="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_9004857_1339284_1_1">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_9004857_1339284_2_1">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1504362_3_1">Stock Issued During Period Value Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1504362_1_1">Stock Issued During Period Value Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises_lbl" xml:lang="en-US" id="id_9004857_1504362_2_1">Issuance of common shares pursuant to warrant exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="mnkd_StockIssuedDuringPeriodValueWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesLineItems" xlink:label="mnkd_StockOptionActivityAndChangesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockOptionActivityAndChangesLineItems_lbl" xml:lang="en-US" id="id_9004857_1399531_3_1">Stock Option Activity And Changes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockOptionActivityAndChangesLineItems_lbl" xml:lang="en-US" id="id_9004857_1399531_1_1">Stock Option Activity And Changes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockOptionActivityAndChangesLineItems_lbl" xml:lang="en-US" id="id_9004857_1399531_2_1">Stock Option Activity And Changes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="mnkd_StockOptionActivityAndChangesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesTable" xlink:label="mnkd_StockOptionActivityAndChangesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockOptionActivityAndChangesTable_lbl" xml:lang="en-US" id="id_9004857_1373163_3_1">Stock Option Activity And Changes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockOptionActivityAndChangesTable_lbl" xml:lang="en-US" id="id_9004857_1373163_1_1">Stock Option Activity And Changes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockOptionActivityAndChangesTable_lbl" xml:lang="en-US" id="id_9004857_1373163_2_1">Stock Option Activity And Changes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockOptionActivityAndChangesTable" xlink:to="mnkd_StockOptionActivityAndChangesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionsGrantedVestingRate" xlink:label="mnkd_StockOptionsGrantedVestingRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_StockOptionsGrantedVestingRate_lbl" xml:lang="en-US" id="id_9004857_1503061_3_1">Stock Options Granted Vesting Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_StockOptionsGrantedVestingRate_lbl" xml:lang="en-US" id="id_9004857_1503061_1_1">Stock Options Granted Vesting Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_StockOptionsGrantedVestingRate_lbl" xml:lang="en-US" id="id_9004857_1503061_2_1">Stock option grants vest exercisable rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_StockOptionsGrantedVestingRate" xlink:to="mnkd_StockOptionsGrantedVestingRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="id_9004857_1333302_1_1">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="id_9004857_1333302_2_1">Shares purchased under ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SubleaseAgreementMember" xlink:label="mnkd_SubleaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1441734_3_1">Sublease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1441734_1_1">Sublease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9004857_1441734_2_1">Sublease Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SubleaseAgreementMember" xlink:to="mnkd_SubleaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_9004857_1326938_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_9004857_1326938_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_9004857_1330134_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_9004857_1330134_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330135_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_9004857_1330135_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335954_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_9004857_1335954_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_9004857_1326939_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_9004857_1326939_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1335955_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_9004857_1335955_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1330136_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_9004857_1330136_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1517992_3_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1517992_1_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9004857_1517992_2_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9004857_1503314_3_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9004857_1503314_1_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9004857_1503314_2_1">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mnkd_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_9004857_1333299_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_9004857_1333299_2_1">SUPPLEMENTAL CASH FLOWS DISCLOSURES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xml:lang="en-US" id="id_9004857_1333320_1_1">Supply Commitment Arrangement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xml:lang="en-US" id="id_9004857_1333320_2_1">Supply Commitment Arrangement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xml:lang="en-US" id="id_9004857_1330148_1_1">Supply Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xml:lang="en-US" id="id_9004857_1330148_2_1">Supply Commitment [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:label="us-gaap_SupplyCommitmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentMember_lbl" xml:lang="en-US" id="id_9004857_1326956_1_1">Supply Commitment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplyCommitmentMember_lbl" xml:lang="en-US" id="id_9004857_1326956_2_1">Supply Commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentMember" xlink:to="us-gaap_SupplyCommitmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TerminationDateOfLicenseAgreement" xlink:label="mnkd_TerminationDateOfLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TerminationDateOfLicenseAgreement_lbl" xml:lang="en-US" id="id_9004857_1439249_3_1">Termination Date Of License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TerminationDateOfLicenseAgreement_lbl" xml:lang="en-US" id="id_9004857_1439249_1_1">Termination Date Of License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TerminationDateOfLicenseAgreement_lbl" xml:lang="en-US" id="id_9004857_1439249_2_1">Termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TerminationDateOfLicenseAgreement" xlink:to="mnkd_TerminationDateOfLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_9004857_1336003_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_9004857_1336003_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ThirdPartyLogisticsMember" xlink:label="mnkd_ThirdPartyLogisticsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ThirdPartyLogisticsMember_lbl" xml:lang="en-US" id="id_9004857_1472762_3_1">Third Party Logistics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ThirdPartyLogisticsMember_lbl" xml:lang="en-US" id="id_9004857_1472762_1_1">Third Party Logistics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ThirdPartyLogisticsMember_lbl" xml:lang="en-US" id="id_9004857_1472762_2_1">Third party logistics</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ThirdPartyLogisticsMember" xlink:to="mnkd_ThirdPartyLogisticsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_9004857_1330194_1_1">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_9004857_1330194_2_1">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_9004857_1330195_1_1">Relationship to Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_9004857_1330195_2_1">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_9004857_1327017_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_9004857_1327017_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheAchievementDate" xlink:label="mnkd_TrancheAchievementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TrancheAchievementDate_lbl" xml:lang="en-US" id="id_9004857_1534957_3_1">Tranche Achievement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TrancheAchievementDate_lbl" xml:lang="en-US" id="id_9004857_1534957_1_1">Tranche Achievement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TrancheAchievementDate_lbl" xml:lang="en-US" id="id_9004857_1534957_2_1">Tranche achievement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TrancheAchievementDate" xlink:to="mnkd_TrancheAchievementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheBMember" xlink:label="mnkd_TrancheBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TrancheBMember_lbl" xml:lang="en-US" id="id_9004857_1387193_3_1">Tranche B</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TrancheBMember_lbl" xml:lang="en-US" id="id_9004857_1387193_1_1">Tranche B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TrancheBMember_lbl" xml:lang="en-US" id="id_9004857_1387193_2_1">Less portion of commitment asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TrancheBMember" xlink:to="mnkd_TrancheBMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheOneMember" xlink:label="mnkd_TrancheOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TrancheOneMember_lbl" xml:lang="en-US" id="id_9004857_1477399_3_1">Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TrancheOneMember_lbl" xml:lang="en-US" id="id_9004857_1477399_1_1">Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TrancheOneMember_lbl" xml:lang="en-US" id="id_9004857_1477399_2_1">Tranche 1 note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TrancheOneMember" xlink:to="mnkd_TrancheOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheThreeMember" xlink:label="mnkd_TrancheThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TrancheThreeMember_lbl" xml:lang="en-US" id="id_9004857_1455824_3_1">Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TrancheThreeMember_lbl" xml:lang="en-US" id="id_9004857_1455824_1_1">Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TrancheThreeMember_lbl" xml:lang="en-US" id="id_9004857_1455824_2_1">Tranche 3 note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TrancheThreeMember" xlink:to="mnkd_TrancheThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheTwoMember" xlink:label="mnkd_TrancheTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TrancheTwoMember_lbl" xml:lang="en-US" id="id_9004857_1488748_3_1">Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TrancheTwoMember_lbl" xml:lang="en-US" id="id_9004857_1488748_1_1">Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TrancheTwoMember_lbl" xml:lang="en-US" id="id_9004857_1488748_2_1">Tranche 2 note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TrancheTwoMember" xlink:to="mnkd_TrancheTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_9004857_1330211_1_1">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_9004857_1330211_2_1">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TransfersFromToParentAbstract" xlink:label="mnkd_TransfersFromToParentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TransfersFromToParentAbstract_lbl" xml:lang="en-US" id="id_9004857_1534349_3_1">Transfers From (To) Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TransfersFromToParentAbstract_lbl" xml:lang="en-US" id="id_9004857_1534349_1_1">Transfers From (To) Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TransfersFromToParentAbstract_lbl" xml:lang="en-US" id="id_9004857_1534349_2_1">Transfers From (To) Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TransfersFromToParentAbstract" xlink:to="mnkd_TransfersFromToParentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentyFifteenRestructuringPlanMember" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1350207_3_1">Twenty Fifteen Restructuring Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1350207_1_1">Twenty Fifteen Restructuring Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1350207_2_1">Twenty Fifteen Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwentyFifteenRestructuringPlanMember" xlink:to="mnkd_TwentyFifteenRestructuringPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentySixteenRestructuringPlanMember" xlink:label="mnkd_TwentySixteenRestructuringPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwentySixteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1530804_3_1">Twenty Sixteen Restructuring Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwentySixteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1530804_1_1">Twenty Sixteen Restructuring Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwentySixteenRestructuringPlanMember_lbl" xml:lang="en-US" id="id_9004857_1530804_2_1">Twenty Sixteen Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwentySixteenRestructuringPlanMember" xlink:to="mnkd_TwentySixteenRestructuringPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandEighteenNotesMember" xlink:label="mnkd_TwoThousandEighteenNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwoThousandEighteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1487319_3_1">Two Thousand Eighteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwoThousandEighteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1487319_1_1">Two Thousand Eighteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwoThousandEighteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1487319_2_1">2018 Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwoThousandEighteenNotesMember" xlink:to="mnkd_TwoThousandEighteenNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFifteenNotesMember" xlink:label="mnkd_TwoThousandFifteenNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1470870_3_1">Two Thousand Fifteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1470870_1_1">Two Thousand Fifteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1470870_2_1">2015 Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwoThousandFifteenNotesMember" xlink:to="mnkd_TwoThousandFifteenNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourEquityIncentivePlanMember" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_9004857_1445632_3_1">Two Thousand Four Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_9004857_1445632_1_1">Two Thousand Four Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_9004857_1445632_2_1">2004 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwoThousandFourEquityIncentivePlanMember" xlink:to="mnkd_TwoThousandFourEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9004857_1503078_3_1">Two Thousand Four Non Employee Directors Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9004857_1503078_1_1">Two Thousand Four Non Employee Directors Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9004857_1503078_2_1">2004 Non Employee Directors Stock Option Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" xlink:to="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_TwoThousandNineteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1466792_3_1">Two Thousand Nineteen Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_TwoThousandNineteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1466792_1_1">Two Thousand Nineteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_TwoThousandNineteenNotesMember_lbl" xml:lang="en-US" id="id_9004857_1466792_2_1">Senior convertible notes due December 31, 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_TwoThousandNineteenNotesMember" xlink:to="mnkd_TwoThousandNineteenNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_9004857_1327036_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_9004857_1327036_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_9004857_1333396_1_1">Type of Restructuring [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_9004857_1333396_2_1">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US" id="id_9004857_1341005_1_1">Unamortized Debt Issuance Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US" id="id_9004857_1341005_2_1">Unamortized debt issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US" id="id_9004857_1341005_14_1">Unaccreted debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UncategorizedAbstract" xlink:label="mnkd_UncategorizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_9004857_1344427_3_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_9004857_1344427_1_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_9004857_1344427_2_1">Uncategorized [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UncategorizedAbstract" xlink:to="mnkd_UncategorizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnderwritersMember" xlink:label="mnkd_UnderwritersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UnderwritersMember_lbl" xml:lang="en-US" id="id_9004857_1436435_3_1">Underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UnderwritersMember_lbl" xml:lang="en-US" id="id_9004857_1436435_1_1">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UnderwritersMember_lbl" xml:lang="en-US" id="id_9004857_1436435_2_1">Underwriters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UnderwritersMember" xlink:to="mnkd_UnderwritersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldByUnderwritingPrice" xlink:label="mnkd_UnitsSoldByUnderwritingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UnitsSoldByUnderwritingPrice_lbl" xml:lang="en-US" id="id_9004857_1438210_3_1">Units sold by underwriting price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UnitsSoldByUnderwritingPrice_lbl" xml:lang="en-US" id="id_9004857_1438210_1_1">Units Sold By Underwriting Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UnitsSoldByUnderwritingPrice_lbl" xml:lang="en-US" id="id_9004857_1438210_2_1">Purchased Price of the units by underwriters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UnitsSoldByUnderwritingPrice" xlink:to="mnkd_UnitsSoldByUnderwritingPrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwritten" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten_lbl" xml:lang="en-US" id="id_9004857_1486718_3_1">Units sold under public offer underwritten.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten_lbl" xml:lang="en-US" id="id_9004857_1486718_1_1">Units Sold Under Public Offer Underwritten</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten_lbl" xml:lang="en-US" id="id_9004857_1486718_2_1">Number of Unit Sold in an Underwritten public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UnitsSoldUnderPublicOfferUnderwritten" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwritten_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription_lbl" xml:lang="en-US" id="id_9004857_1501101_3_1">Units sold under public offer underwritten composition description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription_lbl" xml:lang="en-US" id="id_9004857_1501101_1_1">Units Sold Under Public Offer Underwritten Composition Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription_lbl" xml:lang="en-US" id="id_9004857_1501101_2_1">Units sold composition description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock_lbl" xml:lang="en-US" id="id_9004857_1490870_3_1">Units sold warrant portion convertible into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock_lbl" xml:lang="en-US" id="id_9004857_1490870_1_1">Units Sold Warrant Portion Convertible Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock_lbl" xml:lang="en-US" id="id_9004857_1490870_2_1">Warrant to purchase of a share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" xlink:to="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpfrontFee" xlink:label="mnkd_UpfrontFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UpfrontFee_lbl" xml:lang="en-US" id="id_9004857_1456632_3_1">Upfront Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UpfrontFee_lbl" xml:lang="en-US" id="id_9004857_1456632_1_1">Upfront Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UpfrontFee_lbl" xml:lang="en-US" id="id_9004857_1456632_2_1">Up-front fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UpfrontFee" xlink:to="mnkd_UpfrontFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpFrontPaymentMember" xlink:label="mnkd_UpFrontPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_UpFrontPaymentMember_lbl" xml:lang="en-US" id="id_9004857_1507406_3_1">Up Front Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_UpFrontPaymentMember_lbl" xml:lang="en-US" id="id_9004857_1507406_1_1">Up Front Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_UpFrontPaymentMember_lbl" xml:lang="en-US" id="id_9004857_1507406_2_1">Up Front Payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_UpFrontPaymentMember" xlink:to="mnkd_UpFrontPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_9004857_1333430_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_9004857_1333430_2_1">Financial Statement Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValenciaMember" xlink:label="mnkd_ValenciaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ValenciaMember_lbl" xml:lang="en-US" id="id_9004857_1353762_3_1">Valencia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ValenciaMember_lbl" xml:lang="en-US" id="id_9004857_1353762_1_1">Valencia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ValenciaMember_lbl" xml:lang="en-US" id="id_9004857_1353762_2_1">Valencia</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ValenciaMember" xlink:to="mnkd_ValenciaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_9004857_1336678_1_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_9004857_1336678_2_1">Change in the valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" id="id_9004857_1327094_1_1">Valuation Technique [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" id="id_9004857_1327094_2_1">Valuation Technique [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" id="id_9004857_1330326_1_1">Valuation Technique [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" id="id_9004857_1330326_2_1">Valuation Technique [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValueOfRestrictedStockUnitsVested" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested_lbl" xml:lang="en-US" id="id_9004857_1402071_3_1">Value of Restricted Stock Units Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested_lbl" xml:lang="en-US" id="id_9004857_1402071_1_1">Value of Restricted Stock Units Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested_lbl" xml:lang="en-US" id="id_9004857_1402071_2_1">Total intrinsic value of restricted stock units expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_ValueOfRestrictedStockUnitsVested" xlink:to="mnkd_ValueOfRestrictedStockUnitsVested_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_9004857_1333456_1_1">Variable Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_9004857_1333456_2_1">Variable Rate [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_9004857_1333457_1_1">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_9004857_1333457_2_1">Variable Rate [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_9004857_1336123_1_1">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_9004857_1336123_2_1">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_9004857_1336124_1_1">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_9004857_1336124_2_1">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantIssuanceCosts" xlink:label="mnkd_WarrantIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WarrantIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1532394_3_1">Warrant Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WarrantIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1532394_1_1">Warrant Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WarrantIssuanceCosts_lbl" xml:lang="en-US" id="id_9004857_1532394_2_1">Series A Warrant issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WarrantIssuanceCosts" xlink:to="mnkd_WarrantIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1359335_3_1">Warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1359335_1_1">Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_9004857_1359335_2_1">Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WarrantLiabilityMember" xlink:to="mnkd_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_9004857_1336129_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_9004857_1336129_2_1">Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsExercisableExpirationPeriod" xlink:label="mnkd_WarrantsExercisableExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WarrantsExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1507943_3_1">Warrants exercisable expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WarrantsExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1507943_1_1">Warrants Exercisable Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WarrantsExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_9004857_1507943_2_1">Duration for Expiration of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WarrantsExercisableExpirationPeriod" xlink:to="mnkd_WarrantsExercisableExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsPolicyTextBlock" xlink:label="mnkd_WarrantsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1425256_3_1">Warrants Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1425256_1_1">Warrants [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1425256_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WarrantsPolicyTextBlock" xlink:to="mnkd_WarrantsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1353624_3_1">Weighted average grant date fair value of restricted stock units expected to vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1353624_1_1">Weighted Average Grant Date Fair Value Of Restricted Stock Units Expected To Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest_lbl" xml:lang="en-US" id="id_9004857_1353624_2_1">Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" xlink:to="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327121_1_1">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327121_2_1">Shares used to compute diluted net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327121_6_1">Adjusted weighted average common shares (denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9004857_1327121_12_1">Weighted average common shares used to compute diluted net income (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_9004857_1330297_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_9004857_1330297_2_1">Weighted average common shares used to compute basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9004857_1327124_1_1">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9004857_1327124_32_1">Weighted average common shares (denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9004857_1327124_33_1">Weighted average common shares used to compute basic net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9004857_1327124_2_1">Shares used to compute basic net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9004857_1327124_12_1">Weighted average common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WholesalerDistributionFeesPolicyTextBlock" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535382_3_1">Wholesaler Distribution Fees [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535382_1_1">Wholesaler Distribution Fees [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9004857_1535382_2_1">Wholesaler Distribution Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WholesalerDistributionFeesPolicyTextBlock" xlink:to="mnkd_WholesalerDistributionFeesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfCommitmentAsset" xlink:label="mnkd_WriteOffOfCommitmentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WriteOffOfCommitmentAsset_lbl" xml:lang="en-US" id="id_9004857_1346803_3_1">Write Off of Commitment Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WriteOffOfCommitmentAsset_lbl" xml:lang="en-US" id="id_9004857_1346803_1_1">Write Off of Commitment Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mnkd_WriteOffOfCommitmentAsset_lbl" xml:lang="en-US" id="id_9004857_1346803_2_1">Write-off of Tranche B commitment asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WriteOffOfCommitmentAsset" xlink:to="mnkd_WriteOffOfCommitmentAsset_lbl"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfDerivativeLiability" xlink:label="mnkd_WriteOffOfDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mnkd_WriteOffOfDerivativeLiability_lbl" xml:lang="en-US" id="id_9004857_1347955_3_1">Write Off of Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mnkd_WriteOffOfDerivativeLiability_lbl" xml:lang="en-US" id="id_9004857_1347955_1_1">Write Off of Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mnkd_WriteOffOfDerivativeLiability_lbl" xml:lang="en-US" id="id_9004857_1347955_14_1">Write-off of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnkd_WriteOffOfDerivativeLiability" xlink:to="mnkd_WriteOffOfDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="exch_XTAE_lbl" xml:lang="en-US" id="id_9004857_1326373_1_1">TEL AVIV STOCK EXCHANGE [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="exch_XTAE_lbl" xml:lang="en-US" id="id_9004857_1326373_2_1">TEL AVIV STOCK EXCHANGE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_XTAE" xlink:to="exch_XTAE_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>mnkd-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 9 -->
<!-- Creation date: 2017-03-16T20:03:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfInventories" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRelatedPartyArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfBorrowings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureBorrowingsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCollaborativeArrangementAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstrumentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommonAndPreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureNetIncomeLossPerCommonShareAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockAwardPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedAwardPlans" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureFairValueOfEmployeeStockOptionsAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfStockOptionsOutstanding" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureAnnualPurchaseRequirementsUnderContract" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureProvisionForIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureEffectiveIncomeTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureRestructuringChargesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommonAndPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mnkd-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DocumentAndEntityInformationAbstract" xlink:label="mnkd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestNoncurrent" xlink:label="mnkd_AccruedInterestNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeCreditCurrent" xlink:label="mnkd_DeferredCollaborativeCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCollaborativeRevenueCurrent" xlink:label="mnkd_DeferredCollaborativeRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" xlink:label="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationCurrent" xlink:label="mnkd_PurchaseObligationCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationNoncurrent" xlink:label="mnkd_PurchaseObligationNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherDeferredCostsNet" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_AccruedInterestNoncurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LossContingencyAccrualCarryingValueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_PurchaseObligationNoncurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLongTermDebtCurrent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_DeferredCollaborativeCreditCurrent" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_DeferredCollaborativeRevenueCurrent" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnkd_PurchaseObligationCurrent" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CostsOfRevenueCollaboration" xlink:label="mnkd_CostsOfRevenueCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromBulkInsulin" xlink:label="mnkd_NetRevenueFromBulkInsulin"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="mnkd_CostsOfRevenueCollaboration" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mnkd_NetRevenueFromBulkInsulin" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome" xlink:title="148400 - Statement - Statement of Comprehensive Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" xlink:label="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" xlink:label="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementValue" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="mnkd_DeficitAccumulatedDuringDevelopmentStageMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodSharesForDebtExchange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueForDebtExchange" xlink:label="mnkd_StockIssuedDuringPeriodValueForDebtExchange"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" xlink:label="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="mnkd_StockIssuedDuringPeriodValueWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnkd_DeficitAccumulatedDuringDevelopmentStageMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesWarrantExercises" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueWarrantExercises" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesForDebtExchange" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueForDebtExchange" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountContributions" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_StockIssuedDuringPeriodValueShareLendingAgreement" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" order="1.3100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementValue" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.3500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_EntityListingsExchangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ChangeInFairValueOfWarrantLiability" xlink:label="mnkd_ChangeInFairValueOfWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossOnPurchaseCommitments" xlink:label="mnkd_GainLossOnPurchaseCommitments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" xlink:label="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInOtherDeferredCharges" xlink:label="mnkd_IncreaseDecreaseInOtherDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" xlink:label="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterestOnNotePayableToPrincipalStockholder" xlink:label="mnkd_InterestOnNotePayableToPrincipalStockholder"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansAssumed1" xlink:label="us-gaap_LoansAssumed1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePayments" xlink:label="mnkd_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" xlink:label="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantIssuanceCosts" xlink:label="mnkd_WarrantIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfCommitmentAsset" xlink:label="mnkd_WriteOffOfCommitmentAsset"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WriteOffOfDerivativeLiability" xlink:label="mnkd_WriteOffOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_ChangeInFairValueOfWarrantLiability" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_InterestOnNotePayableToPrincipalStockholder" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WarrantIssuanceCosts" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.2200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_GainLossOnPurchaseCommitments" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WriteOffOfCommitmentAsset" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnkd_WriteOffOfDerivativeLiability" order="1.2700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.3100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInOtherDeferredCharges" order="1.3200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.3300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.3400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.3500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnkd_IncreaseDecreaseInPurchaseCommitmentLoss" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.4400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.4600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="1.4900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1.5000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="mnkd_MilestonePayments" order="1.5300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.5500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.5600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.5700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.5800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.5900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.6000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.6100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.6200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.6300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.6400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.6500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.6600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.6700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_LoansAssumed1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_EntityListingsExchangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AventisubLlcMember" xlink:label="mnkd_AventisubLlcMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InsulinMember" xlink:label="mnkd_InsulinMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanArrangementMember" xlink:label="mnkd_LoanArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheBMember" xlink:label="mnkd_TrancheBMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpfrontFee" xlink:label="mnkd_UpfrontFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheBMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_AventisubLlcMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="us-gaap_PutOptionMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_UpfrontFee" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_OpenOptionContractsWrittenTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ProductOrServiceAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_CreditFacilityAxis" order="19.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_InsulinMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LoanArrangementMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesIntellectualProperty" xlink:label="mnkd_AccruedExpensesIntellectualProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CashDiscountPercent" xlink:label="mnkd_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsiderationReceived" xlink:label="mnkd_ConsiderationReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredCostRelatedToSaleOfRawInsulin" xlink:label="mnkd_DeferredCostRelatedToSaleOfRawInsulin"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredRevenueFromSaleOfRawInsulin" xlink:label="mnkd_DeferredRevenueFromSaleOfRawInsulin"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EstimatedAmountsCreditExchangeReceivable" xlink:label="mnkd_EstimatedAmountsCreditExchangeReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MaturityPeriodOfCashEquivalents" xlink:label="mnkd_MaturityPeriodOfCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCreditExchangeReceivable" xlink:label="mnkd_PercentageOfCreditExchangeReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustments" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustments"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" xlink:label="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesReturnPeriod" xlink:label="mnkd_SalesReturnPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:label="mnkd_SummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ThirdPartyLogisticsMember" xlink:label="mnkd_ThirdPartyLogisticsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnkd_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mnkd_ThirdPartyLogisticsMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_SalesReturnPeriod" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_CashDiscountPercent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_DeferredRevenueFromSaleOfRawInsulin" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_DeferredCostRelatedToSaleOfRawInsulin" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_MaturityPeriodOfCashEquivalents" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_PercentageOfCreditExchangeReceivable" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_ConsiderationReceived" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_AccruedExpensesIntellectualProperty" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mnkd_EstimatedAmountsCreditExchangeReceivable" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InterestCostsCapitalized" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ProductOrServiceAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mnkd_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputerEquipmentAndSoftwareMember" xlink:label="mnkd_ComputerEquipmentAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="mnkd_FurnitureFixturesAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_FurnitureFixturesAndOfficeEquipmentMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_ComputerEquipmentAndSoftwareMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetHeldForSaleMember" xlink:label="mnkd_AssetHeldForSaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DanburyFacilityMember" xlink:label="mnkd_DanburyFacilityMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:label="mnkd_DepreciationAndOtherAmortizationExpensesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfAssetGroups" xlink:label="mnkd_NumberOfAssetGroups"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PropertyAndEquipmentImpairmentMember" xlink:label="mnkd_PropertyAndEquipmentImpairmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValenciaMember" xlink:label="mnkd_ValenciaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="mnkd_NumberOfAssetGroups" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DepreciationAndOtherAmortizationExpensesTable" xlink:to="mnkd_DepreciationAndOtherAmortizationExpensesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="mnkd_PropertyAndEquipmentImpairmentMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="mnkd_AssetHeldForSaleMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="mnkd_ValenciaMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="mnkd_DepreciationAndOtherAmortizationExpensesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_DanburyFacilityMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CustomerDiscountsAndAllowances" xlink:label="mnkd_CustomerDiscountsAndAllowances"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SalesAndMarketingRelatedExpensesAccrued" xlink:label="mnkd_SalesAndMarketingRelatedExpensesAccrued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_SalesAndMarketingRelatedExpensesAccrued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="mnkd_CustomerDiscountsAndAllowances" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_ConstructionPayableCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mnkd_AccruedExpensesAndOtherCurrentLiabilitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccruedInterestOfRelatedPartyDebt" xlink:label="mnkd_AccruedInterestOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AlfredMannFoundationMember" xlink:label="mnkd_AlfredMannFoundationMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AmendedAgreementMember" xlink:label="mnkd_AmendedAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AreaOfOfficeSpaceLeased" xlink:label="mnkd_AreaOfOfficeSpaceLeased"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AvailableLoanBalanceCancelled" xlink:label="mnkd_AvailableLoanBalanceCancelled"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:label="mnkd_LeaseAgreementTypeOfAgreementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:label="mnkd_LeaseAgreementTypeOfAgreementDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LeaseExpirationMonthYear" xlink:label="mnkd_LeaseExpirationMonthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LetterOfAgreementMember" xlink:label="mnkd_LetterOfAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanAgreementWithRelatedParty" xlink:label="mnkd_LoanAgreementWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanArrangementMember" xlink:label="mnkd_LoanArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NumberOfMonthsAdvancesOutstanding" xlink:label="mnkd_NumberOfMonthsAdvancesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OfficeLeaseExpense" xlink:label="mnkd_OfficeLeaseExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForUseOfAircrafts" xlink:label="mnkd_PaymentsForUseOfAircrafts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyDebtMember" xlink:label="mnkd_RelatedPartyDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" xlink:label="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyTransactionPrepaymentPeriod" xlink:label="mnkd_RelatedPartyTransactionPrepaymentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SubleaseAgreementMember" xlink:label="mnkd_SubleaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_LeaseAgreementTypeOfAgreementAxis" xlink:to="mnkd_LeaseAgreementTypeOfAgreementDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_LeaseAgreementTypeOfAgreementDomain" xlink:to="mnkd_SubleaseAgreementMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mnkd_RelatedPartyDebtMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LoanArrangementMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_AlfredMannFoundationMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_AmendedAgreementMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mnkd_LetterOfAgreementMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_LoanAgreementWithRelatedParty" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_RelatedPartyTransactionDebtInstrumentPrepayment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_NumberOfMonthsAdvancesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_RelatedPartyTransactionPrepaymentPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AvailableLoanBalanceCancelled" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AccruedInterestOfRelatedPartyDebt" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_AreaOfOfficeSpaceLeased" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_LeaseExpirationMonthYear" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_OfficeLeaseExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mnkd_PaymentsForUseOfAircrafts" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VariableRateAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="mnkd_LeaseAgreementTypeOfAgreementAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsAxis" xlink:label="mnkd_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DanburyFacilityMember" xlink:label="mnkd_DanburyFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DebtInstrumentDateOfLastRequiredPayment" xlink:label="mnkd_DebtInstrumentDateOfLastRequiredPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityAgreementMember" xlink:label="mnkd_FacilityAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" xlink:label="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="us-gaap_OtherShortTermBorrowings"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentForContingentLiabilities" xlink:label="mnkd_PaymentForContingentLiabilities"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrincipalAmountPerShare" xlink:label="mnkd_PrincipalAmountPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheBMember" xlink:label="mnkd_TrancheBMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheOneMember" xlink:label="mnkd_TrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheThreeMember" xlink:label="mnkd_TrancheThreeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheTwoMember" xlink:label="mnkd_TrancheTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandEighteenNotesMember" xlink:label="mnkd_TwoThousandEighteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFifteenNotesMember" xlink:label="mnkd_TwoThousandFifteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AgreementsDomain" xlink:to="mnkd_FacilityAgreementMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheBMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheOneMember" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheTwoMember" order="1.5300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_TrancheThreeMember" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_DebtInstrumentDateOfLastRequiredPayment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_ContingentLiability" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherShortTermBorrowings" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_PaymentForContingentLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueInputsEntityCreditRisk" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherLongTermDebt" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mnkd_PrincipalAmountPerShare" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionDescription" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_TwoThousandEighteenNotesMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_TwoThousandFifteenNotesMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="mnkd_AgreementsAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mnkd_DanburyFacilityMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AventisubLlcMember" xlink:label="mnkd_AventisubLlcMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InsulinMember" xlink:label="mnkd_InsulinMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossSharingAgreementAmount" xlink:label="mnkd_LossSharingAgreementAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentOneMember" xlink:label="mnkd_MilestonePaymentOneMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestonePaymentTwoMember" xlink:label="mnkd_MilestonePaymentTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MortgageLoanMember" xlink:label="mnkd_MortgageLoanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:label="us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:label="us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossSharingMember" xlink:label="mnkd_OperatingLossSharingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PotentialMilestonePaymentsToBeReceived" xlink:label="mnkd_PotentialMilestonePaymentsToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" xlink:label="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProfitLossSharingAgreementAllocationPercentage" xlink:label="mnkd_ProfitLossSharingAgreementAllocationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReceptorLifeScienceIncMember" xlink:label="mnkd_ReceptorLifeScienceIncMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecognitionPeriodForDeferredRevenue" xlink:label="mnkd_RecognitionPeriodForDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentExpensesOffsetAmount" xlink:label="mnkd_ResearchAndDevelopmentExpensesOffsetAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TerminationDateOfLicenseAgreement" xlink:label="mnkd_TerminationDateOfLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UpFrontPaymentMember" xlink:label="mnkd_UpFrontPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_ReceptorLifeScienceIncMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="mnkd_OperatingLossSharingMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ResearchAndDevelopmentExpensesOffsetAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_RecognitionPeriodForDeferredRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_ProfitLossSharingAgreementAllocationPercentage" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_TerminationDateOfLicenseAgreement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_PotentialMilestonePaymentsToBeReceived" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCosts" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mnkd_LossSharingAgreementAmount" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnkd_MortgageLoanMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_AventisubLlcMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="us-gaap_OpenOptionContractsWrittenTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="us-gaap_PutOptionMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_UpFrontPaymentMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_MilestonePaymentOneMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_MilestonePaymentTwoMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mnkd_InsulinMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_OpenOptionContractsWrittenTypeAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:label="mnkd_FairValueOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FairValueOfFinancialInstrumentsTable" xlink:label="mnkd_FairValueOfFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LoanFacilityForgivenDate" xlink:label="mnkd_LoanFacilityForgivenDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember" xlink:label="us-gaap_MarketApproachValuationTechniqueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandNineteenNotesMember" xlink:label="mnkd_TwoThousandNineteenNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="mnkd_FairValueOfFinancialInstrumentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_ContingentLiability" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="mnkd_LoanFacilityForgivenDate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_CreditFacilityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="dei_LegalEntityAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_RangeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_FairValueOfFinancialInstrumentsTable" xlink:to="mnkd_FairValueOfFinancialInstrumentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_TwoThousandNineteenNotesMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_MarketApproachValuationTechniqueMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_FacilityFinancingObligationMember" xlink:label="mnkd_FacilityFinancingObligationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesMember" xlink:label="mnkd_SeniorConvertibleNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CreditFacilityAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_FacilityFinancingObligationMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_2"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" xlink:label="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForFinancialAssets" xlink:label="mnkd_PaymentsForFinancialAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TransfersFromToParentAbstract" xlink:label="mnkd_TransfersFromToParentAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mnkd_PaymentsForFinancialAssets" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_TransfersFromToParentAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassAWarrantsMember" xlink:label="mnkd_ClassAWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassBWarrantsMember" xlink:label="mnkd_ClassBWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisablePeriod" xlink:label="mnkd_ClassOfWarrantExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" xlink:label="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantsOrRightsExpirationDate" xlink:label="mnkd_ClassOfWarrantsOrRightsExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyAxis" xlink:label="mnkd_CommonStockIssuedToByPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockIssuedToByPartyDomain" xlink:label="mnkd_CommonStockIssuedToByPartyDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonStockLoanedUnderShareLendingAgreementShares" xlink:label="mnkd_CommonStockLoanedUnderShareLendingAgreementShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DirectOfferingMember" xlink:label="mnkd_DirectOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NominalLendingFee" xlink:label="mnkd_NominalLendingFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PublicMember" xlink:label="mnkd_PublicMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RegisteredOfferingMember" xlink:label="mnkd_RegisteredOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RelatedPartyMember" xlink:label="mnkd_RelatedPartyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" xlink:label="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReturnedUnderShareLendingAgreement" xlink:label="mnkd_SharesReturnedUnderShareLendingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" xlink:label="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UncategorizedAbstract" xlink:label="mnkd_UncategorizedAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnderwritersMember" xlink:label="mnkd_UnderwritersMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldByUnderwritingPrice" xlink:label="mnkd_UnitsSoldByUnderwritingPrice"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwritten" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwritten"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" xlink:label="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" xlink:label="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantLiabilityMember" xlink:label="mnkd_WarrantLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsExercisableExpirationPeriod" xlink:label="mnkd_WarrantsExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd#exch_XTAE" xlink:label="exch_XTAE"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_RegisteredOfferingMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_DirectOfferingMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantExercisablePeriod" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_CommonStockLoanedUnderShareLendingAgreementShares" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_NominalLendingFee" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_SharesReturnedUnderShareLendingAgreement" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwritten" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_UnitsSoldByUnderwritingPrice" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_WarrantsExercisableExpirationPeriod" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mnkd_ClassOfWarrantsOrRightsExpirationDate" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassAWarrantsMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassBWarrantsMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommonStockIssuedToByPartyAxis" xlink:to="mnkd_CommonStockIssuedToByPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommonStockIssuedToByPartyDomain" xlink:to="mnkd_UnderwritersMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommonStockIssuedToByPartyDomain" xlink:to="mnkd_PublicMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XTAE" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mnkd_RelatedPartyMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_EntityListingsExchangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="mnkd_CommonStockIssuedToByPartyAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="mnkd_WarrantLiabilityMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_UncategorizedAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareLineItems" xlink:label="mnkd_NetIncomeLossPerCommonShareLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetIncomeLossPerCommonShareTable" xlink:label="mnkd_NetIncomeLossPerCommonShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesOutstanding" xlink:label="us-gaap_OwnshareLendingArrangementSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mnkd_NetIncomeLossPerCommonShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_NetIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_OwnshareLendingArrangementSharesOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_NetIncomeLossPerCommonShareTable" xlink:to="mnkd_NetIncomeLossPerCommonShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ComputationOfEarningsPerShareLineItems" xlink:label="mnkd_ComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EarningsPerShareTable" xlink:label="mnkd_EarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mnkd_EarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_EarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_EarningsPerShareTable" xlink:to="mnkd_ComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsultantMember" xlink:label="mnkd_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" xlink:label="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeStockPurchasePlansMember" xlink:label="mnkd_EmployeeStockPurchasePlansMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfCommonStockSharesOutstanding" xlink:label="mnkd_PercentageOfCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PercentageOfShareReservedForShareBasedCompensation" xlink:label="mnkd_PercentageOfShareReservedForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" xlink:label="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationAwardTrancheFourMember" xlink:label="mnkd_ShareBasedCompensationAwardTrancheFourMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SharesReservedForEmployeeStockPurchasePlan" xlink:label="mnkd_SharesReservedForEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeAxis" xlink:label="mnkd_StockAwardPlanTypeAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockAwardPlanTypeDomain" xlink:label="mnkd_StockAwardPlanTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionsGrantedVestingRate" xlink:label="mnkd_StockOptionsGrantedVestingRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TrancheAchievementDate" xlink:label="mnkd_TrancheAchievementDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ValueOfRestrictedStockUnitsVested" xlink:label="mnkd_ValueOfRestrictedStockUnitsVested"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" xlink:label="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EquityIncentivePlanTwentyThirteenMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EmployeeStockPurchasePlansMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="mnkd_StockAwardPlanTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_SharesReservedForEmployeeStockPurchasePlan" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_PercentageOfCommonStockSharesOutstanding" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_PercentageOfShareReservedForShareBasedCompensation" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_StockOptionsGrantedVestingRate" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_ValueOfRestrictedStockUnitsVested" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnkd_TrancheAchievementDate" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockAwardPlanTypeAxis" xlink:to="mnkd_StockAwardPlanTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockAwardPlanTypeDomain" xlink:to="mnkd_ConsultantMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="mnkd_ShareBasedCompensationAwardTrancheFourMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EquityIncentivePlanTwentyThirteenMember" xlink:label="mnkd_EquityIncentivePlanTwentyThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourEquityIncentivePlanMember" xlink:label="mnkd_TwoThousandFourEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" xlink:label="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_TwoThousandFourEquityIncentivePlanMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_EquityIncentivePlanTwentyThirteenMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ConsultantMember" xlink:label="mnkd_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EmployeeMember" xlink:label="mnkd_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mnkd_EmployeeMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mnkd_ConsultantMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TransfersFromToParentAbstract" xlink:label="mnkd_TransfersFromToParentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_TransfersFromToParentAbstract" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesLineItems" xlink:label="mnkd_StockOptionActivityAndChangesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_StockOptionActivityAndChangesTable" xlink:label="mnkd_StockOptionActivityAndChangesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mnkd_StockOptionActivityAndChangesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesLineItems" xlink:to="mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_StockOptionActivityAndChangesTable" xlink:to="mnkd_StockOptionActivityAndChangesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsAxis" xlink:label="mnkd_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AgreementsDomain" xlink:label="mnkd_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BeforeAmendmentMember" xlink:label="mnkd_BeforeAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesLineItems" xlink:label="mnkd_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommitmentsAndContingenciesTable" xlink:label="mnkd_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ContingentLiability" xlink:label="mnkd_ContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeerfieldManagementCompanyLpMember" xlink:label="mnkd_DeerfieldManagementCompanyLpMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentCancellationFees" xlink:label="mnkd_LongTermPurchaseCommitmentCancellationFees"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongTermPurchaseCommitmentExpirationDate" xlink:label="mnkd_LongTermPurchaseCommitmentExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" xlink:label="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MilestoneRightsLiabilityMember" xlink:label="mnkd_MilestoneRightsLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:label="us-gaap_SupplyCommitmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AgreementsAxis" xlink:to="mnkd_AgreementsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_AgreementsDomain" xlink:to="mnkd_BeforeAmendmentMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="mnkd_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_ContingentLiability" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongTermPurchaseCommitmentCancellationFees" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongTermPurchaseCommitmentExpirationDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="mnkd_LongtermPurchaseCommitmentRenewalTimePeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="mnkd_AgreementsAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_CommitmentsAndContingenciesTable" xlink:to="mnkd_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnkd_MilestoneRightsLiabilityMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_DeerfieldManagementCompanyLpMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSeventhYear" xlink:label="mnkd_PurchaseObligationDueInSeventhYear"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PurchaseObligationDueInSixthYear" xlink:label="mnkd_PurchaseObligationDueInSixthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInFourthYear" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationDueInFifthYear" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="mnkd_PurchaseObligationDueInSixthYear" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="mnkd_PurchaseObligationDueInSeventhYear" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:label="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxExpenseBenefitNet" xlink:label="mnkd_IncomeTaxExpenseBenefitNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" xlink:to="mnkd_IncomeTaxExpenseBenefitNet" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesTable" xlink:to="mnkd_IncomeTaxesProvisionBenefitSummaryOfIncomeTaxesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedCosts" xlink:label="mnkd_DeferredTaxAssetsCapitalizedCosts"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" xlink:label="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLineItems" xlink:label="mnkd_DeferredTaxAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" xlink:label="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsMilestoneRights" xlink:label="mnkd_DeferredTaxAssetsMilestoneRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTable" xlink:label="mnkd_DeferredTaxAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" xlink:label="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsCapitalizedResearchExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsMilestoneRights" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsLossOnPurchaseCommitment" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="mnkd_DeferredTaxAssetsCapitalizedCosts" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DeferredTaxAssetsLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DeferredTaxAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_DeferredTaxAssetsTable" xlink:to="mnkd_DeferredTaxAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mnkd_DeferredTaxAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" xlink:label="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesLineItems" xlink:label="mnkd_IncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_IncomeTaxesTable" xlink:label="mnkd_IncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardAnnualLimitation" xlink:label="mnkd_NetOperatingLossCarryforwardAnnualLimitation"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetOperatingLossCarryforwardsBeginsToExpire" xlink:label="mnkd_NetOperatingLossCarryforwardsBeginsToExpire"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_OperatingLossCarryforwardsSubjectToLimitation" xlink:label="mnkd_OperatingLossCarryforwardsSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ResearchAndDevelopmentCreditsBeginToExpire" xlink:label="mnkd_ResearchAndDevelopmentCreditsBeginToExpire"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mnkd_IncomeTaxesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_DeferredTaxAssetIncreaseDecreaseInEquity" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_NetOperatingLossCarryforwardsBeginsToExpire" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_OperatingLossCarryforwardsSubjectToLimitation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_NetOperatingLossCarryforwardAnnualLimitation" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesLineItems" xlink:to="mnkd_ResearchAndDevelopmentCreditsBeginToExpire" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_IncomeTaxesTable" xlink:to="mnkd_IncomeTaxesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesLineItems" xlink:label="mnkd_ScheduleOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfIncomeTaxesTable" xlink:label="mnkd_ScheduleOfIncomeTaxesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mnkd_ScheduleOfIncomeTaxesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_ScheduleOfIncomeTaxesTable" xlink:to="mnkd_ScheduleOfIncomeTaxesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassAWarrantsMember" xlink:label="mnkd_ClassAWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassBWarrantsMember" xlink:label="mnkd_ClassBWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExercised" xlink:label="mnkd_ClassOfWarrantOrRightExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mnkd_ClassOfWarrantOrRightExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" xlink:label="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsValuationTechniques" xlink:label="us-gaap_FairValueMeasurementsValuationTechniques"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RegisteredOfferingMember" xlink:label="mnkd_RegisteredOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" xlink:label="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_UncategorizedAbstract" xlink:label="mnkd_UncategorizedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_RegisteredOfferingMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassAWarrantsMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnkd_ClassBWarrantsMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_SaleOfCommonStockInUnderwrittenPublicOffering" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightExpirationPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnkd_ClassOfWarrantOrRightExercised" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueMeasurementsValuationTechniques" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_UncategorizedAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_SellingGeneralAndAdministrativeExpensesTable" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentyFifteenRestructuringPlanMember" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentySixteenRestructuringPlanMember" xlink:label="mnkd_TwentySixteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentySixteenRestructuringPlanMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentyFifteenRestructuringPlanMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2" xlink:label="us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentyFifteenRestructuringPlanMember" xlink:label="mnkd_TwentyFifteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_TwentySixteenRestructuringPlanMember" xlink:label="mnkd_TwentySixteenRestructuringPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveSettledWithoutCash2" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentySixteenRestructuringPlanMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="mnkd_TwentyFifteenRestructuringPlanMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingLineItems" xlink:label="mnkd_InterimReportingLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingTable" xlink:label="mnkd_InterimReportingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingTable" xlink:to="mnkd_InterimReportingLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="mnkd_InterimReportingTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CollaborationAndLicenseAgreementMember" xlink:label="mnkd_CollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingLineItems" xlink:label="mnkd_InterimReportingLineItems"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_InterimReportingTable" xlink:label="mnkd_InterimReportingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetRevenueFromCollaboration" xlink:label="mnkd_NetRevenueFromCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SanofiAventisMember" xlink:label="mnkd_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnkd_CollaborationAndLicenseAgreementMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mnkd_SanofiAventisMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="mnkd_NetRevenueFromCollaboration" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnkd_InterimReportingTable" xlink:to="mnkd_InterimReportingLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="mnkd_InterimReportingTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" xlink:label="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandBuildingsAndImprovementsMember" xlink:label="us-gaap_LandBuildingsAndImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_MinimumClosingBidPriceOfCommonStock" xlink:label="mnkd_MinimumClosingBidPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NasdaqStockMarketMember" xlink:label="mnkd_NasdaqStockMarketMember"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_NetProceedsFromSaleOfProperty" xlink:label="mnkd_NetProceedsFromSaleOfProperty"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PaymentsForCommissionsAndOtherFees" xlink:label="mnkd_PaymentsForCommissionsAndOtherFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandBuildingsAndImprovementsMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="mnkd_NasdaqStockMarketMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="stpr_CA" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_MinimumClosingBidPriceOfCommonStock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_NetProceedsFromSaleOfProperty" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnkd_PaymentsForCommissionsAndOtherFees" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementGeographicalAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" xlink:label="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_AssetsHeldForSalePolicyTextBlock" xlink:label="mnkd_AssetsHeldForSalePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BasisOfPresentationPolicyTextBlock" xlink:label="mnkd_BasisOfPresentationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_BusinessPolicyTextBlock" xlink:label="mnkd_BusinessPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ClinicalTrialExpensePolicyTextBlock" xlink:label="mnkd_ClinicalTrialExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_GrossToNetAdjustmentsPolicyTextBlock" xlink:label="mnkd_GrossToNetAdjustmentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" xlink:label="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" xlink:label="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" xlink:label="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAndResaleAgreementsPolicy" xlink:label="us-gaap_RepurchaseAndResaleAgreementsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" xlink:label="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionDiscounts" xlink:label="us-gaap_RevenueRecognitionDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:label="us-gaap_RevenueRecognitionMultipleElementArrangements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="us-gaap_RevenueRecognitionSalesOfGoods"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ReverseStockSplitPolicyTextBlock" xlink:label="mnkd_ReverseStockSplitPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SaleOfIntellectualPropertyPolicyTextBlock" xlink:label="mnkd_SaleOfIntellectualPropertyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WarrantsPolicyTextBlock" xlink:label="mnkd_WarrantsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_WholesalerDistributionFeesPolicyTextBlock" xlink:label="mnkd_WholesalerDistributionFeesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_BusinessPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_BasisOfPresentationPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ReverseStockSplitPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleElementArrangements" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionSalesOfGoods" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_GrossToNetAdjustmentsPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_WholesalerDistributionFeesPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionDiscounts" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StandardProductWarrantyPolicy" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_RevenueRecognitionBulkSalesPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SaleOfIntellectualPropertyPolicyTextBlock" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_AssetsHeldForSalePolicyTextBlock" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_WarrantsPolicyTextBlock" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepurchaseAndResaleAgreementsPolicy" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ClinicalTrialExpensePolicyTextBlock" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_CommonAndPreferredStockTextBlock" xlink:label="mnkd_CommonAndPreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_CommonAndPreferredStockTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" xlink:label="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="mnkd-20161231.xsd#mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g305327dsp29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327dsp29.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M!/\ PI_$'_R+0 ?\/OOB;_T0OP)_X4_B#_Y%H /^'WWQ-_Z(7X$_\*?Q!_\
M(M !_P /OOB;_P!$+\"?^%/X@_\ D6@ _P"'WWQ-_P"B%^!/_"G\0?\ R+0
M?\/OOB;_ -$+\"?^%/X@_P#D6@ _X???$W_HA?@3_P *?Q!_\BT '_#[[XF_
M]$+\"?\ A3^(/_D6@ _X???$W_HA?@3_ ,*?Q!_\BT '_#[[XF_]$+\"?^%/
MX@_^1: #_A]]\3?^B%^!/_"G\0?_ "+0!^VG[*GQHU/]H7X!_#_XP:QH=AX<
MU'QE:ZS<7&C:9=7%[96?]F>(]7T2(0W%TB2R>9#IL<K;E^5I64$A02 ?0M !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_"!\52/^%H?$C'3_ (3W
MQ@1CT_X2'4<4 <%0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_8?_ ,$S
MR#^Q%\#<$$#3?%@XYP5\>^*01]001^% 'W;0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 A'&.G&/I0!^(OB7_@JM^R?X?\1^(-!U#]G/Q/>7^B:YJV
MDWMY'X8^&CI=7FG:A<6=S=(\VI)(RRS0O(&=58[\L <T;!M\C$_X>V?LA_\
M1M7BK_PEOAA_\M: #_A[9^R'_P!&U>*O_"6^&'_RUH /^'MG[(?_ $;5XJ_\
M);X8?_+6@ _X>V?LA_\ 1M7BK_PEOAA_\M: #_A[9^R'_P!&U>*O_"6^&'_R
MUH /^'MG[(?_ $;5XJ_\);X8?_+6@ _X>V?LA_\ 1M7BK_PEOAA_\M: #_A[
M9^R'_P!&U>*O_"6^&'_RUH /^'MG[(?_ $;5XJ_\);X8?_+6@ _X>V?LA_\
M1M7BK_PEOAA_\M: #_A[9^R'_P!&U>*O_"6^&'_RUH /^'MG[(?_ $;5XJ_\
M);X8?_+6@ _X>V?LA_\ 1M7BK_PEOAA_\M: #_A[9^R'_P!&U>*O_"6^&'_R
MUH /^'MG[(?_ $;5XJ_\);X8?_+6@ _X>V?LA_\ 1M7BK_PEOAA_\M: /UF_
M9P^*?A3XU_!KP;\3_ _ARY\(^%O%4&ISZ3X>O+73+*YTZ/3];U+2+A9;;1Y'
MLXC)=V$\P$+L"LH+'<2 ;?(-OD>X4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 '3\.W3I0!^-?B+X'?\$@;OQ#KUUXB\7?#.+Q!<:UJD^N13_'#Q/:
M31ZQ+?3R:G'+:KXL1;:1;UIPT2H@0@J% & ?H&QC?\*&_P""-/\ T.7PN_\
M#\>*?_FPH /^%#?\$:?^AR^%W_A^/%/_ ,V% !_PH;_@C3_T.7PN_P##\>*?
M_FPH /\ A0W_  1I_P"AR^%W_A^/%/\ \V% !_PH;_@C3_T.7PN_\/QXI_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MYKV[-MY8U(0X-Q)N\G=D;L V#8][H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /XR?B1^US^U'IWQ$\?:?8_M!_&"TL;#QKXIL[.TM_'_B2*WM;6
MUUV_AM[>"*/4 L4,<2(BHH 55   % '%_P##8O[5O_1Q?QE_\.%XF_\ EC0
M?\-B_M6_]'%_&7_PX7B;_P"6- !_PV+^U;_T<7\9?_#A>)O_ )8T '_#8O[5
MO_1Q?QE_\.%XF_\ EC0 ?\-B_M6_]'%_&7_PX7B;_P"6- !_PV+^U;_T<7\9
M?_#A>)O_ )8T '_#8O[5O_1Q?QE_\.%XF_\ EC0 ?\-B_M6_]'%_&7_PX7B;
M_P"6- !_PV+^U;_T<7\9?_#A>)O_ )8T '_#8O[5O_1Q?QE_\.%XF_\ EC0
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MX(!% '*?\.D_VTO^A-\(?^' \-__ "50 ?\ #I/]M+_H3?"'_AP/#?\ \E4
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MI"]_XKUW5;7RKZU)BGW6-];,VPD*S,N25-&P;'U/0 4 % !0 4 % !0 4 %
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MK'% 'TE0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MHV.H3V*R-:7"ZI(%-O*P;?(A^,'[->I6_C']H[_A3_P)\*V.O_$O1_@OX'\
M>,K?PSH^@Z7X?3Q6?'.G_&KQ+'K^FZ=)>:#'_P (O?26VIWME;O<RR:I9C9<
M,=M'Z!L9T/[-WBN[^"(^%OQ#^!GA76=?^%W[0WP_/P[FTVRA\;Z-9_!#Q/\
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MZ(]^RY_X<CQS_P#*>@ _X2[_ (*0?]$>_9<_\.1XY_\ E/0 ?\)=_P %(/\
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MV!/ ^GVUU/%<1ZM;6\4(FGO;1!E'RAD(8,F" ??U !0 4 % !0 4 % !0 4
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MDN;^^D;3I+SX@2,T4EP%BBT"U6,$R 0FWR#;Y'U70 4 % !0 4 % !0 4 %
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M]^R,;>>&<+\,/VA WDRQR;"=,\.XW;&.W.#C/H?2@#[YH * "@ H * "@ H
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MA/6=7M[2._DL+#XY^'I9?L4MMI]XMS"[>%5BNHUM=6TN5_(DE,2ZE;>:$,R
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M="B,\;S0"3XZ>%$,T,48EDEB#>'AYD:1$.S+D*I!)P: *G_"Y/C/]MT[3?\
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M;_\ F:H /^%B?M"_]&X:=_X>OPW_ /,U0 ?\+$_:%_Z-PT[_ ,/7X;_^9J@
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M * "@ H * "@#X,^+7_)_P#^R)_V2_\ :$_]-GAV@#[SH * "@ H * "@ H
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M^G?VO'9S6]O.[Q73Z3B]6)@&:V(G4&(AB >9/^T%X,B\!?%;XBR:9XGC\/\
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M[.S_ &@?_4H@H ^BO"FBZO:?'/XPZY<Z;>0:-K'A'X16>E:I+"R66H76D/\
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\&?\$_/^2??'+_L[/\
M:!_]2B"@#[SH \@^-'@O4OB5X/OOAPEG'+X:\9V&L:+XQO9+CRWM=%GTF[2.
MVMK>*ZMKB:YNK][2,213QB)8W,@9&*D ^*+[]G;]HKQ7'X?U?Q<VD2>)-/\
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M\.:_%HFO3S6MQ'XEGA^$L'BK2_MEPEPI;5K:U(D%JEQ&;?(-CF]1_9\_:?\
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M_FWGXU<?]._P]XQ_W/\ 1_:V*7_,AS#3_L$_^:R_^(>Y*O\ FZG"6G]_/?\
MYQA_PNKQ4/\ FWGXU<?]._P][?\ <_T?VMBE_P R',/_ "T_^:P_XA[DO_1U
M.$E;^_GO_P XQ/\ A=7BK_HWGXU?^ _P][?]S_3_ +6Q2_YD.8:?]@G_ ,U@
MO#[)/^CJ<)?^!Y[_ /.,/^%U>*A_S;S\:O\ P'^'O;_N?Z7]K8K_ *$.8:?]
M@G_S6'_$/<E7_-U.$O\ P//?_G&*/C3XJZ?\,\_&H?\ ;O\ #T8Q_P!S_1_:
MV)7_ #(<P5O+"?\ S6)^'V2Q5_\ B*?";MT4\]_^<9Z?X$\86?CWPGH_BVPL
M-1TNUUB&:5-.U>.WBU*RDMKNXL;BVO8[2YN(5GCN+652(IY5X&&.:]+!XJ.,
MPU+$0BZ<:B?NR<>:+4G%Q?*Y*Z::=F_4^*X@R6OP[G./R7$8BABZN G&#KX:
M4YX>M&=.%6G4I2J4Z4W"<)QDN>G"2O9Q3.L8[0.,\XQTQ71M;97:6KM_3[+J
M>,WRK9NW1*[^[R_(^<=(_:%OO$5E_:OAOX(?&#7=&>[U*SM-7L;7P,EG?-I6
MHW6E74MLMYXW@F\D7EE<(#)%&3LSBO"IYW4JQY\/DV.KTN:48SC'#QC+DDX-
MI5,1"=N:+2O%'ZOB?##"Y?4CALU\1>%\KQZI4*M7"UZF<.M06(H4\13A5=')
MZM)35*K!R4*DTF[<S-+_ (75XJ_Z-Y^-8_[=_A\,8_[GZK_M;%+_ )D./T_[
M _\ YK.?_B'N2K_FZG"6G]_/?_G&+_PNGQ5_T;S\:N/^G?X>]O\ N?Z/[6Q7
M_0AQ_P#Y:?\ S6'_ !#W)?\ HZG"6G]_/?\ YQA_PNGQ4/\ FWGXU<?]._P]
M_P#F_H_M;%?]"''Z?]@G_P UA_Q#W)5_S=3A+3^_GO\ \XQ/^%U>*A_S;S\:
MAC_IW^'O;_N?Z/[6Q2_YD.8:?]@G_P UA_Q#W)5_S=3A)?\ ;^>__.,HZI\?
M=;T33-0UC5?@%\9[+2])LKK4M1O)+7P"T=G86,#W-W=2+%X\=S'%;Q22,$5F
MPAP">*F><UJ4)5*N28ZE3IIRE.7U6T8Q5Y2?+BI.T4KNR;LM$S;#>&F78S$4
M,'@_$[A3$XO%5(4:%&-3.HRJUJDE"G2C*IDL(1E.;C"+G.,4VN:26I]!VERE
MW;6]S&K*EQ!#<(K@!@DT:R(& ) 8*P!&3S7N1:E",XN\9)-/R:NOP/RZI"5&
MK5HRTE1G*#MM>+<6X]6KIV=E<LTR H * "@ H * "@ H * /@S_@GY_R3[XY
M?]G9_M _^I1!0!]YT ?-_P"TSXB\3^&/"W@+4?"FMZWH]VWQK^#MCK"Z);+=
M/?\ @_4/'NBV?C*UU.,:?=31:(OAR;4)[N: V[10P.[S+&'#'Z!^A\TZSXN^
M(6I:Y\<T^'7Q,^)>JZ=X<\=^"S/X;UOP]XBM-2O[/3[7Q)'XMT;X5>)(O",%
MOOUW5Y]*MM.LM,^UV\<?@FYFN+JVCUDS,?H&WR.Q^"B_M.P?$_0K/XI>*/[=
MT2T\ W5[\1[BQ1K;PWI>J7'@[X:V.C>&K=5TZ"WB\96?C&P^(FIW5UI=S<1R
MV6K1&=HL6L$9M\@V\CS;P+X]_:'\(?#KPI\3_P"TM6\;IKGB36OAMJGA;Q5%
MXHU7^R+B_P#BKXK&A_$GQ68[$ZCH.E:?X:M-!T../2H)HIX/$EKJ5XS+9IO
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M$,4$$*)%%!#&D<44<2JD<<<: *B(BJJJ   H X%&WE8-O*Q)M'H..!QR/QH
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M)1C>/9J*5OP/QS$3C4Q.)G!\T)5:DHR7PR3G)W3ZK7LC1JS$* "@ H * "@
MH * "@#X,_X)^?\ )/OCE_V=G^T#_P"I1!0!]4:!XUU#5?BC\1? L]G91:;X
M-\/?#W6-/O(C.;VZG\7GQ<M]%>!W,0B@_P"$=MO*\M5/[^7>3\N #MM;T+1O
M$FF7.BZ_IEEK&DWGD?:M.U&WCNK.X-M<0W=OYL$H*OY=U;P2KD</$K#E10!R
M>O\ PI^''BBPN-+\1>#=!U?3KOQ(/&%W9WEC$\%UXI6T%A_;UPBA?-U)K$?9
MVE;):(F-LJ<4?H&Q@/\  #X,2?V3O^'/AICH4%M:Z*QM'#:5:VEAJ&EV]KI[
MB7-I:QV&J:C"(8RJ;;R3*DMF@-O*QFO^S1\!GCDA?X7>%FBFT=_#\L1M9C&^
MB/X;T[P>^ENGVC!LSX7TC3-+,9&/LMC##]U *-OD'Z&/X=_9B^&>A:QXFU.>
MRN]:L_$VNMXENM$U>^U"^T<:_'XH'B[2]<_L^ZOYK:+6M(U4!-.OK."REMX"
M\;&4N9*-OD&WR.LE^ ?P:FC,4OPZ\,M&;^^U+:+'RPEYJ.D:QH-X\0C=?)B?
M1O$&NV8@CVQ1Q:S>K'&@N9-YM\@V^0S3_@)\*--\.W_A&#PG:-X8U#Q1IWC%
M]!>>\&F6VOZ+#HT.C7EC;1W""T^PMH&DSP+&0$N;-;K_ (^/W@-@V^1N)\)/
MAFEK/8GP1X=EL[NR\2:??VMSIL%U#J5IXQGM+KQ7'JJ7*R#59-7N+"RDO);S
MSY)VMHR[G;1L'Z%_3/ASX+T>[TW4-/T*W@U#1Q.NEW\DUW=WMDMS81:7,D-W
M>W$LOE-IT$-L(V=D6.,*BKSDV\@V^1RNF? 'X-:.?%3:;\//#MK)XWU6+7/%
MDXMI)+K7-8M[B\NXM2O;N>9YC>"XU"_<RHZ,WVR8,2LC FWE8-OD=+-\,/A[
M/-J5Q+X.T!IM7LK;3[^1=.@C,MI:?V?]FCB$2J+-XSH^C%9;<12;M%TYBY-A
M;F$ FMOASX$LM4\-:W:>$M MM7\&Z;J&C^%M1@TRUAN]!TO58;2WU*QTZ:*-
M6AM[B&QM$D7)W"$>K;@#M: "@ H * "@ H * "@ H * "@ H * "@ H * /'
M+SXCZK;?'[0/A(EAI[:)JWPC\4?$*;5&-S_:D.J:#XO\*>';>QB E\C[!):Z
M_<2N6C,GF01[6"[@0#YO^+7_ "?_ /LB?]DO_:$_]-GAV@#[SH * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/_\ X9W7?_DBC] #_AYQ\ ?^A,^/_P#X9W7>W_;Q0 ?\/./@"/\ F3/C^/\
MNCNNC_VXHV\@#_AYQ\ ?^A,^/_\ X9W7?_DB@ _X><? '_H3/C__ .&=UW_Y
M(H /^'G'P!_Z$SX__P#AG==_^2* #_AYQ\ ?^A,^/_\ X9W7?_DB@ _X><?
M'_H3/C__ .&=UW_Y(H /^'G'P!_Z$SX__P#AG==_^2* #_AYQ\ ?^A,^/_\
MX9W7?_DB@ _X><? '_H3/C__ .&=UW_Y(H /^'G'P!_Z$SX__P#AG==_^2*
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M "@ H * "@ H * "@ H * "@ H * $/0T >7_!'_ )(]\,?^Q&\,_P#IIM:
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MFK6']GV*VDUII6IG5IH-6^UV,JSW=E>ZC?7CVK,K3(+?RF@C@$QD-@_0P_\
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M1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4
M'_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'
M3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C
M_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_P
MGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)
M_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\
M\F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X
M&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\
MX4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E
M !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^
MAT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'
MH_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?
M\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/
M"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_
M /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">
M^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R90 ?\)[X&_Z'3PG_
M .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;_H=/"?\ X4>C_P#R
M90 ?\)[X&_Z'3PG_ .%'H_\ \F4 '_">^!O^AT\)_P#A1Z/_ /)E !_PGO@;
M_H=/"?\ X4>C_P#R90!/:^,_!][<0V=EXK\-W=W.XCM[6UUS2[BXGD()$<,$
M-TSRN0#\JJ3Q0!TM !0 4 ?G7XL_97_8YM/B]HGA#6_V=/AU<GQQ;:OJT_B1
MM>O5U&#7Q%JNLR1:GX>6\62TL;VWTW4'AOVF6.6:*>%(P;=BP'Z'G?PX_P""
M?7[,_P 0K;QIK%_X'T_1QI?Q3^)?A73M-T73-%CL+31O"OB_4]#TF%3J6F7E
MS-,+&SA,DLUP[.Y9N,X!^@;?(RF_9O\ V,? /A;P4?%?P \)^)M2UWXA>-/"
MU_JGE:M:3Z;X3\+>.M;\-W7C'58='#VPBT^TBT47&V&QA<W$DGF1E"K'Z!^A
MDZK\&OV.=-/B%%_98^#;/HVN/;P+-\1M33S/#5O_ ,)3YWB*[-I8W(^;_A%W
MVVNFG4Y(?MDWVO[/_9=U1^@;?(OWOP7_ &)[36I+$_LO?#.VTZP\0)H%[<ZC
MXGUZWU&_EOO&7B?P;I=QX:TNUM;G^TK<77AQ9KN:[GT^" ZG!;)-+.0K@;>5
MCS_4?"_[$>F6EK--^QKX:^U-X7GU+4=+'B'4#>Z7XJE\*Z;X@\/^%9-FY;B#
M6;[6-)L;35D(B:/5K*[$12?RE .U_P"%*_LA_:/$+0?L?>![^TT#4/ &F"ST
M_6_$LFN:C/XT_P"$#DG?3HYK*/3[M[&V\9S.EI%J#7%T^EI&%A-XK0FWR [;
MX>_LR?L@_$'6-.;3OV7OA;%X-U3P7>^,K+78O$GB2ZU6:UMO$FI^'((H]'%G
M' 8II---SYIOP5CG5#&74BC;Y =)+^R[^PE;+?"Z_9O\,6LUK9Z%=VL$G]H%
MM3&NZ*^NQ)9E=<(S;VD;K*9-F'0@ J59C;Y ;EW^R%^PK8QZ5Y_[.WAEKG6-
M-TG4;.RM+;5[F9SK9":?99_MI$^U2,L_.X1JMLY>1,H)#] V^15U7]E+]@31
M+B]M=1^ /A:WDL-6M-&F_P!#UIPUU=^8%>$1ZR6DMXVAE$C[01Y9959/FH Q
MQ^S1^P-$CM>_LY:!IF;_ $JPLX;VTU-;F\;6H;>73;I8;?7I?(LY?M,*EI2D
MD>[=)$B\T =[H7[$'[%6N13O%^SGX/MS;"R9UF;4V!34-+L=7MRC1ZP=Q-K?
MQ C PRL,G@D XG3OV5_V';BPM[Z__9CT"P2[@-W:M%;Z[/;RVAGTVUC?S[O4
M;(^:;O5;2 JL;Q[V8QRR1J7!^@;$U[^RW^P-:6LMS!^SYX8O?+2\V0PVFMPR
MR36"P27D7^EZM$D?D17"O)O<,-I54=\*38/T+T7[)O[ ]QI5KK5K\ /"]SIM
MUJ]WHRSQ6.NCR9K&VEO;JZG275D*6$=E$9C*-S88)L\W=&I^@;?(R8/V:/\
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MM=E_9Q\,IIS:]#HEHQCU0W%W&UE:ZC=ZJENFM,T5A:VDUP[ER'_T0J%S+&&
M%D_98_8#A8J_P!\*1[9;Z-GDMM9$:G3KVWL[GB/6'D:3_2$F2)8VD,.)'5 Z
M;@"K+^S'_P $_P"VBNIKK]GO0;6*R>6">2;3-:*"\@U"VTZ6P1HM<<272S7E
MLYP?+\N4$2%OEHV^0&G%^R=^P+<:%=^(K+X!^%+O3;'5;C2)3'8^(%N)+NVL
M9-1*VUO)J:M+YEL@*!MARX5]C @&WR#8AU/]D_\ 80TB/3Y[O]G7PTMM>6KW
M<SB#5?,TR".'7I)#?1-K8^=9_#UY;%8&G/F/&?\ 5$R _0-OD6=#_9(_8/\
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M^3!(P!38[FWR ZNU_8K_ &)KGQ=<>$!^SIX-6\@TI-62??K#1R6Y^Q[V,?\
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M;G(+')R>:-O(/T&2:7IDP42Z=82A,[!+:6[A,B=3M#1G;E;FY!QVN)?^>C9
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M1C_RAT (/VJOVTEZ?\$[_$R_3XY>"1T^FAT +_PU7^VG_P!([_$__A\O!/\
M\HZ ,/4_VA?VK]:F6XUC_@F?=ZM.D0@2?4_BY\.K^9(5=I%A62Z\-NRQ"1F8
M*#@%B<9)H -,_:%_:OT29[C1O^"9]WI%Q)&89)],^+GPZL)GB+*YB>6T\-QL
MT9=5;:21E0<9% &Y_P -5_MI_P#2._Q/_P"'R\$__*.@ _X:K_;3''_#N_Q.
M .W_  O+P2,?A_8= !_PU7^VF/\ G'?XG'_=<O!(Z?\ <#H 0_M5?MI'@_\
M!._Q,1Z'XY>"3^G]AT +_P -5_MI_P#2._Q/Q_U7+P3Q_P"4.@ _X:K_ &TQ
M_P X[_$XQ_U7+P2,?^4.@!/^&JOVTQC_ (UW^)AMZ?\ %\O!(QVX_P")'Q0
MO_#5?[:8_P"<=_B<?]UR\$CI_P!P.@ _X:K_ &T_^D=_B?C_ *KEX)X[?] /
MTH /^&J_VT_^D=_B?C_JN7@GC_RAT '_  U7^VF/^<=_B<=O^2Y>"1T_[@=
M!_PU7^VGT_X=W^)\=,?\+R\$_P O[#H /^&J_P!M,?\ .._Q.,<?\ER\$C '
M0?\ (#H_0-O(/^&J_P!M/_I'?XG_ /#Y>"?_ )1T '_#5?[:?_2._P 3_P#A
M\O!/_P HZ #_ (:K_;3_ .D=_B?_ ,/EX)_^4= !_P -5_MI_P#2._Q/_P"'
MR\$__*.@ _X:K_;3_P"D=_B?_P /EX)_^4= !_PU7^VG_P!([_$__A\O!/\
M\HZ #_AJO]M/_I'?XG_\/EX)_P#E'0 ?\-5_MI_]([_$_P#X?+P3_P#*.@ _
MX:K_ &T_^D=_B?\ \/EX)_\ E'0 ?\-5_MI_]([_ !/_ .'R\$__ "CH /\
MAJO]M/\ Z1W^)_\ P^7@G_Y1T '_  U7^VG_ -([_$__ (?+P3_\HZ #_AJO
M]M/_ *1W^)__  ^7@G_Y1T '_#5?[:?_ $CO\3_^'R\$_P#RCH /^&J_VT_^
MD=_B?_P^7@G_ .4= !_PU7^VG_TCO\3_ /A\O!/_ ,HZ #_AJO\ ;3_Z1W^)
M_P#P^7@G_P"4= !_PU7^VG_TCO\ $_\ X?+P3_\ *.@ _P"&J_VT_P#I'?XG
M_P##Y>"?_E'0 ?\ #5?[:?\ TCO\3_\ A\O!/_RCH /^&J_VT_\ I'?XG_\
M#Y>"?_E'0 ?\-5_MI_\ 2._Q/_X?+P3_ /*.@ _X:K_;3_Z1W^)__#Y>"?\
MY1T '_#5?[:?_2._Q/\ ^'R\$_\ RCH /^&J_P!M/_I'?XG_ /#Y>"?_ )1T
M '_#5?[:?_2._P 3_P#A\O!/_P HZ ._^%W[0W[4OC#Q[X=\->//V*]?^&7A
M+5+FYBUGQU=_%GPKX@M_#T,5A=W,%Q+HUAI,-Q>K-=P6]J%BD4J;H.<JA% '
MV_0 4 % 'C&O>&OBA+\6_#OB[3->T>?X>:/X<UO3KKP8\VJ:9?76L:BMH8M5
MFFB:6RU&9)+:-8GN85^RPK<+$K/>.Z&WR#;Y'G7PE\<:/X%LO'^A>*K'QEIF
MHM\9?B[JT$*?#OX@:C;W&E:UX[UG4]*U"SOM+\-75K=6=W97,-Q'+#.ZLLH.
M<YHV#;Y$&D>"/$GC#PSX5UC3K*PGMK/Q9\7M2&@>._\ A+O#")_PE/Q&U75/
M#GC6.PM+6'4/[8L=-29[6UO(K-FAUZ62.XM90DA-O*P;?(R)?V?_ !W+?VLJ
M^+].\-36.OQZO<^(]'UOQ'+K?CC4;+6+[6M(\2^)["[CCM8=2TX/;VO]FQS7
MEM=6]WJ%O+*EFMM;QFWR#8T(OV>?$7]EZ1=3ZIH"^-K;X=_#CPMJ7B"UGUQ/
M.USPMXML=:\17MM-(&G-A?:1:"PB:;-PZ+'%<'RP31M\@V^1@Z?\!_BGX;TF
MZT^+Q]H^L1P^&(?"&GOK>O>)+:ZTO1=4\"+X6N]0O-2-O=2:EJ&EZ[]HGL'D
M2&2[M885N+F&[C::0V^0;?(W;OX ^,-1M/B#;^*O%NA^(;#Q]>Z%JPTR_BU:
MVL_"^J^&=9L[71ETNY-U*9H+CP9&NG7+1PV):XLHG,<QNYY0;?(-O*Q+KWP,
M\8W^M:K?:9JWA^6PU'5C=^%[ZZUCQ%;7OPTMUU"RNUU7PK9V5N]K?ZA=Z=;1
MV,MO+):PHEA:*)9K::ZMY#;RL&QUOP:^%GC3X:,UGXB\6KXETY;'P;I6CF35
MM6DU"TM= \+:K:ZC9W\FI12G75&MW\GV21I(9C9VMK)<L\]EB<V^0;?(Z.^\
M)>(M3\1ZS>6GB&:WL+^]T.[L)K+Q#,GV6QTY]':^TZ/35LG6(73V%[N=961A
M<LI4&1R#;Y!M\C,C\'_%6TT"YTNZ\=0SA+2:UM;Z*X33;VV2/388;>ZN-4ET
MBYDF;?'*')5)#/*+OS2H-N3;Y!^AM-X;^*BQV:P>,]+C6&_L'N$?3HYVDTY+
M>1M0MY9GM5\R5KR5HT<(A\F&$Y$BMO-OD!4?PS\68Q)'!XYLYXX-*2"%9;:T
M2\DU07:3O-=7BZ3M19+=O*5H[=3'&&4*7D$B&WR#]#>@TOX@'0/LX\06$NK'
M79KA=0S%(DVBN7^SPDII@C41S&*0PI#F2WA:#SHY)C-&;?(-OD8U[X)\:J-!
M^P^,[^U.FVVL/J-S+JC,M_J-W>W%WIYN()M+E2Z@5YXX2&,>R"$Q(I)5T/T#
M8M0>$?&6IV-I9^(_%R7$UIXLEU2XGT=6T\MI$>GW$<&C%+<)F-KV:*<QRLS1
MQ[1YCM$K$V^0;>5C-N/#GQ6\A_['\;Z8UQ+<VTR+,L,EM9V:1VQMUMU_LEW>
M&:1+MYQ*\C2I(HB>,KP!L76\,_$]8&MX_&,$LGE1F&]G%LK0W 2U:Y^T01:&
M%NPUU]H-N%,*P11[)5N#-^Z-@V\K#M)L/'UOXAGT[5-8:]T==$U:.SOYKG3[
M=[B\N)H%T?-M:V,5T^HVL4=Z\]ZGDPE9X(XX6>/S";!^AR\G@SXJVEM=6^G>
M+K;3!=)8A1<ZS<W[6=C9-J2ZBR27VE2LL\T=_"\EU 81YBVA6.+[.QF-OD&W
MR-9?"WQ5\AQ)\0+:U7ST.GF.&R+B-X["*WM[JZFTB3[:2HND+A(FDG?SAA95
MBA/T#;Y!JWA#XL7]MK4<?CN"U,\]Z=+CT^*'3/*MI[FR\BW:Z_LJYEA\O3EO
M(4="66Y=9RSJWEQFP?H:_BWPU\1=0FF;PQXFM-'C:]MKJT61G_T7[-::4I6[
M46$AU&W>>VU0?9E>V4F^BDD=TB:!C;RL&WR*"^$?B<;S1;JY\:)<I;7L$^I6
MT9BLK66&/3+:T=%M[?2<SHUS_:$\D3R@-)-;2(T0@\NC] V^14L_!OQ7T^%K
M6/QO;W=HNGS)MGR=2GO9;M9I9#J\^FRM;SM$SI!/]GE6WV8\B0.#&;!M\BQK
MOA7XHW'_  BD&B^*+:TLM+TS1H_$*B]>"\UC4M/:!KV=+Z;1;MP9WAC(9U"2
M(;A)HLS!E-OD!H_\(]\4B+G'B_2(G>.^1&.F1RP_:&LYCI]W;P?95:TMTO?L
M:/:/+<G9'<R"=FG5(@-OD6+[0?B9-IOAR"Q\7Z9:WMI9M%XDFN--CF.I3-=6
M:JUI(L %O(FFOJ0\X1KNN8[.0Q^7YL;&WR#]"CH'A'X@Z:DKWGBY[N>33;^R
M:*YN3?6AO'G\1W5EJ4*2Z7&]N\<NH:+&(PS*L&G-$PEVHQ-OD&WR*EWX=^+=
MI%J#6?C"VOQ'.9-+MY[>QMYF@33+R-4N[@:61+-]M:S; 6-'EB,K[8W,2FWR
M#8L6_A_XL+,LL_BJP-K]BM%_L]5MUO$G6^6642:O_8[1RW2VF^-[H6*QS!@@
MMXBHEHV^0;>5AS>%/B'!8^'8[+Q,PO\ 3]!O-,U>>[U$SQZAJ,E_836NI,)-
M&<32*EO*Q=HXW$#36GWKG[3 ;!^@NK^$?B%-J>L:AH7B\Z6T^XZ5!<2F\TN)
MI[+P[:R+-I4E@WEQ1-IVL31JEPS>=J*R;PI>.C8-OD:&I:)\29=,T"'3_$UC
M#JEKI&IVVM7<UM"MM=:E-:(NG7RVZ63&26WN5(&UX(SYCR-$^%C!L'Z&3<Z#
M\75LWBL_$^DM?R6UG;?;;@106]O*+2Q2YOXK*/0Y3YZ7,.HN4:5TG-_$0L M
M]KFP?H20^'_B%I_B%9$\1O?Z3>WNDQW7VQX+A;31[%]2N+]XK9;" 0:U=.VG
M6PFBWQ.EQ.SQ1FUB<FWD&WR$U/PG\2Y[MKBP\90V\2ZMJ%U;V9"K:06;VLL>
MDQS1#3&DO!#>7,LUS!).$F2"!$9&0, !D/A?XKH-.>7QU:LZ^8NJ1BPLRKQ#
M2X88/LQ.F@+<?;OM;2R,&#L]M,%586AD-OD&WE8HVOAGXIV\DQF\1^;>7!L[
MB*<ZBLEC%Y(T.&_LI;=M('DI<16ES+NAB;:XNO+>'[;L!M\@V^1OWFA>.KW3
M8[;3-;&DN]SXI65YI_,O(;>^O;IM";[2;6X,SVNGR+&H1HFAE>"7=*+4PRFW
ME8-OD5?$7A'QU)=12^%/$$>GM!H=GIR7FIWM[?-OM0$G*Z>T7V87]R/F-].M
MP 1N, <!B?H&PMUH7Q6VSQ6?B32A).3$;Z40QK:XFLIEOK*P70Y!$WV6*YM?
MLTL\Z^;.USOVE84 V^0D/ACXEI?VOVKQA#>Z7;>)[2]6-%CL+LZ%:7-O,MM=
MS6^FM]M,EI'-;RVX^SB2>43F819MZ-OD&WR*]QX*^(5C$\F@>,$6^O\ Q1-J
M5^;]KF>S@T1]8O;U;&WBO4O29CIMTMHYB6U7_1;81*BQ%G-@_0T?"^A>/M'U
MB.WU/Q#)J^D&/4KZ\NM0DM[JZN+Z8)'86EF8;"U^R60::ZEEA$6(O[.LQ"[+
M=3)$ <[_ ,(O\9+FVL[6_P#%6G-MUJSU"ZNK.Y^PW0TZVGNC-I(,&@8N(IO/
MMI"Q,)\JP%N3F5I*/T#;Y&Q:>%/B3!+IEK+XU\S3;00I>SL+:34[RWBDN6:)
MY9-%VM=29L5-T"A\FWFCV>9-YZ&P?H5+;PO\4A#%]H\6QVDT#W[2E)[6^CGV
MVMI'I:6^[PY"UO8->6\D]Q!()IL7,D<=P4"X-OD&WR(XO#_Q)UO2)HKW6KS1
M=076]<$$T>HVUO-_95UX;N-+LI\:?ITB"%==D.H6]J[/)!&(-\\CQ;& _0Z#
M2O#_ ,0+2]VW_BB"[L6M?$$&\1P&6&6XN6.@7S1+IT/VB_@M3")AYD4!,4A6
M,F0$&WD'Z%%O"_CV.T@M=)UBWT/$6H)=NVJWFN237LMJ(8M4676--G>-Y+D"
M=+="D5NV2RW'F,@-O*P;?(I6O@_XGP7=_(?&X\E]1BN[4RO%<M);PV?D):2P
MR:*$MK0NL+S10;3)*LLJR1B4H#;RL'Z%.]\,?&*^FL2WB?3+"T@^S/>6UA=&
M.6Y:TDLF/^EG0=ZF:6U>5E4*GDW<]LP;*R*;>0;?(Z'3O#GQ%BOK*:_\5VKV
MEI=6[SVD$4/EZA"+NR^TK(7TP20V_P#9274,5NLNY+G-PT[K.([<#;Y&)?>#
MOB2EYJEWHOB*.R,\NL-9I+K%[<J7U"6%[:ZFAN].GMU6UMHVAM[=8E\F1B[2
MS1A5!^@;?(CM_"'Q@2.2)O'MI$)+:5Y)!##<S'4Y=8DOI9X)[C2<6UG]C=;:
M&W\EQ#%&T8SO5XS8/T-1_"_Q2>X"#QS;QV"V<40\NRM!J#746K/<?:'NGTMH
M_,?2PENY6!4;>P"*RB4GZ!L6$\-_$*W\-Z!8P>)8SK>GZ<+?5;V>X\\ZG?\
M]KV%Q)<&YETS*VKV,-ZFT0)*JS)&K%@9";?(-OD>K(-JJO=0 <=,@<XSVS0
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M(T"Q  @V#;Y$$_P3BN=5NM3G\6:J_P!H1H5MA;H([*%X(8)!IQ:Y86<K)!'
MSJI#6P,+JQ/F4?H&WR.@MOABEKHVL:./$NM3#5-:@UJ*]N76>YTZ2VGBN+>W
MM%D8HD2/$J@J$PB1J #&&)MY!^A'X0^%D?A2_P!/U#_A*O$>K26%M-;_ &.^
MO'.ER&2,Q)*+)I)"CPI).(R9'($H!8[!1M\@V^1ZO0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZ/A_;-_\.H?_ )!HL ?\.^_$G_1\/[9O_AU#_P#(-%@#_AWWXD_Z/A_;-_\
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M/[9O_AU#_P#(-%@#_AWWXD_Z/A_;-_\ #J'_ .0:+ '_  [[\2?]'P_MF_\
MAU#_ /(-%@#_ (=]^)/^CX?VS?\ PZA_^0:+ '_#OOQ)_P!'P_MF_P#AU#_\
M@T6 /^'??B3_ */A_;-_\.H?_D&BP!_P[[\2?]'P_MF_^'4/_P @T6 /^'??
MB3_H^']LW_PZA_\ D&BP!_P[[\2?]'P_MF_^'4/_ ,@T6 /^'??B3_H^']LW
M_P .H?\ Y!HL ?\ #OOQ)_T?#^V;_P"'4/\ \@T6 /\ AWWXD_Z/A_;-_P##
MJ'_Y!HL ?\.^_$G_ $?#^V;_ .'4/_R#18 _X=]^)/\ H^']LW_PZA_^0:+
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M?%OABRMKF[GUW3$M;.[L;&[G6[BDCM;K4I(8;"*X:)F$)FDGB56?"_/R0 <
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M;Y'HWARUUBSTNSAUVX6[U*.UMX[NXCG,L<UPD2+)(H,$6TLP);Y<%BQ7"D
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MU&+3-/BU!H_):^CLK9+PQ9W>4;E8Q(8\C.TMCVH T* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H \Z\7?%?P'X$O'L?$^LR:
M=+!IRZI>RII6L7UCI=C,+\6,NKZCI]A/:Z2U]+IE_#9QW<L+W<UJT-NLDA56
M V\K'E,WQ7^'WB_Q?\)_%6C^);&/0K34_B'HMU?:QYOA]+;58_"^FW1L94UN
M.U83FUN[:90 0R2@J3AMH![3_P +%^'W_0]>#?\ PI]$_P#DZ@ _X6+\/O\
MH>O!O_A3Z)_\G4 '_"Q?A]_T/7@W_P *?1/_ ).H 7_A8GP^'_,]>#A_W,^B
M#I_V_4 )_P +%^'W_0]>#?\ PI]$_P#DZ@!?^%B?#X?\SUX.'_<SZ(.G_;]0
M ?\ "Q/A]_T/7@[_ ,*?1/\ Y.HV\@$_X6+\/O\ H>O!O_A3Z)_\G4 '_"Q?
MA]_T/7@W_P *?1/_ ).H /\ A8OP^_Z'KP;_ .%/HG_R=0 ?\+%^'W_0]>#?
M_"GT3_Y.H /^%B_#[_H>O!O_ (4^B?\ R=0 ?\+%^'W_ $/7@W_PI]$_^3J
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M?^WU ;>5@_X6)\/O^AZ\'?\ A3Z)_P#)U !_PL3X?#_F>O!P_P"YGT0?^WU
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M&/\ M^H /^%B?#[_ *'KP=_X4^B?_)U "?\ "Q?A]_T/7@W_ ,*?1/\ Y.H
M/^%B_#[_ *'KP;_X4^B?_)U !_PL7X??]#UX-_\ "GT3_P"3J %_X6)\/O\
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M0!Y/XN_Y*C\(/^Z@?^H]:T >L4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % "'H?H?Y4 ?/O[/_P#S6W_LX/XD_P#N%H ^@_\ /Y4;
M>5@#I[?ITH * #I[8_#% !_3]*/T#;R#I[?I1^@;>0=/;].E !T]OTZ4?H&W
MD% !0 4 % !0 4 >6_%S_D7?#_\ V4[X2?\ JR_"U 'J5 !0 4 % !0 4 %
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M_P -4?MMC_G'=X@_\/UX([?]P*@ _P"&J/VVQ_SCN\0<?]5Z\$=O^X%0 ?\
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M_E%0 ?\ #5'[;8_YQW>(/_#]>"/_ )14 '_#5'[;?_2.[Q!_X?KP1_\ **@
M_P"&J/VV_P#I'=X@X_ZKUX(_^45 !_PU1^VU_P!([O$ Q_U7KP0/_<%0 ?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M']/TH \G\7?\E1^$'_=0/_4>M: /6* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\7__ #\J #_A'/VG/^BL?!C_ ,,AXO\ _GY4 '_".?M.?]%8^#'_ (9#Q?\
M_/RH /\ A'/VG/\ HK'P8_\ #(>+_P#Y^5 !_P (Y^TY_P!%8^#'_AD/%_\
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M )^5 !_PCG[3G_16/@Q_X9#Q?_\ /RH /^$<_:<_Z*Q\&/\ PR'B_P#^?E0
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MX5.3PC+U-&WR#]#2H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \B\:W$%K\3OA!)<SPV\8/C]=\\J1)N/AZUPNZ1@-QP>
M,YX/I0!Z7_;&D?\ 05T[_P #K;_X[0 ?VQI'_05T[_P.MO\ X[0 ?VQI'_05
MT[_P.MO_ ([0 ?VQI'_05T[_ ,#K;_X[0 ?VQI'_ $%=._\  ZV_^.T ']L:
M1_T%=._\#K;_ ..T ']L:1_T%=._\#K;_P".T ']L:1_T%=._P# ZV_^.T '
M]L:1_P!!73O_  .MO_CM !_;&D?]!73O_ ZV_P#CM !_;&D?]!73O_ ZV_\
MCM !_;&D?]!73O\ P.MO_CM !_;&D?\ 05T[_P #K;_X[0 ?VQI'_05T[_P.
MMO\ X[0 ?VQI'_05T[_P.MO_ ([0 ?VQI'_05T[_ ,#K;_X[0 ?VQI'_ $%=
M._\  ZV_^.T ']L:1_T%=._\#K;_ ..T ']L:1_T%=._\#K;_P".T ']L:1_
MT%=._P# ZV_^.T ']L:1_P!!73O_  .MO_CM !_;&D?]!73O_ ZV_P#CM !_
M;&D?]!73O_ ZV_\ CM !_;&D?]!73O\ P.MO_CM !_;&D?\ 05T[_P #K;_X
M[0 ?VQI'_05T[_P.MO\ X[0 ?VQI'_05T[_P.MO_ ([0 ?VQI'_05T[_ ,#K
M;_X[0 ?VQI'_ $%=._\  ZV_^.T ']L:1_T%=._\#K;_ ..T ']L:1_T%=._
M\#K;_P".T ']L:1_T%=._P# ZV_^.T ']L:1_P!!73O_  .MO_CM !_;&D?]
M!73O_ ZV_P#CM !_;&D?]!73O_ ZV_\ CM !_;&D?]!73O\ P.MO_CM !_;&
MD?\ 05T[_P #K;_X[0 ?VQI'_05T[_P.MO\ X[0 ?VQI'_05T[_P.MO_ ([0
M ?VQI'_05T[_ ,#K;_X[0 ?VQI'_ $%=._\  ZV_^.T ']L:1_T%=._\#K;_
M ..T ']L:1_T%=._\#K;_P".T ']L:1_T%=._P# ZV_^.T ']L:1_P!!73O_
M  .MO_CM !_;&D?]!73O_ ZV_P#CM !_;&D?]!73O_ ZV_\ CM !_;&D?]!7
M3O\ P.MO_CM !_;&D?\ 05T[_P #K;_X[0 ?VQI'_05T[_P.MO\ X[0 ?VQI
M'_05T[_P.MO_ ([0 ?VQI'_05T[_ ,#K;_X[0 ?VQI'_ $%=._\  ZV_^.T
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MGMC\,8H * "@ H \G\7?\E1^$'_=0/\ U'K6@#UB@ H * "@ H * "@ H *
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M6OPL\3/'(L3H)/$_PYM9ML\]E;0,]M=^+XIHEEGU+3UC9XU#_;864E7W4?H
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MBQM/^%7>)Y+C4IHK:PCM?$?P]OOM%Q-'YL4:O8^+)4C#PYD621D0JK-NPIP
M7+7XOZ[>W,5G9_"OQ%<W4R6[Q6\/B[X8M*Z7=I<:A:LJ_P#":=)+&UN)QT^2
M$DXX! V\K$%M\9]8O'>.U^%?B:<Q26D+/'XG^''D"6_DABLHENF\7B"22:2X
MMPJ)(S#[1$6"B123] .@_P"$[\??]$1\8_\ A4_##_YMJ #_ (3OQ]_T1'QE
M_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_#
M#_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@
M_P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'
MW_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE
M_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_#
M#_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@
M_P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'
MW_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE
M_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_#
M#_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@
M_P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'
MW_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_##_YMJ #_ (3OQ]_T1'QE
M_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@ _P"$[\??]$1\9?\ A4_#
M#_YMJ #_ (3OQ]_T1'QE_P"%3\,/_FVH /\ A._'W_1$?&7_ (5/PP_^;:@
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M /)_%W_)4?A!_P!U _\ 4>M: /6* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ+'\6/\ P+\!_P#S T '_"L=9_Z+'\6/_ OP'_\ ,#0 ?\*QUG_HL?Q8_P#
MOP'_ /,#0 ?\*QUG_HL?Q8_\"_ ?_P P- !_PK'6?^BQ_%C_ ,"_ ?\ \P-
M!_PK'6?^BQ_%C_P+\!__ # T '_"L=9_Z+'\6/\ P+\!_P#S T '_"L=9_Z+
M'\6/_ OP'_\ ,#0 ?\*QUG_HL?Q8_P# OP'_ /,#0 ?\*QUG_HL?Q8_\"_ ?
M_P P- !_PK'6?^BQ_%C_ ,"_ ?\ \P- !_PK'6?^BQ_%C_P+\!__ # T '_"
ML=9_Z+'\6/\ P+\!_P#S T '_"L=9_Z+'\6/_ OP'_\ ,#0 ?\*QUG_HL?Q8
M_P# OP'_ /,#0 ?\*QUG_HL?Q8_\"_ ?_P P- !_PK'6?^BQ_%C_ ,"_ ?\
M\P- !_PK'6?^BQ_%C_P+\!__ # T >-Z19^,;C7/$&F7?Q>^(R6EAX[UCP[9
MW<[^$ 'M-/T_PM<6VE0BR\ MOUB=M9OYDFF#(([%PT;!2\9L&WR-'2]"^)-W
MIYOKGX@_$7?/K>D:7;64-UX8M)K6VU>PL)UO[U[KP%+]ICM+S4%BG\F.+]W:
M7#KAUV*?H'Z'J8^&6LX'_%XOBP/;[7X#./\ RP: #_A6.L_]%C^+'_@7X#_^
M8&@ _P"%8ZS_ -%C^+'_ (%^ _\ Y@: #_A6.L_]%C^+'_@7X#_^8&@ _P"%
M8ZS_ -%C^+'_ (%^ _\ Y@: #_A6.L_]%C^+'_@7X#_^8&@ _P"%8ZS_ -%C
M^+'_ (%^ _\ Y@: #_A6.L_]%C^+'_@7X#_^8&@ _P"%8ZS_ -%C^+'_ (%^
M _\ Y@: #_A6.L_]%C^+'_@7X#_^8&@ _P"%8ZS_ -%C^+'_ (%^ _\ Y@:
M#_A6.L_]%C^+'_@7X#_^8&@ _P"%8ZS_ -%C^+'_ (%^ _\ Y@: /*OBSH?C
M#P5IG@Z\T;XQ?$_S=;^*'PZ\(WPNG\!W"G1_$_B:RTG55A7_ (0-?*NC9SR"
M*7YC&^U@IQ@@%2UM/'4\,-[_ ,+'^)CVL&H:O::E;VJ^&I[MUL-'EU*SATJ8
M^"A')=RW,<=DYN(DVS2['A@D1HP;?(-OD9]W#\3+73KC4)?'/Q&L)+2V\/Q7
M.G:E<^$HY[/5-1\2R:'J7G7W_")1V<NFP64(U")EEC/EWMOYL@VMN-OD&WR/
M1]2\%^(8/!NI:];_ !D^)YO+7PY>:M"T-WX$DLS=V^ERWD91?^$&8R6WG(,*
M9'RO!9LY(&WD>;>'K?XEWOANQUO4_B#\2+2SNX;!4UFYN/""6@EDLS*]Y-96
MG@N>XGL[N>,11/$EFD,M[;J!/'EZ _0UK73OB!>ZBME%\1?B38>7J6D07L5Z
MWAFZEL+"_AE>Y$]Q;^"84CU.%HCA)((X]A#IY\965@-BWX:@\0ZQJMUI&K_$
M#XQ^';HVSW^B0W]YX&276["2>Z-C-;'_ (5^T2RO8P))-"9!+ ^\2(JE23]
MV^15BM?&+G3@OQ+^)-Q)>3I'-:V\_AE;BWN7ELHY_#V^3X?&/^W;&&YN+JXF
M/[EHK"4"&,Y>,#]#)TJ3QO?:UX:TR7XG>/%L=8M!=7NKQWOA*WMX;LRZ=')X
M?LXM0\'Q/+K%K]KD$Q7[2"QBVPILE53;Y!L>X_\ "LM9_P"BQ?%C_P "_ ?_
M ,P- !_PK'6?^BQ_%C_P+\!__,#0 ?\ "L=9_P"BQ_%C_P "_ ?_ ,P- 'G7
MQ?\ AQJ]M\)?BC._Q;^*5TD'PZ\;3-:W%UX(-O<+%X:U-S!.(? L<GDN%VMY
M<D;;6.UE." -OD<9X6TWQ1:>%?#%O'\5/B!8PP>&?"B*D\OAR1=.L9_#^FSI
MKMV;?P*X?1&GD-C%&CB82A6DF95F$)M\@V^1L;/&K1VBP>,/C VH++*VL:2=
M0\'"\TVS%U#]C96_X5J$DN[O3#=7$$;%5D>!8RR;F*'Z 4A:_%!7LY?^$W^)
M<]G=_89P($\.Q7%E:7.E^'K^7^T9+OP:@M_*GUR:!YTMY3"-+G9K5R'6$V#8
M].T3P-XJU&;6(K[XI?%/3TTO4GTZW>/4? \WV]$CCN5OX]_P]41VTEO<VJJH
M+,LL5RC$A%) _0Z[2_A_JFFZA:7TWQ1^)&KQ6DPE?3-5N?!S:=>*H(\B\6P\
M&VMP83G)$5Q"W ^84;!L>DC@ >G]* "@ H 3 ]!Q^G;^5 "]/;'X8Q0 =/;]
M.E !@>G3]/\ .!^5 ;>0F .P'Z=.E "T '3VQ^&,4 '3V_3I0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!Y/\ "[_C]^*X[?\ "U]<&/\ N7O"
MO:@#UC ].GZ4 % !0 4 % !0 4 % !0 4 % !0 4 % '@7[0?_(%^&?_ &7K
MX*_^IWI= 'ON!Z?Y'2@ P!VQCIVQ0!R_C?CP9XN[?\4QK_M_S";N@"M\/./
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MO1M\@_0/^&P/V4O^CD?@?_X<_P '?_+>@ _X; _92_Z.1^!__AS_  =_\MZ
M#_AL#]E+_HY'X'_^'/\ !W_RWH /^&P/V4O^CD?@?_X<_P '?_+>@ _X; _9
M2_Z.1^!__AS_  =_\MZ #_AL#]E+_HY'X'_^'/\ !W_RWH /^&P/V4O^CD?@
M?_X<_P '?_+>@ _X; _92_Z.1^!__AS_  =_\MZ #_AL#]E+_HY'X'_^'/\
M!W_RWH /^&P/V4O^CD?@?_X<_P '?_+>@ _X; _92_Z.1^!__AS_  =_\MZ
M#_AL#]E+_HY'X'_^'/\ !W_RWH /^&P/V4O^CD?@?_X<_P '?_+>@ _X; _9
M2_Z.1^!__AS_  =_\MZ #_AL#]E+_HY'X'_^'/\ !W_RWH /^&P/V4O^CD?@
M?_X<_P '?_+>@ _X; _92_Z.1^!__AS_  =_\MZ #_AL#]E+_HY'X'_^'/\
M!W_RWH /^&P/V4O^CD?@?_X<_P '?_+>@ _X; _92_Z.1^!__AS_  =_\MZ
M#_AL#]E+_HY#X(<?]5/\'<?^5>@ _P"&P/V4Q_S<A\$ !_U4_P '#'_E7H_0
M _X; _92_P"CD?@?_P"'/\'?_+>@#S7X=?M7?LPZ==_$I[W]H7X,6B:A\2]8
MU"Q:?XD^$H5N[&30O#<,=W;&355\ZV:6WG02IN0M"X!)4X-@/2O^&P/V4O\
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M+-WX3\3VMK^T7\$Y[FX\.ZW!;P0_$SPA)+--+IEU'%%%&FK%I)&=E554$DD
M#)H @\#?M;?LM6/@KP?97?[17P4M;JT\+>'K:YMI_B7X0BFM[B#2+.*:&:)]
M6#1RI(K*RL 5*D$ @BC8#J?^&P/V4O\ HY'X'_\ AS_!W_RWH /^&P/V4O\
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M3Z/97/[-_P +$N]1_M*>XCA^&O@"5+#3],_M/SKHDZ2DEU,XTUO*MX8F>5I
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MK7]G3X707^LPPWD7VWX7^ (TM[">TN+V">X%OITS1326T=JZPOM;%YAB'B=
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M^'/%%M->>&M=TG7;6VG-K<3Z1?VU_';7(BBG^S7#6TC^1.8)X)1')M8QS1N
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M7+F#2+@>'-(B\8VT%MJDQCBL+GQ79WMY9A5+QP7!4F/S&C!L&WR/J&@ H *
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M^%8?"_C;Q#X<U?XY^)]5TS4[C0?B$FJZ+X=TS]H?X<:+8Z99:]8WB1OX1O/
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M!VC6EWJ_B+3M332KCQ5\3]+T9-(M1=75KX5^$'C#1?A[XO\ %6NF\N+8 _\
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MFDZ7X6OK4Z%\4O%=IX,@M)-1OYH;.[M+K6?#MM#<6$-Q-<;?#4,4=N\ME;P
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M1N;!M\C0U?\ 9 \!:M8ZWILOB/QA'9ZIXU^(7C:Q3[1HT\N@W/Q7T+Q7H'Q
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MH>25KA[B56"O;,\Y^@;?(]NH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P#%H?V5!M&3_P 5EXR&!ZG_ (F? X/Y4 '_  F/_!4/_HD'[*O_ (6/C/\
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M0_\ HD'[*O\ X6/C/_Y9T  \8_\ !4/M\(/V5.../&7C+C'_ '$Z #_A,?\
M@J'_ -$@_95_\+'QG_\ +.@ _P"$Q_X*A_\ 1(/V5?\ PL?&?_RSH /^$Q_X
M*AC_ )I!^RH,?]3EXR&/_*G0 #QE_P %0NWPA_94X]/&7C+CT_YB= !_PF/_
M  5#_P"B0?LJ_P#A8^,__EG0 G_"9_\ !4'_ *)%^RGZ?\CGXR[?]Q/VH 7_
M (3'_@J'_P!$@_94_P#"R\9=O^XG0 ?\)C_P5#_Z)!^RK_X6/C/_ .6= !_P
MF/\ P5#''_"H/V5![?\ "9>,AT]O[3H !XQ_X*A]OA!^RIQQQXR\9<8_[B=
M /&/_!4/M\(/V5/P\9>,NW_<3H /^$Q_X*AC_FD'[*@ _P"IR\9#&/\ N)T
M)_PF7_!4(?\ -(OV4Q_W.7C(?^Y.@!?^$Q_X*AC_ )I!^RH!_P!CEXR'T_YB
M= !_PF/_  5#_P"B0?LJ?^%CXR_^6= !_P )C_P5#Z?\*@_94SZ?\)EXR_E_
M:= !_P )C_P5#Z?\*@_94X[?\)EXRX_#^TZ #_A,?^"H?_1(/V5?_"Q\9_\
MRSH #XR_X*A+U^$/[*B_7QEXR'3_ +B= !_PF/\ P5#_ .B0?LJ?^%CXR_\
MEG0 ?\)C_P %0_\ HD'[*O\ X6/C/_Y9T '_  F/_!4/_HD'[*O_ (6/C/\
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M$FO:;XC\.:P=%U^W\*Z?I<NK0:UKBVL&N6WC#P?J$FH+X>:\%AJ$:^'+'Q3
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M E0!EIXB3@=3A@,_2@!?MEI_S]6W_?\ B_\ BJ #[9:?\_5M_P!_XO\ XJ@
M^V6G_/U;?]_XO_BJ #[9:?\ /U;?]_XO_BJ #[9:?\_5M_W_ (O_ (J@ ^V6
MG_/U;?\ ?^+_ .*H /MEI_S]6W_?^+_XJ@ ^V6G_ #]6W_?^+_XJ@ ^V6G_/
MU;?]_P"+_P"*H /MEI_S]6W_ '_B_P#BJ #[9:?\_5M_W_B_^*H /MEI_P _
M5M_W_B_^*H /MEI_S]6W_?\ B_\ BJ #[9:?\_5M_P!_XO\ XJ@ ^V6G_/U;
M?]_XO_BJ #[9:?\ /U;?]_XO_BJ #[9:?\_5M_W_ (O_ (J@ ^V6G_/U;?\
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M#TW)IP/ZT 2_\*6^$'_1+_ /_A)Z'_\ (5 !_P *6^$'_1+_  #_ .$GH?\
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M_P  _P#A)Z'_ /(5 !_PI;X0?]$O\ _^$GH?_P A4 '_  I;X0?]$O\  /\
MX2>A_P#R%0 ?\*6^$'_1+_ /_A)Z'_\ (5 !_P *6^$'_1+_  #_ .$GH?\
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M_P  _P#A)Z'_ /(5 !_PI;X0?]$O\ _^$GH?_P A4 '_  I;X0?]$O\  /\
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M4L4\:RP21S1-G9)$ZR1MM)4[70D'!!'!ZB@"2@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+;7,4T7VG4;MC++<6;72R-<ZI=R,8[F,.Q4R!BIW ;?(]"H * "@ H * "@
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M>_Y'_"@ R/?\C_A0 9'O^1_PH ,CW_(_X4 &1[_D?\* #(]_R/\ A0 9'O\
MD?\ "@ R/?\ (_X4 &1[_D?\* #(]_R/^% !D>_Y'_"@#RGX8!DOOBMN5ES\
M5M:9<JPRI\.^%=K#C[I['I1^@;>1ZMD>_P"1_P * #(]_P C_A0 9'O^1_PH
M ,CW_(_X4 &1[_D?\* #(]_R/^% !D>_Y'_"@ R/?\C_ (4 &1[_ )'_  H
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M /E/0 ?\.TOA-_T6;]J7_P /5?\ _P IZ #_ (=I?";_ *+-^U+_ .'JO_\
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M,_\ %;_YCZ #_AY7^R7_ -#;XX_\,_\ %;_YCZ #_AY7^R7_ -#;XX_\,_\
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M /\ AY7^R7_T-OCC_P ,_P#%;_YCZ %_X>4_LF<#_A+/''.-H_X4]\5N<\#
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M_P#PL[QEI7CCQ]]FU6STV'4M9%_JVE+%;B_NI#96]Y.L1:7RI83] V.AU/\
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M\,7?A^RM;.6(*R"ZEGCGNI92S/&DL(^6<E#8-OD>L@;0!_= 'Y<4 +0 4 %
A!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g305327dsp30a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327dsp30a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M.7UR6X6ZB"W-RG[@'"SS*,^8XZ*XYP!4QJU5\522MM=@Z=/I"/W(PQ/= _\
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M['\V'Q.\1>+['XE^,[-/%_BZ&.'Q#J#Q11>*=>CCCCED\Z-41-0"HH21<*
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MY(_<B!KZ^_Y_[[(_Z?+G_P".T*I47VY+YL%2IK_EW%6\D4WU"_&?]/OQR?\
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M][=$*.(4G;HCZG?(..@'X8Q6#5M.QK=+8J2'H.W^%)*PTK?(@9L=ON_TH:_
M/T,^9NF/<X]*:T^0]OD5';'Z_ABC;Y";L4W8C/OT]N.*/T&C.=CS]<8[<<4?
MH&WR*DGIT'7 X'%:PTCZ7$>C_!+ ^).C^OV35\>P&G3UTY;IBH^49?D<>/TP
M[_Q1/D'XK>"/"=I\1_B7KNJO;6L+^-/$U[>7=[-!:VT!GUBZ9FEN)B%13(X4
M;B,E@!R:RQ4JD\36A?:I))6Z+;8UPR4</1:T=CR-_&WP5T9FB37=*NYHMH>'
M38;K5I0<;@@6QMG1G((( 8Y'/05$</7MI%V7?0T]K3CI*?*UT2, _M$_#.U;
M48-)T+Q%?/H[6\=_YVDVFBQVYND>6V;=JMTLLJ.B,0T<+@;2#@BMOJ&(LKI1
M3\]?N,GBH6VT1ZO\*_B1I/Q0T74M8TJQ.GII>L2:1<6AO+6^(=+.SO8Y3-:H
MJ+NCN]ACP2KPN"3UKFKX>>'<8R^TKKY.QI2J1J)\JMRNQVWB*$7FB:M:",$S
MZ;>(G&26-NY3'ON"_C6=->_'HDRWLULCXX\7:7;>)-!33KUI8+6?4M$E:6W"
M^="3?VQAECW*1N69HR20< -7K8>4:<UY^?8\^LEJOY=D?EC+I:1ZAJ8F56DC
MU*^CRR ?ZNZECSCMRN<5]91:=.#M;0\>?NR?D2[5C8(JY# /'C"@*V>,# &&
M#+_P&M5I\A+3Y'UW^R)XC\5>&]>\?GP]I5EJ:W&@Z9?ZG_:%PT$=C9Z5>S?:
M+N.-70S2K'<[0@SR5'>O#SJES0I2VLW^!WY=5]G4<-D]S+^-GP?L=3^+OC2Z
M36+NQ.JZ_)J+)]E@FB1M3CANV\O+HVS=,< Y/3FL<)BW2PU.+7-**]#6O0M6
M;6G-N>F_#7]B'1O%)@DN_B)JUFDFPE+;0;)W )Q@-->D9_"AYG.+:]E?YDQP
MJDK^TY;=#]*OV;/V'/!'P?\ B%H'Q.T_QQXLUW5M"L=4M;73[ZTTFST^635K
M*;3[B2<6L;2LBV\[%561?G5221Q7-5QM2M#V;I\L>C[=3JA0C2LU]D_2V, !
M1BN78O;Y%V-<>P&./I1^@UIMT.2UX 7_ -(8A],YI-)_(N,GU>QE!% ''(^H
MI<D5TV+/B3]HNXDD\;K:H(/)@T#38W81#[0"\MU. 9LD^7\V=N!WYYK*M907
MDT5%:V['RUJ $:-QTYR<A0!GDGH!P:Y=OD5I'^Z?+'QE^*NE^%+.&TTW5-,N
M-6N)FC:"&XBO9+2-1\\LL-O(3&V=H7?CGL<5Z6%PU2<;M--;-ICGB8TGHUHK
M??H?-VCR)?R7GB#55$NGVC+-*,[&U/4+@M+9Z9'QUE92\A'^KBC<GJ*PQ,Y0
M:I0TDWJ[7_X8_4\"X4\)A*-&T?:0C:V]FO>UWW._\*/IUYXB\-:E>ZI]EU"[
M\7^'T@TRUTTF,2/KUA$DDMSYJ0PVXYPB*S *J]:Q5:N\3#!4Z',[1<JC=N6/
M=+J>IF4:V"P%::H)4X4)-R;OHH;V?5G]A4"[+>)-VXPH(68 KEH?W3'!Z993
M7UE6GRTJ::O**6OW=#^;W+FG*2]U2;=OF3GY1Z8'Y8K6<I1IKEW2_0G]#@_'
M44MYX<UZQ0E?M>BZI:@C&0;BPGB4CW5G4_@*\"O)SG:6O0]7!PARM]4M#^53
MXC7%_>>(XKK4[J6\OI=/ACGNIFW2RM:7%W:+O;N5C@1>>R@=JCEC#W8JR70W
M;;>O3^D-\..%FA;.W:Z'T^Z<X_2HEI'T'^%C]K? +B;P_H,HQ\VE6!!^MO'7
MGO1OH=*T2\CU6(%0O^<5GM\BKV^1J6WY<GVZ"C8:?X'M_@6SMIM#D:>UMY]U
M](1Y\$4O$:1*O$BMP#NQ]:Z:.L?\.WRV.6KI)6;7HW^A6^*DD.E_#/X@7D$4
M,#6G@WQ)*CPQ1Q,C+I-SM*M&HVD-C!&,$"M8+WXZ?@1\,=WIYO\ 4_F.U.:V
MT^V-Q=RB.-61%;!)+N"RC YZ G\*]>*222V5CG;[Z%/3+JWOI['[+<;Q<7<,
M*;2R.LGFQK\HX.X%U((Z9'/%8XFI"A.G2G9J2U"*5XVV/W\MX_)M+6'G]Q;6
M\//)_=Q(G.>_%>+47+.26BOH>FDHI):60.!C/<<5 [LJR' ^G%-?D-/Y6*+C
MD_[/\AVHV^0]EZ%9P.<]OP[4OT)_0H.,]P,9_3I3V^12T2Z6*+@#'&.?Y4#*
ML@ 'IC^F::DXJRTL'Z'I/P44+\1]'P,?Z'J_Z:=/7;ENF*C_ (9?D<6/TPS\
MI1/EWX^^''\5:E\7?#T3)'<:MJOBVUL99,;+?43?74FFW+Y!&V&_CMY,X./+
MSVK.K-0Q]6H[\L:CT6_NO4VH0?U.ET]T^#O#W[,OQ3OK>UE\;^*?!RZBEZUY
M<26\6H:CYRNCJ(7BL8-/CWH9I&#K* '"D[L'/=+,J47[M-R7FE?\S&&'G!-7
M2U;T9ZUX<_9ATW2I9Y]2\=^(M1ENGD>5;73]'LD5)(5A-O#+>P7TL4 4,0%9
M3ND9N#C'-/,9-^[34;;,JGAE%-2FVNW]=CV/X:?"7P1\)M+OM(\$Z?=V%IJE
MW'?W_P!LU*ZU&2XNXH/LZ3;KAML.(0%VQ*B_*,CBN.MB*N(DG5M[BM&W;<WA
M"-)6CI<]"EB0\,#C#*1V(/!%8K3Y%6^1\>:Y:&"SU?3PFZ6Q>]@B7[K/)IEZ
MS0\]F)MXR/J*[Z,D^16V?Y'%4BXR;Z),_,CQK:I9^+/%-M%]R/Q%J7E,<#,+
M7<S+]WCD$'(K[3#R4Z4+:67Y'B5%[.33[Z'))&))X@\GE(MKNW$%AE))BP"@
MY)W'''J*VV^1/Z'U)^S)K>H6'C/Q!:Z)H6H^(;S7O!^K:,MCIZQB>594LVDN
M9(Y6 \B-HGD<EEP#U%>-FZM1W2MT.W .U:UGT/;?C+:367Q';[1$T$\VF^'+
MFXB;&Y)SI-E%.A*D@LLT3J2"02IP2*\;#R7L7;I^AVUHN$['UU\"WW6]MVP(
MCCOPPJ-FQ4]$?I1X(_X]X_PHV^1LM#U5!SZ8/TH_09>A'S*/R_&C]!K2QR&N
MK_Q,I ?X8XAQ[+G^HH_06WR,Q>/;'X8Q1MZ(N,E%);6/SP_:A\57\WB/7/#_
M (:L-:75%NM$L9M:LM"CN[*"6+3[:Z-@MW='RY+YHIQLC\N0#<2?NXK1TZ+H
M?$G9Z+K]Q2G=VBFFNY\3ZMX-TCQ%:7<'C63Q[,L:3--+>:[J%I$9X%R]E';:
M)]EMH9W8%?)\AR,$$$ UY\7BJ<_W-6G&$=E*"D[^K_+H4TI0M+XOZL>&P_"[
MX7&*YM[+PC-%%'>W$+7VL7T][>LR2-B='E".EMY2JP#H",D')Y/T%+$57#5I
MNR5E_DMCF^KQC;:/*T[M]GW,*W^&^L>._&6F_#_P#IJ6MAIRPSQ37TEQ"DU_
MJ:QRSR!\%)L(;= %7]W@JS@<5QU80I.562:DT[6/L\JSJCAU%5Y^]2M&%MK?
MAU/L'0_V+?C'YW@O3;R^\*:?:VGB#PW?W9TS2#(\W]EZU97I^V:U-="5G<0M
MGRH]F[ "L!7DX3"T*..6-YJM2K.RM*;Y8WTLH[65]%T-LWSU8O"8J$954W"2
MC>?N_P#@/:W0_I) QG''/TZ5]K)<^WV=#\I3V\M!<8&/;Z525H6[(1\Z>/X?
MC/INIK=:%?>%=5\.W^J:7;OIEW::@FIVEFU[MOEMY887AC5K!L%Y3)F2/*F/
M=Q\_B(.%2^C1ZF#Y&N2*Y9KJ]OD?S=?%RTATWQIX@L95F>73O$/B;1[?#QQQ
MV_\ 9VMSHPDC$8+EA)NSD'+\YK)N[TTM8ZK[Z6Y=/N.3T_SI()(K67R+AHV2
M*4C(1R.#C]..F:S22WV2);4;>3/VD^##W<GP^\&M?%&NQH-BL[(24+I'LR">
MIVJN??->?5Y5/W=$CKB[I=+'NL:[5'T'X<5%A[%^VP,>V1^)II6#]#V_PQ:W
MTOA:U&GWJV%P;R>997MUN(W1)65X)$8@A7 ^\IRN 1GI791@XQOT:T.:6DWY
M=#AOCI<ZK9?!+XLRZF]I\OA?6H[)[3>N;2XMQ GGA^DZM*RDC (&<<XK=:-$
M[)^2/P1^'WP:^)_QOU;4[/X>Z7:#0]!=(]7\3:S(+71+.Z9-\=LDABD:[O3$
M6<PPHQ2/YY"JLN[LC+V2N^JT.3V4IRTLDCF9_ S^#O%T-CJ?B#0]4;0=>M(M
M1GT2&]ELMEG>Q->M9S26Z"<!4D&57#%< ]">7$1A7E&33O%?B;0_<VI_970_
M;;1M:TGQ'I=GK6A7T&HZ5?PB>RNX&)22/.TAE(#12HP*O&X#*RD$ BN"4)7[
M6T1WQ=UVL7V&1@<?ITK';Y#*\B$#''%5&+>W0-B@XV[O:E;7E[%7LK=BHX_#
M/X8Q3<7$(Z%*1,9_V>GMBD44F /MMZ=L8H#8IR+T[<YYXQC- ?H>D?!48^(^
MC^UIJ_Y#3I\5W9;_ +U'RC+\CBQ_^[/RE$\.^(4;?\+ \;D< ^*]?//MJ=S7
M-BM,37\JD_S.K#Z8.AY)?D<JL..,Y [#CI7/^A7X6+4<6/X3D'CVP!1M\A;>
M5BZD/8C&>G;&*-OD!7NHBH]%7'). ,?_ *J6WR&M&NA\I>.1I]GXC\06E_+%
M%:7DR2_,X7?%J%I&LH4@\?OUGYR.2?2NRC[JB^S5CDJ_:\D?FM\1/(FUZ"/6
MIYCJ\%C;6=W_ &;9620,+;=;VK$1"(27+0Q S.4W&0D9)!+?8X3G5'W;6C9(
M\/$_&TM-C(TGX>:UKTT3Z+I'B"X*H^QIK&*&"42* (0[R !\;FR2!@=:)8M4
MWR2M>)4*$Y1TT/MW]F'P'J/ACQSX1MKW2++2KRWC\3/XAN;Z:2WUVXENM-'V
M2RCM]K+]C^SFVDMR T<J)=2K+O5D7R,R<:\;W:79.VQW82'L'_>7];&_^TS;
MI!\1K*XB38ESH6F2)E_,W>5-<0,=VU>?W8&,<8K@PC@Z=ET-JS;EV:/??@)+
MNM[;/&%CX'/<?KFDU9OR%3V^9^F_@?\ X]HNW ]L<"EM\C9'K2#A>W&/3H*-
MOD,NVP^<>QQ^5&P;?(Y#7!C4Y_81 ?A&G^-"#\+&5T_#^E&WR!:?(_*/X[:O
MJ]G\8/&$=IJ*Q2#Q(MW9V4FJPV4Z7-O86,,<\6GWH"3CR4B='B#*X<X(P0&Z
M+<+V4?30OVD%Y'F]CXB\8Z<EM#/;7WS:TNK*\D-C=1)J7F!Q>SLC[I&D_>95
MOE F8\5Q>QG&Z3=BXSA;T/5-,^$GBCQ??ZEK_BZRT>WMM4FN+Z[N-1A'VNYD
ME7<DMKI\((B#$!A&[)@$X&15<\Z4?=DU;J:)(X/QSX;\6>%/%O@G5?@WX1L)
M[W2;#5K?6+O5$DL]*N(KQ5M[>-KB6X3,\;AY45%95#MDG<,:TZU.4)1Q%?E=
M]+[V\B)4JK:=*DI*.YZ7X.U']K[5_%/AR\U#4/AUI&@PZGI2W.GVUIK>I3/;
MK?P&<J\4HB,WE,^U\E%.#ZUO3^J<U.,'*4DU9WT=OD*<:\:<N?1*+NK;:;?(
M_=0<?YZ8KZA*WSU/F?T%IAM\BA>*#$WJ.![8KQ\7!*3_ +IU8:3C->1_/]^V
M-\'M5?Q=<:]I.EVFFZ1%KWBLZGJL5C.UH)KG55:*34)=,M93;7+/'+\]T(PR
ME=K'H.2C0G5U6B_R/0JU5#79GR5I?@R.TV23>(+#>I!VP6=_,I7U5WCC&:IX
M.JU9'.\1&RYMD?=/@C]HKPQX.\-:-H=QI&LZG<Z79Q6KW$!M;>";R^ Z+*Y9
M1C'!%<T\KK7]U:&U/&04?0^DO#_QM\.ZW;V<LEI>Z4+J)9$^TF.=%!_AD>$\
M'WP:4\MK0LHJ[2V+^N07HCUO3=:L;^(2VEQ#/&1E6BD#?3C.1QV(%<CI.#Y9
MQ<&C=5&TFM$]CZ=\%X'AG2R!C=',_I]ZYF/\JZ(^[!6^RM"'N>-?M:79L_V>
MOB<4;:TVB16J\X)^TW]I%@'U()%3&;YET!*VAQOP<\):5X7_ &9/!_ACP]8"
MPNM5\*VFMZM?QE1<7FI^(K==2U>ZFD50SS.TZP*3]V&&-!P@KK=2/*HO>),:
M,HMRC+W7TL?D7\8?#3^&O&NH0>64BG8R)\NT9'#8'Y4J>CVZ&4])=K'OW[)?
MQ"^QWU]\.]1G(@U#SM4T#S'P$OHHU-_9Q[CQYT""55'5X&QRYSE6IM>]'0Z*
M,Y/W=%8^].3^'X8Q7G;?(Z"-UX],#'ITK2GHGY!M\C+<=NPR/RJE!)W[!^A5
M< ''/'3\*FII;R&G8H2L 2.>G\JRV^07:^12/?MQ],8%,+M%-QGCMC^72C\"
MEL>D_!<8^(^C^@M-6'_E.G_PKTLOBHXF-ND9?D<>/_W=]/>C^9Y+X]M,^//&
M6<_-XIUP],?>U&X-<.*?^TU_*I/\SMPJMA:'G'0YU+( _3BL-O*PYZ2^1<BM
MH1MW-&I)VKO95RV=NT;B,MVP.<U*DMM=/(FUNVGF&I+#I6[[64M/+"O)YY\K
MRE895I2^/+! ."V.AH;4?(3]U>2/-?&+G6-#GN-*O&,%HT;27%C,'60.<G$D
M)(*@'!Z]*M4KIRCTU)JR7+&SZ(^0OB5#?-]EO]/TNYU;_B6O#/)B=XX+BSE9
M[=[J1(VV0D3'+9! 3BNNA)0M=J/J<S7X',?"RQ\"10W>I^-_!^M^-/&4VHLY
M7P]9H;(6TL%O.%!>0M"_VDSE4 ;Y6'0]>^IBYPA&,:MH1V2_+0Q5%>T<FM&^
MQ]%7'CFR\*/I%U;>%O!/PNTA98[C4KKQWKVE76J7%DCX>U31X%,]M<2IW6-Y
M!@#Y:XG5JSE>$9->C-G[.FM'Y')>-?'FF7L^@?'CP[K4O_",#5)OAU;ZUIB6
MY::^L/MEV+Q5NXE>&RDBNM0MDC93_P >2OG,F*VHTJU6HZ4URV6S\S*I)0IJ
MK%W>WW'R+\7/C]HGBKQMY6IQFRMM$MH--L]72WFVZG&2UU)/=VZ[FM94FF>,
M;%*,J$\'KZ-/+YX2'(H[^:,'B8U>5JZBUI=6V/IKX%_&[X2Z9#;_ -I_$/PQ
MIK*J%DO[YK5EV]<K-$I[=.37-/#5D_@?R*A4A%6N?H#H'[8/[,N@6T?]H_&7
MPFS#8@BTW^U-6F+,P50(].TZ8]>*%A:Z^Q9(M58+J?=MO(DL,,T9W1RQ1RQM
M@KF.1%>-MIP1E6!P0",\UE:W]=C:,DTNR+T#B-\\#MSVI6L5=>AQ.M7$8U*[
M)=%160%W9508C0$;F( (P.,]ZFUOD*Z^X^?OB_\ M(?";X&-H,7Q!UJ_MKGQ
M)%J$^C6>C:1=:U/=1:6UNEZQ-KB*W"-=0 >;*FXO@=#C2G2G5;C35VO.Q,YQ
MIJ\G9=#^>OXZ?%_5_BM\5/%GB*UTZY?P[J/BO5M1\-+):&UU>VTV]:""S6^B
MMY9=TZVMK$=L>XJ78%F[>U2I1A3A%Z.*MMU//J5'-JVB7R(/"OQ#\1>';NPE
MBUO4-2LK.\MS=:'?WT@C>.-U>2%UN[22:Q4Q*07"DXX'-<]3#0<;[&D*K4TE
MLD?3*?M<7NL7SVGB>>XL=,BN8)-.M?#ZRQ6U@RQRQAY)I9ENM2EV2LID9D3Y
M?DA7K7BUE3P\[6YH+?0_0N'^&*N:X..,>(HT8R?+&G9QE)WLM7I'Y[G=7W[2
M6G_#^PBU/2]0DUOS&<0:+J,#W5C--+G N3<G=:?-%EFMVWX'O6<(8?&VIQ7+
M=::?KT.O..&L=D&#J8S%4_94XR48MR5Y::.,4[RC_>6B>AQ.E?MP?$G7/%WA
M;3K6#P]HUI?^*_#MI(MI8RR%(+K6+*WECB>ZNWVYBD8 A<]Z[\/ED:/*W4M"
M-K+R1\#B,=4JQE&VDDTS^H48QQT''Y5]#"4)17(U*,=/NT/G[6%JP()URC#@
M<<9XP1TK@Q:LGT_X8UI/EDNEC\^?'=U+9_$_Q]I$N/(@:RU*WC4*C&VU2T@E
MNDE#_N[FW,TI8QR#!W$$XXKDPLW",XKKL>A-7IQ:Z(^5_'7P-\"^*5O=5\.,
MOAG5H]\TKZ1;B72+E]N]C>^'4*-;.0&S-IA1<DXM)#EJ[[->5CD=K>A\:>)-
M%TSPM.T&L^*=(MW0[/DM->8G/*XC?2$=200<%>,XIJ5E;:Q*=NFQZ;H7Q5^&
MUKH=JJ^)FD;3([*QNO-TN]L?-NK@7#+]D-^L*S0H+=@S[EP63Y?FK2GAZ]9-
MTJ4ZD8[RBFXKYK2Y$IPIVYFHM[)[_<:<G[1&E>')(3H6F^)]6!!<O9+906ZE
M?F&XRW;?*1TP3WQ53RC%5HIO"3E;8E8N%-KW]/F?L-\!?B!HWC_X5^#-8TS4
M=/NM0ET"QN-9TJUU*SOM1T.\G#O+9ZM;VSF2SN$?<I$J("5.,U\UB\'7PM:5
M*K1E2U=DUT]3UZ%6-6%XR6R>NGW>?EOY'F7[9&LVB? CQG91W5LUV)_#Z7%H
MEQ$UU!%<Z@);>2YMU<R0Q2K:RE&=5#^2^TG8<8PBX7NK=C6]O*QZ#\.HA'\.
MO L&W"IX-\-)L/& -&LP1BM5^0UIY)'YQ_MP^";W3+.?Q)H<$$E_;0S7%K%*
MCF*;.YO+D$3*W.T@888.*VH\O.N;1&.(;M>*Z^A^5'@3XL>-K+Q1HFOPW&F6
M<>CZK:W,\4</D7 *,KQM'(7D<C=@%<@, Z-U->C6P\)4I:V<E9?IZ')3K2C+
M71(_H'\'^*+/Q=X7T'Q-:86#6M-MK[9G(AED0+<0;O\ IG<+*F3UV5\Z[0<H
M/W7#=/1_+N>Q%\R5D]/(Z9GCV_*PYR!R.H^E-6Z6T[%;='&W=6,J0A2P],__
M %Z8?H9TCXSVZ[>W2E^@%"3H/7FL)?$^@MOD5F!QQQC\.E*SVVL-+Y6*K=?\
M\52@^G0:]W3L>E?!?_DHNC_]>FK?^FZXKTL!_O$?*,OR./'Z8=_XH_F>/?%#
M7=.T[Q/XHU"WN[6^D'C/7K*^TV-F34;5H=3NA)B.4!2-J9#GY?WBX)YK@Q$+
M5Z[O_P O9_F=.'J-87#Z+W8V1P-SXZTRRUI9+"TN=:T.:R\N2WO$:SN[>XE7
M!\N2'.6C(P&.0=Q(/ -1&FFKW:L:.5_*QAQ:SXAO=)N=&-MOT]KX7T-Q/%FZ
MM-Q9O)6^ 5T3H<L<]<-TQ:IQCTV.7F:>]K$6MM?^(;673+O5Y-3U#5+1+&'3
MK/S]8U*X6V^91;6]D&::5%5@=Q4<G+#DT.G?9;#4VE;<R=&U73]/CDTJT@N+
M9(8_LUS97MG'IT\-S;$Q-'+8([F&5" &61V.[.<&O3PE*#C:2MRK5(YJM51<
M=?AZ'P]\9_VH]4^&/B_Q%X'T;P=IMS-;M;3&_P!6GEELIH;^SBNXVBTZ%4!C
M FV%7=AE&]JUCE<:DW-WY%LNQC+%J-M%^)\R>)_C?\3]5\,GQ'9^+?\ A'I=
M>U'[/KNG>%2VC12P6L#VNDYBM($6V\N*UEC95F#.&1\=379# X>%ER\UK6O_
M , S>(J23Y9<L7LCYQUJ[UC[:TFMR:A/>2JDS2ZC+-/-()XTG219)6;>'BEC
M<$$Y#@]Z[H4J=*+Y8*-MV8<[2UFUV]3]+?!OC/15^%&E^"[OPAHL7A[4]*MY
M8$;5M]K#<M $DU*&V6S=TU83S-.)&>)PQ)WG)SC[.E/VE6G4M4@MG;IZ IU(
M2IQG%N$GNCYL_:8\&QZ%:^"-2TRS":8UEJ&FS7$09LSV\T5U&]U* =\DBW$A
M\QCR5P.@%>?E.*E7J8J->HY.+5ET5COQE!4Z=)I<J\CY9L67<!D?>'<'&"*]
MQ-1TAMZ'G<MOM.RV/3/#$MM%J>D_:&00+J>G&92ZKF(7L!<9)_N@BN>I.;C-
M7TL^@XQLUJ].A_91"R_9H&0;4\F)D7KA#&A09] N!7SVWR;/4I:170\T^*WQ
M3T+X3^&1XBUV.XN4EO;:PL["S,8N;NXN&P IE8*D2(&=V/0+@ D@4):I%MV^
M1^-/[>O[0_BKP]\5/L7A74#_ &3<^$_#5]_9][YAAMY=02XG=X/LTT3QS-&(
MP[!CDKZ5UX?"?6(NTN7E?E8YW7Y)6LEV/AOQ;\6-;\?Z)H-KJMI:6D=A%YCB
M*2:ZDN;QS(7NS/=EI+8;&5?*A<(=@+ D<=E'!O#R;4N9_@8U:KJ+ELDD>=?:
M8D88<@CD$'!&/0@YKL]FEU>AS_A8S!>1QZC'/YDLA2WE2>9V+RL&8[6=FY(C
M."H/14Q45()1WV'"7+.UC&FFN#=R70NWAW2[@I(*@+C&U&4CM7'.A2E!J<>9
M/34^HRW.\9EZBZ&*<(P=TK)Q7R>AI2SZKK;F4?:KHC[UY=LRPH!][RE;@#_=
M_*ML)EZI6Y*:BFK)V-\ZXDQN;P4<9C)U815E%OW5;LNGH=K\/M AC\<^"'NI
M6NIQXQ\*E5SLBC8:]IY4J!RV#W/''2O4>"2I.+6T=OD?*^WA'3I$_K?TWXY^
M#=4;6[;0GN-0U3P]J%YIFN:1<E-.U72+ZTN)+=X[_3KC]_#"S(&BN%C:*5'5
MD<@\>'3J1P7M+Q=I2T7H"PU2LDXVBHI'"Z_^T/JM@9$L?#NGKM!V/>7=Q/@C
MIF.%(OYT?VDVO=@EVO>YHL!9>])IKM:Q\W>+?VL/BI!YR:=+X>TQ5W#]SHXN
M'4#@8:]N)1G'JM9*O.O>,DHJW03PL*=FI-V]#\POCA\7/BUKWQ!;QJ_Q O['
M6CI\&GQ1Q06MKHUU9Q;3-;7EE9PQI,\AB@0-,KA5B&QD+,3T8:"CIO;^OP)G
MHN1>ZH[&OX"_:OL;:XT[1OB);77AZ]N[M=.BUF-,:4\TG$3O(LGF002,R*QP
MZ*67<2C$CJ_0Q_0R/CSX,\4:OXIL+'PM#KOB:74D:XCTS3-&.J7D,4<:,9HA
MI=D9&MU4\O(A ^7+G.:[\MP7UW$1H>UA0@W>52H[1BO7N<^(K?5X.?*Y/:,5
M\3?IV/BWQ1:W<)UC2ID,3Z?:SKJB7EE>-/;R6DRI):!;2S<6-Z95*%[CRD'E
MLI<5]%F^99?@,.LERZI&-"FDZE:+M[:>C:4ET4E=6/-P.'KXBM/$8I.3?PQ>
MT%T^:6AZ3^S%\/\ _A<7B6T\(.-?BL-)TO4K^]DT::&UEDCME9K86]W<QB%7
M:<XD0AV5(RR\9Q\5B<PJ82E*<*\VY-<JYY6^>I[='!TY3Y'325MUY'5ZGI^K
M_"'X\7^A_"?QQ\3[#QG-!I-IHZ6(BGU.XGO$,<>C6]_9W")>+<WEU;6]N'M&
M\N6XE8Y'S"(8RKC</&6)?,HO1[M+M=]ANE&C**A[K36A^G^K_LK_ !2L?AUX
MQ\5^)?B5+XS^+GQ%T?P<?B$/%IFDT>RN?#\]W_9VG:-=:8%,5KIT>K-!(S0,
MK_8V>/8)#N\NM)2ERQ2C&.SZGH0A**3>G8_0GPS8SZ5X>T'2+DQ&XTK1-*TZ
M<P%F@,UC86]K*868 M#YD3;20"5P2,UE:WR-%HNUCYX_:.T9=;T&:TDA\P"#
M,;[<E&PW?GCCI35DU=\MNQ$HN4;+H?BWK'@71_">HWGF:!8VPEG<FX\I29B7
M9_F\QQW8D C S77[64XI7T1QJDHWULTSZ1T#QWXL\,^ M _X1SQ@=)M=.B:[
MGM;K3+.6"!&N9YGMH98(%NY;5U93(K22D9(3:M<WUO!TY^RKX25:4-JL5K\^
MAI6JYA1IT_J:C7J:<T&[67D].G<S[/\ ;<U;PE?:3:^)#I'BS2;K4X;.\OM*
MMKZQU'3K>ZF6/[0C7$ACO(H-V=I1G*J1N)YK3#4,'C74C05:A.*;2FDH^5]-
MCH>*QBA3EBJ$:+6EE*^G?0^[O#7Q(\.>,+5[S0-6M=4MXW\J5[>0EX7(R%FA
M8*\1(Y&Y0#SC.*X94IT[J5KPT=MM--/(Z?:1MI\CK/M4<B@@Y 'Y9]JS_"PX
M2O?2W+8BEE1$#,0JY"KD\EFX50/[Q/ %0Z:;WW*V^1QFK?&'X<^"=;'A?QEH
M^LWCRV^F7=UJVCR1!]&_M9KZ&R61/M4+LI>P)8@L )TX/;V,+A82II5(WL<L
MJZ3LM+'4V.N_";Q%(L/ASXF6NFW4Q4PZ9XO@%A*=YPJK/<"S+G:.=K2].OK<
MLOIMOD;BDM$K6T'&NK'L_P */">O:5X^TF]GBT^[TM;74]FK:5J$=U9N)+"9
M(OD=4D4L6'0./]HCDF"P<Z5=2FN5)/\ X!GC9IT&EW1^"7[1>I:A#\??C8D>
MHW\2)\5/'2JB7MTB(B^(]0 5464*J@     5\_B6UBL0NBJU-/F>]A80^IX;
MW%_"I]%O8\2;Q!K$(PFL:JNTG[FI7BCCITGK-.2V;5O,MP@G\"7R11NO%OB'
MR_*;Q!KC1*<K$=7U!D!'3$;7!7]*VA"3:6J7J<KC"-_=2M?HC]#M&\:^(_$W
MPL\,>.=8\01V.B>!] ^U_P!KVEJPO='M[9(X;^:Y_LJ%[J=U>!E(*,Q"9R!N
M:O4I1A&T%9RELCR:L9IRDDU"/8\\T3XR>%]<NO[0\)SZKK*S7=W;W.HZQ:"P
M2XG3YWEC@DFDNF9I#&P>81[AR1DUVP@Z5U*/+_7D>?4:E9K5'R!^T ND:]\4
MK34_$ET;"+4O#L"?:(0$A-QIDL\26[A59A))%);1)(.%<@R?("1Z-*34+0U\
MC*R[;'GUIKOAZ/PIK$7A?0(I&\-FQU2Z.LB6^EN8[J\-BZNOV@01Q65W?0%)
M%A=W,C#>$"BDTU)77+<>WDD>5Z[JD_B?[$9+%(+^":[7_046.T>TE:)K2VM]
M.AC @> K,ID!)D5D!Y3)TLJ=KRT>A$K-6CJX['OWA.YU@>&;.WN-"EMCIML@
M@OM2N;>UM4F""..Y6.5'G*J%W,J1GC@-TSY#IU*-:HX33C)[/LV=ZG25&$9)
MN4>VECU[4OB'8^*/!WACP[>6F/$FCO<-JES @?1+R 1+ DMLTZK)OF8I(83$
M53#C<<#/+0P=;#XJO5O:G)Z6T_+L;U\52JX6A247&I'XK]+=RQX#N_AOH^JV
M[>,_AGX7\3:8TB"XE_LJV&H0)N^:14.([O Q\C%">S5V2E73]RIRKLVSSXV4
ME?1(_9_X$?#G]GG6M%T_Q)X)^''PSN["<#RKVW\+:3//;W";&DM[E;NVDEM+
MV)R T4@5E(!&003R2G43:<Y7]6;I1MHEH?9.IZAI^C:;=ZKJ=W!IVEZ7:2WE
M_>W#>7;6=E;1F2:>5@#MBCB4DX!X' J(Q<G9*[[&T)Q@G=\J1^97[=OQ;\'#
MX;?#GQ7'K AT/5]6NKO2%O8GL;_5[.T>>VDO=.TNYVW5Q:R-$QCE\L*RR1L2
MHD%;0H57-1Y'H]?(S=1)MJ6B/Q9_:.^,FD?&?QQ-XLT+3-0TC3FT?0](M;+4
MY(9+ORM'LTM5NI/L^4B\]@\@C#,4# ,Q(->Q0H^Q3NK')*?-+:R6QP9;RM(T
M]O-CB(CRRR*&#!40E021L.&!S_C6_-&.E^6PDK;:'.W<-[-,/+DG6W9%93O,
M,.TY!(8 $C<.FZGSJ%GO?8:IN6BTM^A>LM#OS!<2VXP&B8FYFW)$BHI+^46)
M:0[<^W(INE.O]EQCM?8%R4=6[R70[2U\/V5E#!-<H]]<LJ']X,QPGR]Y(BR,
MX(VY.>2.*[Z> ITH<TK2Y;:/_@]C.=:I4?LX6II];:::[+\"IK'B.PT]?LP/
MF7*JH%E;^6SH1T5BN$A4#^_SSTK3GC2:BEJ]DD*:BE%0YE;XFWI?ROLBEX)U
M34M1^(/@4S/]FMSXX\(_Z-!D$@>(M-QYTC?,_';@>U9R<_>W6_<RO%:=ON^_
M8_IU_;H\-C1-*\&_%+PIL\/>,].\0'1[CQ+IL207UU9W6GW,]I9ZHZ+C4;-9
M[-E$5R)%Q,R@8.*\YX:->\&DGTT-J>*EA_./;HCXZ\"?&W5/'^LV/@C7/#]T
M/&M]OBTR70;.:[T_Q \$1DD:*WA#R:?="..21U.8L*2"@P*\?%Y=5PLWRP<H
M]_(]*CB85HJ49KS5[6^14\<V&J6MQ-!+IFI07*EE:WDL+I)E8,4(,30ALAQC
MIUK*C%Q;;5E8J<HV23V/C'XJZ)>30L\^D7]K+ S S3QW,(5HAO?=%/&NQ@K1
MD[2, CCYZ[Z&_H<D])>ECPKPS\,[SQ_X@\,0ZG"]WX9M_$%G::G,=0^R(FGO
M<02:K#',C$QSK8),X8 %,,0<@UUQC*\5;=I)&+5]+\I^TNA?"7Q!\*/$%]JW
MPC\4ZS!I<WA1/"2:;<:A-J'B*'28[F.\6&UU?6)9O-=9X(=CKY<JJ"@R,"M\
M3B(?4)X5)1DI.7,E:3=N5QNNFGIJ52PR5>-6<K**5DSWCX2^#? ^@:!-<Z;;
MR3:SXMFG_P"$FOO$>GQ07TITZ\NKF2SU;3;O3T>YF6::9)6G5UGW9#F(K7Q]
M?GJ4H4ZLG[6#;@HMI12[K;8]!<M*I)QBI0DM[=_U,/Q5<^&/"]UXF'AC3-(L
M-4\37-K;61L(M-L[9IK2*[%A;K:Q0Q+;+//=,LQC 4KL+?=S7BXC%PBHQJSE
MRPDE>[M\S:$.M/=ZOI:Q\C?LM?!WQEKG[3>J^./BKH*Z3KGPV\,VVMS:3/'9
M//IGB/Q1+J&G>%;:=[*22%3'HEKJNKQ(),A+S3I2B,RJ/H:*E1H<JNE4LTK[
M)BJN+]FE!/EM=V73S/T;^+WCCPSX!\&:GJ?B6>3R[Z,Z1IFEV<8N-4UK4[P"
M*UT[2[/<&N;EI'0X'"CDGD B5K$N26[LEL<;\,?VAO@[\3V.E>%/'NAW'B2Q
M8V&I^%M1N5T?Q+8ZC:$V]Y:/I.H^5)<2PW$4L;&V\]<H<'UMTYQ^S:Q*G%OE
M3U70]ON!9Q:5JKW]C:7<*"2:6*]M5D 2W@#L-SX:/$88\$=2:JE&S]Z.ENJ^
MXN2]WFORJ.S3_#0_F\^)_P"U#XBU'6]4TN^\V\F@NI EEH^AZ'IUK#'.?.@A
MCGBLWN9=L+QKNRS?+DDGFNE4ET]U=DCSI5^5M-:H\TTOQEXBUQKV?4M%O=*T
MRVTR[N$N+UKDR23(J^5''YH1,%2Y($8^X*IJ,(NR26E]":527M(JSBFU_P
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M<*^H:+/LE$3/C,L:+MSU['CY\1AVE5C>-^OW(WAR75K7M^A^>?Q"62RU+4-
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M-&CKD*B0D[6Z8PJJ<_AFM<-.<G>_*DSDQ&BMM9'UM\'_ !GX+MKJ&:ZO(X)
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M4"-LY^8@XQ\K<$U\WBX.I&JNES^E>!:M3 T,!*[C3C2@K?)?D?67PX,=C?\
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MHM/;2QZAX<N(]/U"X72[2XL+R/3IY5O+O8;!Y%:/%DT0=O.,A/SLNS8 S#G
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M(O%7A+P[X2T'3]/L-<T/6]0N["WL89%:]L71[>>:1HW=Y(9)I2'+X4$8^4*
M2O*]VR-OD?+OCS]F7QGXR^,)O]=U*7^P#X@&HBUO8K2ZM;K2I;]Y9+6&:V\F
MYM+E(. +A90<CYV#?*DN5:?9V*22MTL?H_XL^%WPGU#X-7G@[XD6L;>!;HZ5
M!J$?VF]T]1/:W,,^G'[9ITB2VNV\AC(8,$X ?Y<BL)UW23GR\W*F_N&HN3C%
M;/<_#C]KSX#_  N^&4OPM/PR.M63>/\ QE<:.^GZAXKTOQ+I*06K6$EC=6%^
M8H9[*);NY197N)ID"H<<J:SRG-)X]U82I>R5)M*=M';3;\#:M0A1@K5.5]GJ
M?'+K-8SS0>8)T@FFB^T(QV.(G9/-5CQM;;D<D 'J:]E+Y6.>.C]#ZI^"?[.O
MBOXBQP>(]=2Z\->!X\3'49K1VUG6HXR"T&A63KN9&P5^URKY8R-@D[<=:LHW
M2^-;>G30Z:5)U.EDCD_B#\1-5\>0_$[X3?#;P))I?@?X>6]WIL6EZ7:MJ?BS
MQ)K*ZA_9>J>(M;O8DWS-'I]OJ)2UB#!%E8DLV!&X0=.G3J2_B._DON.FDO\
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M[>/RY24^U+&R^:>+$X&E"E4=.G)SD[JW3R.B->JY1Y9J*BK6?7S,7]L_XS>
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MD2^5)/&\(9LD"0KE"PSW<8_$UWXC9=EL81YDU9-(Z"*[DN96:Y9EN8),3([
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M4<A>G(V&NJK",W&45R\O0Y(24-+7L3SV%Y>V\MPVYP1E&<DO(PSCRU] 1UX
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M0R,UQ%+ON$554'S95^^&5ONGCBN5/E:_NF_X&/I4"0I-=W$08VP)0. P+\%
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M$-V&" "/RP:]"&L/-' [QJ)+1?Y'7Z3(LEO*'G\M+?#Y+!0(WXY+?=7<,?\
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M1,_3B^N_)1F$L:J,< 8QM)&W?[C!([8J=%\CLV^1Y7XEU^*))8\A K':R,2
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MHCCC8[68(-RD,-^>."!E1Z5CSM>5@E[J[6/B?XI>/Q!#-<//'E(Y>2^TG*X
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MD7Y$QT:/V(^+-G#XO\#ZGI[1?:+VT/\ :NEQ)D.UY8J=R1R*"8Q/:>? 0/\
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M.Y>69G8R^=,SL1Y6,C4BXJ.L6KW5]U]^_P#2L=>"A2BYW]]QZL^TI 5SR?\
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M!ON(XY()"\@>W$2[0H)0DYZGU.?6E[.?]W3U#ZQ37V9:>A6O;G4X0S,;=RQ
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7JQJ566QC7AF7.6'&?3!Z)II&:?X'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g305327dsp47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327dsp47.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M9>,=!L+77[.+_5P>)?!^H3R6MEXDTI6.2(+Z&;3[^W!8VUU"ISY%W;L_HXC
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M2OL]5J?JG&ZR1I)&=R.BNC#H58!E(^H(K\M:<6ULXZ?<?HZ>BMMT'T@"@ H
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MN,:U&I0<M8J<)0;7DI)7^1VTZU&JFZ56%11T;A*,DO5Q;L5_^$I\,"YLK/\
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MSMUY4>=_M#^)8OVA[;XD_M%0Q7,?A7POK/PD^%O@"&Y61/+N+V.7Q!XOD56
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M P%  'H!P!^5?,'N[>5A: "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
8"@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g305327g95u55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327g95u55.jpg
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M 0$! 0$! ?_  !$( 8("1 ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M    !P@&"0,$!0(!"O_$ %P0   & @$ ! L$!@<$!0H""P(#! 4&!P !"!$7
M5]<)$A,5%E65EI?5UA08(58B,3=WE-0C)#)!>+:X)T)1828S-5*!"ADH-#9#
M1%1B<D6W)3A&4V9SA(>(D:?_Q  8 0$! 0$!                 0,"!/_$
M # 1 0 ! @,) 0 " @$$ P     !$2$Q49$"06%Q@:'!T?"Q$N$#\2(R0E)B
MDJ+2_]H # ,!  (1 Q$ /P#>]7EWN4+<>8"&S9MRPL-I0VO!-D/D*FUP1%T>
MY*Y@9-MU-22.2YL^T<7G#:ES5.$S>Z@LB/QU9!XTY.!;?"HNCA#1,V?W^OI=
M94B+Q-M;Y\J]Y28?+^1<=E-4.L?M9_OJ?$TU5D4B-8-)O(B.,\EDCH@MY9);
MI*D/G**5=9[!#%ZR,M$W56S"'IS=V:#,ASJNK^=RQE;9:+7W7G+G$<-_]T72
MX-223/Y4]!J46=-:[3Q>D5C=(K942U;)B[B=H.K4WE'B5,V))>DB-H7EPY6[
M1=( F/PB</$RA[0W, V9=&V<D\HCE]_N*<YLS<EC2JLF9F?&*(,$K1NDQKV$
M'%.LS<(JJ3.UE6'%JZ8SRBTD(E9*IO2.4I3+W4X:A(H(1)3])$BX\0"]D<_G
MR].S2K?C1*>XS+;.=(]I?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJW
MXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%
MLYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*
M-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T
M[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2
MGN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYT
MCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]
M'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*
MM^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,
MQ;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7
MRC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR
M].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-
M$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.
M=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6
M?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S
M2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[
MC,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]
ME\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y
M\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?
MC1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6
MSG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\H
MUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3
MLTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*
M>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2
M/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT
M>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJ
MWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS
M%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+T[-*M^-$I[C,6SG2/9?
M*-9]'GR].S2K?C1*>XS%LYTCV7RC6?1Y\O3LTJWXT2GN,Q;.=(]E\HUGT>?+
MT[-*M^-$I[C,6SG2/9?*-9]'GR].S2K?C1*>XS%LYTCV7RC6?2KUV<TY-0DJ
M;X?-*?95SHY1]+)4YT9M%8O0!;UCBZM919ISG6;*>%7I0SJA&%@2F$Z)&0(*
M@8QF%E=1LUO$]O[<SM4M,=_Z7Y 446(T9998!'F:-.$  0B.-T463HPW>M:V
M89HDDHK0Q[V+1119>M^* .M<.W)@,"O7)K]GD5_Q"\3_ /5#4&!87 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MH3LS*5C2Z:0:<OLP')N5'(EP"PJDX]E&AZ#F8I,QE9+N P& P& P& P& P&
MP& P-(7A*OVZ13]TS%_G"=YKL8=?$,MO'IYEN]S)J8# KUR:_9Y%?\0O$_\
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MG$F .).  THTH83"S2S Z& PL8-[", P[T( P[V$0=ZWK>];UO"/O 8# 8#
M8# 8# 8# 8# TA>$J_;I%/W3,7^<)WFNQAU\0RV\>GF5TJOYT-%P"N$4"HBZ
MI035-H$U0DU'=U<Z+9=(P+TK<]%&)!V4C!7!D9$<-XD"6V54(,;V#:<)H]3#
M3M#&;)M,4I>+Q7ZC]9_""TT\)X\]!C5D((2X(X"*86&O;X6&(58]V<]2:-0J
M+S=0CG2QW<')YD49VTE.U<,\_AVO2&(O&I..-R%&]Z%/.Z;TQW)IHOD1';V
M[E((=/*_>FF.P&:^C5B)(NE>U\"M%K<G2 35&&(RR8MQ33(O,4D;0M[FXMTG
M:GB-/*%[8&W920U:3OKYHX^37[/(K_B%XG_ZH:@P+"X# 8# 8# 8# 8# 8#
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M;7'4MR-R]WJ2S8#9[2UJ24;DYP"6L4O;T*I21I4G3JUC"N7IR#CTV]*"2S#
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MEET<HVRR^(O1"EJ>4.CU*0PPDMQ:5SFRKFUS6$F*)8P& P& P& P& P& P&
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M%<^RRS?X&(_6. ZQ7/LLLW^!B/UC@.L5S[++-_@8C]8X#K%<^RRS?X&(_6.
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M8W($JI5QWE#D>(V3Q! JJMY.W,X9&W2S2XWWQCQOC^5CKROIA# 8# PV?6)
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M-L.5!9);%6<+IN\6;#[+@#KQ.L:1JGRZX"S3*.N"KCU.I&O$H=K]@#.B<CE
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M<V>H!R"C)N]?V"W5TO.!3>WE9 -=.MZ;[=9U1O\ :/6&BUK>A6,H[QI>G:G
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MCXOB?AT'-LOW[_?)^^@G/1+^BCY.\6%Y0?U:?^%MH&K3/_I&M8^<;$C+WO\
M[X&86M;Z?Z/?3K6A;*=8]'V'G^W_ /[3</)=XO\ _ MU5WY7_P#Z):/D.G_^
MI\7I_P![H_$6X]NF[[-3N32/G#=_)I@A/4YQ3ED9X?N#!9LS0E<E+=B$3D=W
M3V+/B:KV!P=!<49VKV\U+!W!?:3G#5#,J1:<[(I";)Y$A<HXF1JRQ&S2\S?_
M -8G+_VCE7A/2XG6ES50?]K<1*J<>C^UZ"\M!O6]_P#'R7IKQ^K7Q_\ EY79
M'3_?T?KPEL]8_N6H;B=9E]BY^\L8U'? =4919M9%MQL,OQK;JLJ64.IDP\8Q
M^-DEZ,D%>$5FAM )I\H+#62=:=%TJ%4RSH+J\*@JR5(R=3$?QV9C;K,_]N5.
MMO.YMX]+>?;G^B10O$F)%#_$"USY4V[,UQ0=_P!RE@;N(411>4#^O8$\O.+%
M_9T=KI\;1S;C/2GF?P]'>?[K^F*W^'\&#O\ 6E*XZ7/:)@=;_P!TMS-Y0U(7
MX^M?V3ALHP=.ND2;>M^+@MOK/6GB3J5Y9.__ +1\UU#)XW_6=4G'2K8MXG3^
MO27K45WIY+H_W?M/VWH_#QO'_'I%8RUF?%#[JD[7_HRKF]S"E)6_[1 '+CI7
MX.C?ZP!4T]QQKAR"']>@B^WB/#KH_IMBUH6"O"._F7FO/ 2BI<T.3%84HY/6
M.SO:%4UOS+,>9G+)3&']L7$B3KFQ[A+3<K/!W1N6D#&2J0*XV:D/)&,D9.RA
M"!L5GAI'I_/OR9\"-(DWA5^*]Z<?>)A4]X<UTD@J.VV.;\DC DICBEKVUC6U
M>QR6;%6''V^I6M6QS2-QLF2EQUUEC0-K:&5H:#%(G4TV=NFQM16DSA;]XSA7
M5_0U]QJED?Z4:E?)Z%C!_P"KE1/F=RV;6=)O^[[/$CKI60O6M?AK0#8X:#0=
M:#H/B_HX9UY:1Z/NK3]N_"(\W^7T6(U_81J%O'*Q4^]:_LEFJ[?XYV$_#+_5
MH>RGLA2,/3_6@BWXV"O"._B3JCYD,OX1CF/#W[0?P!NY>+;!+1BU_=M1NHK2
MX_ ,%T?VMD%I0[W^(0 U^C@K&6D^XG]/L_A 6/\ _&.'=H>)_=Z-W50_VCH_
MNZ?2KD=]C\;_ (^*N\3_ +H^C\1;=6.M?$'6=S;:/TI#Q*IQ]*U^/157+=QD
M*X8=?WZ26?QPIA$ T6OQT5MX&4'>_%VJWK]/!;/M_<^.:D?/WPJEU<'Z'U;C
MAX./DD]K1SB&Q$!SA+*)=J[3AD+N4E4G.DBIVU;;G#&8M*UMEBRA]K1J:G27
M.K$T&KBU"PE(J.MG9C:FG\]F-?,1'=;&)3;G%?L7CLH9()67#B*RIE;7Q,GM
M]/(;MY (&]V2%*]-LBJV/*ZOKRKY<D).T$92ZS+>+:UNA$/<9^T)E#;LYM''
M\YUQF.D,A^Y%7LPWI1R*GEM\JU0]]*EFNF7$E50H#O?C;2J>/E9M5>4&])"=
M_P!&D.EM;R9\*3Z\FH?%AIRQ0J%<K;[8ZX]Z+81F+1B%,3=%X;'&&)1IH("E
M:8[&6AO86)K3!Z=A3-S2U)TB!$0'>]["2F3E%ZZ=] <(][ 8# 8# 8# 8# 8
M# 8&D+PE7[=(I^Z9B_SA.\UV,.OB&6WCT\RW>YDU,!@5ZY-?L\BO^(7B?_JA
MJ# L+@,!@,!@,!@,!@,!@,!@,!@,!@,"J7+>!2MXA$=MRK6DYYNKCA)@V_7#
M(BV$M=.D;>V+V>RZ? 8,190]6]6;I*(8S!7F>:FF=JX3,E9)BB)(1%%C]MZF
MNZDWY6WI]KV>Q2TX'#++@KL2_0N?Q=BF44>4^A@*<X])&Q,[M"T)9H0&D[/0
MJR3!ISP%GIS-B)/++-+& )&88# 8# QF:3*+5U#Y3/YP^((S#85'WB52N1.I
MWD&UCCS @/='AU7'= M@2H$"4]2=L(1#\0O>@ &/80["L/%Z&RF3.4MY5VTQ
MN#!9UX(FM'$(2^$^2=:5X_,RA6NK:L5206Q:;)D^><5=E7&67L2@-AR8V&GK
MW9@K>'')BSE'^Y^M&MJRN)A# 8$/WW4+=>U23*L%[HKCJM^1(UL6F#:44<\0
M&?QET0RFN;%80'_T&Y!7T[98],F/1^A)Q.C(E I 8G$:6,L328G'AGG'5X?&
MBWG*Z*D99)*6M)'++C[@]5W<L01F&FIHA<, <CXS83(@&HT%4HCQCZA/>H2[
M*2BMR2"/$8E"8&T+VE,&)M,TPW<MW9/F$,!@,!@,"+[JM>/T;5$[MF3$+5[7
M"(^K=@,S4 )SW)W<6P(HY#HXE%O7V^43.1*FN*QAM!TFN4@>&U 3H1JD&MC%
M@O%NJ'^IJD;TL]/1.-OSYY>[8O%Z;S!'HG2W;"5:>Y8E:U1FO+J(O#_'0UY
M@J.DU!7D/B;5OH W@UHL]MWW[Q6*PA@,!@,!@,!@,!@,!@,#X,++-#XAI8#
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MXXTS82RBBBPB&88,00  '8A;T'6]YDU<N P*]<FOV>17_$+Q/_U0U!@6%P&
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M?\0O$_\ U0U!@6%P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MOL1L_P!K4QWNX#T^E?8C9_M:F.]W >GTK[$;/]K4QWNX#T^E?8C9_M:F.]W
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M((@[WK>MX1%\\HNJ;-=TS].H@F?W=(VDM"=8<XO2013<G5+%I*;1;<Y(R!!
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MXRA=(X("QY?6<NKVLW6()&&*FP5R7&2>*P^V+ LU*.8EOCPO9A/"PN9MK0-
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MK>C/[.];P.MOK3TW@=MVA4.FHTLHXISW5TBTWF$G["$@T"SKR^S#+.V,&BC
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M55PU>0I3V?8#C.0NM94\%T&ZSB6S@\%SM2:9)KC?&<^6DZ.98E(P'03;"S-
MV]H*.:W565&6-6K6'NPF\K481&%0_P#LDX_O)N?_ /.*=X$GX# 8# 8# 8#
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M#KNN?M=L_P!_I7\VP'7=<_:[9_O]*_FV Z[KG[7;/]_I7\VP'7=<_:[9_O\
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..864P& P& P& P&!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g305327mn3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327mn3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@#*@'L P$1  (1 0,1 ?_$ +X  0 " P$! 0
M       #! $"!08'" $! 0$! 0$               $" P0%$  " 0," P,%
M"P@'!P,# @<! @, $002!2$3!C$B%$%1,I,58=%"TB-3TU15%@=QD>%28I(S
ME(&AL61U5A?PLD-S)+0UP8(W\7(THD1C@Z.SPR5%$0$  0(#!04( @(!!0 #
M     1$"(3$#0:$24A/P46'1!'&!D2(RHM(4L>'!0O%B<B,%%;)#)/_:  P#
M 0 "$0,1 #\ _5- H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H* W2<J#[-R@2K
M-I(AOW?)_$[3Y*[=&.:W?Y/-'J+N2_[?R9]I3WM[/R>U!?Y+X8N3_$^#\+^J
M].E'-;O\C]B[DNV<OY;-I[3GM?V=E=C&WR/P>P?Q/A>2G2CFMW^1^Q=R7?;^
M1[3GO_X[*[4'_!^&+G_B?!^%_5>G2CFMW^1^Q=R7;.7\MFT]ISV_\=E?#\D/
MP>S_ (GPO)_7:G2CFMW^1^Q=R7?;^6T]IS_9V5\#YGX8X_\ $^#\+^J].E'-
M;O\ (_8NY+MG+^6S:>TY_L[*^'Y(O@"X_P")\+X/]=J=*.:W?Y'[%W)=MY?R
MV[#VG/\ 9V5\'R0_"[?^)\'R_P!5Z=*.:W?Y'[%W)=]OY;#VE/>WL_)[7%_D
MO@"X/\3X7P?Z[4Z4<UN_R/V+N2[;R_EMV'M.>U_9V5V*;6A^%VC^)\'RTZ4<
MUN_R/V+N2[[?R/:4][>S\GM<7^2^ +@_Q.QO@_UVITHYK=_D?L7<EVWE_+;L
M#N<]B?9V5V*;6AOWO)_$[5\M.E'-;O\ (_8NY+OM_)GVE/JM[/R?29;_ "5N
MZ+@_Q.QO)_7:G2CFMW^1UYY+OM_+:U.YSZ;^SLH]U6M:&]R;:?XG:/+3I1S6
M[_(_8NY+OM_)M[2GU:?9^3;4RZODK647#?Q.QO)3I1S6[_(Z\U^B[=YM3ND^
MG5[-RKZ0VFT-[DVT_P 3M';3HQS6[_(_8NY+_M_)M[2FU:?9^3;4RZODK647
MU?Q.P^2G2CFMW^2]>:_1=N\VOM2?1J]FY5](;3:&]R;:?XG;Y:O1CFMW^3/[
M%U/HO^W\FWM&;5I\!DVUE-7R5K 7U?Q.PU.E'-;O\FNO/)=N\VOM2?3J]FY5
M]&K3:&]]5M/\7M\OY*O1CFMW^3/[%W)?]OY-O:,VO3X#)MKT:ODK6M?5_$[/
MZZG2CFMW^377FOT7;O-K[4GTZO9N5?1JTVAO?5;3_%[?+^2KT8YK=_DS^Q=R
M7_;^3;VC-KT^ R;:]&KY*UK7U?Q/1_KJ=*.:-_DUUYK]%V[S:^U,C3J]FY5]
M.K3:&]]5M/\ %[?+^2KT8YK=_DS^Q=R7_;^3;VC-KT^ R;:PFKY*UB+ZOXG8
M/SU.E'-;O\FNO-?HNW>;4;I/IU>S<H'26TVAO<&VG^)VGMJ]&.:W?Y,_L74^
MB_[?R;>T9M6GV?DVU*NKY*UF%]7\3L'EJ=*.:W?Y-=>>2[=YM1ND^G5[-RKZ
M2VFT-[@VT_Q.T]M.C'-;O\D_8NY+_M_)M[2GU6]GY-M2KJ^2M9A<M_$[%\M.
ME'-;O\CKSR7;ORV-1N<^F_L[*]%FM:&]U-M/\3M/DIT8YK=_D?L7<EWV_DV]
MI3ZK>S\FUT&KY*W>%R?XG8OE_JO3I1S6[_(_8GDNV<OY;-K'M.>U_9V5V,;6
MAOW>P?Q.UO)3I1S6[_(_8NY+OM_(]I3WM[/R>U!?Y*W?%R?XGP?+_5>G2CFM
MW^1^Q=R7;.7\MFT]ISVO[.RNQC:T/P>P?Q/A>2G2CFMW^1^Q=R7?;^1[2G^S
MLGM0?\'X8N?^)\'X7]5Z=*.:W?Y'[%W)=LY?RV;3VG/;_P =E?#\D/P>S_B?
M"\G]=J=*.:W?Y'[%W)=]OY;3VG/]G97P/)#\,<?^)\'R_P!5Z=*.:W?Y'[%W
M)=LY?RV;3VG/]G97P_)#\ 7'_$^%\'^NU.E'-;O\C]B[DNV\OY;=A[3GM_X[
M*[$\D/PNW_B?!\O]5Z=*.:W?Y'[%W)=]OY;#VE/>WL_)[7%_DO@"X/\ $^%\
M'^NU.E'-;O\ (_8NY+MO+^6W8>TY[7]G978IM:'X7:/XGP?+3I1S6[_(_8NY
M+OM_(]I3ZK>S\GM<7^2MW!<'^)\+X/\ 7:G2CFMW^1^Q=R7;>7\MNQ@[G/IO
M[.RO15K6AOWO)_$[5\M.E'-;O\C]B[DN^W\FWM*?5;V?D^DZW^2MW1<'^)V-
MY/Z[4Z4<UN_R.O/)=]OY;6IW2<+?V;E'NAK6AO<FVG^)VCRTZ,<UN_R/V+N2
M_P"W\FWM*?5;V?DVU,NKY*UE%PW\3L;R4Z4<UN_R7KSR7;O-J=TGTZO9N43I
M#:;0WN3;3_$[1VU>C'-;O\D_8NY+_M_)M[1FU:? 9-M3+J^2M91?5_$[#Y*G
M2CFMW^2]>:_1=N\VIW2?3J]FY5](;3:&]R;:?XO;Y:O1CFMW^3/[%U/HO^W\
MFWM&;7I\!DVUE-7R5K 7U?Q/1/YZG2CFMW^377FOT7;O-K[4GT:O9N5?1JTV
MAO?5;3_%[?+^2KT8YK=_DS^Q=3Z+_M_)M[1FUZ? 9-M>C5\E:UKZOXG9_74Z
M4<UN_P FNO-?HNW>;7VI/IU>S<J^C7IM#>^JVG^)Z7E\UJO1CFMW^3/[%W)?
M]OY-O:,VK3X#)MK":ODK6(OJ_B=G]=3I1S6[_)KKS7Z+MWFU]J3Z=7LW*OHU
MZ;0WOJMI_B=OE_)5Z,<UN_R9_8NI]%_V_DV]HS:]/@,FVH+J^2M8B^K^)V"I
MTHYK=_DUUYK]%V[S:C=)]&KV;E7TEM-H;W!MI_B=I[:=&.:W?Y,_L74^B_[?
MR;>TI]6GV?DVU*NKY*UF%]7\3L'EITHYK=_DUUYK]%V[S:C=)].KV;E Z2VF
MT-[@VT_Q.T]HIT8YK=_DG[%W)?\ ;^3;VE/JM[/R?25;_)6LPN6_B=B^6G2C
MFMW^1UYY+MWGL:^TY](/L[*OI9K6AOW3:W\3M/DIT8YK=_D?L7<EWV_D>U)^
M9H]FY5K7UVAT^C>W\2]_)V=M7HQ3ZK=_DG[%U:<%_P!OY+]<'J*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*#42QD ZAWC8<1V^;\M!D.AM9AQ) X^4=H_JH
M,"2,@D,+#MXCRT#FQ<.^O>]'B./$#A^>@P\\")K>152VK42 +>>Y_+0;"1&0
M2!@4(U!P>%O/>@C.9B"%9S/'R7("2ZETDDV #7M09\1C\[D\U.<>(BU#5;M]
M'MH,+EXK1O(LT9CC_B.&!"V\YOPH!R\51&6FC EL8B6'>OV:>/&@VDGAB!,D
MBH%MJ+$ "_ 7OYZ#496*8VE$R&)02SAAI ':2;VH-UEB90RNI4KK# @@KY_R
M4&P-^(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MR9.K0Q\@%!SDBZUQ(MQQG&5ER2XS)@9*O$0LRI?4=3*5U-V<*#L[]'O.Y;-
MNV"7!R9<B$RB0Z'2%9!S-7*D4V*CX+WH.+GX76SDX&*\ZK'D:_&F0<M\=VB
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M5 LC(Y<.MR&*=P]HN;WHJ_B[)U8N:TNY#QK&8^%EBRG@2$+*?EF0=O-BTW0
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M=+EY./&O.PH<9XUEDELZF02C5)Q8%&1=1XFU!QH^B]UQX<:&!8]:Q1*F2)Y
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MGIT[!M_)Q]<&2D\V(SKR,A%%BDC0P0#B>/&,\0+WH*&?T/N^3CS0QC$QY9D
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MCB@C#DN+$1BXU*WGHCT/3.S#9]M&"L42*'>0M#P#,\C'B+#L72/_ *4'6H%
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M!N,>0@D9TI )!($/ CM_X=!&VE<A,=MQD$\JL\<1Y.IE0@,0.7Y"PH-UB9B
MN?(2U]-N2;V[;?)T&3!(" <Z4%C91\CQ/N?)^Y01.T:/"C;DX;(8I /D;NP!
M8A?D^/!2:#*Z6C:0;C)H4%F8\D647N3>/@.%!IC38^5&9,;=&FC#:"Z&!AJO
M:UPE!*$)D,7CY>8I *VAO<BX_P"'YJ!HX7]H26MJO\AZ/9?T.R@ADR,>.-))
M-T=4DMR[\D%B5+@ <N]]*DV]R@G$3$@#/DN25 ^1[1VC^'VB@&)@2#GR J0"
M#R>!/8/X?EH(3-CC+&&=U899%Q!>#7;@?1T7\M!G)EAQHTDGW-XTDD6&-CR>
M]([:506CXDM02:.[J]H2:=)>_P A;2.T^AV4&,@+CQ-+/N,D42*TCN_) "H-
M3-QC[ .)H($S<)Y(8EW9N;D(LD,1,(=E<%E(4QWXA3:@L1(94UQY\K+8-<"'
ML(N+_)T I92YW"0*%#ECR+!3V&^CLH*D.Y;=-D+CP[NTDK1\X*O)(Y9O9[B.
MVDV-CY:"R^A'1'W)U>1M"*3 "S:2]@-';I4M^04&_(?E\SQTO+MJU_(VMY[\
MN@CB>*4.8]S=Q&YB>Q@[K@Z2I[G;>@BBS<*5%DCW<LC2<E6!@L9-.O1?E]NG
MC06N0]F/CI;)Z9^1X<+\?D^'"@UY9L3[0DL+7_@_"[/@>6@U8QK*(FW-EE8,
MP0F ,0E@QMH^#K%_RT$A@<$ YTMSV#Y&YMQ^;H(H6CFCYD6Y.\9=H@Z\@C6K
M%2M^7VAA:@URIL?%@,^3NC0P@E>8Y@"W )(N4[>Z>%!*L9?3HW"1M0U+;DFX
M[+CY/LH-)WB@*";<WC+L$0,8!=FOI'%/+8T&LDV/%E)B2;JR94EM$!, <ZM1
M%ET7XZ&M^2@G$$AO;.E-C8VY/:.%OX= :!U4LV=*%'$D\D ?_P!.@QR7U:/'
MRZNS3\C>X%^SET!H712S9\JJ.TGD@?\ ]N@@Q\G$R69<?=C*ZVUJK0%EU$J+
MC1<78$?EH)^2VEF\?)I2^MOD;"W;?Y.@UD41-&LFXNC3-HB5N0"SV+:5NG$V
M!- 1=8)7<)#:]^$/#22I_P"'YQ05AN.WG"ASO:[#$R;<B<\D*]P2-),?&X%Z
M"[X2?ZY-^:'Z.@>$G^N3?FA^CH'A)_KDWYH?HZ!X2?ZY-^:'Z.@U@,Z9SPO,
MTJ<I7&L("#J(^ JT%N@4"@P_H-^0T$&W?^/Q?^3'_NB@AWN##R-ME@R\@8T$
MFD-,65;$,".+<.)%!YC<NB.FLS*=SN AGDR',J(T8URR/+(5<"Q9U6<Z;\0
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M.=E^%Q9)))>6L]^3,J<M[A6YC($L=)MQ\AH+\TT,$32S2+%$@N\CD*H'G)/
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M[;^>@Z73V)U9#D&3><M)T>,AHTT:5=2N@II1#Q&K5<]OFH._0* 0#VB] H%
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M%CL=-K_!\MJ#C=0;S-M"*.;+,S(6))BC  *I>_+:YNU[ 4'*3\0L E"PSA<
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M</#SMKY,4ZDRY$:RE5)A$J\650 I;0Q_6\U!6FZIZMA221]G&@\(0B3.REF
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MEOI*!RMR^L1>I;Z2@<K<OK$7J6^DH'*W+ZQ%ZEOI*!!C3KD-/-*LC% @"(4
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M6-LDLJ)')KL\MKFW<TWX=XVL+4&D_6.]XV/--+MG,&G7$L=QRQ:%K3:['_\
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MI%_R4'3_ -+/P[_R_A^K% _TL_#O_+^'ZL4#_2W\//\ +^'ZL4#_ $L_#O\
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MO^HL".TB_900MUGI5V.8@Y=RX\+8BS:?+D<23:P''C0;P=729$@2'*5RTJP
M^$(&M@QMWL@$6TF]^R@[>/[8R,>.>+.QS'*H="<9QP87'_&H)/#[Y]=Q_P"6
M?Z:@>'WSZ[C_ ,L_TU \/OGUW'_EG^FH'A]\^NX_\L_TU \/OGUW'_EG^FH'
MA]\^NX_\L_TU \/OGUW'_EG^FH'A]\^NX_\ +/\ 34#P^^?7<?\ EG^FH'A]
M\^NX_P#+/]-0/#[Y]=Q_Y9_IJ!X??/KN/_+/]-0/#[Y]=Q_Y9_IJ!X??/KN/
M_+/]-0/#[Y]=Q_Y9_IJ!X??/KN/_ "S_ $U \/OGUW'_ )9_IJ!X??/KN/\
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M/!_W4U!Z2@4"@4$>3C8^3 \&1&LT,@L\;@,I';Q!H-HHHH8DBB18XHP%2-0
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0>;C_^1\C_  >#_NIJ#TE H% H% H% H%
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MN+V]RE%FV8SAO1DH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MU;R<+\>VK6.5UZEE+9C2PFOCA_7]+F+BYHCR,4[RF1D3\EX1S#KTH 9!=2&
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M_FH,>T7T%Q&"MD(LQ/IMI'P?.*#"[J&12(^\\G*"EK<;7N>'902+G2%B&C
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MN=/+N^'CWL8?3'A\T3/G/,VE@L;BY ,?+8K=B1VC_;C2=2L9&IZ[BLI%M/\
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M+#A29LK"7ZOI..V;;9I6:^SX^6#.V8/76/EX:9&9#-@*S'*UV:4J57NZM*W
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L0*!0*!0*!0*!04MT_@I_^3Z7_P"U]+L/;[E!P/\ _M?_ /4__&__ ,E!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g305327mnkd2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305327mnkd2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@"%@-P P$1  (1 0,1 ?_$ ,D   $% 0$!
M       ! @,$!@4'" $! 0$! 0$!              $" P0%!A   @$# P$%
M! <#" <$"0 + 0(# !$$(1(%,4%1(A,&87$R%(&10E(C%0>AL='!X6)RTC-5
M%O""DJ)#)!?QPE,ELF-S@],T5-0U194(DT1DQ(1E1E81  ("  0#! @$! 8"
M 04! 0 !$0(A,1(#05$$87$B$X&1H;'!,E(%\$(C%='A8A3Q<H*2HC.R4P;"
MTN)#8S1S_]H # ,!  (1 Q$ /P#ZIH H H H H H H H H H H H H H H H
M H H H H H H H"CD(AYC"<Q2,ZQ3A95_NU!,=P^G5K>'W&NU7^G;'BOB>:Z
M7FU</*V/#\N?P])>KB>D* * * * * * * * * * * * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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MA]8H \R/[P^L4 >9']X?6* /,C^\/K% 'F1_>'UB@#S(_O#ZQ0!YD?WA]8H
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MD,C#N)H#7>F HY?FRK WG4D"]P?%UO72AHT=;(% % % % % % % % % % %
M% % % % % % % % % % % % 4YXR>5Q)/E]X2*8')W6\O<8_#M[=]OV5UJ_
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MW= 95CW1-U .M^M"0=GCO7F=RWZ>\]ZEP98(I<?*RX>,ESQY$,:1NJ1)D V
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MXC4!Q_IWT @VWL"4/<?YZ@%NPZBX[Q_"A1001<&XH!: * * * * * * * *
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M\PK\9_U@1;]VE 2 L1<$D=X*F@"]]"1[F%J 3:!U6WM7^:@'#=:ZMN'M_B*
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M^K6A0=P@)[>P=IH015>UOA ^DF@&H5NS*-Q.E_8/;0 PW&TA\ ZJ- 3V#VT
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M2A8N6XK*EX[EH8_A3*QV*ETO]B4>-??;LH&:=3<:]1H10"T 4 4 4 4 4 4
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MGR">::4*R1X65#D(F.0A@#39$.Y?[Q%DW)M;Q7M:X- ;P$$7% (-&8>X_70
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M3;J2>K'K]%NE)!"4>-A&Q)4F\3]+'NH"2]P)+V/0M^RS#V4 YA9P?@<Z'N-
M# ;E;X9.A/>/Y: ) "!NT==58?MM0#G4%2LFH/VO].E"@I8*"?$.WO'\:$!+
M6(!N =/=0HMK/[&'[10'&]2$197 Y3B\$'*1"6_0&:&6")C_ .^D3ZZ X>/#
MEX&5C8<>.^6WIJ>;;C16,TG'9Z,,>>%6*AVA(,3+>_A:VI ("\_ZJBXF',]9
MYN+-A\9PG'S11#*3R9LK)R)(V2-(F\84-$J@L!<MH+"] ><?_LI'D\Q/5W,Y
M9)CS\N$N>QL@^9+*1[A**K*SV;E/5/I[BN8XWB>0SH\;D>8)CX['<->9E(%E
M(!4:M;4U""\CZJ].\;S7'<'G9T<'+<M?\NPV#%Y=NAM8$#Z2* ZVTVO;3OJ
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MF2*17:!V4,=KJ-IT(]A&E 97.]#\Q+CRQP-BXL\ZWAR8Y)]^/&L#1G%CN#^
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MP.>.NO\ \I#_ !I \G=^O_BAF5C<[BP2965ZD2#'A0O-/+BP(B(-2S,Q  I
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M\ .GAB&,K$'4WM<=:@*7$_J?ZKDYJ*62".<<C%Q17@@DWF[LB*7YE\-N@"%
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M!_90H;'ZVT[^M""4 7H H H H H H L3TUH!=C=NGOTH LO:WU"@"Z=Q/TT
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M&V[;CQ7U[:W7-FS15L@4 4 4!B?3_I'T_G)DOG\7 SK)9#\EDX6AUZ3NY?\
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M)>KB>DQGJL#\\)W $8,FU#>_VM=-*YVS!D.49QB)?X6R<5;?^_0WK"/%UO\
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M2UK @?RT 7CD;=:VS0$=03UZT GX<C['T*B]NPD]HH *G?M;Q #1AVW[_;0
M&;>RN;C0(Q^OZZ B<*54_"XZ]Q[010$ZG<BN.C"XM4 \/V,+C]M &T'5=?9V
MT T,1TH!N0P$1VZ.WA5>\G32@(0 J/W*?#;J6 J@E8WMT\XD$GLL=-?KH!)
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M&!(-NM]=VO<*YVS!CN38#"0$7ODXQ4GL_'2L(\/6_)Z5[SU9F\1]]=SWB;J
M-U &Z@#=0!NH W4 ;J -U &Z@,]Z7W>=SK#7_P TG!7_ %4.E9/'TWY_\[.V
M1=U9#KK<=]M-?KH>H4@.+CPL" U_?T-4!*=RFW@9>SV7_;0",I:[#PLI&X=A
M%Z 1RI:P!$9N"O:IZWH!N,;'RF-NI4]GT?O% BRS:670=I[34 T*3_*: 4LJ
M"X[.K&@*MWD9Y3<6\*W[+_\ >JD)2J*4##PB]HQV^_\ A0HK,Q>[^%+?#V:'
MMJ 4(S/XO A'0]38U0!9=X$8N"+;N@T[J &?RRNT>(FUAU-Z 5TE*[W.J^(
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M/$1&@U(% )$IVE@NT,;DG_2YH W#>23N(T4>[KI0"[7=UW'8HN3;KW4!4Y;
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MQ$\O9*D5P 24,B[@Q5MK=* HS?IWZ?E6=2V1"D\4\*HLEQ&,B02LT>X,P99
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MF9\EZDQ),6#D9<W%QUXW)6#&@CO&7!B:%%15E0NQ\W[2D#3;0%SE_16;F^I
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MV%\T60PF7S#$ P4^8$,B[=^W;?MK7DQQQS/4OMBI#\WQ*NJ(<Q$]TQC&9/\
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M_4_)X,^IX\;,X)<^;Y:!6RWS9,1A\S,\4(C52%(23XV/2]>WIU;3@X]!^O\
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MMN$W?T7VK>ZK/1HEV1HIM=0!ITT'9>O(?F;.6.H0* * * * * * * * * *
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M'(_U=*]%Z-Y? ^]UG1[NZTZK)<7M+_Q:]IM58,H8=&%QV:&O.?":@6A H H
MH H H H H H H H H#)^K/3'+\KGK-B8W"2P^2(V;D\-LB>]VN X9;+KH/?7
M?;W%58ZO0S['V_KMK9I%GO)S/@OI7JC,ZWI+@GX'TWQ_$/,)WPXA&TH&T$W)
M-AKIK85SW+ZK-GC^X=4NHW[;J4:GD=:L'C"@"@"@*61&#R^')Y#.4BG R ;+
M'N,?A8=I>VGNKM5^"RGBL/7[CSWK^K5QPMCR^7W_  +M<3T&-]4;OSN;PC;^
M7OXR+ZW.EZYVS#R,S&552S"X&B@]I_A6#DQWX>SSI002#Y:BP%M.P:Z7[Z$4
MY($ED;PQ[90+V0FSV'7J;FA6A=\UC^%9=;BX+$]X/LH9PY@\LJJ-P2);7U(9
MB.AZ:T+ @$;+NB!\U+W!(-Q?K8W[Z 1Y%>.ZJ%;HRCZ[BA4C6^C;?E3_ /M&
M_P"[6Z9&ZG<M6C0EJ 4#6@%<>(^^@!!J?<?W50(14 H'@/OJ@2U0"L-![JH$
M4:BH!6'B/OH 4=?=5 EJ@'!25%N\T &PT'TFJ 9;M]7[J 5; V7VW/?0&>>(
M3\QD(,C/QB-Q>1;""P4 ;#;NM8=]=5@N!]*KT[2<;=O?Z2G\S"T)WY7+1.C;
MVNAOJ";:"VFHK4=QWT-/"NTUWDZO!+FQJDW(PO)L7<$MN\(7QL;_ -;7VU(P
MX'/2U1MK;:4\?=[B)YL=D">=R,<D1+"15+M9U5?CM;0+]&M6'V&]-IF-N'Z,
MAQ=8\A/,R>3^&*2)%\=RR[B&.MM#8TCN"4U<5V^/86H\GC,Z66#'QLI9I4E
M>SH+V(=0S-L5NZ]9AKD<'3<HD[.L)KEZ.T;EPR8O%B.49]EEWAT>.24LP8_9
M+>&_9[:)R^!K;LK;DK1ER:7#VD4O_+&!Y,SE)(WC+DJ-VTG0![#XM+VJK'@C
M=/%,5VE#_$$0FQ!CRP^=R4R@JPWQDE;7L%OVF_[J0YX&G6VI.-M>DE,L,20Y
M$D_(S1E9 1(/%HMK^78,=7TI'<9TMMU2VT\/Q/H(P%2"4QY7)?AA" 1L&W<J
MV53:_6KZC6;4UV\9)H<[BX\94G7/R@"WD/*CAN@NJ[2M[;>ZHZOL,6VMQVE>
M77G$%N''/S47(8T>7Y#(OEP^8BI8J%\2.P:]E%[UF<(<'&U_"Z6=9G.,?6BK
MCP@R9:KE<G%\N'9KVVL59M(]/$6ZCWUMO+([VMA6:[;F/PRL<O'++*^3RH,5
M@R%&);I<&P[?92'V&GMV>"KM8]H]#"^5)%'-R,1?>Q14"I?XS<ZB^EO;4X<#
M+354VMMY=_(C:: A7$W(QO&BK((U)W@$G^\]M^M6.XTJVRC;:?/^!8@GCQLY
MHYY^1GL640V+HR,M[,1W;N^F:X&75VI@MM=O$F5^-SXI(<.',A>RN'4LA(4@
M>%Y&*_:U%1RLX,-7VVG=T?M]B&\DDD./C-,>0C\H&.)H&21R+!BS[2U^@%2N
M? NPT[./+<XXRO41Y@7'F\B7+Y.2.5%VN@W*N\FXNHZCMJKT%V_$I5=M0R*7
M(Q3 MI^3=XR?^8,9\R[A>A(^R%Z =XJPYX&U2VK+;A\)PP'S-CB*[R\A)'DH
M""PW.GX@ .P#_P!7U]OMJ1W&:IS@MM.K^'/TC"RLA8Y?)E4=4E8Z,5DW6LI'
M1;=U7T(TL_EV\O=!,.2XM(XO/@S9Y @M(Z2!W5; L0K"]K]U9TOL.?D;LN'1
M*>:A%N' E$DS0_-M%F @LTB!464[B44G<I7>>R]1ONP.-]U-*=$U['C'\8.=
MC!FQLAERN3C&/9O+<JI.HT0D=EJT\^!Z;.+).NTY_&(#)Q4D:7S^3='W1B-E
M;:6VD :ZD@=*0^P/;LU$;?,L0X4TV&K02\@\$@\"[HXMA!*[=CE6%1VYP8MN
MJMHLMN5WOVH00>9R>1")L^"Q=SM(6)B+?"XZ^RG#@1VC;3C;?O(<3,PHT=LN
M3D,@.B"995.Q6TLUP5UTZ@UIU?"#IN[5FUI6W7'",SM\/+C2Q.V/#+ JN0R3
M!PVZPU&\DVKE9.<3P=32U;+4T\.$? NV#>QOWU@\X6(4]A!J@+!O8W[Z 1QT
M]U "#Q"H!"-: 5>C>[^6@$H!Q'A'O- -M0"N-?H'[J $'C%4"6J 51X6_P!.
MV@$M0"6H M0&7];?W^'V^%_^[6+F;&?+[0$1096]QL>P#VUDY@_D0D*I(<$W
M;J+WL!9=.SI0)-CM\Q0$QK(O3?&P%S_VT$(4/.6%XMQ[+$ 6[C[J##F,::S
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M$=MJAI/@P8J[([C6,7DL;^U1KK?Q4"-7Z-)/%RDC7S6_<M=*9'6IW*IH* *
M<_Q&J 3XO?0#: </A/T4 V@''X10#10#G^(T )U]X-  %S^\T I(V$#I?ZZ
M0"_L':: 5ST Z6% $8U!/2@$+$Z= .@H!PN$N3VZ"@&EF/;]% .8[3UNW[J
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M!<C0LP/OZ7H3A)7W6CN3=I&+,WNT TH;-EZ--^*E_P#:M_W:W3(Z+([E:*%
M-,D8D6,L!(X)1"1N(6UR!U-KB] /E=$4,[!5MJS$ :>_W50)&RL%=2&4@,K#
M4$'4$$4 K"Q([J 5>T=X_GH!MJ =]CW']] 0MD8Z3ICM*BY$JLT<)8!V5+;F
M5;W(6^IH"9^P]XH 0>(=PZF@!C]D: 4 J"X:_3OH!";Z#0#H* 6PVJQZ=/?0
M";B2#W=!0"D!2;_0* !<ANTF@#1>GQ?NH ()M[M30 #]D=+'Z: 0  7/T#OH
M!6!8KWD4 N@#!>[4T B@ @GJ>@H!.I)/2_UU .(W.;_"-/YJH%ZL6/9\(]U
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MR0 $;OC4A7O[+>*A4;STV7_.>9W-N7S$VC=NV_%I;LKK7-G4T=; 4 4 4 4
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M#/$-S^-0;"]=:42C&?$?0Z3IMNJI-]>K>JL,<(^5Y8,U/,<A/Q_%<+^7YN/
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MU]]0"@!O>.ONJ@0G6]0"Z:N.SL]M4##0#NB^_P#=0#: <^@ [NOOH!M % %
M% 9/USID8E_N/;_=KG<S8SD1.I'P_;N=+5@Y6&K;PE;]?"S:K<#V:4*!WD7.
MOW2.GT6H61%U(VZ]UOYJ$''<2H;4[N@U:_T4 L?P,$O?[0)%^SK]- \R/2X]
MXM0T;STS_P#FN:\( \Q/%8@GKWFNM,V=#25L!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0%'($?YQA$K*7$4^UE_N@+QWW^W[OTUVK/EVRS7
M?Q_#/->/-KG,6[ORY_#TEZN)Z3&>KBPY=_$ OR$ET+6UNVMJYVS#R,FA-V0?
M&>I[A:YZ5S.+%9BB^3&QW'XK=_<!I0B4XL#'U,JW[V0V8=@N*#5R%_ ^^;DB
MS7-Q]-"8\A-B-=HUOK\;G2_46'TT+/, [:Q3$@-W]ESW=U UQ02%D58W[?A;
MZ2#UM0M<<39^B3_Y5+_[9OW+72F1TJ=XULT% % % *IL=>AT- # @VH!5U!7
MZ1[Z 5; ;C]'OJ #JM^T=?=5 ?"+_:/2H!&%[$=O[ZH%'AT_VJ 3:=UA0"Z&
MZCIV>^@&J._H.M *WB%^[2@%7PC=V]@H#B\A%.)Y8<6+%R/FG_&B9BKVMU8[
M_P#T172O;)[MEJ$[.RTK!\/=[RDW&@7,G!XT2DA3(\X(4*PL2-!^W6M:NT]"
MW^"W;/\ TEJ4SQ8JX\'R4\ 'EF)6VV4:"Q:3^6LK.<3C55=M5M:>?XP,=E^C
M^5DY?)Y3%SDPWREC3RD.+(L:1@62-I2S!;^*U^MO]7TK=40U/K/N4^Y[:VJ[
M=JZE6?J4M\7'J[I]-J?T7R[94,F'RHDE^52#+,*8PWB*1Y%N'# -^)M\( M:
MLK>48KWG*GW3:56K4A:I4ZL)27#NGF3X?I"9,S!R^3CC>6#SPV3,\2JWS"@6
M=(A'\ C\.WOJ/=P:1SW/N2=;5VVX>G!)_EY-SG.,\B7EO2\61D\EKC96'S*H
MV9B)((HQ/%\&0AW[DDL!<CNOU&LKN1'88Z?KW54^:MMJ=+B7I>=7A#7\8[N?
M!Z1S&S,67D\I.2@Q7#P0SO!&GF G;+-Y3*966]Q<]23UZ[>ZHPP/3?[E739;
M=71VS:U-QR4_*G[H]';YCA\CD9^/(QX,J#AYO/@$,BJ)',;)L;<SZ>*YOK<5
MRK>)[3P=/U-=JML;5>XH<K+&9X?AE?)](X65R1DS<+'Q('Q)<0QO,'C99'5W
M86*2;^R][5I;K2P?$ZT^XWI2*6M9JZMEC@FNU05CZ8Y1<C"^=Y1>9P>,828,
M,I@B =5VHSNA221D'2YZV]XUYBAPH;.W]_MZ;:*>5?<PLUJ??$RE)77T5BS\
M))P>1'C103/+(N8)5\R%Y9&E!0*X'@9MJZ:@"_L><]6HT_NEJ[RWJNS:26F,
M'"C'#CF_8&1Z+Y>7+&5AY)51C08&Z$XQ5X\<$+)^*LNTV?LHMY1CWBGW3:K7
M3:OYK7QU9VX806^*]'XF!/Q\B+%@9'&2RS^9/,)Y,EYXVC=I3=+?%?0=W=6;
M;K:?&3AU'W*VY6Z<WKN)+!:555::C,@Y_P!*R<GF\C,K0Q?F6.,;),,B*KLA
M\&0 SW$@7P>U3KTUM-V$NPZ]']P6U2BQ>BVI2GASKEEQ[Q.*]-<Q%EB3,YB.
M2!5:\4J8P5KJ0-8MK"V[=UJVW*Q@O>.HZ[:=8IMM/LU?'#L*V#^G_)+C8F-F
MO)R?'XX0)BF3'AC98 !&LC1H7877H&U[:MM]3*P9VW?O&WJM:B6W=SC%F_%G
M$N%ZNX[C>GL7(Y+#Y"5,3!DP'E88+,)4>21=@D>S#X S;1;J:Y>8TFL7)\Y=
M9:NW:BUW5X\64)8PL./$Y'-^D?S3/GRVBQ\?YB**'(CBDB".()EF1RI:VX;"
MG]4UTINZ5![>E^X^315FUM+;4IRM5=+67;/>7'],PR\[B^H%7&P^1XX2!(DD
M#+D;T9 )+N?@WFQ]MJSYGA=<TS@NN:V;;'BM2\8Q\L-/##C!S,/].,],;'P<
MLRYO&P[7.&9,>)) &N(W=$\QE[QNUK;ZA3*P9[-S[W1V=ZQ3<?&+..U)N)]!
MWN:]-KR?!2\;!DXW%).4>:" K(S^5TA8NQ0JUA?37H:Q7<BTYG@Z;K?*WEN6
M5MR)AO#/C@IDX>1Z1YO,Q,O&SN27*BRXS&1;$C*$LI#IY>S4=@Z5M;M5BE[S
MW4^X[5+5M2FEU<_G<YX.?\2_QO <_B1F4\S'DLZM$_'%,50Z.NW^\3:1;J+=
MP[-*S:]7P]YY]_K-F^'ENL8ZIOAZ'^,1,KT0LOIO'X=^,53@1Q+C<BN0BRAX
M5_OA<%;DC6XZ&BWO%,YEV_NL;[W5?YVYKI<0_P O/_ L2^G<[%;)RN#YB+C6
MR]K9F'"L,D<DFW:9%$Y=8WVCQ%=#;I46XGA92<J=;2Z5=[;=]/RV<II<O#$K
MO]8G'<(O'X:8<.#BR*FXM+-D;I)&8L7>1O,U+$F^G:?I6O+F1O\ 5/=N[.UE
M/*N"Y1AP_@=7RL@8PBQH,.0Y!MD8X<@@=Y;S&]YVUSE=IXW:KM-G=:<G'\O>
M1-QP%WEX/&C1B$,C3CPJ&%F(Z?M[*JMVFUO\%NV?^DM3?,18J8V/\E/%;RQ$
MK;;)[VD_EK*SXG&J5K:K:T\Y_".><>0BXX_"&VW28=!;I^(.G9[E_P!7<]K/
M5K7UW]7\OQCZ=)Q<,<&%&(UC4:G;"28[GN))Z=.M<;/$^5OV=KMN?3F6"!U'
M0UDY"W &T]O6J!-IW6J 4G=IW?#5 BZ:]W[Z@%.HOV]M  \(OVG]U4",-+CH
M>H]M0"WVV'UU0&W46Z'H:@$8W.G3H* $&MST%4"'6@$H H H H#)>N]9\/IH
MCGZMM<[F;&; \Q%).V)?IU U/:*P<WAW@7EE8[?@%]&U [=>SMH32DNT-D2G
M4&-B-"K74CIH;=PH&VQ6.. ?$UNT"^I&O2@4B&-TOY:;+=0#N?KI^SNH)YB@
MF8A@WXBGMUZG0@B@R[AA;<^[X;6W ]]Z&D;WTUN_.>9NUQYB;5W7MU[.RNM.
M)U-'6P% % % % % % % % % % % % % % % % % % % % % % % 4LB11R^$
MAF=6:*<B #P/8QW9C?JM]/>:[57Z=G'%?$\U[?JU4O*V'!_+GW<.\NUQ/28O
MU?L_.')+!_D).EMMKMU[:YVS#R,D) $)UTLK@: @]O\ )7,XM8DD:;1)M%VZ
M?ZIUN+]]"-S!)$Z168BY)(11VWT-63-E)&7F(9ABKMOTN;_10TDN9(\J2K;;
ML=%U330=;BU&92@B="T(!%C>R=YW:'3NJ&D\1N\!3;54.U>XD]OT4-0;3T/;
M\IEM_P"*W[EKI3(Z5-#6BA5 4 4 5 ..HOVC0U0(H-^[VT K&YOV=E0 NAN>
M@ZT C7W'MJ@<F@]_3WT RH!^NVWVAU]U4#0#?3K0"O[.G;[Z $ZZ_#VT C7W
M&] <'DL6:7+F>3B/FE0;898Y?+9@>VUQJ+G6NM7AF?2V+JM$EN:?1(S XHKD
M!HN)7%DB%E>:9I$;JO07N;:ZBCMVEW>HE8[FJ>2@.3P\N6:S<3%.JBP>)RBF
MXU^[WD=**RYEV=VJ6&XUWJ1F'Q4S9"D\3'%8[A))*Y7<+G4 M>_N[:KMVEW.
MH6G_ +&^Y(;-@2SS2-/PGF/(^S?%-Y8VC[5KZ Z=.M%:.):[RJEIW<N:DM8'
M',LCS1<9%B,18ID2-)>]C=0NX:'2I:W:<M[>34.[MW*"OEX.7+,SOPR,U]N]
M)"JD ]0H*]W[/;55E&9UV]VJ4+<?J'\?QN0CM*.*BA:,73S)&<$VZ 78?7[Z
M.W:9WM^K4:VYY(A''NP+2\"S2,3*Q6?:MQJ 1?\ W::NTZ><EENX9?*7L#CI
M8<=W@X^" .3^%.[2-X=!K9@+U';M/-O;ZL\;M]J4%*; RG,DC<(NYC?24J+]
M>@:P_DO[*UJ7,]*WJI1YGL_'X[R3%P,F&&::/BXD<#:(G=F9A_1!) [.WV5E
MV3XG+<WJV:3N^^"O^5KX5;@'8J-2,C0E]#VZD"M:OZCI_<?_ -?^)T8,/(Q\
M.\.!CA2"_P NY9Y 6U*DD6O]-8=I>9YK[M;7QO;OR1S/RR<]>$&O7\9CUZ_:
MUZG_ $-;U=IZO/7_ +/9_+\>@LC RH\%PG%Q'SFVO!YC&0===QT&O<?;6=2G
M,Y/>J[XW>'&,"$\8FXG\@<VLNF1W>*ZB_:1U[:NK^HZ+??\ [5_M+\V%EP80
MABP<:9 H01HS>9;^NP!^F]95DWF>:N[6UY=K+W>HYOY9./AX4:=/QF'3I]K3
MX5_T%;U=IZO/7_L]G\N_\,M2\?.N)#CCBHI(9#N>-)&5TM;1G/L[+FLZL<SE
M7>J[.VMIKL^! O%1RM8\$\?F'XVR-$^S<A3HMC>PJZNTZ?W#2_[9C^DZ7)XN
M8<?RCQV/D(]MPB)4@#O)"G]OLJ5:YGGV=RLSKM7O.:>,R"1?A!KU_&8];W^U
M_2;ZSWUK5VGJ\^O_ +/9^.PM9F!.KQ0OQ,>3#"-P,4A6Y[B6MN-^^LJW:<=O
M=KBUN.K?-?B"*#B5,\8'#?+L/&LTLY=0=&LVTDG46JNW:;OU&#_4GL52QRF)
MF.40\9#.!XM\+%+-W'X3V U*M<SEL;E5CK:[\2G#Q,S,J'AECN;!S,]E&FNC
M7TVCZJUJ[3O;J$E/F3Z$396'.\[&7AER%B79&8)/+!!'8#MZ7.O96:OM.>WN
M)+#<B>:D7#XH+D*T7$KBM$/#)-,TB,-5M9;W.M]12UNT;O437'<U3R4"\AAY
M<TNU^)BGVBRO$Y12"-1;P]Y'UTJUS)L[M4L-QKO1#B<5.V0E^)2(@[A))*Y6
MXN=0">M^[MJNW:;W.H2K_P!C?<D=["?(: ^? N.4=E5$^$J#HP]]<K1P/G;R
MJGX7JP+*=M_A[:R<A#>^O6A1P^&W:>GNJD&U"CGU'M'Q>^J01>H_;4*#ZFXZ
M=E4@)I<GI0","#4 Y?AL>WI5 RQO4 XZ"WUU0-H H H H J Q_KLA<G"/6RO
M<=_PUBYFQFF\0V"YLN^.^IMU(TK!R6&)(RV5 H.RUU;OO0DXCGE58VB2/S6!
M\0Z $_MJR15;Q;@1)98Y SXH%A<%3T^@]M60ZIY,'*L5>.Y5M5(K)5R9'*JK
M(TATV@%AV;CV7H:J\(&NP+ -\1(9B?;;2@2-[Z:V?G7,D7W%X]U[6'Q6M8UU
MIFSL:2M@* * * * * * * * * * * * * * * * * * * * * * * ISR,.5
MQ(QD! \<Q.-MN9-IC\0;LV7_ &UUJO W'%8\L_>>>]OU:J>%L.>7N^)<KD>@
MQ?J\G\X8;18X$EGL2>K:7Z"N=LQP,CT1B>T6%N_K7,Y3B2."IB86#@6OV6M;
MZJ&%C(XJ6R9$) 5 JBQ%]=3;V523%2P9U280; 0;>.^GT^VK)RT2M17F7RY8
MRIN/,VZD$D'0VJ':KE !_P TVZUT!"VU  /90GY2&UX[=J'7MO?N-0Z<3;^B
M/_Q4H_\ 6M^Y:Z4R-U- :T:"@"@"@"@%4V/L[:H%;P^'OZFH 77P]_3WT -W
M#H/WT**HW:=VM_90@TM<_NH!W4;^[J/;5 W<;WJ <; 7'VNGNJ@13K8]#4 -
MIX>[K[ZH%%F&O9U]U -W'=>@'&P%QV]* 1=?#W]/?4 $ZZ=G2@%.@W?>Z?RU
M0(GBT/9K0 &NWOTH )VL!]V@%/A8#L'\M *+;MO8!^[6@!C>,>V@(Z *@"@"
M@"@"@"@"@"@"@)B;JH[[#]E4# ;EOZ.H_=0 I\-^U?Y: %%Q_5UJ 13=K'MJ
M@";&P[* 4V N/M?L[Z 1?%X?I%0"$ZZ=G2@''IN';^_MJ@:I[.PU *VGA[NO
MOH!0-PU[/W4 TFYO]5 .[-_T6]M4#0UOY:@%;PBW?K]%4"+KX>P_OJ 5M-.Z
M@!?$+=U4"$W-0#AJ-QZK^VJ!A-0!0!0!0!0!0&/]> >?A_U7_P"[6+F;&;CT
MEC .JWO[B.SOK!RMDQT1*M+MMM4,X%_M =1WU26X#\-!Y:LQ!(4GJ "?;1&=
MQXP/$J9$3DKY>T#ML3_-W53.G2R%"X;( (NEF4WZ7T/3MJ'1PX&6 QEL/M7;
MVZV[*A?S#6'CW=^H^FAI&^],M?FN: 4"TB:@$$FQZWKK7B=325L!0!0!0!0!
M0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0%.<M^:X@#1!?+FNK6\TF\=O
M+_HC[7T5UK\CSS7=QS^!Y[SYM<LK=_#+X^@N5R/08[U4^3^:Y$8=OES@,60-
MX2US8E;USMF'D9 #:C-V_"/>:YG&99+Y89@&T2.VX6ZM;I0Q,=X2(2WG!>H"
MRV[+=MNZA*O@.7DH1&;D%A;LUO5DGDL9&I=A,P)1#N#'M;V4-V<8#MNV02#0
M/82*!T)/6AF<((K70@Z&-K$>^H=%@S:>B;_E4O\ [5OW+72F1TH: UHT% %
M% % *H[>ZJ!=6'M[*@ :"_:>E4 =1?M'6H4/AM;KU-" 5O8CM_?0!<7M]D:4
M FW7V#6]4"WW7![>E  \(OV]!0!\0]H_=0 3ML!UZF@#:+W^S0!>]P>WI[*
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MKEHUD00@D&R^+0?376AV-#6P% % % % % % % % % % % % % % % % % %
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M=X78HSIY;^4RAPQ\6AUH!8/7GIV;FX^&227YN7,R./1C&1$<C%B2:1=]^EI
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MP4I(1\8D7[K=>_2@P&W55V("KF]R=+:WMT]E!GB(PC5-JF_:3WU"HV?HK_\
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M3<MFZ:$7H!WI;T:/3TI,<V)-$1(IDCPD@R7WR>9^+D+(Q>U_NZT!1C_3R?\
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M8&)8=5;56[]#0SJYC/$!8Q6%_$/;]5"^D>86V 370-\,:V&G>?II!-7(B93
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MQ8*9?&+ZH'&.[8,.))(!D'$:.\:OY-_.\LWMUH4;R\/H;!]5X\'Z</BKAY'
M<NWJ.'BY!)C?*KBDXDD^PL@E\WX2?$>V@.)^FW#+A>H_TWDS,# ].QY>$,O
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MT-  \'];]U (P\6G;TH!RV'A[]": 8 2;=M /TVV'9^V@&5 *VH#=^A^BJ!
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MX'I^\T2=6DXC#A6)>"6BK3F7CWG!Q.7R<7F6QN.7D(\9.2D^9P(Y4*1";,V
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MBPM8]MS;^6H.)&=OF =6TW'O/;0TC>>F/-_-.8WWV^:OE].GB[JZ4XG0T5;
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M&[VT!+%Z;]&L)(%P<.V<1*RJ%O)M8R*R6-P Q+ IVZT!(?2OIL38DGY7C"7
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M%+@W;?XK_$=_BNU]=: EF]*>F9)%EFXO'=UEDGN4'][(XD=CW[G 8@Z;M>M
M6<_A.)Y$,<[$BRB4"!Y%NP4.)  >HLZAA;M%Z ?!Q7&1XV/BQ8L28^(ROC0!
M1MC=+E70=X))O0%=?3/IULJ#)_+L<9.*28'V"ZL7,MQV:2,7%^A)(H"Q#PW$
M)QLW%IA0CCIA*)\':/*99B3*I0Z6?<;B@(,OTOZ<GRX\]^.QY,B,1^7*4%U\
MC^Z('2\?V3U% 5I_2?I?(QABS\5BR8ZD$1&,;=(Q#;W>4BI;H5 % 6>0X+AN
M2QH<;/PH<K'QR#!%(H*I9=GA]FT[2.T:5 2+Z=X$8WD/Q\!A))$/EC;N:'Y8
MFW?Y'X?]72J"*7TKZ9DRIYGXO&DGRD:/)9HPVY& #W!T\04 GJ;"] 1IZ2],
M+)CE.,Q_,QFW0/LN5.[S+DG5SO&[Q7\6M 3<GP/!\CDQ9/(8,.7DP6\B25 Q
M3:P=??M<!A?H=>M 11^E?3<&5)E1<9CQY$KB1Y5C&XN)!,&]EI5#_P!;7K0$
MG!\)!Q.#)CQ.9I,G(FR\O(=45I9IV+2.RH%07O;0=!0%8>C/2/RYQ!Q&+Y#2
M"5D$8 W!2HL>H&PE;=+:6M0$DGI3TS-E',FXO&:=D\LR&-;E/*,.T#I_='9_
M5TZ4!-D<%PD[))-@0/(KK(K,@)W)&85/MM&Q3W:4 S ],^GN/V+B<=CPE69E
M"H+@NGEMJ;G6/PV[M.E 59/1OIWY&?"Q,&+#$R.BRPQH702)Y9V^8'6VSP[2
M-MM+6H!O!>B>"XC!R(%A3*DRFF.3+)'&H9<E426-40*JHRPH".VVMS0%K_*_
MIYLJ;)/&XS3Y$;19$C1@[T=0CA@=/$JA6TU'6H"6#@."Q./GXW%P(8\'+#?-
MP!+I-YBA'\P&^[<H -^HJ@I'T=PK#!@QX5Q<'#RUSVQ(D39+D16\IY&8,_X;
M $6/8!TTH"_R7$\3R7E?/XD65Y._RC*H8@2KM<#V,NA% 19GIGT_R(D;.X_'
MR"\GG2-(@):0H(V9CU.Z-%4CM  - 7,G&Q<B$8\T*20*R.L; %=T3!XS;^BR
M@CNM4!4S?3_!Y:;<K AE#2G);<NIF9=C27&MV3PGO&AJ@2'T_P %% L$7'XZ
M0*R,L0C78#%'Y*';T\,?@'LTJ ;C^F/3F(ABQN-QXXP7LNP$?B)Y3CQ7T,?@
MMTVZ=*H'\;Z?X+CBIP<"'':/>R,B^(&155CN-SJJ*ON % 22<5QDF/DXTF+$
M^/FR&7+B*@K+(;7=QVMX!K[!4!P^-_3O@,3(S<K(7Y]LY?*=9HH4 02F?7RD
MCW/YECO.NFFMR:#KP\!P<,/D0X$$<.V--BH "L,AFC![]LK%Q_2-Z <_ \*W
M'OQYPH?D97,\F.%LAE9_-,@ Z-YGBN.W6@(\?TWZ>@B:"'C<>.&0;)(UC #*
M9#*0>^\A+^_6@'XW \)A\A-R&)@PP9T^\39*( ["1@[B_<SC<;=3KUJ Z"'K
M[JH$O4 EZ +T!EO6H)R,3LLK]MONUBYFQGD"L!&P!'V3>Q%ZP8?,4R2%1N((
M!U9!=['6UQ:U!@1A8U!VH.XEM2=+4* 11<6#WU)-C]&E +&%4@1BVHNK79;#
MV4(^T?<G\63:[7\(!&T=#T %ZH[",W+;B03<=M"FZ]-^;^<\QOOM\Q-EP!IX
MK]*Z4XG0T5; 4 4!GO7T!R/3&1"(Y)"\D "Q@'7SDL7NKCRQ]OPGPWTKKLN+
M'TOM-]/4)REA;/\ RO++'EBL1OH+'GQ^$D@R?/.3%E31Y#Y#!]TB-M9HV"QW
M0VZ[1K>F\Y9?NUU;=3KITNJB.7;B\?25,;!Q8.8QCC8.6ZM,2\D^.#%$=3O4
MWCVW.@8 VK3;:S.U]VUMIZK5RX6Q?9Q]6!9]386-)DG(^6RY\I8K*N/$'C<"
MY",VG;WM4VVSGT.[95TS55GB\5V_A%K-Q<6?T_C19&/,L8$96#'A"R(0- (O
MQ-FWV'2LIM6..UN6KO-U:G'%O!^G"1OIF%4AS$^5EQUWV#30B.25=OQEMS;^
M[4"U-QY%ZZTNKU)X<'*7\#G\1A8V-S&,,;"R_*(?\;)QP%B(70*UTV;KD7"G
MN[:W9RL6>GJ-VUMIZK5G#"ML_?/K'^I,+%.9-D+AY>5DE5W1Q0K)#( .AOLW
M:=[5*-QF9Z+=MI5=5:U[7#7O]QT.;Q,7(XW%6>*=@A4QC%B!=&VV^ AMH[/V
M5FC:9YNEW+5O:'7_ %/\25>/9,;TUR<CXTF*D2Y#,)<=1(ZHG]XR%R)=RC[1
M'W36K8V1VWD[;]$FK3IRMAGE,8>WF9K],.%QSG9'+K+C3S;0))A%AF8K*"55
M6Q)Y4A46^$(+UUZBV$?Q^)]3[YU5M"VXLERF\8?YZIV?;+/2:\A^7"@/).:X
MC$RO5N3QX1LM\S*E>*&*?$\R*5U5I9G!#2*1'"4C9A>/=8:D5[J6:K/\3]ET
MO46ITRO\NFJQ=;PUC"Y9N;)?-&/$T?ZE_F1^13'5)<5UF$T,N.\\98[ I;9C
M95K M;X===;6KET\8_CXH^9]DT>)VPMA#5E5\>=Z]G/T&C]+18<7!8L>(CQQ
M*MBKQRP^._C*QSV=5+7*CNZ:5QW)U8GS.OM9[UG9R^]/NQK@WS.K6#QA0!0!
M0!0%'(=!S&$ADD5VBG*Q+_=L 8[E_:M_#[S7:J_3M@LU\3S7:\VJEY6PX?ES
M^'I+U<3TF+]6A?SIB6\7R$FU;'^EVUSMF'D9F(@ GJW14U.I[=+Z5S.;',0J
M;YD#RN#9&TL.P[>SK_-5)W#4)8@1NH%O#'(+:#[I]]0,?\M*06T !MLN;'W^
MTT$H8XDC-FD4:?!&"7(Z&]_8>TT*+'L==L2!)4OL(-B>[3M.M"/ 1SN7<R[9
M>U;$7OV@$#W52HU_HW_\5)V?B-I_LUNF1NIW*T4* S_J?TJO.9>)*[I&N+C9
MT,<C+NDBFRTC2*>+L#1[";W![JH,:_H?DN"@QLJ3$BY$I(B-QR++F8[A,22
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MV0P),J;@ =#KWUTIFSH:2M@* * SWKUH5],9)E^'S( +CP;C,@7S+O$HCO\
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MX$*@R0AA<.K(R=XL;?7?]E9,,DA92624AO(NRR =40?"3;LH1KD+A0C(_&D
MV.-\I:QL!H !;H*)$MA@6LB+$F1GQV1V10&T \)'2X_=5,IM9E.%T"R(X+#%
M( !U)5NB_74-OWC'W/C>8Y&^9U4L- %%[+I;WT*LX(Y%)F.A%B+?U1TZ4*;K
MTYYOYSS.[X/,0)>W3Q7Z5TIFSH:*MD"@"@"@"@,)#Q$&#R>/*V'E')^:ABCF
M58&&WS"6,DT*M)?Q78R6)&E]3?TNTK,_06ZA[FVUJKITMQXN7"ML.[3,/'@C
MI>H^'Q\CE4R<C%FR(-L9<QKCS6,+EAMCD'F@7/C\N^X:6K&W:$>7HNI==MUK
M9)X_4LUS6'=.0Y\-LOTAQH$$UXDAD\F4QEQ9"+2KD!4;K\+ :]UJ3%V1;FCJ
M;XK&5*GV:<5WJ1?2F'CXQS\+'QLG&BC2%")E$5V*L&VB-52_:74GJ!V"FXYA
MC[AN6MIO9ULVWECRYX^AQ[3F\5Q4&!RV ?DLE,II1$90D'EB.*&4>.7'4[C<
M^+?M+&W=6[6E/$]/4=0]S;MXJZ8F/%,MUR5O9$QCS)_4O#X\G)3Y>1BSSQ!/
M-#Q)CSD,L1C%E8-.$%_A52+Z]]9V[808Z+J;+;5:VJGEB[+C/^6>UPX+O*\>
MV=P7&DP2NT:1LT+&&1AOBVD2+DV21ANMK8WK-;19G#8WO+WKXK&<<5QX:<5_
M CX+%\OAN7P^.Q9(REXL:'.3:CO\K& &3:J[2VCD7W&YOK5N\4W[.\UU>Y.[
MMVO9<VZ_YGQY\N6"(_0O!\IQTO(9&?@8O'G,$/EPXBHEO*,BV=8B8]VTJ21V
MDCH!5WKIQ#DU]UZK;W%2M+6OIG&TO.,IQC/\,UE<#XX4 4 4 4 4 4 4 4 4
M!3G#?FF(1'$RB.:\C'\523'8(+]&^U[A76OR//-=W$\]T_-K@LK=_#+X^@N5
MR/08SU8J'FV-_'\A(-MKZ7;6_97.V8>1F-H\IR_]VHOV?%T'[ZYG,L2))*T,
M:W#!0[/K900#N/9<U2)CIV=,QI5<[<D*5![77J.EKT(LBZ$Q977,8R"=;;3<
M^$6^$>PWUK6!F7D469\G+B5F*JCB:1?Z(Z7T[^E0W$(<%<YA9KNN3\#F]C<_
M">SLJ#@5;7BW*;EF(D8V.HU'[Z&C7>DBHXF3=_XK?]VMTR-([/C;^B.[M_FK
M0$%@?PQ<]K?S]M 9_P!7^E9N?BBA_,6Q(Q%D0RPJCLKC(0+OM')"2T=O"'+)
MKJITH4YC?IQ-*KXS<IY?'N,AEB$ \P2Y6!\B[&3?;:!XU6W70DU0/S/T]BS\
M%L;+Y!W>7)R<N:6&%4!DR<7Y8V#,U@I\6I-^AH))CZ'FGS<ODN0SUDY#-AR8
M9WCB\J.V1CQ8RE$+R$;%AN;L=Q/8 * IS_I]EY<&=C9G+)/!E0PX\+?+N)H(
ML4H\$4;B;;L$D>]P%!<GKTL!'+^G,AP\M,7DHX,GDH<C%Y*40,\;19!4_AB6
M5W#KY=MSN]^WH+!)V?4'IW(Y.=9L;.^6R#AY''3WA7(5L;*V&3:N]-K@QC:Q
MN.\&H0H3_I]C^6\:Y[1Q2"<1QE+LJS/BM8DGQ;?D0/;N]E4$>3Z GEPX,)^2
MV8>!/\QQ47D7*L97D(G>.19)=)"O@9/O&[4+(Z#]/(,?C<O"CR8G.7'C*QD@
MW+OQIY<@MY8?>-[SG42!UZAMVM!)<?TOE?Y9QN%_-9ER,>5)FS9?,8N%E,GE
M-ME618_%LOYV^P%V.MQ#G\?^GT>)A3XGSQR!.( SB.Q'R_(2\ATW-\33;.O9
M?K02=#TYZ3FXG.CF?D#-#B8?Y?@8Q@,;+!YPE'F.&/F.+!= !VVO>@*H_3\F
M#/B;/$BY<3P1LL(#1H^<^=K=SN(>4KV:6TH62QZ:]#8?"\H^8LXD5%GCQ4*.
M)%7*F$S[Y&D<&Q 4;$2_4W- 5.:_3B?D(9X$Y>2/'R&RVDA:-F .7D'(W*%E
MC5F6^S\0,+:V!J"2UD^ALC(P9,(<C&W'+-+D8F-+BAFCDFR?FG\R42+*=KW"
M-&T;#J22!5 SCO0'RN1#+/R<N5-$FTR2I=G_ .6FQK[BS-H)]+DFP%R=3021
MYOZ8X\L"JG(N%7$BPS:)>D.')A[[;NZ7=;V6H"YP/H7%XCFWY!9Q-$&RWQHV
M1_,0YLOG27D:1UT.@V1I<?%>U0#9O1&7*DD4/*"/%CS7Y+"A.,CM'EODKEWD
MD+7DC$@-E&PV;4FPJ@Y_)>@LW\OYIL?+&3RO+8\B->-8HA/+D^>S*K,VU0+
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M7PC33^2@%N(P+#Q'X%_E- -VDZNWT#04 VZ 61 2>I/=0#2K=I5#V  D_L-
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M!X)527U4Z _QH40@K\.H^[_"A L&\2FQ/0]_OH %G!##4=1W4  D':=>X]]
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M4D>%?Y: &B.TF0A1;IV4 *YVJ(A86'C/\@H!L:@$G5G)/OZV^B@%MXF9FM8
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M7/\ ' W;[3MSX;/3C/J\/K9V)^6Y%\T8.'!&3D1M/!),'C 1/ R2(=K[S(4
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M,!;]E"FQ]+J!RW-$,"#,N@OI\6AO72N;.AHZV0* * * * * * * * * * *
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MM"-H9E8[KJ".H%N'U%GYV7C8LO%1.^;$L\Y>/*8"/S3&JNKXP(M8F\FU>XT
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M"AQXE4[?+"Z%]UO9:@-#FKS\N+Z5XKGI,6;F\GDTR<QL%77'\K #Y)9%D\0
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M_04 (I#^+0'55[N^@ F[W7X&T9O;V6H!9"$ *C4=%'=VT ;+J23=CKN_=]%
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MV!Z=UZ BD#I)Y;'J5OKU'90(V'IO9^><W:^[S$W7(L>MK6KI3-FS1UL@4 4
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M81E\L93PQ\?8;BO,? "@"@*<[N.4Q$$J*K1S%H2/Q'(,=BIMH%OXM>T5UJO
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M(!,JA+%O !HB]6J <MU!=K1@]2=3:@%CW:LHU;[3=W9[: 12NXMJ[=!]'[J
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MMU[J%-GZ<+?G?- J%7S$VL%VW^*]SVUTIQ-&BK9 H H H H H H H H H H
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MT]PH .K@=VI_=0&>]97\S$L0/"]CW?#6+E.(J--*JNWAR(RI9M0KH"01T'4
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M"T2O)BY+$O*^@\Y5(;P]E]]^]!6MV8Q<G;[G:UJIVNMQSG7@N7X7=9CUX;U
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M] +N[-P]RC_MH  UNJDGO:H -OMM_JC_ $O5 OB(LHVCV_PH!+JITNS=O?\
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MOH!=W]/_ &1_VT 6![&;WZ?PJ  &'P@+^W]U +MO\1)]G0?LH44 #0:"@%H
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M!HO38!XERGA#2L1^P?R5JN0.A=QU%_:/X&M$$_#OH2A^K]] *-W8P/O_ )J
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M_P#1G^+0?[_]FDH?N&Q]2#_/_HS_ !:#_?\ [-)0_<-CZD'^?_1G^+0?[_\
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M5(\(W2,;*1UH#JWMVL/>+T EP>U#[Q:@#8/N*?=_V4 NW_U8_P!/HH!0''0
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MG_AT@0 Q)!TC_8*0(%^7F^X:0(#Y>?[AI @/EYON&D" ^7F^X:0(#Y>;[AI
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MW3"+:EK';?KJ;+0$\:!$51V"U .) !)Z#4T 4 4 4 4 4 4 4 4 4 4 4 4
M4 4 4 4 4 4 4 4 4 4 4!S\F2,<Y@(8E9VAR2LI-F4 Q7"CM#7U]U=Z)^79
MSQK\3R[EEYU%&.FV/^TZ%<#U!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!I0
F+=E  MV?30!0!I_"@ V[>E % % 59LF81R#Y24BQU!B_^)0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850123712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 10, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MNKD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MANNKIND CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,776,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,097,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850683152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,895<span></span>
</td>
<td class="nump">$ 59,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Receivable from Sanofi</a></td>
<td class="nump">30,557<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset held for sale</a></td>
<td class="nump">16,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Deferred costs from commercial product sales</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,364<span></span>
</td>
<td class="nump">4,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,488<span></span>
</td>
<td class="nump">76,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment - net</a></td>
<td class="nump">28,927<span></span>
</td>
<td class="nump">48,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">107,063<span></span>
</td>
<td class="nump">126,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,263<span></span>
</td>
<td class="nump">15,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="nump">7,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">Facility financing obligation</a></td>
<td class="nump">71,339<span></span>
</td>
<td class="nump">74,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - net</a></td>
<td class="nump">3,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredCollaborativeCreditCurrent', window );">Deferred payments from collaboration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">140,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredCollaborativeRevenueCurrent', window );">Deferred sales from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PurchaseObligationCurrent', window );">Recognized loss on purchase commitments - current</a></td>
<td class="nump">5,093<span></span>
</td>
<td class="nump">12,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">92,051<span></span>
</td>
<td class="nump">268,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Note payable to principal stockholder</a></td>
<td class="nump">49,521<span></span>
</td>
<td class="nump">49,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AccruedInterestNoncurrent', window );">Accrued interest - note payable to principal stockholder</a></td>
<td class="nump">9,281<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Senior convertible notes</a></td>
<td class="nump">27,635<span></span>
</td>
<td class="nump">27,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Sanofi loan facility and loss share obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PurchaseObligationNoncurrent', window );">Recognized loss on purchase commitments - long term</a></td>
<td class="nump">95,942<span></span>
</td>
<td class="nump">53,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
<td class="nump">7,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent', window );">Milestone rights liability and other liabilities</a></td>
<td class="nump">8,845<span></span>
</td>
<td class="nump">8,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">290,656<span></span>
</td>
<td class="nump">476,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2016 and 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.05 par value - 140,000,000 and 110,000,000 shares authorized at December 31, 2016 and 2015, respectively; 95,680,831 and 85,734,188 shares issued and outstanding at December 31, 2016 and 2015, respectively</a></td>
<td class="nump">4,784<span></span>
</td>
<td class="nump">4,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,549,212<span></span>
</td>
<td class="nump">2,508,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,737,565)<span></span>
</td>
<td class="num">(2,863,229)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(183,593)<span></span>
</td>
<td class="num">(350,329)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 107,063<span></span>
</td>
<td class="nump">$ 126,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredCollaborativeCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Collaborative Credit Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredCollaborativeCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredCollaborativeRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Collaborative Revenue Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredCollaborativeRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Rights Liability and Other Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PurchaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PurchaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6390208&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850166256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">95,680,831<span></span>
</td>
<td class="nump">85,734,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">95,680,831<span></span>
</td>
<td class="nump">85,734,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6851431024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue - collaboration</a></td>
<td class="nump">$ 171,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net revenue - commercial product sales</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromBulkInsulin', window );">Revenue - bulk insulin sales</a></td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total net revenue</a></td>
<td class="nump">174,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CostsOfRevenueCollaboration', window );">Costs of revenue - collaboration</a></td>
<td class="nump">32,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">17,121<span></span>
</td>
<td class="nump">$ 64,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">14,917<span></span>
</td>
<td class="nump">29,674<span></span>
</td>
<td class="nump">$ 100,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">46,928<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
<td class="nump">79,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Property and equipment impairment</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">140,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">(Gain) loss on foreign currency translation</a></td>
<td class="num">(3,433)<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_GainLossOnPurchaseCommitments', window );">(Gain) loss on purchase commitments</a></td>
<td class="num">(2,265)<span></span>
</td>
<td class="nump">66,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">107,498<span></span>
</td>
<td class="nump">344,655<span></span>
</td>
<td class="nump">179,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">67,260<span></span>
</td>
<td class="num">(344,655)<span></span>
</td>
<td class="num">(179,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">5,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes</a></td>
<td class="num">(15,576)<span></span>
</td>
<td class="num">(21,231)<span></span>
</td>
<td class="num">(17,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Interest expense on note payable to principal stockholder</a></td>
<td class="num">(2,901)<span></span>
</td>
<td class="num">(2,894)<span></span>
</td>
<td class="num">(2,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">72,024<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(597)<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">58,404<span></span>
</td>
<td class="num">(23,790)<span></span>
</td>
<td class="num">(18,755)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before benefit for income taxes</a></td>
<td class="nump">125,664<span></span>
</td>
<td class="num">(368,445)<span></span>
</td>
<td class="num">(198,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 125,664<span></span>
</td>
<td class="num">$ (368,445)<span></span>
</td>
<td class="num">$ (198,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net income (loss) per share</a></td>
<td class="nump">92,053<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net income (loss) per share</a></td>
<td class="nump">92,085<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CostsOfRevenueCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Revenue Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CostsOfRevenueCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_GainLossOnPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(Gain) Loss on Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_GainLossOnPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetRevenueFromBulkInsulin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Revenue From Bulk Insulin</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetRevenueFromBulkInsulin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetRevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Revenue From Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetRevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68048823&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Impairment<br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834765120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 125,664<span></span>
</td>
<td class="num">$ (368,445)<span></span>
</td>
<td class="num">$ (198,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Cumulative translation loss</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 125,660<span></span>
</td>
<td class="num">$ (368,451)<span></span>
</td>
<td class="num">$ (198,392)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32022-110900<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32157-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6853115600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>TEL AVIV STOCK EXCHANGE</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>TEL AVIV STOCK EXCHANGE</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>TEL AVIV STOCK EXCHANGE</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Deficit Accumulated During the Development Stage</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2013</a></td>
<td class="num">$ (30,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,261,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (2,296,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units</a></td>
<td class="num">(26,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance of common shares pursuant to warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodValueWarrantExercises', window );">Issuance of common shares pursuant to warrant exercises</a></td>
<td class="nump">$ 27,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">61,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">25,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodSharesForDebtExchange', window );">Issuance of common shares pursuant to debt conversions by Deerfield (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodValueForDebtExchange', window );">Issuance of common shares pursuant to debt conversions by Deerfield</a></td>
<td class="nump">93,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Remeasurement of performance based grants pursuant to the modification of terms</a></td>
<td class="nump">$ 22,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockLoanedUnderShareLendingAgreementShares', window );">Return of loaned common stock (in shares)</a></td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on foreign currency translation</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(198,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,382)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="num">(73,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,416,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(2,494,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance of common shares pursuant to warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodValueWarrantExercises', window );">Issuance of common shares pursuant to warrant exercises</a></td>
<td class="nump">$ 10,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">64,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock units taxes paid in cash</a></td>
<td class="num">(1,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contribution</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares pursuant to conversions of certain 2015 note holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares pursuant to conversions of certain 2015 notes</a></td>
<td class="nump">7,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement', window );">Issuance of common stock for lender financing fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodValueShareLendingAgreement', window );">Issuance of common stock for lender financing fees</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion', window );">Discount on notes-for-stock exchange</a></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockLoanedUnderShareLendingAgreementShares', window );">Return of loaned common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockLoanedUnderShareLendingAgreementValue', window );">Return of loaned common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">27,843<span></span>
</td>
<td class="nump">$ 34,710<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">27,754<span></span>
</td>
<td class="nump">$ 34,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="nump">2,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrant liability</a></td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on foreign currency translation</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(368,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(368,445)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="num">$ (350,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(2,863,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">55,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares from the release of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">104,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock units taxes paid in cash</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue', window );">Issuance of direct placement - common stock and warrants (value)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares', window );">Issuance of direct placement - common stock and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement', window );">Issuance costs associated with direct placement</a></td>
<td class="num">(2,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrant liability</a></td>
<td class="num">(12,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on foreign currency translation</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">125,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,664<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="num">$ (183,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,549,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (2,737,565)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Shares Issued In Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Stock Option Issued Upon Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock and Warrants Issued in Direct Placement Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockAndWarrantsIssuedInDirectPlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock and Warrants Issued in Direct Placement Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockAndWarrantsIssuedInDirectPlacementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockLoanedUnderShareLendingAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock loaned under share lending agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockLoanedUnderShareLendingAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockLoanedUnderShareLendingAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Loaned Under Share Lending Agreement Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockLoanedUnderShareLendingAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodSharesForDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, For Debt Exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodSharesForDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares share lending agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodSharesShareLendingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodValueForDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares pursuant to debt conversions by Deerfield.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodValueForDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodValueShareLendingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value share lending agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodValueShareLendingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity-based compensation, related to restricted stock units or restricted stock awards, recognized as expense or an asset, if compensation is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32022-110900<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32157-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XTAE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XTAE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mnkd_DeficitAccumulatedDuringDevelopmentStageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mnkd_DeficitAccumulatedDuringDevelopmentStageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850866304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 125,664,000<span></span>
</td>
<td class="num">$ (368,445,000)<span></span>
</td>
<td class="num">$ (198,382,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">4,158,000<span></span>
</td>
<td class="nump">13,276,000<span></span>
</td>
<td class="nump">18,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,135,000<span></span>
</td>
<td class="nump">8,725,000<span></span>
</td>
<td class="nump">48,622,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(5,369,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">(Gain) loss on foreign currency translation</a></td>
<td class="num">(3,433,000)<span></span>
</td>
<td class="nump">2,697,000<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(72,024,000)<span></span>
</td>
<td class="nump">1,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest incurred through borrowings under Sanofi Loan Facility</a></td>
<td class="nump">4,478,000<span></span>
</td>
<td class="nump">1,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_InterestOnNotePayableToPrincipalStockholder', window );">Interest on note payable to principal stockholder</a></td>
<td class="nump">2,901,000<span></span>
</td>
<td class="nump">2,894,000<span></span>
</td>
<td class="nump">2,894,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WarrantIssuanceCosts', window );">Series A Warrant issuance costs</a></td>
<td class="nump">653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on sale, abandonment/disposal or impairment of property and equipment</a></td>
<td class="nump">1,259,000<span></span>
</td>
<td class="nump">140,582,000<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_GainLossOnPurchaseCommitments', window );">(Gain) loss on purchase commitments</a></td>
<td class="num">(2,265,000)<span></span>
</td>
<td class="nump">66,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Write-off of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WriteOffOfCommitmentAsset', window );">Write-off of Tranche B commitment asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WriteOffOfDerivativeLiability', window );">Write-off of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(363,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(302,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable', window );">Receivable from Sanofi</a></td>
<td class="num">(30,534,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,331,000)<span></span>
</td>
<td class="num">(26,434,000)<span></span>
</td>
<td class="num">(9,670,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Receivables from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,413,000<span></span>
</td>
<td class="num">(50,436,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncreaseDecreaseInOtherDeferredCharges', window );">Deferred costs from commercial product sales</a></td>
<td class="num">(309,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred costs from collaboration</a></td>
<td class="nump">13,539,000<span></span>
</td>
<td class="num">(13,539,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(346,000)<span></span>
</td>
<td class="nump">13,481,000<span></span>
</td>
<td class="num">(14,734,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">361,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="num">(615,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(12,118,000)<span></span>
</td>
<td class="nump">8,413,000<span></span>
</td>
<td class="nump">3,622,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">348,000<span></span>
</td>
<td class="num">(12,467,000)<span></span>
</td>
<td class="nump">2,276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">3,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits', window );">Deferred payments from collaboration</a></td>
<td class="num">(134,056,000)<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">200,436,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue', window );">Deferred sales from collaboration</a></td>
<td class="num">(17,503,000)<span></span>
</td>
<td class="nump">17,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncreaseDecreaseInPurchaseCommitmentLoss', window );">Recognized loss on purchase commitments</a></td>
<td class="nump">40,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Milestone rights liability and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(78,090,000)<span></span>
</td>
<td class="num">(57,232,000)<span></span>
</td>
<td class="nump">4,086,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,144,000)<span></span>
</td>
<td class="num">(10,285,000)<span></span>
</td>
<td class="num">(24,097,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(1,127,000)<span></span>
</td>
<td class="num">(10,203,000)<span></span>
</td>
<td class="num">(24,097,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from direct placement of common stock and warrants</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance costs associated with direct placement</a></td>
<td class="num">(2,690,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payment of notes payable to Deerfield</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employment taxes related to vested restricted stock units</a></td>
<td class="num">(165,000)<span></span>
</td>
<td class="num">(1,858,000)<span></span>
</td>
<td class="num">(26,908,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">4,146,000<span></span>
</td>
<td class="nump">12,341,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants for common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,123,000<span></span>
</td>
<td class="nump">27,779,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payment of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,287,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs on 2018 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of facility financing obligation and milestone rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of Tranche B of the facility financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,219,000)<span></span>
</td>
<td class="num">(3,150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to at-the-market issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs associated with the Tel Aviv Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(548,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">43,038,000<span></span>
</td>
<td class="nump">5,668,000<span></span>
</td>
<td class="nump">70,062,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(36,179,000)<span></span>
</td>
<td class="num">(61,767,000)<span></span>
</td>
<td class="nump">50,051,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">59,074,000<span></span>
</td>
<td class="nump">120,841,000<span></span>
</td>
<td class="nump">70,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">22,895,000<span></span>
</td>
<td class="nump">59,074,000<span></span>
</td>
<td class="nump">120,841,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOWS DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid in cash, net of amounts capitalized to construction in progress</a></td>
<td class="nump">8,991,000<span></span>
</td>
<td class="nump">13,355,000<span></span>
</td>
<td class="nump">11,218,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of 2015 notes and interest through issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common stock pursuant to debt conversion by Deerfield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Non-cash construction in progress and property and equipment</a></td>
<td class="nump">588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAssumed1', window );">Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share obligation</a></td>
<td class="nump">5,174,000<span></span>
</td>
<td class="nump">59,337,000<span></span>
</td>
<td class="nump">$ 3,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash', window );">Reclassification of property and equipment to asset held for sale</a></td>
<td class="nump">$ 17,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XTAE', window );">TEL AVIV STOCK EXCHANGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs associated with the Tel Aviv Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,432,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_GainLossOnPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(Gain) Loss on Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_GainLossOnPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Deferred Collaborative Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_IncreaseDecreaseInDeferredCollaborativeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_IncreaseDecreaseInOtherDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Other Deferred Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_IncreaseDecreaseInOtherDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_IncreaseDecreaseInPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in Purchase Commitment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_IncreaseDecreaseInPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_InterestOnNotePayableToPrincipalStockholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest on Note Payable to Principal Stockholder</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_InterestOnNotePayableToPrincipalStockholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments include payments to our partners related to alliance and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity including any warrants issued. Proceeds are net of cash outflows for issuance costs related to the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Property Plant And Equipment To Assets Held For Sale Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WriteOffOfCommitmentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off of Commitment Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WriteOffOfCommitmentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WriteOffOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off of Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WriteOffOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of loans assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XTAE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XTAE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840510528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <b>1. Description of Business</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Business</i> &#x2014; MannKind Corporation and subsidiaries (the
 &#x201C;Company&#x201D;) is a biopharmaceutical company focused on
 the discovery and development of therapeutic products for diseases
 such as diabetes. The Company&#x2019;s only approved product,
 Afrezza, (insulin human [rDNA origin]) inhalation powder, is a
 rapid-acting inhaled insulin that was approved by the U.S. Food and
 Drug Administration (the &#x201C;FDA&#x201D;) on June&#xA0;27, 2014
 to improve glycemic control in adult patients with diabetes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Basis of Presentation</i> &#x2014; On August&#xA0;11, 2014, the
 Company entered into a license and collaboration agreement (the
 &#x201C;Sanofi License Agreement&#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (&#x201C;Sanofi&#x201D;)), pursuant to which Sanofi was responsible
 for Afrezza global commercial, regulatory and development
 activities for Afrezza.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On January&#xA0;4, 2016, the Company received written notification
 from Sanofi of its election to terminate in its entirety the Sanofi
 License Agreement. The effective date of termination (the
 &#x201C;Termination Date&#x201D;) was April&#xA0;4, 2016, which was
 when the Company assumed responsibility for worldwide development
 and commercialization of Afrezza. Under terms of a transition
 agreement, Sanofi continued to fulfill orders for Afrezza in the
 United States until the Company began distributing MannKind-branded
 Afrezza product to major wholesalers in late July 2016. The Company
 began recognizing commercial product sales revenue when
 MannKind-branded Afrezza was dispensed from pharmacies to patients
 in August 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On November&#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &#x201C;Settlement Agreement&#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 (the &#x201C;Sanofi Loan Facility&#x201D;) between the Company and
 Aventisub LLC (&#x201C;Aventisub&#x201D;), a Sanofi affiliate, was
 terminated, with Aventisub agreeing to forgive the full outstanding
 loan balance of $72.0&#xA0;million, which includes
 $0.5&#xA0;million of previously uncharged costs pursuant to the
 Sanofi License Agreement. Sanofi also agreed to purchase
 $10.2&#xA0;million of insulin from the Company in December 2016
 under an existing insulin put option as well as make a cash payment
 of $30.6&#xA0;million to the Company in early January 2017 as
 acceleration and in replacement of all other payments that Sanofi
 would otherwise have been required to make in the future pursuant
 to the insulin put option, without the Company being required to
 deliver any insulin for such payment. The Company and Sanofi also
 agreed to a general release of potential claims against each
 other.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During their initial transition of the commercial responsibilities
 from Sanofi, the Company utilized a contract sales organization to
 promote Afrezza while the Company focused its internal resources on
 establishing a channel strategy, entering into distribution
 agreements and developing <font style="WHITE-SPACE: nowrap">co-pay</font> assistance programs, a voucher
 program, data agreements and payor relationships. In early 2017,
 the Company recruited their own sales force, which included some of
 the sales reps that previously were employed by the contract sales
 organization. The Company intend to continue the commercialization
 of Afrezza in the United States through their own commercial
 organization. The Company&#x2019;s current strategy for the future
 commercialization of Afrezza outside of the United States, subject
 to receipt of the necessary foreign regulatory approvals, is to
 seek and establish regional partnerships in foreign jurisdictions
 where there are appropriate commercial opportunities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 It has been costly to develop our therapeutic product, conduct
 clinical studies, and market and sell Afrezza. As of and for the
 year ended December&#xA0;31, 2016, the Company has reported an
 accumulated deficit of $2.7&#xA0;billion and has reported negative
 cash flow from operations for each year since inception, except for
 2014, when the Company received the $150.0&#xA0;million upfront
 payment from Sanofi.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2016, the Company&#x2019;s capital resources
 consisted of cash and cash equivalents of $22.9&#xA0;million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &#x201C;Facility Agreement&#x201D;) with Deerfield
 Private Design Fund II, L.P. (Deerfield Private Design Fund) and
 Deerfield Private Design International II, L.P. (collectively,
 &#x201C;Deerfield&#x201D;) and the First Amendment to Facility
 Agreement and Registration Rights Agreement (the &#x201C;First
 Amendment&#x201D;) that resulted in additional sales of an
 additional tranche of notes (the &#x201C;Tranche B notes&#x201D;)
 (see Note 7 &#x2014; Borrowings) requires the Company to maintain at
 least $25.0&#xA0;million, which can be comprised of cash and cash
 equivalents and available borrowings under the loan arrangement,
 dated as of October&#xA0;2, 2007, between the Company and The Mann
 Group LLC (as amended, restated, or otherwise modified as of the
 date hereof, &#x201C;the Mann Group Loan Arrangement&#x201D;), as of
 the last day of each fiscal quarter.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Additional funding sources that are, or in certain circumstances
 may be available to the Company, include approximately
 $30.1&#xA0;million principal amount of available borrowings under
 The Mann Group Loan Arrangement. A portion of these available
 borrowings may be used to capitalize accrued interest into
 principal, upon mutual agreement of the parties, as it becomes due
 and payable under The Mann Group Loan Arrangement (see Note 6
 &#x2014; Related-party Arrangements). The Company cannot provide
 assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 will need to raise additional capital, whether through a sale of
 equity or debt securities, a strategic business collaboration with
 a pharmaceutical company, the establishment of other funding
 facilities, licensing arrangements, asset sales or other means, in
 order to continue the commercialization of Afrezza and development
 of other product candidates and to support its other ongoing
 activities. The Company cannot provide assurances that such
 additional capital will be available on acceptable terms or at all.
 These factors raise substantial doubt about the Company&#x2019;s
 ability to continue as a going concern. The financial statements do
 not include any adjustments that might result from the outcome of
 this uncertainty.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On September&#xA0;14, 2016, the Company received notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that, for the previous 30 consecutive business days, the
 bid price for the common stock closed below the minimum $1.00 per
 share required for continued inclusion on The NASDAQ Global Market.
 The notification letter stated that the Company would be afforded
 180 calendar days, or until March&#xA0;13, 2017, to regain
 compliance with the minimum bid price requirement. In order to
 regain compliance, shares of the Company&#x2019;s common stock must
 maintain a minimum bid closing price of at least $1.00 per share
 for a minimum of 10 consecutive business days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Reverse Stock Split</i> &#x2014; On March&#xA0;1, 2017, following
 stockholder approval, the Company&#x2019;s board of directors
 approved a reverse stock split ratio of <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5.&#xA0;On</font></font> March&#xA0;1,
 2017, the Company filed with the Secretary of State of the State of
 Delaware a Certificate of Amendment of the Company&#x2019;s Amended
 and Restated Certificate of Incorporation to effect the
 <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5</font></font> reverse stock split of
 the Company&#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&#xA0;The Company&#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&#xA0;3,
 2017.&#xA0;See Note 20 &#x2014; Subsequent Events for further
 information. As a result, all common stock share amounts included
 in these consolidated financial statements have been retroactively
 reduced by a factor of five, and all common stock per share amounts
 have been increased by a factor of five, with the exception of the
 Company&#x2019;s common stock par value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Principles of Consolidation</i> &#x2014; The consolidated
 financial statements include the accounts of the Company and its
 wholly-owned subsidiaries. Intercompany balances and transactions
 have been eliminated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Segment Information</i> &#x2014; Operating segments are
 identified as components of an enterprise about which separate
 discrete financial information is available for evaluation by the
 chief operating decision-maker in making decisions regarding
 resource allocation and assessing performance. To date, the Company
 has viewed its operations and manages its business as one segment
 operating in the United States of America.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830317296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>2. Summary of Significant Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Financial Statement Estimates</i> &#x2014; The preparation of
 financial statements in conformity with accounting principles
 generally accepted in the United States of America (GAAP) requires
 management to make estimates and assumptions that affect the
 amounts reported in the financial statements and accompanying
 notes. Actual results could differ from those estimates. Management
 considers many factors in selecting appropriate financial
 accounting policies, and in developing the estimates and
 assumptions that are used in the preparation of the financial
 statements. Management must apply significant judgment in this
 process. The more significant estimates reflected in these
 accompanying consolidated financial statements include revenue
 recognition, assessing long-lived assets for impairment, accrued
 expenses, including clinical study expenses, inventory
 recoverability, valuation of the facility financing obligation,
 loss on purchase commitment, warrant liability, milestone rights,
 stock-based compensation and the determination of the provision for
 income taxes and corresponding deferred tax assets and liabilities
 and any valuation allowance recorded against net deferred tax
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Reclassifications</i> &#x2014; Certain amounts from previous
 periods have been reclassified to conform to the 2016 presentation.
 Specifically, accrued interest &#x2014; note payable to principal
 stockholder has been reclassified from the previously reported
 classification of other liabilities in the accompanying
 consolidated balance sheets. Additionally, the remaining balance
 from the previously reported classification of other liabilities is
 now identified as milestone rights liability, and is disclosed as a
 separate line item on the consolidated statements of cash flows.
 Additionally, on the consolidated statement of operations, product
 manufacturing has been renamed to cost of goods sold. The Company
 also reclassified (gain) loss on foreign currency translation from
 the previously reported classification of product manufacturing in
 the accompanying consolidated statements of operations.
 Additionally, certain balances from prepaid expenses and other
 current assets were reclassed to (gain) loss on foreign currency
 translation in the consolidated statements of cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Revenue Recognition</i> &#x2014; Revenue is recognized when the
 four basic criteria of revenue recognition are met: (1) persuasive
 evidence that an arrangement exists; (2) delivery has occurred or
 services have been rendered; (3) the fee is fixed or determinable;
 and (4) collectability is reasonably assured. When the accounting
 requirements for revenue recognition are not met, the Company
 defers the recognition of revenue by recording deferred revenue on
 the consolidated balance sheets until such time that all criteria
 are met. To date, the Company has had revenue from collaborations,
 commercial sales of Afrezza, and from sales of bulk insulin, which
 are described more fully below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Revenue Recognition &#x2014; Net Revenue &#x2014; Collaborations
 &#x2014;</i> The Company enters into collaborations under which we
 must perform certain obligations and we receive periodic payments.
 We evaluate the collaborations under the multiple element revenue
 recognition accounting guidance. Revenue arrangements with multiple
 elements are divided into separate units of accounting if certain
 criteria are met, including whether the delivered elements have
 stand-alone value to the customer. When deliverables are separable,
 consideration received is allocated to the separate units of
 accounting based on the relative selling price of each deliverable
 and the appropriate revenue recognition principles are applied to
 each unit.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The assessment of multiple element arrangements requires judgment
 in order to determine the appropriate units of accounting and the
 points in time that, or periods over which, revenue should be
 recognized. The terms of and the accounting for the Company&#x2019;s
 collaborations are described more fully in Note 8 &#x2014;
 Collaboration Arrangements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Revenue Recognition &#x2014; Net Revenue &#x2014; Commercial
 Product Sales &#x2014;</i> Between July&#xA0;1, 2016 and
 December&#xA0;15, 2016, the Company sold Afrezza to Integrated
 Commercialization Solutions Direct (ICS) and title and risk of loss
 transferred to ICS upon shipment. After December&#xA0;15, 2016, ICS
 became a third party logistics provider and stopped taking title
 and risk of loss upon shipment of Afrezza to ICS. The Company sells
 Afrezza in the United States to wholesale pharmaceutical
 distributors through ICS, and ultimately to retail pharmacies,
 which are collectively referred to as &#x201C;customers&#x201D;.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company provides the right of return to ICS (through
 December&#xA0;15, 2016) and its wholesale distributors and, through
 them, to its retail pharmacy customers for unopened product for a
 period beginning six months prior to and ending twelve months after
 its expiration date. Once the product has been prescribed and
 dispensed to the patient, any right of return ceases to exist.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Given the Company&#x2019;s limited sales history for Afrezza, the
 Company cannot reliably estimate expected returns of the product at
 the time of shipment into the distribution channel. Accordingly,
 the Company defers recognition of revenue on Afrezza product
 shipments until the right of return no longer exists, which occurs
 at the earlier of the time Afrezza is dispensed from pharmacies to
 patients or expiration of the right of return. The Company
 recognizes revenue based on Afrezza patient prescriptions dispensed
 as estimated by syndicated data provided by a third party. The
 Company also analyzes additional data points to ensure that such
 third-party data is reasonable including data related to inventory
 movements within the channel and ongoing prescription demand.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 For the year ended December&#xA0;31, 2016, net revenue from
 commercial product sales consisted of $1.9&#xA0;million of net
 sales of Afrezza dispensed to patients. As of December&#xA0;31,
 2016, the Company recorded $3.4&#xA0;million in deferred revenue on
 its consolidated balance sheet, of which $1.6&#xA0;million (net of
 estimated <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">gross-to-net</font></font> adjustments)
 represents product shipped to the Company&#x2019;s third-party
 logistics provider and wholesale distributors, but not yet
 dispensed to patients. The difference represents deferred revenue
 from bulk insulin sales, which is described more fully under the
 heading <i>Revenue Recognition &#x2014; Revenue &#x2014; Bulk Insulin
 Sales</i> below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">Gross-to-net</font></font> Adjustments
 &#x2014;</i> Estimated <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">gross-to-net</font></font>
 adjustments for Afrezza include wholesaler distribution fees,
 prompt pay discounts, estimated rebates and patient discount and
 <font style="WHITE-SPACE: nowrap">co-pay</font> assistance
 programs, and are based on estimated amounts owed or to be claimed
 on the related sales. These estimates take into consideration the
 terms of the Company&#x2019;s agreements with its customers and the
 levels of inventory within the distribution and retail channels
 that may result in future rebates or discounts taken. In certain
 cases, such as patient support programs, the Company recognizes the
 cost of patient discounts as a reduction of revenue based on
 estimated utilization. If actual future results vary, the Company
 may need to adjust these estimates, which could have an effect on
 product revenue in the period of adjustment. The Company records
 product sales deductions in the consolidated statements of
 operations at the time product revenue is recognized. At
 December&#xA0;31, 2016, year to date total <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">gross-to-net</font></font> adjustments were
 approximately $0.8&#xA0;million, which represents 30% of gross
 revenue from product sales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Wholesaler Distribution Fees &#x2014;</i> The Company pays
 distribution fees to certain wholesale distributors based on
 contractually determined rates. The Company accrues the
 distribution fees on shipment to the respective wholesale
 distributors and recognizes the distribution fees as a reduction of
 revenue in the same period the related revenue is recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Prompt Pay Discounts &#x2014;</i> The Company offers cash
 discounts to its customers, generally 2% of the sales price, as an
 incentive for prompt payment. The Company accounts for cash
 discounts by reducing accounts receivable by the prompt pay
 discount amount and recognizes the discount as a reduction of
 revenue in the same period the related revenue is recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Rebates &#x2014;</i> The Company participates in federal and
 state government-managed Medicare and Medicaid rebate programs and
 intends to pursue participation in certain other qualifying federal
 and state government programs whereby discounts and rebates are
 provided to participating federal and state government entities.
 Rebates provided through these other qualifying programs are
 included in the Medicaid and Medicare rebate accrual. The Company
 accounts for these rebates by establishing an accrual equal to the
 estimate of rebate claims attributable to a sale and determines its
 estimate of the rebates accrual based on historical payor data
 provided by a third-party vendor along with additional data
 including a forecasted participation rate for Medicare and
 Medicaid. From that data, as well as input received from
 MannKind&#x2019;s commercial team, an estimated participation rate
 for Medicare and Medicaid is determined and applied at the mandated
 rate for those sales. Any new information regarding changes in the
 programs&#x2019; regulations and guidelines or any changes in the
 Company&#x2019;s government price reporting calculations that would
 impact the amount of the rebates will also be taken into account in
 determining or modifying the appropriate reserve. The time period
 between the date the product is sold into the channel and the date
 such rebates are paid ranges from approximately six to nine months.
 As such, continuous monitoring of these estimates are performed on
 a periodic basis and if necessary, adjusted to reflect new facts
 and circumstances. Rebates are recognized as a reduction of revenue
 in the period the related revenue is recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Patient Discount and <font style="WHITE-SPACE: nowrap">Co-Pay</font> Assistance Programs &#x2014;</i>
 The Company offers discount card programs to patients for Afrezza
 in which patients receive discounts on their prescriptions or a
 reduction in their <font style="WHITE-SPACE: nowrap">co-pay</font>
 amounts that are reimbursed by the Company. The Company estimates
 the total amount that will be redeemed based on levels of inventory
 in the distribution and retail channels and recognizes the discount
 as a reduction of revenue in the same period the related revenue is
 recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Product Returns &#x2014;</i> The Company does not provide a
 reserve for product returns of sales of Afrezza due to its revenue
 recognition policy of deferring recognition of revenue on product
 shipments of Afrezza until the right of return no longer
 exists.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Revenue Recognition &#x2014; Revenue &#x2014; Bulk Insulin Sales
 &#x2014;</i> In 2016, revenue from bulk insulin sales was recognized
 after delivery and customer acceptance of the bulk insulin. When
 the accounting requirements for revenue recognition of bulk insulin
 sales are not met, the Company defers recognition of revenue by
 recording deferred revenue on the balance sheet until such time
 that all criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Deferred revenue includes $1.8&#xA0;million received from a sale of
 surplus bulk insulin to a third party that was delivered prior to,
 but accepted after, December&#xA0;31, 2016. No deferred cost was
 recognized related to this sale because the inventory was written
 off on December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Deferred Costs from Collaboration &#x2014;</i> Deferred costs
 from collaboration represents the costs of product manufactured and
 sold to Sanofi, as well as certain direct costs associated with a
 firm purchase commitment entered into in connection with the
 collaboration with Sanofi. During the third quarter of 2016, the
 costs related to the Sanofi product sales were recognized as costs
 of revenue &#x2014; collaboration in the consolidated statements of
 operations, as related revenue was recognized at that time.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Deferred Costs from Commercial Product Sales &#x2014;</i>
 Deferred costs from commercial product sales represents the cost of
 product (including labor, overhead and costs to ship to third party
 logistics) shipped to ICS and wholesale distributors, but not yet
 dispensed by pharmacies to patients.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Cost of Goods Sold &#x2014;</i> Cost of goods sold includes the
 costs related to Afrezza product dispensed by pharmacies to
 patients as well as under-absorbed labor and overhead and inventory
 write-offs, which are recorded as expenses in the period in which
 they are incurred, rather than as a portion of the inventory
 cost.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Cash and Cash Equivalents</i> &#x2014; The Company considers all
 highly liquid investments with original or remaining maturities of
 90 days or less at the time of purchase, that are readily
 convertible into cash to be cash equivalents. As of
 December&#xA0;31, 2016 and 2015, cash equivalents were comprised of
 money market accounts with maturities less than 90 days from the
 date of purchase.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Concentration of Credit Risk</i> &#x2014; Financial instruments
 which potentially subject the Company to concentration of credit
 risk consist of cash and cash equivalents. Cash and cash
 equivalents are held in high credit quality institutions. Cash
 equivalents consist of interest-bearing money market accounts,
 which are regularly monitored by management.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Accounts Receivable and Allowance for Doubtful Accounts</i>
 &#x2014; Accounts receivable are recorded at the invoiced amount and
 are not interest bearing. The Company maintains an allowance for
 doubtful accounts for estimated losses resulting from the inability
 of its customers to make required payments. The Company makes
 ongoing assumptions relating to the collectability of its accounts
 receivable in its calculation of the allowance for doubtful
 accounts. As of December&#xA0;31, 2016 and 2015, there was no
 allowance for doubtful accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Inventories</i> &#x2014; Inventories are stated at the lower of
 cost or net realizable value. The Company determines the cost of
 inventory using the <font style="WHITE-SPACE: nowrap">first-in,</font> <font style="WHITE-SPACE: nowrap">first-out,</font> or FIFO, method. The
 Company capitalizes inventory costs associated with the
 Company&#x2019;s products based on management&#x2019;s judgment that
 future economic benefits are expected to be realized; otherwise,
 such costs are expensed as cost of goods sold. The Company
 periodically analyzes its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value, and writes down such inventories as appropriate.
 In addition, the Company&#x2019;s products are subject to strict
 quality control and monitoring which the Company performs
 throughout the manufacturing process. If certain batches or units
 of product no longer meet quality specifications or become obsolete
 due to expiration, the Company will record a charge to write down
 such unmarketable inventory to its estimated net realizable
 value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company analyzed its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value. The Company performed an assessment of projected
 sales and evaluated the lower of cost or net realizable value and
 the potential excess inventory on hand at December&#xA0;31, 2016
 and 2015. As a result of these assessments, the Company recorded a
 $0.2&#xA0;million charge at December&#xA0;31, 2016 to <font style="WHITE-SPACE: nowrap">write-off</font> inventory that will expire
 prior to sale. At December&#xA0;31, 2015, the Company recorded a
 charge of $39.3&#xA0;million to record the inventory raw materials
 on hand at the lower of cost or net realizable value, inventory
 expiry and <font style="WHITE-SPACE: nowrap">write-off</font> other
 inventory related assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>State Research and Development Credit Exchange Receivable</i>
 &#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for foregoing the
 carryforward of the research and development credits. The program
 provides for an exchange of research and development income tax
 credits for cash equal to 65% of the value of corporation tax
 credit available for exchange. Estimated amounts receivable under
 the program are recorded as a reduction of research and development
 expenses. These amounts are included in prepaid expenses and other
 current assets on the consolidated balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Prepaid Expenses and Other Current Assets &#x2014;</i> As of
 December&#xA0;31, 2016 and 2015, prepaid expenses and other current
 assets primarily consist of prepaid expenses for goods and services
 to be received and includes a certificate of deposit for $350,000
 as collateral as required by an agreement with the bank.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Sale of intellectual property &#x2014;</i> On July&#xA0;18, 2014,
 the Company entered into an assignment agreement with a third party
 whereby the third party acquired all proprietary rights, technology
 and <font style="WHITE-SPACE: nowrap">know-how</font> that related
 to a small molecule inhibitor compound and all <font style="WHITE-SPACE: nowrap">pre-clinical</font> data and results related
 thereto. Under the terms of the assignment agreement, the Company
 received total consideration of $9.3&#xA0;million and accrued
 $1.4&#xA0;million in expense for a net amount of $7.9&#xA0;million
 recorded as other income. In 2015, the Company recorded other
 income of $1.4&#xA0;million related to the relief of the
 $1.4&#xA0;million accrual for expenses associated with the sale of
 intellectual property related to oncology in 2014, which was
 subsequently resolved without payment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Assets Held for Sale &#x2014;</i> The Company classifies
 long-lived assets anticipated to be sold within one year as held
 for sale at the lower of their carrying value or fair value less
 estimated selling costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Property and Equipment</i> &#x2014; Property and equipment are
 depreciated using the straight-line method over the estimated
 useful lives of the related assets. Leasehold improvements are
 amortized over the term of the lease or the service lives of the
 improvements, whichever is shorter. Maintenance and repairs are
 expensed as incurred. Assets under construction are not depreciated
 until placed into service.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Impairment of Long-Lived Assets</i> &#x2014; The Company
 evaluates long-lived assets for impairment whenever events or
 changes in circumstances indicate that the carrying value of an
 asset may not be recoverable. Assets are considered to be impaired
 if the carrying value may not be recoverable.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 If the Company believes an asset to be impaired, the impairment
 recognized is the amount by which the carrying value of the asset
 exceeds the fair value of the asset. Fair value is determined using
 the market, income or cost approaches as appropriate for the asset.
 Any write-downs are treated as permanent reductions in the carrying
 amount of the asset and an operating loss would be recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recorded an asset impairment of $1.3 million and $140.4
 million for the years ended December 31, 2016 and 2015,
 respectively. No asset impairment was recognized during the year
 ended December 31, 2014 (see Note 4 &#x2014; Property and Equipment
 and Note 20 <i>&#x2014;</i> Subsequent Events).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Recognized Loss on Purchase Commitments &#x2014;</i> The Company
 assesses whether losses on long term purchase commitments should be
 accrued. Losses that are expected to arise from firm, <font style="WHITE-SPACE: nowrap">non-cancellable,</font> commitments for the
 future purchases of inventory items are recognized unless
 recoverable. The recognized loss on purchase commitments is reduced
 as inventory items are purchased. Changes in estimates are recorded
 in the relevant period in (gain) loss on purchase commitments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the year ended December&#xA0;31, 2015, the Company recorded
 a loss on purchase commitments amounting to $116.2&#xA0;million
 offset by $50&#xA0;million expected to be recovered from Sanofi,
 primarily due to a long term purchase commitment for insulin raw
 materials. During the year ended December&#xA0;31, 2016, the
 balance was adjusted for the recovery received from Sanofi, current
 purchases on the contracts and a reduction in the recognized loss
 related to amendments to purchase contracts. No new contracts were
 identified in 2016 requiring a new loss on purchase commitment
 accrual.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Milestone Rights Liability</i> &#x2014; On July&#xA0;1, 2013, in
 conjunction with the execution of the Facility Agreement, the
 Company issued Milestone Rights to Deerfield whereby the Company
 agreed to provide Deerfield with <font style="WHITE-SPACE: nowrap">pre-specified</font> Milestone Payments upon
 the achievement of 13 specific Milestone Events related to the
 commercial release and future cumulative net sales of Afrezza. The
 Company analyzed the Milestone Rights and determined that the
 agreement does not meet the definition of a freestanding
 derivative. Since the Company has not elected to apply the fair
 value option to the Milestone Rights Purchase Agreement, the
 Company recorded the Milestone Rights at their estimated initial
 fair value and accounted for the Milestone Rights as a
 liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The initial fair value estimate of the Milestone Rights was
 calculated using the income approach in which the cash flows
 associated with the specified contractual payments were adjusted
 for both the expected timing and the probability of achieving the
 milestones and discounted to present value using a selected market
 discount rate. The expected timing and probability of achieving the
 milestones was developed with consideration given to both internal
 data, such as progress made to date and assessment of criteria
 required for achievement, and external data, such as market
 research studies. The discount rate was selected based on an
 estimation of required rate of returns for similar investment
 opportunities using available market data. The Milestone Rights
 liability will be remeasured as the specified milestone events are
 achieved. Specifically, as each milestone event is achieved, the
 portion of the initially recorded Milestone Rights liability that
 pertains to the milestone event being achieved, will be remeasured
 to the amount of the specified related milestone payment. The
 resulting change in the balance of the Milestone Rights liability
 due to remeasurement will be recorded in the Company&#x2019;s
 consolidated statements of operations as interest expense.
 Furthermore, the Milestone Rights liability will be reduced upon
 the settlement of each milestone payment. As a result, each
 milestone payment would be effectively allocated between a
 reduction of the recorded Milestone Rights liability and an expense
 representing a return on a portion of the Milestone Rights
 liability paid to the investor for the achievement of the related
 milestone event (see Note&#xA0;7 &#x2014; Borrowings). As of
 December&#xA0;31, 2016, the remaining liability balance is
 $8.9&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Fair Value of Financial Instruments</i> &#x2014; The Company
 utilizes fair value measurement guidance to value its financial
 instruments. The guidance includes a definition of fair value,
 prescribes methods for measuring fair value, establishes a fair
 value hierarchy based on the inputs used to measure fair value and
 expands disclosures about the use of fair value measurements. The
 valuation techniques utilized are based upon observable and
 unobservable inputs. Observable inputs reflect market data obtained
 from independent sources, while unobservable inputs reflect
 internal market assumptions. These two types of inputs create the
 following fair value hierarchy:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 1&#xA0;&#x2014;&#xA0;Quoted prices for identical instruments
 in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 2&#xA0;&#x2014;&#xA0;Quoted prices for similar instruments in
 active markets; quoted prices for identical or similar instruments
 in markets that are not active; and model-derived valuations whose
 inputs are observable or whose significant value drivers are
 observable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 3&#xA0;&#x2014;&#xA0;Significant inputs to the valuation model
 are unobservable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Income Taxes</i> &#x2014; The provisions for federal, foreign,
 state and local income taxes are calculated on <font style="WHITE-SPACE: nowrap">pre-tax</font> income based on current tax
 law and include the cumulative effect of any changes in tax rates
 from those used previously in determining deferred tax assets and
 liabilities. Deferred income tax assets and liabilities are
 measured using enacted tax rates expected to apply to taxable
 income in the year in which the temporary differences are expected
 to be recovered or settled. A valuation allowance is recorded to
 reduce net deferred income tax assets to amounts that are more
 likely than not to be realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Income tax positions are considered for uncertainty. The Company
 believes that its income tax filing positions and deductions will
 be sustained on audit and does not anticipate any adjustments that
 will result in a material change to its financial position.
 Therefore, no liabilities for uncertain income tax positions have
 been recorded. If a tax position does not meet the minimum
 statutory threshold to avoid payment of penalties, the Company
 recognizes an expense for the amount of the penalty in the period
 the tax position is claimed in the tax return of the Company. The
 Company recognizes interest accrued related to unrecognized tax
 benefits in income tax expense, if any. Penalties, if probable and
 reasonably estimable, are recognized as a component of income tax
 expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Significant management judgment is involved in determining the
 provision for income taxes, deferred tax assets, deferred tax
 liabilities, and any valuation allowance recorded against deferred
 tax assets. Due to uncertainties related to the realization of the
 Company&#x2019;s deferred tax assets as a result of its history of
 operating losses, a full valuation allowance has been established
 against the total deferred tax asset balance. The valuation
 allowance is based on management&#x2019;s estimates of taxable
 income by jurisdiction in which the Company operates and the period
 over which deferred tax assets will be recoverable. In the event
 that actual results differ from these estimates or the Company
 adjusts these estimates in future periods, a change in the
 valuation allowance may be needed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Contingencies</i> &#x2014; The Company records a loss contingency
 for a liability when it is both probable that a liability has been
 incurred and the amount of the loss can be reasonably estimated.
 These accruals represent management&#x2019;s best estimate of
 probable loss. Disclosure also is provided when it is reasonably
 possible that a loss will be incurred or when it is reasonably
 possible that the amount of a loss will exceed the recorded
 provision. On a quarterly basis, the Company reviews the status of
 each significant matter and assesses its potential financial
 exposure. Significant judgment is required in both the
 determination of probability and the determination as to whether an
 exposure is reasonably estimable. Because of uncertainties related
 to these matters, accruals are based only on the best information
 available at the time. As additional information becomes available,
 the Company reassesses the potential liability related to pending
 claims and litigation and may revise its estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Stock-Based Compensation</i> &#x2014; As of December&#xA0;31,
 2016, the Company had three active stock-based compensation plans,
 which are described more fully in Note 12 &#x2014; Stock Award
 Plans. The Company accounts for all share-based payments to
 employees, including grants of stock awards and the compensatory
 elements of the employee stock purchase plan. All share-based
 payments to employees, including grants of stock options,
 restricted stock units, performance-based awards and the
 compensatory elements of employee stock purchase plans, are
 recognized in the consolidated statements of operations based upon
 the fair value of the awards at the grant date. The Company uses
 the Black-Scholes option valuation model to estimate the grant date
 fair value of employee stock options and the compensatory elements
 of employee stock purchase plans. Option valuation models require
 the input of assumptions, including the expected life of the
 stock-based awards, the estimated stock price volatility, the
 risk-free interest rate and the expected dividend yield. The
 expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Restricted
 stock units are valued based on the market price on the grant date.
 The Company evaluates stock awards with performance conditions as
 to the probability that the performance conditions will be met and
 estimates the date at which the performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Warrants</i> &#x2014; The Company has issued warrants to purchase
 shares of its common stock. The Company accounts for its warrants
 as either equity or liabilities based upon the characteristics and
 provisions of each instrument and evaluation of sufficient
 authorized shares available to satisfy the obligations. Warrants
 classified as derivative liabilities are recorded on the
 Company&#x2019;s consolidated balance sheets at their fair value on
 the date of issuance and are revalued at each subsequent balance
 sheet date, with fair value changes recognized in the consolidated
 statements of operations. The Company estimates the fair value of
 its derivative liabilities using a third party valuation analysis
 that utilizes a Monte Carlo pricing valuation model and assumptions
 that are based on the individual characteristics of the warrants or
 instruments on the valuation date, as well as expected volatility,
 expected life, yield and a risk-free interest rate. The expected
 volatility assumption is primarily based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not <font style="WHITE-SPACE: nowrap">re-measured</font> in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Comprehensive Income (Loss)</i> &#x2014; Other comprehensive
 income (loss) requires that all components of comprehensive income
 (loss) to be reported in the financial statements in the period in
 which they are recognized. Other comprehensive income (loss)
 includes certain changes in stockholders&#x2019; equity that are
 excluded from net income (loss). Specifically, the Company includes
 unrealized gains and losses on foreign exchange translation in
 accumulated other comprehensive loss on the consolidated balance
 sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Research and Development Expenses</i> &#x2014; Research and
 development expenses consist of costs associated with the clinical
 trials of the Company&#x2019;s product candidates, manufacturing
 supplies and other development materials, compensation and other
 expenses for research and development personnel, costs for
 consultants and related contract research, facility costs, and
 depreciation. Research and development costs, which are net of any
 tax credit exchange recognized for the Connecticut state research
 and development credit exchange program, are expensed as incurred.
 The Company began commercial manufacturing in the latter part of
 the fourth quarter of 2014. Commercial manufacturing costs incurred
 in the fourth quarter of 2014 were included in research and
 development expense and were immaterial for the year ended
 December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>State Research and Development Credit Exchange Receivable</i>
 &#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for forgoing the
 carryforward of the research and development income tax credits.
 The program provides for an exchange of research and development
 income tax credits for cash equal to 65% of the value of
 corporation tax credit available for exchange. Estimated amounts
 receivable under the program are recorded as a reduction of
 research and development expenses. During the years ended
 December&#xA0;31, 2016, 2015 and 2014, research and development
 expenses were offset by research and development tax credits of
 $246,000, $743,000 and $816,000, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Clinical Trial Expenses</i> &#x2014; Clinical trial expenses,
 which are reflected in research and development expenses in the
 accompanying consolidated statements of operations, result from
 obligations under contracts with vendors, consultants and clinical
 site agreements in connection with conducting clinical trials. The
 financial terms of these contracts are subject to negotiations
 which vary from contract to contract and may result in payment
 flows that do not match the periods over which materials or
 services are provided to the Company under such contracts. The
 appropriate level of trial expenses are reflected in the
 Company&#x2019;s consolidated financial statements by matching
 period expenses with period services and efforts expended. These
 expenses are recorded according to the progress of the trial as
 measured by patient progression and the timing of various aspects
 of the trial. Clinical trial accrual estimates are determined
 through discussions with internal clinical personnel and outside
 service providers as to the progress or state of completion of
 trials, or the services completed. Service provider status is then
 compared to the contractually obligated fee to be paid for such
 services. During the course of a clinical trial, the Company may
 adjust the rate of clinical expense recognized if actual results
 differ from management&#x2019;s estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Interest Expense</i> &#x2014; Interest costs are expensed as
 incurred, except to the extent such interest is related to
 construction in progress, in which case interest is capitalized.
 Interest cost capitalized for the years ended December&#xA0;31,
 2015 and 2014 was $0.1&#xA0;million and $0.8&#xA0;million,
 respectively. There were no capitalized interest costs for the year
 ended December&#xA0;31, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Net Income (Loss) Per Share of Common Stock</i> &#x2014; Basic
 net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Recently Issued Accounting Standards</i> &#x2014; From time to
 time, new accounting pronouncements are issued by the Financial
 Accounting Standards Board (FASB) or other standard setting bodies
 that are adopted by the Company as of the specified effective date.
 Unless otherwise discussed, the Company believes that the impact of
 recently issued standards that are not yet effective will not have
 a material impact on the Company&#x2019;s consolidated financial
 position or results of operations upon adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In May 2014, the FASB issued Accounting Standards Update (ASU)
 <font style="WHITE-SPACE: nowrap">No.&#xA0;2014-09,</font>
 <i>Revenue from Contracts with Customers (Topic 606)</i>, which
 requires an entity to recognize the amount of revenue when promised
 goods or services are transferred to customers in an amount that
 reflects the consideration that is expected to be received for
 those goods or services. This new guidance supersedes previous
 revenue recognition requirements, along with most existing
 industry-specific guidance. In August 2015, the FASB issued ASU
 <font style="WHITE-SPACE: nowrap">2015-14,</font> <i>Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date</i>, which delayed the effective date of the new standard from
 January&#xA0;1, 2017 to January&#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In 2016 the FASB has issued additional
 ASUs which clarify certain aspects of the new guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company will adopt the new guidance for the year beginning
 January&#xA0;1, 2018. The Company has the option to either apply
 the new guidance retrospectively for all prior reporting periods
 presented (full retrospective) or retrospectively with the
 cumulative effect of initially applying the guidance recognized at
 the date of initial application (modified retrospective). The
 Company currently anticipates it will apply the new guidance using
 the modified retrospective approach with the cumulative effect of
 initial application recognized as of January&#xA0;1, 2018. The
 Company plans to continue analyzing the potential impacts of the
 application throughout 2017 and, depending on factors that may
 impact the results, could elect to apply the new guidance on a full
 retrospective basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Currently, for commercial sales of Afrezza, the Company has limited
 sales and returns history, and as such, is unable to reliably
 estimate expected returns of the product at the time of shipment
 into the distribution channel. Accordingly, the Company defers
 recognition of revenue on Afrezza product shipments until the right
 of return no longer exists, which occurs at the earlier of the time
 Afrezza is dispensed from pharmacies to patients or expiration of
 the right of return. The Company recognizes revenue based on
 Afrezza patient prescriptions dispensed, a sell-through model, as
 estimated by syndicated data provided by a third party. The Company
 also analyzes additional data points to ensure that such
 third-party data is reasonable, including data related to inventory
 movements within the channel and ongoing prescription demand.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Upon adoption of the new guidance, the Company expects that it will
 move from its current sell-through model to a <font style="WHITE-SPACE: nowrap">sell-to</font> model for revenue related to
 commercial sales of Afrezza and will record revenue at the time
 title and risk of loss passes to its distributors (generally at
 shipment or delivery to the distributors) along with an estimate of
 potential returns as variable consideration. The Company also
 anticipates that its ability to estimate potential returns will
 improve with an additional 12 months of sales history that it will
 have obtained by January&#xA0;1, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, the Company has historically entered into
 collaborative agreements with third-parties under which periodic
 payments have been received. Revenue recognition for certain
 payments received has been deferred until the price is fixed and
 determinable. Further, revenue for certain payments to be received
 in the future has been prohibited from recognition until received.
 The Company expects that some of these amounts will be considered
 variable consideration and may be able to be recognized earlier
 under the new guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has begun its evaluation of the impact of adoption and
 plans to continue its evaluation throughout 2017. The financial
 impact upon adoption will be dependent upon a number of factors
 including; the amount of revenue that has been deferred under the
 sell-through model for Afrezza, the amount of the revenue deferred
 under collaborative arrangements and the Company&#x2019;s estimates
 of variable consideration at the date of adoption. At this time,
 the Company has not completed its evaluation of the inputs,
 assumptions and methodologies that will be used to recognize
 revenue related to variable consideration under the new
 guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July 2015, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-11,</font> <i>Inventory (Topic
 330): Simplifying the Measurement of Inventory.</i> Topic 330
 currently requires an entity to measure inventory at the lower of
 cost or market. Market could be replacement cost, net realizable
 value, or net realizable value less an approximately normal profit
 margin. The amendments indicate that after adoption an entity
 should measure inventory within the scope of this ASU at the lower
 of cost or net realizable value. The amendments are effective for
 fiscal years beginning after December&#xA0;15, 2016, including
 interim periods within those fiscal years. The amendments should be
 applied prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The adoption of
 ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-11</font> will
 have no impact on the Company&#x2019;s annual consolidated financial
 statements because the Company currently measures inventory at the
 lower of cost or net realizable value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August&#xA0;2014, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2014-15,</font> <i>Presentation of
 Financial Statements &#x2014; Going Concern</i>, which requires
 management of an entity to evaluate whether there are conditions or
 events, considered in the aggregate, that raise substantial doubt
 about the entity&#x2019;s ability to continue as a going concern
 within one year after the date that the financial statements are
 issued or available to be issued. This update was effective for
 annual periods ending after December&#xA0;15, 2016. The adoption of
 this standard did not have a material impact on its consolidated
 financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In January 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-01,</font> <i>Financial
 Instruments &#x2014; Overall (Subtopic <font style="WHITE-SPACE: nowrap">825-10):</font> Recognition and Measurement
 of Financial Assets and Financial Liabilities.</i> The update is
 intended to improve the recognition and measurement of financial
 instruments. The update is effective for fiscal years beginning
 after December&#xA0;15, 2017, including interim periods within
 those fiscal years. The Company is evaluating the impact the
 adoption of ASU <font style="WHITE-SPACE: nowrap">2016-01</font>
 will have on its consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In February 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-02,</font> <i>Leases (Topic
 842)</i>. The new standard requires that a lessee recognize the
 assets and liabilities that arise from operating leases. A lessee
 should recognize in the statement of financial position a liability
 to make lease payments (the lease liability) and a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> asset representing
 its right to use the underlying asset for the lease term. For
 leases with a term of 12 months or less, a lessee is permitted to
 make an accounting policy election by class of underlying asset not
 to recognize lease assets and lease liabilities. In transition,
 lessees and lessors are required to recognize and measure leases at
 the beginning of the earliest period presented using a modified
 retrospective approach. The new standard will be effective on
 January&#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-02</font> will have on its
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 In March 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-09,</font> <i>Compensation
 &#x2014; Stock Compensation (Topic 718): Improvements to Employee
 Share-Based Payment Accounting</i>. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&#xA0;15, 2016, and interim periods within
 those annual periods. The Company has evaluated the effect that
 this guidance will have on its consolidated financial statements
 and related disclosures and has determined it will not result in a
 material impact.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15,</font> <i>Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments</i>. The new standard seeks to reduce diversity in
 practice related to the classification of certain transactions in
 the statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&#xA0;15, 2017, and interim periods within
 those annual periods. The amendments should be applied using a
 retrospective transition method to each period presented. If it is
 impracticable to apply the amendments retrospectively for some of
 the issues, the amendments for those issues would be applied
 prospectively as of the earliest date practicable. The Company is
 evaluating the impact the adoption of ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15</font> will have on its
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In November 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-18,</font> <i>Statement of Cash
 Flows (Topic 230): Restricted Cash.</i> This ASU requires that the
 reconciliation of the <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">beginning-of-period</font></font>
 and <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">end-of-period</font></font> amounts shown in
 the statement of cash flows include cash and restricted cash
 equivalents. ASU <font style="WHITE-SPACE: nowrap">2016-08</font>
 is effective for fiscal years beginning after December&#xA0;15,
 2018, including interim periods within those periods, using a
 retrospective transition method to each period presented. The
 Company has evaluated the effect that this guidance will have on
 its consolidated financial statements and related disclosures and
 has determined it will not result in a material impact.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6595452160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>3. Inventories</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Inventories consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <font style="white-space:nowrap"><font style="white-space:nowrap">Work-in-process</font></font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,120</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total Inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,331</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December 31, 2015, the Company recorded a write-off of all of
 its inventory. There were no raw materials as of December 31, 2016
 because purchases of raw materials in 2016 were recorded at zero
 value because they had been accrued at December 31, 2015 through
 the loss on purchase commitment. Work-in-process and finished goods
 as of December 31, 2016 include conversion costs but not materials
 cost because the materials used in its production were previously
 written off.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830263760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>4. Property and Equipment</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Property and equipment consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000">Estimated<br />
 Useful&#xA0;Life<br />
 (Years)</td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Land</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="center">&#x2014;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">875</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,435</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Buildings</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">39-40</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,389</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,590</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Building improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">5-40</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,957</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,584</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Machinery and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">3-15</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62,992</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68,434</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture, fixtures and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">5-10</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">3</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,531</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,519</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">202</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">586</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,502</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">168,262</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(99,575</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(119,513</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,927</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,749</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Depreciation and amortization expense related to property and
 equipment for the years ended December&#xA0;31, 2016, 2015 and
 2014, was $2.4&#xA0;million, $11.0&#xA0;million and
 $9.8&#xA0;million, respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The December&#xA0;31, 2016 amounts do not include the Valencia
 property because it is classified as held for sale as of that
 date.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with the Company&#x2019;s quarterly assessment of
 impairment indicators, the Company evaluated the continued lower
 than expected sales of Afrezza as reported by Sanofi throughout the
 fourth quarter of 2015, revised forecasts for sales of Afrezza
 provided by Sanofi in the fourth quarter of 2015 and level of
 commercial production in the fourth quarter of 2015, as well as the
 uncertainty associated with Sanofi&#x2019;s announcement during the
 fourth quarter of their intent to reorganize their diabetes
 business. These factors indicated potentially significant changes
 in the timing and extent of cash flows, and the Company therefore
 determined that an impairment indicator existed in the fourth
 quarter of 2015 and recorded an impairment for the year ended
 December&#xA0;31, 2015. No such indications were identified in the
 current year ended December&#xA0;31, 2016.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company identified two primary asset groups to be evaluated for
 impairment: the Danbury manufacturing facility, which currently
 performs all the manufacturing of Afrezza, and the Valencia
 facility, which was previously the Company&#x2019;s corporate
 headquarters. The Danbury manufacturing facility was the primary
 asset group that was impacted by the impairment indicators noted
 above but the Company also evaluated the Valencia facility for
 potential impairment given the circumstances and identified an
 impairment charge of $1.8&#xA0;million based on a valuation
 utilizing a combination of market, income and cost approaches.
 Within the Danbury manufacturing facility, the Company identified
 the machinery and equipment as the primary assets within the asset
 group as they are associated with the production of Afrezza. As
 such, the Company performed the fixed asset impairment test and
 performed the first step to test for recoverability of the Danbury
 manufacturing facility by utilizing two undiscounted cash flow
 projections and applying a probability weighted average to those
 cash flow projections. The first undiscounted cash flow projection
 was developed under a scenario assuming Sanofi would continue to
 sell and market Afrezza as the termination of the arrangement by
 Sanofi was not known as of the balance sheet date. The second
 undiscounted cash flow projection assumed Sanofi would terminate
 the Sanofi License Agreement and that the Company would
 manufacture, sell and market Afrezza independently.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Based on the evaluation performed, the probabilities assigned to
 the two undiscounted cash flows were not significant to the
 evaluation due to the projected negative cash flows over the
 estimation period, and it was determined that the probability
 weighted undiscounted cash flows were not sufficient to recover the
 carrying value of the Danbury manufacturing facility. As such, the
 Company was required to determine the fair value of the Danbury
 manufacturing facility to recognize an impairment loss if the
 carrying amount exceeds its fair value. The Company determined the
 fair value of the Danbury manufacturing facility by applying the
 highest and best use valuation concept and utilizing the market
 approach valuation technique to value the machinery and equipment
 and a combination of the market approach and cost approach in
 valuing the land, buildings and building improvements. As a result
 of this assessment, the Company recorded, as of December&#xA0;31,
 2015, an impairment charge of $138.6&#xA0;million for the Danbury
 manufacturing facility.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The December&#xA0;31, 2015 balances have been reclassified to the
 current year presentation by allocating an impairment of
 $140.4&#xA0;million, which was previously disclosed in total, to
 the individual asset groups. An additional impairment of
 $0.7&#xA0;million was charged to the individual asset groups for
 the year ended December&#xA0;31, 2016, which is included in
 property and equipment impairment in the accompany consolidated
 statements of operations, additionally with a $0.6&#xA0;million
 impairment charge related to assets held for sale.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840510528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>5. Accrued Expenses and Other Current Liabilities</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities are comprised of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Salary and related expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,814</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,634</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restructuring</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,376</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sales and marketing services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">875</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">931</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Discounts and allowances for commercial product sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">754</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">615</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">483</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">238</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,937</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,929</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840522528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Arrangements</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>6. Related-Party Arrangements</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October 2007, the Company entered into The Mann Group Loan
 Arrangement, which has been amended from time to time. On
 October&#xA0;31, 2013, the promissory note underlying The Mann
 Group Loan Arrangement was amended to, among other things, extend
 the maturity date of the loan to January&#xA0;5, 2020, extend the
 date through which the Company can borrow under The Mann Group Loan
 Arrangement to December&#xA0;31, 2019, increase the aggregate
 borrowing amount under The Mann Group Loan Arrangement from
 $350.0&#xA0;million to $370.0&#xA0;million and provide that
 repayments or cancellations of principal under The Mann Group Loan
 Arrangement will not be available for reborrowing.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2016, the total principal amount
 outstanding under The Mann Group Loan Arrangement was
 $49.5&#xA0;million, and the amount available for future borrowings
 is $30.1&#xA0;million. Interest, at a fixed rate of 5.84%, is due
 and payable quarterly in arrears on the first day of each calendar
 quarter for the preceding quarter, or at such other time as the
 Company and The Mann Group mutually agree. All or any portion of
 accrued and unpaid interest that becomes due and payable may be
 <font style="white-space:nowrap"><font style="white-space:nowrap">paid-in-kind</font></font> and capitalized as
 additional borrowings at any time upon mutual agreement of the
 parties, and has been classified as <font style="white-space:nowrap">non-current.</font> The Mann Group can require
 the Company to prepay up to $200.0&#xA0;million in advances that
 have been outstanding for at least 12 months, less approximately
 $105.0&#xA0;million aggregate principal amount that has been
 cancelled in connection with two common stock purchase agreements.
 If The Mann Group exercises this right, the Company will have 90
 days after The Mann Group provides written notice, or the number of
 days to maturity of the note if less than 90 days, to prepay such
 advances. However, pursuant to a letter agreement entered into in
 August 2010, The Mann Group has agreed to not require the Company
 to prepay amounts outstanding under the amended and restated
 promissory note if the prepayment would require the Company to use
 its working capital resources. In addition, The Mann Group entered
 into a subordination agreement with Deerfield pursuant to which The
 Mann Group agreed with Deerfield not to demand or accept any
 payment under The Mann Group Loan Arrangement until the
 Company&#x2019;s payment obligations to Deerfield under the Facility
 Agreement have been satisfied in full. Subject to the foregoing, in
 the event of a default under The Mann Group Loan Arrangement, all
 unpaid principal and interest either becomes immediately due and
 payable or may be accelerated at The Mann Group LLC&#x2019;s option,
 and the interest rate will increase to the <font style="white-space:nowrap">one-year</font> LIBOR rate calculated on the
 date of the initial advance or in effect on the date of default,
 whichever is greater, plus 5%&#xA0;per annum. All borrowings under
 The Mann Group Loan Arrangement are unsecured. The Mann Group Loan
 Arrangement contains no financial covenants.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2016 and 2015, the Company had accrued and
 unpaid interest related to the above note of $9.3&#xA0;million and
 $6.4&#xA0;million, respectively, and had $30.1&#xA0;million of
 available borrowings. Interest expense on the Company&#x2019;s note
 payable to the Company&#x2019;s principal stockholder for each of
 the years ended December&#xA0;31, 2016, 2015 and 2014 was
 $2.9&#xA0;million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In May 2015, the Company entered into a sublease agreement with the
 Alfred Mann Foundation for Scientific Research (the &#x201C;Mann
 Foundation&#x201D;), a California <font style="white-space:nowrap"><font style="white-space:nowrap">Not-For-Profit</font></font> Corporation. The
 lease is for approximately 12,500 square feet of office space in
 Valencia, California and expires in April 2017. The office space
 contains the Company&#x2019;s principal executive offices. Lease
 payments to the Mann Foundation for the year ended
 December&#xA0;31, 2016 and 2015 were $268,000 and $175,000,
 respectively. There were no lease payments to the Mann Foundation
 for the year ended December&#xA0;31, 2014.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with certain meetings of the Company&#x2019;s board of
 directors and on other occasions when the Company&#x2019;s business
 necessitated air travel for the Company&#x2019;s principal
 stockholder and other Company employees, the Company utilized the
 principal stockholder&#x2019;s private aircraft, and the Company
 paid the charter company that manages the aircraft on behalf of the
 Company&#x2019;s principal stockholder approximately $18,000 and
 $79,000 for the years ended December&#xA0;31, 2015 and 2014,
 respectively, on the basis of the corresponding cost of commercial
 airfare. There were no payments to the principal stockholder
 related to the usage of the aircraft during the year ended
 December&#xA0;31, 2016.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has entered into indemnification agreements with each
 of its directors and executive officers, in addition to the
 indemnification provided for in its amended and restated
 certificate of incorporation and amended and restated bylaws (see
 Note 13 &#x2014; Commitments and Contingencies).</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840488992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>7. Borrowings</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Borrowings consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Facility Financing Obligation (2019 Notes)</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Principal amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">75,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">80,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unamortized debt discount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,661</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,418</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net carrying amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,339</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">74,582</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Senior Convertible Notes (2018 Notes)</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Principal amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,690</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,690</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unamortized premium</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">426</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">660</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unaccreted debt issuance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(481</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(737</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net carrying amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,635</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,613</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Note payable to principal stockholder &#x2014; net carrying
 amount</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,521</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,521</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Facility Financing Obligation (2019 Notes)</i> &#x2014; As of
 December&#xA0;31, 2016, there were $55.0&#xA0;million principal
 amount of 2019 notes and $20.0&#xA0;million principal amount of
 Tranche B notes outstanding. As of December&#xA0;31, 2015, there
 were $60.0&#xA0;million principal amount of 2019 notes and
 $20.0&#xA0;million principal amount of Tranche B notes outstanding.
 The 2019 notes accrue interest at annual rate of 9.75% and the
 Tranche B notes accrue interest at an annual rate of 8.75%.
 Interest is paid quarterly in arrears on the last day of each
 March, June, September and December. The Facility Financing
 Obligation principal repayment schedule is comprised of annual
 payments beginning on July&#xA0;1, 2016 and ending December&#xA0;9,
 2019. Future principal payments for the years ended
 December&#xA0;31, 2017, 2018 and 2019 are $20.0&#xA0;million,
 $20.0&#xA0;million and $35.0&#xA0;million, respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In conjunction with the Facility Agreement, the Company entered
 into a Milestone Rights Agreement with Deerfield which requires the
 Company to make contingent payments to Deerfield, totaling up to
 $90.0&#xA0;million, upon the Company achieving specified
 commercialization milestones. The Milestone Rights were initially
 recorded as a short-term liability equal to $3.2&#xA0;million
 included in accrued expenses and other current liabilities in the
 accompanying consolidated balance sheets and a long-term liability
 equal to $13.1&#xA0;million included in other liabilities. During
 the first quarter of 2015, a milestone triggering event was
 achieved following the Company&#x2019;s product launch on
 February&#xA0;3, 2015, which resulted in a $5.8&#xA0;million
 incremental charge to interest expense due to the increase in
 carrying value of the liability to the required $10.0&#xA0;million
 payment made in February of 2015. During the year ended
 December&#xA0;31, 2014, the first milestone triggering event was
 achieved following the Company&#x2019;s entry into the Sanofi
 License Agreement, which resulted in a $1.9&#xA0;million
 incremental charge to interest expense due to the increase in
 carrying value of the liability to the required $5.0&#xA0;million
 payment, which was paid to Deerfield pursuant to the terms of the
 Milestone Agreement. As of December&#xA0;31, 2016 and 2015, the
 remaining liability balance of $8.9&#xA0;million is classified as a
 long-term liability.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2016, the unamortized debt discount and
 debt issuance costs were $3.7&#xA0;million and $0.1&#xA0;million,
 respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accretion of debt issuance cost and debt discount in connection
 with the Deerfield financing during the years ended
 December&#xA0;31, 2016, 2015 and 2014 are as follows (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accretion expense &#x2014; debt issuance cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">326</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accretion expense &#x2014; debt discount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,722</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,553</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,550</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Facility Agreement includes customary representations,
 warranties and covenants, including, a restriction on the
 incurrence of additional indebtedness, and a financial covenant
 which requires the Company&#x2019;s cash and cash equivalents, which
 includes available borrowings on the note payable to principal
 stockholder, on the last day of each fiscal quarter to not be less
 than $25.0&#xA0;million. As discussed in Note 1 &#x2014; Description
 of Business, the Company will need to raise additional capital to
 support its current operating plans. Due to the uncertainties
 related to maintaining sufficient resources to comply with the
 aforementioned covenant, the 2019 notes and the Tranche B notes
 have been classified as current liabilities in the accompanying
 consolidated balance sheets as of December&#xA0;31, 2016 and 2015.
 In the event of <font style="white-space:nowrap">non-compliance,</font> Deerfield may declare
 all or any portion of the 2019 notes and/or Tranche B notes to be
 immediately due and payable.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Milestone Rights</i> &#x2014; The Milestone Agreement includes
 customary representations and warranties and covenants by the
 Company, including restrictions on transfers of intellectual
 property related to Afrezza. The Milestone Rights are subject to
 acceleration in the event the Company transfers its intellectual
 property related to Afrezza in violation of the terms of the
 Milestone Agreement. The Company has initially recorded the
 Milestone Rights at their estimated fair value &#x2014; See Note 2
 &#x2014; Summary of Significant Accounting Policies under Milestone
 Rights Liability.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In determining the fair value of the Milestone Rights, the 13
 individual milestone payments were adjusted for both (i)&#xA0;the
 expected timing and (ii)&#xA0;the probability of achieving the
 milestones, and then discounted to present value using a discount
 rate of 14.5%. Once the initial valuation of each specified
 milestone payment was determined, the individual milestone payments
 were then aggregated to arrive at a total fair value of
 $18.4&#xA0;million. The discount rate was based on the estimated
 cost of equity which was derived using the capital asset pricing
 model. In addition, a 5% risk premium was added to the computation
 of the cost of equity to adjust for <font style="white-space:nowrap">non-systemic</font> risk factors, such as the
 Company&#x2019;s lack of product diversification and history of
 financial losses, which were not captured in other model
 inputs.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Security Agreement</i> &#x2014; In connection with the Facility
 Agreement, the Company and its subsidiary, MannKind LLC, entered
 into a Guaranty and Security Agreement (the &#x201C;Security
 Agreement&#x201D;) with Deerfield and Horizon Sante FLML SA&#x2019;RL
 (collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
 Company and MannKind LLC each granted the Purchasers a security
 interest in substantially all of their respective assets, including
 respective intellectual property, accounts, receivables, equipment,
 general intangibles, inventory and investment property, and all of
 the proceeds and products of the foregoing. The Security Agreement
 includes customary covenants by the Company and MannKind LLC,
 remedies of the Purchasers and representations and warranties by
 the Company and MannKind LLC. The security interests granted by the
 Company and MannKind LLC will terminate upon repayment of the 2019
 notes and Tranche B notes, if applicable, in full. The
 Company&#x2019;s obligations under the Facility Agreement and the
 Milestone Agreement are also secured by the mortgage on the
 Company&#x2019;s facilities in Danbury, Connecticut, which has a
 carrying value of $28.7&#xA0;million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Embedded Derivatives</i> &#x2014; The Company identified and
 evaluated a number of embedded features in the notes issued under
 the Facility Agreement to determine if they represented embedded
 derivatives that are required to be separated from the notes and
 accounted for as freestanding instruments. In 2014, the Company
 analyzed the Tranche&#xA0;B notes and identified embedded
 derivatives which required separate accounting. However, all of the
 embedded derivatives were determined to have a <i>de minimis</i>
 value at December&#xA0;31, 2016 and 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Conversion Option &#x2014;</i> During 2014, Deerfield elected to
 convert a total of $93.5&#xA0;million of principal, which consisted
 of $20.0&#xA0;million, $33.5&#xA0;million, and $40.0&#xA0;million
 of Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes,
 respectively, into an aggregate 3,464,616 shares of common stock.
 In conjunction with the conversion by Deerfield, we recorded an
 aggregate expense of $6.4&#xA0;million for the difference between
 the principal amount of the notes converted and their carrying
 amount (which included unamortized discount and debt issuance
 costs) which consisted of $1.2&#xA0;million, $3.0&#xA0;million, and
 $2.2&#xA0;million related to the Tranche 1 notes, Tranche 2 notes,
 and Tranche 3 notes, respectively. Further, upon Deerfield
 converting $40.0&#xA0;million of Tranche 3 notes and
 $20.0&#xA0;million of Tranche 1 notes, Deerfield has reached the
 conversion limits (i.e., &#x201C;Applicable Limits&#x201D;) with
 respect to the Facility Agreement and therefore, no additional
 amount of the 2019 notes is convertible.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Issuance of new 5.75% Convertible Senior Subordinated Exchange
 Notes Due 2018 in Exchange for 2015 Notes</i> &#x2014; On
 July&#xA0;28, 2015, the Company entered into privately-negotiated
 exchange agreements (the &#x201C;Note Exchange Agreements&#x201D;)
 with a select holder of the Company&#x2019;s 5.75% Senior
 Convertible Notes due 2015 (the &#x201C;2015 notes&#x201D;), pursuant
 to which the Company agreed to issue $27.7&#xA0;million aggregate
 principal amount of new 5.75% Convertible Senior Subordinated
 Exchange Notes due 2018 (the &#x201C;2018 notes&#x201D;) to such
 holders in exchange for the delivery to the Company of the same
 principal amount of 2015 notes. The 2018 notes were issued at the
 closing of the exchange on August&#xA0;10, 2015. The Company
 analyzed this exchange and concluded that the exchange represents
 an extinguishment of the 2015 notes and a new issuance of 2018
 notes and recorded such notes at fair value, which resulted in a
 premium of $0.7&#xA0;million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The 2018 notes are the Company&#x2019;s general, unsecured, senior
 obligations, except that the 2018 notes were subordinated to the
 Sanofi Loan facility prior to the extinguishment of the facility on
 November&#xA0;9, 2016. The 2018 notes rank equally in right of
 payment with the Company&#x2019;s other unsecured senior debt. The
 2018 notes bear interest at the rate of 5.75%&#xA0;per year on the
 principal amount, payable semiannually in arrears in cash on
 February&#xA0;15 and August&#xA0;15 of each year, beginning
 February&#xA0;15, 2016, with interest accruing from August&#xA0;15,
 2015. The 2018 notes mature on August&#xA0;15, 2018. Accrued
 interest related to these notes is recorded in accrued expenses and
 other current liabilities on the accompanying consolidated balance
 sheets.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The 2018 notes are convertible, at the option of the holder, at any
 time on or prior to the close of business on the business day
 immediately preceding the stated maturity date, into shares of the
 Company&#x2019;s common stock at an initial conversion rate of 29
 shares per $1,000 principal amount of the 2018 notes, which is
 equal to a conversion price of approximately $34.00 per share, the
 same conversion price as that of the 2015 notes on the date of
 exchange. The conversion rate is subject to adjustment under
 certain circumstances described in an indenture governing the 2018
 notes dated August&#xA0;10, 2015 with Wells Fargo, National
 Association, including in connection with a make-whole fundamental
 change.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 If certain fundamental changes occur, the Company will be obligated
 to pay a fundamental change make-whole premium on any 2018 notes
 converted in connection with such fundamental change by increasing
 the conversion rate on such 2018 notes. In such instances, the
 amount of the fundamental change make-whole premium will be based
 on the Company&#x2019;s common stock price and the effective date of
 the applicable fundamental change. If the Company undergoes certain
 fundamental changes, except in certain circumstances, each holder
 of 2018 notes will have the option to require the Company to
 repurchase all or any portion of that holder&#x2019;s 2018 notes.
 The fundamental change repurchase price will be 100% of the
 principal amount of the 2018 notes to be repurchased plus accrued
 and unpaid interest, if any.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On or after the date that is one year following the original issue
 date of the 2018 notes, the Company will have the right to redeem
 for cash all or part of the 2018 notes if the last reported sale
 price of its common stock exceeds 130% of the conversion price then
 in effect for 20 or more trading days during the 30 consecutive
 trading day period ending on the trading day immediately prior to
 the date of the redemption notice. The redemption price will equal
 the sum of 100% of the principal amount of the 2018 notes to be
 redeemed, plus accrued and unpaid interest. Under the terms of the
 2018 Note Indenture, the conversion option can be <font style="white-space:nowrap">net-share</font> settled and the maximum
 number of shares that could be required to be delivered under the
 indenture, including the make-whole shares, is fixed and less than
 the number of authorized and unissued shares less the maximum
 number of shares that could be required to be delivered during the
 term of the 2018 notes under existing commitments. Applying the
 Company&#x2019;s sequencing policy, the Company performed an
 analysis at the time of the offering of the 2018 notes and each
 reporting date since and has concluded that the number of available
 authorized shares at the time of the offering and each subsequent
 reporting date was sufficient to deliver the number of shares that
 could be required to be delivered during the term of the 2018 notes
 under existing commitments.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The 2018 notes provide that upon an acceleration of certain
 indebtedness, including the 9.75% Senior Convertible Notes due in
 2019 (the &#x201C;2019 notes&#x201D;) and the 8.75% Senior
 Convertible Notes due in 2019 (the &#x201C;Tranche B notes&#x201D;)
 issued to Deerfield pursuant to the Facility Agreement, the holders
 may elect to accelerate the Company&#x2019;s repayment obligations
 under the notes if such acceleration is not cured, waived,
 rescinded or annulled. There can be no assurance that the holders
 would not choose to exercise these rights in the event such events
 were to occur.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company incurred approximately $0.8&#xA0;million in issuance
 costs, which are recorded as an offset to the 2018 notes in the
 accompanying consolidated balance sheets. These costs are being
 accreted to interest expense using the effective interest method
 over the term of the 2018 notes.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accretion of debt issuance expense in connection with the 2018
 notes during the years ended December&#xA0;31, 2016 and 2015 was
 $257,000 and $93,000, respectively. Amortization of the 2018 notes
 premium during the years ended December&#xA0;31, 2016 and 2015 was
 $234,000 and $86,000, respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Issuance of Common Stock in Exchange for the 2015 Notes</i>
 &#x2014; On July&#xA0;28, 2015, the Company entered into separate,
 privately-negotiated exchange agreements (the <font style="white-space:nowrap"><font style="white-space:nowrap">&#x201C;Stock-for-Note</font></font> Exchange
 Agreements&#x201D;) with certain holders of the 2015 notes pursuant
 to which the Company agreed to issue shares of its common stock to
 such holders in exchange for the delivery to the Company of up to
 $56.9&#xA0;million aggregate principal amount of the 2015
 notes.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Pursuant to the <font style="white-space:nowrap"><font style="white-space:nowrap">Stock-for-Note</font></font> Exchange
 Agreements, the parties agreed to price the exchange transactions
 over a 10 trading day period spanning from July&#xA0;29, 2015 to
 and including August&#xA0;11, 2015. Between July&#xA0;28, 2015 and
 August&#xA0;10, 2015, the Company issued an aggregate of 380,000
 shares of common stock to such holders in exchange for such
 holders&#x2019; delivery to the Company of $8.0&#xA0;million
 aggregate principal amount of the 2015 notes, resulting in a
 weighted-average exchange price of $110.00 per share.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Issuance of New 5.75% Convertible Senior Subordinated Exchange
 Notes Due 2015 in Exchange for the 2015 Notes</i> &#x2014; On
 August&#xA0;14, 2015, the Company exchanged $32.1&#xA0;million
 aggregate principal amount of newly issued, 5.75% Convertible
 Senior Subordinated Exchange Notes due 2015 (the &#x201C;Exchange
 Notes&#x201D;) for the same principal amount of the Company&#x2019;s
 previously outstanding 2015 notes. The Exchange Notes, payable at
 maturity on September&#xA0;30, 2015, were convertible, at the
 option of each holder thereof, at any time on or prior to the close
 of business on the business day immediately preceding the stated
 maturity date. The holders of the Exchange Notes did not elect to
 convert any of the outstanding principal amount of the Exchange
 Notes into shares of the Company&#x2019;s common stock. As a result,
 on September&#xA0;30, 2015, the Company paid $32.1&#xA0;million to
 settle the Exchange Notes.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Settlement of 2015 Notes and Exchange Notes</i> &#x2014; On
 August&#xA0;17, 2015, the Company paid $32.2&#xA0;million to settle
 the remaining 2015 notes. As of September&#xA0;30, 2015, all 2015
 notes, including the Exchange Notes, have been settled resulting in
 a total loss on extinguishment of debt equal to $1.0&#xA0;million.
 The loss on extinguishment of debt resulted from the <font style="white-space:nowrap">write-off</font> of debt discount and debt
 issuance costs associated with the 2015 notes and Exchange Notes
 and the difference between the principal amounts being exchanged
 for shares of the Company&#x2019;s common stock, pursuant to the
 various <font style="white-space:nowrap"><font style="white-space:nowrap">Stock-for-Note</font></font> Exchange
 Agreements, and the fair market value of the Company&#x2019;s common
 stock issued in exchange for such reduction in principal.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accretion of debt issuance costs in connection with the 2015 notes
 during the years ended December&#xA0;31, 2015 and 2014 was
 $0.6&#xA0;million and $0.9&#xA0;million, respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Refer to Note 6 &#x2014; Related-Party Arrangements for information
 regarding the Note payable to principal stockholder.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840520064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Arrangements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <b>8. Collaboration Arrangements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Receptor Collaboration and License Agreement</i>&#xA0;&#x2014; On January&#xA0;20,
 2016, the Company entered into a Collaboration and License
 Agreement (the &#x201C;CLA&#x201D;) with Receptor Life Sciences, Inc.
 (&#x201C;Receptor&#x201D;) pursuant to which the Company performed
 initial formulation studies on compounds identified by Receptor.
 Following successful completion of the studies, Receptor obtained
 the option to acquire an exclusive license to develop, manufacture
 and commercialize certain products that use MannKind&#x2019;s
 technology to deliver the compounds via oral inhalation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company received $0.4&#xA0;million in nonrefundable payments in
 2016 prior to Receptor exercising the option. On December&#xA0;30,
 2016, Receptor exercised the option and paid the Company a
 $1.0&#xA0;million nonrefundable option exercise and license fee.
 Under the CLA, the Company may receive the following additional
 payments:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="3%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Nonrefundable milestone payments upon
 the completion of certain technology transfer activities and the
 achievement of specified sales targets.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="3%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Royalties upon Receptor&#x2019;s and
 its sublicensee&#x2019;s sale of the product.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="3%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Milestones upon total worldwide sales
 reaching certain agreed upon levels.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company evaluated the accounting for the payments received in
 2016 under the multiple element accounting guidance and determined
 that the $0.4&#xA0;million in payments received prior to Receptor
 exercising its option are separable from the other elements of the
 agreement and represented payments to offset costs incurred.
 Therefore, those payments reduced the Company&#x2019;s research and
 development expense in 2016. The $1.0&#xA0;million license fee
 received in 2016 does not have standalone value from
 the&#xA0;<font style="WHITE-SPACE: nowrap">follow-on</font>&#xA0;transfer of technology.
 Therefore, the license fee was recorded in deferred payments from
 collaboration at December&#xA0;31, 2016 and will be recognized in
 net revenue &#x2014; collaboration over four years. See Note 2
 &#x2014; Summary of Significant Accounting Policies for additional
 information on the Company&#x2019;s accounting for multiple element
 arrangements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Sanofi License Agreement and Sanofi Supply Agreement and Loan
 Facility</i>&#xA0;&#x2014; On August&#xA0;11,
 2014, the Company executed a license and collaboration agreement
 (the &#x201C;Sanofi License Agreement&#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (Sanofi)), pursuant to which Sanofi was responsible for global
 commercial, regulatory and development activities for Afrezza. The
 Company manufactured Afrezza at its manufacturing facility in
 Danbury, Connecticut to supply Sanofi&#x2019;s demand for the
 product pursuant to a supply agreement dated August&#xA0;11, 2014
 (the &#x201C;Sanofi Supply Agreement&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 During the term of the Sanofi License Agreement, worldwide profits
 and losses were determined based on the difference between the net
 sales of Afrezza and the costs and expenses incurred by the Company
 and Sanofi that were specifically attributable or related to the
 development, regulatory filings, manufacturing, or
 commercialization of Afrezza. These profits and losses were shared
 65% by Sanofi and 35% by the Company. On January&#xA0;4, 2016 the
 Company received a&#xA0;<font style="WHITE-SPACE: nowrap">90-day</font>&#xA0;notification from Sanofi of
 its election to terminate in its entirety the Sanofi License
 Agreement. The effective date of termination (the
 &#x201C;Termination Date&#x201D;) was April&#xA0;4, 2016. On
 April&#xA0;5, 2016 the Company assumed responsibility for the
 worldwide development and commercialization of Afrezza from Sanofi.
 Under the terms of the transition agreement, Sanofi continued to
 fulfill orders for Afrezza in the United States until the Company
 began distributing MannKind-branded Afrezza product to major
 wholesalers during the week of July&#xA0;25, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company analyzed the agreements entered into with Sanofi at
 their inception to determine whether the consideration, paid or
 payable to the Company, or a portion thereof, could be recognized
 as revenue.<i>&#xA0;</i>Under the terms of the
 Sanofi License Agreement, the Sanofi Supply Agreement and the
 Sanofi Loan Facility, the Company determined that the arrangement
 contained significant deliverables including (i)&#xA0;licenses to
 develop and commercialize Afrezza and to use the Company&#x2019;s
 trademarks, (ii)&#xA0;development activities, and
 (iii)&#xA0;manufacture and supply services for Afrezza. Due to the
 proprietary nature of the manufacturing services to be provided by
 the Company, the Company determined that all of the significant
 deliverables should be combined into a single unit of accounting.
 The Company believed that the manufacturing services are
 proprietary due to the fact that since the late 1990&#x2019;s, the
 Company has developed proprietary knowledge and patented equipment
 and tools that are used in the manufacturing process of Afrezza.
 Due to the complexities of particle formulation and the specialized
 knowledge and equipment needed to handle the Afrezza powder,
 neither Sanofi nor, to the Company&#x2019;s knowledge, any
 third-party contract manufacturing organization currently possesses
 the capability of manufacturing Afrezza.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 In order for revenue to be recognized, the seller&#x2019;s price to
 the buyer must be fixed or determinable. Prior to December&#xA0;31,
 2015, because the Company did not have the ability to estimate the
 amount of costs that would potentially be incurred under the loss
 share provision related to the Sanofi License Agreement and the
 Sanofi Supply Agreement, the Company believed this requirement for
 revenue recognition had not been met. Therefore, the Company had
 recorded the $150.0&#xA0;million&#xA0;<font style="WHITE-SPACE: nowrap">up-front</font>&#xA0;payment and the two milestone
 payments of $25.0&#xA0;million each as deferred payments from
 collaboration. In addition, as of December&#xA0;31, 2015 the
 Company had recorded $17.5&#xA0;million in Afrezza product
 shipments to Sanofi as deferred sales from collaboration and
 recorded $13.5&#xA0;million as deferred costs from collaboration.
 Deferred costs from collaboration represented the costs of product
 manufactured and shipped to Sanofi, as well as certain direct costs
 associated with a firm purchase commitment entered into in
 connection with the collaboration with Sanofi.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 In the first and second quarters of 2016, after the Company
 received notice of termination from Sanofi, the Company evaluated
 whether the revenue recognition criteria had been met. The Company
 determined that the requirement had not been met because Sanofi had
 not finalized necessary adjustments to the profit and loss share
 provision statements and Sanofi had not yet transferred all of the
 information to enable the Company to commercialize Afrezza on its
 own. Therefore, the Company was still unable to estimate the costs
 to be incurred under the agreement with Sanofi. During the three
 months ended September&#xA0;30, 2016, Sanofi provided enough
 information to the Company to enable it to reasonably estimate the
 remaining costs under the Sanofi License Agreement and the Sanofi
 Supply Agreement. Accordingly, the fixed or determinable fee
 requirement for revenue recognition was met and there were no
 future obligations to Sanofi. Therefore, the Company recognized
 $172.0&#xA0;million of net revenue &#x2014; collaboration for the
 year ended December&#xA0;31, 2016. The revenue recognized includes
 the upfront payment of $150.0&#xA0;million and the two milestone
 payments of $25.0&#xA0;million each, net of $64.9&#xA0;million of
 net loss share with Sanofi, as well as $17.5&#xA0;million in sales
 of Afrezza and $19.4&#xA0;million from sales of bulk insulin, both
 to Sanofi. These payments and sales were made pursuant to the
 contractual terms of the agreements with Sanofi.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Sanofi Loan Facility</i>&#xA0;&#x2014; On September&#xA0;23,
 2014, the Company entered into the Sanofi Loan Facility, consisting
 of a senior secured revolving promissory note and a guaranty and
 security agreement (the &#x201C;Security Agreement&#x201D;) with an
 affiliate of Sanofi, which provided the Company with a secured loan
 facility of up to $175.0&#xA0;million to fund the Company&#x2019;s
 share of net losses under the Sanofi License Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The obligations of the Company under the Sanofi Loan Facility were
 guaranteed by the Company&#x2019;s wholly-owned subsidiary, MannKind
 LLC, and were secured by a first priority security interest in
 certain insulin inventory located in the United States and any
 contractual rights and obligations pursuant to which the Company
 purchases or has purchased such insulin, and a second priority
 security interest in the Company&#x2019;s assets that secure the
 Company&#x2019;s obligations under the Facility Agreement, as
 amended. In addition, the Company granted to Sanofi, as additional
 security for the obligations under the Sanofi Loan Facility, a
 first priority mortgage on the Company&#x2019;s facility in
 Valencia, California, which had a carrying value of
 $17.9&#xA0;million as of December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Advances under the Sanofi Loan Facility bore interest at a rate of
 8.5%&#xA0;per annum and were payable&#xA0;<font style="WHITE-SPACE: nowrap">in-kind</font>&#xA0;and compounded quarterly and
 added to the outstanding principal balance under the Sanofi Loan
 Facility. The Company was required to make mandatory prepayments on
 the outstanding loans under the Sanofi Loan Facility from its share
 of any profits (as defined in the Sanofi License Agreement) under
 the Sanofi License Agreement within 30 days of receipt of its share
 of any such profits.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s total portion of the loss sharing was
 $57.7&#xA0;million for the year ended December&#xA0;31, 2015, of
 which $44.5&#xA0;million was borrowed under the Sanofi Loan
 Facility as of December&#xA0;31, 2015. Subsequent to
 December&#xA0;31, 2015, the Company borrowed $17.9&#xA0;million
 under the Sanofi Loan Facility to finance the portion of the
 Company&#x2019;s loss for the quarter ended December&#xA0;31, 2015.
 The total amount owed to Sanofi at December&#xA0;31, 2015 was
 $62.4&#xA0;million, which includes $1.7&#xA0;million of&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">paid-in-kind</font></font>&#xA0;interest.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On November&#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &#x201C;Settlement Agreement&#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 between the Company and Aventisub LLC (&#x201C;Aventisub&#x201D;), a
 Sanofi affiliate, was terminated, with Aventisub agreeing to
 forgive the full outstanding loan balance of $72.0&#xA0;million.
 Sanofi also agreed to purchase $10.2&#xA0;million of insulin from
 the Company in December 2016 under an existing insulin put option
 as well as make a cash payment of $30.6&#xA0;million to the Company
 in early January 2017 as acceleration and in replacement of all
 other payments that Sanofi would otherwise have been required to
 make in the future pursuant to the insulin put option, without the
 Company being required to deliver any insulin for such payment. The
 Company was also relieved of its obligation to pay Sanofi
 $0.5&#xA0;million in previously uncharged costs pursuant to the
 Sanofi License Agreement. The Company and Sanofi also agreed to a
 general release of potential claims against each other.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The forgiveness of the full outstanding loan balance on the Sanofi
 Loan Facility and the previously uncharged costs related to the
 collaboration were accounted for in (gain) loss on extinguishment
 of debt in the accompanying consolidated statements of operations.
 The $10.2&#xA0;million sale of insulin was accounted for as net
 revenue &#x2014; collaboration, consistent with the Company&#x2019;
 sales of insulin to Sanofi in the third quarter of 2016 (see Note 2
 &#x2014; Summary of Significant Accounting Policies
 &#x2014;&#xA0;<i>Revenue
 Recognition &#x2014; Net Revenue &#x2014; Collaboration</i>). The
 $30.6&#xA0;million accelerated put option payment was recognized as
 a receivable from Sanofi at December&#xA0;31, 2016 and an increase
 in the recognized loss on purchase commitments as the purchase
 commitment obligation had previously been reduced to reflect the
 Company&#x2019;s expectation that amounts associated with purchases
 of insulin were recoverable (see Note 2 &#x2014; Summary of
 Significant Accounting Policies &#x2014;&#xA0;<i>Inventories</i>).</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830327072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>9. Fair Value of Financial Instruments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The carrying amounts reported in the accompanying consolidated
 financial statements for cash, accounts receivable, accounts
 payable and accrued expenses and other current liabilities
 approximate their fair value due to their relatively short
 maturities. The fair value of the cash equivalents, note
 payable&#xA0;to principal stockholder, senior convertible notes,
 the Facility Financing Obligation (as defined below), the Milestone
 Rights (as defined below) and warrant liability are discussed
 below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Cash Equivalents</i> &#x2014; As of December&#xA0;31, 2016 and
 2015, the Company held $20.5&#xA0;million and $55.8&#xA0;million,
 respectively, of cash equivalents, consisting of money market
 funds. The fair value of these money market funds was determined by
 using quoted prices for identical investments in an active market
 (Level 1 in the fair value hierarchy).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Note Payable to Principal Stockholder</i> &#x2014; The fair value
 of the note payable to the Company&#x2019;s principal stockholder
 cannot be reasonably estimated as the Company would not be able to
 obtain a similar credit arrangement in the current economic
 environment. Therefore, the fair value is based upon carrying
 value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Financial Liabilities</i> &#x2014; The following tables set forth
 the fair value of the Company&#x2019;s financial instruments (in
 millions):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center">As of December&#xA0;31, 2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Carrying&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;1</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;2</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;3</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Financial liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Senior convertible notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Facility Financing Obligation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability (at recurring fair values)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total financial liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">115.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center">As of December&#xA0;31, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Carrying&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;1</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;2</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;3</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Financial liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Senior convertible notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Facility Financing Obligation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Sanofi Loan Facility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total financial liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">155.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">150.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">150.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table provides a roll forward of the fair values of
 financial assets and liabilities that are carried at fair value (in
 millions):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Warrants</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Assets&#xA0;Held&#xA0;for<br />
 Sale</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, January&#xA0;1, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5.4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.6</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.7</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Senior Convertible Notes</i> &#x2014; The estimated fair value of
 the 2018 notes was calculated based on model-derived valuations
 where inputs were observable, such as the Company&#x2019;s stock
 price and yields on U.S. Treasury notes and actively traded bonds,
 and <font style="WHITE-SPACE: nowrap">non-observable,</font> such
 as the Company&#x2019;s longer-term historical volatility, and
 estimated yields implied from any available market trades of the
 Company&#x2019;s issued debt instruments. As there is no current
 active and observable market for the 2018 notes, the Company
 determined the estimated fair value using a convertible bond
 valuation model within a lattice framework. The convertible bond
 valuation model combined expected cash flows based on terms of the
 notes with market-based assumptions regarding risk-free rate,
 risk-adjusted yields (20%), stock price volatility (111%) and
 recent price quotes and trading information regarding Company
 issued debt instruments and shares of common stock into which the
 notes are convertible.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Facility Financing Obligation</i> &#x2014; As discussed in Note 7
 &#x2014; Borrowings, in connection with the Facility Agreement, the
 Company issued 2019 notes and subsequently issued Tranche B notes
 (the &#x201C;Facility Financing Obligation&#x201D;). As there is no
 current observable market for the Facility Financing Obligation,
 the Company determined the estimated fair value using a bond
 valuation model based on a discounted cash flow methodology. The
 bond valuation model combined expected cash flows associated with
 principal repayment and interest based on the contractual terms of
 the debt agreement discounted to present value using a selected
 market discount rate. On December&#xA0;31, 2016 the market discount
 rate was recalculated at 12.0% for the Facility Financing
 Obligation. Under the terms of the Facility Agreement, the Company
 is restricted from distributing any of its assets or declaring and
 distributing a dividend to its stockholders.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Milestone Rights Liability</i> &#x2014; In addition to the
 Facility Financing Obligation, the Company also issued certain
 rights to receive payments of up to $90.0&#xA0;million upon
 occurrence of specified strategic and sales milestones (the
 &#x201C;Milestone Rights&#x201D;). These rights are not reflected in
 the Facility Financing Obligation. The estimated fair value of the
 Milestone Rights was calculated using the income approach in which
 the cash flows associated with the specified contractual payments
 were adjusted for both the expected timing and the probability of
 achieving the milestones discounted to present value using a
 selected market discount rate (Level 3 in the fair value
 hierarchy). The expected timing and probability of achieving the
 milestones, starting in 2014, was developed with consideration
 given to both internal data, such as the Company&#x2019;s forecast,
 progress made to date towards meeting the milestones, and
 assessment of criteria required for achievement, and external data,
 such as market research studies. The discount rate (14.5%)&#xA0;was
 selected based on an estimation of required rate of returns for
 similar investment opportunities using available market data. As of
 December&#xA0;31, 2016, the carrying value of the Milestone Rights
 is $8.9&#xA0;million, classified as a long-term liability and the
 fair value is estimated at $18.4&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Warrant Liability</i> &#x2014; Warrant liabilities are measured
 at fair value using a Monte Carlo pricing valuation model and
 various assumptions. The significant unobservable input used in
 measuring the fair value of the common stock warrant liabilities is
 the expected volatility. Significant increases in volatility would
 result in a higher fair value measurement (Level 3 in the fair
 value hierarchy). See Note 16 &#x2014; Warrants for further
 discussion of the valuation technique and inputs used in the fair
 value measurement.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 <i>Sanofi Loan Facility</i> &#x2014; As discussed in Note 8 &#x2014;
 Collaboration Arrangements, the Sanofi Loan Facility consisted of a
 senior secured revolving promissory note and a guaranty and
 security agreement with an affiliate of Sanofi which provided the
 Company with a secured loan facility of up to $175.0&#xA0;million
 to fund the Company&#x2019;s share of net losses under the Sanofi
 License Agreement. The estimated fair value was determined using a
 discounted cash flow model where time outstanding and discount rate
 were primary variables. This method considered the key elements of
 the contractual terms of the Sanofi Loan Facility, market-based
 estimated cost of capital, and time value of money, namely the
 amount of time to settlement and the estimated discount rate
 (11%)&#xA0;appropriate for the liability (Level 3 in the fair value
 hierarchy). The Sanofi Loan Facility was forgiven on
 November&#xA0;9, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 There were no transfers of assets or liabilities between the fair
 value measurement levels during the twelve months ended
 December&#xA0;31, 2016, 2015 and 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Assets and Liabilities Measured at Fair Value on a <font style="WHITE-SPACE: nowrap">Non-recurring</font> Basis</i> &#x2014; Land,
 buildings, and machinery and equipment, with a carrying amount of
 $189.2&#xA0;million, were written down to a fair value of
 $48.8&#xA0;million, resulting in an impairment charge of
 $140.4&#xA0;million, which is included in our consolidated
 statements of operations for the year ended December&#xA0;31, 2015.
 See Note <font style="WHITE-SPACE: nowrap">4-</font> Property and
 Equipment for further discussion of the valuation technique and
 inputs used in the fair value measurement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 An additional impairment of $0.7&#xA0;million was charged for the
 year ended December&#xA0;31, 2016. At that time, an analysis of the
 lower of carrying value to fair value, which was deemed to be the
 sales price of the property, less selling costs determined a loss
 of $0.6 million, which is included in property and equipment
 impairment on the consolidated statement of operations for
 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our assessment of the real property includes Level&#xA0;3 inputs,
 and was based on a combination of the income, market and cost
 approaches and the market approach was used for machinery and
 equipment which required Level&#xA0;3 inputs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Embedded Derivatives</i> &#x2014; The Company identified and
 evaluated a number of embedded features in the notes issued under
 the Facility Agreement to determine if they represented embedded
 derivatives that are required to be separated from the notes and
 accounted for as freestanding instruments. The Company analyzed the
 Tranche B notes and identified embedded derivatives, which required
 separate accounting. However, all of the embedded derivatives were
 determined to have a <i>de minimis</i> value at December&#xA0;31,
 2016 and 2015.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840493632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonAndPreferredStockTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>10. Common and Preferred Stock</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&#x2019;s common
 stock par value. See Note 1 &#x2014; Description of Business.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company is authorized to issue 140,000,000 shares of common
 stock, par value $0.05 per share, and 10,000,000 shares of
 undesignated preferred stock, par value $0.01 per share, issuable
 in one or more series as designated by the Company&#x2019;s board of
 directors. No other class of capital stock is authorized. As of
 December&#xA0;31, 2016 and 2015, 95,680,831 and 85,734,188 shares
 of common stock, respectively, were issued and outstanding and no
 shares of preferred stock were outstanding.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As more fully described in Note 16 &#x2014; Warrants, in May 2016,
 the Company sold in a registered offering an aggregate of 9,708,737
 shares of common stock together with certain warrants exercisable
 for up to an aggregate of 7,281,553 shares of common stock
 (&#x201C;A Warrants&#x201D;) and certain warrants exercisable for up
 to an aggregate of 2,427,184 shares of common stock (&#x201C;B
 Warrants&#x201D;) in a direct offering for proceeds of
 $50.0&#xA0;million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On November&#xA0;9, 2015, the Company entered into a series of
 stock purchase agreements to sell up to an aggregate of 10,000,000
 shares of its common stock in a registered direct offering to
 selected investment funds in Israel that hold securities included
 within certain stock indexes of the Tel Aviv Stock Exchange (the
 &#x201C;TASE&#x201D;). Pursuant to the agreements, the shares of
 common stock were sold at a price per share equal to 97% of the
 closing price of the Company&#x2019;s common stock on the TASE on
 November&#xA0;12, 2015. During November 2015, the Company sold
 2,770,487 shares of common stock for an aggregate price of
 approximately $34,710,000, or $13.05 per share, which is net of
 $1,432,000 of issuance costs.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company engaged Sunrise Securities Corporation as its exclusive
 placement agent in connection with the offering of the 10,000,000
 shares. In connection with the services provided, the Company
 issued to Sunrise Securities Corporation, or its designee,
 restricted warrants to purchase a number of shares of the
 Company&#x2019;s common stock in an aggregate equal to 1.15% of the
 aggregate shares sold in the offering, which totaled 31,860 shares
 on November&#xA0;16, 2015. The warrants are exercisable for a five
 year period at an exercise price of $13.05, the price paid per
 share in connection with the offering. The Company had an
 obligation to register the common stock that may be issued pursuant
 to the exercise of the warrants, which resulted in their initial
 classification as liability and were deemed immaterial. On
 December&#xA0;15, 2015 the warrants were reclassified to equity as
 the Company registered the common stock pursuant to a registration
 statement and continue to be classified in equity as of
 December&#xA0;31, 2016.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Included in the common stock outstanding as of December&#xA0;31,
 2014 is 1,800,000 shares of common stock loaned to Bank of America
 under a share lending agreement in connection with the offering of
 the $100.0&#xA0;million aggregate principal amount of the 2015
 notes. Bank of America was obligated to return the borrowed shares
 (or, in certain circumstances, the cash value thereof) to the
 Company on or about the 45th business day following the date as of
 which the entire principal amount of the 2015 notes ceases to be
 outstanding, subject to extension or acceleration in certain
 circumstances or early termination at Bank of America&#x2019;s
 option. On October&#xA0;23, 2015, the 1,800,000 shares of common
 stock loaned to Bank of America were returned, as the Company
 settled all payments and deliveries in respect of such convertible
 notes on August&#xA0;17, 2015. The Company did not receive any
 proceeds from the sale of the borrowed shares by Bank of America,
 but the Company did receive a nominal lending fee of $0.05 per
 share from Bank of America for the use of borrowed shares.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On February&#xA0;8, 2012, the Company sold 7,187,500 units in an
 underwritten public offering, including 937,500 units sold pursuant
 to the full exercise of an over-allotment option granted to the
 underwriters, with each unit consisting of one share of common
 stock and a warrant to purchase 0.1 of a share of common stock. All
 of the securities were offered by the Company at a combined price
 to the public of $12.00 per unit and the underwriters purchased the
 units at a price of $11.28 per unit. Net proceeds from this
 offering were approximately $80.6&#xA0;million, excluding any
 warrant exercises. The 4,312,500 shares of common stock underlying
 the warrants are exercisable at $12.00 per share and expire four
 years from the date of the issuance.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 For the years ended December&#xA0;31, 2015 and 2014, the Company
 received $10.1&#xA0;million and $27.8&#xA0;million in proceeds,
 respectively, from the exercise of the February 2012 public
 offering warrants. There were no warrant exercises during the year
 ended December&#xA0;31, 2016 and any unexercised February 2012
 public offering warrants expired on February&#xA0;8, 2016.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonAndPreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonAndPreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830327072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>11. Net Income (Loss) per Common Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&#x2019;s common
 stock par value. See Note 1 &#x2014; Description of Business.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive. During 2015, 1,800,000 shares of the Company&#x2019;s
 common stock, which were loaned to Bank of America pursuant to the
 terms of a share lending agreement, were issued and outstanding,
 with the holder of the borrowed shares having all the rights of a
 holder of the Company&#x2019;s common stock. As the share borrower
 was required to return all borrowed shares to the Company, the
 borrowed shares were not considered outstanding for the purpose of
 computing and reporting basic or diluted loss per share during the
 period presented for 2015. These shares were returned to the
 Company in the third quarter of 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following tables summarize the components of the basic and
 diluted net income (loss) per common share computations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(In thousands,
 except per share data)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Basic EPS:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) (numerator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">125,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(368,445</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(198,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average common shares (denominator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.37</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.54</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Diluted EPS:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) (numerator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">125,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(368,445</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(198,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average common shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities &#x2014; common shares issuable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted weighted average common shares (denominator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,085</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.36</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.54</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Common shares issuable represents incremental shares of common
 stock which consist of stock options, restricted stock units,
 warrants, and shares that could be issued upon conversion of the
 senior convertible notes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Potentially dilutive securities outstanding that are considered
 antidilutive are summarized as follows (in shares):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,955,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,308,332</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Conversion of senior convertible notes into common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,464,616</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,740,597</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,919</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,997,575</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">702,867</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">360,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">522,144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,788,281</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,946,249</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,292,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840530128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Award Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Award Plans</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <b>12. Stock Award Plans</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On March 1, 2017, the Company effected a 1-for-5 reverse stock
 split of the Company&#x2019;s outstanding common stock. As a result,
 all common stock share amounts included in these consolidated
 financial statements have been retroactively reduced by a factor of
 five, and all common stock per share amounts have been increased by
 a factor of five, with the exception of the Company&#x2019;s common
 stock par value. See Note 1 &#x2014; Description of Business.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On May&#xA0;23, 2013, the Company adopted the 2013 Equity Incentive
 Plan (the &#x201C;2013 Plan&#x201D;) as the successor to and
 continuation of the 2004 Equity Incentive Plan (the &#x201C;2004
 Plan&#x201D;). The 2013 Plan consists of 4.3&#xA0;million additional
 shares and the number of unallocated shares remaining available for
 grant for new awards under the 2004 Plan. The 2013 Plan provides
 for the granting of stock awards including stock options and
 restricted stock units, to employees, directors and consultants.
 The 2013 Plan also provides for the automatic,&#xA0;<font style="WHITE-SPACE: nowrap">non-discretionary</font>&#xA0;grant of options to the
 Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;directors. No additional
 awards will be granted under the 2004 Plan or under the
 2004&#xA0;<font style="WHITE-SPACE: nowrap">Non-Employee</font>&#xA0;Directors&#x2019; Stock Option
 Plan (the &#x201C;NED Plan&#x201D;) as all future awards will be made
 out of the 2013 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The following table summarizes information about the
 Company&#x2019;s stock-based award plans as of December&#xA0;31,
 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Outstanding<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Outstanding<br />
 Restricted<br />
 Stock Units</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Shares&#xA0;Available<br />
 for Future<br />
 Issuance</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2004 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,052,345</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,203</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2013 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,399,245</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">723,763</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,743,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2004&#xA0;<font style="WHITE-SPACE: nowrap">Non-Employee</font>&#xA0;Directors&#x2019; Stock Option
 Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">737,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,840,587</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 In March 2004, as part of the 2004 Plan, the Company&#x2019;s board
 of directors approved the Employee Stock Purchase Plan
 (&#x201C;ESPP&#x201D;), which became effective upon the closing of
 the Company&#x2019;s initial public offering. Initially, the
 aggregate number of shares that could be sold under the 2004 Plan
 was 400,000 shares of common stock. On January&#xA0;1 of each year,
 for a period of ten years beginning January&#xA0;1, 2005, the share
 reserve automatically increased by the lesser of: 140,000 shares,
 1% of the total number of shares of common stock outstanding on
 that date, or an amount as may be determined by the board of
 directors. However, under no event can the annual increase cause
 the total number of shares reserved under the ESPP to exceed 10% of
 the total number of shares of capital stock outstanding on
 December&#xA0;31 of the prior year. On January&#xA0;1, 2013 and
 2014 the ESPP share reserve was increased each year by 140,000
 shares. There was no ESPP share reserve increases during 2015 or
 2016. As of December&#xA0;31, 2016, 445,782 shares were available
 for issuance under the ESPP. For the years ended December&#xA0;31,
 2016, 2015 and 2014, the Company sold 104,758, 64,245 and 61,015
 shares, respectively, of its common stock to employees
 participating in the ESPP. The ESPP purchase of 43,672 shares for
 the period ending December&#xA0;31, 2016 was initiated prior
 to&#xA0;<font style="WHITE-SPACE: nowrap">year-end</font>&#xA0;but did not settle until
 January&#xA0;5, 2017. As a result, the shares sold are reflected in
 the ESPP share reserves but are excluded from common stock
 outstanding as of December&#xA0;31, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s board of directors determines eligibility,
 vesting schedules and criteria and exercise prices for stock awards
 granted under the 2013 Plan. Options and restricted stock unit
 awards under the 2013 Plan expire not more than ten years from the
 date of the grant and are exercisable upon vesting. Stock options
 that vest over time generally vest over four years. Current
 time-based vesting stock option grants vest and become exercisable
 at the rate of 25% after one year and ratably on a monthly basis
 over a period of 36 months thereafter. Restricted stock units with
 time-based vesting generally vest at a rate of 25%&#xA0;per year
 over four years with consideration satisfied by service to the
 Company. The Company also issues stock awards with performance
 conditions. The 2013 Plan provides for full acceleration of vesting
 if an employee is terminated within three months of a change in
 control, as defined in the 2013 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Share-based payment transactions are recognized as compensation
 cost based on the fair value of the instrument on the date of
 grant. The Company accounts for&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;stock-based compensation
 expense based on the estimated fair value of the options, which is
 determined using the Black-Scholes option valuation model and
 amortizes such expense on a straight-line basis over the service
 period for time-based awards and over the expected dates of
 achievement for performance-based awards. These awards are subject
 to&#xA0;<font style="WHITE-SPACE: nowrap">re-measurement</font>&#xA0;until service is complete. As
 of December&#xA0;31, 2016, there were options to purchase 100,697
 shares of common stock outstanding to consultants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 During the years ended December&#xA0;31, 2016, 2015 and 2014 the
 Company recorded stock-based compensation expense of
 $5.1&#xA0;million, $8.7&#xA0;million and $48.6&#xA0;million,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is as follows
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,407</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Consultant-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,725</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is included in
 the following categories (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">695</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,131</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,696</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,725</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company uses the Black-Scholes option valuation model to
 estimate the grant date fair value of employee stock options. The
 expected term of an option granted is based on combining historical
 exercise data with expected weighted time outstanding. Expected
 weighted time outstanding is calculated by assuming the settlement
 of outstanding awards is at the midpoint between the remaining
 weighted average vesting date and the expiration date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. The Company
 has selected risk-free interest rates based on U.S. Treasury
 securities with an equivalent expected term in effect on the date
 the options were granted. Additionally, the Company uses historical
 data and management judgment to estimate stock option exercise
 behavior and employee turnover rates to estimate the number of
 stock option awards that will eventually vest. The Company
 calculated the fair value of employee stock options granted during
 the years ended December&#xA0;31, 2016, 2015 and 2014 using the
 following assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="31%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center">Year Ended December&#xA0;31,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2016</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2015</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 1.18%&#xA0;&#x2014;&#xA0;1.80%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">1.61%
 &#x2014;1.86%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 1.64%&#xA0;&#x2014;&#xA0;2.11%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected lives</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.13&#xA0;&#x2014;&#xA0;5.82&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.79&#xA0;&#x2014;&#xA0;5.86&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.77&#xA0;&#x2014;&#xA0;6.09&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 77.57%&#xA0;&#x2014;&#xA0;82.75%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 69.76%&#xA0;&#x2014;&#xA0;71.84%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 73.98%&#xA0;&#x2014;&#xA0;84.85%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The following table summarizes information about stock options
 outstanding:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of<br />
 Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average&#xA0;Exercise<br />
 Price per&#xA0;Share</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic<br />
 Value&#xA0;($000)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,955,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,236,693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55,231</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(407,161</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(199,890</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23.65</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested and expected to vest at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,399,777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,414,586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The weighted average grant date fair value of the stock options
 granted during the years ended December&#xA0;31, 2016, 2015 and
 2014 was $3.05, $12.80 and $23.80 per option, respectively. The
 total intrinsic value of options exercised during the years ended
 December&#xA0;31, 2016, 2015 and 2014 was $0.1&#xA0;million,
 $6.2&#xA0;million and $14.9&#xA0;million, respectively. Intrinsic
 value is measured using the fair market value at the date of
 exercise for options exercised or at December&#xA0;31 for
 outstanding options, less the applicable exercise price.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Cash received from the exercise of options during the years ended
 December&#xA0;31, 2016, 2015 and 2014 was approximately
 $0.5&#xA0;million, $3.3&#xA0;million and $11.0&#xA0;million,
 respectively. The weighted-average remaining contractual terms for
 options outstanding, vested and expected to vest and exercisable at
 December&#xA0;31, 2016 was 5.31 years, 5.22 years and 2.93 years,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 A summary of restricted stock unit activity for the year ended
 December&#xA0;31, 2016 is presented below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Grant&#xA0;Date<br />
 Fair Value<br />
 per Share</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">360,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24.25</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">800,530</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(131,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(292,488</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">737,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The total restricted stock units expected to vest as of
 December&#xA0;31, 2016 was 629,424 with a weighted average grant
 date fair value of $8.60 per share. The total intrinsic value of
 restricted stock units expected to vest as of December&#xA0;31,
 2016 was $2.0&#xA0;million. Intrinsic value of restricted stock
 units expected to vest is measured using the closing share price at
 December&#xA0;31, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Total intrinsic value of restricted stock units vested during the
 years ended December&#xA0;31, 2016, 2015 and 2014 was
 $0.6&#xA0;million, $5.2&#xA0;million and $62.7&#xA0;million,
 respectively. Intrinsic value of restricted stock units vested is
 measured using the closing share price on the day prior to the vest
 date. The total grant date fair value of restricted stock units
 vested during the years ended December&#xA0;31, 2016, 2015 and 2014
 was $2.6&#xA0;million, $5.5&#xA0;million and $36.4&#xA0;million,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 As of December&#xA0;31, 2016, there was $4.0&#xA0;million and
 $4.8&#xA0;million of unrecognized compensation expense related to
 options and restricted stock units with performance conditions,
 respectively, which is expected to be recognized over the weighted
 average vesting period of 2.9 years. The Company evaluates stock
 awards with performance conditions as to the probability that the
 performance conditions will be met and uses that information to
 estimate the date at which those performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 As of December&#xA0;31, 2016, the Company reviewed the probability
 of achieving the performance conditions for each of the four
 vesting tranches of the performance-based stock options and
 determined that it was probable that the Company would achieve the
 first vesting tranche in December 2017. Therefore, the Company
 recorded a&#xA0;<font style="WHITE-SPACE: nowrap">non-material</font>&#xA0;cumulative catchup of the
 expense from the grant date through December&#xA0;31, 2016 and will
 record the unrecognized compensation cost related to the first
 tranche in the amount of $0.3&#xA0;million through
 December&#xA0;31, 2017. The Company further determined that no
 compensation costs would be recognized for the second, third and
 fourth vesting tranches as it had not been determined that it was
 probable that the performance conditions related to these tranches
 would be achieved.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 During the year ended December&#xA0;31, 2015, there was
 $1.6&#xA0;million of stock compensation expense related to certain
 executives who entered into severance agreements which resulted in
 a modification to the terms of their awards. The severance
 agreements generally allowed for the separated executives to
 continue to vest under their original award terms for a stated
 period of time without providing substantive services. There were
 no modifications in 2016.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830327072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <b>13. Commitments and Contingencies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Operating Leases</i>&#xA0;&#x2014; The Company leases its
 executive offices in Valencia, California and certain equipment
 under various operating leases, which expire at various dates
 through 2017 and beyond. Future payments are insignificant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Rent expense under all operating leases, including office space and
 equipment, for the years ended December&#xA0;31, 2016, 2015 and
 2014 was approximately $373,000, $426,000 and $737,000,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Guarantees and Indemnifications</i>&#xA0;&#x2014; In the ordinary course
 of its business, the Company makes certain indemnities, commitments
 and guarantees under which it may be required to make payments in
 relation to certain transactions. The Company, as permitted under
 Delaware law and in accordance with its Bylaws, indemnifies its
 officers and directors for certain events or occurrences, subject
 to certain limits, while the officer or director is or was serving
 at the Company&#x2019;s request in such capacity. The term of the
 indemnification period is for the officer&#x2019;s or
 director&#x2019;s lifetime. The maximum amount of potential future
 indemnification is unlimited; however, the Company has a director
 and officer insurance policy that may enable it to recover a
 portion of any future amounts paid. The Company believes the fair
 value of these indemnification agreements is minimal. The Company
 has not recorded any liability for these indemnities in the
 accompanying consolidated balance sheets. However, the Company
 accrues for losses for any known contingent liability, including
 those that may arise from indemnification provisions, when future
 payment is probable and the amount can be reasonably estimated. No
 such losses have been recorded to date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Litigation</i>&#xA0;&#x2014; The Company is subject
 to legal proceedings and claims which arise in the ordinary course
 of its business. As of December&#xA0;31, 2016, the Company believes
 that the final disposition of such matters will not have a material
 adverse effect on the consolidated financial position, results of
 operations or cash flows of the Company and no accrual has been
 recorded. The Company maintains liability insurance coverage to
 protect the Company&#x2019;s assets from losses arising out of or
 involving activities associated with ongoing and normal business
 operations. The Company records a provision for a liability when it
 is both probable that a liability has been incurred and the amount
 of the loss can be reasonably estimated. The Company&#x2019;s policy
 is to accrue for legal expenses in connection with legal proceeding
 and claims as they are incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Following the public announcement of Sanofi&#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 of the price of its common stock, several complaints were filed in
 the U.S. District Court for the Central District of California
 against the Company and certain of its officers and directors on
 behalf of certain purchasers of its common stock, which were
 consolidated into a single action. The amended complaint alleged
 that the Company and certain of its officers and directors violated
 federal securities laws by making materially false and misleading
 statements regarding the prospects for Afrezza, thereby
 artificially inflating the price of its common stock. The Company
 and the named defendants brought a motion to dismiss the class
 action that was pending against them, which the District Court
 granted in August 2016 without leave to amend the complaint. The
 lead plaintiff appealed that decision to the Ninth Circuit Court of
 Appeals. On March&#xA0;2, 2017, the lead plaintiff filed a
 voluntary motion to dismiss his appeal, which the Court of Appeals
 granted on March&#xA0;9, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Following the public announcement of Sanofi&#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 of the price of its common stock, two motions were submitted to the
 District Court at Tel Aviv, Economic Department for the
 certification of a class action against the Company and certain of
 its officers and directors. In general, the complaints allege that
 the Company and certain of its officers and directors violated
 Israeli and U.S. securities laws by making materially false and
 misleading statements regarding the prospects for Afrezza, thereby
 artificially inflating the price of its common stock. The
 plaintiffs are seeking monetary damages. In November 2016, the
 district court dismissed one of the actions without prejudice. In
 the remaining action, a hearing is scheduled for May 2017 to
 determine whether Israeli or U.S. law is applicable before the case
 can be certified as a class action. The Company will vigorously
 defend against these claims.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Subsequent to the filing of the federal securities class action
 against the Company, two shareholder derivative complaints were
 filed in the Superior Court for the State of California, County of
 Los Angeles against certain of the Company&#x2019;s directors and
 officers. The complaints allege breaches of fiduciary duties by the
 defendants and other violations of law. Among other allegations,
 the complaints allege that the defendants caused the Company to
 make false and misleading statements or omissions of material fact
 regarding the Company&#x2019;s business and the prospects for sales
 of Afrezza, thereby artificially inflating the price of the
 Company&#x2019;s common stock. Following the dismissal of the
 federal securities class action, each derivative complaint was
 voluntarily dismissed by its plaintiff.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Contingencies &#x2014;</i>&#xA0;In connection with the
 Facility Agreement, on July&#xA0;1, 2013 the Company also entered
 into a Milestone Rights Purchase Agreement (the &#x201C;Milestone
 Agreement&#x201D;) with Deerfield Private Design Fund and Horizon
 Sant&#xE9; FLML S&#xC1;RL (collectively, the &#x201C;Milestone
 Purchasers&#x201D;), pursuant to which the Company sold the
 Milestone Purchasers the Milestone Rights to receive payments up to
 $90.0&#xA0;million upon the occurrence of specified strategic and
 sales milestones, including the first commercial sale of an Afrezza
 product in the United States and the achievement of specified net
 sales figures (see Note 7 &#x2014; Borrowings).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Commitment &#x2014;</i>&#xA0;On July&#xA0;31, 2014, the
 Company entered into a supply agreement (the &#x201C;Insulin Supply
 Agreement&#x201D;) with Amphastar France Pharmaceuticals S.A.S., a
 French corporation (Amphastar), pursuant to which Amphastar will
 manufacture for and supply to the Company certain quantities of
 recombinant human insulin for use in Afrezza. Under the terms of
 the Insulin Supply Agreement, Amphastar will be responsible for
 manufacturing the insulin in accordance with the Company&#x2019;s
 specifications and agreed-upon quality standards. The Company had
 agreed to purchase annual minimum quantities of insulin for
 calendar years 2015 through 2019 under the Insulin Supply Agreement
 of an aggregate total of approximately &#x20AC;120.1&#xA0;million.
 The Company could have requested to purchase additional quantities
 of insulin over such annual minimum quantities with a cancellation
 fee.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On November&#xA0;9, 2016, the supply agreement with Amphastar was
 amended to extend the term over which the Company is required to
 purchase insulin, without reducing the total amount of insulin to
 be purchased. Under the amendment, annual minimum quantities of
 insulin to be purchased for calendar years 2017 through 2023 total
 an aggregate purchase price of &#x20AC;93.0&#xA0;million at
 December&#xA0;31, 2016. The Insulin Supply Agreement specifies that
 Amphastar will be deemed to have satisfied its obligations with
 respect to quantity, if the actual quantity supplied is within plus
 or minus ten percent (+/- 10%) of the quantity set forth in the
 applicable purchase order. In addition, the aggregate cancellation
 fees that the Company would incur in the event that the above
 insulin quantities are not purchased was lowered from
 $5.3&#xA0;million for the period October&#xA0;1, 2016 through 2018
 to $3.4&#xA0;million over the same period. The annual purchase
 requirements under the contract are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">2.7&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.9&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.6&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.5&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2021</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.5&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2022</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.4&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2023</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.4&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Unless earlier terminated, the term of the Insulin Supply Agreement
 expires on December&#xA0;31, 2023 and can be renewed for
 additional, successive two year terms upon 12 months&#x2019; written
 notice given prior to the end of the initial term or any additional
 two year term. The Company and Amphastar each have normal and
 customary termination rights, including termination for material
 breach that is not cured within a specific time frame or in the
 event of liquidation, bankruptcy or insolvency of the other party.
 In addition, the Company may terminate the Insulin Supply Agreement
 upon two years&#x2019; prior written notice to Amphastar without
 cause or upon 30 days&#x2019; prior written notice to Amphastar if a
 controlling regulatory authority withdraws approval for Afrezza,
 provided, however, in the event of a termination pursuant to either
 of the latter two scenarios, the provisions of the Insulin Supply
 Agreement require the Company to pay the full amount of all unpaid
 purchase commitments due over the initial term within 60 calendar
 days of the effective date of such termination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company also has another firm commitment with another supplier
 for an aggregate of $0.9&#xA0;million.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830213648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>14. Employee Benefit Plans</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company administers a 401(k) savings retirement plan (the
 &#x201C;MannKind Retirement Plan&#x201D;) for its employees. For the
 years ended December&#xA0;31, 2016, 2015 and 2014, the Company
 contributed $418,000, $593,000 and $623,000, respectively, to the
 MannKind Retirement Plan.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840488448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <b>15. Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 At December&#xA0;31, 2016, the Company has concluded that it is
 more likely than not that the Company may not realize the benefit
 of its deferred tax assets due to its history of losses. There is
 no provision for income taxes in 2015 or 2014 because the Company
 had incurred operating losses since inception. Accordingly, the net
 deferred tax assets have been fully reserved. The provision for
 income taxes consists of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. state</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-U.S.</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,814</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">109,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,873</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. state</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,311</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29,394</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,631</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-U.S.</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(48,125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">65,504</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(80,118</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(65,504</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Deferred income taxes reflect the tax effects of temporary
 differences between the carrying amounts of assets and liabilities
 for financial reporting and income tax purposes. A valuation
 allowance is established when uncertainty exists as to whether all
 or a portion of the net deferred tax assets will be realized.
 Components of the net deferred tax assets as of December&#xA0;31,
 2016 and 2015, are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">712,124</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">721,588</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,646</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized research</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments from collaboration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,484</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss on purchase commitment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,084</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-qualified</font>&#xA0;stock option expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,941</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized patent costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,380</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,186</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45,310</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">914,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">962,623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(914,498</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(962,623</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The table of deferred tax assets and liabilities does not include
 certain deferred tax assets as of December&#xA0;31, 2016, that
 arose directly from tax deductions related to equity compensation
 which are greater than the compensation recognized for financial
 reporting. Equity would be increased by $11.6&#xA0;million if and
 when such deferred tax assets are ultimately realized. The Company
 considers certain realization requirements when excess tax benefits
 have been realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s effective income tax rate differs from the
 statutory federal income tax rate as follows for the years ended
 December&#xA0;31, 2016, 2015 and 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal tax benefit rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intercompany transfer of intellectual property</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31.8</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effective income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Management of the Company has evaluated the positive and negative
 evidence bearing upon the realizability of its deferred tax assets.
 Management has concluded, in accordance with the applicable
 accounting standards, that it is more likely than not that the
 Company may not realize the benefit of its deferred tax assets.
 Accordingly, the net deferred tax assets have been fully reserved.
 Management reevaluates the positive and negative evidence on an
 annual basis. During the years ended December&#xA0;31, 2016, 2015
 and 2014, the change in the valuation allowance was
 $(48.1)&#xA0;million, $80.1&#xA0;million and $65.5&#xA0;million,
 respectively, for income taxes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 At December&#xA0;31, 2016, the Company had federal and state net
 operating loss carryforwards of approximately $1.9&#xA0;billion and
 $1.3&#xA0;billion available, respectively, to reduce future taxable
 income. The federal net operating loss carryforwards will expire at
 various dates beginning in 2018 and the state net operating loss
 carryforwards have started expiring, starting in the current year
 through various future dates. As a result of the Company&#x2019;s
 initial public offering, an ownership change within the meaning of
 Internal Revenue Code Section&#xA0;382 occurred in August 2004. As
 a result, federal net operating loss and credit carry forwards of
 approximately $216.0&#xA0;million are subject to an annual use
 limitation of approximately $13.0&#xA0;million. The annual
 limitation is cumulative and therefore, if not fully utilized in a
 year can be utilized in future years in addition to the
 Section&#xA0;382 limitation for those years. The federal net
 operating losses generated subsequent to the Company&#x2019;s
 initial public offering in August 2004 are currently not subject to
 any such limitation as there have been no ownership changes since
 August 2004 within the meaning of Internal Revenue Code
 Section&#xA0;382. At December&#xA0;31, 2016, the Company had
 research and development credits of $53.0&#xA0;million and
 $38.5&#xA0;million for federal and state purposes, respectively.
 The federal credits begin to expire in 2024, and the state credits
 may be carried forward indefinitely.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 The Company has evaluated the impact of uncertainty related to
 income taxes on its consolidated financial statements. The
 evaluation of an uncertain tax position is a&#xA0;<font style="WHITE-SPACE: nowrap">two-step</font>&#xA0;process. The first step is
 recognition: the enterprise determines whether it is&#xA0;<font style="WHITE-SPACE: nowrap">more-likely-than-not</font>&#xA0;that a tax position will be
 sustained upon examination, including resolution of any related
 appeals or litigation processes, based on the technical merits of
 the position. In evaluating whether a tax position has met
 the&#xA0;<font style="WHITE-SPACE: nowrap">more-likely-than-not</font>&#xA0;recognition threshold, the
 enterprise should presume that the position will be examined by the
 appropriate taxing authority that would have full knowledge of all
 relevant information. The second step is measurement: a tax
 position that meets the&#xA0;<font style="WHITE-SPACE: nowrap">more-likely-than-not</font>&#xA0;recognition threshold is
 measured to determine the amount of benefit to recognize in the
 financial statements. The tax position is measured at the largest
 amount of benefit that is greater than 50&#xA0;percent likely of
 being realized upon ultimate settlement. Tax positions that
 previously failed to meet the&#xA0;<font style="WHITE-SPACE: nowrap">more-likely-than-not</font>&#xA0;recognition threshold should
 be recognized in the first subsequent financial reporting period in
 which that threshold is met. Previously recognized tax positions
 that no longer meet the&#xA0;<font style="WHITE-SPACE: nowrap">more-likely-than-not</font>&#xA0;recognition threshold should
 be derecognized in the first subsequent financial reporting period
 in which that threshold is no longer met. The Company believes that
 its income tax filing positions and deductions will be sustained on
 audit and does not anticipate any adjustments that will result in a
 material change to its consolidated financial position. Therefore,
 no liabilities for uncertain income tax positions have been
 recorded. Tax years since 2012 remain subject to examination by the
 major tax jurisdictions in which the Company is subject to tax.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840530128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>16. Warrants</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In May 2016, the Company sold in a registered offering an aggregate
 of 9,708,737 shares of common stock together with A Warrants
 exercisable for up to an aggregate of 7,281,553 shares of common
 stock and B Warrants exercisable for up to an aggregate of
 2,427,184 shares of common stock with a total fair value of
 $44.7&#xA0;million. Each of the warrants has an exercise price of
 $7.50 per share. The A Warrants became exercisable upon issuance
 and will expire two years thereafter. The B Warrants will become
 exercisable beginning in May 2017 and will expire 30 months after
 the date of issuance. The shares of common stock and the warrants
 are immediately separable and issued separately. There have been no
 warrants exercised as of December&#xA0;31, 2016.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company determined that the A Warrants require liability
 classification primarily due to a price-protection clause that
 applies in the event of certain dilutive financings. The fair value
 of the A Warrants was recorded as warrant liability in the
 consolidated balance sheet at issuance and is adjusted to fair
 value at each reporting period until exercise or expiration. The
 Company determined that the B Warrants met the criteria for equity
 classification and has accounted for such warrants in additional
 paid in capital.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2016 and May&#xA0;12, 2016, the fair value
 of the A Warrants liability was $7.4&#xA0;million and
 $12.8&#xA0;million, respectively. As of May&#xA0;12, 2016, the fair
 value of the B Warrants at issuance was $5.0&#xA0;million. The fair
 value of the A Warrants liability as of December&#xA0;31, 2016 was
 estimated using a Monte Carlo valuation pricing model with the
 following underlying assumptions: (a)&#xA0;a risk-free interest
 rate of 1.1%; (b) an assumed dividend yield of zero percent;
 (c)&#xA0;an expected term of 1.4 years; and (d)&#xA0;an expected
 volatility of 118%. The fair value of the A Warrants liability as
 of May&#xA0;12, 2016, was estimated using a Monte Carlo valuation
 pricing model with the following underlying assumptions: (a)&#xA0;a
 risk-free interest rate of 0.76%; (b) an assumed dividend yield of
 zero percent; (c)&#xA0;an expected term of 2.0 years; and
 (d)&#xA0;an expected volatility of 95%. The Company assumed a
 probability of a dilutive financing event or an equity event, as
 defined in the agreement, of 10% for the each of the measurement
 periods.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 For the year ended December&#xA0;31, 2016, the Company recognized a
 change in fair value of warrant liability of $5.4&#xA0;million in
 the consolidated statements of operations to reflect the fair value
 adjustments of the A Warrant liability from the date of
 issuance.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840510528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selling, General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>17. Selling, General and Administrative Expenses</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Selling, general and administrative expenses consist of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000">Year Ended
 December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Selling and marketing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,854</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,587</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,074</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,373</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">75,827</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">46,928</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">40,960</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">79,383</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expenses Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SellingGeneralAndAdministrativeExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840522528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>18. Restructuring Charges</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In September&#xA0;2016, the Company initiated a restructuring of
 its organization in order to conserve resources for commercial
 sales and marketing of Afrezza and to align cost of goods sold in
 support of these commercial efforts (2016 Restructuring). In
 connection with the 2016 Restructuring, the Company reduced its
 total workforce by approximately 18% to 155 employees. The Company
 recorded charges of approximately $1.5&#xA0;million, primarily for
 employee severance as well as other related termination benefits.
 The $1.5&#xA0;million of costs associated with the 2016
 Restructuring are included in cost of goods sold, research and
 development and selling, general and administrative in the
 consolidated statements of operations as $0.4&#xA0;million,
 $0.7&#xA0;million and $0.4&#xA0;million, respectively, for the year
 ended December&#xA0;31, 2016. The Company substantially paid out
 the obligation for the 2016 Restructuring in the fourth quarter of
 2016, resulting in a remaining accrual balance for the 2016
 Restructuring of $0.2 million at December&#xA0;31, 2016. The
 Company expects to substantially pay out the remainder of this
 obligation by the first quarter of 2017.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In 2015, the Company initiated a restructuring of the organization
 as a result of its shift to commercial production of Afrezza
 (&#x201C;2015 Restructuring&#x201D;). In connection with the 2015
 Restructuring, the Company reduced its total workforce by
 approximately 26% to 198 employees. The Company recorded charges of
 approximately $6.0&#xA0;million, primarily for employee severance
 as well as other related termination benefits. The
 $6.0&#xA0;million of costs associated with the 2015 Restructuring
 are included in operating expenses for cost of goods sold, research
 and development and selling, general and administrative in the
 consolidated statements of operations as $1.4 million,
 $1.3&#xA0;million and $3.3&#xA0;million, respectively, for the year
 ended December&#xA0;31, 2015. As of December&#xA0;31, 2016 and
 2015, the Company had a remaining accrual balance for the 2015
 Restructuring of $1.2&#xA0;million and $3.0&#xA0;million,
 respectively. Certain of the severance arrangements for executives
 in the 2015 Restructuring were long-term, which the Company expects
 to substantially pay out the remainder of this obligation by the
 third quarter of 2017.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 A reconciliation of beginning and ending liability balances for the
 2016 and 2015 Restructuring charges, which is included in accrued
 expenses and other current liabilities, is as follows (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016<br />
 Restructuring</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015<br />
 Restructuring</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; January 1, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs incurred and charged to expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,040</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,040</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs paid or settled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,012</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,012</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; December 31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs incurred and charged to expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,475</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">560</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,035</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs paid or settled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,266</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,421</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,687</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">209</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,167</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,376</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840530128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected quarterly financial data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected quarterly financial data (unaudited)</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>19. Selected quarterly financial data (unaudited)</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Summarized quarterly financial data for the years ended
 December&#xA0;31, 2016 and 2015, are set forth in the following
 tables:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March&#xA0;31</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June&#xA0;30</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September&#xA0;30</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">162,354</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(24,873</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(29,959</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">126,520</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,976</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss) per share &#x2014; basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.29</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.33</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.32</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.56</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss) per share &#x2014; diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.29</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.33</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.31</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.56</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute basic net income
 (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,771</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,061</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,627</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,676</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute diluted net income
 (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,771</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,061</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96,548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96,510</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(30,658</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(28,910</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,857</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(277,020</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss per share &#x2014; basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.38</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.36</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.39</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.30</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute basic and diluted
 net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,783</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,203</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,039</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">83,862</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Impairment charges of $242.7&#xA0;million were recorded in the
 fourth quarter of 2015 related to long-lived assets, inventory and
 loss on purchase commitments.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In the third quarter of 2016, the Company recognized net
 revenue-collaboration of $161.8&#xA0;million attributable to
 collaboration with Sanofi (See Note 8 &#x2014; Collaboration
 Arrangements).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In the fourth quarter of 2016, the Company recognized net
 revenue-collaboration of $10.2&#xA0;million attributable to
 collaboration with Sanofi and $72.0&#xA0;million gain on
 extinguishment of debt (See Note 8 &#x2014; Collaboration
 Arrangements)</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830326640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <b>20. Subsequent Events</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Reverse Stock Split</i>&#xA0;&#x2014; On September&#xA0;14,
 2016, NASDAQ notified the Company that the bid price of the
 Company&#x2019;s common stock had closed below the required $1.00
 per share for 30 consecutive trading days, and, accordingly, the
 Company did not comply with the applicable NASDAQ minimum bid price
 requirement. The Company was provided 180 calendar days by NASDAQ,
 or until March&#xA0;13, 2017, to regain compliance with this
 requirement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On March&#xA0;1, 2017, the Company held a Special Meeting of
 Stockholders at which the Company&#x2019;s stockholders approved a
 proposal to amend the Company&#x2019;s Amended and Restated
 Certificate of Incorporation to effect a reverse stock split of the
 Company&#x2019;s outstanding common stock at a ratio to be
 determined in the discretion of the Company&#x2019;s board of
 directors and with such reverse stock split to be effected at such
 time and date as determined by the Company&#x2019;s board of
 directors in its sole discretion, and to reduce the number of
 authorized shares of the Company&#x2019;s common stock in a
 corresponding proportion to the reverse stock split, rounded to the
 nearest whole share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 On March&#xA0;1, 2017, following stockholder approval of the
 reverse split proposal, the Company&#x2019;s board of directors
 approved a reverse stock split ratio of&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5.&#xA0;On</font></font>&#xA0;March&#xA0;1, 2017, the
 Company filed with the Secretary of State of the State of Delaware
 a Certificate of Amendment of the Company&#x2019;s Amended and
 Restated Certificate of Incorporation to effect the&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5</font></font>&#xA0;reverse stock split of the
 Company&#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&#xA0;The Company&#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&#xA0;3,
 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 As of the date of this filing, the shares of the Company&#x2019;s
 common stock have maintained a minimum bid closing price of at
 least $1.00 per share for 10 consecutive business days.
 Accordingly, the Company expects to receive a notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that the Company has regained compliance with the
 minimum closing bid price requirement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 <i>Sale of Valencia Facility</i>&#xA0;&#x2014; On January&#xA0;6,
 2017, the Company and Rexford Industrial Realty, L.P.
 (&#x201C;Rexford&#x201D;) entered into an Agreement of Purchase and
 Sale and Joint Escrow Instructions (the &#x201C;Purchase
 Agreement&#x201D;), pursuant to which the Company agreed to sell and
 Rexford agreed to purchase certain parcels of real estate owned by
 the Company in Valencia, California and certain related
 improvements, personal property, equipment, supplies and fixtures
 (collectively, the &#x201C;Property&#x201D;) for $17.3&#xA0;million.
 The sale and purchase of the aforementioned Property for
 $17.3&#xA0;million pursuant to the terms of the Purchase Agreement,
 as amended, was completed on February&#xA0;17, 2017. Net proceeds
 were approximately $16.7&#xA0;million after deducting
 broker&#x2019;s commission and other fees of approximately $624,000
 paid by the Company.&#xA0;In the fourth quarter of 2016 the
 property met the requirements for reclassification from property
 and equipment, net to asset held for sale when it became probable
 that the property would be sold within one year. At that time, an
 analysis of the lower of carrying value which was deemed to be the
 sales price of the property, to fair value less selling costs
 determined a loss of $564,000, which was recorded as a property and
 equipment impairment on the consolidated statement of operations
 for 2016.&#xA0;At December, 31 2016, this property had a carrying
 value of $16.7&#xA0;million and was classified as held for sale.
 The sale of this property will be reflected in the consolidated
 financial statements for the quarter ended March&#xA0;31, 2017.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6842730144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_BusinessPolicyTextBlock', window );">Business</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Business</i> &#x2014; MannKind Corporation and subsidiaries (the
 &#x201C;Company&#x201D;) is a biopharmaceutical company focused on
 the discovery and development of therapeutic products for diseases
 such as diabetes. The Company&#x2019;s only approved product,
 Afrezza, (insulin human [rDNA origin]) inhalation powder, is a
 rapid-acting inhaled insulin that was approved by the U.S. Food and
 Drug Administration (the &#x201C;FDA&#x201D;) on June&#xA0;27, 2014
 to improve glycemic control in adult patients with diabetes.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Basis of Presentation</i> &#x2014; On August&#xA0;11, 2014, the
 Company entered into a license and collaboration agreement (the
 &#x201C;Sanofi License Agreement&#x201D;) with Sanofi-Aventis
 Deutschland GmbH (which subsequently assigned its rights and
 obligations under the agreement to Sanofi-Aventis U.S. LLC
 (&#x201C;Sanofi&#x201D;)), pursuant to which Sanofi was responsible
 for Afrezza global commercial, regulatory and development
 activities for Afrezza.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On January&#xA0;4, 2016, the Company received written notification
 from Sanofi of its election to terminate in its entirety the Sanofi
 License Agreement. The effective date of termination (the
 &#x201C;Termination Date&#x201D;) was April&#xA0;4, 2016, which was
 when the Company assumed responsibility for worldwide development
 and commercialization of Afrezza. Under terms of a transition
 agreement, Sanofi continued to fulfill orders for Afrezza in the
 United States until the Company began distributing MannKind-branded
 Afrezza product to major wholesalers in late July 2016. The Company
 began recognizing commercial product sales revenue when
 MannKind-branded Afrezza was dispensed from pharmacies to patients
 in August 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On November&#xA0;9, 2016, the Company entered into a settlement
 agreement with Sanofi (the &#x201C;Settlement Agreement&#x201D;).
 Under the terms of the Settlement Agreement, the promissory note
 (the &#x201C;Sanofi Loan Facility&#x201D;) between the Company and
 Aventisub LLC (&#x201C;Aventisub&#x201D;), a Sanofi affiliate, was
 terminated, with Aventisub agreeing to forgive the full outstanding
 loan balance of $72.0&#xA0;million, which includes
 $0.5&#xA0;million of previously uncharged costs pursuant to the
 Sanofi License Agreement. Sanofi also agreed to purchase
 $10.2&#xA0;million of insulin from the Company in December 2016
 under an existing insulin put option as well as make a cash payment
 of $30.6&#xA0;million to the Company in early January 2017 as
 acceleration and in replacement of all other payments that Sanofi
 would otherwise have been required to make in the future pursuant
 to the insulin put option, without the Company being required to
 deliver any insulin for such payment. The Company and Sanofi also
 agreed to a general release of potential claims against each
 other.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During their initial transition of the commercial responsibilities
 from Sanofi, the Company utilized a contract sales organization to
 promote Afrezza while the Company focused its internal resources on
 establishing a channel strategy, entering into distribution
 agreements and developing <font style="WHITE-SPACE: nowrap">co-pay</font> assistance programs, a voucher
 program, data agreements and payor relationships. In early 2017,
 the Company recruited their own sales force, which included some of
 the sales reps that previously were employed by the contract sales
 organization. The Company intend to continue the commercialization
 of Afrezza in the United States through their own commercial
 organization. The Company&#x2019;s current strategy for the future
 commercialization of Afrezza outside of the United States, subject
 to receipt of the necessary foreign regulatory approvals, is to
 seek and establish regional partnerships in foreign jurisdictions
 where there are appropriate commercial opportunities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 It has been costly to develop our therapeutic product, conduct
 clinical studies, and market and sell Afrezza. As of and for the
 year ended December&#xA0;31, 2016, the Company has reported an
 accumulated deficit of $2.7&#xA0;billion and has reported negative
 cash flow from operations for each year since inception, except for
 2014, when the Company received the $150.0&#xA0;million upfront
 payment from Sanofi.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2016, the Company&#x2019;s capital resources
 consisted of cash and cash equivalents of $22.9&#xA0;million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &#x201C;Facility Agreement&#x201D;) with Deerfield
 Private Design Fund II, L.P. (Deerfield Private Design Fund) and
 Deerfield Private Design International II, L.P. (collectively,
 &#x201C;Deerfield&#x201D;) and the First Amendment to Facility
 Agreement and Registration Rights Agreement (the &#x201C;First
 Amendment&#x201D;) that resulted in additional sales of an
 additional tranche of notes (the &#x201C;Tranche B notes&#x201D;)
 (see Note 7 &#x2014; Borrowings) requires the Company to maintain at
 least $25.0&#xA0;million, which can be comprised of cash and cash
 equivalents and available borrowings under the loan arrangement,
 dated as of October&#xA0;2, 2007, between the Company and The Mann
 Group LLC (as amended, restated, or otherwise modified as of the
 date hereof, &#x201C;the Mann Group Loan Arrangement&#x201D;), as of
 the last day of each fiscal quarter.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Additional funding sources that are, or in certain circumstances
 may be available to the Company, include approximately
 $30.1&#xA0;million principal amount of available borrowings under
 The Mann Group Loan Arrangement. A portion of these available
 borrowings may be used to capitalize accrued interest into
 principal, upon mutual agreement of the parties, as it becomes due
 and payable under The Mann Group Loan Arrangement (see Note 6
 &#x2014; Related-party Arrangements). The Company cannot provide
 assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 will need to raise additional capital, whether through a sale of
 equity or debt securities, a strategic business collaboration with
 a pharmaceutical company, the establishment of other funding
 facilities, licensing arrangements, asset sales or other means, in
 order to continue the commercialization of Afrezza and development
 of other product candidates and to support its other ongoing
 activities. The Company cannot provide assurances that such
 additional capital will be available on acceptable terms or at all.
 These factors raise substantial doubt about the Company&#x2019;s
 ability to continue as a going concern. The financial statements do
 not include any adjustments that might result from the outcome of
 this uncertainty.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On September&#xA0;14, 2016, the Company received notice from the
 Listing Qualifications Department of the NASDAQ Stock Market
 indicating that, for the previous 30 consecutive business days, the
 bid price for the common stock closed below the minimum $1.00 per
 share required for continued inclusion on The NASDAQ Global Market.
 The notification letter stated that the Company would be afforded
 180 calendar days, or until March&#xA0;13, 2017, to regain
 compliance with the minimum bid price requirement. In order to
 regain compliance, shares of the Company&#x2019;s common stock must
 maintain a minimum bid closing price of at least $1.00 per share
 for a minimum of 10 consecutive business days.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Reverse Stock Split</i> &#x2014; On March&#xA0;1, 2017, following
 stockholder approval, the Company&#x2019;s board of directors
 approved a reverse stock split ratio of <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5.&#xA0;On</font></font> March&#xA0;1,
 2017, the Company filed with the Secretary of State of the State of
 Delaware a Certificate of Amendment of the Company&#x2019;s Amended
 and Restated Certificate of Incorporation to effect the
 <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-5</font></font> reverse stock split of
 the Company&#x2019;s outstanding common stock and to reduce the
 authorized number of shares of the Company&#x2019;s common stock
 from 700,000,000 to 140,000,000 shares.&#xA0;The Company&#x2019;s
 common stock began trading on The NASDAQ Global Market on a
 split-adjusted basis when the market opened on March&#xA0;3,
 2017.&#xA0;See Note 20 &#x2014; Subsequent Events for further
 information. As a result, all common stock share amounts included
 in these consolidated financial statements have been retroactively
 reduced by a factor of five, and all common stock per share amounts
 have been increased by a factor of five, with the exception of the
 Company&#x2019;s common stock par value.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Principles of Consolidation</i> &#x2014; The consolidated
 financial statements include the accounts of the Company and its
 wholly-owned subsidiaries. Intercompany balances and transactions
 have been eliminated.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Segment Information</i> &#x2014; Operating segments are
 identified as components of an enterprise about which separate
 discrete financial information is available for evaluation by the
 chief operating decision-maker in making decisions regarding
 resource allocation and assessing performance. To date, the Company
 has viewed its operations and manages its business as one segment
 operating in the United States of America.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Financial Statement Estimates</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Financial Statement Estimates</i> &#x2014; The preparation of
 financial statements in conformity with accounting principles
 generally accepted in the United States of America (GAAP) requires
 management to make estimates and assumptions that affect the
 amounts reported in the financial statements and accompanying
 notes. Actual results could differ from those estimates. Management
 considers many factors in selecting appropriate financial
 accounting policies, and in developing the estimates and
 assumptions that are used in the preparation of the financial
 statements. Management must apply significant judgment in this
 process. The more significant estimates reflected in these
 accompanying consolidated financial statements include revenue
 recognition, assessing long-lived assets for impairment, accrued
 expenses, including clinical study expenses, inventory
 recoverability, valuation of the facility financing obligation,
 loss on purchase commitment, warrant liability, milestone rights,
 stock-based compensation and the determination of the provision for
 income taxes and corresponding deferred tax assets and liabilities
 and any valuation allowance recorded against net deferred tax
 assets.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Reclassifications</i> &#x2014; Certain amounts from previous
 periods have been reclassified to conform to the 2016 presentation.
 Specifically, accrued interest &#x2014; note payable to principal
 stockholder has been reclassified from the previously reported
 classification of other liabilities in the accompanying
 consolidated balance sheets. Additionally, the remaining balance
 from the previously reported classification of other liabilities is
 now identified as milestone rights liability, and is disclosed as a
 separate line item on the consolidated statements of cash flows.
 Additionally, on the consolidated statement of operations, product
 manufacturing has been renamed to cost of goods sold. The Company
 also reclassified (gain) loss on foreign currency translation from
 the previously reported classification of product manufacturing in
 the accompanying consolidated statements of operations.
 Additionally, certain balances from prepaid expenses and other
 current assets were reclassed to (gain) loss on foreign currency
 translation in the consolidated statements of cash flows.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Revenue Recognition</i> &#x2014; Revenue is recognized when the
 four basic criteria of revenue recognition are met: (1) persuasive
 evidence that an arrangement exists; (2) delivery has occurred or
 services have been rendered; (3) the fee is fixed or determinable;
 and (4) collectability is reasonably assured. When the accounting
 requirements for revenue recognition are not met, the Company
 defers the recognition of revenue by recording deferred revenue on
 the consolidated balance sheets until such time that all criteria
 are met. To date, the Company has had revenue from collaborations,
 commercial sales of Afrezza, and from sales of bulk insulin, which
 are described more fully below.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleElementArrangements', window );">Revenue Recognition - Net Revenue - Collaboration</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Revenue Recognition &#x2014; Net Revenue &#x2014; Collaborations
 &#x2014;</i> The Company enters into collaborations under which we
 must perform certain obligations and we receive periodic payments.
 We evaluate the collaborations under the multiple element revenue
 recognition accounting guidance. Revenue arrangements with multiple
 elements are divided into separate units of accounting if certain
 criteria are met, including whether the delivered elements have
 stand-alone value to the customer. When deliverables are separable,
 consideration received is allocated to the separate units of
 accounting based on the relative selling price of each deliverable
 and the appropriate revenue recognition principles are applied to
 each unit.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The assessment of multiple element arrangements requires judgment
 in order to determine the appropriate units of accounting and the
 points in time that, or periods over which, revenue should be
 recognized. The terms of and the accounting for the Company&#x2019;s
 collaborations are described more fully in Note 8 &#x2014;
 Collaboration Arrangements.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesOfGoods', window );">Revenue Recognition - Net Revenue - Commercial Product Sales</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Revenue Recognition &#x2014; Net Revenue &#x2014; Commercial
 Product Sales &#x2014;</i> Between July&#xA0;1, 2016 and
 December&#xA0;15, 2016, the Company sold Afrezza to Integrated
 Commercialization Solutions Direct (ICS) and title and risk of loss
 transferred to ICS upon shipment. After December&#xA0;15, 2016, ICS
 became a third party logistics provider and stopped taking title
 and risk of loss upon shipment of Afrezza to ICS. The Company sells
 Afrezza in the United States to wholesale pharmaceutical
 distributors through ICS, and ultimately to retail pharmacies,
 which are collectively referred to as &#x201C;customers&#x201D;.</p>
 <p style="font-size:1px;margin-top:6px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company provides the right of return to ICS (through
 December&#xA0;15, 2016) and its wholesale distributors and, through
 them, to its retail pharmacy customers for unopened product for a
 period beginning six months prior to and ending twelve months after
 its expiration date. Once the product has been prescribed and
 dispensed to the patient, any right of return ceases to exist.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Given the Company&#x2019;s limited sales history for Afrezza, the
 Company cannot reliably estimate expected returns of the product at
 the time of shipment into the distribution channel. Accordingly,
 the Company defers recognition of revenue on Afrezza product
 shipments until the right of return no longer exists, which occurs
 at the earlier of the time Afrezza is dispensed from pharmacies to
 patients or expiration of the right of return. The Company
 recognizes revenue based on Afrezza patient prescriptions dispensed
 as estimated by syndicated data provided by a third party. The
 Company also analyzes additional data points to ensure that such
 third-party data is reasonable including data related to inventory
 movements within the channel and ongoing prescription demand.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 For the year ended December&#xA0;31, 2016, net revenue from
 commercial product sales consisted of $1.9&#xA0;million of net
 sales of Afrezza dispensed to patients. As of December&#xA0;31,
 2016, the Company recorded $3.4&#xA0;million in deferred revenue on
 its consolidated balance sheet, of which $1.6&#xA0;million (net of
 estimated <font style="white-space:nowrap"><font style="white-space:nowrap">gross-to-net</font></font> adjustments)
 represents product shipped to the Company&#x2019;s third-party
 logistics provider and wholesale distributors, but not yet
 dispensed to patients. The difference represents deferred revenue
 from bulk insulin sales, which is described more fully under the
 heading <i>Revenue Recognition &#x2014; Revenue &#x2014; Bulk Insulin
 Sales</i> below.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_GrossToNetAdjustmentsPolicyTextBlock', window );">Gross-to-net Adjustments</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i><font style="white-space:nowrap"><font style="white-space:nowrap">Gross-to-net</font></font> Adjustments
 &#x2014;</i> Estimated <font style="white-space:nowrap"><font style="white-space:nowrap">gross-to-net</font></font> adjustments for
 Afrezza include wholesaler distribution fees, prompt pay discounts,
 estimated rebates and patient discount and <font style="white-space:nowrap">co-pay</font> assistance programs, and are
 based on estimated amounts owed or to be claimed on the related
 sales. These estimates take into consideration the terms of the
 Company&#x2019;s agreements with its customers and the levels of
 inventory within the distribution and retail channels that may
 result in future rebates or discounts taken. In certain cases, such
 as patient support programs, the Company recognizes the cost of
 patient discounts as a reduction of revenue based on estimated
 utilization. If actual future results vary, the Company may need to
 adjust these estimates, which could have an effect on product
 revenue in the period of adjustment. The Company records product
 sales deductions in the consolidated statements of operations at
 the time product revenue is recognized. At December&#xA0;31, 2016,
 year to date total <font style="white-space:nowrap"><font style="white-space:nowrap">gross-to-net</font></font> adjustments were
 approximately $0.8&#xA0;million, which represents 30% of gross
 revenue from product sales.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WholesalerDistributionFeesPolicyTextBlock', window );">Wholesaler Distribution Fees</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Wholesaler Distribution Fees &#x2014;</i> The Company pays
 distribution fees to certain wholesale distributors based on
 contractually determined rates. The Company accrues the
 distribution fees on shipment to the respective wholesale
 distributors and recognizes the distribution fees as a reduction of
 revenue in the same period the related revenue is recognized.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDiscounts', window );">Prompt Pay Discounts</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Prompt Pay Discounts &#x2014;</i> The Company offers cash
 discounts to its customers, generally 2% of the sales price, as an
 incentive for prompt payment. The Company accounts for cash
 discounts by reducing accounts receivable by the prompt pay
 discount amount and recognizes the discount as a reduction of
 revenue in the same period the related revenue is recognized.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Rebates &#x2014;</i> The Company participates in federal and
 state government-managed Medicare and Medicaid rebate programs and
 intends to pursue participation in certain other qualifying federal
 and state government programs whereby discounts and rebates are
 provided to participating federal and state government entities.
 Rebates provided through these other qualifying programs are
 included in the Medicaid and Medicare rebate accrual. The Company
 accounts for these rebates by establishing an accrual equal to the
 estimate of rebate claims attributable to a sale and determines its
 estimate of the rebates accrual based on historical payor data
 provided by a third-party vendor along with additional data
 including a forecasted participation rate for Medicare and
 Medicaid. From that data, as well as input received from
 MannKind&#x2019;s commercial team, an estimated participation rate
 for Medicare and Medicaid is determined and applied at the mandated
 rate for those sales. Any new information regarding changes in the
 programs&#x2019; regulations and guidelines or any changes in the
 Company&#x2019;s government price reporting calculations that would
 impact the amount of the rebates will also be taken into account in
 determining or modifying the appropriate reserve. The time period
 between the date the product is sold into the channel and the date
 such rebates are paid ranges from approximately six to nine months.
 As such, continuous monitoring of these estimates are performed on
 a periodic basis and if necessary, adjusted to reflect new facts
 and circumstances. Rebates are recognized as a reduction of revenue
 in the period the related revenue is recognized.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock', window );">Patient Discount and Co-Pay Assistance Programs</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Patient Discount and <font style="white-space:nowrap">Co-Pay</font> Assistance Programs &#x2014;</i>
 The Company offers discount card programs to patients for Afrezza
 in which patients receive discounts on their prescriptions or a
 reduction in their <font style="white-space:nowrap">co-pay</font>
 amounts that are reimbursed by the Company. The Company estimates
 the total amount that will be redeemed based on levels of inventory
 in the distribution and retail channels and recognizes the discount
 as a reduction of revenue in the same period the related revenue is
 recognized.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Returns</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Product Returns &#x2014;</i> The Company does not provide a
 reserve for product returns of sales of Afrezza due to its revenue
 recognition policy of deferring recognition of revenue on product
 shipments of Afrezza until the right of return no longer
 exists.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_RevenueRecognitionBulkSalesPolicyTextBlock', window );">Revenue Recognition - Revenue - Bulk Insulin Sales</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Revenue Recognition &#x2014; Revenue &#x2014; Bulk Insulin Sales
 &#x2014;</i> In 2016, revenue from bulk insulin sales was recognized
 after delivery and customer acceptance of the bulk insulin. When
 the accounting requirements for revenue recognition of bulk insulin
 sales are not met, the Company defers recognition of revenue by
 recording deferred revenue on the balance sheet until such time
 that all criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Deferred revenue includes $1.8&#xA0;million received from a sale of
 surplus bulk insulin to a third party that was delivered prior to,
 but accepted after, December&#xA0;31, 2016. No deferred cost was
 recognized related to this sale because the inventory was written
 off on December&#xA0;31, 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Deferred costs</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Deferred Costs from Collaboration &#x2014;</i> Deferred costs
 from collaboration represents the costs of product manufactured and
 sold to Sanofi, as well as certain direct costs associated with a
 firm purchase commitment entered into in connection with the
 collaboration with Sanofi. During the third quarter of 2016, the
 costs related to the Sanofi product sales were recognized as costs
 of revenue &#x2014; collaboration in the consolidated statements of
 operations, as related revenue was recognized at that time.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Deferred Costs from Commercial Product Sales &#x2014;</i>
 Deferred costs from commercial product sales represents the cost of
 product (including labor, overhead and costs to ship to third party
 logistics) shipped to ICS and wholesale distributors, but not yet
 dispensed by pharmacies to patients.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Cost of Goods Sold &#x2014;</i> Cost of goods sold includes the
 costs related to Afrezza product dispensed by pharmacies to
 patients as well as under-absorbed labor and overhead and inventory
 write-offs, which are recorded as expenses in the period in which
 they are incurred, rather than as a portion of the inventory
 cost.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Cash and Cash Equivalents</i> &#x2014; The Company considers all
 highly liquid investments with original or remaining maturities of
 90 days or less at the time of purchase, that are readily
 convertible into cash to be cash equivalents. As of
 December&#xA0;31, 2016 and 2015, cash equivalents were comprised of
 money market accounts with maturities less than 90 days from the
 date of purchase.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Concentration of Credit Risk</i> &#x2014; Financial instruments
 which potentially subject the Company to concentration of credit
 risk consist of cash and cash equivalents. Cash and cash
 equivalents are held in high credit quality institutions. Cash
 equivalents consist of interest-bearing money market accounts,
 which are regularly monitored by management.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Accounts Receivable and Allowance for Doubtful Accounts</i>
 &#x2014; Accounts receivable are recorded at the invoiced amount and
 are not interest bearing. The Company maintains an allowance for
 doubtful accounts for estimated losses resulting from the inability
 of its customers to make required payments. The Company makes
 ongoing assumptions relating to the collectability of its accounts
 receivable in its calculation of the allowance for doubtful
 accounts. As of December&#xA0;31, 2016 and 2015, there was no
 allowance for doubtful accounts.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Inventories</i> &#x2014; Inventories are stated at the lower of
 cost or net realizable value. The Company determines the cost of
 inventory using the <font style="white-space:nowrap">first-in,</font> <font style="white-space:nowrap">first-out,</font> or FIFO, method. The Company
 capitalizes inventory costs associated with the Company&#x2019;s
 products based on management&#x2019;s judgment that future economic
 benefits are expected to be realized; otherwise, such costs are
 expensed as cost of goods sold. The Company periodically analyzes
 its inventory levels to identify inventory that may expire or has a
 cost basis in excess of its estimated realizable value, and writes
 down such inventories as appropriate. In addition, the
 Company&#x2019;s products are subject to strict quality control and
 monitoring which the Company performs throughout the manufacturing
 process. If certain batches or units of product no longer meet
 quality specifications or become obsolete due to expiration, the
 Company will record a charge to write down such unmarketable
 inventory to its estimated net realizable value.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company analyzed its inventory levels to identify inventory
 that may expire or has a cost basis in excess of its estimated
 realizable value. The Company performed an assessment of projected
 sales and evaluated the lower of cost or net realizable value and
 the potential excess inventory on hand at December&#xA0;31, 2016
 and 2015. As a result of these assessments, the Company recorded a
 $0.2&#xA0;million charge at December&#xA0;31, 2016 to <font style="white-space:nowrap">write-off</font> inventory that will expire
 prior to sale. At December&#xA0;31, 2015, the Company recorded a
 charge of $39.3&#xA0;million to record the inventory raw materials
 on hand at the lower of cost or net realizable value, inventory
 expiry and <font style="white-space:nowrap">write-off</font> other
 inventory related assets.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">State Research and Development Credit Exchange Receivable</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>State Research and Development Credit Exchange Receivable</i>
 &#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for foregoing the
 carryforward of the research and development credits. The program
 provides for an exchange of research and development income tax
 credits for cash equal to 65% of the value of corporation tax
 credit available for exchange. Estimated amounts receivable under
 the program are recorded as a reduction of research and development
 expenses. These amounts are included in prepaid expenses and other
 current assets on the consolidated balance sheets.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Prepaid Expenses and Other Current Assets &#x2014;</i> As of
 December&#xA0;31, 2016 and 2015, prepaid expenses and other current
 assets primarily consist of prepaid expenses for goods and services
 to be received and includes a certificate of deposit for $350,000
 as collateral as required by an agreement with the bank.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SaleOfIntellectualPropertyPolicyTextBlock', window );">Sale of intellectual property</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Sale of intellectual property &#x2014;</i> On July&#xA0;18, 2014,
 the Company entered into an assignment agreement with a third party
 whereby the third party acquired all proprietary rights, technology
 and <font style="white-space:nowrap">know-how</font> that related
 to a small molecule inhibitor compound and all <font style="white-space:nowrap">pre-clinical</font> data and results related
 thereto. Under the terms of the assignment agreement, the Company
 received total consideration of $9.3&#xA0;million and accrued
 $1.4&#xA0;million in expense for a net amount of $7.9&#xA0;million
 recorded as other income. In 2015, the Company recorded other
 income of $1.4&#xA0;million related to the relief of the
 $1.4&#xA0;million accrual for expenses associated with the sale of
 intellectual property related to oncology in 2014, which was
 subsequently resolved without payment.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AssetsHeldForSalePolicyTextBlock', window );">Assets Held for Sale</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Assets Held for Sale &#x2014;</i> The Company classifies
 long-lived assets anticipated to be sold within one year as held
 for sale at the lower of their carrying value or fair value less
 estimated selling costs.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Property and Equipment</i> &#x2014; Property and equipment are
 depreciated using the straight-line method over the estimated
 useful lives of the related assets. Leasehold improvements are
 amortized over the term of the lease or the service lives of the
 improvements, whichever is shorter. Maintenance and repairs are
 expensed as incurred. Assets under construction are not depreciated
 until placed into service.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Impairment of Long-Lived Assets</i> &#x2014; The Company
 evaluates long-lived assets for impairment whenever events or
 changes in circumstances indicate that the carrying value of an
 asset may not be recoverable. Assets are considered to be impaired
 if the carrying value may not be recoverable.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 If the Company believes an asset to be impaired, the impairment
 recognized is the amount by which the carrying value of the asset
 exceeds the fair value of the asset. Fair value is determined using
 the market, income or cost approaches as appropriate for the asset.
 Any write-downs are treated as permanent reductions in the carrying
 amount of the asset and an operating loss would be recognized.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company recorded an asset impairment of $1.3 million and $140.4
 million for the years ended December 31, 2016 and 2015,
 respectively. No asset impairment was recognized during the year
 ended December 31, 2014 (see Note 4 &#x2014; Property and Equipment
 and Note 20 <i>&#x2014;</i> Subsequent Events).</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock', window );">Recognized Loss on Purchase Commitments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Recognized Loss on Purchase Commitments &#x2014;</i> The Company
 assesses whether losses on long term purchase commitments should be
 accrued. Losses that are expected to arise from firm, <font style="WHITE-SPACE: nowrap">non-cancellable,</font> commitments for the
 future purchases of inventory items are recognized unless
 recoverable. The recognized loss on purchase commitments is reduced
 as inventory items are purchased. Changes in estimates are recorded
 in the relevant period in (gain) loss on purchase commitments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the year ended December&#xA0;31, 2015, the Company recorded
 a loss on purchase commitments amounting to $116.2&#xA0;million
 offset by $50&#xA0;million expected to be recovered from Sanofi,
 primarily due to a long term purchase commitment for insulin raw
 materials. During the year ended December&#xA0;31, 2016, the
 balance was adjusted for the recovery received from Sanofi, current
 purchases on the contracts and a reduction in the recognized loss
 related to amendments to purchase contracts. No new contracts were
 identified in 2016 requiring a new loss on purchase commitment
 accrual.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Milestone Rights Liability</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Milestone Rights Liability</i> &#x2014; On July&#xA0;1, 2013, in
 conjunction with the execution of the Facility Agreement, the
 Company issued Milestone Rights to Deerfield whereby the Company
 agreed to provide Deerfield with <font style="white-space:nowrap">pre-specified</font> Milestone Payments upon
 the achievement of 13 specific Milestone Events related to the
 commercial release and future cumulative net sales of Afrezza. The
 Company analyzed the Milestone Rights and determined that the
 agreement does not meet the definition of a freestanding
 derivative. Since the Company has not elected to apply the fair
 value option to the Milestone Rights Purchase Agreement, the
 Company recorded the Milestone Rights at their estimated initial
 fair value and accounted for the Milestone Rights as a
 liability.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The initial fair value estimate of the Milestone Rights was
 calculated using the income approach in which the cash flows
 associated with the specified contractual payments were adjusted
 for both the expected timing and the probability of achieving the
 milestones and discounted to present value using a selected market
 discount rate. The expected timing and probability of achieving the
 milestones was developed with consideration given to both internal
 data, such as progress made to date and assessment of criteria
 required for achievement, and external data, such as market
 research studies. The discount rate was selected based on an
 estimation of required rate of returns for similar investment
 opportunities using available market data. The Milestone Rights
 liability will be remeasured as the specified milestone events are
 achieved. Specifically, as each milestone event is achieved, the
 portion of the initially recorded Milestone Rights liability that
 pertains to the milestone event being achieved, will be remeasured
 to the amount of the specified related milestone payment. The
 resulting change in the balance of the Milestone Rights liability
 due to remeasurement will be recorded in the Company&#x2019;s
 consolidated statements of operations as interest expense.
 Furthermore, the Milestone Rights liability will be reduced upon
 the settlement of each milestone payment. As a result, each
 milestone payment would be effectively allocated between a
 reduction of the recorded Milestone Rights liability and an expense
 representing a return on a portion of the Milestone Rights
 liability paid to the investor for the achievement of the related
 milestone event (see Note&#xA0;7 &#x2014; Borrowings). As of
 December&#xA0;31, 2016, the remaining liability balance is
 $8.9&#xA0;million.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Fair Value of Financial Instruments</i> &#x2014; The Company
 utilizes fair value measurement guidance to value its financial
 instruments. The guidance includes a definition of fair value,
 prescribes methods for measuring fair value, establishes a fair
 value hierarchy based on the inputs used to measure fair value and
 expands disclosures about the use of fair value measurements. The
 valuation techniques utilized are based upon observable and
 unobservable inputs. Observable inputs reflect market data obtained
 from independent sources, while unobservable inputs reflect
 internal market assumptions. These two types of inputs create the
 following fair value hierarchy:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 1&#xA0;&#x2014;&#xA0;Quoted prices for identical instruments
 in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 2&#xA0;&#x2014;&#xA0;Quoted prices for similar instruments in
 active markets; quoted prices for identical or similar instruments
 in markets that are not active; and model-derived valuations whose
 inputs are observable or whose significant value drivers are
 observable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 3&#xA0;&#x2014;&#xA0;Significant inputs to the valuation model
 are unobservable.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Income Taxes</i> &#x2014; The provisions for federal, foreign,
 state and local income taxes are calculated on <font style="white-space:nowrap">pre-tax</font> income based on current tax law
 and include the cumulative effect of any changes in tax rates from
 those used previously in determining deferred tax assets and
 liabilities. Deferred income tax assets and liabilities are
 measured using enacted tax rates expected to apply to taxable
 income in the year in which the temporary differences are expected
 to be recovered or settled. A valuation allowance is recorded to
 reduce net deferred income tax assets to amounts that are more
 likely than not to be realized.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Income tax positions are considered for uncertainty. The Company
 believes that its income tax filing positions and deductions will
 be sustained on audit and does not anticipate any adjustments that
 will result in a material change to its financial position.
 Therefore, no liabilities for uncertain income tax positions have
 been recorded. If a tax position does not meet the minimum
 statutory threshold to avoid payment of penalties, the Company
 recognizes an expense for the amount of the penalty in the period
 the tax position is claimed in the tax return of the Company. The
 Company recognizes interest accrued related to unrecognized tax
 benefits in income tax expense, if any. Penalties, if probable and
 reasonably estimable, are recognized as a component of income tax
 expense.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Significant management judgment is involved in determining the
 provision for income taxes, deferred tax assets, deferred tax
 liabilities, and any valuation allowance recorded against deferred
 tax assets. Due to uncertainties related to the realization of the
 Company&#x2019;s deferred tax assets as a result of its history of
 operating losses, a full valuation allowance has been established
 against the total deferred tax asset balance. The valuation
 allowance is based on management&#x2019;s estimates of taxable
 income by jurisdiction in which the Company operates and the period
 over which deferred tax assets will be recoverable. In the event
 that actual results differ from these estimates or the Company
 adjusts these estimates in future periods, a change in the
 valuation allowance may be needed.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Contingencies</i> &#x2014; The Company records a loss contingency
 for a liability when it is both probable that a liability has been
 incurred and the amount of the loss can be reasonably estimated.
 These accruals represent management&#x2019;s best estimate of
 probable loss. Disclosure also is provided when it is reasonably
 possible that a loss will be incurred or when it is reasonably
 possible that the amount of a loss will exceed the recorded
 provision. On a quarterly basis, the Company reviews the status of
 each significant matter and assesses its potential financial
 exposure. Significant judgment is required in both the
 determination of probability and the determination as to whether an
 exposure is reasonably estimable. Because of uncertainties related
 to these matters, accruals are based only on the best information
 available at the time. As additional information becomes available,
 the Company reassesses the potential liability related to pending
 claims and litigation and may revise its estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Stock-Based Compensation</i> &#x2014; As of December&#xA0;31,
 2016, the Company had three active stock-based compensation plans,
 which are described more fully in Note 12 &#x2014; Stock Award
 Plans. The Company accounts for all share-based payments to
 employees, including grants of stock awards and the compensatory
 elements of the employee stock purchase plan. All share-based
 payments to employees, including grants of stock options,
 restricted stock units, performance-based awards and the
 compensatory elements of employee stock purchase plans, are
 recognized in the consolidated statements of operations based upon
 the fair value of the awards at the grant date. The Company uses
 the Black-Scholes option valuation model to estimate the grant date
 fair value of employee stock options and the compensatory elements
 of employee stock purchase plans. Option valuation models require
 the input of assumptions, including the expected life of the
 stock-based awards, the estimated stock price volatility, the
 risk-free interest rate and the expected dividend yield. The
 expected volatility assumption is based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Restricted
 stock units are valued based on the market price on the grant date.
 The Company evaluates stock awards with performance conditions as
 to the probability that the performance conditions will be met and
 estimates the date at which the performance conditions will be met
 in order to properly recognize stock-based compensation expense
 over the requisite service period.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Warrants</i> &#x2014; The Company has issued warrants to purchase
 shares of its common stock. The Company accounts for its warrants
 as either equity or liabilities based upon the characteristics and
 provisions of each instrument and evaluation of sufficient
 authorized shares available to satisfy the obligations. Warrants
 classified as derivative liabilities are recorded on the
 Company&#x2019;s consolidated balance sheets at their fair value on
 the date of issuance and are revalued at each subsequent balance
 sheet date, with fair value changes recognized in the consolidated
 statements of operations. The Company estimates the fair value of
 its derivative liabilities using a third party valuation analysis
 that utilizes a Monte Carlo pricing valuation model and assumptions
 that are based on the individual characteristics of the warrants or
 instruments on the valuation date, as well as expected volatility,
 expected life, yield and a risk-free interest rate. The expected
 volatility assumption is primarily based on an assessment of the
 historical volatility, with consideration of implied volatility,
 derived from an analysis of historical trade activity. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not <font style="WHITE-SPACE: nowrap">re-measured</font> in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Comprehensive Income (Loss)</i> &#x2014; Other comprehensive
 income (loss) requires that all components of comprehensive income
 (loss) to be reported in the financial statements in the period in
 which they are recognized. Other comprehensive income (loss)
 includes certain changes in stockholders&#x2019; equity that are
 excluded from net income (loss). Specifically, the Company includes
 unrealized gains and losses on foreign exchange translation in
 accumulated other comprehensive loss on the consolidated balance
 sheets.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Research and Development Expenses</i> &#x2014; Research and
 development expenses consist of costs associated with the clinical
 trials of the Company&#x2019;s product candidates, manufacturing
 supplies and other development materials, compensation and other
 expenses for research and development personnel, costs for
 consultants and related contract research, facility costs, and
 depreciation. Research and development costs, which are net of any
 tax credit exchange recognized for the Connecticut state research
 and development credit exchange program, are expensed as incurred.
 The Company began commercial manufacturing in the latter part of
 the fourth quarter of 2014. Commercial manufacturing costs incurred
 in the fourth quarter of 2014 were included in research and
 development expense and were immaterial for the year ended
 December&#xA0;31, 2014.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepurchaseAndResaleAgreementsPolicy', window );">State Research and Development Credit Exchange Receivable</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>State Research and Development Credit Exchange Receivable</i>
 &#x2014; The State of Connecticut provides certain companies with
 the opportunity to exchange certain research and development income
 tax credit carryforwards for cash in exchange for forgoing the
 carryforward of the research and development income tax credits.
 The program provides for an exchange of research and development
 income tax credits for cash equal to 65% of the value of
 corporation tax credit available for exchange. Estimated amounts
 receivable under the program are recorded as a reduction of
 research and development expenses. During the years ended
 December&#xA0;31, 2016, 2015 and 2014, research and development
 expenses were offset by research and development tax credits of
 $246,000, $743,000 and $816,000, respectively.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClinicalTrialExpensePolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Clinical Trial Expenses</i> &#x2014; Clinical trial expenses,
 which are reflected in research and development expenses in the
 accompanying consolidated statements of operations, result from
 obligations under contracts with vendors, consultants and clinical
 site agreements in connection with conducting clinical trials. The
 financial terms of these contracts are subject to negotiations
 which vary from contract to contract and may result in payment
 flows that do not match the periods over which materials or
 services are provided to the Company under such contracts. The
 appropriate level of trial expenses are reflected in the
 Company&#x2019;s consolidated financial statements by matching
 period expenses with period services and efforts expended. These
 expenses are recorded according to the progress of the trial as
 measured by patient progression and the timing of various aspects
 of the trial. Clinical trial accrual estimates are determined
 through discussions with internal clinical personnel and outside
 service providers as to the progress or state of completion of
 trials, or the services completed. Service provider status is then
 compared to the contractually obligated fee to be paid for such
 services. During the course of a clinical trial, the Company may
 adjust the rate of clinical expense recognized if actual results
 differ from management&#x2019;s estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Interest Expense</i> &#x2014; Interest costs are expensed as
 incurred, except to the extent such interest is related to
 construction in progress, in which case interest is capitalized.
 Interest cost capitalized for the years ended December&#xA0;31,
 2015 and 2014 was $0.1&#xA0;million and $0.8&#xA0;million,
 respectively. There were no capitalized interest costs for the year
 ended December&#xA0;31, 2016.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Net Income (Loss) Per Share of Common Stock</i> &#x2014; Basic
 net income (loss) per share excludes dilution for potentially
 dilutive securities and is computed by dividing net income (loss)
 by the weighted average number of common shares outstanding during
 the period. Diluted net income (loss) per share reflects the
 potential dilution under the treasury method that could occur if
 securities or other contracts to issue common stock were exercised
 or converted into common stock. For periods where the Company has
 presented a net loss, potentially dilutive securities are excluded
 from the computation of diluted net loss per share as they would be
 antidilutive.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Recently Issued Accounting Standards</i> &#x2014; From time to
 time, new accounting pronouncements are issued by the Financial
 Accounting Standards Board (FASB) or other standard setting bodies
 that are adopted by the Company as of the specified effective date.
 Unless otherwise discussed, the Company believes that the impact of
 recently issued standards that are not yet effective will not have
 a material impact on the Company&#x2019;s consolidated financial
 position or results of operations upon adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In May 2014, the FASB issued Accounting Standards Update (ASU)
 <font style="WHITE-SPACE: nowrap">No.&#xA0;2014-09,</font>
 <i>Revenue from Contracts with Customers (Topic 606)</i>, which
 requires an entity to recognize the amount of revenue when promised
 goods or services are transferred to customers in an amount that
 reflects the consideration that is expected to be received for
 those goods or services. This new guidance supersedes previous
 revenue recognition requirements, along with most existing
 industry-specific guidance. In August 2015, the FASB issued ASU
 <font style="WHITE-SPACE: nowrap">2015-14,</font> <i>Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date</i>, which delayed the effective date of the new standard from
 January&#xA0;1, 2017 to January&#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In 2016 the FASB has issued additional
 ASUs which clarify certain aspects of the new guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company will adopt the new guidance for the year beginning
 January&#xA0;1, 2018. The Company has the option to either apply
 the new guidance retrospectively for all prior reporting periods
 presented (full retrospective) or retrospectively with the
 cumulative effect of initially applying the guidance recognized at
 the date of initial application (modified retrospective). The
 Company currently anticipates it will apply the new guidance using
 the modified retrospective approach with the cumulative effect of
 initial application recognized as of January&#xA0;1, 2018. The
 Company plans to continue analyzing the potential impacts of the
 application throughout 2017 and, depending on factors that may
 impact the results, could elect to apply the new guidance on a full
 retrospective basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Currently, for commercial sales of Afrezza, the Company has limited
 sales and returns history, and as such, is unable to reliably
 estimate expected returns of the product at the time of shipment
 into the distribution channel. Accordingly, the Company defers
 recognition of revenue on Afrezza product shipments until the right
 of return no longer exists, which occurs at the earlier of the time
 Afrezza is dispensed from pharmacies to patients or expiration of
 the right of return. The Company recognizes revenue based on
 Afrezza patient prescriptions dispensed, a sell-through model, as
 estimated by syndicated data provided by a third party. The Company
 also analyzes additional data points to ensure that such
 third-party data is reasonable, including data related to inventory
 movements within the channel and ongoing prescription demand.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Upon adoption of the new guidance, the Company expects that it will
 move from its current sell-through model to a <font style="WHITE-SPACE: nowrap">sell-to</font> model for revenue related to
 commercial sales of Afrezza and will record revenue at the time
 title and risk of loss passes to its distributors (generally at
 shipment or delivery to the distributors) along with an estimate of
 potential returns as variable consideration. The Company also
 anticipates that its ability to estimate potential returns will
 improve with an additional 12 months of sales history that it will
 have obtained by January&#xA0;1, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, the Company has historically entered into
 collaborative agreements with third-parties under which periodic
 payments have been received. Revenue recognition for certain
 payments received has been deferred until the price is fixed and
 determinable. Further, revenue for certain payments to be received
 in the future has been prohibited from recognition until received.
 The Company expects that some of these amounts will be considered
 variable consideration and may be able to be recognized earlier
 under the new guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has begun its evaluation of the impact of adoption and
 plans to continue its evaluation throughout 2017. The financial
 impact upon adoption will be dependent upon a number of factors
 including; the amount of revenue that has been deferred under the
 sell-through model for Afrezza, the amount of the revenue deferred
 under collaborative arrangements and the Company&#x2019;s estimates
 of variable consideration at the date of adoption. At this time,
 the Company has not completed its evaluation of the inputs,
 assumptions and methodologies that will be used to recognize
 revenue related to variable consideration under the new
 guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July 2015, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-11,</font> <i>Inventory (Topic
 330): Simplifying the Measurement of Inventory.</i> Topic 330
 currently requires an entity to measure inventory at the lower of
 cost or market. Market could be replacement cost, net realizable
 value, or net realizable value less an approximately normal profit
 margin. The amendments indicate that after adoption an entity
 should measure inventory within the scope of this ASU at the lower
 of cost or net realizable value. The amendments are effective for
 fiscal years beginning after December&#xA0;15, 2016, including
 interim periods within those fiscal years. The amendments should be
 applied prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The adoption of
 ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-11</font> will
 have no impact on the Company&#x2019;s annual consolidated financial
 statements because the Company currently measures inventory at the
 lower of cost or net realizable value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August&#xA0;2014, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2014-15,</font> <i>Presentation of
 Financial Statements &#x2014; Going Concern</i>, which requires
 management of an entity to evaluate whether there are conditions or
 events, considered in the aggregate, that raise substantial doubt
 about the entity&#x2019;s ability to continue as a going concern
 within one year after the date that the financial statements are
 issued or available to be issued. This update was effective for
 annual periods ending after December&#xA0;15, 2016. The adoption of
 this standard did not have a material impact on its consolidated
 financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In January 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-01,</font> <i>Financial
 Instruments &#x2014; Overall (Subtopic <font style="WHITE-SPACE: nowrap">825-10):</font> Recognition and Measurement
 of Financial Assets and Financial Liabilities.</i> The update is
 intended to improve the recognition and measurement of financial
 instruments. The update is effective for fiscal years beginning
 after December&#xA0;15, 2017, including interim periods within
 those fiscal years. The Company is evaluating the impact the
 adoption of ASU <font style="WHITE-SPACE: nowrap">2016-01</font>
 will have on its consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In February 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-02,</font> <i>Leases (Topic
 842)</i>. The new standard requires that a lessee recognize the
 assets and liabilities that arise from operating leases. A lessee
 should recognize in the statement of financial position a liability
 to make lease payments (the lease liability) and a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> asset representing
 its right to use the underlying asset for the lease term. For
 leases with a term of 12 months or less, a lessee is permitted to
 make an accounting policy election by class of underlying asset not
 to recognize lease assets and lease liabilities. In transition,
 lessees and lessors are required to recognize and measure leases at
 the beginning of the earliest period presented using a modified
 retrospective approach. The new standard will be effective on
 January&#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-02</font> will have on its
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 In March 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-09,</font> <i>Compensation
 &#x2014; Stock Compensation (Topic 718): Improvements to Employee
 Share-Based Payment Accounting</i>. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&#xA0;15, 2016, and interim periods within
 those annual periods. The Company has evaluated the effect that
 this guidance will have on its consolidated financial statements
 and related disclosures and has determined it will not result in a
 material impact.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15,</font> <i>Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments</i>. The new standard seeks to reduce diversity in
 practice related to the classification of certain transactions in
 the statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&#xA0;15, 2017, and interim periods within
 those annual periods. The amendments should be applied using a
 retrospective transition method to each period presented. If it is
 impracticable to apply the amendments retrospectively for some of
 the issues, the amendments for those issues would be applied
 prospectively as of the earliest date practicable. The Company is
 evaluating the impact the adoption of ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15</font> will have on its
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In November 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-18,</font> <i>Statement of Cash
 Flows (Topic 230): Restricted Cash.</i> This ASU requires that the
 reconciliation of the <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">beginning-of-period</font></font>
 and <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">end-of-period</font></font> amounts shown in
 the statement of cash flows include cash and restricted cash
 equivalents. ASU <font style="WHITE-SPACE: nowrap">2016-08</font>
 is effective for fiscal years beginning after December&#xA0;15,
 2018, including interim periods within those periods, using a
 retrospective transition method to each period presented. The
 Company has evaluated the effect that this guidance will have on
 its consolidated financial statements and related disclosures and
 has determined it will not result in a material impact.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable Allowance For Doubtful Accounts [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AssetsHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets Held for Sale, Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AssetsHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_BusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_BusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClinicalTrialExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClinicalTrialExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_GrossToNetAdjustmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross To Net Adjustments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_GrossToNetAdjustmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on Purchase Commitments, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patient Discount and Co Pay Assistance Programs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PatientDiscountAndCoPayAssistanceProgramsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_RevenueRecognitionBulkSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Bulk Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_RevenueRecognitionBulkSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SaleOfIntellectualPropertyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of intellectual property [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SaleOfIntellectualPropertyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WholesalerDistributionFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Wholesaler Distribution Fees [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WholesalerDistributionFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepurchaseAndResaleAgreementsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for repurchase and resale agreements. This disclosure may address (a) the reasons for entering into repurchase and resale agreements, (b) how securities transferred under such agreements are classified in the entity's financial statements, (c) whether multiple agreements with the same counterparty are offset (d) the entity's accounting policy for requiring collateral or other security for such transactions, and (e) how the entity ensures that the market value of the underlying assets remains sufficient to protect the entity in the event of default by the counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(m)(2)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64858031&amp;loc=SL6224234-111729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49176635&amp;loc=d3e9760-107771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepurchaseAndResaleAgreementsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68073604&amp;loc=d3e63150-111658<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleElementArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for multiple-deliverable arrangements including, at a minimum (as applicable): (1) the nature of such arrangements, (2) the significant deliverables within the arrangements, (3) the general timing of delivery or performance of service for the deliverables within the arrangements, (4) performance-, cancellation-, termination- or refund-type provisions, (5) a discussion of the significant factors, inputs, assumptions, and methods used to determine selling price (whether vendor-specific objective evidence, third-party evidence, or estimated selling price) for the significant deliverables, (6) whether the significant deliverables in the arrangements qualify as separate units of accounting and the reasons that they do not qualify as separate units of accounting, if applicable, and (7) the general timing of revenue recognition for significant units of accounting. This element is applicable to all multiple-deliverable arrangements, including software arrangements (for example, software products, upgrades or enhancements, postcontract customer support, or services).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68059916&amp;loc=d3e50766-111635<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 25<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68059916&amp;loc=SL6750900-111635<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleElementArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197222<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076378&amp;loc=d3e47119-111625<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830260304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventories</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Inventories consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <font style="white-space:nowrap"><font style="white-space:nowrap">Work-in-process</font></font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,120</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total Inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,331</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830346272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Property and equipment consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000">Estimated<br />
 Useful&#xA0;Life<br />
 (Years)</td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Land</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="center">&#x2014;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">875</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,435</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Buildings</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">39-40</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,389</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,590</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Building improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">5-40</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,957</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,584</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Machinery and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">3-15</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62,992</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68,434</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture, fixtures and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="white-space:nowrap">5-10</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">3</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,531</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,519</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">202</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">586</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,502</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">168,262</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(99,575</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(119,513</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,927</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,749</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830260304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities are comprised of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Salary and related expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,814</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,634</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restructuring</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,376</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sales and marketing services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">875</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">931</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Discounts and allowances for commercial product sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">754</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">615</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">483</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">238</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,937</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,929</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840672928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Borrowings</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Borrowings consist of the following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Facility Financing Obligation (2019 Notes)</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Principal amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">75,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">80,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unamortized debt discount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,661</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,418</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net carrying amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,339</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">74,582</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Senior Convertible Notes (2018 Notes)</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Principal amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,690</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,690</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unamortized premium</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">426</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">660</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unaccreted debt issuance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(481</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(737</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net carrying amount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,635</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,613</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Note payable to principal stockholder &#x2014; net carrying
 amount</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,521</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,521</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Accretion of Debt Issuance Cost and Debt Discount</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Accretion of debt issuance cost and debt discount in connection
 with the Deerfield financing during the years ended
 December&#xA0;31, 2016, 2015 and 2014 are as follows (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accretion expense &#x2014; debt issuance cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">326</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accretion expense &#x2014; debt discount</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,722</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,553</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,550</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850214496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following tables set forth the fair value of the
 Company&#x2019;s financial instruments (in millions):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of December&#xA0;31, 2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Carrying&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;1</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;2</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;3</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Financial liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Senior convertible notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Facility Financing Obligation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability (at recurring fair values)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total financial liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">115.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of December&#xA0;31, 2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Carrying&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;1</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;2</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level&#xA0;3</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Financial liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Senior convertible notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Facility Financing Obligation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Sanofi Loan Facility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total financial liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">155.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">150.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">150.6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Fair Values of Financial Liabilities which Include Level 3 Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table provides a roll forward of the fair values of
 financial assets and liabilities that are carried at fair value (in
 millions):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Warrants</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Assets&#xA0;Held&#xA0;for<br />
 Sale</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, January&#xA0;1, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5.4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.6</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value, December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.7</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840705520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Components of Basic and Diluted Net Income (Loss) Per Common Share Computations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following tables summarize the components of the basic and
 diluted net income (loss) per common share computations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(In thousands,
 except per share data)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Basic EPS:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) (numerator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">125,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(368,445</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(198,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average common shares (denominator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.37</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.54</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Diluted EPS:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) (numerator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">125,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(368,445</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(198,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average common shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities &#x2014; common shares issuable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted weighted average common shares (denominator)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,085</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net income (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.36</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.54</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Securities Outstanding that are Considered Antidilutive</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Potentially dilutive securities outstanding that are considered
 antidilutive are summarized as follows (in shares):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,955,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,308,332</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Conversion of senior convertible notes into common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,464,616</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,740,597</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">814,919</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,997,575</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">702,867</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">360,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">522,144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,788,281</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,946,249</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,292,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830222288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Award Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock Based Award Plans</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table summarizes information about the
 Company&#x2019;s stock-based award plans as of December&#xA0;31,
 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Outstanding<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Outstanding<br />
 Restricted<br />
 Stock Units</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares&#xA0;Available<br />
 for Future<br />
 Issuance</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2004 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,052,345</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,203</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2013 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,399,245</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">723,763</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,743,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2004 <font style="WHITE-SPACE: nowrap">Non-Employee</font>
 Directors&#x2019; Stock Option Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">737,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,840,587</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is as follows
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,407</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Consultant-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,725</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock', window );">Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Total stock-based compensation expense recognized in the
 accompanying consolidated statements of operations is included in
 the following categories (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">695</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,131</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,696</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,725</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Assumptions Used to Calculate Fair Value of Employee Stock Options</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company calculated the fair value of employee stock options
 granted during the years ended December&#xA0;31, 2016, 2015 and
 2014 using the following assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="31%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center">Year Ended December&#xA0;31,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2016</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2015</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 1.18%&#xA0;&#x2014;&#xA0;1.80%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">1.61%
 &#x2014;1.86%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 1.64%&#xA0;&#x2014;&#xA0;2.11%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected lives</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.13&#xA0;&#x2014;&#xA0;5.82&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.79&#xA0;&#x2014;&#xA0;5.86&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 5.77&#xA0;&#x2014;&#xA0;6.09&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 77.57%&#xA0;&#x2014;&#xA0;82.75%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 69.76%&#xA0;&#x2014;&#xA0;71.84%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 73.98%&#xA0;&#x2014;&#xA0;84.85%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="center">
 &#x2014;&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Outstanding</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes information about stock options
 outstanding:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of<br />
 Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average&#xA0;Exercise<br />
 Price per&#xA0;Share</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic<br />
 Value&#xA0;($000)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,955,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,236,693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55,231</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(407,161</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(199,890</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23.65</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,530,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested and expected to vest at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,399,777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,414,586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A summary of restricted stock unit activity for the year ended
 December&#xA0;31, 2016 is presented below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Grant&#xA0;Date<br />
 Fair Value<br />
 per Share</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">360,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24.25</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">800,530</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(131,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(292,488</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">737,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share Based Compensation Activity by Category</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ScheduleOfShareBasedCompensationActivityByCategoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840488992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentTextBlock', window );">Annual Purchase Requirements under Contract</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The annual purchase requirements under the contract are as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">2.7&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.9&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.6&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.5&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2021</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.5&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2022</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.4&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2023</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.4&#xA0;million</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840664304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The provision for income taxes consists of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Year Ended December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. state</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-U.S.</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,814</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">109,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,873</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. state</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,311</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29,394</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,631</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-U.S.</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(48,125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">65,504</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(80,118</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(65,504</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 Components of the net deferred tax assets as of December&#xA0;31,
 2016 and 2015, are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">712,124</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">721,588</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">77,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,646</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized research</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Payments from collaboration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,484</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Milestone Rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss on purchase commitment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,084</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-qualified</font>&#xA0;stock option expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,941</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized patent costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,380</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,186</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45,310</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">914,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">962,623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(914,498</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(962,623</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective Income Tax Rate</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s effective income tax rate differs from the
 statutory federal income tax rate as follows for the years ended
 December&#xA0;31, 2016, 2015 and 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal tax benefit rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intercompany transfer of intellectual property</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31.8</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effective income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850230064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selling, General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of Selling, General and Administrative Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Selling, general and administrative expenses consist of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000">Year Ended
 December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Selling and marketing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,854</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,587</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,074</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,373</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">75,827</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">46,928</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">40,960</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">79,383</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General and Administrative Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SellingGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833497888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 A reconciliation of beginning and ending liability balances for the
 2016 and 2015 Restructuring charges, which is included in accrued
 expenses and other current liabilities, is as follows (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016<br />
 Restructuring</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015<br />
 Restructuring</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; January 1, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs incurred and charged to expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,040</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,040</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs paid or settled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,012</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,012</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; December 31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs incurred and charged to expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,475</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">560</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,035</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Costs paid or settled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,266</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,421</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,687</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrual &#x2014; December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">209</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,167</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,376</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830295744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected quarterly financial data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Summarized quarterly financial data for the years ended
 December&#xA0;31, 2016 and 2015, are set forth in the following
 tables:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March&#xA0;31</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June&#xA0;30</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September&#xA0;30</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">162,354</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(24,873</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(29,959</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">126,520</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,976</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss) per share &#x2014; basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.29</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.33</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.32</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.56</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net income (loss) per share &#x2014; diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.29</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.33</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.31</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.56</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute basic net income
 (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,771</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,061</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,627</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,676</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute diluted net income
 (loss) per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,771</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,061</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96,548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96,510</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(30,658</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(28,910</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,857</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(277,020</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss per share &#x2014; basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.38</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.36</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.39</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.30</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average common shares used to compute basic and diluted
 net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,783</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,203</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,039</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">83,862</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850943392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2016</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,024,000<span></span>
</td>
<td class="num">$ (1,049,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,737,565,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,737,565,000)<span></span>
</td>
<td class="num">(2,863,229,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,895,000<span></span>
</td>
<td class="nump">59,074,000<span></span>
</td>
<td class="nump">$ 120,841,000<span></span>
</td>
<td class="nump">$ 70,790,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember', window );">Loan Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available for future borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100,000<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=mnkd_InsulinMember', window );">Insulin Put</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder | Loan Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available for future borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_AventisubLlcMember', window );">Aventisub LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Outstanding loan balance forgive</a></td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH | License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">$ 161,800,000<span></span>
</td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UpfrontFee', window );">Up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH | Insulin Put | License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH | Subsequent Event | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payment for insulin put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity', window );">Available amount of credit facility under covenant restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Restricted Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetRevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Revenue From Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetRevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mnkd_InsulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mnkd_InsulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_AventisubLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_AventisubLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6851822432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 18, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net revenue - commercial product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CashDiscountPercent', window );">Cash discount as incentive for prompt payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredRevenueFromSaleOfRawInsulin', window );">Deferred revenue from sale of raw insulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredCostRelatedToSaleOfRawInsulin', window );">Deferred cost related to sale of raw insulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_MaturityPeriodOfCashEquivalents', window );">Maturity period of cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days or less at the time of  purchase<span></span>
</td>
<td class="text">90 days or less at the time of  purchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PercentageOfCreditExchangeReceivable', window );">Percentage of credit exchange receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(597,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,000<span></span>
</td>
<td class="nump">$ 1,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Property and equipment impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,412,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">long term purchase commitment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_EstimatedAmountsCreditExchangeReceivable', window );">Estimated amounts receivable under program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000<span></span>
</td>
<td class="nump">816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest cost capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mnkd_ThirdPartyLogisticsMember', window );">Third party logistics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ConsiderationReceived', window );">Total consideration received</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Intellectual property sold, net</a></td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AccruedExpensesIntellectualProperty', window );">Accrued expense associated with intellectual property</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">long term purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Milestone Rights Liability | Senior convertible notes due December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember', window );">AFREZZA product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProductSalesRevenueGrossToNetAdjustments', window );">Product sales revenue gross to net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage', window );">Product sales revenue gross to net adjustments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | AFREZZA product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SalesReturnPeriod', window );">Sales return right following product expiration in months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | AFREZZA product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SalesReturnPeriod', window );">Sales return right following product expiration in months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AccruedExpensesIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses Intellectual Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AccruedExpensesIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CashDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Discount Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CashDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredCostRelatedToSaleOfRawInsulin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Cost Related To Sale Of Raw Insulin</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredCostRelatedToSaleOfRawInsulin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredRevenueFromSaleOfRawInsulin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue From Sale Of Raw Insulin</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredRevenueFromSaleOfRawInsulin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_EstimatedAmountsCreditExchangeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amounts credit exchange receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_EstimatedAmountsCreditExchangeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_MaturityPeriodOfCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_MaturityPeriodOfCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PercentageOfCreditExchangeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of credit exchange receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PercentageOfCreditExchangeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProductSalesRevenueGrossToNetAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product sales revenue gross to net adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProductSalesRevenueGrossToNetAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product sales revenue gross to net adjustments percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProductSalesRevenueGrossToNetAdjustmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SalesReturnPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Return Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SalesReturnPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68048823&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Impairment<br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Allowance for Funds Used during Construction<br> -URI http://asc.fasb.org/extlink&amp;oid=6504829<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mnkd_ThirdPartyLogisticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mnkd_ThirdPartyLogisticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833499888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of Inventories (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 2,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830140144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6852892368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 128,502<span></span>
</td>
<td class="nump">$ 168,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(99,575)<span></span>
</td>
<td class="num">(119,513)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">28,927<span></span>
</td>
<td class="nump">48,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 17,389<span></span>
</td>
<td class="nump">21,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 34,957<span></span>
</td>
<td class="nump">60,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 62,992<span></span>
</td>
<td class="nump">68,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember', window );">Furniture, fixtures and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="nump">4,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember', window );">Furniture, fixtures and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember', window );">Furniture, fixtures and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 8,531<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment - gross</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836958112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>asset_group</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems', window );"><strong>Depreciation and Other Amortization Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NumberOfAssetGroups', window );">Number of primary asset groups | asset_group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 242.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentChargeOnReclassifiedAssets', window );">Impairment charges allocated to assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=mnkd_ValenciaMember', window );">Valencia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems', window );"><strong>Depreciation and Other Amortization Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_DanburyFacilityMember', window );">Danbury Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems', window );"><strong>Depreciation and Other Amortization Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mnkd_PropertyAndEquipmentImpairmentMember', window );">Property And Equipment Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems', window );"><strong>Depreciation and Other Amortization Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mnkd_AssetHeldForSaleMember', window );">Asset held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems', window );"><strong>Depreciation and Other Amortization Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DepreciationAndOtherAmortizationExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Other Amortization Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DepreciationAndOtherAmortizationExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NumberOfAssetGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Asset Groups</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NumberOfAssetGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentChargeOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -URI http://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentChargeOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=mnkd_ValenciaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=mnkd_ValenciaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_DanburyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_DanburyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mnkd_PropertyAndEquipmentImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mnkd_PropertyAndEquipmentImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mnkd_AssetHeldForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mnkd_AssetHeldForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850283264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salary and related expenses</a></td>
<td class="nump">$ 3,814<span></span>
</td>
<td class="nump">$ 2,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SalesAndMarketingRelatedExpensesAccrued', window );">Sales and marketing services</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CustomerDiscountsAndAllowances', window );">Discounts and allowances for commercial product sales</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,937<span></span>
</td>
<td class="nump">$ 7,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses and Other Current Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CustomerDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer Discounts And Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CustomerDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SalesAndMarketingRelatedExpensesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales And Marketing Related Expenses Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SalesAndMarketingRelatedExpensesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6852210368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Arrangements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2007 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AccruedInterestOfRelatedPartyDebt', window );">Accrued interest of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Interest expense on note payable principal stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901,000<span></span>
</td>
<td class="nump">2,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PaymentsForUseOfAircrafts', window );">Expenses related to charter service on behalf of principal shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember', window );">Loan Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available for future borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mnkd_AlfredMannFoundationMember', window );">Mann Foundation | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AreaOfOfficeSpaceLeased', window );">Area of office space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LeaseExpirationMonthYear', window );">Lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OfficeLeaseExpense', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LoanAgreementWithRelatedParty', window );">Loan agreement with related party</a></td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder | Loan Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Principal amount outstanding under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available for future borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Fixed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_RelatedPartyTransactionPrepaymentPeriod', window );">Related party transaction prepayment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AvailableLoanBalanceCancelled', window );">Aggregate principal amount cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder | Loan Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_RelatedPartyTransactionDebtInstrumentPrepayment', window );">Amount prepaid for cancellation of indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder | Loan Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NumberOfMonthsAdvancesOutstanding', window );">Number of months advances outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Principal stockholder | Amended Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  05,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyDebtMember', window );">Related Party Debt | Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The interest rate will increase to the one-year LIBOR rate  calculated on the date of the initial advance or in effect on the date of  default, whichever is greater, plus 5% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyDebtMember', window );">Related Party Debt | Letter Agreement | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AccruedInterestOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest of related party debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AccruedInterestOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AreaOfOfficeSpaceLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Office Space Leased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AreaOfOfficeSpaceLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AvailableLoanBalanceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available Loan Balance Cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AvailableLoanBalanceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LeaseExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Expiration Month Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LeaseExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LoanAgreementWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan agreement with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LoanAgreementWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NumberOfMonthsAdvancesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months advances outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NumberOfMonthsAdvancesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_OfficeLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_OfficeLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PaymentsForUseOfAircrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Use of Aircrafts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PaymentsForUseOfAircrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_RelatedPartyTransactionDebtInstrumentPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Debt Instrument Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_RelatedPartyTransactionDebtInstrumentPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_RelatedPartyTransactionPrepaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction prepayment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_RelatedPartyTransactionPrepaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnkd_AlfredMannFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnkd_AlfredMannFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LeaseAgreementTypeOfAgreementAxis=mnkd_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LeaseAgreementTypeOfAgreementAxis=mnkd_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnkd_AmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnkd_AmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnkd_LetterOfAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnkd_LetterOfAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850063840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Borrowings (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 10, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Note payable to principal stockholder - net carrying amount</a></td>
<td class="nump">$ 49,521<span></span>
</td>
<td class="nump">$ 49,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(3,661)<span></span>
</td>
<td class="num">(5,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">71,339<span></span>
</td>
<td class="nump">74,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember', window );">5.75% Senior convertible notes due August 15, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">27,690<span></span>
</td>
<td class="nump">27,690<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized premium</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unaccreted debt issuance costs</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 27,635<span></span>
</td>
<td class="nump">$ 27,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6859931104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 17, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 10, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2015 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 18, 2010 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Facility Agreement, total principle payment in 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Facility Agreement, total principle payment in 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Facility Agreement, total principle payment in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,576,000<span></span>
</td>
<td class="nump">$ 21,231,000<span></span>
</td>
<td class="nump">$ 17,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payments on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,024,000<span></span>
</td>
<td class="num">(1,049,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnkd_TwoThousandEighteenNotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnkd_TwoThousandFifteenNotesMember', window );">2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Principal repayment schedule, start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DebtInstrumentDateOfLastRequiredPayment', window );">Principal repayment schedule, end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  09,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion Option, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,464,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion Option, aggregate expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Premium of issuance of 2018 debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,722,000<span></span>
</td>
<td class="nump">1,553,000<span></span>
</td>
<td class="nump">7,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Milestone Rights Liability | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ContingentLiability', window );">Contingent liability for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Tranche 1 note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion Option, aggregate expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Tranche 2 note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion Option, aggregate expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Tranche 3 note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion Option, aggregate expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember', window );">5.75% Senior convertible notes due August 15, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt facility principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000<span></span>
</td>
<td class="nump">737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,635,000<span></span>
</td>
<td class="nump">27,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,000<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">No of convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PrincipalAmountPerShare', window );">Principal amount per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.00<span></span>
</td>
<td class="nump">$ 34.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Percentage of repurchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, redemption description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of conversion price equaling stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Premium of issuance of 2018 debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember', window );">Senior convertible notes due August 15, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt facility principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">$ 32,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion Option, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.00<span></span>
</td>
<td class="nump">$ 110.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payments on senior notes</a></td>
<td class="nump">$ 32,100,000<span></span>
</td>
<td class="nump">$ 32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt facility principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661,000<span></span>
</td>
<td class="nump">5,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,339,000<span></span>
</td>
<td class="nump">74,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt facility principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Facility Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Short term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PaymentForContingentLiabilities', window );">Required payment pursuant to the terms of the Milestone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsEntityCreditRisk', window );">Risk premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Fair value of milestone rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability | Danbury Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt facility principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity', window );">Available amount of credit facility under covenant restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset | Minimum | Facility Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity', window );">Available amount of credit facility under covenant restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember', window );">Senior convertible notes due December 31, 2019 | Sanofi-Aventis Deutschland GmbH | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PaymentForContingentLiabilities', window );">Required payment pursuant to the terms of the Milestone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DebtInstrumentDateOfLastRequiredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Date Of Last Required Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DebtInstrumentDateOfLastRequiredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Restricted Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LineOfCreditFacilityRestrictedBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PaymentForContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PaymentForContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PrincipalAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PrincipalAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Conversion Rate<br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsEntityCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk associated with risk of default, credit spread risk and downgrade risk, expressed as a percentage, used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsEntityCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnkd_TwoThousandEighteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnkd_TwoThousandEighteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnkd_TwoThousandFifteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnkd_TwoThousandFifteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AgreementsAxis=mnkd_FacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AgreementsAxis=mnkd_FacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_DanburyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_DanburyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840530928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail) - Deerfield - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Accretion expense - debt issuance cost</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion expense - debt discount</a></td>
<td class="nump">$ 1,722<span></span>
</td>
<td class="nump">$ 1,553<span></span>
</td>
<td class="nump">$ 7,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6858846336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Nov. 09, 2016</div></th>
<th class="th"><div>Feb. 10, 2016</div></th>
<th class="th"><div>Jan. 04, 2016</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 23, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,478,000<span></span>
</td>
<td class="nump">$ 1,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,024,000<span></span>
</td>
<td class="num">(1,049,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Balance payment of settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,557,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=mnkd_InsulinMember', window );">Insulin Put</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH | Subsequent Event | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payment for insulin put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH | Mortgage Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_AventisubLlcMember', window );">Aventisub LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Outstanding loan balance forgiven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_ReceptorLifeScienceIncMember', window );">Receptor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Nonrefundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived', window );">Nonrefundable option exercise and license fee</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ResearchAndDevelopmentExpensesOffsetAmount', window );">Reduction in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue - nonrefundable license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_RecognitionPeriodForDeferredRevenue', window );">Deferred revenue recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProfitLossSharingAgreementAllocationPercentage', window );">Profits and losses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_TerminationDateOfLicenseAgreement', window );">Termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  04,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum secured loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue - nonrefundable license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProfitLossSharingAgreementAllocationPercentage', window );">Profits and losses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PotentialMilestonePaymentsToBeReceived', window );">Milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">$ 161,800,000<span></span>
</td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum secured loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Secured loan facility, amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Secured loan facility, amount owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue - nonrefundable license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LossSharingAgreementAmount', window );">Company's total portion of loss sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LossSharingAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Sharing Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LossSharingAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetRevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Revenue From Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetRevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PotentialMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PotentialMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Option Exercise and License Fees Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProfitLossSharingAgreementAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Loss Sharing Agreement Allocation Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProfitLossSharingAgreementAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_RecognitionPeriodForDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition Period for Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_RecognitionPeriodForDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ResearchAndDevelopmentExpensesOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expenses Offset Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ResearchAndDevelopmentExpensesOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_TerminationDateOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Date Of License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_TerminationDateOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mnkd_InsulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mnkd_InsulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnkd_MortgageLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnkd_MortgageLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_AventisubLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_AventisubLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_ReceptorLifeScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_ReceptorLifeScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mnkd_UpFrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mnkd_UpFrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mnkd_MilestonePaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mnkd_MilestonePaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mnkd_MilestonePaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mnkd_MilestonePaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=mnkd_OperatingLossSharingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=mnkd_OperatingLossSharingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836830400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Sep. 23, 2014</div></th>
<th class="th"><div>Jul. 01, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents, money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="nump">$ 55,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of Milestone Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,927,000<span></span>
</td>
<td class="nump">48,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Property and equipment impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259,000<span></span>
</td>
<td class="nump">140,412,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember', window );">Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LoanFacilityForgivenDate', window );">Loan facility forgiven date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  09,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum secured loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum secured loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember', window );">Milestone Rights Liability | Deerfield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember', window );">Milestone Rights Liability | Deerfield | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ContingentLiability', window );">Contingent liability for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember', window );">Milestone Rights Liability | Senior convertible notes due December 31, 2019 | Deerfield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Market discount rate</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Property, plant, and equipment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Property and equipment impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="num">$ (140,412,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of Milestone Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | 5.75% Senior convertible notes due August 15, 2018 | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumption, risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumption, stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Market discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Market discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_FairValueOfFinancialInstrumentsLineItems', window );"><strong>Fair Value of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Market discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_FairValueOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Financial Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_FairValueOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LoanFacilityForgivenDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Facility Forgiven Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LoanFacilityForgivenDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68048823&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Impairment<br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_TwoThousandNineteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837238672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">115.2<span></span>
</td>
<td class="nump">$ 155.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Senior Convertible Notes | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Facility Financing Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">71.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">123.2<span></span>
</td>
<td class="nump">150.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">123.2<span></span>
</td>
<td class="nump">150.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Milestone Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Senior Convertible Notes | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Senior Convertible Notes | Fair Value, Inputs, Level 3 | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Facility Financing Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">78.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Facility Financing Obligation | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="nump">$ 74.5<span></span>
</td>
<td class="nump">$ 78.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_FacilityFinancingObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_FacilityFinancingObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6859082240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Additions</a></td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities', window );">Changes in fair value</a></td>
<td class="num">(5.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair values of financial liabilities, ending balance</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Assets Held for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Additions</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Changes in fair value</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PaymentsForFinancialAssets', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair values of financial assets, ending balance</a></td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss From Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_GainLossFromChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PaymentsForFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PaymentsForFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35711157&amp;loc=d3e42546-110969<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6859475744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 09, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 16, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2012 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Right </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 23, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,680,831<span></span>
</td>
<td class="nump">85,734,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,680,831<span></span>
</td>
<td class="nump">85,734,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares sold aggregate price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs associated with the Tel Aviv Stock Exchange | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice', window );">Percentage of shares of common stock issued for offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Restricted warrants issued to purchase number of common stock for offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of restricted warrants per share in connection with the offering | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockLoanedUnderShareLendingAgreementShares', window );">Common stock loaned under share lending agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NominalLendingFee', window );">Nominal lending fee | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SharesReturnedUnderShareLendingAgreement', window );">Returned shares of common stock under share lending agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldUnderPublicOfferUnderwritten', window );">Number of Unit Sold in an Underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock', window );">Warrant to purchase of a share of common stock | $ / Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,123,000<span></span>
</td>
<td class="nump">$ 27,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantsOrRightsExpirationDate', window );">Warrants expiration, date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  08,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,281,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,427,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember', window );">Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SaleOfCommonStockInUnderwrittenPublicOffering', window );">Number of shares sold in underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,708,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_DirectOfferingMember', window );">Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of restricted warrants per share in connection with the offering | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WarrantsExercisableExpirationPeriod', window );">Duration for Expiration of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockIssuedToByPartyAxis=mnkd_UnderwritersMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldUnderPublicOfferUnderwritten', window );">Number of Unit Sold in an Underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldByUnderwritingPrice', window );">Purchased Price of the units by underwriters | $ / Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommonStockIssuedToByPartyAxis=mnkd_PublicMember', window );">Public</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldByUnderwritingPrice', window );">Purchased Price of the units by underwriters | $ / Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription', window );">Units sold composition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each unit consisting of  one share of common stock and a warrant to purchase 0.1 of a share of common  stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XTAE', window );">TEL AVIV STOCK EXCHANGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage', window );">Percentage of shares price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,770,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares sold aggregate price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs associated with the Tel Aviv Stock Exchange | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember', window );">Senior convertible notes due August 15, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split of common stock</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Exercise Price Of Warrants Stated As Percentage Of Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockLoanedUnderShareLendingAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock loaned under share lending agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockLoanedUnderShareLendingAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NominalLendingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal lending fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NominalLendingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SaleOfCommonStockInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Common Stock In Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SaleOfCommonStockInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SharesReturnedUnderShareLendingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Returned Under Share Lending Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SharesReturnedUnderShareLendingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares New Issues Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockIssuedDuringPeriodSharesNewIssuesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_UnitsSoldByUnderwritingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units sold by underwriting price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_UnitsSoldByUnderwritingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_UnitsSoldUnderPublicOfferUnderwritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units sold under public offer underwritten.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_UnitsSoldUnderPublicOfferUnderwritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units sold under public offer underwritten composition description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_UnitsSoldUnderPublicOfferUnderwrittenCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units sold warrant portion convertible into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_UnitsSoldWarrantPortionConvertibleIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WarrantsExercisableExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WarrantsExercisableExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mnkd_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockIssuedToByPartyAxis=mnkd_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockIssuedToByPartyAxis=mnkd_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommonStockIssuedToByPartyAxis=mnkd_PublicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommonStockIssuedToByPartyAxis=mnkd_PublicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XTAE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XTAE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mnkd_SeniorConvertibleNotesDueTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830298480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 01, 2017</div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetIncomeLossPerCommonShareLineItems', window );"><strong>Net Income Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnshareLendingArrangementSharesOutstanding', window );">Common shares loaned under the share lending arrangement, issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetIncomeLossPerCommonShareLineItems', window );"><strong>Net Income Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split of common stock</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetIncomeLossPerCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Loss Per Common Share [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetIncomeLossPerCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnshareLendingArrangementSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares outstanding as of the date of the statement of financial position in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnshareLendingArrangementSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837300848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic EPS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) (numerator)</a></td>
<td class="nump">$ 53,976<span></span>
</td>
<td class="nump">$ 126,520<span></span>
</td>
<td class="num">$ (29,959)<span></span>
</td>
<td class="num">$ (24,873)<span></span>
</td>
<td class="num">$ (277,020)<span></span>
</td>
<td class="num">$ (31,857)<span></span>
</td>
<td class="num">$ (28,910)<span></span>
</td>
<td class="num">$ (30,658)<span></span>
</td>
<td class="nump">$ 125,664<span></span>
</td>
<td class="num">$ (368,445)<span></span>
</td>
<td class="num">$ (198,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares (denominator)</a></td>
<td class="nump">95,676<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
<td class="nump">91,061<span></span>
</td>
<td class="nump">85,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,053<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted EPS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) (numerator)</a></td>
<td class="nump">$ 53,976<span></span>
</td>
<td class="nump">$ 126,520<span></span>
</td>
<td class="num">$ (29,959)<span></span>
</td>
<td class="num">$ (24,873)<span></span>
</td>
<td class="num">$ (277,020)<span></span>
</td>
<td class="num">$ (31,857)<span></span>
</td>
<td class="num">$ (28,910)<span></span>
</td>
<td class="num">$ (30,658)<span></span>
</td>
<td class="nump">$ 125,664<span></span>
</td>
<td class="num">$ (368,445)<span></span>
</td>
<td class="num">$ (198,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares</a></td>
<td class="nump">95,676<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
<td class="nump">91,061<span></span>
</td>
<td class="nump">85,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,053<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Effect of dilutive securities - common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Adjusted weighted average common shares (denominator)</a></td>
<td class="nump">96,510<span></span>
</td>
<td class="nump">96,548<span></span>
</td>
<td class="nump">91,061<span></span>
</td>
<td class="nump">85,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,085<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 55<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e2626-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e2538-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingently Issuable Shares<br> -URI http://asc.fasb.org/extlink&amp;oid=6508586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838271600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Potentially Dilutive Securities Outstanding that are Antidilutive (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">16,788,281<span></span>
</td>
<td class="nump">5,946,249<span></span>
</td>
<td class="nump">10,292,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">5,530,256<span></span>
</td>
<td class="nump">3,955,845<span></span>
</td>
<td class="nump">4,308,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">814,561<span></span>
</td>
<td class="nump">814,561<span></span>
</td>
<td class="nump">3,464,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">9,740,597<span></span>
</td>
<td class="nump">814,919<span></span>
</td>
<td class="nump">1,997,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">702,867<span></span>
</td>
<td class="nump">360,924<span></span>
</td>
<td class="nump">522,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6851239920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Award Plans - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2017</div></th>
<th class="th">
<div>Mar. 31, 2004 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SharesReservedForEmployeeStockPurchasePlan', window );">Share reserve | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PercentageOfCommonStockSharesOutstanding', window );">Share of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares sold to employees | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,758<span></span>
</td>
<td class="nump">64,245<span></span>
</td>
<td class="nump">61,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares purchased under ESPP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockOptionsGrantedVestingRate', window );">Stock option grants vest exercisable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530,256<span></span>
</td>
<td class="nump">3,955,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,135,000<span></span>
</td>
<td class="nump">$ 8,725,000<span></span>
</td>
<td class="nump">$ 48,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of the stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 12.80<span></span>
</td>
<td class="nump">$ 23.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Cash received from the exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 22 days<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">2 years 11 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest', window );">Restricted stock units expected to vest | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ValueOfRestrictedStockUnitsVested', window );">Total intrinsic value of restricted stock units expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value of restricted stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 62,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period for unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,135,000<span></span>
</td>
<td class="nump">8,725,000<span></span>
</td>
<td class="nump">$ 48,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split of common stock</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock vesting rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_TrancheAchievementDate', window );">Tranche achievement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=mnkd_ShareBasedCompensationAwardTrancheFourMember', window );">Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PercentageOfShareReservedForShareBasedCompensation', window );">Shares reserved under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_StockAwardPlanTypeAxis=mnkd_ConsultantMember', window );">Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Equity incentive plan, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,399,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnkd_EmployeeStockPurchasePlansMember', window );">Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">445,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares', window );">Share reserve automatic increase each year | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan Annual Increase In Reserved Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_EmployeeStockPurchasePlanAnnualIncreaseInReservedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PercentageOfCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Common Stock Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PercentageOfCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PercentageOfShareReservedForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Share Reserved For Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PercentageOfShareReservedForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement Restricted Stock Units Number Of Units Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SharesReservedForEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Reserved For Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SharesReservedForEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockOptionsGrantedVestingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Options Granted Vesting Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockOptionsGrantedVestingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_TrancheAchievementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tranche Achievement Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_TrancheAchievementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ValueOfRestrictedStockUnitsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Restricted Stock Units Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ValueOfRestrictedStockUnitsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value of restricted stock units expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mnkd_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mnkd_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_StockAwardPlanTypeAxis=mnkd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_StockAwardPlanTypeAxis=mnkd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnkd_EmployeeStockPurchasePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnkd_EmployeeStockPurchasePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833630992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Based Award Plans (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options</a></td>
<td class="nump">5,530,256<span></span>
</td>
<td class="nump">3,955,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding Restricted Stock Units</a></td>
<td class="nump">737,966<span></span>
</td>
<td class="nump">360,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Future Issuance</a></td>
<td class="nump">3,840,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnkd_TwoThousandFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options</a></td>
<td class="nump">2,052,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding Restricted Stock Units</a></td>
<td class="nump">14,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Future Issuance</a></td>
<td class="nump">97,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options</a></td>
<td class="nump">3,399,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding Restricted Stock Units</a></td>
<td class="nump">723,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Future Issuance</a></td>
<td class="nump">3,743,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember', window );">2004 Non Employee Directors Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options</a></td>
<td class="nump">78,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnkd_TwoThousandFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnkd_TwoThousandFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnkd_EquityIncentivePlanTwentyThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnkd_TwoThousandFourNonEmployeeDirectorsStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830458032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 5,135<span></span>
</td>
<td class="nump">$ 8,725<span></span>
</td>
<td class="nump">$ 48,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnkd_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 5,135<span></span>
</td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">$ 48,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnkd_ConsultantMember', window );">Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnkd_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnkd_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnkd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnkd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830481056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 5,135<span></span>
</td>
<td class="nump">$ 8,725<span></span>
</td>
<td class="nump">$ 48,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
<td class="nump">22,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 3,131<span></span>
</td>
<td class="nump">$ 5,696<span></span>
</td>
<td class="nump">$ 26,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6839058544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Employee Stock Options Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.18%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">77.57%<span></span>
</td>
<td class="nump">69.76%<span></span>
</td>
<td class="nump">73.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">82.75%<span></span>
</td>
<td class="nump">71.84%<span></span>
</td>
<td class="nump">84.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives</a></td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
<td class="text">5 years 9 months 15 days<span></span>
</td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives</a></td>
<td class="text">5 years 9 months 26 days<span></span>
</td>
<td class="text">5 years 10 months 10 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833652528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Options Outstanding (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at January 1, 2016 | shares</a></td>
<td class="nump">3,955,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">2,236,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(55,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(407,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(199,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2016 | shares</a></td>
<td class="nump">5,530,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2016 | shares</a></td>
<td class="nump">5,399,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2016 | shares</a></td>
<td class="nump">3,414,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at January 1, 2016 | $ / shares</a></td>
<td class="nump">$ 22.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">4.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">8.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">13.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">23.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2016 | $ / shares</a></td>
<td class="nump">16.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at December 31, 2016 | $ / shares</a></td>
<td class="nump">16.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2016 | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at December 31, 2016 | $</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at December 31, 2016 | $</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2016 | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836557968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Restricted Stock Unit Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at January 1, 2016 | shares</a></td>
<td class="nump">360,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">800,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(131,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(292,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2016 | shares</a></td>
<td class="nump">737,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value Per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at January 1, 2016 | $ / shares</a></td>
<td class="nump">$ 24.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">21.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">11.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at December 31, 2016 | $ / shares</a></td>
<td class="nump">$ 8.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6855561264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,000<span></span>
</td>
<td class="nump">$ 737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase commitment amount under Insulin Supply Agreement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LongTermPurchaseCommitmentExpirationDate', window );">Supply Agreement expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LongtermPurchaseCommitmentRenewalTimePeriod', window );">Supply Agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_AgreementsAxis=mnkd_BeforeAmendmentMember', window );">Before Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase commitment amount under Insulin Supply Agreement | &#8364;</a></td>
<td class="nump">&#8364; 120.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LongTermPurchaseCommitmentCancellationFees', window );">Purchase commitment cancellation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario Forecast | Before Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_LongTermPurchaseCommitmentCancellationFees', window );">Purchase commitment cancellation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember', window );">Supply Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember', window );">Deerfield | Milestone Rights Liability | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ContingentLiability', window );">Contingent liability for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LongTermPurchaseCommitmentCancellationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Purchase Commitment Cancellation Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LongTermPurchaseCommitmentCancellationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LongTermPurchaseCommitmentExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Purchase Commitment, Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LongTermPurchaseCommitmentExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_LongtermPurchaseCommitmentRenewalTimePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term purchase commitment, renewal time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_LongtermPurchaseCommitmentRenewalTimePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_AgreementsAxis=mnkd_BeforeAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_AgreementsAxis=mnkd_BeforeAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830675088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Annual Purchase Requirements under Contract (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Annual Purchase Requirements under Contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2017</a></td>
<td class="nump">&#8364; 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2018</a></td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2019</a></td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2020</a></td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">2021</a></td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PurchaseObligationDueInSixthYear', window );">2022</a></td>
<td class="nump">19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PurchaseObligationDueInSeventhYear', window );">2023</a></td>
<td class="nump">&#8364; 19.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PurchaseObligationDueInSeventhYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation Due In Seventh Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PurchaseObligationDueInSeventhYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PurchaseObligationDueInSixthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation Due In Sixth Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PurchaseObligationDueInSixthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fourth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6840517376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution savings retirement plan</a></td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="nump">$ 593,000<span></span>
</td>
<td class="nump">$ 623,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by the employer to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 35<br> -Paragraph 123<br> -Subparagraph B<br> -URI http://asc.fasb.org/extlink&amp;oid=64937487&amp;loc=d3e36068-114959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 35<br> -Paragraph 63<br> -Subparagraph B<br> -URI http://asc.fasb.org/extlink&amp;oid=64937038&amp;loc=d3e12551-114930<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830489312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. state</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="num">(43,814)<span></span>
</td>
<td class="nump">109,512<span></span>
</td>
<td class="nump">57,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. state</a></td>
<td class="num">(4,311)<span></span>
</td>
<td class="num">(29,394)<span></span>
</td>
<td class="nump">7,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(48,125)<span></span>
</td>
<td class="nump">80,118<span></span>
</td>
<td class="nump">65,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Valuation allowance</a></td>
<td class="nump">48,125<span></span>
</td>
<td class="num">(80,118)<span></span>
</td>
<td class="num">(65,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncomeTaxExpenseBenefitNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_IncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense Benefit Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_IncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6853371984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 712,124<span></span>
</td>
<td class="nump">$ 721,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">77,998<span></span>
</td>
<td class="nump">73,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetsCapitalizedResearchExpenses', window );">Capitalized research</a></td>
<td class="nump">5,117<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Payments from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetsMilestoneRights', window );">Milestone Rights</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment', window );">Accrued expenses</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetsLossOnPurchaseCommitment', window );">Loss on purchase commitment</a></td>
<td class="nump">36,775<span></span>
</td>
<td class="nump">24,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-qualified stock option expense</a></td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">16,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetsCapitalizedCosts', window );">Capitalized patent costs</a></td>
<td class="nump">8,781<span></span>
</td>
<td class="nump">8,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other</a></td>
<td class="nump">7,380<span></span>
</td>
<td class="nump">7,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Depreciation</a></td>
<td class="nump">45,310<span></span>
</td>
<td class="nump">48,755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total net deferred tax assets</a></td>
<td class="nump">914,498<span></span>
</td>
<td class="nump">962,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(914,498)<span></span>
</td>
<td class="num">(962,623)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetsCapitalizedResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Research Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetsCapitalizedResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetsLossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Loss on Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetsLossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetsMilestoneRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Milestone Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetsMilestoneRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense (Accrual Adjustment)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6853352208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes -Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2004</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_DeferredTaxAssetIncreaseDecreaseInEquity', window );">Amount Equity would be increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in the valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,100)<span></span>
</td>
<td class="nump">$ 80,100<span></span>
</td>
<td class="nump">$ 65,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_OperatingLossCarryforwardsSubjectToLimitation', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetOperatingLossCarryforwardAnnualLimitation', window );">Net operating loss and credit carryforwards, annual use limitation</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,998<span></span>
</td>
<td class="nump">$ 73,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetOperatingLossCarryforwardsBeginsToExpire', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ResearchAndDevelopmentCreditsBeginToExpire', window );">Federal research and development credits begin to expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_DeferredTaxAssetIncreaseDecreaseInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Increase Decrease in Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_DeferredTaxAssetIncreaseDecreaseInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetOperatingLossCarryforwardAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforward Annual Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetOperatingLossCarryforwardAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetOperatingLossCarryforwardsBeginsToExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforwards Begins To Expire</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetOperatingLossCarryforwardsBeginsToExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_OperatingLossCarryforwardsSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Subject To Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_OperatingLossCarryforwardsSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ResearchAndDevelopmentCreditsBeginToExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Credits, Begin to Expire</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ResearchAndDevelopmentCreditsBeginToExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6697147408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Intercompany transfer of intellectual property</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(31.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ScheduleOfIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ScheduleOfIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6851120592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 13.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantOrRightExercised', window );">Class of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassAWarrantsMember', window );">A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrants liability</a></td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrants expiration period upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsValuationTechniques', window );">Valuation technique</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Monte  Carlo valuation pricing model<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Warrant liability fair value assumptions, risk-free rate</a></td>
<td class="nump">0.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Warrant liability fair value assumptions, dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant liability fair value assumptions, remaining term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Warrant liability fair value assumptions, volatility rate</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Warrant liability fair value assumptions, assumed probability</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassBWarrantsMember', window );">B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrants liability</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrants expiration period upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,281,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,427,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember', window );">Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SaleOfCommonStockInUnderwrittenPublicOffering', window );">Number of shares sold in underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,708,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Month Year From Which Warrants Or Rights Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SaleOfCommonStockInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Common Stock In Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SaleOfCommonStockInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsProbabilityOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the inputs and valuation technique(s) used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnkd_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830322512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Selling, General and Administrative Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_SellingGeneralAndAdministrativeExpensesLineItems', window );"><strong>Selling General And Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">$ 19,854<span></span>
</td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,074<span></span>
</td>
<td class="nump">39,373<span></span>
</td>
<td class="nump">75,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">$ 46,928<span></span>
</td>
<td class="nump">$ 40,960<span></span>
</td>
<td class="nump">$ 79,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_SellingGeneralAndAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_SellingGeneralAndAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6859832000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Additional information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">$ 6,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining accrual balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">$ 3,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember', window );">Twenty Sixteen Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated | Employee</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining accrual balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember', window );">Twenty Sixteen Restructuring Plan | Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember', window );">Twenty Sixteen Restructuring Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember', window );">Twenty Sixteen Restructuring Plan | Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember', window );">Twenty Fifteen Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">$ 6,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining accrual balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember', window );">Twenty Fifteen Restructuring Plan | Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember', window );">Twenty Fifteen Restructuring Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember', window );">Twenty Fifteen Restructuring Plan | Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837040752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Costs incurred and charged to expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">$ 6,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Costs paid or settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,687)<span></span>
</td>
<td class="num">(3,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual - Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember', window );">Twenty Sixteen Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Costs incurred and charged to expense</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Costs paid or settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual - Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember', window );">Twenty Fifteen Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Costs incurred and charged to expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">6,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Costs paid or settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,421)<span></span>
</td>
<td class="num">(3,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual - Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="nump">$ 3,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentySixteenRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mnkd_TwentyFifteenRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6839698480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_InterimReportingLineItems', window );"><strong>Interim Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
<td class="nump">$ 12,404<span></span>
</td>
<td class="nump">$ 162,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 53,976<span></span>
</td>
<td class="nump">$ 126,520<span></span>
</td>
<td class="num">$ (29,959)<span></span>
</td>
<td class="num">$ (24,873)<span></span>
</td>
<td class="num">$ (277,020)<span></span>
</td>
<td class="num">$ (31,857)<span></span>
</td>
<td class="num">$ (28,910)<span></span>
</td>
<td class="num">$ (30,658)<span></span>
</td>
<td class="nump">$ 125,664<span></span>
</td>
<td class="num">$ (368,445)<span></span>
</td>
<td class="num">$ (198,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">81,039<span></span>
</td>
<td class="nump">80,203<span></span>
</td>
<td class="nump">79,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used to compute basic net income (loss) per share</a></td>
<td class="nump">95,676<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
<td class="nump">91,061<span></span>
</td>
<td class="nump">85,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,053<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares used to compute diluted net income (loss) per share</a></td>
<td class="nump">96,510<span></span>
</td>
<td class="nump">96,548<span></span>
</td>
<td class="nump">91,061<span></span>
</td>
<td class="nump">85,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,085<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_InterimReportingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interim Reporting [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_InterimReportingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830395216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_InterimReportingLineItems', window );"><strong>Interim Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,024<span></span>
</td>
<td class="num">$ (1,049)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_InterimReportingLineItems', window );"><strong>Interim Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember', window );">License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_InterimReportingLineItems', window );"><strong>Interim Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetRevenueFromCollaboration', window );">Net revenue from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="nump">$ 161,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_InterimReportingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interim Reporting [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_InterimReportingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetRevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Revenue From Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetRevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnkd_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnkd_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6852810864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Cash received from property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_MinimumClosingBidPriceOfCommonStock', window );">Minimum closing bid price of common stock | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Land, Buildings and Improvements | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Amount of divestiture of long-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Cash received from property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_NetProceedsFromSaleOfProperty', window );">Net cash received from property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_PaymentsForCommissionsAndOtherFees', window );">Payments for commissions and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (564,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegulatoryAgencyAxis=mnkd_NasdaqStockMarketMember', window );">NASDAQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare', window );">Bid price of common stock, closing price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare', window );">Bid price of common stock, period less than required closing bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare', window );">Bid price of common stock, period provided to regain compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare', window );">Bid price of common stock, date provided to regain compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 13,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing Bid Price of Common Stock, Closing Date Provided to Regain Required Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClosingBidPriceOfCommonStockClosingDateProvidedToRegainRequiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing Bid Price of Common Stock, Period Below Required Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClosingBidPriceOfCommonStockPeriodBelowRequiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing Bid Price of Common Stock, Period Provided to Regain Required Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClosingBidPriceOfCommonStockPeriodProvidedToRegainRequiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing Bid Price of Common Stock, Required Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_ClosingBidPriceOfCommonStockRequiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_MinimumClosingBidPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Closing Bid Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_MinimumClosingBidPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_NetProceedsFromSaleOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Sale Of Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_NetProceedsFromSaleOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnkd_PaymentsForCommissionsAndOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Commissions And Other Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnkd_PaymentsForCommissionsAndOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=mnkd_NasdaqStockMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=mnkd_NasdaqStockMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^5V$7C-W;?VQ\$90M_+H+^0502P,$%     @ %8AP2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M?XOA:C(T%._&:Q>:[G[K?U!+ P04    "  5B'!*?*D,4(<$  " %@  &
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M&Q*]%L>?I?@#SC6K<KH:!)4&XVW"CDP_X/2SE'[ P9:#HK>K$&3@ B8?#)F
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MX@H,K, ,%9CS"E3,.NJH<8-F>]20=<XHI;(62^45NV",%=(*2'4,'.A<>M$
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MKY)'P'.I).]].6<RF.P&D#WF+W(,2L0-A0E@8 @; .'(N360BP<NCXG%?+6
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MNR8YJCZD_GAIZL?3CW7SU/5???J^/U[*._[HVMUXX7!QNO5X]S]02P,$%
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M_0.?EO6K<*TTGEQLP!^3QM=8&P"E[&YP SI\'XNCH G1_(BVF[9D<H+MYP?
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MT8Y?8.[G/25S\]_@"@KA40G6J*SRZ4NJP0>KYRPH18N7Z90FG>-TP_<S;9O
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M_?N8'06U"^87;YMI2R;'89\> )M?8?$'4$L#!!0    ( !6(<$K*KI"JJ $
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MX(])XVNL#8!2=C>X 1V^C\51T(1H?D#;35LR.<'V\P-@RRLL?P-02P,$%
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MK!%RM[L35NF.%UGRG5V1X1",[N#LF!^L5>[7"0R..=_S-\>S;MH0':+(>M7
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M?O-G,TW)9#CLYP_ EE]8_ -02P,$%     @ %8AP2J>HWRRL 0  D0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL;5-A;YPP#/TK47Y  V%M3R=
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MD7[ YV7]+6PK>T=.QN./B>-KC/& 4I(KW( .W\?J*&A\,&_1MO.6S(XWP_(
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M=V]R:W-H965T<R]S:&5E=#,X+GAM;&U3VV[;, S]%4$?4"7*T@2!;:#I,&S
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MM-VT)9,3;#\_ +:\PO(O4$L#!!0    ( !6(<$KU>%1>O@,  &P2   9
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M!KO3NE6&E7PQK'N5;4^#0NW:[E:8^WKX_C$,6GVPWW:BTP>FU7]02P,$%
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MN[VF^EC-H3B@]?;M!VB=]=B]*?#P^_=0)!N%?%8-@ Y>.MZK'#5:#SN,5=E
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M6U_"#_:?.>ET?WO(]:%I;R-[7_7G;/U#8\[#&6)P.\C<_ =02P,$%     @
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MV[6;@AR%6B9RS9H!I]D(6IOAS6TGR.4_4$L#!!0    ( !:(<$H$.@L:4@(
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MW/=T[[^(#Y$W\)9)4V,K\[K[[VTOM9*%SM)0*;)?_?54=M=K_R:F.@P/ !T
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MFZ[^&$(*()26Z48Q792XMX5:-B&T"]VV91!-T2 !NVD+E)D58S7^6++#X%(
MKK2L0!0C2?F"'F$D*=C"YCT28 >A;+:#0)V(K),'(TX!XM(6 F-)Y8+&8"PI
MV,MF^\@@FA3,8ML^0C&]%- K;68)\\8B]WH9YHV!W6PV$0:1VS[",)4,4"EM
MN5K,X0)WR# ZS,4?#J+I?$Y&]?:S ,JXM2T81 9 E)85A6%PV (WR3 XS,5/
M,F0HP7( =?;E@&$0&0 QL9A*A@EC"VPEQX1Q%UO)@:VT+P<<@\@!B(G%5G*,
M&%]@*SE&C+O82K[$5G++<QH ,;'82H[1X0ML)<?H<!=;R8%A!,L!E%F7 XY!
MY #$Q&(L.0:'+S"6'(/#78PE1XZ1SNPVE(V-UO1Y&V,H (:)[9$=\R46&$N!
M^1(NQE( QPC: F7VMF!:!: UL2P[ G,H%GA)87D;XN(E!?"(<OSH/;0%R0QK
MT>AC610%1EP Q!/+5B0PE&*!K1082N%@*Q\'T>I.BX#J3H?"T5O$]K7N7VGU
MDI6U]ZR;1A?=:\.CUHTRX:/ _ (GE1ZN)[DZ-NVA-,=5_SJU/VGT>7A5'%[?
M5V__ U!+ P04    "  6B'!*A"G-<W0"   ="   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6R-5MN.FS 0_17$>P$#X1(1I"15U4JM%&W5]MDA3D!K
M,+6=L/W[VL9A"9A57H(]G#EG9C(>DW6$OK(2(6Z]U;AA&[ODO%V[+BM*5$/F
MD!8UXLV9T!IRL:47E[44P9-RJK'K>U[DUK!J[#Q3M@/-,W+EN&K0@5KL6M>0
M_MLA3+J-#>R[X:6ZE%P:W#QKX07]1/Q7>Z!BYPXLIZI&#:M(8U%TWMA;L-Z#
M4#HHQ.\*=6RTMF0J1T)>Y>;;:6-[,B*$4<$E!12/&]HCC"63B..O)K4'3>DX
M7M_9OZCD13)'R-">X#_5B9<;.[&M$SK#*^8OI/N*=$(KV]+9?T<WA 5<1B(T
M"H*9^K6**^.DUBPBE!J^]<^J4<].\]_=S Z^=O '!Q!]Z!!HA^#=0573[2-3
MJ7Z&'.89)9U%^W^KA;(IP#H0Q2RD4=5.O1/9,F&]Y5$29^Y-$FG,KL?X(PP8
M$*Y@'R1\D\3.G[G[CP+[.2+PS0J!,8E ^8?C)*+83! :"4)%$#Q4(3$3K(P$
MJWD$23HI8X])%:;IR^@["RJ1426:JZ3>1*7' &\D\VGEA&:9V"@3&V3 1*;'
MK$8JDT#V/2(R(AZ"2(Q!)(8@)GVS2^:YQDNIID:5=*;BIPNM)V5,!\A[OG?
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MD]T->:;1W?U&OLE$X?5(5!_;/"F;_\;V7%9YVKFHH:31K_889\WQTOE?95C
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M02D.QG69[:OV9&\'1C;=K26Z79V6?P%02P,$%     @ %HAP2IW&<U\^ @
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MPMK/M$\H<)T^^Z_T1DL%UTY4C(R5POPZV55(5O4JRDI%WKJQJ,W8]OIWFIV
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M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R-EM&.FS 017\%\=Z
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M6)'SD_>!8"O :-F>N>\/&^YPC(%<W:G BK)IKAX*; (8,('<-0$K(O]!@1T
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M0J@)X51"I G15$*L"?%40J()R51"J@FI0?"Z[6CW=TT$6<PXNSB\.Z(U49F
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M%V<T*.3*;)_T7O1SUQN*-\.3@L=W+?D/4$L#!!0    ( !:(<$IW0(X8R0(
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MO,NV<VH'6ARZKC#J6]/%7U!+ P04    "  6B'!*X'=/Y3X"  !J!P  &0
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MG WM?U@(VHTO&YJ>U_P?4$L#!!0    ( !:(<$J@=0X"/ ,  (8.   9
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M-A7;*[.<Z;7HAJ]NHWC;#Y;1,-TN_P%02P,$%     @ %HAP2B$+2@#8 P
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MKM197,;C8:[/3MY,MF-<S6GZ8%3&>-5:UW[]I:G6PK2^CRFA=.B]5Z9::-)
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MDR"7<YN2D;RUFU;G0/3@1;#.@5Q/6JKK*^+"VE=PC(&I/L,P2@2HJ$<$,]N
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M=ZL"/:6XM-M_9.>/#M_4.S= 4(==KAH#B!H*$^%G>.'W>([Q)Y 4-^6R .[
M^P$OHI>G11W?'W;T,[J:>!>](7/L%'_=[O)L3<Z#>U!RO@]*SK>HHZ_9,W "
M\VE8,+577WK\4_MM)XV'? H)^12JAZ:[GK@YN9]VQ=VA;1FGG;L]<GP0='Y4
M#]'[P=JER,Y__&Z_]*63[CKM$BJ'ZYSN97 HK_)O9T#'1VO(M:(B)[G7T"_A
MU4L>)/^Z(/O@FTCYU"F>O)3S$UC B_;*IWRQSJHJNJ:-E_! T2ILOG[Z[6FX
M#X_?GL;C=E7+8I>#=?^XSA:Y1%"BG4$K5A8!5$+&V]%=^K;Q7B(Y#C7!II:+
M@M2AIV+_T/C&']_)1HC[^$XV'C]F$& \\,VZ?*JZ4Q1NKF__-7GS[L-?;Y,W
MGS[\DGSX^/K3]>>W[W].KF\^O_WM[>>WKV^;$:?EWPZ5>-*!F& K2KAZ&'IH
M&#+P,_Z10I/G9/^@N^!Q5WXIEO _0%*)=8_^7'36ML>X7N6@P>(! %&G2;;!
M4//?F<3)'[)8[/(3W!.GV<O6ZC^0WW#_L"L/]P_)7;G;E4\PA.H6$E9YAV$5
MC91U#O='C?[;?(=>W^M$8RA%1)RM-ES:%GA[)]N SC'8Q3O8NG*+._']LJ@>
MRPKM_YWQ$Y%ZT.I,:D1W=L4^ORQ7*WREZ H/1T]]AJ4L0*WXR?B*. IZ]#78
MG^(+&YZ=;)#]/>3=--1% 5:.>1V)IH8(^#>%)3L<BB<&SMJ<%=]X95ZZV&_?
M__;Z]J6+[77CDP_^XZY<Y/E2]@H)Z_1W_2IED40XU3>NZ\W;]]?O;UY:5S3+
MAH"HRV(K(1I#<<P:WR%%PM[F3J7;O)23-4+_BW5%L/"(=\/[N'JBI5,,O7A-
MQ8GZA[5]O1!<402Y^R4S_6Z5SSQ$!DG,I)#RX=UYQ[N=:UD=2S^@@]K4XL:G
MCQTX$%HS\(^C'ZN/&^+5DL;PQPXHTK.S_27,XW*3[7[/PPY^HVZ"*_F<KY/K
M+\47L7E?=ZBX)"HZKZ5E.6%'NJ_F^]>?D_-7KV\^O;Z^?7T!'(?_!?](Z-9>
M8]X;_N/U7WY]^]OUN]?O/]^V7N^V!]/DI]<_OWW_'F_ZAS<)J"EO/S22\(Z\
M_1K^VOG>[:\?/[Y[_0L\>?TN,1SFU=O;FW<?;G_]U,)3O%BWQAZ)73QB4%$H
M)T>BRB0!V)""NWU8$/7".[#%]S!(<RL_O+^D>1BV#0LXC=FUW5:Z*C[91/69
M4[E&I]5RQ UQU OQOMQ>$HUU;0C-]S0QTF;T+$](,<(Y_\-I,8TOM\^9+O<I
MR7'58E<\ZE@_':IBVT(=@U[2\:0+_\BJ@JR CYBTLMW3!-V';?)OV?: R99C
MMB=2XA?H(LZVSY(9B)P$=*Y]3@JK7YXS*8&DY\&VYNM\H9N)#J$"0^XDR_''
M[1Y$+5J<\ E^S[TK%A0!NX9C)NG;2S[#K_EJQ;D:"5HRZE["T7#P<QC _>__
MVWPX[/_XV?P=,U[ISX,?+T"<@8X,"O4Z+.WIH5@\X _NZ0$68U<*IW'8L+!]
M!!HLQ#;&DWDJ=^OE$W ^&Y=UG#*D06FU/F"BUZM=_O>_9[WD5S()R"U&+( =
M5>3-=YDN-]4-Y/2C _.%U6&]*M:H?I/#!F<AP^)>XNI_!1U +3RT/O:P3KN>
MN_P>:'B)06%R*@&G_B7;;O]<;)>7=S /X.-.A]2 .GQXD_T-5PR&1XX$N2.E
M&162Y-\.ZV?:1CX@^8[C[^Q$K\7/=$7J?:P<]][5)^/7A\>&Y@=2Q9*OZ2/<
MNTU&:5EH(\%.XQ5V,+/KPSU8GCPM).;WY1?._[EJH^:<^!WQ/;A^"5R__3KG
MP]3C8)$I1X)DE@B9W?J' ZDJJ?6<'#4\[H^;:+SE)9X2[,P&N"T81<2/7?2I
M%B/24_5=OG_*Z[2[A;-$&ZNH#G?)NW<WR;D,Y?^J[X.9IZO+5D!BJ">D="/\
M;5VFO EA1-H=BOF42(KW%.5#_>B )!J24!SQS3OQ5, >G,V&O3YJ9&NRT_GZ
M@86[/BSSRIWU>Q/]D5EE_J4H#Q70V0$4L6QW[U-[:[YGIUO49!ZZN'55\KSI
M/JF1Y<X&_=[0?E031'R$13<5_N:SR9"4'%OX&7H-"K9*]-W'PUY"1L!&DJ=\
MC>F[<)5^SV&W675BL>-P3T;]WM3/0'SIYJ-YMH,-4*Z,U1XPF,LTGUW5W (O
M762R9&L-UWLAMW_(]LIHG\K#6E+6GE#A?\B^8(P^QW% +.UXHVC2S&+@>/<'
MD'>Z]T[FVEPU$PP00HT#X1Z9P=TR7P/IX!X^AWU'T7=8^"V*N NMU)RH"R>:
M^008$Q)[A*L$-(O>]'56P#W,,': >1;9XL'1VGLNQ"\+3$PHZ/G FO7N&C86
MR03@0E;PQ1P&&"WK=AG[\S//_.#:9%N5$K 7R #0^>/9W@,ZS.Q8*RQ-06ZU
MKUA3V_)42J!E''#K0'4#4[.H'D@/3U"GW^;H.L*ZA_OGE!D>4RHJ9%X86 %4
MV8PCYM^7<!;N+>@F0,5$(7@)U\^LU-%S<.N)W>VRQQS&6RBG3W'9^ ^W@,/%
M1$*8S6$)>Y:R<<:6#"4LXC7QLO*:1>26=2&\XL]8QI*3:&AD=<:;CM/<4;D)
M)87B7:FG6Q(S&O9FR9W<._Q2]-XVOR<ODJ/[NEJ73_5D(YH9$E)"4P.]:D'I
M"[G<@?PK_A.?<A@@2I.&CN&U*?SCV6#2#\PQ.3S"Y^"2R36PY18]=]V2V1KM
M ;+WP>Q';U\$.G&H41?D1T!EO:LVA#=HV+O2"=$]=%YR?L74V4I,%M)3\-_D
M$$TPL9*4PJTD-"T+9!SXM*L.C[C!]C9M@+6!;KWG:TBD0#<DT <9VEZ1(DT+
MUVJT+_Q9>)VH& L40:@K5LQ!5'LWHMW*6%_&T!#F+/R\I>(^DG\1<QUPG<D;
M$ /)V[=I\J[WL8=)*!JV;7GN@B1SYR-O^5)+=D<8$ZT2351.5<WUH_AYZK:\
M*7; X4(-'IR+KL[YU='36HQ&/.@39]5?MV\/CNG\F/Z;)%#@: _K/;OHLI">
M(GQN15<P_'DO7A7O(+/?"2X7^DV_X\ZK/$\H W]&CPZ&/R8_>6?[A4J5*KI>
M)+Z TV$H,ML[E I[(.I)4P59H)J2<UY34;5<#6>O!D44OF3%FOQZ#9\_3H$4
M'W*?W;.2YS@ DW'&[6)?DAJ!-[<_2[N4.")<5(S=SV"//[(F!T-D&^*#E,*^
M9PT-4_N]*.=(O/\<<D^RFN#WO%RENME[&3V1T7'.UV'.1D7$81RM"[=PF3V3
MIQ)9WXIK#/\#E),]"E.3GK0Z<*1*!131"AC,-%GTATB4>%'L@#^CSHCL:9.A
MIF#V-]:(4E47D^P1KOK78@,+6S\[U*(&GGF&L G[68@*.T_,?3Z^$2"-$BI>
M],I 92;HS' R>9_'YYT[%(&*ZGE0 CL_SQ3X/8R^ 0T+)^WOH.@>C["[+#-!
M]._A$QA" [/HD!,S5!<ST]\+JTG"79HZO4N?V,E\B1]ZMD]7%[$"!C<%;J:Z
M_AQ:R3LZ.#Y>U$U "07A^(3F*C[*GL6$I'BF_W/IHE,/3S,O48US"1IMKOM>
M!'>9"VK/!E-+0>THEJB0P."X05*5M<9;!-H([+"7 VJG\A=%>=QE>&T,DY+O
MD,PFL:(>L4QC&(Y#Y+@N<FQ5.7RTD%-2E0L4H3MQN-1\2RA47*:6+.E,E/,A
M1(Z+]]I<+.#D6CD1:/3!-=D])#[-T:7B4E*%4P;8Y' ^>(\<>1-B&1XINDTG
M1CT;W1V1NRR0RD1%/IX?/UMN[TM<0G 5'R.RI$YD:!ZXYF$Q$46\ Q6[!6IA
MS$G8%-]AS!R,HQ[>^XHT@WVYJX0(P+Y%HB0C8%D>X&3AT&)+1I4K9Q(F_ XB
M>TYH>?@WX'%;T3_804X*L _"+TN'"_4L#=F^C9WC:C<HE_5>>*L4ID1A=.++
M!3(R8:?[9W)\W,*B63\<''?DH0-OD?N!W3NQ9?\"C,A[]BI049 U6)[T_OKV
MU?5?)(#P"^EIKH"S7W#D$>>>JO+N3?EDU">7+EP6<N;YVP$RI:(9NKL"';LT
M)WDY\B@OUB5RU[L<-7)*.P.[8G/8@/[<Z_<Q6\VQ6]8;FAR]4F<:[37YG\LM
M'8RLX^=U>0>'PPLATHA\FPGPH3TF7>\Y&(<G8_>3K6DDOM4*K]72#>:P5-08
MEF <\/)@(NR8^X4J.P8C1F](.4D"35.''&!=D+_$!VMTA6%G9&TLG-YN$[W(
MCD=)PBBA-FC5;A_8O=T Y;F@,D4?QGW'<^4)H#S=)Z)1Z<;SIQSN=W@7GAP<
M.?.>PP*=7:79E[<P[WTRH/2K22\!2I9_H]Z-LE)TRI#6@L;K;7Y?1[1HA' .
MFPTZ4#!OW-@G4AR-*_L(XRU:PE;#7G+ZR^Z-O^<^V29Y#5<*]93*U2,"E=/Z
M),D$H.6T_,UKO1A]T]_U;S=6M%0JU(F&40)4E=Y;L(+WN(7HEF<KP(B+H$3_
M[;"D_42/JI<1RYP]@BPD2/L"6D"UDC,;D23"?H@QXAZ!$Y*_(H$MR(4K ($\
M$MP&O(7^'U+"4^\/KA[D,KF=3X]@)AI\YV+KF"\JMZ@SZ4CN5JB PE(P.'('
M]YBT!W1;DJN-E**Y;JN+MC52BGI_X(A4J (ALZ2\);%L#TN9B0@^MF8H:LWY
MW91O"$?Q]N86K2;22)QW!&!-*S)ZM@3Q2+S;/KAZ4-#!SZDJ-*C5;X@!%40!
M<//7JI6 ( :& %)&(@Z'+>+E4,$DKX!NNN.CQ "#).=7Q5?86,*U 0HIB7HH
MVL7V )@ZZR^Y/I&MX% =18.^/A:RUZ@_X.5?Y.H<I^]Y_Q,66LL)HD4=P@-B
M+$A(("6)6M_ !7H'R75!CMN>^QFXTK:5.ZZ+#4556(,".8M92S;ZPB*KIK?L
M<DP@ I+*Y=Z+NX2B23@%SXUU86"=4JR@V'#1P8.6Y&UE0=95IWZ]'O&?'>XI
M^@6L-*+P9J51&-7A]'XA,<>1'J=?M)&C^KYM2ZK>!TJC?:O4>"X7H/F",L0"
M$=W5!>IXO$):D@]5'8_D.(WD((,PU"!#U>83J_.>4X2P$B>KV\7R\$H]4@CB
M9P3&C#\QRFFHGEF=0;=AML^B?(<,IE3LEF29/<>^,0XU@&+ZC+,Q>BH/P@P1
MJ6^+:?9&I:41Q02C9PM<#,+ND/K*6B+>(/K1Y 7YA#JWP7@7;2%J#V)%J1^8
MZN-9]8[V ,AE [_UW!MAH<==K:8^E@[1=0;X(E<CJ E7-M "PSCO(M(CBFZR
MDH-Z@^U<7*M*2YI7<C;JC?V7BFT(]H<+0 QG85-C-4I%R%\II3\1=<.T0W3F
MG+,W7""3^UU959?[\G)KF'Z;4*@+A)^P&ODM!ST<B0)T\H2QHH'9!1_]S?W5
MQV235Y8[O,F-5 %9LWG<)Q_A94UQ#S]^RN_(3O,/R_WPR?!(,#?E);XM00"5
M79^$CX6A_MC*60AZC:6!#Z.Q03R&N3\&;[P0#PDF.=RG1U#NXTIOB@V9R\H7
MCJ+*''XB@<9B*G6PB6(RHFQ!V90V[T /-(5 51@,H8AIT%;LY23SC&9XER^R
M0Y5+T$RN+,U$LBD<Y;!N&Q^<],+.W 1HHU@_:>QA]*2_H>W:A]:C_TSUZ+<E
MJ%_^)_6#TC]>!S\HO 079KL/7/H&/@O:^Z>B^MUYU"$#&86C7*_!<*.;AF+T
M%5K8H'^I*ETYQ8Y"D;!"K_-EL4WE7V#TII&B)%Q68V*ZI6MT4!"/!78-\FSU
M;%@D&]79,TL8<DP]D-%.YWA':3$8=OVZ0!M%TUCTPCNN0J+E4*E![+F08BG2
M2VJZ-[#&OY$2X$)X(\<AQ*!$I_$3"TZ:"<R+.6W\/5)X2'?PL4V9:E@_G,8#
M.:E;PD1. 5"(JV;J6 A^33_IJH.]9ABH#S%S#LRW@ZU@V9]/SO;_<F09)1'"
M@:T<%3+2I$1#04X!NUY;K"JI8A4DIFO.XU;RO9648W2\4ACEP&**D["4)R'&
MW>5#^81R\5)#E4Z&^E=-R:*Q#&L-B5RO-9'+O8VRX]^!O+U\1[R*!W-O(SL<
M_1@%++U2>J%PS5TN2?;YDL\@I-Q;)E.P@2 N;E!*6&*1R ?#[AGEO,<RV(LQ
MN'=(+IAVRAFM%N_ /]-+WH0?4&M3VV^9H/%^3P3(L;E4"SK(RP)T2Y9AMGC
M-561G:@6&G_"7:/;A&AB63Z)9;8'<I<X"6PN:"6XC[ -G !8J5]8E^>">]\/
MS.$9F]E/N7K>06-LRHB7!/K6DX@+'4 "C3S1XS?.!N-^;^ST3RNC/%5=VE.
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MJ>;6@!9]T<55VB97LGPH[BB-D<["+H&GY)<9Z1/1D59<:Z Y @)>HTIT\%.
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MM.5T< 7_-W&\Y:/))!G/1YWN,N\X'X[FWWH69\DLO1K-^+_#JV;_#4:U_-A
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M%K68B^_"L:?RH!;:L%\B2'Z8U&*7K?8-)[WCPE'.I23>LO#>^TSKE0281<;
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MV!P(BTM*2RBJ8K%5/RJK:BERM0A>OARY6(:;2SL<\HL\VG/L-&2J9BJEE5O
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M"9D*IFER] 7W@7W2,,5W%,-VGVSG,2ED1O1>_QPA D<M>\O5"B]R]9AQ/[<
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M3;Q<V3!1QJI/>B0]VRBA+3F>(8S[,C8MG2)O)^MRB(7M9_&8,HK5\_#O761
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MR^W^"DEI@\ET;)#$A*L(=O"RGR,Q%]SKCM0))P \?WU[AV_[YO[J7[$[WS<
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MKP['ZK;?;4<C0>.Y>F8PF]D.'0%OM28LQ[9D!_$8=YJ/HMQIH5,FGTK9;)R
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M*H0P_7L*P5Q?)NX#.XQ)62AEMA")F6(+I92%TIU::%NGZ^FO\#:ME+)0RKT
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MT.-RT",]R&Z!C%M^$L*:K[4%7%N^UQ: ;?EB6T"VY9MM =J6K[8%;%N^VQ;
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M<R\N<F5L<U!+ 0(4 Q0    ( !6(<$IF\PM@@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ %8AP2EF.$!?O
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ %8AP2IE<G",0!@  G"<  !,              ( !MP(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  5B'!*KN]'A*D"   '"@
M&               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ %8AP2GRI#%"'!   @!8  !@              ( !UPL  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !6(<$J-_VC8- (
M &L'   8              "  900  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  5B'!*O2&YVX<$  !_%0  &               @ '^
M$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ %8AP2G0H
MUE0N @  2 8  !@              ( !NQ<  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( !6(<$K#2];01 <  .4H   8
M  "  1\:  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  5
MB'!*"H5!ADP'   !*0  &               @ &9(0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ %8AP2F4MZM>H 0  D0,  !@
M         ( !&RD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( !6(<$IQ^S81J0$  )$#   8              "  ?DJ  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  5B'!*_N!P/J<!  "1 P
M&0              @ '8+   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( !6(<$I.N,1.J0$  )$#   9              "  ;8N  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ %8AP2J%8M@FH
M 0  D0,  !D              ( !EC   'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  5B'!*.V1C3Z@!  "1 P  &0
M@ %U,@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !6(
M<$K:U1YLIP$  )$#   9              "  50T  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ %8AP2HZ:W &H 0  D0,  !D
M         ( !,C8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  5B'!*GOV&"JD!  "1 P  &0              @ $1.   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !6(<$KN)XG=IP$  )$#
M   9              "  ?$Y  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ %8AP2HY*C76H 0  D0,  !D              ( !SSL
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  5B'!*>="X
MO*@!  "1 P  &0              @ &N/0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( !6(<$K*KI"JJ $  )$#   9
M  "  8T_  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M%8AP2A#'WOZI 0  D0,  !D              ( !;$$  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  5B'!*!J+J=J<!  "1 P  &0
M            @ %,0P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( !6(<$IH(YA7IP$  ) #   9              "  2I%  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %8AP2GTO0A.I 0
MD0,  !D              ( !"$<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  5B'!*W <AFZ@!  "1 P  &0              @ 'H
M2   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !6(<$H-
M)1RPJ0$  )$#   9              "  <=*  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ %8AP2F^I6/FG 0  D0,  !D
M     ( !ITP  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6(<$IMLM>YN $  /8#   9              "
M 198  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ %8AP
M2A4H5<BZ 0  ]@,  !D              ( !!5H  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  5B'!*^N/IR+4!  #V P  &0
M        @ 'V6P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( !6(<$KW47'9Z@$  (H%   9              "  >)=  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ %8AP2A0QWG>L 0  D0,
M !D              ( ! V   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  5B'!*,4$R>\<!  !;!   &0              @ 'F80
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !6(<$K$&+IB
MK $  )$#   9              "  >1C  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ %8AP2GZGE@6G 0  D0,  !D
M ( !QV4  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  5
MB'!*H>2VP:L!  "1 P  &0              @ &E9P  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !6(<$KU>%1>O@,  &P2   9
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M970T-2YX;6Q02P$"% ,4    "  6B'!*.&0\:+L"  !-"@  &0
M    @ %.>@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M !:(<$H$.@L:4@(  +D'   9              "  4!]  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ %HAP2G\\U57S P  1Q,  !D
M             ( !R7\  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  6B'!*E81^O8X"  !A"0  &0              @ 'S@P  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !:(<$H!?LF"Z <
M $8R   9              "  ;B&  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ %HAP2AY_/:0) @  B 4  !D              ( !
MUXX  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  6B'!*
MF*@SC3P%  #M'0  &0              @ $7D0  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( !:(<$JI;1R<&@0  )$5   9
M      "  8J6  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ %HAP2H\#0TP'!   NQ8  !D              ( !VYH  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  6B'!*A"G-<W0"   ="
M&0              @ $9GP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( !:(<$HB-<N$G 4  $D?   9              "  <2A  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ %HAP2LNZBYG3
M 0  FP0  !D              ( !EZ<  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  6B'!**;Z!%^8#  !&$@  &0
M@ &AJ0  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( !:(
M<$H*)R <OP(  .8)   9              "  ;ZM  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ %HAP2HEYTZM>!0  5QX  !D
M         ( !M+   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    "  6B'!*W-NA.X,"  !&"0  &0              @ %)M@  >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !:(<$J=QG-?/@(  /P&
M   9              "  0.Y  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ %HAP2LV<?[]P @  .0@  !D              ( !>+L
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  6B'!*2M)1
M;)4"  #]"0  &0              @ $?O@  >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( !:(<$KXZ(LO"0,  -$+   9
M  "  >O   !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M%HAP2D3OTS]O @  R@<  !D              ( !*\0  'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    "  6B'!*-I<'5^4"  ! #   &0
M            @ '1Q@  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( !:(<$JLE,%)_ $  ,L%   9              "  >W)  !X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ %HAP2N"='$GR 0
MXP0  !D              ( !(,P  'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    "  6B'!*=T".&,D"  !#"P  &0              @ %)
MS@  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( !:(<$HG
M8>4OTP(  .@*   9              "  4G1  !X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ %HAP2CU\;E[; @  I@H  !D
M     ( !4]0  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !:(<$H:K7:5X0(  .D*   9              "
M 7+C  !X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ %HAP
M2B$+2@#8 P  SQ   !D              ( !BN8  'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    "  6B'!*=NU>!6<"  "*"   &0
M        @ &9Z@  >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( !:(<$I@.\"L%P,  )L-   9              "  3?M  !X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ %HAP2I?PD/^LJ   !(L"
M !0              ( !A?   'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ %HAP2K#O=+!O @  6@T   T              ( !8YD! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  6B'!*'/.(T3@&   R-   #P
M    @ ']FP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %HAP2E+:4AR!
M @  U2\  !H              ( !8J(! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ %HAP2MS>R^$D @  EBX  !,
M ( !&Z4! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D 60!A&   <*<!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>317</ContextCount>
  <ElementCount>519</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Stockholders' (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Statements of Stockholders' (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Related-Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related-Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Collaboration Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Collaboration Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Common and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommonAndPreferredStockTextBlock</Role>
      <ShortName>Common and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Net Income (Loss) per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Net Income (Loss) per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Stock Award Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock Award Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Selling, General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock</Role>
      <ShortName>Selling, General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Selected quarterly financial data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Selected quarterly financial data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Net Income (Loss) per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Net Income (Loss) per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Stock Award Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock Award Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Selling, General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlockTables</Role>
      <ShortName>Selling, General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSellingGeneralAndAdministrativeExpensesDisclosureTextBlock</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Selected quarterly financial data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Selected quarterly financial data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Components of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfInventories</Role>
      <ShortName>Components of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Inventory - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureInventoryAdditionalInformation</Role>
      <ShortName>Inventory - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Related-Party Arrangements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyArrangementsAdditionalInformation</Role>
      <ShortName>Related-Party Arrangements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Summary of Borrowings (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfBorrowings</Role>
      <ShortName>Summary of Borrowings (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Borrowings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation</Role>
      <ShortName>Borrowings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccretionOfDebtIssuanceCostAndDebtDiscountInConnectionWithFacilityFinancingAgreement</Role>
      <ShortName>Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Collaborative Arrangement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborativeArrangementAdditionalInformation</Role>
      <ShortName>Collaborative Arrangement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Fair Value of Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValuesOfFinancialAssetsAndLiabilitiesCarriedAtFairValue</Role>
      <ShortName>Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Common and Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonAndPreferredStockAdditionalInformation</Role>
      <ShortName>Common and Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Net Income (Loss) per Common Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformation</Role>
      <ShortName>Net Income (Loss) per Common Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfBasicAndDilutedNetIncomeLossPerCommonShareComputations</Role>
      <ShortName>Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Potentially Dilutive Securities Outstanding that are Antidilutive (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesOutstandingThatAreAntidilutive</Role>
      <ShortName>Potentially Dilutive Securities Outstanding that are Antidilutive (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Stock Award Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockAwardPlansAdditionalInformation</Role>
      <ShortName>Stock Award Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Stock Based Award Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedAwardPlans</Role>
      <ShortName>Stock Based Award Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperation</Role>
      <ShortName>Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedInAccompanyingConsolidatedStatementsOfOperationsByCategory</Role>
      <ShortName>Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Fair Value of Employee Stock Options Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueOfEmployeeStockOptionsAssumptions</Role>
      <ShortName>Fair Value of Employee Stock Options Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Summary of Stock Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfStockOptionsOutstanding</Role>
      <ShortName>Summary of Stock Options Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivity</Role>
      <ShortName>Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>168 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>169 - Disclosure - Annual Purchase Requirements under Contract (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureAnnualPurchaseRequirementsUnderContract</Role>
      <ShortName>Annual Purchase Requirements under Contract (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>170 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformation</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>171 - Disclosure - Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureProvisionForIncomeTaxes</Role>
      <ShortName>Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>172 - Disclosure - Components of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureComponentsOfNetDeferredTaxAssets</Role>
      <ShortName>Components of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>173 - Disclosure - Income Taxes -Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes -Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>174 - Disclosure - Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureEffectiveIncomeTaxRate</Role>
      <ShortName>Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>175 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>176 - Disclosure - Schedule of Selling, General and Administrative Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureScheduleOfSellingGeneralAndAdministrativeExpenses</Role>
      <ShortName>Schedule of Selling, General and Administrative Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>177 - Disclosure - Restructuring Charges - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestructuringChargesAdditionalInformation</Role>
      <ShortName>Restructuring Charges - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>178 - Disclosure - Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingLiabilityBalancesForRestructuringCharges</Role>
      <ShortName>Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>179 - Disclosure - Selected Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>180 - Disclosure - Selected Quarterly Financial Data - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataAdditionalInformation</Role>
      <ShortName>Selected Quarterly Financial Data - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mnkd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>181 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mnkd-20161231.xml</File>
    <File>mnkd-20161231.xsd</File>
    <File>mnkd-20161231_cal.xml</File>
    <File>mnkd-20161231_def.xml</File>
    <File>mnkd-20161231_lab.xml</File>
    <File>mnkd-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001193125-17-085519-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-17-085519-xbrl.zip
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M. ,-=#/V3A7\/,F\=S6]#>XQP>(__>_?SF?@*2]_O)V,P+>:>L_JX;[G%9Z
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M'^R%,-0LKV=GN#PTKPJ8.G0'4D4'!+S1ON#%Z303^_9%*<Y]N;C&T\0QY.K
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MA:EO$G:L0^$%( NA1(.,CC,@RX^F@%SMM7D4;C<#/[;06JH/)O2= 93A"O=
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M/+ZYN+Y["XOE9OPPFKR>XN4?OLUZ#-$U:CO'BY.4W?;Y;=#MZOY\8AH&72(
M#ELG@TNZ#HUU$\OC.[&\?<MA]C@?ZK*6IRSK-8Y&L'\!H!^^99.OV1M _:6[
M9]@9>-^5J!GV*I@CXPV&&R:P.*!55,:N[[O_NOFDN1)_#C%.C(@HM0MT+X0S
MQ37NCT'*:[N:!W.6O$9XYRJT+_/L<B[=.129;E0:XMM[)#)8H< Q?YA3M1V;
M.![_KXQ;0L\W/\>=3&;?L%M@CU";CHV"_X#.<TQ*5VW#=11.U5R9?@7';?QI
MDJT62CF<,\#'K'T7ODH5]1$8M5[H<UC4#+:T<96NE@U%_SD3O_J 1@&:R>>
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MY>@XCJ@3BE">PE;BL2%!&G'"(BU-0H/$I3P7M@K,,JZ;T5#@NKA@Z0^]]!-
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M0%=!!H$)N15@E 1HGD04_.,T(6 LQT$:B9"&12MPXV/Q;VK]PCTW?0SDX@V
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M@:MP&R7?;R:/MZ"XP85&??V8JZGKNV0TG^)PF%7RR:E)K6"SY9RUZ9,$YGG
M4A>24!M.)/K'8)$H' 0DE7(TH5SGJE@YJ;DLI:1U K,R?+/RF1B__B1/>1\7
M;4K'4PO&,+,!$3+ <8Y! F:*LL1&F-^.6<,Q3BOD!IL;OE2R-#>S'D<%[-U=
M=I-+WYO9??9A]!U/!W%&YA2[;^<SZ)9IALG1$TQ(>%S.YC^V/MP!,4V.);B@
MJ8VD(SP!;2UA-\(B,6#&*F=EX$(E8EPDWN\%*Z7$P_D03^<L\DW*7D]7PZG@
M0WD"/>[9_$].)K-OITU\;,Q?S93P9NQA.QN@3YY(WPEHMZD$6QI[VZT*K<,?
MORXPX+^VKS<&0.0G%#W"[XHW3YKBW&1+=M++[Z- "I7A%5UV'M".YF4V+W0J
M>NY?8&GNADAC&X7.!!'1*C1 K$V)39DBD11!XD1JG4L_>@N!OC3,EB1<?T1L
M/X"_9QB.S6Z#K_" /F>K\%DA8,^)"377HC4KM*FJ<+XGF=AN?'TBID:$[%P%
M#V)\,S0Z[ ETU"/J87NVJ[9MO"MW[8Z&NU)7BVLOCKY_69A730])%OKPG';E
MHLW^B+C@ ZBK,AT@_44VKV87HO\ #37D?SK^5S_M&==>.C"M"+QWV?UHC.X#
MFB/SD1^)B#6")Z275)]#-1@=! IL*DI<*D$\!RH@UCI)*+<Z58Z##1]^] E8
M;]5O_ US<87M?G%WM.J+&_BK/[=^71SD5N[!OXG]A]9KXXE\SX39D 6"@CV;
MGQ<D6%N=$"6DT2D7.K TWPZ,O[1=*(%V]!SVW[LR.B[IO>NCWGN-H='$,_.-
M3H+;_WA<^(+>+ERFSIQ-[IU-RDYT-JN0^M9'PW.-\A1G9B]E#AR@X82X_-Y3
MUBX698='Q )=32UY.9.^); F^_5"@8WC%G[#7;K3/J<YC&WXN[&@:KAH%4;J
M+/A\PH&65(&(."9F6:P/5QSL$HT3M$VB61C$7(I<U=F=_@FG JL_N_DP"VY\
M>\$.$NI[#'?AP0V8;*KVY.8XIIK14BBPYMD7D%GK-9;.YF #3",_HOWFQP>0
M8@NPS9#RZ:U_-?$/8-7$))B/?0_'TE;%4_L[>!Z]DMBHF;A>#3U!+LGV.*8>
M"-E^ JM<EU5M&:S9&U\TM.Z:MAF\,<CX*\?I.(K*RERWDW!=K*ZR QJ:6I04
M)RQ0Z<ZII-R_RE;K*LSNX#-];ZN&2P&-:EX=#'4"ILJ!ZL;B!+%V>^LS)4>3
MMZ/Q[>MI-'H8+T>3>JO+IQ:.,9[B+03?R=RWDEV,E]G[;/XU[R,">Q(-W<_3
M\8FI4'W+J7QM6;4MJGKFIWD"0*FCSUVI^<3FM'C(5 MLU<5K9O2U!=N<MPYF
M)_7.%\-@OJV9HW,JQF[[+_0G\Z3QODN%@B8])CK*(>H-J<). =+6VIW',X;6
M!Z^Y/85R?XAJG&%C9"&E5ML&=LWM[QRL#QL91V-7: N.5_6@?!\FS+9<^+#$
M2?6?/1H<"C.4A-C>?%NW7;6V\X **LE! L+0+I9F5&SIS5T?\QZ\:;W)<CBQ
M1V:/;@,NQ[PHY)#34 ?G& 6O00M/E[-YWY9&4^38Y$U+(8] +\$XAG@5_CB]
M**@_U )7MA+N".H*E)TA7E7'_$G"#%SQ( RB@(0QC<%08@RK&!1ATIG0"15%
M+BZ2NU#BJLJ,T?TH6GI .R=S1ZWY"YQR=6M78LZ,X:J=Q].2CWK[K"@Q^#"#
MYX,E!]AO 611%X5&_5FI?MJZJC?>3@6XSXSUS9*&;L5*=%@$VV/%[D"H8ITO
MI^#M%6NMB&CYD^OQI\?^4R1/]&T9SHJL(#\*J*I[OF;Y%LP%U\HT&:+%RW#$
MLZWHF_K;;^ZD^_>VLQJZ3E7O5I!*[ =8V?DG [QL]4?O<7^&94!6BL:D[*GY
M*%TR3/\(Q+[E:B].5G,:],ML.MMV=C$Y;;KHUUIHZM1B9;'0-6<X>V%4W/9G
MA183.+C(NXF5//AF4'=M[;?S[ %LIY7)75RU.I\9L.^(01HFI&5'G(DF '=(
M*D(A>2G3[AE[?EJQ/HK'VJ?E?#2;@\DTFO]XO<SN%_! D+7Y;#+QCV2X*I*+
M^J#0!6EH-.5CN&N/\7R2NK+;]28'@9QZRO<N&TU.FTS=HU7%VIWRK3"=[N(6
M37ERE35DL\)/OMQ>%B?CJ] SF<QN1JMZD!U/["ETE8QX[%+JB-)681.QB%@>
M&Q(!5YH'/(S"(D=UUW]OA*;:A2^7W46YX%K@%!\.LVEV-^Y7ML*3#SA(":(%
MA8TBN2+.! %A<1SQP,6)Y'%^&LZH@S^TQ4$S//4</"/P#(^L+645_^L(DGK8
MOBTWCCJ%Q?.<%@!6"',GG*REH FJ*A\/<[BM?&YW]C#)BO2CX'XV7X[_\]+!
MIYHFN"*.I90!H=IB]\E $VO@I151$O(@#0V/BG3UG2$$3<!43+-[L.7F>>H,
M3E#Z&6=&Y?KUW[()ML;Y=9AF.^X%L!AD11(TPE-GG3[MXF]J66(::]6@/++
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MTJM,;=A$EA9NP58;N^X@[TL,RX]XKZ?P#3C/<WPW7F54]9L7ET84Y%Y"K(K
M$J#@/8+BB8A.1,(394(NDH]^NA>FA57#H W0U#M.WKTN<HHOG#U>@YD&01@K
M2N) :,"<X)1A4+M*F3@R*=>QY$7P9R?N6W_[G0Z_[*#F.PK"2*J(J-2"2<%4
M2 (+\B%D,66I83I,%4Z[]!.X-*T$0_=/NZS]1#'O[WVV7$ZR6SR"GCUZQXH/
M%#,&?&@EP;$AHH[<@J.65VYB;5G(%^KWW(U="HZ"J@Y-?1IV2F,%]RBWBSKD
M9R0"Y)D 1^Z\!*])N<9&'-\40ZY68[%18:W"6S\^S'+.AURP(GV) EV/5[P
M_.VULZ_9QVPR&7V:Y7'2=]G7;-IS<XJFX4Y47X86#DT+4"<NM9+-DU<'_?J
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M:G+O:E+)3G,UJY#ZUD?#<XV8UT><L3[U49UCU%<+@R8>05T$R3$J5&@-L85
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M&4]OX=M?R?_>"L/JOK/R?<_R])KBOB>EK'/81O!H[Q_F/C [N[N"3\*WW,U
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M'.3U0&&K75@<>OG<$#SQ^EYSXK599'5Y!\_HUOI?U@,!/N!;^\/8Z\09:I;
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M;H27S.7>/ CJA_7O.%.A/ 8J,YDT1$'HN$>@S!#@.Q-/CK*4RJO9B $7QE^
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MT/)911E.EV"X:KE&"/ZZ^K:%CF@%"*Y]&E3JHE(7]Z4NJ-$V8BN6VXBRL0P
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M BD>T$7&5CI+ILYP%><B\ST2"NB^\; 74'Q3]4$*.^M/LO.H7P$US;:&"Z(
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MZ2??U]&,F8F"XP7B3-7FR A'E&)@G[)<23;^0TX/T53&E1[YCT[HHV@38ON
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M8'+48DW=D<HW5BO?!VVDP,G?/8W1$^/0XNB)&\2!8(UBY3BMK=6,JMKDDM3
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M4 E3)K!5" 2)/M 9;3%<C5* C;C3"77,,W&%S.FI6BD[;>&:B$XI9*&UF%C
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M%4,95RX*-<AL[\!HY.;Q8"0?5A39F&H@$W?D]3_I B\3^IZ[IGEQ6FXF:(S
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M=Y_G-XPWV'GY_E)8DDM-WU47+0+W6@:(S.I]9P1,YOJ$9J-0 N0 6-'-86Y
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M7Y$\=B\[VN/3SK#1:3FG[7X=9$=WY SKXU.GVQF?M+N-\;C>'90$-$<#P%=
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M=+JC9K<_.#TM75_*TV"Y<OT;:^HNILG"Q21\BG>Z7HADF3",@#*QNS!)W+"
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MN)GW(6T1L]II(0E&34F:&R:EXR#A+L]"!$<$3I0KIO4G[BLS2>(FI#!4Y)L
M245.?A!7S)@O--)@-:;)\_RR+=;4,OY!& \1.&>-5SY)"7>Q*)OMPJK]X)=T
MR/F"Y?G*C5D7=P<H,C]E\U\+7NLVVTVM-6Q:FF5TAUJW80PUO6'HK4'3:IE&
M\_F;:K=K2HY*2I_L?HEZ:E]ZRA5$KRLNE;O37-$%C ^OAU XF$&)[QN@]/'J
MLRT+Y;0+B*J)\LB".[(7?AQ,A %(*^SH8:F"GV:H^6H@SW1]?A:!1[?PQQO?
M!PL&HB[\?!B3G11F(&39&CZ;P2<!R O:&,HQY7T-J$ 5__7MD_6G5P->T'94
MU BK0!0X00(>?(>/@<[Q7"+P?Y!1@0#!:/^,:!B-1K:E>":!>?-3:DYXC$ 1
M1WZ5=T:M41#8\3H7\%H$3O(+D/QCE0:-0&9_@DQ(&H!DJB%CT?6[)@+9PL]Q
M\THC$PI*94@V>#LO^ZN6;9V-:LY@TG9!Z@?H<C  3SRX 1@#FY<T9"OX@&?F
M:8D^:P8W17 *'X50$"AOC&#%C(2BV#K?H'W?P0>Y3#:,QUB^%3LRY +\.)(!
MP1@4@7-+?F1=4C=N5O$$K*F*O$X\BGH]AVB"6#69!.A7I?/(?F2-KYBQZ353
M2>@3/81DIKS -PIIPV$5XZ4BM@,%8%.Y[>6@KF5(("KNO+J8WR%J/7\N"!:6
MI[N[FE/.X8PQI2V') W')]#<AK?.+.+FM6BG,K<9>I%&HWUJ^)IG8?K7P:]D
M#3?9PL8J\S=:PP);* LAB1TSF]P:=MH;K&&1+5Q;Y5VSX!##BC4LL(6<J'M8
M0R&XA9][T!JN$!P_OF(-A4D""4@B/>XD-QM)415Z(B-IU"PE:QN-6GV#;:P7
M_.5QMK%!A:A-!25QV$,>>EE1M5M[NJMM6Q-OL2=F;D2T0/+>K [*Z8LL36AV
MQAMGYL6)1(1!4@BO9;;;UX6'%X%=W[O14%!EV2-W1H-;50I)]K&KZU:5'(X#
M*=_N=C5_6C-O97^LS7WXL<-IL'VF=1S!8G?)[J1ST!#G,8,/><G!!X]*I?!W
ML2&65/1FR7@8*91%'!3FK+ABQ264ZD[K25^2\LEO.[@,E63%C(X0)W00VZH9
M':LM6B2,Q3,Z&IW]9W086^9Z'.OW3=_> N[9?_KY9AP4#59>59M]CL&*GXKZ
M[__*R?FAWJJ9C7RQH;WS2=-P$CB+)[_J>?SY"IE!(?G@='],S@GWQFO%G:XI
M'0/!ZGKX]FA&Q+NY#8F_VUZ,9Z)$>'U:T['#K:#BJT@[SJ-(KR:M[+L<$\(3
MJEA%GU=.G^KZ:J[Y&]91Y-A=?IPE/2_ ,N-\SW^2SK-+7OFZ2S15W3K);(E7
MA&H5$>U@8?B6"MA:%D4N>RFSN2J+LMZOIJ[JQL&-J<ZM.<_ID#VGV_F/*=A4
M+54JGE0\J7BR&T^JW.VA6I/<LU7J9:DV5:'6B:(/"#[,=H5JE;R]Z/+0":3)
M4*US&3#\6%0;S5=2WC%5O1JI_!*+.:=(VPW5;!X\CN+<:A2F:ID'CQ Z-V3K
M:K-]<$/(JB!3)9H53RJ>5#PYO"!3Y4\[EVA2NLIC]4\>21W:=UD_24?BTN!G
MJ$;S9;>5-M1ZZ]4/9'NLC:UZ 5=<J;A2<>6P8&FM;W91<XC]FSZLM8V@VXOP
M<J:MRI 7;GG#B:-UB3#:5DMOCQI:VVKV-0NB/ZW7,-I:P^@U&MV^T:DW1Z7K
M/[.Q\XR@$>\>08_FH[BOFR_/)Q?)\+ZGPZ^4;KZP.G$=SYE07X8H<&PWZ7A8
MV%U57#I6)O!9ND@:JOG&7&]X:P;7R5UDRX*'5WGI0RHUP %0T];ILM=)[EKL
MQFXQ"Q:$>'?9505^O!<"HAV[> LR%#V#^4U?%+0 X$P65--.</2^FA S[>A>
MRS<'RC6^X>_P:WUXQ==C1&O>VB'3A2=I?9/TPILF-U&S#8+H2NZV&[^KZXG.
M-"I]7=",6M/(+1/9UD'>%1VS&]O+7B+/-U43UU"!7'C[<V$'HKO7QC;85@V7
M+EYLDMN\>?/3QA8%M)#HOIRY&;FE/81LJH_TX>_-I53MV0K:VJU)SH-6;-7L
MW3$O9E\YNU&,!FS&D SB+T<S>L-AI]\;#MJ:WK0ZFM7LMK0V]N#J=)O6H&_U
MAEU3+YW1D\00]?Q9X,_A/UW7'LL&3KD=]M0")B^2;,&2].HD]VK 1.^\4/1'
M"OD-=VFY,JU2IT*TJ*M,Y(O>J[G.[K+KUM0!W8TVF%%J5^T$<V41@Y38HAF-
M$W%9Q?M2)-'P!:>PVP+9K"P.F9;Q-660=(8OO)W=5),E0NIAE729R[23E<CS
MSCND,AE;A'@*@E(?*RZB.7>3A\\IZ#V5ZR> *V4;YZ5PR=5YJ]$4A$BT2071
M>?XV'@](:F+PO@BR7A%9BX66K$]6;*70KC;R$,PID%].4/G8!3>2="<=6:)2
M4UIL=9ZT ^4M5FX=WE":A :-.;HEU[^!D,"9A._I@047E<O^%3>FMS[ @%,O
MIM@_PAG'?"8$-B_'3K1+:G$*?Q.N9KQ4%K=V, <WRNBC"V Y-1/=R:P^8"4?
M-*JB;6YX-'-JZNVN;M2[FF[ :U;;!$M:;]>UT<AL-9IFJ]_M]_<QIYN:>66+
M?NV?CRNS()1SR#J^V$LE)= &@YJ-#?P9$#^D3GN<Q^)5-%M(XC@$\!E*@^@U
M@EU=DCY\7'@7@3-AI.^\[[R'UT6Q!PEZY04';&$OT4SDF[]@-\Y8ML98 V$L
MVLV(EAYKW?I$4Z#T YFW94=A.3V"# [7K?21U69^;WY*#)6P=:$]9Z+/LVBG
MD;=G3M:<[6;!GD,XOK(Q!NV[R -:#&?B+.AYH,*,366'F3>B2ZIR@Z;'0W9J
M\#4;#^;\P7  0L"#,_X/!\F$WY4!:R@6H7DF4VXXXB $,J8?%7Y&.F">1V #
M2&=&_9H%.")*7@4G_=(]3B09+S/2Q"6!T\&F227)_!BR8 D$Z5>*OX&RC6DP
M1MF2L.E2?,J-Z$ZW!GY*"8(@&_BB>"6$2ZE(/INH*+K:K#:3R^D0_ZQ$$_"'
M7!YTQ0&CSWL(R]8X25/-7%=ST::3/C=Q;0<!C;A#((W#_GQB/!+E**(3=RB:
MXV57X=HBR)WTXQ&]WV_!S?@!YI^HM@ W!!.K$WUL[L(T<F$*J-L4.XIB3QP1
M?J5MB<7;J8>TD^%!;+HB7#@CA$B5E5AX69*^IHS045-8@NOFXD+'6\21,$&8
MS<&3^*KM>?\ 3<WGS!E7'S'*UKR$0$5 832Y E8J#TZNM;P<V^#($(J&K,A.
MQ@F&-*Z!FVALY+R$3/4>4, V^S)HOK&#J>A6@R. TJ914E"S..'S.'\\&1UQ
M$P.S7!( ZO:Z7%^GL)R04UAP'6)<% %BNY/D&WSRBAAVP*>O\";.W+:O2-F]
M@TS"^2IC["7[G7D\^A8*PAM(2BI2YZ= F?M3H9FT+G8= XAD/A[<B=[S&)\*
M-P!KC%ETS\04%B1Z=G0(<DJTJQ2Q.)+$8VXR[&;*>4USB#+VB)]O"CCY*%;,
M]T +G1^H?AZVY9^#Z;\E^Y-T]!>#,?PXQ+\ZJ%U)ISD0 BEXXE/)(!+>>4Z@
MYDQ00QTQ3&8&XC)A86@'2^R!_=\X% E&P&8N9D4H39A2A<(8YP;2U!+3:*]E
M'6L==,F7IJ6"P_WM3M&F] @/Q9E_8./$A<N&+B4XW6PKKV-%GBV]9XX,S-S-
MAJ%90[.A]5I65^L/1GW#J.MFUS2.'7E:1P\N.&\RI,MGD9]8I'PM2B]SV7^8
MEKVWQ2>46(=<O7+I:2AFR(CF]RA/<Y!9*>QI2)'T/PM%)4D:]%0-1+#*1QBE
M0[)$:E;P43+!0EX4Q@4F(]A!AC3"'*%ZHOU$;:DEY,GUBR,W)U=%]^J*/Z!*
M43]]66 (&?@3!! ;B/-VLNE70),%[E@N"!RJF-$:<S' 27A-B)DH7B$K!7;]
MCBH8R5=QD@$/ ;VIAHY8MN&6ADZD"C7EW[=@'<4*U&2:OL:!A'^JHEKK3%E2
MO1$>U0GES(.TF+&&7!KT(-3C[$ 9LA?(2M$A4?@7( C#,1D9F(316C?[G!%9
MCL&?O GR@.,A/2\-3Z!E$;#C!?]'TL]K,?TJF?VX+J Y:1,38$+EO_'T1G0P
MS[9XSD^%R=*L2.@$;3&2\!TOXA$!>E'TZ2JZ7JYL8K8.*:V:4#^\I2E)XXSN
MH+WGOICA<#DJN$^3D0[BJVEY?3WJ6"VW"36BYEIC8.<<(D9E%F-^"[!^\@&Q
M=LX@4323K8=E/<)AOFB+B\E[IZO)+;A,EWV>#2%?I[Z3E]0T_]K^\15X\#77
MS? :!?SX#=F-;MVL=PQ+:QE#4[/ZPY'6-H=#K=4>-ON]_JC3KP\>=%9_=+_^
M?OE)ZWV^OO[\QP>%I'GT^=.U=G7Y_X8?%"/]8=3]X_+C?SXH:Z>SQ!+7G[_
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MDX!%3)DYGNU-'-O-G93&[FAWMN.2&8:?%0;2&?._C9>BZ]KDUF%)3S6 <<K
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M@AUK$3 J($YC^!V+'M/--$ <*'?(F-FY3X1PG>\\E8<X#'>^)$RV"R(_W>(
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M%W,'"(\>RE14V?&-@SO+F6J]4=P][\PQ,U5+/PEBFPQD?O.CG%WS=C*H(AO
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MJ0R:=^YD38D&'9U\UQ+PFT7K]D:8]5"Y!_\(W@Y-L#-AI'BXH!>CG>.:0JL
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M)U2<0@X)W]_#3#R_-E[G0J-P-3>%[,A#[[62A(5<;S$^P!+@C!*_O#:NVMJ
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M<L$4G0UR("SOU5)#U\MTM[1I['^WM/Y\=TNK3Y_DT]4USGVO.?Z!O86RENH
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MT-52O@(OR.,:CR(4 66U@*-#:.6*%=A0W&DM;LB\I #]& 5572[@$VBMPK.
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MY:#7:K"4SJAS= J63'&UB-; +HO)_:<J6]09&:"P*/TT)];Z!:RV]Z A@JI
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M=%?**1N%24L%3>]QXK O*VS@)[:G#G)H@3[IMT^D'M+87UX= @1"J(?JCCK
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M%I6HYJ*":3%5>J<-8Y6>HOM4-+:QI3OE*/76PM36MO0;:^8HZ54D9;P0<A_
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MS$>C**OFY>A6[I(R&3$Y\J:<YO,!C.R ;7^>P:SD(\ $%F_K_[!^!?-[/X[
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MK8I9D5>C>G*=W^3_^>YZM5K^].<_W]W=G=;YY/2JO/US=/9_P!N$_^?YON4
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M"O4F&=V!$ZCJXL:SS0@Q>IXN"G$.F][IZR55Z.'BO!Y\7D:Q3"F\>EAF::7
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M[PR479<6:29^E,:B^$B^HTB<H<*Z C)-)J>.0*CEBXW(<VT3*M;"VCFHCGC
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M$>3H3,"M>#.FE3>@@EJ=ZCL-]K#-K4&M#%)>!:GEC<&VB&[]&Q$O>V&FRBQ
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MI4WBD)G9@E,MG+9&_M8AFU. O"V5I\3JD/'5,LNMQ[LE:(>LK[8EW"VF7[+
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MX.Z"Y4M<$!1=*WWI69>352\DB.71;2?K772;W]JYZFXE+LSG"HH26$V\5=%
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ML>^3C,R;<!;1; J,OBY1$GS'1(*N;F=W9!Z2&?%8LE)FT\#43** >$Q36XR
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M>@N:DZ&[X65K>U-Q,K(W/*,ZZ:G=HH/&;<:OB-7SL;L@SIWWB/TTP+>S.QQ
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MLCJ)19*K.S.S/N@[#)*M%AVNAQ^CP,<T9DYELF)MW6&\XOGB:P!DM9S5POZ
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M;!4H@AO)&@E5'#K-RH9BA([2H\89/CD-2P)]01F]CAPBML<8X6UXR4HL)$_
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MM"60"]\8_G@CIY7<<'^#+O@']6B$F:]^BQ\W<9YZT?(+OI,90D7/#<%UD<R
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M;@]?4U[I6+6Y(%@QE!6AB"N8  4_J4E=]&>M6CH%_SJ1B:7#86 GQHHXV9.
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MK_B#V5*1'Z&*.JF]TQUB39H74SN\ ?[.*CU+YR6+'>^U_#'K&,QRW$>:%W-
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MYDPW>8+?3?RPW00OY'](HO-\M0I\5.\E?]O5)X.T0O"BI7"O&P.LEDW/VBK
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MCGR);#[?\R::81$&0C^N>,XHL-!N=3OF6*E_QLE!VCEI,W82<L0<; ?<PN/
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MV3I!2!PTS1EI!HH$>?-565GA8>?YZ YY*5MCY@TU \>S%X3D2;F+O>C""XD
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M:FJF'K!<^<$'E3+,&ZP19HI=UVOR:[^>C '[LG:)64/-'TN9T"NC)LEU. C
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M)<P.NKRA$'M[G\0[E&3[^]"+LEFTO/XS#W9%A<Z]A,6JS+0*(RD;4YDY.HR
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M=%^@L+ )> E6O?@JCG *$ [+W&?;4=EC *&<)P\H><:[+VX@?#H4$&9B<:U
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M85=ZYRA4[VN?[9."IO0H6R^ J6-Y4C25QM'8>6$UZHZQK .<LEOP)UAX:8=
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MBM W+WS$\A,S,D%[.L29/FK5QCS [3%&J/HY"+&<'$=H0>3DNEGCGO]J2F9
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ML^46PT *ZY.<B;H=V:L/*Y-0B.,(E,V: BE*.E7'$-/ILY?\@4@1'#%A!1,
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MM!J961/6:B8&6M-HIK68!7@_'8.Z0"E^-_VLBB_ BO[1+U_Q:YSVH8[93UI
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MX(GU\EGOW]Z13Y ^5/C__!]02P,$%     @ %HAP2J[<>UOJW   7K@, !4
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M2Z[0;SM:2OF87<91<=?+8+=2$.UDQ.W76Y43BS-:5Z ;=EG2DRM01A.J MN
MB&HE' R^IBVG&X$A+6<@#ILV'PO&])QJ>BH>O5F)[@E/3[=Q<IIGUOC;^IG(
M 9GP&"-$Z85A17.[.G%1S%'GNA\QVFO+<6SRH*6<^G[%R9*3OO4,_XNFBL !
MMIUD9*/,6PD:;V'(]6$UU^]U!\:')@2G.1UK1^N '5I:E[,_Q)=^^GR;Q*_!
M!F_>O_V6TJ3Q9D=OTPNBIXMU%KRR#:M]-WJ-T114L#"DOT;5]H(_G5@IPK:8
MM$JVZ9^I/JA4"#V^H1^I3B3J_(0JM5"M%_Q]9.!&]CA&3BHC1\3(06'DL#0R
M_26=#D0_[DOC[AHFCRM#^Y5NOS@3XPR37A@&37Y,,X/3\E:L].);P#\AN?V$
M]:%BJWG5Q'N^7*S*HW-* ;9/QSE"\6E+<1J0B B0(SF/ .$I@[ SQN%Z>CU4
M.41JF& ?XA<_Z/'QXADXDN4**)^M.O/FLP[-4C">#=']@&FY$%BN#0%RP#8)
M$,M\:SL^AW$-O&8X%VX3O/G5CZ)/].9IYO;<+2U]3UOGH5 5Y1FG^6195LHR
M88A*0[6X<;>RB%EJ"-D4"ED/=PW!8RSNX()C<"^-:B[+\8,,ZD,F'&_XB^_%
M$;:B$9C:RS8'WDH::1PE-BM/8RT%"PMORN.;@0;#(P#/RP^I/'18?@AV/_ 8
M7[@NM.0@=:+04HNFK8&UNKW,9!6DZR;#\RIMD604_">M9Q-<-50=Z&SIK<H#
MZW-!J)($E408 #0% -23.QA Y7%1P64.4JK468,8^?",(<7K=T_QZ\\;'-!D
M84Y_H&R>-W($\JN\<=KJI]!_ZGR7P[];Z.D/&E7?V>UYBX9C,X>F NPZ\Y'Z
M>VKZC^V_0M>@7LN'")+=-HY6N]G2Y?*RP. VP2_!_D649/2^9S.G[5-&_>[$
MR:*<-6W(I.NJK.:D*K[XL1#,/<G'0BYK%G!U]#%N9G/HE!T;CC:%:+!\UO#7
M+8YE9:_2+QLT5L\)2\[!#DO7YF0KBU6R$GR(^11$Q-A!]'1)BTF5/GGG%;#
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MDM+W^R"D!\E=O=![/_,Y+.G.7LD+%M-5L1;JDYB+>=GQ%<)04QH0,TP#](0
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M4TW![!JT0C2J9%L.1R,@G2HB!3TX>P3<+-*4*-D5=RT;U+C9H0'W?A1O [B
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MB*-]AH+B9QS1$P=NMA^*7<8/_K>+-,59JM#+]K]KF9N]"FET*EY=W%3(I4O
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M*<KEUWIEUX'_&(1!]B:P\\%C ,3KZJ!^^ZHW]2KN%5)0)<8Z^8[#,;6*HY>
MQX'Q.F#"4@P[E_TE"'&:Q1%&._^-744'25(14YH\Y5H#**U\)9^.53WD=SZ\
MQ/LHRW^=X<U4G/?TO&<WR90KH[Q</?$6U?)\*9/.(!9;5G.YJ!(,EG.:A.MU
MX-[L\BEB_XDDG_003H3I]$(*?&J/HI]VLE$%0\'1+@M(?OP!/V;W>+U/@BS
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MY__!?U.;%=(0YP*#>W14/T3V;#)7(735'FHTB(H6$6W2,8H;-5!U)U8)/"N
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M)A0?C$#T!D.TQY >!VPS1685D&+1/_9$J[X+Q-H/V2P+;;6L[#O+E5=F0TP
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MT%%N-V!F5C_^.< )L<OSVS5^)>95ZLAD+\.P4Z*1QCZI%2??K02ZTMD9@WI
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M/F^?6\OJ0[:5*7QVL\L)PM&&GC?UF)_4-"+^^\Q/,KL66"A9X!$_!5'48P3
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M"5AD;@"!R?<P>?%CG-WH>!7'Y#.PE&):K:&IRGT7"3;!I*Z6QIITD=+[/?S
MQ!<WD%8:N$"\B0NXXO"#>X'G#$6[710BUD*"MI$?XC4ZA/0R&-+/^<^+BTW]
MJH.")*&YT'0U'[BH? \@U("MZ6@(K-_[P?HV_-]!2/Y+>@Y.9(LT@@<M(O>T
M=>7MV-%\E!41HT(^!.$'*@;E<F PV-<>CY?QY*_28/' ]IG3ES@Z/+^@IV(0
MR:#WX(?1)D!?"!Q1ONP)%3+W_I9>]6/^23]FT/ Q;9&%'$E53I 8#P/]. U)
M1_WD[X/4WUZM5O1R+E9P.'@ZT#5P66"L\J95<FA51V-Q\W*4LP67^K]0)A=E
M@B]03304@1BVF0_>F:6KBAQ83"EWT3K(U)QCI%[#/9G@DB&='K:CK5R%ZT_1
MO?]VE20!'=U7^#Z.GF-_E]Q'VV#U)CM\VT^6[3H,7155O8%L/!TO)KSF0M84
MRMMB >*GB%XSB<KV4-X@^H,WB88^-2MB)(N^&;GLF^:Z"78<Y#4XZ(/$06"U
M#_J22%'GH)=O8:(0=J=F0C1E1R[];5L&7],;5J,.J1H:T^9Y,3?ATE@'S>6!
MY^T9L]'K:J.]2*.U&]8CC&;'&(HLV)5=-U%,0Q<RFR/_J)Q'%E-K\ROVXX1&
M?509_7*V]"[S<(!)I"< 42FS>H+>]FAOT,(1H(5M8[9!,QD;?,/_. 1TT2*[
MF0[M#W%R\,E?TH@M%=+5_(2F+])__%JD,%X]QQB#7F6GB,O*F-SN.Z"AE^I5
MU X)GPF=/=#;NV\3^B56F*7XR\<&I;?M#LDJ*FD<\+R<US%9ENNAJ]=D&&/2
M42Z>GUR!RE(9QGR6LU(8R$^R^$D2K0*J#_H>I"]H38"\(@C>^BLP:';LU4>C
MNK(#38[P":.&W2X@47H4TJ""[0G>X,9!ONDMH'&^0275$6(RGHZFM:$^R4;"
M0BPB<A'?S::20<9[8Y:.H"U5&O>-F>O5S-U$[$!J82[;^V/F;B3FVAS@%6!Y
M/,:W^0EPF*>J?<9Q\,H*.MR&9+;",%URW8K\0C2SZ"'(_N"OH9U&GLET?@14
MVG/+9E#9SD4E0"B; IN^#^J2*IB91X(P.1!%2"A/;RJ"WSWHVO$%08&N$TW'
M!T5]/UZ%J86KCY\&C >.5%$?+N:3RZ,X@':QLEKFE;1\EI71OY==IV0RK%WM
MDPBSYDVJ]KDPCDO@(QJ_19:;1O-O";[;7 7$#G_3"N:CAP&Q7-=$M4]XWF0\
M$D"92*,3ZD(>&)3[F'6*9"MF*4?M?6QCXWMQLC[&6S;C3R.T>O%CH@%*</P:
MK#"M<_6$7_SMAAJ^CP,"GSUA,I;]]A)MUS 50-5 )Z( @=,@(_>[#3V>IK$H
M)WP#(!87J*&>E3*='\^.2>>B\MQ:;C-@Y.1HB7%-C0SJ2VX$8J27+% 8I;#%
M8A0ZI2A\EGD)%E>ZJ]WB5T"0U6-A=SX?+4^A-?Q2MNZ\M;^1GL+B-=U>>B1F
M7;T&KYD3KG^0$2Y\-GRJK NU]/[**LOWFAZPSS1:R_=RKT%RS3<>/3U&C_Z/
MOQ.GT[ H")])L,$. WST$UI1:T=C+5$DWEL< $?IZJ@Q:N9G;@K^^E8&I[3
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MY^Y[B./F5"O1HU;G J?M:VQJ+$XPP>1 ITKU-NH($6QV#E=Z3Z5?U2-WB?U
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MB,\2'V8V9YZQJFQKZ#N8HF6:K$(UN<=Q$-&&/N,-CLGL^AL]!G$XKMFG_!H
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ML,;;X!7'[*;(:D-T+$Q6<;#GM]"Y"U5CSFJ(6[_BM!*[?HJV1*LH]N%S1CO
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M926 _\#M[<WA_%,<K\-Y!CS+S+A-D@.9X=.MB23EVQGTQ_D=<&XP0!>0B/E
MV[^P[% 4(B5?."4*7__C$.QW.8^U]J:6UT$8H%DGC06K6;8&F N\0$PDZ\.%
M4%>RF4U:[?6RVCYZU3JQ&*\*?H-%Z'\<_)CT@^U;L5)Z&VZB>-=E]U!'%@AV
M-114/_L]][) O)!>6W4NY#LX6@_F#SX[QK0<-5XCD6,^^ZGO!KP[($",=5UO
MP@(_*^5[3W1^JQY8^/A6^XW2.*TC"P3X&@IJ1*5SP2Y>7N2:":P=H+E 3V]'
MOW9D<!_,.R>GD4QYQSY+=("+F"5TG0W-$G37=)4>Z 8AB5\R'>ED2_%T9+L$
M($9H44MGP!.<Z:[)9]%MWKE9$^Y WZ@;!(#O[ 8(C"MV=AFR57SI$)[)/W#\
MBC^^/1(%Z$FE)%4/]M4EP>.[23V-$6TA2#:N=_"L(3J6T:;X><#$Q47X@?R3
M73!82XFDR<;X.0C#G *N>=V%?.'J#7WTMW0-+V$G NL>_?3BQ\^NK.1KHT>!
M*%I];WBK/4]MIL2THZ<0V4>ZHMF,Y%-\?/M$..LYBM\:Y_YF9,)MVW=36/DZ
MF-%H,3K:W"<@X"GTK%54;1;E[5+:R%N&VO6WX9D3$M7R##B9 GB,QU7L DF!
ME_*3Y=E-X/_$['K%J]6*/.2';XQ&R0PCV@9K%GH]$(AD-2#H/M,>\SM-DK;^
M9SEUH1]3"1(<>GPIV*BM67'-55HM82"QFXZ&.N&)8).5-?7AZ013%R7U0-.-
M3?_8X1DW@KDNH!+'<]K?PTDVJ92W^?A6/G/OO]&?77WWX[7:BD]?^2YQCJK2
M&CN@.C14+]A$AN?J@YD2B&GARH*253^>+#<-ZT=G.$H7JEJTI?6I'&"RIV,+
MV/0ZH#N/;"1C*W&UG_P6!FG2)WHRVR0<WQFU0P>Z@HTS>216JH!X:,*7D8]^
MR#1S/FH#]/AQQ1^A!PL'.L1_@P"\@1+-?R,'6/*$YYGB=WL6D!N=22H(=BC"
M:]=68P:U%*3DRWF-HRYK^PPGG*9==TQ0-?]4*S8[Q$T]8*43E"FZVA6>J<:*
MU[O]-GK#F)EP3SKI"WF"ID/2H\D\XDR2PVY?5DOM0D"F6@1F)D-FJ)^A68IJ
M,4LG1Q<H5RH#9ZX62^*]0(5FJ**:TWP&XG!^E*'BH=^HI],(??*WJP--&D#U
M*@9'7L^(P#4:-(SZ-GXT^>F B9-J_?'MT]9/%).J3M^ (:YC-31F)$L1\;#N
M37>AJ$1GEK3Z67FZ2*5L)0":95U1@D:A:T#0A)\I&_R"H^?8W[\$*W_;?->E
M]'F;2)(IH9%UM\C.VE>%0%]Q:<8L3\LL:UAIZV@UI#1Z A GW_ ^BE,RE[J/
MML'JC?^W-?!6>M<^?IH54I^$CKQ)-B9QN:@0?(&X4/1']B=\,&O>=*]J>N7H
MB@-H4^NN N0I^ <&A=LM3Q+^U8__Q%3!;'-=^KFE+UC%FTP+U9XV&2WSXW*9
M,+::7XC+<PR@0&7&/N_8OETN#A9+;9VN#J!&7P"BYA<<XMC?$LVNUKL@#)*4
MW\"CA*"VE^VCJ44CG9XWKB'K F6B61>L"W<"9T8M]VJ6/U<L]VO"A[$X2OVM
M;8MGBA8CG%U&[0#Y*&)70$0JKC.3*J_47D(KC&PC6D.S.4F^NS3KZ?&=554M
MG3:;SL=YU;ML=,PIZDI*40DJ6T1_#!UXRU/D+7EGY+)W6G+B+;G(TQSD0(C/
M$)>4:>S]G&N3&K\TEO75E>$H#7[1K19[N9C-+_7)#[ :\*".T.8YZ)+!@WK#
M,^T-E^CMA ]T2>U+C]K#-J>>R:]X]X3CH^[3389S$]%,,?7-+\];:,]'2<?F
MS8 MJP[FBK.(6GKU=_U96]61-B,4>9%QG?<=C4RTJEE/O/FD2U0"4IM\,/OU
M@Q&X N:#.4$_!H&N<MX![+JA1]>L!@/\9&)=";KB0A<M58?5Q62^G(FIJS'
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MF=%K[%9!A!02</UE+"X]HG-9KHM_IQ!MA4?@HZ8I9);:&CCHY'"XWNV#Z !
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MI-$.Q#S6@M)0"S?WR4LSK&-#0C^,5D7YN)HB@L;$B;J8P?%5G"*]T48/>C!
MMW@4@@>XV:;)'?2><[F4+2\*>MB87EX/E9BA7*X;QX![8;';&TETGFY!7-U
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M-WON7"*U&2FZ.'L>737A'8%NMNS[T:@HSMYYNNJ>DT=+G$N @#5[%IZ7((;
M-%OVG?$F\K+=$=1FR[OSXVX(0+-GVA521!+49L^^2Z<A(I@YIEXF&17!R_'V
M0Y-@'K'\X#A_M32:!+G9,_[]T] 2$)T\P,YX15":O2 @7WV#@#9[L4"B  M!
MJX<X<(9%_X;I@+J*LP^S%Q)84=($HME+!!))UPA:/62!?91 _,2>$V#=9+FT
M$G#48%@2TC,'%88<4+3X7!*S,0<>WY4NU5?L=B9Q&LPM0PM5K;!Y/W-L:*%
M%38?9HY-+>-.!<G'F4,BE2BJ NNGF8)%S:-0@?*GF8(B9+3M+JY]3<DN7HM:
M$N=\)R*%7>IR(3C4=%E$:+!+''5UV%T=]LD5&/]HI^I5(W2MA',$.;ON:D7D
M1,F]B$;#3MN;0E95*1Y[3O>:0OY6PD;1BTZ3TVBGW:V3&+8CPW:0L'334)+0
MUK%HY80G^\+.ZT>$1C/+.T%C;/>EO[VM@X$DP*_%S^U?&QB!UQ2$*W"<:@,E
MN -I#%]_ *N-%W\?A:@%^,&/=F]3[S4*H]VAH+*6$<CW8T#LJ%4L&;8_8_-S
MS;1ZBPV'(?!QX]]@NJTNEZ/-^BCG?V<@\Z2$2;CX:%"LHGP_$WDT>5X!4A-I
M=3%56^[\:[9W[)\4PJ=9=73<:HKG4[//?-6[/M0,J+!E2./ILLR-[0_F4H+U
M] &;12HP-4NX=:8%9WPYK?'%LER.$S8W3$!*O(P"Q'E$L8>]\19QC.7IW$MB
MM8(%K;?A.HIW.2U&Q#^_<)-&,FN>9> !^ "^X,.?? ;I);>\F%Q?(V(@01I3
M]QD!37[!V8P3+Q?'Z44B^HYB9*9) M+D,0I67]"NC8G+P%/T /99[&^]A%?R
M2;[_9&<G+,>E.HH6@:ZT-F?/=X'/%N HK;1\O7;OH!<@7-U!'Z<XDJ@3+MG3
MQ&Y@7:;EX?09?ZZ?5)%60NLGS*LR. >?TM \O>WD+1*4M[J8G\,5\&. +I0;
M-!;:)2%(Y): UL_\;/B9MB6FQ1W _/RZSO3<V=2:FZ&]X)5Y^NQF&Y-4/@"T
MC3/V-FFVLD51V1\WB:@@*I+B?EIX"G0*,M2*S3HT&TQ:U7O*\N>49(JE&9F2
M29&ZP$I#&)ECF9ON+D)\T+UWX%A0J$VU[$]\ G#*EKI%E<I(B%IKH>98FZM,
M9\NMG<EN/ HMW'J6[,9Z:(GB=(/>?KS^'"*ZK;1\_3-(R_?F)HYV#5F'1@:O
MN8ESMMR#<)DKN7!J9&PJ2GZ+89J"L.T-UCIU$AVG-Q\N7R;55<N>05_"2QYN
M:E<&>^=R6ALI8N[!U6WX[S!<58PX T]*0S/T%J'C-SAJ/(8ON:1=JXYT])E!
MPO9+F0^<,1_E@;3LEOLHQ2H=+VC?H\E3= $*%2G1+M=WCF1/(ZL21SX JZ1Y
M"T8Q$WQF>ST8UX8O[H#K5R14P@00A=4-P,4_.&BKCF$:]P<0Y-*S%R,AA2T,
M<+L8FL,J\^D:1WH;@U0NXT<0OZ#5Y[REU*8&:<:ZR9*4A/MDLMOK.I5KF%+Y
MZB ?!Z>\8RF/^HQ@!/,L+6X+_GYNM=*"+[Z)]JCQ'5R#1Q^"T$?O&<>VP&VO
MBZ)H$\)R66"TRA];GO)'NIN)M:U?EW6-OL %4]A-$]8)\&)_FSL7OX @RD,9
MRM(5R7*]3@!'VE7HK85::L1EERQ:,Q,K_^AOP2H+L))EN &(YS\ZPH>,X)4]
M)^"/#&^A%Y8UD=]V E0+1&96ZXE0SGWIV>VUG&ZLOT/R4YZ/M:B/V3(2T\ZZ
MN),)9#$TRW7=,X>](^AMM2#Z98_X]3 M!3[VA4EM9])KL*>GS=%UCL_4V%XE
M8"AZLFX>MB=*5O:":CA$JSH9V>YUW]/KZK@K>0I3VZL-C.&CU(KL9FGB;/4P
M'AO:GBI%VT-*1H5;19JU/1IE["NCHY&QO7#]R#M70N=E>V7[L:]B)3TR =O.
MU-NC@BTARA-\[4J4=IK-+&D.)B#;6?KG5(]<)][73H%WU#W+=9(B]51["+]G
M41]B[*UZI^002O!V4EV_BT&N.K 3XH:CRP\6(5@[.4[Y3N8Y-Q-@G3PW5*?6
M];(BZ#I9KM=S1XT-(*@ZH:W7GJ7X]1),>PAJCC63B^0D(/<0U!S(/5V\">I.
MGNN#N4K!L?=.L.L'LF0N%0*TG1(=.P4!^ZJMAV';;EZ7KN9&"Y6SM1C]P!H>
M[^T2*85HT+++V%J'>L(9QLQ<(/)1H/4+5R[6<M[8=4\;,^Z#7#UV6L5X 5$M
MY0DK",GVO22,OZ+@U-T^=NKLI+#AN#Z3QVS&>T>42(* 9*?UHC](M0P7!"2[
M>$1UD%H)? @P=EY!LN%\]5MZC$ PVY_!\8+GZBO#"-2Q/BWWN.C.L^CW:78L
MKRZVM37#3P.M0KR/]97(3X,X71RTOJ;Y:<!E!B9;7P;]-/C**,RL+ZY^&JCU
MVMCLK2DBF9- <$O,1=,FS'_ P:FK<;/3PYZ;R:#!/*D&G<^J8LN-!^-?O2 #
MQR)BN$9+Q<4GTRG<,IL2)Y7/-N+LHS@%J\+M];A.9.FX,U4=Q<8R'$PJ0^P0
M!' Y+^\YCT>@D]1M9J8,2/@"XA0B#@2+V(_ S^+<38R__H)>1F;2B 'A9)ZA
M-#1/+S<#$;6IJY0Z[0($Q]NPT*]\ AZ^$%?+\ &?%AQ[<.$E,/D21HC#BG//
MMMMPGZ4X)CK$*YW?5A>'O/MEX"7\?)2C?<XT=MDN9VL2G,_ 1V_-KU& 2,4'
M 4?&2* A&& J\WN R=<;]"#5XWX49D?M;G1N];W$N8[9[0U3?_SGOT$0(]%A
M>[C#V37DIL+K;'A>Y=6 ;^W\2I";$+67T9D0+A,K. H65/*.Y'6=R)Q$B5*Y
M78S.(7]6DJH.LLPU1NDQ@1GD!_8#EP_F]3 Z@]II3;I7D=PAD1I#"Q<J4!/<
M,>H,JO4]!:6T;+7R_4R5R<*A+,OPT</J[/LXVB/)[G ?>&%Z_4<&]Y04I(J=
M3<SK%HDC,"Y"<G#0Y!W.#%*PQO^&!)>;*/Z2L.XEN;Y&9A7ZT0XL]OLX\OPM
MWE YU_X$_&T(_\CX2AO)SJ[46!EJ6^IE($@H;RT#8T$G5S)-NOR8%U9?JB)&
MK[J<!+^MJ>)M2 #;8;68("<VM>D4:.:R!XS&)NC^Y,5?0=KS-I3L;&9>^=$2
MD%]OH[>PW0/<;#'G5.JE):K;T7L8P0Y1<RC6]B8+5\GBF*4FOXM9: IZ&2GG
MAJ->JWP/^+1ABW\5]DJ=!:^'D?(N49P;7(AA2-7.I#*"H:)!A.%=A*LCSRO/
M,2@-,:DY?@:<LEGL+D:*T6 K+.<I)G\W1AWW'-1;G%=)&=;W00BCN&9&_!RE
M(+G*P-.WZ&D;98F'=@U^5 #@%#;M,8J>DAUD^,^(-<;#YU]F4RKH,8=B'7JH
M[C)J'+(9C:=!-Y?+9C:?5X$-.R/QV)X*#>=/JG^ [<Z)/*^(;H B0U*Q-<&1
M,).%C#O'H-1$YPR.(.F)72E@3N6%TG17%_B2#4KW=DY@LUP?ZFB-MS*VOQ%J
M/AI4S.7LHS,"DN<40D60ZWTQ&^ D?% :@7\J&C';2U#U!5'9A=W6Q&8JWD-'
M+DC.@V$V!UC%489Z#])\A6S-<MW+6:>.FM Z8VL=N,'(R7L,VUKA;10(64[E
MME9UTP<BS<MS4*6V26<]'HR;R)MH4-TUNZ'C&L)MK:?6&S5V$**M5=$TG,U>
M-:0LJX8V;,>Q'?8&U3BS$2\YQXI!I<KL?A#4O&YLK4HV&$9)%WE;*XT-QD\V
M=,+6BF+* 3%4.4*@P[<V)>4@]%A>,-8FFQR$%LW?PMK<D8.0HD<O6)OU<1!6
M@ARZUF5QU'7=MRWCUJ9E[ 48-X>P=>D4!^VIFE-W!="?'4#T0T<W[U>P_<7!
M)FD>O9M#.DU7(ZIE+>8%=?+8I[GBPW+ [!'T,:@,KSW0B2).B(N+71X'S "N
M#B-P^ORJ!I'H!E@P8H=M+X]J0YY>,\CQ ZGXRJ:YO&NBH*WFP9-+1D >-#L#
M#E0PDTUG<[KZ?M//F6TB/?8Y)(W6-%.7#GD6Z9#[I*VZGGC"X>LDA3LOQ?=&
MWWP;2D-H2JA7^HP45UVX63X'<)/?L^QH>G$GTTE]7<+GGMA=> %:4O"X!2#]
M)8ZR/9K'\1E\1 ]P$=3J%>Z['?L\"Z.^P[H$R@.HIX%.RY"IU-4EA79)H5U2
M:/FY3"HIM$NIK#VELJ99=B5-W@W :&V4\E[Y6F5[3WAFHBM!<127_E=L\VM!
M/.-$KC:G$IUR^LJS2NNGFL#/9%(\; E:@QC;B(KBS%B[0/<?0;0D]#]QSYW6
M3VA9M=]R4U@J<4H9+:>3,,PE4QLQF9I=\3,#\X59EJ#@5$K,?OG"+ NUU*WU
M;#A]JDH-@X+VSPIDEY3M-# +];Z]G)2M<[,=BAP_6,=M-/9&DXHXM"XR3".
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M("VNGFRAK3RZ P?MGQXX ?X/F^CE[0I #,%'_ \\\X^UF7=S<3;FT/FSEC3
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M5+]/!ZDKK=Y-%(AZ:#HLVT]]GVU;'5WU(DAA  ;%GN_S2+$7\#0# -D\\J!
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M,#$V,3(S,2YX<V102P$"% ,4    "  6B'!*QD>0XTL<  "BK $ %0
M        @ %W10( ;6YK9"TR,#$V,3(S,5]C86PN>&UL4$L! A0#%     @
M%HAP2FS'R"*M?   *[() !4              ( !]6$" &UN:V0M,C Q-C$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( !:(<$JNW'M;ZMP  %ZX#  5
M      "  =7> @!M;FMD+3(P,38Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  6
MB'!*DG-@\U&#  "U.PL %0              @ 'RNP, ;6YK9"TR,#$V,3(S
?,5]P<F4N>&UL4$L%!@     &  8 B@$  '8_!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
